INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

2019 FINAL PROGRAM

39TH ANNUAL MEETING AND SCIENTIFIC SESSIONS

ORLANDO, FLORIDA, USA

APRIL 3-6, 2019

ISHLT 2019 ACADEMIES

APRIL 2, 2019
TABLE OF CONTENTS

ABOUT ISHLT

2018-2019 BOARD OF DIRECTORS and ISHLT STAFF

2019 ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

2019 ABSTRACT REVIEWERS

COMMITTEE ROSTERS:
   Education Committee
   Finance Committee
   Governance Committee
   Grants and Awards Committee
   International Engagement Committee
   ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry Steering Committee
   International DCD Registry Steering Committee
   International Pediatric Heart Failure Registry Steering Committee
   International Thoracic Organ Transplant Registry Steering Committee
   Registries and Databases Committee
   Standards and Guidelines Committee

JOURNAL FOR HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD

PULSE NEWSLETTER EDITORIAL STAFF

SCIENTIFIC COUNCIL OPERATING BOARDS:
   Basic Science and Translational Research
   Chronic Thromboembolic Pulmonary Hypertension
   Heart Failure and Transplantation
   Infectious Diseases
   Junior Faculty and Trainees
   Mechanical Circulatory Support
   Nursing, Health Sciences and Allied Health
   Pathology
   Pediatric Thoracic Transplantation and Heart Failure
   Pharmacy and Pharmacology
   Pulmonary Hypertension
   Pulmonary Transplantation

PAST PRESIDENTS

PAST PROGRAM CHAIRS
PAST REGISTRY MEDICAL DIRECTORS, JOURNAL AND NEWSLETTER EDITORS

ISHLT AWARD RECIPIENTS:

OUTSTANDING ACHIEVEMENT AWARDS:
ISHLT Lifetime Achievement Award
ISHLT Lifetime Service Award
ISHLT Pioneer Award
ISHLT Emeritus Membership

GRANTS AND SCHOLARSHIPS:
GRANT AWARDS:
ISHLT Norman E. Shumway Career Development Award
ISHLT Joel D. Cooper Career Development Award
ISHLT/Enduring Hearts Transplant Longevity Research Award
ISHLT Nursing Research Grant Award
ISHLT Research Fellowship Award
ISHLT Transplant Registry Early Career Award
ISHLT/Bayer Pulmonary Hypertension Research Grant Award
ISHLT/HeartWare Award for Translational Research in MCS
ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic
ISHLT Branislav Radovancevic Memorial Fellowship Grant (Supported by Thoratec)
ISHLT International Traveling Scholarship Award
ISHLT Leach-Abramson-Imhoff Links Travel Awards

ABSTRACT AWARDS:
Philip K. Caves Award
Nursing, Health Sciences & Allied Health Excellence in Research Award
Early Career Scientist Award
Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award
Branislav Radovancevic Memorial Best MCSD Paper Award (Supported by Thoratec)

ACCREDITATION INFORMATION/CONTINUING MEDICAL EDUCATION INFORMATION

UNRESTRICTED EDUCATIONAL GRANTS

COMMERCIAL SUPPORT

ANNUAL MEETING HIGHLIGHTS

LOEWS MEETING COMPLEX FLOOR PLANS

ACRONYMS

SCIENTIFIC COUNCIL MEETINGS & RECEPTIONS
ANNUAL MEETING SCIENTIFIC SESSIONS:

WEDNESDAY, APRIL 3, 2019

OPENING PLENARY SESSION
SESSION 01 (ORAL): The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies
SESSION 02 (SYMPOSIUM): Future Shock: Great Debates in Cardiogenic Shock
SESSION 03 (ORAL): Chronic Lung Allograft Dysfunction: Anything New?
SESSION 04 (ORAL): So Wrong It’s Right: The Right Ventricle and MCS
SESSION 05 (SYMPOSIUM): Limiting the Invasiveness of the VAD Therapy
SESSION 06 (ORAL): Pediatric Donor Utilization, MCS, Readmissions and More
SESSION 07 (SYMPOSIUM): Making Co-Morbidities Great Again
SESSION 08 (ORAL): ISHLT Spotlight: Heart Transplantation in Latin America
SESSION 09 (SYMPOSIUM): Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection
SESSION 10 (ORAL): Heart Donor Management and Allocation: Setting It Up For Success
SESSION 11 (ORAL): Chronic Lung Allograft Dysfunction: Overcoming the Hurdle?
SESSION 12 (ORAL): When Short-Term Becomes Long-Term: Transition from Temp to Perm MCS
SESSION 13 (SYMPOSIUM): They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Receipts
SESSION 14 (SYMPOSIUM): Part of (Their) World: Discharging Patients Home with a New Device
SESSION 15 (ORAL): Pharmacotherapy in Transplantation: Reading the Tea Leaves to Improve Outcomes
SESSION 16 (ORAL): Junior Faculty and Trainees Clinical Case Dilemmas: The Best of the Best
SESSION 17 (ORAL): Tolerance Is All We Need in Thoracic Transplantation
SESSION 18 (ORAL): Ex-Vivo Heart Perfusion and Preservation: Some Like It Hot - or Not!
SESSION 19 (SYMPOSIUM): Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning?
SESSION 20 (ORAL): The Beat Goes On: Arrhythmias and Pacing During MCS
SESSION 21 (SYMPOSIUM): Short Term Mechanical Support: Taking the Next Leap Forward
SESSION 22 (SYMPOSIUM): What Do We Do? Burning Platforms in Pediatric Thoracic Transplant
MINI ORAL 01: Deciphering the Role of Antibodies and Inflammation in Thoracic Rejection
MINI ORAL 02: Cardiac Donor Selection: More Than Meets the Eye
MINI ORAL 03: Chronic Lung Allograft Dysfunction
MINI ORAL 04: MCS: A Focus on Stroke
MINI ORAL 05: Do It Quick and Do It NOW: ECMO Update
MINI ORAL 06: Pediatrics

POSTER SESSION 1:

Basic Science and Translational Research
Economics, Ethics, Public Policy
Heart Transplantation (Adult)
Nursing, Health Sciences, Allied Health
Pathology
Pharmacy and Pharmacology

Junior Faculty Clinical Case Reports:

Infectious Diseases
Mechanical Circulatory Support
Pediatrics
Pulmonary Hypertension

THURSDAY, APRIL 4, 2019

SUNRISE SYMPOSIUM 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies
SUNRISE SYMPOSIUM 02: Immunobiology of the Older Lung Transplant Recipient
SUNRISE SYMPOSIUM 03: From Isolated to Mainstream: Evolving ECMO Strategies Reshaping Outcomes
SUNRISE SYMPOSIUM 04: Nobody is CLAD to See AMR in Lung Transplantation
SUNRISE SYMPOSIUM 05: I Want to Ride My Bicycle: CPET for PAH and CTEPH
SUNRISE SYMPOSIUM 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant
SESSION 23 (ORAL): Hepatitis C+ Cardiac Donors: Do They Get an A+?
SESSION 24 (ORAL): Molecular Diagnostics in Heart Transplantation: It's All in the Genes
SESSION 25 (SYMPOSIUM): The Magic Kingdom of the Bronchoscopy
SESSION 26 (ORAL): Mechanical Lung Support for Isolated Organs and Patients
SESSION 27 (SYMPOSIUM): Medical Management of LVAD Patients
SESSION 28 (ORAL): Tissue is Not the Only Issue: Advances in Thoracic Transplant Pathology
SESSION 29 (ORAL): Pediatric Lung Transplantation: Are We Moving Forward?
SESSION 30 (ORAL): Get up and Go! Predicting Survival in Heart Failure
SESSION 31 (ORAL): Slaying the Dragon: Hepatitis C and Thoracic Transplantation
SESSION 32 (SYMPOSIUM): Ex-Vivo Lung Perfusion (EVLP) in 2019
SESSION 33 (ORAL): Brain Attack: Strokes and MCS
SESSION 34 (ORAL): Never Mind the Leaks: Addressing Valvular Disease with LVADs
SESSION 35 (SYMPOSIUM): Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Tx Setting
SESSION 36 (SYMPOSIUM): Learning from the Children
SESSION 37 (SYMPOSIUM): JHLT at ISHLT: The Year in a Capsule
SESSION 38 (ORAL): Early Career Scientist Award Candidate Presentations
SESSION 39 (ORAL): Walking a Tightrope: The Double-Edged Sword of Drugs after Heart Transplant
SESSION 40 (SYMPOSIUM): Heart Failure in Adult Congenital Heart Disease
SESSION 41 (ORAL): Perfecting the Graft: LVAD Pump Management, Outcomes and Medications
SESSION 42 (ORAL): Too Much or Two Little? Obesity and Frailty in MCS
SESSION 43 (SYMPOSIUM): Changes in the World of Pulmonary Hypertension: Nice or Not Nice
SESSION 44 (ORAL): Philip K. Caves Award Candidate Presentations
SESSION 45 (ORAL): Acute Cardiac Rejection: New Approaches to an Old Problem
SESSION 46 (SYMPOSIUM): FUN and Games with FUNgal Infections in Lung Transplantation
SESSION 47 (ORAL): Back to the Basics: Physiological Alterations During Continuous Flow VAD Support
SESSION 48 (SYMPOSIUM): Advances in Short- and Long-Term MCS - What’s Next
SESSION 49 (ORAL): Personal Connection: Psychological Issues & Care for Donor Families, Patients & Providers
SESSION 50 (ORAL): PH in Translation: From Novel Biomarkers to Cutting Edge Clinical Results
MINI ORAL 07 A&B: Basic Science and Heart Transplantation
MINI ORAL 08: Lung Donor Management and Organ Allocation
MINI ORAL 09: MCS: GI Bleeding
MINI ORAL 10 A&B: Nursing, Health Sciences, Allied Health, Pharmacy and Pharmacology
MINI ORAL 11 A&B: Heart Failure (Adult) and Pediatrics
MINI ORAL 12 A&B: Pulmonary Hypertension and Heart Transplantation
POSTER SESSION 2:
   Infectious Diseases
   Lung Transplantation (Adult)
   Mechanical Circulatory Support (Adult)
   Junior Faculty Clinical Case Reports:
      Heart Failure/Transplantation
      Lung Failure/Transplantation

FRIDAY, APRIL 5, 2019
SUNRISE SYMPOSIUM 07: Highways to Hell: Chronic Lung Allograft Dysfunction
SUNRISE SYMPOSIUM 08: Print, Replace or Innovate: Alternative Strategies to Cardiac Tx
SUNRISE SYMPOSIUM 09: MCS Infections: New Twists in an Old Saga
SUNRISE SYMPOSIUM 10: Cardiac Reverse Remodeling in MCS: State of the Art
SUNRISE SYMPOSIUM 11: The Mission IS Possible If You Choose to Accept it…Performing Research
SUNRISE SYMPOSIUM 12: A Bloody Mess: Management of Hematologic Complications in Tx and MCS
PLENARY SESSION
SESSION 51 (ORAL): Cardiac Allograft Vasculopathy: A Never-ending Story
SESSION 52: JOINT ISHLT/SCMR SYMPOSIUM: Cardiac MRI and the World of Heart Failure
SESSION 53 (ORAL): Chasing the Golden Snitch: Optimizing Outcomes of MCS Infections
SESSION 54 (ORAL): Swipe Right or Swipe Left? Matching Donors and Recipients in LTX
SESSION 55 (ORAL): Score Now - Or Forever Hold Your Peace: Prediction and Risk in MCS
SESSION 56: JOINT ISHLT/IPTA SYMPOSIUM
SESSION 57 (SYMPOSIUM): Take These Broken Lungs and Learn to Fly: Great Debates … PAH
SESSION 58 (SYMPOSIUM): Resilience in the Face of Calamity: The Art of Preventing PTE Disasters
SESSION 59 (ORAL): Heart Transplant Short-Term Outcomes: Getting it Right From the Start
SESSION 60: JOINT ISHLT/ABTO SYMPOSIUM
SESSION 61 (SYMPOSIUM): Making Them Count: Enhancing Lung Donor Utilization
SESSION 62 (ORAL): Under New Management: Novel Strategies for MCS
SESSION 63: JOINT ISHLT/ICCAC SYMPOSIUM
SESSION 64 (ORAL): Highlights of Challenging Topics in Pediatric Heart Transplant and MCS
SESSION 65 (SYMPOSIUM): All Talk, No Action? New Strategies … Donor Heart Utilization
SESSION 66 (ORAL): Between the Devil and the Deep Blue Sea: Fungus or CMV?
SESSION 67 (ORAL): Diagnostics and Immunosuppression in Lung Transplantation
SESSION 68 (ORAL): LV Recovery after MCS: From Promise to Reality?
SESSION 69 (ORAL): Tricks of the Trade: Management Considerations with Continuous Flow LVADs
SESSION 70 (SYMPOSIUM): Matters of Life and Death: Palliative and End of Life Care in Tx Medicine
SESSION 71 (SYMPOSIUM): Breaking Bad: The RV and Exercise Hemodynamics Rediscovered
MINI ORAL 13: Cardiac Donors and Recipients: Valuable Insights
MINI ORAL 14: Unique Considerations for Special Heart Transplant Populations
MINI ORAL 15 A&B: Infectious Diseases and Basic Science
MINI ORAL 16: Lung Transplant Outcomes
MINI ORAL 17: MCS: Right Heart Failure
MINI ORAL 18: LVAD Physiology: Effects on End Organs
POSTER SESSION 3:
  Heart Failure/Transplantation (Adult)
  Lung Failure/Transplantation (Adult)
  Mechanical Circulatory Support (Adult)
  Pediatrics
  Pulmonary Hypertension and CTEPH

SATURDAY, APRIL 6, 2019
SUNRISE SYMPOSIUM 13: How Can We Compare Interventional Therapies in CTEPH?
SUNRISE SYMPOSIUM 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation
SUNRISE SYMPOSIUM 15: Lung Transplant Candidate Selection: Challenging Cases
SUNRISE SYMPOSIUM 16: Fragility: Not Necessarily Failure
SUNRISE SYMPOSIUM 17: A Brand-New Day: The New Normal in Pediatric Thoracic Transplantation
SUNRISE SYMPOSIUM 18: So Your Patient is on ECMO … Now What?
PLENARY SESSION
SESSION 72 (SYMPOSIUM): Seeing the Light: Antibodies in Thoracic Transplantation
SESSION 73 (ORAL): Life on the Cutting Edge: CTEPH and Surgical Management of PH
SESSION 74 (ORAL): Frontiers of Cost-Efficacy and Policy in Transplant and MCS
SESSION 75 (SYMPOSIUM): Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter
SESSION 76 (SYMPOSIUM): Location, Location, and Allocation: Worldwide … LTX
SESSION 77 (ORAL): Thicker than Water? Bleeding and LVADs
SESSION 78 (ORAL): The Beginning of the End in Lung Transplantation: PGD, AMR and CLAD
SESSION 79 (ORAL): Go with the Flow: Hemodynamic Guiding Therapies in Heart Failure
SESSION 80 (ORAL): Heart Transplant Long-Term Outcomes: In It for the Long Haul
SESSION 81 (ORAL): Primary Graft Dysfunction and Acute Lung Rejection
SESSION 82 (ORAL): Donor Lung Management: Can We Do Better?
SESSION 83 (ORAL): What's Holding Me Back? Exercise in LVAD Patients

POSTER MAPS:
  Poster Session 1, Wednesday (Banda Sea 1&2, Gardenia 1&2, Hibiscus 1&2, Timor Sea 1&2)
  Poster Session 2, Thursday (Banda Sea 1&2, Gardenia 2, Hibiscus 1&2, Timor Sea 1&2)
  Poster Session 3, Friday (Banda Sea 1&2, Gardenia 2, Hibiscus 1&2, Timor Sea 1&2)

ISHLT ACADEMIES:
  CORE COMPETENCIES IN NURSING, HEALTH SCIENCES AND ALLIED HEALTH: Care of Patients Requiring Mechanical Circulatory Support and Transplantation
  CORE COMPETENCIES IN PEDIATRIC HEART FAILURE
  MASTER CLASS IN HEART FAILURE AND TRANSPLANTATION
  MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT

AFFILIATE EVENTS

CORPORATE EVENTS AND INDUSTRY THEATER LISTINGS

EXHIBIT HALL FLOOR PLAN

2019 EXHIBITORS AND BOOTH NUMBERS

2019 EXHIBITOR PRODUCT DESCRIPTIONS

FUTURE ANNUAL MEETINGS
ABOUT ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support, and innovative therapies via research, education, and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3800 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The purposes of the Society are:

1. Promoting the association of persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences;
2. Encouraging and stimulating basic and clinical research in heart and lung transplantation and end-stage heart and lung disease, and promoting new therapeutic strategies;
3. Holding scientific meetings featuring presentations and discussions relevant to heart and lung transplantation and the treatment of end-stage heart and lung disease;
4. Sponsoring a scientific journal for the publication of manuscripts related to these disciplines;
5. Maintaining an international registry for heart and lung transplantation;
6. Awarding research grants and establishing endowments for the study of heart and lung transplantation and end-stage heart and lung disease, when funds are available and without jeopardizing the financial well-being of the organization; and
7. Sponsoring and conducting educational activities and providing educational resources, which promote expert development and improve standards of care in advance heart and lung disease, heart and lung transplantation, and relevant medical and device therapies.
2018-2019 BOARD OF DIRECTORS

Jeffrey J. Teuteberg, MD, President
Stuart Sweet, MD, PhD, President-Elect
Andrew J. Fisher, FRCP, PhD, Past President
Raymond Benza, MD, Treasurer
Jason D. Christie, MD, Secretary
Kevin Chan, MD, Director
Jennifer Cowger, MD, MS, Director
Teresa De Marco, MD, FACC, Director
Goran Dellgren, MD, PhD, Director
Howard J. Eisen, MD, Director
Stephan M. Ensminger, MD, DPhil, Director
Martin Goddard, FRCS, MRCPa, Director
Kathleen Grady, PhD, RN, FAAN, Director
Manreet Kanwar, MD, Director
Michael Shullo, PharmD, Director
Dirk Van Raemdonck, MD, PhD, Director

ISHLT STAFF

Amanda W. Rowe, Executive Director
Christy Norcross, Interim Senior Director of Meetings
Lisa Edwards, Director of Meetings
Lee Ann Mills, Director of Finance and Operations
Nancy Mays, Director of Communications
Jenny Clark, Director of Continuing Medical Education
Susie Newton, Programs and Services Manager
Megan Barrett, Programs and Services Assistant
Justin Hickman, Finance and Operations Assistant
Phyllis Glenn, Administrative Assistant

14673 Midway Road, Suite 200
Addison, TX  75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org
2019 ANNUAL SCIENTIFIC PROGRAM COMMITTEE

♦ Symposium Planning Committee
☆ Abstract Selection Committee
• Liaison

**All Program Committee Members also served as Abstract Reviewers

Lara Danziger-Isakov, MD, MPH, ISHLT 2019 Scientific Program Chair, Cincinnati Children’s Hospital, Cincinnati, OH, USA♦☆
Jeff Teuteberg, MD, ISHLT President, Stanford University, Stanford, CA, USA♦☆
Christian Benden, MD FCCP, ISHLT 2018 Scientific Program Chair, University Hospital Zurich, Zurich, Switzerland♦☆
Stephan Ensminger, MD, DPhil, ISHLT 2020 Scientific Program Chair, University of Lübeck, Lübeck, Germany♦☆
Clemens Aigner, MD, University of Essen, Essen, Germany☆
Annalisa Angelini, MD, University of Padua, Padova, Italy♦☆●
Pavan Atluri, MD, University of Pennsylvania, Philadelphia, PA, USA☆
Estela Azeka, PhD, Heart Institute (InCor) University of São Paulo Medical School, Sao Paulo, Brazil☆
Lavanya Bellumkonda, MD, Yale University, New Haven, CT, USA☆
Ryan Butts, MD, UT Southwestern Medical Center, Dallas, TX, USA☆●
Stephen Clark, MD, Freeman Hospital, Newcastle Upon Tyne, UK♦☆
Monica Colvin, MD, University of Michigan, Ann Arbor, MI, USA☆
Melissa Cousino, PhD, C.S. Mott Children's Hospital, Ann Arbor, MI, USA♦☆
Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, UK♦☆●
Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada♦☆
Todd Dardas, MD, University of Washington, Seattle, WA, USA☆●
Kyle Dawso, PharmD, BCPS, University of Kentucky, Lexington, KY, USA◆☆●
Teresa De Marco, MD, UCSF Medical Center, San Francisco, CA, USA◆☆
Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, USA☆
Mary Amanda Dew, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA☆
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France◆☆●
Patricia Ging, PharmD, Mater Misericordiae, Dublin, Ireland☆
Jose Gonzalez-Costello, MD, Belvitge Hospital, Barcelona, Spain☆
Ed Horn, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA☆
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA◆☆●
Mary Keebler, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA☆
Feras Khaliel, MD, PhD, King Faisal Specialist Hospital, Riyadh, Saudi Arabia☆
Kiran Khush, MD, MAS, Stanford University, Stanford, CA, USA◆☆●
Hanneke Kwakkel van Erp, MD, PhD, UMC Utrecht, Utrecht, Netherlands☆
Erika Lease, MD, University of Washington, Seattle, WA, USA☆
Angela Lorts, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA◆☆●
Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia◆☆●
Jiri Maly, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic☆
Mandeep Mehra, MD, MBBS, FACC, FACP, Brigham and Women's Hosp, Harvard Med School, Boston, MA, USA◆☆
Anna L. Meyer, PD, Leipzig Heart Center, Leipzig, Germany◆☆
Orla Morrissey, MD, Alfred Hospital, Melbourne, Australia◆☆●
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic◆☆
Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland☆
Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany◆☆
Joanna Pepke-Zaba, MD, Papworth Hospital, Papworth Everard, UK◆☆
Stephanie Pouch, MD, Emory University, Atlanta, GA, USA☆
Anja Roden, MD, Mayo Clinic, Rochester, MN, USA◆☆
Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA☆●
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA◆☆
Marc Simon, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA◆☆●
Jon Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA◆☆
Jacqueline Smits, PhD, Eurotransplant International, Leiden, Netherlands☆
Laurie Snyder, MD, Duke University Medical Center, Durham, NC, USA◆☆
Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada◆☆
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, USA◆☆
Stijn Verleden, MD, PhD, KU Leuven, Leuven, Belgium◆☆●
Tomasz Zielinski, MD, Institute of Cardiology, Warsaw, Poland☆
2019 ABSTRACT REVIEWERS

David Abelson, FRACP, MD, St Vincent’s Hospital, Sydney, Australia
Linda Addonizio, MD, Columbia University College of Physicians and Surgeons, New York, NY, USA
Mustafa Ahmed, MD, University of Florida, Gainesville, FL, USA
Philipp Aigner, MSc, Medical University of Vienna, Vienna, Austria
Natasha Aleksova, MD, University of Toronto, Toronto, ON, Canada
Peta Alexander, MBBS, Boston Children's Hospital, Boston, MA, USA
Tamas Alexy, MD, PhD, University of Minnesota, Minneapolis, MN, USA
Rami Alharethi, MD, Intermountain Medical Center, Murray, UT, USA
Arezu Aliabadi-Zuckermann, MD, PhD, Medical University of Vienna, Vienna, Austria
Larry Allen, MD, University of Colorado, Denver, CO, USA
Christopher Almond, MD, MPH, Stanford University, Stanford, CA, USA
Natasha Altman, MD, University of Colorado, Denver, CO, USA
Elvis Amao, PhD, Hospital Clinico, Valladolid, Spain
Cristiano Amarelli, MD, Monaldi Hospital, Naples, Italy
Amrut Ambardar, MD, University of Colorado, Denver, CO, USA
Antonio Amodeo, MD, Bambino Gesù Pediatric Hospital, Rome, Italy
Samantha Anthony, PhD, The Hospital for Sick Children, Toronto, ON, Canada
Christina Aquilante, PharmD, University of Colorado, Denver, CO, USA
Selim Arcasoy, MD, MPH, Columbia University, New York, NY, USA
Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA
William Auger, MD, Temple University Hospital, Philadelphia, PA, USA
Sanjeet Singh Avtaar Singh, MRCS, MSc, Golden Jubilee National Hospital, Glasgow, UK
Arnold Baas, MD, UCLA Medical Center, Los Angeles, CA, USA
Roberto Badagliacca, MD, PhD, University of Rome Sapienza, Rome, Italy
John Baddley, MD, University of Alabama at Birmingham, Birmingham, AL, USA
Maral Bakir, RN, PHN, UCLA Medical Center, Los Angeles, CA, USA
Carlo Banfi, MD, PhD, FCCP, University Hospital, Geneva, Switzerland
Aliessa Barnes, MD, Children's Mercy Hospital, Kansas City, MO, USA
Markus Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Ray Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Alejandro Bertolotti, MD, Favalo Foundation, Buenos Aires, Argentina
Sai Kiran Bhagra, MRCP, Royal Papworth Hospital, Papworth Everard, UK
Jay Bhama, MD, University of Iowa Health Care, Iowa City, IA, USA
Joshua Blatter, MD, MPH, Washington University of St. Louis, St. Louis, MO, USA
Emily Blood, MSN, University of Southern California, Los Angeles, CA, USA
Peggy Blood, MSN, University of Alabama at Birmingham, Birmingham, AL, USA
Nancy Blumenthal, DNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Emanuele Bobbio, MD, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden
Entela Bollano, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden
Edith Boyes, MSN, FNP-BC, Amita Health, Chicago, IL, USA
Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, USA
Michela Brambatti, MD, MS, UCSD Medical Center, San Diego, CA, USA
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children's Hospital, San Francisco, CA, USA
Fay Burrows, BPharm (Hons), St Vincent's Hospital, Sydney, Australia
Yasmeen Butt, MD, UT Southwestern Medical Center, Dallas, TX, USA
Daniel Calabrese, MD, UCSF Medical Center, San Francisco, CA, USA
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Kadir Caliskan, MD PhD, Erasmus Medical Center, Rotterdam, The Netherlands
Paul Callan, MD (UK), Manchester Foundation Trust, Manchester, UK
Sylvia Campos, MD, Heart Institute (InCor) University of São Paulo Medical School, Sao Paulo, Brazil
Edward Cantu, MD, University of Pennsylvania, Philadelphia, PA, USA
Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI, USA
María Angeles Castel, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain
Javier Castrodeza, MD, Hospital Clinico Universitario Valladolid, Valladolid, Spain
Pedro Catarino, MD, Royal Papworth Hospital, Papworth Everard, UK
Kevin Chan, MD, University of Michigan, Ann Arbor, USA
Wandy Chan, PhD, The Prince Charles Hospital, Brisbane, Australia
Sandra Chaparro, MD, University of Miami, Miami, FL, USA
Leway Chen, MD, University of Rochester Medical Center, Rochester, NY, USA
Robert J Chen, MD, MPH, Taipei Medical University Hospital, Taipei, Taiwan
Christiane Kugler, PhD, University of Freiburg, Freiburg, Germany
Ashwin Lal, MD, Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA
Harveen Lamba, MD, Baylor College of Medicine / Texas Heart Institute, Houston, TX, USA
Brent Lampert, DO, Ohio State University Medical Center, Columbus, OH, USA
Brandon Larsen, MD, PhD, Mayo Clinic Arizona, Phoenix, AZ, USA
Lorriana Leard, MD, UCSF Medical Center, San Francisco, CA, USA
Hye Won Lee, PhD, Pusan National University Hospital, Seoul, Republic of Korea
James Lee, MD, University of Pennsylvania, Philadelphia, PA, USA
Anthony Lemaire, MD, Rutgers Robert Wood Johnson Medical School, Princeton, NJ, USA
Karl Lemstrom, MD, PhD, University of Helsinki, Helsinki, Finland
Deborah Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA
Bronwyn Levey, RN, Grad Dip Clin Ep, The Alfred Hospital, Melbourne, Australia
Clive Lewis, MA MD PhD, Royal Papworth Hospital, Papworth Everard, UK
Sern Lim, MD, University Hospital Birmingham NHS Trust, Birmingham, UK
Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA
Antonio Loforte, MD, PhD, S. Orsola Hospital, Bologna University, Bologna, Italy
Brian Lowes, MD, PhD, University of Nebraska, Omaha, NE, USA
Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada
Haifa Lyster, MSc, Royal Brompton & Harefield NHS Foundation Trust, Middlesex, UK
Peter Macdonald, MD, PhD, St Vincent's Hospital, Sydney, Australia
Michael Madani, MD, UCSD Medical Center, San Diego, CA, USA
Pradeep Mammen, MD, UT Southwestern Medical Center, Dallas, TX, USA
Erin Mancl, PharmD, Loyola University Medical Center, Maywood, IL, USA
Daniel Marelli, MD, MSc, Bayhealth/University of Pennsylvania, Philadelphia, PA, USA
Tereza Martinu, MD, University of Toronto, Toronto, ON, Canada
Marco Masetti, MD, University of Bologna, Bologna, Italy
Sofia Carolina Masri, MD, University of Washington, Seattle, WA, USA
Paul Mather, MD, University of Pennsylvania, Philadelphia, PA, USA
Jeremy Mazurek, MD, University of Pennsylvania, Philadelphia, PA, USA
David McGiffin, MB,BS, Alfred Hospital, Melbourne, Australia
Colleen McIlvennan, DNP, University of Colorado, Denver, CO, USA
Hirsch Mehta, MD, San Diego Cardiac Center, San Diego, CA, USA
Bruno Meiser, PhD, University of Munich Transplant Center, Munich, Germany
Ahmed Menouar, PhD, CRCHUM Université de Montréal, Montreal, QC, Canada
Christopher Michaud, PharmD, Spectrum Health, Grand Rapids, MI, USA
Sebastian Michel, MD, Ludwig Maximilian University, Munich, Germany
Oliver Miera, MD, German Heart Center, Berlin, Germany
Robert Miller, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
Yasbanoo Moayedi, MD, University of Toronto, Toronto, ON, Canada
Nader Moazami, MD, NYU Langone Health, New York, NY, USA
asim Mohammed, MD, Medical College of Wisconsin, Milwaukee, WI, USA
Joshua Mooney, MD, Stanford University, Stanford, CA, USA
David Morales, MD, Cincinnati Childrens Hospital, Cincinnati, OH, USA
Paola Morejon, MD, Fundación Favaloro, Buenos Aires, Argentina
Letizia Corinna Morlacchi, PhD, Fondazione IRCCS Ca' Granda, Milan, Italy
Alanna Morris, MD, MSc, Emory University, Atlanta, GA, USA
Margaret Murray, DNP, University of Wisconsin Hospital and Clinics, Madison, WI, USA
Kavitha Muthiah, PhD, St Vincents Hospital, Sydney, Australia
Emil Najjar, MD, Karolinska University Hospital, Stockholm, Sweden
Samer Najjar, MD, MedStar Washington Hospital Center, Washington, DC, USA
Sanem Nalbantgil, MD, Ege University Medical School, Izmir, Turkey
Deipanjan Nandi, MD, Nationwide Children's Hospital, Columbus, OH, USA
Desley Neil, FRCPath, Queen Elizabeth Hospital, Birmingham, UK
Minoru Ono, MD, PhD, The University of Tokyo, Tokyo, Japan
Robert Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, USA
Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA
Maryse Palardy, MD, University of Michigan, Ann Arbor, MI, USA
Francesco Parisi, MD, Ospedale Pediatrico Bambino Gesù, Rome, Italy
Amit Parulekar, MD, Baylor College of Medicine, Houston, TX, USA
Jignesh Patel, MD PhD, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA
Caroline Patterson, MD, Royal Papworth Hospital, Papworth Everard, UK
Daniel Pauly, MD, PhD, University of Missouri, Kansas City, MO, USA
ISHLT COMMITTEE ROSTERS (Parentheses indicate year rotating off committee)

EDUCATION COMMITTEE
To Be Determined

FINANCE COMMITTEE
Raymond Benza, MD, Chair (2019)
Stuart Sweet, MD, PhD, President-Elect (2020)
Howard Eisen, MD, At Large Member (2021)
Shaf Keshavjee, MD, FRCSC, At Large Member (2020)
Scott Silvestry, MD, At Large Member (2019)
Jeffrey Teuteberg, MD, President (2019)
Amanda Rowe, ISHLT Executive Director
Lee Ann Mills, ISHLT Director of Finance

GOVERNANCE COMMITTEE
Andrew Fisher, FRCP, PhD, Chair (2019)
Jeffrey Teuteberg, MD, ISHLT President (2020)
Stuart Sweet, MD, PhD, ISHLT President-Elect (2021)
Christian Benden, MD, FCCP, At Large Member (2021)
Lara Danziger-Isakov, MD, MPH, At Large Member (2020)
Michael Petty, PhD, RN, CNS, At Large Member (2021)
David Taylor, MD, At Large Member (2019)
Amanda Rowe, ISHLT Executive Director

GRANTS AND AWARDS COMMITTEE
Kathleen Grady, PhD, RN, FAAN, Chair (2020)
Daniel Kreisel, MD, PhD, Past Chair (2019)
Stephan Ensminger, MD, DPhil, Board of Directors Liaison (2019)
Louise Fuller, PT, Committee Member
Josef Stehlik, MD, MPH, Committee Member
Megan Barrett, ISHLT Staff Liaison

INTERNATIONAL ENGAGEMENT COMMITTEE
Are Martin Holm, MD, PhD, Chair (2020)
Jeffrey Teuteberg, MD, ISHLT President (2020)
Stuart Sweet, MD, PhD, Board of Directors Liaison (2021)
Bart Meyns, MD, PhD, Committee Member (2019)
Ryan Tedford, MD, Committee Member (2020)
Mauricio Villavicencio, MD, Committee Member (2019)
Amanda Rowe, ISHLT Executive Director

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS) REGISTRY STEERING COMMITTEE
Daniel J. Goldstein, MD, Chair
Jennifer Cowger, MD, MS, Vice Chair for Data Studies
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Bart Meyns, MD, PhD, Committee Member
Takeshi Nakatani, MD, PhD, JMACS Representative
Steve Shaw, UK Representative
Rongbing Xie, DrPH, MPH, Biostatistician
Amanda Rowe, ISHLT Executive Director

INTERNATIONAL DCD REGISTRY STEERING COMMITTEE
Dirk Van Raemdonck, MD, PhD, Chair
Wida Cherikh, PhD, Biostatistician
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Marcelo Cypel, MD, Committee Member
Frank D’Ovidio, MD, PhD, Committee Member
Kumud Dhital, MD, PhD, Committee Member
Michiel Erasmus, MD, PhD, Committee Member
Allan Glanville, MBBS, MD, FRACP, Committee Member
Marshall Hertz, MD, Committee Member
Peter Hopkins, FRACP, Committee Member
Shaf Keshavjee, MD, FRCSC, Committee Member
Stephen Large, FRCS, Committee Member
Bronwyn Levey, RN, Grad Dip Clin Epi, Committee Member
Peter MacDonald, MD, PhD, Committee Member
INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY STEERING COMMITTEE

Anne Dipchand, MD, Chair (2019)
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Scott Auerbach, MD, Committee Member (2019)
Estela Azeka, MD, Committee Member (2019)
Aliessa Barnes, MD, Committee Member (2019)
Wida Cherikh, PhD, Biostatistician (2019)
Jennifer Conway, MD, Committee Member (2019)
Beth Kaufman, MD, Committee Member (2019)
Richard Kirk, FRCP, FRCPC, Committee Member (2019)
David Peng, MD, Committee Member (2019)
Philip Thrush, MD, Committee Member (2019)
Warren Zuckerman, MD, Committee Member (2019)

INTERNATIONAL THORACIC ORGAN TRANSPLANT REGISTRY STEERING COMMITTEE

Josef Stehlik, MD, MPH, Registry Medical Director, Committee Chair
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Daniel Chambers, MBBS, MRCP, FRACP, MD, Associate Medical Director-Adult Lung/Heart-Lung (2021)
Wida Cherikh, PhD, Biostatistician
Don Hayes, MD, Associate Medical Director-Pediatric Lung
Kiran Khush, MD, Associate Medical Director-Adult Heart (2021)
Bronwyn Levey, RN, Grad Dip Clin Ep, Associate Medical Director-Outcomes (September 2019)
Bruno Meiser, MD, OEO Relations (September 2019)
Joseph Rossano, MD, Associate Medical Director-Pediatric Heart (2019)
Andreas Zuckermann, MD

REGISTRIES AND DATABASES COMMITTEE

Josef Stehlik, MD, MPH, Chair (2022)
Daniel J. Goldstein, MD, IMACS Registry Steering Committee Chair
Anne Dipchand, MD, International Pediatric Heart Failure Registry Steering Committee Chair (2019)
Dirk Van Raemdonck, MD, PhD, International DCD Registry Steering Committee Chair
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Wida Cherikh, PhD, Biostatistician
Rongbing Xie, DrPH, MPH, Biostatistician
Roger Yusen, MD, MPH, At Large Member

STANDARDS AND GUIDELINES COMMITTEE

Peter Hopkins, FRACP, Chair (2021)
David Taylor, MD, Past Chair (2019)
Manreet Kanwar, MD, Board of Directors Liaison (2019)
Agnieszka Ciarka, MD, Junior Faculty and Trainees Council Workforce Leader (2020)
Kevin Daly, MD, Pediatric Thoracic Transplantation and Heart Failure Council Workforce Leader (2019)
Elie Fadel, MD, Chronic Thromboembolic Pulmonary Hypertension Council Workforce Leader (2021)
Steven Kindel, MD, Pediatric Thoracic Transplantation and Heart Failure Council Workforce Leader (2019)
Hrishikesh Kulkarni, MD, Basic Science and Translational Research Council Workforce Leader (2021)
Colleen J. LaBuhn, RN, MSN, Nursing, Health Sciences and Allied Health Council Workforce Leader (2020)
Erika Lease, MD, Pulmonary Transplantation Council Workforce Leader (2020)
Sern Lim, MD, Heart Failure and Transplantation Council Workforce Leader (2021)
Robert Page, PharmD, MS, Pharmacy and Pharmacology Council Workforce Leader (2019)
Stephanie Pouch, MD, Infectious Diseases Council Workforce Leader (2021)
Anja Roden, MD, Pathology Council Workforce Leader (2019)
Oksana Shlobin, MD, Pulmonary Hypertension Council Workforce Leader (2020)
Megan Barrett, ISHLT Staff Liaison
PULSE NEWSLETTER EDITORIAL STAFF

Editor
David Weill, MD

Board Members
Paul Corris, MB, FRCP
Mary Amanda Dew, PhD
Matt Hartwig, MD
Kiran Khush, MD
Deborah Levine, MD
David McGiffin, MB, BS, FRACS
Kapil Patel, MD
Amparo Sole, MD, PhD
Jussi Tikkanen, MD

Associate Editors
Natasha Altman, MD
Shahnawaz Amdani, MD
Are Martin Holm, MD, PhD
Angela Logan, PharmD
Marco Masetti, MD
Joshua Mooney, MD
Mike Mulligan, MD
David Nelson, MD
Stephanie Pouch, MD
Reinaldo Rampolla, MD
Nirmal Sharma, MD

ISHLT Staff
Megan Barrett
Nancy Mays
Basic Science and Translational Research (BSTR)
Edward Cantu, MD, Chair (2021)
Joshua Diamond, MD, Vice Chair (2023)
Stijn Verleden, PhD, Vice Chair Elect (2025)
Sonja Schrepfer, MD, PhD, Past Chair (2019)
Dirk Van Raemdonck, MD, PhD, Board of Directors Liaison (2019)
Doris Taylor, PhD, FAHA, FACC, Senior Advisor (2019)
Jeffrey Platt, MD, Senior Advisor (2019)
Hrishikesh Kulkarni, MD, Standards and Guidelines Workforce Leader (2021)
Pradeep Mammen, MD, FACC, FAHA, HFTX Council Liaison (2020)
Aric Gregson, MD, ID Council Liaison (2020)
Simon Pecha, MD, JFTC Liaison (2019)
J. Michael DiMaio, MD, MCS Council Liaison (2020)
Monica Horn, RN, NHSAH Council Liaison (2020)
Annalisa Angelini, MD, PATH Council Liaison (2020)
Aaron Waxman, MD, PhD, PH Council Liaison (2020)
Pablo Sanchez, MD, PULMTX Council Liaison (2020)

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
William Auger, MD, Chair (2021)
Marc De Perrot, MD, Vice Chair (2023)
Isabelle Opitz, MD, FEBTS, Vice Chair Elect (2025)
Raymond Benza, MD, Board of Directors Liaison (2019)
Irene Lang, MD, Council Advisor (2019)
Michael Madani, MD, Education Workforce Leader (2021)
Elie Fadel, MD, Standards and Guidelines Workforce Leader (2021)
Anastasia Bykova, NP, NHSAH Council Liaison (2021)

Heart Failure and Transplantation (HFTX)
Jignesh Patel, MD, PhD, Chair (2022)
Marta Farrero Torres, MD, PhD, Vice Chair (2024)
Michael Pham, MD, MPH, Past Chair (2020)
Howard Eisen, MD, Board of Directors Liaison (2019)
Daniel Kim, MD, Education Workforce Leader (2020)
Sern Lim, MD, Standards and Guidelines Workforce Leader (2021)
Pradeep Mammen, MD, FACC, FAHA, BSTR Council Liaison (2020)
Natasha Altman, MD, JFTC Liaison (2020)
Jamila Kremer, MD, JFTC Liaison (2021)
Edith Boyes, MSN, FNP-BC, CHFN, NHSAH Council Liaison (2020)

Infectious Diseases (ID)
Me-Linh Luong, MD, Chair (2022)
Saima Aslam, MD, MS, Vice Chair (2024)
Paolo Grossi, MD, PhD, Past Chair (2020)
Goran Dellgren, MD, PhD, Board of Directors Liaison (2019)
Joanna Scheneman, MD, PhD, Education Workforce Leader (2020)
Stephanie Pouch, MD, Standards and Guidelines Workforce Leader (2021)
Aric Gregson, MD, BSTR Council Liaison (2020)
Jonathan Hand, MD, JFTC Liaison (2021)

Junior Faculty and Trainees (JFTC)
Evan Kransdorf, MD, PhD, Chair (2022)
Martin Schweiger, MD, Vice Chair (2024)
Keyur Shah, MD, Past Chair (2020)
Andrew Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Marco Masetti, MD, PhD, Education Workforce Leader (2021)
Agnieszka Ciarka, MD, Standards and Guidelines Workforce Leader (2020)
Simon Pecha, MD, BSTR Council Liaison (2019)
Natasha Altman, MD, HFTX Council Liaison (2020)
Jamila Kremer, MD, HFTX Council Liaison (2021)
Jonathan Hand, MD, ID Council Liaison (2021)
Jaime Hernandez Montfort, MD, MPH, MCS Council Liaison (2020)
Jaime-Juergen Eulert-Grehn, MD, MCS Council Liaison (2021)
Colleen McIlvennan, DNP, ANP, NHSAH Council Liaison (2019)
Ann Punnoose, MD, PEDTXHF Council Liaison (2020)
Kyle Hope, MD, PEDTXHF Council Liaison (2021)
Marco Caccamo, DO, PH Council Liaison (2019)
Joshua Mooney, MD, PULMTX Council Liaison (2020)

Mechanical Circulatory Support (MCS)
   Nir Uriel, MD, Chair (2021)
   Simon Maltais, MD, PhD, Vice Chair (2023)
   Diyar Saeed, MD, PhD, Vice Chair Elect (2025)
   Stephan Schueler, MD, PhD, FRCS, Past Chair (2019)
   Jennifer Cowger, MD, MS, Board of Directors Liaison (2019)
   Diyar Saeed, MD, PhD, Education Workforce Leader (2019)
   Dawn Christensen, MS, CRNP, VAD Coordinator Liaison (2019)
   J. Michael DiMaio, MD, BSTR Council Liaison (2020)
   Jaime-Juergen Eulert-Grehn, MD, JFTC Liaison (2021)
   Jennifer Beckman, ARNP, NHSAH Council Liaison (2019)
   Angela Lorts, MD, PEDTXHF Council Liaison (2019)

Nursing, Health Sciences and Allied Health (NHSAH)
   Pamela Combs, PhD, RN, Chair (2022)
   Caron Burch, RN, MSA, FNP, CCTC, Vice Chair (2024)
   Kevin Carney, MSN, CRNP, CCTC, Past Chair (2020)
   Kathleen Grady, PhD, RN, FAAN, Board of Directors Liaison (2019)
   Angela Velleca, RN, BSN, CCTC, Education Workforce Leader (2021)
   Louise Fuller, PT, Grants and Awards Committee Workforce Leader
   Colleen LaBuhn, RN, MSN, Standards and Guidelines Workforce Leader (2020)
   Jesus Casida, PhD, Research Workforce Leader (2022)
   Monica Horn, RN, BSTR Council Liaison (2020)
   Anastasia Bykova, NP, CTEPH Council Liaison (2021)
   Edith Boyes, MSN, FNP-BC, CHFN, HFTX Council Liaison (2020)
   Colleen McIlvennan, DNP, ANP, JFTC Liaison (2019)
   Jennifer Beckman, ARNP, MCS Council Liaison (2019)
   Jodie Lantz, CNS, PEDTXHF Council Liaison (2020)
   Rachel Crackett, MSc, PH Council Liaison (2019)
   Nicole Davis, BSN, MPH, PULMTX Council Liaison (2020)

Pathology (PATH)
   Robert Padera, MD, PhD, Chair (2021)
   Fiorella Calabrese, MD, Vice Chair (2023)
   Anja Roden, MD, Vice Chair Elect (2025)
   Martin Goddard, FRCS, MRCPa, Board of Directors Liaison (2019)
   Anja Roden, MD, Standards and Guidelines Workforce Leader (2019)

Pediatric Thoracic Transplantation and Heart Failure (PEDTXHF)
   Brian Feingold, MD, MS, Chair (2021)
   Carol Conrad, MD, Vice Chair (2023)
   Simon Urschel, MD, Vice Chair Elect (2025)
   Tajinder Singh, MD, MSc, Past Chair (2019)
   Kevin Chan, MD, Board of Directors Liaison (2019)
   Beth Kaufman, MD, Education Workforce Leader (2020)
   Steven Kindel, MD, Standards and Guidelines Workforce Leader (2019)
   Kevin Daly, MD, Standards and Guidelines Workforce Leader (2019)
   Ashwin Lal, MD, Pediatric Heart Failure Workforce Leader (2021)
   Marc Schecter, MD, Pediatric Lung Failure Workforce Leader (2020)
   Ann Punnoose, MD, JFTC Liaison (2020)
   Kyle Hope, MD, JFTC Liaison (2021)
   Angela Lorts, MD, MCS Council Liaison (2020)
   Jodie Lantz, CNS, NHSAH Council Liaison (2020)
Pharmacy and Pharmacology (PHARM)
    Adam Cochrane, PharmD, MPH, Chair (2021)
    Haifa Lyster, MSc, Vice Chair (2023)
    Edward Horn, PharmD, Vice Chair Elect (2025)
    Walter Uber, PharmD, Past Chair (2019)
    Michael Shullo, PharmD, Board of Directors Liaison (2019)
    Jennifer Eshelman, PharmD, Education Workforce Leader (2020)
    Robert Page, PharmD, MS, Standards and Guidelines Workforce Leader (2019)

Pulmonary Hypertension (PH)
    Jean-Luc Vachiery, MD, Chair (2022)
    Ioana Preston, MD, Vice Chair (2024)
    Dana McGlothlin, MD, Past Chair (2020)
    Teresa De Marco, MD, FACC, Board of Directors Liaison (2019)
    Colin Church, MD, Education Workforce Leader (2021)
    Oksana Shlobin, MD, Standards and Guidelines Workforce Leader (2020)
    Aaron Waxman, MD, PhD, BSTR Council Liaison (2020)
    Marco Caccamo, DO, JFTC Liaison (2019)

Pulmonary Transplantation (PULMTX)
    Ramsey Hachem, MD, Chair (2022)
    Glen Westall, FRACP, PhD, Vice Chair (2024)
    Cynthia Gries, MD, MSc, Past Chair (2020)
    Jason Christie, MD, Board of Directors Liaison (2019)
    Daniel Dilling, MD, Education Workforce Leader (2021)
    Erika Lease, MD, Standards and Guidelines Workforce Leader (2020)
    Jonathan Singer, MD, Quality of Life Workforce Leader
    Pablo Sanchez, MD, BSTR Council Liaison (2020)
    Joshua Mooney, MD, JFTC Liaison (2019)
    Nicole Davis, BSN, MPH, NHSAH Council Liaison (2020)
PAST PRESIDENTS

1981-1982 Michael Hess, MD
1982-1984 Jack Copeland, MD
1984-1986 Terence English, FRCS
1986-1988 Stuart Jamieson, MD
1988-1990 Bruno Reichart, MD
1990-1991 Margaret Billingham, MD
1991-1992 Christian Cabrol, MD
1992-1993 John O’Connell, MD
1993-1994 Eric Rose, MD
1994-1995 John Wallwork, FRCS
1995-1996 Sharon Hunt, MD
1996-1997 William Baumgartner, MD
1997-1998 Leslie Miller, MD
1998-1999 Alan Menkis, MD, FRCS(C)
1999-2000 Robert L. Kormos, MD
2000-2001 Anne Keogh, MBBS, MD
2001-2002 James B. Young, MD
2002-2003 Stephan Schueler, MD
2003-2004 Jon Kobashigawa, MD
2004-2005 Alec Patterson, MD
2005-2006 Mark L. Barr, MD
2006-2007 Robert C. Robbins, MD
2007-2008 Paul A. Corris, MB FRCP
2008-2009 Mandeep R. Mehra, MD
2009-2010 James K. Kirklin, MD
2010-2011 John Dark, MB, FRCS
2011-2012 Lori J. West, MD, DPhil
2012-2013 David O. Taylor, MD
2013-2014 Allan R. Glanville, MBBS, MD, FRACP
2014-2015 Hermann Reichenspurner, MD, PhD
2015-2016 Duane Davis, MD, MBA
2016-2017 Maryl Johnson, MD
2017-2018 Andrew Fisher, FRCP, PhD
<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Program Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981</td>
<td>San Francisco, CA</td>
<td>Edward B. Stinson, MD and Michael L. Hess, MD</td>
</tr>
<tr>
<td>1982</td>
<td>Phoenix, AZ</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1983</td>
<td>New Orleans, LA</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1984</td>
<td>New York, NY</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1985</td>
<td>Anaheim, CA</td>
<td>Bartley Griffith, MD</td>
</tr>
<tr>
<td>1986</td>
<td>New York, NY</td>
<td>Terence A. H. English</td>
</tr>
<tr>
<td>1987</td>
<td>New Orleans, LA</td>
<td>John C. Baldwin, MD</td>
</tr>
<tr>
<td>1988</td>
<td>Los Angeles, CA</td>
<td>John C. Baldwin, MD</td>
</tr>
<tr>
<td>1989</td>
<td>Munich, Germany</td>
<td>Joel D. Cooper, MD</td>
</tr>
<tr>
<td>1990</td>
<td>San Diego, CA</td>
<td>D. Glenn Pennington, MD</td>
</tr>
<tr>
<td>1991</td>
<td>Paris, France</td>
<td>John B. O’Connell, MD</td>
</tr>
<tr>
<td>1992</td>
<td>San Diego, CA</td>
<td>Eric A. Rose, MD</td>
</tr>
<tr>
<td>1993</td>
<td>Boca Raton, FL</td>
<td>Maria Rosa Costanzo, MD</td>
</tr>
<tr>
<td>1994</td>
<td>Venice, Italy</td>
<td>John Wallwork, MBChB, FRCS</td>
</tr>
<tr>
<td>1995</td>
<td>San Francisco, CA</td>
<td>Leslie W. Miller, MD</td>
</tr>
<tr>
<td>1996</td>
<td>New York, NY</td>
<td>William A. Baumgartner, MD</td>
</tr>
<tr>
<td>1997</td>
<td>London, England</td>
<td>Stephan Schueler, MD</td>
</tr>
<tr>
<td>1998</td>
<td>Chicago, IL</td>
<td>James B. Young, MD</td>
</tr>
<tr>
<td>1999</td>
<td>San Francisco, CA</td>
<td>Mark L. Barr, MD</td>
</tr>
<tr>
<td>2000</td>
<td>Osaka, Japan</td>
<td>Jon Kobashigawa, MD</td>
</tr>
<tr>
<td>2001</td>
<td>Vancouver, Canada</td>
<td>David O. Taylor, MD</td>
</tr>
<tr>
<td>2002</td>
<td>Washington, DC</td>
<td>Robert C. Robbins, MD</td>
</tr>
<tr>
<td>2003</td>
<td>Vienna, Austria</td>
<td>Bruce R. Rosengard, MD</td>
</tr>
<tr>
<td>2004</td>
<td>San Francisco, CA</td>
<td>Mandeep R. Mehra, MD</td>
</tr>
<tr>
<td>2005</td>
<td>Philadelphia, PA</td>
<td>Shaf Keshavjee, MD</td>
</tr>
<tr>
<td>2006</td>
<td>Madrid, Spain</td>
<td>John Dark, MB, FRCS</td>
</tr>
<tr>
<td>2007</td>
<td>San Francisco, CA</td>
<td>Duane Davis, MD</td>
</tr>
<tr>
<td>2008</td>
<td>Boston, MA</td>
<td>Lori J. West, MD, DPhil</td>
</tr>
<tr>
<td>2009</td>
<td>Paris, France</td>
<td>Randall C. Starling, MD, MPH</td>
</tr>
<tr>
<td>2010</td>
<td>Chicago, IL</td>
<td>Hermann Reichenspurner, MD, PhD</td>
</tr>
<tr>
<td>2011</td>
<td>San Diego, CA</td>
<td>Richard N. Pierson, III, MD</td>
</tr>
<tr>
<td>2012</td>
<td>Prague, Czech Rep.</td>
<td>Stuart C. Sweet, MD, PhD</td>
</tr>
<tr>
<td>2013</td>
<td>Montreal, Canada</td>
<td>Allan R. Glanville, MBBS, MD, FRACP</td>
</tr>
<tr>
<td>2014</td>
<td>San Diego, CA</td>
<td>Jason D. Christie, MD</td>
</tr>
<tr>
<td>2015</td>
<td>Nice, France</td>
<td>Andreas Zuckermann, MD</td>
</tr>
<tr>
<td>2016</td>
<td>Washington, DC</td>
<td>Andrew J. Fisher, FRCP, PhD</td>
</tr>
<tr>
<td>2017</td>
<td>San Diego, CA</td>
<td>Jeffrey J. Teuteberg, MD</td>
</tr>
<tr>
<td>2018</td>
<td>Nice, France</td>
<td>Christian Benden, MD, FCCP</td>
</tr>
</tbody>
</table>
Past Registry Medical Directors
1987-1993 Michael P. Kaye, MD
1993-2001 Jeffrey D. Hosenpud, MD
2001-2012 Marshall I. Hertz, MD
2012-Present Josef Stehlik, MD, PhD

Past Journal of Heart and Lung Transplantation Editors
1981-1985 Jacques G. Losman, MD
1986-1994 Michael P. Kaye, MD
1995-1999 Maria Rosa Costanzo, MD
2000-2009 James K. Kirklin, MD

Past Links Newsletter Editors
2008-2011 David S. Feldman, MD, PhD
2011-2018 Vincent G. Valentine, MD
ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS:

**ISHLT Lifetime Achievement Award**
- 1996 Norman Shumway, MD
- 1999 Keith Reemtsma, MD
- 2004 Sir Magdi Yacoub, MD
- 2010 Margaret Billingham, MD
- 2012 Sharon Hunt, MD
- 2014 Sir Terence English, KBE, FRCS
- 2016 Adrian Kantrowitz, MD
  - Jean Kantrowitz, MPH
- 2018 O. Howard Frazier, MD
- 2019 John Wallwork, FRCS

**ISHLT Lifetime Service Award**
- 1996 Michael P. Kaye, MD
- 1997 Jacques G. Losman, MD

**ISHLT Pioneer Award**
- 2000 Christiaan Barnard, MD
  - Joel D. Cooper, MD
  - Norman E. Shumway, MD
- 2002 Michael DeBakey, MD
  - Bruce A. Reitz, MD
- 2006 Leonard L. Bailey, MD
- 2008 Richard E. Lower, MD
- 2009 Christian E. A. Cabrol, MD
- 2011 Elizabeth Hammond, MD
- 2013 Jack G. Copeland, MD
- 2015 Bruno Reichart, MD
- 2016 Sir Roy Calne, FRCP, FRCS, FRS
- 2017 Stuart Jamieson, MB, FRCS

EMERITUS MEMBERSHIP
Margaret D. Allen, MD
William Baumgartner, MD
Christian Cabrol, MD
Jack Copeland, MD
Sir Terence English, KBE, FRCS
Albert J. Guerraty, MD
Jeffrey Hosenpud, MD
Sharon A. Hunt, MD
Carl V. Leier, MD
Bruno Reichart, MD
Marlene Rose, PhD
John Wallwork, FRCS
Elaine M. Winkel, MD
Prof. Magdi Yacoub, MD

GRANTS AND SCHOLARSHIPS:

**GRANT AWARDS:**

**ISHLT Norman E. Shumway Career Development Award**
- 2000 Gordon D. Wu, MD (supported by Roche)
- 2002 Anthony Azakie, MD (supported by Roche)
- 2004 Allan M. Ramirez, MD (supported by Novartis Pharma)
- 2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
- 2008 Glen Westall, MD, PhD (supported by Roche)
2010  Sonja Schrepfer, MD, PhD (supported by Astellas)
2012  Tereza Martinu, MD, PhD
2014  Keshava Rajagopal, MD, PhD
2015  Xingan Wang, MD, PhD
2016  Stephen Juvet, MD, PhD, FRCPC
2017  Nicole Valenzuela, PhD, D(ABHI) (funded by Enduring Hearts)
2018  David Schibilsky, MD
2019  Julien Guihaire, MD, PhD

**ISHLT Joel D. Cooper Career Development Award**
2017  Keki Blasara, MD
2018  Brian Wong, PhD
2019  Daniel Calabrese, MD

**ISHLT/Enduring Hearts Transplant Longevity Research Award**
2019  Kiran Khush, MD  
Shelley Miyamoto, MD

**ISHLT Nursing Research Grant Award**
1997  Eileen Collins, RN, PhD
1998  Katherine St. Clair, RN, MSN
1999  Jeanne Salyer, PhD
2000  Nancy M. Albert, MSN, RN
2001  Lynn Doering, RN, DNSc
2002  Annette J. De Vito Dabbs, RN, MN, PhD
2003  Diane H. Leloudis, RN, MSN  
Janet E. Madill, PhD
2004  Deidre E. Logan, PhD
2005  Annemarie F. Kaan, MCN
2006  Thierry Troosters, PhD
2007  Mi-Kyung Song, PhD
2008  Stacey M. Pollock-BarZiv, PhD
2009  Jane MacIver, RN, MSc
2010  Heike Spaderna, PhD  
Gerdi Weidner, PhD
2011  Christiane Kugler, PhD (supported by CSL Behring)  
Hilde Bollen, RN
2012  Lut Berben, PhD, RN (supported by CSL Behring)  
Connie White-Williams, PhD, RN, FAAN
2013  Jo Wray, PhD and Jane Haines, DNP, RN, CMSRN
2014  Lea Ann Matura, PhD, RN
2015  JiYeon Choi, PhD, RN
2016  Mohammad AlRawashdeh, BSN, MSN
2016  Melissa Cousino, PhD (Jointly Funded by Enduring Hearts)
2017  Samantha Anthony, PhD, MSW
2018  Martha Abshire, PhD, RN  
Mary Amanda Dew, PhD
2019  Benjamin Tarrant, B.Physio  
Brittany Koons, PhD, RN

**ISHLT Research Fellowship Award**
1995  Frances L. Johnson, MD (supported by Ortho-Biotech)
1996  Tuija S. Ikonen, MD (supported by Roche)  
Andrew F. Pierre, MD (supported by Ortho-Biotech)
1997  Jonathan Chen, MD (supported by Roche)  
Alyssa M. Krasinskas, MD (supported by Astellas)  
Owen T. Lawrence, MD (supported by Ortho-Biotech)  
Anne K. Raisanen-Sokolowski, MD (supported by Roche)
1998  Kelly S.A. Blair, MD (supported by Roche)  
A.M. El Gamel, MD (supported by Roche)  
Christine L. Lau, MD (supported by Wyeth-Ayerst)  
Scott D. Ross, MD
<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Margaret L. Schwarze, MD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>George Juang, MD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Sivasai Krovvidi, PhD (supported by Roche)</td>
</tr>
<tr>
<td></td>
<td>Satoshi Saito, MD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Donald Wong, PhD (supported by Roche)</td>
</tr>
<tr>
<td>2000</td>
<td>Richard S. Lee, MD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Christopher H. Wigfield, FRCS (supported by Roche)</td>
</tr>
<tr>
<td>2001</td>
<td>Arnar Geirsson, MD (supported by Roche)</td>
</tr>
<tr>
<td></td>
<td>Matteo Vatta, PhD (supported by Roche)</td>
</tr>
<tr>
<td>2002</td>
<td>Ruediger Hoebelt, MD (supported by Roche)</td>
</tr>
<tr>
<td>2003</td>
<td>Ewout J. van den Bos, MD (supported by Astellas)</td>
</tr>
<tr>
<td></td>
<td>Felix Fernandez, MD (supported by Roche)</td>
</tr>
<tr>
<td>2004</td>
<td>Christian A. Gleissner, MD (supported by Astellas)</td>
</tr>
<tr>
<td></td>
<td>Tsuyoshi Shoji, MD, PhD (supported by Actelion)</td>
</tr>
<tr>
<td></td>
<td>Kendra N. Taylor, PhD (supported by Roche)</td>
</tr>
<tr>
<td></td>
<td>Monica Zwierzchonieuska, MD (supported by XDx)</td>
</tr>
<tr>
<td>2005</td>
<td>Ryan C. Fields, MD (supported by Chiron)</td>
</tr>
<tr>
<td></td>
<td>Arne Neyrinck, MD (supported by Astellas)</td>
</tr>
<tr>
<td></td>
<td>Ahmad Saad, MD (supported by Roche)</td>
</tr>
<tr>
<td>2006</td>
<td>Rachel L. Anderson, MBBS (supported by Roche)</td>
</tr>
<tr>
<td></td>
<td>Zhaohui Li, PhD (supported by Transmedics)</td>
</tr>
<tr>
<td></td>
<td>Heather E. Merry, MD (supported by Encysive)</td>
</tr>
<tr>
<td></td>
<td>Edward N. Seung, PhD (supported by XDx)</td>
</tr>
<tr>
<td></td>
<td>Matthew J. Weiss, MD (supported by Novartis)</td>
</tr>
<tr>
<td>2007</td>
<td>J. Raymond Fitzpatrick, III, MD (supported by Encysive)</td>
</tr>
<tr>
<td></td>
<td>Howard J. Huang, MD (supported by Transmedics)</td>
</tr>
<tr>
<td></td>
<td>Mylyganam Jeyakanthan, MD (supported by XDx)</td>
</tr>
<tr>
<td></td>
<td>Timothy M. Millington, MD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Satish N. Nadig, MD (supported by Roche)</td>
</tr>
<tr>
<td></td>
<td>Takeshi Oyaizu, MD, PhD (supported by Actelion)</td>
</tr>
<tr>
<td></td>
<td>Sonja Schrepfer, MD (supported by Astellas)</td>
</tr>
<tr>
<td>2008</td>
<td>Jonathan Choy, PhD (supported by XDx)</td>
</tr>
<tr>
<td></td>
<td>Satoshi Itoh, MD (supported by Transmedics)</td>
</tr>
<tr>
<td></td>
<td>Tereza Martinu, MD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Deepti Saini, PhD (supported by Gilead)</td>
</tr>
<tr>
<td></td>
<td>Atsushi Shiozaki, MD, PhD (supported by Astellas)</td>
</tr>
<tr>
<td></td>
<td>Seiichiro Sugimoto, MD, PhD (supported by Roche)</td>
</tr>
<tr>
<td>2009</td>
<td>Hua Shen, MD, PhD (supported by Astellas)</td>
</tr>
<tr>
<td></td>
<td>Tobias Deuse, MD, PhD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Masahiro Miyajima, MD, PhD (supported by XDx)</td>
</tr>
<tr>
<td></td>
<td>Shin Hirayama, MD, PhD (supported by Gilead)</td>
</tr>
<tr>
<td>2010</td>
<td>Esme Dijke, PhD (supported by Novartis)</td>
</tr>
<tr>
<td></td>
<td>Smita Sihag, MD (supported by Genentech)</td>
</tr>
<tr>
<td></td>
<td>Sumiharu Yamamoto, MD (supported by Gilead)</td>
</tr>
<tr>
<td></td>
<td>Khurram Shahzad, MD (supported by United Therapeutics)</td>
</tr>
<tr>
<td></td>
<td>Nina Pilat, MSc, PhD (supported by XDx)</td>
</tr>
<tr>
<td>2011</td>
<td>Alejandro Bribiesco, MD (supported by Astellas)</td>
</tr>
<tr>
<td></td>
<td>Alexey Dashkevich, MD (supported by XDx)</td>
</tr>
<tr>
<td></td>
<td>Patricia E. de Almeida, DVM, MS, PhD</td>
</tr>
<tr>
<td></td>
<td>Tiago Machuca, MD, PhD</td>
</tr>
<tr>
<td>2012</td>
<td>Stephen C. Juvet, MD, FRCPCH</td>
</tr>
<tr>
<td></td>
<td>Maria Lucia L. Madariga, MD</td>
</tr>
<tr>
<td></td>
<td>Jessica H. Spahn, PhD</td>
</tr>
<tr>
<td></td>
<td>Konstantinos Malliaras, PhD</td>
</tr>
<tr>
<td>2013</td>
<td>Nikolaos Diakos, MD</td>
</tr>
<tr>
<td></td>
<td>Raymond Givens, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Pablo Sanchez, MD, PhD</td>
</tr>
<tr>
<td>2014</td>
<td>Charles Evans, MD</td>
</tr>
<tr>
<td></td>
<td>Christine Lin, MD</td>
</tr>
<tr>
<td></td>
<td>Stijn Verleden, PhD</td>
</tr>
<tr>
<td>2015</td>
<td>Jonathan Merola, MD</td>
</tr>
<tr>
<td>2016</td>
<td>Hsi-Min Hsaio, PhD</td>
</tr>
</tbody>
</table>
Nikolas Skartsis, MD, PhD
Corey Tabit, MD, MBA, MPH
2017 Ramiro Fernandez, MD
2018 Ei Miyamoto, MD
2019 Maria-Nieves Sanz, PhD

**ISHLT Transplant Registry Early Career Award** (formerly Junior Faculty Award)
2007 Beth D. Kaufman, MD
2008 Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
2010 Jennifer Conway, MD, FRCPC
Kiran K. Khush, MD, MAS
2011 Jose Nativi, MD
2012 Erin M. Lowery, MD
Omar E. Wever-Pinzon, MD
2013 Chesney Castleberry, MD
Eugene DePasquale, MD
Aaron Healy, MD
2014 Marian Urban, MD
Miranda Paraskeva, MBBS
Hrishikesh Kulkarni, MD
Agnieszka Ciarka, MD, PhD
2015 Livia Goldraich, MD, MSc
Deipanjan Nandi, MD, MSc
Evan Kransdorf, MD, PhD
Manreet Kanwar, MD
Natasha Loghmanpour, PhD
Alexander Bernhardt, MD
Jong-Chan Youn, MD, PhD
2016 Sai Bhagra, MBBS, MRCP
Forum Kandar, MD
Marco Masetti, MD, PhD
Joshua Mooney, MD
Edit Nagy, MD, PhD
2017 Laith Alshawabkeh, MD, MSc
Yuka Furuya, MD
Christian Heim, MD
Monique Robinson, MBBS, MRCP, DPhil
Lorenzo Zaffiri, MD, PhD
2018 Hakim Ali, MD
Daniel Reichart, MD and Liesa Castro, MD
Laneshia Tague, MD, MSCi
Amanda Vest, MBBS, MPH
Michael Yaoyao Yin, MD
2019 Lauren Cooper, MD, MHS
Michael Harhay, PhD, MPH, MS, M.Bioethics
In-Cheol Kim, MD
Anjan Tibrewala, MD
Jefferson Vieira, MD, MBA, PhD

**ISHLT/Bayer Pulmonary Hypertension Research Grant Award**
2014 Benjamin Freed, MD

**ISHLT/HeartWare Award for Translational Research in MCS**
2014 Leigh Reardon, MD
2015 Alexander Bernhardt, MD

**ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic**
2016 Todd Dardas, MD, MS
2017 Yasuhiro Shudo, MD, PhD
2018 Kavitha Muthiah, MBChB, PhD, FRACP
2019  Jasmin Hanke, MD  

**ISHLT Branislav Radovancevic Memorial Fellowship Grant (Supported by Thoratec)**  
2009  Sasa D. Borovic, MD  
2010  Iki Adachi, MD  
2012  Antigone Koliopoulou, MD  
2014  Masahiro Ono, MD, PhD  

**ISHLT International Traveling Scholarship Award**  
2011  Stephanie T. Yerkovich, PhD  
Sarah E. Gilpin, PhD  
Kimberly M. Derkatz, BNSc  
Jennifer Conway, MD, FRCP  
2012  Ramin E. Beygui, MD  
Kevin C. Carney, MSN  
Alexandre Souza Cauduro, MD  
Esme Dijke, PhD  
Ana Belen Mendez, MD  
David Schibilsky, MD  
Aleem Siddique, MBBS  
Amparo Solé, MD, PhD  
Manon Huibers, MSc  
Daniel R. Goldstein, MD  
Laveena Munshi, MD, FRCP  
Marco Masetti, MD  
Rochelle M. Gellatly, PScPharm, ACPR, PharmD  
2013  Alison Gareau, MSc  
Erin Schumer, MD, MS  
Bojan Vrtovec, MD, PhD  
Marsha Renikunta, PhD (student)  
Katie Morley, BA(Hons), RCN, MA  
Ali Yeginsu, MD  
Fabrizio Gandolfi, MD  
Marian Urban, MD  
Alexander Bernhardt, MD  
Victor Rossel, MD  
Mohammed Quader, MD  
2014  Marny Fedrigo, MD, PhD  
Zachary Kon, MD  
Evgenios Neofytou, MD  
Dong, Wang, MD  
Stephen Clark, DM, FRCS  
Caroline Patterson, BMBS, BMedSci, MRCP  
Tahaunty Pena, MD  
2015  Oisin O’Connell, MD, MRCPI  
Lucas Van Aelst, MD, PhD  
Arezu Aliabadi, MD  
Timothy Sladden, MBBS, BVSc  
Bao Tran, MD  
L G Saptharishi, MD, DM  
Allison Carroll, MD  
Akshay Pendyal, MD  
Stefania Paolillo, MD, PhD  
Soumitra Sinha Roy, MD  
2016  Lucas Van Aelst, MD, PhD  
Espeed Khoshin, MB ChB, MD, FRCS  
2017  Amit Adlakha, MBChB, MRCP, FFICM  
In-Cheol Kim, MD, PhD  
Sanjeev Kumar Khulbey, MBBS, MS, MCH  
Antonios Kourlouros, PhD, FRCS (CTh)  
Mrinalini Krishnan, MD  
Simon Pecha, MD
ISHLT Leach-Abramson-Imhoff Links Travel Awards

2012  Tereza Martinu, MD, Writer of the Year
      Stanley I. Martin, MD, First Runner-Up
      Luciano Potena, MD, PhD, First Runner-Up
      Nancy P. Blumenthal, CRNP, Honorable Mention
      Bronwyn J. Levvey, RN, Honorable Mention
      Javier Carbone, MD, PhD, Honorable Mention
      Stavros G. Drakos, MD, Honorable Mention
      Daniel F. Dilling, MD, Honorable Mention

2013  Michele Estabrook, MD, Writer of the Year
      Melanie Everitt, MD, First Runner-Up
      Christina Migliore, MD, First Runner-Up
      Veronica Franco, MD, Honorable Mention
      Manreet Kanwar, MD, Honorable Mention
      Luciano Potena, MD, PhD, Honorable Mention
      Macé Schuurmans, MD, Honorable Mention
      Jeffrey J. Teuteberg, MD, Honorable Mention

2014  Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year
      Amanda Ingemi, PharmD, First Runner-Up
      Simon Urschel, MD, Honorable Mention

2015  Pamela S. Combs, PhD, RN, Writer of the Year
      Manreet Kanwar, MD, First Runner-Up
      Oveimar De la Cruz, MD, Honorable Mention
      Heather T. Henderson, MD, Honorable Mention
      Simon Urschel, MD, Honorable Mention
      Erin Wells, RN, BSN, CPN, Honorable Mention

2016  Kyle Dawson, PharmD, MBA, BCPS, Writer of the Year
      Adam Cochrane, PharmD, BCPS, First Runner-Up
      Christa Kirk, PharmD, First Runner-Up
      Angela Velleca, RN, BSN, CCTC, Honorable Mention
      Erin Wells, RN, BSN, CPN, Honorable Mention

2017  Quincy Young, PhD, RPsych, Writer of the Year
      Monica Horn, RN, First Runner-Up
      Melissa Cousino, PhD, Honorable Mention
      Erin Wells, RN, BSN, CPN, Honorable Mention

2018  Erin Wells, RN, BSN, Writer of the Year
      Martin Schweiger, MD, First Runner-Up
      Adam Cochrane, Honorable Mention
      Pamela S. Combs, Honorable Mention
      Kylie Dawson, PharmD, MBA, BCPS, Honorable Mention
      Joshua Mooney, MD, Honorable Mention

ABSTRACT AWARDS:

Philip K. Caves Award
1983    Robbin G. Cohen, MD
1984    Hermann Reichenspurner, MD
1985    Michael A. Breda, MD
1986  Stuart J. Knechtle, MD
1987  Wim Van Der Bij, MD
1988  Charles D. Fraser, Jr., MD
1989  A.M. Wood, MD
1990  Andres J. Duncan, MD
1991  A. Jiminez, MD
1992  David P. Kapelanski, MD
1993  David Marshman, MD
1994  Jobst Winter, MD
        Alain Chapelier, MD
1995  Elizabeth A. Davis, MD
1996  Moninder S. Bhabra, MD
1997  Simon D. Eiref, MD
1998  Carla C. Baan, MD
1999  Joerg Koglin, MD
2000  Michael P. Fischbein, MD
2001  Alexander S. Krupnick, MD
2002  Peter Blaha, MD
2003  Sigrid Sandner, MD
2004  M.D. Peterson, MD
2005  Sigrid Sandner, MD
        Frank D'Ovidio, MD
2006  Gregor Warnecke, MD
2007  Heather E. Merry, MD
2008  Satish N. Nadig, MD
2009  Howard Huang, MD
2010  Tobias Deuse, MD, PhD
2011  Ankit Bharat, MD
2012  Simo Syrjälä, MD
2013  Alexey Dashkevich, MD
2014  Jessica Spahn
2015  Simon Pecha, MD
2016  Corey E. Tabit, MD
2017  Stephen Chiu, MD
2018  Jane O, MD

**Nursing, Health Sciences and Allied Health Excellence in Research Award**

2005  Mary Amanda Dew, PhD
2006  Kathleen L. Grady, PhD, RN
2007  Christiane Kugler, PhD
2008  Annette DeVito Dabbs, RN, PhD
2009  Connie White-Williams, MSN
2010  Bronwyn Levvey, RN
2011  Samantha J. Anthony, PhD, MSW
2012  Kate Hayes, MPhysio (Cardio)
2013  Jane Haines, DNP, RN, CMSRN
2014  Louise Fuller, PT
2015  Catherine Murks, PhD, APN
2016  Fabienne Dobbels, MSc, PhD
2017  Maral Bakir, RN, PHN
2018  Tara E. Miller, FNP

**Early Career Scientist Award**

2017  Hsi-Min Hsiao, PhD
2018  Kenneth A. Sinclair, BSC(Hons), PhD

**Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award**

2011  Michelle M. Kittleson, MD, PhD
2012  Erin Albers, MD
2013  Mustafa Ahmed, MD
2014  Lauren Sacha
2015  Ankit Bharat, MD
2016  Yasufumi Goda, MD
2017  Robert Gottlieb, MD, PhD
2018  Tiffany K. Roberts, PhD

Branislav Radovancevic Memorial Best MCSD Paper Award (Supported by Thoratec)
2009  Nishant Shah, MD
2010  Jose N. Nativi, MD
2012  Arun Raghav Mahankali Sridhar, MD, MPH
2013  Claire Watkins, MD
2014  Jason O. Robertson, MD
ACCREDITATION INFORMATION / CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation Statement: The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: ISHLT designates this live activity for a maximum of 33 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity

Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement - Amedco LLC designates this live activity for a maximum of 33.00 contact hours for nurses and 26.25 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Transplant Coordinators
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation’s offering ISHLT 39th Annual Meeting & Scientific Sessions grants up to 33 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Provider Number: #907-00.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

Disclosure
Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Need
Because of the rapid advances in patient health care in general and advanced heart and lung disease management in particular, professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in the field. This meeting is designed to address their needs.

Educational Goals
The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and advanced heart and lung disease management and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience
The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in the care and treatment of patients with advanced heart or lung disease. The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.

Objectives
After attending the Annual Meeting participants should have improved competence and performance in the areas of:

1. The latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from advanced heart and lung disease.

3. Emerging technologies, medical advances, and the clinical applications of basic science models of advanced heart and lung disease management and prevention.

**Activity Designed to Change**
This activity is designed to change knowledge, competence, and performance.

**Learner Attributes**
Patient Care and Medical Knowledge.

**Documenting CME Credits**
The ISHLT provides CME certificates to those who have participated in an ISHLT educational activity. The ISHLT does not submit credits to regulating bodies or certifying organizations on behalf of the participant. It is the participant’s responsibility to submit proof of credits on his or her own behalf.

**Disclaimer**
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the ISHLT.
UNRESTRICTED EDUCATIONAL GRANTS

The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in support of the 39th Annual Meeting and Scientific Sessions:

Abbott
Actelion
Bayer
Medtronic
United Therapeutics

COMMERCIAL SUPPORT

The International Society for Heart and Lung Transplantation is grateful for the support provided by the following companies for the Society and all of its endeavors in 2019:

TIER 1
Medtronic

TIER 2
Abbott
Actelion
United Therapeutics

TIER 3
CareDx

TIER 4
One Lambda (Thermo Fisher)
Transmedics
XVIVO Perfusion

TIER 5
Bayer
Gilead
Paragonix Technologies
TAI Diagnostics
TandemLife | LivaNova
ANNUAL MEETING PROGRAM HIGHLIGHTS

Basic Science and Translational Research
This year’s fascinating basic science and translational research symposia are appealing to all ISHLT attendees. In Session 09: Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection, different biomarkers in diagnosing and monitoring thoracic graft rejection will be discussed, some of which are already in clinical use and others are investigational. Sunrise 07: Highways to Hell: Chronic Lung Allograft Dysfunction will bring exciting lectures about novel and interesting hypotheses involved in the pathophysiology of CLAD. In Session 72: Seeing the Light: Antibodies in Thoracic Transplantation, the aim is to acquire a deeper understanding of antibody-mediated mechanisms, treatments and potential downstream consequences of antibodies in transplantation. These sessions are innovating for both clinicians and researchers and will undoubtedly lead to novel insights.

Chronic Thromboembolic Pulmonary Hypertension
Interventional options for the treatment of CTEPH are expanding with BPA recently emerging as an option, in addition to PTE surgery. Yet, how can we compare the two therapies when there are differences in patient populations, procedures performed, and variability in reporting of risks and outcomes? Sunrise 13: A Fork in the Road: How Can We Compare Interventional Therapies in CTEPH? will address these issues and facilitate discussion on how we can move toward more uniform reporting of outcomes. The success of PTE has improved over the years due to better understanding of the pathophysiological mechanisms leading to major complications. This knowledge has translated into better ability to prevent them, recognize them early on and manage them more appropriately. Session 58: Resilience in the Face of Calamity: The Art of Preventing Pulmonary Thromboendarterectomy (PTE) Disasters will review specific complications related to PTE and discuss how to manage them to achieve a successful outcome.

Heart Failure and Transplantation
ISHLT2019 offers an exciting line-up of eight symposia that are of great interest to the contemporary advanced heart failure and transplant communities. Session 02: Future Shock: Great Debates in Cardiogenic Shock will feature three lively debates between leading clinicians on approaches to manage patients with cardiogenic shock, ranging from hemodynamic management to temporary mechanical circulatory support. Special heart failure populations require unique management approaches, and these will be highlighted in Session 40: Heart Failure in Adult Congenital Heart Disease: Unique Problems Need Unique Solutions, which will discuss controversial topics such as the timing of transplantation in ACHD patients, strategies for combined heart-liver transplantation, and use of mechanical circulatory support. The management of patients with restrictive cardiomyopathies will be highlighted in the cutting-edge Sunrise 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies. Novel and sophisticated imaging techniques have been developed to better characterize and manage complex heart failure patients, and these will be explored in a joint symposium between the ISHLT and Society of Cardiac Magnetic Resonance (SCMR) entitled Session 52: Joint ISHLT/SCMR Symposium: Cardiac MRI and the World of Heart Failure: When Two Disciplines Harmonize. Ultimately, many of these patients will require transplantation, but the donor organ shortage continues to restrict heart transplant activity worldwide. Innovative strategies to increase donor utilization, including use of marginal donors, hepatitis C positive donors, and donors from distant locations will be explored in Session 65: All Talk, No Action? New Strategies and Best Practices to Maximize Donor Heart Utilization, which will culminate in an animated debate about the pros and cons of Opt Out vs Opt In policies for organ donation. Clinicians actively involved in the care of heart transplant recipients will benefit from cutting-edge talks on strategies to personalize and minimize immunosuppression in Sunrise 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation, while experts in coronary imaging and pharmacology will discuss the diagnosis, prevention, and treatment of cardiac allograft vasculopathy in Session 75: Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter, which will end with a captivating debate on the role of revascularization and defibrillators for CAV treatment. Provocative approaches to replace heart transplantation will be presented by outstanding international leaders in the fields of cardiac 3D printing, xenotransplantation, and stem cell therapy in Sunrise 08: Print, Replace, or Innovate: Alternative Strategies to Cardiac Transplantation. Finally, numerous abstract presentations throughout the meeting will present the results of innovative, on-going research in the fields of advanced heart failure and cardiac transplantation.

Infectious Diseases
Come join in the fun at ISHLT2019. In Session 60: Joint ISHLT/ABTO Symposium: Combining Experiences to Enhance Thoracic Organ Transplantation Worldwide, we are partnering with the Associação Brasileira de Transplante de Órgãos (ABTO) to highlight the similarities and differences in transplantation between South America and other areas across the globe. Talks on tuberculosis and Chagas’ disease will be delivered by highly experienced experts. This will be of interest for ID and transplant physicians alike, especially in this age of global travel. Infections in MCS device recipients will be looked at from a new angle in Sunrise 09: MCS Infections: New Twists in an Old Saga, with an update on the consequences of MCS device infection and a very interesting talk on the role of biofilms in MCS device infections. In the Magic Kingdom of the Bronchoscopy, experts will discuss the evidence related to the interpretation and treatment (or not!) of positive culture results from surveillance bronchoscopies post-lung transplantation. To round out the fun on this ID rollercoaster, we will have an update on fungal infections in Session 46: FUN and Games with FUNgal Infections in Lung Transplantation. We will hear cutting edge talks on diagnosis, drug-drug interactions, therapeutic drug monitoring, inhalational medications and in the increasing spectre of antifungal resistance.

Lung Transplantation
Six pulmonary-focused symposia will present scientific data and expert opinions of high clinical relevance to everyone who works in the field of lung failure and lung transplantation. The ongoing scarcity of organs available for transplant remains a challenge in lung transplantation. Session 61: Making Them Count: Enhancing Donor Utilization aims to review strategies to optimize organ utilization by improving donor management and using organs from DCD donors, Hepatitis C donors and older donors. Session 76: Location, Location and Allocation: World Wide Application of Broader Sharing in Lung Transplant covers an overview of the differences in international lung allocation practices, comparing the USA, European, Canadian and Australian experiences. Session 32: Ex-Vivo Lung Perfusion (EVLP) in 2019 – From Research to Implementation looks at current practices and different models used as well as the ongoing clinical trials with EVLP and the rationale for using portable EVLP. Sunrise 02: Immunobiology of the Older Lung Transplant Recipient will address why there are significant differences in this cohort of patients who are more at risk of infection and malignancy but experience decreased rates of rejection. Sunrise 15: Lung Transplant Candidate Selection: Challenging Cases addresses previous contraindications which are now potentially possible leading to increased lung candidate access. Finally, the greatest challenge of all, Session 19: Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning? aims to review how we can make a more accurate diagnosis of the different phenotypes, i.e. obstructive versus restrictive terminology, and will cover the major risk factors for the development of CLAD using the most up to date information on this topic.

Mechanical Circulatory Support
If you are looking for inspiration, cutting edge scientific content, or simply a great ride, you will get it all during ISHLT2019. Begin with leaving planet earth in Session 63: Joint ISHLT/ICCAC Symposium: Faster, Higher, Stronger: Monitoring Exercise in Cyberspace and you can learn how your LVAD patients can get the most out of their heart assist device. The exciting interplay of pacing technologies and durable VAD will be further explored in Session 13: They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients. Exploring the ultimate goal of rebuilding the heart on LVAD, we provide the latest insights on recovery in Sunrise 10: Cardiac Reverse Remodeling in MCS: State of the Art. Surgical approaches to LVAD implantations have evolved dramatically and Session 05: Limiting the Invasiveness of the VAD Therapy: Alternative to Limited Surgical Approaches will update you on how the edges are cut in 2019. Two special symposia, Sunrise 03: From Isolated to Mainstream: Evolving ECMO Strategies That Are Reshaping Outcomes and Session 21: Short Term Mechanical Support: Taking the Next Leap Forward will give a comprehensive primer and expert opinion on the many developments we have witnessed over the past two years in the exciting acute support arena. Hemodynamic tailoring, hemocompatibility assessments, device and patient selection, and ECMO management strategies are just a few of the topics covered here. Lastly, before you leave, get a reality check in a symposium dedicated to serious adverse event currently limiting our abilities to broaden MCS to earlier stages of heart failure in Session 27: Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins. We hope to see you in Orlando for a great meeting!

Nursing, Health Sciences and Allied Health
This year’s Nursing and Allied Health sessions bring together ISHLT’s various disciplines – there is something for everyone in each session! Whether a mechanical circulatory support device or a continuous infusion pump, discharging home with a device can be fraught with challenges and fears. Preparing patients and families for a successful discharge home through self-management interventions and education will be covered in Session 14: Part of (Their) World: Discharging Patients Home with a New Device. This session will also address issues important to patient quality of life, like bathing, drinking, sex and traveling. Session 70: Matters of Life and Death: Palliative and End of Life Care in Transplant Medicine aims to advance the ways in which we care for patients during another important transition: end of life. Physical, emotional and pharmacological interventions will be discussed, while also bringing attention to the importance of collaboration and cultural/religious considerations. Under recognized for much too long, the need for addressing provider burn-out in organ failure/transplant medicine will also be highlighted at the podium. Sunrise 16: Fragility: Not Necessarily Failure will underscore the holistic approach needed to care for a fragile community of patients with frailty, nutritional, cognitive and mental health concerns. Lastly, the advancements in organ failure/transplant medicine that we have witnessed over the years would not be possible without research. To encourage research across all disciplines in our field, Sunrise11: The Mission IS Possible If You Choose to Accept It: The Processes of Performing Research, will include accomplished researchers in the field who will provide guidance for both novice and expert investigators on the processes of research, from study design and funding to the dissemination of findings.

Pathology
Clinical and pathologic definitions for chronic rejection in lung transplantation – antibody-mediated rejection (AMR) and chronic lung allograft dysfunction (CLAD) – have undergone rapid changes over the past decade. Sunrise 04: Nobody is CLAD to See AMR in Lung Transplantation will provide an update on these two major areas of discussion over the recent years and future development. Session 35: Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Transplant Setting will highlight the postmortem examination (“autopsy”) which is underutilized in modern medicine but provides critical information to the clinicians, families and loved ones of the decedent to help them understand the decedent’s clinical course and how data obtained from autopsies may be used by hospital quality personnel, researchers, policy makers, registries and device manufacturers to improve the state of thoracic transplantation and mechanical circulatory support therapy.

Pediatric Thoracic Transplantation and Heart Failure
The pediatric symposia are designed to provide a potpourri of topics in order to capture the interest of a wide range of disciplines and sub-specialties. The content will bring together clinicians and researchers to share their work and to present on high impact topics that are changing how we care for our patients. Session 36: Learning from the Children: Important Lessons from the Pediatric and
Congenital Heart Disease Experience will focus on the pre-transplant support of children and how to improve waiting list survival. Hot topics in transplantation will be addressed in Session 22: What Do We Do? Burning Platforms in Pediatric Thoracic Transplant. Sunrise 17: A Brand New Day: The New Normal in Pediatric Thoracic Transplantation will focus on lung transplant. And after they get an organ what do you do if they develop an infection? This question will be explored in the joint symposium with the International Pediatric Transplant Association (IPTA): Session 56: EBV and CMV are Not as Easy as 1-2-3 When Caring for Pediatric Thoracic Recipients.

Pharmacy and Pharmacology
Pharmacy and pharmacology will appeal to all areas of the ISHLT membership with four symposia highlighting pharmacotherapy needs of our patients to ensure the best outcomes. In Session 07: Making Co-Morbidities Great Again: Practical Updates in Co-Morbidity Management, an expert panel will provide updates to the management of common co-morbidities pre- and post-transplant with a focus on the evidence base and novel medications. Diabetes, dyslipidemia, osteoporosis, psychiatric disorders, complimentary/alternative medicine, and immunizations/ travel medicine will all be reviewed. In Sunrise 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant, our multidisciplinary panel will review substance use and abuse in transplant recipients with a focus on the evidence showing adverse effects of narcotics, anxiolytics, nicotine, marijuana, and alcohol before and after transplant. Novel approaches to assessment and cessation interventions will be discussed. In Sunrise 12: A Bloody Mess: Management of Hematologic Complications in Transplantation and MCS, we will offer insights into the management of neutropenia, thrombocytopenia, and hemoglobin optimization while also discussing direct acting oral anticoagulant use and pharmacologic management of bleeding reversal in both transplant and MCS patients. Lastly, Sunrise 18: So Your Patient is on ECMO... Now What? Considerations for Drug Dosing and Anticoagulation in ECMO will discuss the hot topics of optimal dosing of anti-infective medications and anticoagulation strategies in ECMO patients, especially as the boundaries of ECMO use are expanding.

Pulmonary Hypertension
Session 57: Take These Broken Lungs and Learn to Fly: Great Debates for Patients with PAH Awaiting Transplant will explore the complex decision making in the care of patients with end stage pulmonary hypertension awaiting lung transplantation. Sunrise 05: I Want to Ride My Bicycle: Cardiopulmonary Exercise Testing (CPET) for PAH and CTEPH, will review the various aspects of exercise testing from pathophysiology to outcome prediction. Session 71: Breaking Bad: The Right Ventricle and Exercise Hemodynamics Rediscovered will provide an overview into the mechanisms, clinical diagnosis and management of chronic right heart failure in left heart disease, scleroderma, and pulmonary hypertension. In collaboration with the Pulmonary Vascular Research Institute (PVRI), Session 43: Changes in the World of Pulmonary Hypertension: Nice or Not Nice will bring in experts to focus on controversies and new proposed developments under review since the recent World Symposium on Pulmonary Hypertension.
THE LOEWS MEETING COMPLEX

LOEWS SAPPHIRE FALLS RESORT
FLOOR PLAN

LOEWS ROYAL PACIFIC RESORT
FLOOR PLAN
ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for.

These codes are explained as follows:

- **BSTR**: Basic Science and Translational Research
- **CTEPH**: Chronic Thromboembolic Pulmonary Hypertension
- **EEP**: Economics, Ethics, Public Policy
- **HF/HTX**: Heart Failure/Heart Transplantation
- **ID**: Infectious Diseases
- **LF/LTX**: Lung Failure/Lung Transplantation
- **MCS**: Mechanical Circulatory Support
- **NHSAN**: Nursing/Health Science/Allied Health
- **PATH**: Pathology
- **PEDS**: Pediatrics
- **PHARM**: Pharmacy and Pharmacology
- **PH**: Pulmonary Hypertension
## SCIENTIFIC COUNCIL MEETINGS & RECEPTIONS

<table>
<thead>
<tr>
<th>Council</th>
<th>Meeting</th>
<th>Networking Reception</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science and Translational Research</td>
<td>Wednesday, April 3 12:30 PM – 1:45 PM</td>
<td>Wednesday, April 3 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 1-2</td>
<td>Hibiscus 1 &amp; 2</td>
</tr>
<tr>
<td>Chronic Thromboembolic Pulmonary Hypertension</td>
<td>Friday, April 5 7:00 AM – 8:00 AM</td>
<td>Friday, April 5 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Oceana 3-5</td>
<td>Gardenia 2</td>
</tr>
<tr>
<td>Heart Failure &amp; Transplantation</td>
<td>Friday, April 5 12:30 PM – 1:45 PM</td>
<td>Friday, April 5 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 7</td>
<td>Hibiscus 1 &amp; 2</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Friday, April 5 12:30 PM – 1:45 PM</td>
<td>Thursday, April 4 5:45 PM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 3-5</td>
<td>Gardenia 2</td>
</tr>
<tr>
<td>Junior Faculty and Trainees</td>
<td>Thursday, April 4 7:00 AM – 8:00 AM</td>
<td>Thursday, April 4 5:45 PM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td>Oceana 3-5</td>
<td>Banda Sea 1 &amp; 2</td>
</tr>
<tr>
<td>Mechanical Circulatory Support</td>
<td>Thursday, April 4 12:30 PM – 1:45 PM</td>
<td>Thursday, April 4 5:45 PM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 6</td>
<td>Timor Sea 1 &amp; 2</td>
</tr>
<tr>
<td>Nursing, Health Science, and Allied Health</td>
<td>Wednesday, April 3 12:30 PM – 1:45 PM</td>
<td>Wednesday, April 3 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 3-5</td>
<td>Gardenia 2</td>
</tr>
<tr>
<td>Pathology</td>
<td>Thursday, April 4 12:30 PM – 1:45 PM</td>
<td>Wednesday, April 3 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Coral Sea</td>
<td>Hibiscus 1 &amp; 2</td>
</tr>
<tr>
<td>Pediatric Thoracic Transplantation &amp; Heart Failure</td>
<td>Thursday, April 4 12:30 PM – 1:45 PM</td>
<td>Friday, April 5 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 3-5</td>
<td>Banda Sea 2</td>
</tr>
<tr>
<td>Pharmacy and Pharmacology</td>
<td>Wednesday, April 3 12:30 PM – 1:45 PM</td>
<td>Wednesday, April 3 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Coral Sea</td>
<td>Gardenia 1</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>Thursday, April 4 12:30 PM – 1:45 PM</td>
<td>Friday, April 5 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 1-2</td>
<td>Gardenia 2</td>
</tr>
<tr>
<td>Pulmonary Transplantation</td>
<td>Friday, April 5 12:30 PM – 1:45 PM</td>
<td>Friday, April 5 6:00 PM – 7:15 PM</td>
</tr>
<tr>
<td></td>
<td>Pacifica 10-12</td>
<td>Banda Sea 1</td>
</tr>
</tbody>
</table>
SCHEDULE AT A GLANCE

MONDAY, APRIL 1, 2019

8:00 AM – 12:00 PM
ISHLT Board of Directors Meeting (Oceana 4)

1:00 PM – 5:00 PM
ISHLT Strategic Planning Meeting (Oceana 4)

5:00 PM – 8:00 PM
Academy Registration Open (Pacific Foyer Pre-Function North)
Exhibitor Registration Open (Pacific Foyer Pre-Function South)
Speaker Ready Room Open (Pacifica 8-9)

TUESDAY, APRIL 2, 2019

6:00 AM – 3:00 PM
Academy Registration Open (Pacific Foyer Pre-Function North)

6:00 AM – 8:00 PM
Exhibitor Registration (Pacific Foyer Pre-Function South)
Speaker Ready Room Open (Pacifica 8-9)

7:45 AM – 6:15 PM
ISHLT ACADEMY: Core Competencies in Nursing, Health Sciences and Allied Health: Care of Patients Requiring Mechanical Circulatory Support and Transplantation (Pacifica 3-5)

7:55 AM – 5:15 PM
ISHLT ACADEMY: Core Competencies in Pediatric Heart Failure (Pacifica 1-2)

8:00 AM – 5:00 PM
ISHLT Strategic Planning Meeting (Oceana 4)

8:00 AM – 1:00 PM
ISHLT ACADEMY: Master Class in Heart Failure and Transplantation (Coral Sea and Java Sea)
ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Banda Sea and Timor Sea)

11:30 AM – 1:00 PM
Core Academy Box Lunch Pick-Up (Wantilan Pavilion)

2:00 PM – 7:00 PM
ISHLT ACADEMY: Master Class in Heart Failure and Transplantation (Coral Sea and Java Sea)
ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Banda Sea and Timor Sea)

4:00 PM – 8:00 PM
Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

5:00 PM – 6:00 PM
COMMITTEE MEETING: Grants & Awards (Admiralty Boardroom)

5:00 PM – 7:00 PM
COMMITTEE MEETING: Transplant Registry (Oceana 5)

6:00 PM – 7:00 PM
COMMITTEE MEETING: International Engagement (Oceana 4)
COMMITTEE MEETING: Standards & Guidelines (Admiralty Boardroom)
WEDNESDAY, APRIL 3, 2019

6:00 AM – 7:00 PM
Exhibitor Registration (Pacifica Foyer Pre-Function South)
Speaker Ready Room Open (Pacifica 8-9)

7:00 AM – 7:00 PM
Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

8:00 AM – 9:45 AM
Poster Session 1 Mount (Timor, Banda, Gardenia, Hibiscus)

8:00 AM – 10:00 AM
OPENING PLENARY SESSION (Grand Caribbean 1-7)

9:00 AM – 7:00 PM
Press Office Open (Philippine Sea)

9:30 AM – 7:15 PM
Exhibit Hall Open (Oceana 6-12)

10:00 AM – 10:30 AM
Coffee Break (Oceana 6-12)

10:00 AM – 7:15 PM
Industry Theater Open (Oceana 2)
Poster Halls Open (Timor, Banda, Gardenia, Hibiscus)

10:30 AM – 12:15 PM
SESSION 01 (ORAL): The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies (Pacifica 1-2)
SESSION 02 (SYMPOSIUM): Future Shock: Great Debates in Cardiogenic Shock (Pacifica 7)
SESSION 03 (ORAL): Chronic Lung Allograft Dysfunction: Anything New? (Pacifica 10-12)
SESSION 04 (ORAL): So Wrong It’s Right: The Right Ventricle and MCS (Pacifica 6)
SESSION 05 (SYMPOSIUM): Limiting the Invasiveness of VAD Therapy: Alternative to Limited Surgical Approaches (Grand Caribbean 1-7)
SESSION 06 (ORAL): Pediatric Donor Utilization, MCS, Readmissions and More (Pacifica 3-5)
SESSION 07 (SYMPOSIUM): Making Co-Morbidities Great Again: Practical Updates in Co-Morbidity Management (Coral Sea)

12:15 PM – 2:00 PM
LUNCH BREAK

12:30 PM – 1:45 PM
COMMITTEE MEETING: IMACS Registry (Admiralty Boardroom)
COUNCIL MEETING: Basic Science and Translational Research (Pacifica 1-2)
COUNCIL MEETING: Nursing, Health Sciences and Allied Health (Pacifica 3-5)
COUNCIL MEETING: Pharmacy and Pharmacology (Coral Sea)

12:45 PM – 1:45 PM
SESSION 08 (ORAL): ISHLT Spotlight: Heart Transplantation in Latin America (Pacifica 7)

2:00 PM – 3:45 PM
SESSION 09 (SYMPOSIUM): Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection (Pacifica 1-2)
SESSION 10 (ORAL): Heart Donor Management and Allocation: Setting It Up For Success (Pacifica 7)
SESSION 11 (ORAL): Chronic Lung Allograft Dysfunction: Overcoming the Hurdle? (Pacifica 10-12)
SESSION 12 (ORAL): When Short-Term Becomes Long-Term: Transition from Temporary to Permanent Mechanical Support (Pacifica 6)
SESSION 13 (SYMPOSIUM): They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients (Grand Caribbean 1-7)
SESSION 14 (SYMPOSIUM): Part of (Their) World: Discharging Patients Home with a New Device (Pacifica 3-5)
SESSION 15 (ORAL): Pharmacotherapy in Transplantation: Reading the Tea Leaves to Improve Outcomes (Coral Sea)
3:45 PM – 4:15 PM
Coffee Break (Oceana 6-12)

4:15 PM – 6:00 PM
SESSION 16 (ORAL): Junior Faculty and Trainees Clinical Case Dilemmas: The Best of the Best (Coral Sea)
SESSION 17 (ORAL): Tolerance Is All We Need in Thoracic Transplantation (Pacifica 1-2)
SESSION 18 (ORAL): Ex-Vivo Heart Perfusion and Preservation: Some Like It Hot – or Not! (Pacifica 7)
SESSION 19 (SYMPOSIUM): Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning? (Pacifica 10-12)
SESSION 20 (ORAL): The Beat Goes On: Arrhythmias and Pacing During MCS (Pacifica 6)
SESSION 21 (SYMPOSIUM): Short Term Mechanical Support: Taking the Next Leap Forward (Grand Caribbean 1-7)
SESSION 22 (SYMPOSIUM): What Do We Do? Burning Platforms in Pediatric Thoracic Transplant (Pacifica 3-5)

5:45 PM – 7:15 PM
Exhibit Hall Opening Reception (Oceana 6-12)

6:00 PM – 7:15 PM
POSTER SESSION 1:
Basic Science & Translational Research and Pathology (Hibiscus 1 & 2)
Economics, Ethics, Public Policy (Gardenia 2)
Heart Transplantation (Adult) (Timor Sea 1 & 2)
Junior Faculty Clinical Case Reports: Mechanical Circulatory Support, Infectious Diseases, Pediatrics (Banda Sea 2)
Junior Faculty Clinical Case Reports: Mechanical Circulatory Support, Pulmonary Hypertension (Banda Sea 1)
Nursing, Health Sciences, Allied Health (Gardenia 2)
Pharmacy and Pharmacology (Gardenia 1)

COUNCIL NETWORKING RECEPTIONS:
Basic Science & Translational Research (Hibiscus 1 & 2)
Pathology (Hibiscus 1)
Nursing, Health Sciences, Allied Health (Gardenia 2)
Pharmacy and Pharmacology (Gardenia 1)

6:15 PM – 7:15 PM
MINI ORAL 01: Deciphering the Role of Antibodies and Inflammation in Thoracic Rejection (Pacifica 1-2)
MINI ORAL 02: Cardiac Donor Selection: More Than Meets the Eye (Pacifica 7)
MINI ORAL 03: Chronic Lung Allograft Dysfunction (Pacifica 10-12)
MINI ORAL 04: MCS: A Focus on Stroke (Coral Sea)
MINI ORAL 05: Do It Quick and Do It NOW: ECMO Update (Pacifica 6)
MINI ORAL 06: Pediatrics (Pacifica 3-5)

7:15 PM – 8:15 PM
Poster Session 1 Removal (Timor, Banda, Gardenia, Hibiscus)
THURSDAY, APRIL 4, 2019

6:00 AM – 6:30 PM
Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

6:00 AM – 7:15 PM
Speaker Ready Room Open (Pacifica 8-9)

7:00 AM – 9:45 AM
Poster Session 2 Mount (Timor, Banda, Gardenia, Hibiscus)

7:00 AM – 8:00 AM
COUNCIL MEETING: Junior Faculty and Trainees (Oceana 3-5)
SUNRISE 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies (Pacifica 7)
SUNRISE 02: Immunobiology of the Older Lung Transplant Recipient (Pacifica 10-12)
SUNRISE 03: From Isolated to Mainstream: Evolving ECMO Strategies That Are Reshaping Outcomes (Pacifica 6)
SUNRISE 04: Nobody is CLAD to See AMR in Lung Transplantation (Coral Sea)
SUNRISE 05: I Want to Ride My Bicycle: Cardiopulmonary Exercise Testing (CPET) for PAH and CTEPH (Pacifica 1-2)
SUNRISE 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant (Pacifica 3-5)

8:00 AM – 9:45 AM
SESSION 23 (ORAL): Hepatitis C+ Cardiac Donors: Do They Get an A+? (Pacifica 6)
SESSION 24 (ORAL): Molecular Diagnostics in Heart Transplantation: It’s All in the Genes (Pacifica 7)
SESSION 25 (SYMPOSIUM): Magic Kingdom of the Bronchoscopy: Pathogens with Real Implications and Those to Disregard (Pacifica 3-5)
SESSION 26 (ORAL): Mechanical Lung Support for Isolated Organs and Patients (Pacifica 10-12)
SESSION 27 (SYMPOSIUM): Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins (Grand Caribbean 1-7)
SESSION 28 (ORAL): Tissue is Not the Only Issue: Advances in Thoracic Transplant Pathology (Coral Sea)
SESSION 29 (ORAL): Pediatric Lung Transplantation: Are We Moving Forward? (Pacifica 1-2)

9:00 AM – 6:30 PM
Exhibitor Registration (Pacifica Foyer Pre-Function South)

9:00 AM – 7:00 PM
Press Office Open (Philippine Sea)

9:30 AM – 7:00 PM
Exhibit Hall Open (Oceana 6-12)

9:45 AM – 10:15 AM
Coffee Break (Oceana 6-12)

9:45 AM – 7:00 PM
Industry Theater Open (Oceana 2)
Poster Halls Open (Timor, Banda, Gardenia, Hibiscus)

10:15 AM – 12:00 PM
SESSION 30 (ORAL): Get up and Go! Predicting Survival in Heart Failure (Pacifica 7)
SESSION 31 (ORAL): Slaying the Dragon: Hepatitis C and Thoracic Transplantation (Pacifica 1-2)
SESSION 32 (SYMPOSIUM): Ex-Vivo Lung Perfusion (EVLP) in 2019: From Research to Implementation (Pacifica 10-12)
SESSION 33 (ORAL): Brain Attack: Strokes and MCS (Pacifica 6)
SESSION 34 (ORAL): Never Mind the Leaks: Addressing Valvular Disease with LVADs (Grand Caribbean 1-7)
SESSION 35 (SYMPOSIUM): Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Transplant Setting (Coral Sea)
SESSION 36 (SYMPOSIUM): Learning from the Children: Important Lessons from the Pediatric and CHD VAD Experience (Pacifica 3-5)

12:00 PM – 1:45 PM
LUNCH BREAK

12:30 PM – 1:45 PM
COUNCIL MEETING: Mechanical Circulatory Support (Pacifica 6)
COUNCIL MEETING: Pathology (Coral Sea)
COUNCIL MEETING: Pediatric Thoracic Transplantation and Heart Failure (Pacifica 3-5)
COUNCIL MEETING: Pulmonary Hypertension (Pacifica 1-2)
JHLT Editorial Board Lunch Meeting (Java Sea 1)

1:45 PM – 3:30 PM
SESSION 37 (SYMPOSIUM): JHLT at ISHLT: The Year in a Capsule (Pacifica 10-12)
SESSION 38 (ORAL): Early Career Scientist Award Candidate Presentations (Coral Sea)
SESSION 39 (ORAL): Walking a Tightrope: The Double-Edged Sword of Drugs after Heart Transplant (Pacifica 3-5)
SESSION 40 (SYMPOSIUM): Heart Failure in Adult Congenital Heart Disease: Unique Problems Need Unique Solutions (Pacifica 7)
SESSION 41 (ORAL): Perfecting the Graft: LVAD Pump Management, Outcomes and Medications (Pacifica 6)
SESSION 42 (ORAL): Too Much or Two Little? Obesity and Frailty in MCS (Grand Caribbean 1-7)
SESSION 43 (SYMPOSIUM): Changes in the World of Pulmonary Hypertension: Nice or Not Nice (Pacifica 1-2)

3:30 PM – 4:00 PM
Coffee Break (Oceana 6-12)

4:00 PM – 5:45 PM
SESSION 44 (ORAL): Philip K. Caves Award Candidate Presentations (Coral Sea)
SESSION 45 (ORAL): Acute Cardiac Rejection: New Approaches to an Old Problem (Pacifica 7)
SESSION 46 (SYMPOSIUM): FUN and Games with FUNgal Infections in Lung Transplantation (Pacifica 3-5)
SESSION 47 (ORAL): Back to the Basics: Physiological Alterations During Continuous Flow VAD Support (Pacifica 6)
SESSION 48 (SYMPOSIUM): Advances in Short- and Long-Term MCS – What’s Next (Grand Caribbean 1-7)
SESSION 49 (ORAL): The Personal Connection: Psychological Issues and Care for Donor Families, Patients and Providers (Pacifica 10-12)
SESSION 50 (ORAL): PH in Translation: From Novel Biomarkers to Cutting Edge Clinical Results (Pacifica 1-2)

5:45 PM – 6:45 PM
Past Presidents Meeting (Admiralty Boardroom)

5:45 PM – 7:00 PM
Wine and Cheese Reception (Oceana 6-12)

POSTER SESSION 2:
Infectious Diseases (Gardenia 2)
Junior Faculty Clinical Case Reports: Heart Failure/Transplantation, Lung Failure/Transplantation (Banda Sea 1 & 2)
Lung Transplantation (Adult) (Hibiscus 1 & 2)
Mechanical Circulatory Support (Adult) (Timor Sea 1 & 2)

COUNCIL NETWORKING RECEPTIONS:
Junior Faculty and Trainees (Banda Sea 1 & 2)
Mechanical Circulatory Support (Timor Sea 1 & 2)
Infectious Diseases (Gardenia 2)

6:00 PM – 7:00 PM
MINI ORAL 07: Basic Science and Heart Transplantation (Coral Sea)
MINI ORAL 08: Lung Donor Management and Organ Allocation (Pacifica 10-12)
MINI ORAL 09: MCS: GI Bleeding (Pacifica 6)
MINI ORAL 10 A&B: Nursing, Health Sciences, Allied Health / Pharmacy and Pharmacology (Pacifica 3-5)
MINI ORAL 11 A&B: Heart Failure (Adult) / Pediatrics (Pacifica 1-2)
MINI ORAL 12 A&B: Pulmonary Hypertension / Heart Transplantation (Pacifica 7)

7:00 PM – 8:00 PM
Poster Session 2 Removal (Timor, Banda, Gardenia, Hibiscus)
FRIDAY, APRIL 5, 2019

6:00 AM – 6:30 PM
Annual Meeting Registration Open (Grand Caribbean Foyer Pre-Function North)

6:00 AM – 7:15 PM
Speaker Ready Room Open (Pacifica 8-9)

7:00 AM – 10:00 AM
Poster Session 3 Mount (Timor, Banda, Gardenia, Hibiscus)

7:00 AM – 8:00 AM
COUNCIL MEETING: Chronic Thromboembolic Pulmonary Hypertension (Oceana 3-5)
SUNRISE 07: Highways to Hell: Chronic Lung Allograft Dysfunction (Pacifica 1-2)
SUNRISE 08: Print, Replace or Innovate: Alternative Strategies to Cardiac Transplantation (Pacifica 7)
SUNRISE 09: MCS Infections: New Twists in an Old Saga (Pacifica 3-5)
SUNRISE 10: Cardiac Reverse Remodeling in MCS: State of the Art (Pacifica 6)
SUNRISE 11: The Mission IS Possible If You Choose to Accept it: The Processes of Performing Research (Pacifica 10-12)
SUNRISE 12: A Bloody Mess: Management of Hematologic Complications in Transplantation and MCS (Coral Sea)

8:00 AM – 10:00 AM
PLENARY SESSION (Grand Caribbean 1-7)

9:00 AM – 6:30 PM
Exhibitor Registration (Registration South)

9:00 AM – 7:00 PM
Press Office Open (Philippine Sea)

9:30 AM – 4:30 PM
Exhibit Halls Open (Ocean 6-12)

10:00 AM – 10:30 AM
Coffee Break (Oceana 6-12)
Annual Business Meeting (Grand Caribbean 1-7)

10:00 AM – 4:30 PM
Industry Theater Open (Oceana 2)

10:00 AM – 7:15 PM
Poster Halls Open (Timor, Banda, Gardenia, Hibiscus)

10:30 AM – 12:15 PM
SESSION 51 (ORAL): Cardiac Allograft Vasculopathy: A Never-ending Story (Pacifica 6)
SESSION 52: Joint ISHLT/SCMR Symposium: Cardiac MRI and the World of Heart Failure: When Two Disciplines Harmonize (Pacifica 7)
SESSION 53 (ORAL): Chasing the Golden Snitch: Optimizing Outcomes of MCS Infections (Pacifica 1-2)
SESSION 54 (ORAL): Swipe Right or Swipe Left? Matching Donors and Recipients in Lung Transplantation (Pacifica 10-12)
SESSION 55 (ORAL): Score Now – Or Forever Hold Your Peace: Prediction and Risk in MCS (Grand Caribbean 1-7)
SESSION 56: Joint ISHLT/IPTA Symposium: EBV and CMV are Not as Easy as 1-2-3 When Caring for Ped Thoracic Tx Recipients (Pacifica 3-5)
SESSION 57 (SYMPOSIUM): Take These Broken Lungs and Learn to Fly: Great Debates for Patients with PAH Awaiting Tx (Coral Sea)

12:15 PM – 2:00 PM
LUNCH BREAK

12:30 PM – 1:45 PM
COMMITTEE MEETING: Registries and Databases (Admiralty Boardroom)
COUNCIL MEETING: Heart Failure and Transplantation (Pacifica 7)
COUNCIL MEETING: Infectious Diseases (Pacifica 3-5)
COUNCIL MEETING: Pulmonary Transplantation (Pacifica 10-12)
2:00 PM – 3:45 PM
SESSION 58 (SYMPOSIUM): Resilience in the Face of Calamity: The Art of Preventing PTE Disasters (Coral Sea)
SESSION 59 (ORAL): Heart Transplant Short-Term Outcomes: Getting it Right From the Start (Pacifica 7)
SESSION 60: Joint ISHLT/ABTO Symposium: Combining Experiences to Enhance Thoracic Organ Transplantation Worldwide (Pacifica 3-5)
SESSION 61 (SYMPOSIUM): Making Them Count: Enhancing Lung Donor Utilization (Pacific 10-12)
SESSION 62 (ORAL): Under New Management: Novel Strategies for MCS (Grand Caribbean 1-7)
SESSION 63: Joint ISHLT/ICCAC Symposium: Faster, Higher, Stronger: Monitoring Exercise in Cyberspace (Pacific 6)
SESSION 64 (ORAL): Highlights of Challenging Topics in Pediatric Heart Transplant and MCS (Pacific 1-2)

3:45 PM – 4:15 PM
Coffee Break (Oceana 6-12)
COMMITTEE MEETING: 2020 Symposium Planning (South China Sea)

4:15 PM – 6:00 PM
SESSION 65 (SYMPOSIUM): All Talk, No Action? New Strategies and Best Practices to Maximize Donor Heart Utilization (Pacific 7)
SESSION 66 (ORAL): Between the Devil and the Deep Blue Sea: Fungus or CMV? (Pacific 1-2)
SESSION 67 (ORAL): Diagnostics and Immunosuppression in Lung Transplantation (Pacific 10-12)
SESSION 68 (ORAL): LV Recovery after MCS: From Promise to Reality? (Pacific 6)
SESSION 69 (ORAL): Tricks of the Trade: Management Considerations with Continuous Flow LVADs (Grand Caribbean 1-7)
SESSION 70 (SYMPOSIUM): Matters of Life and Death: Palliative and End of Life Care in Transplant Medicine (Pacific 3-5)
SESSION 71 (SYMPOSIUM): Breaking Bad: The Right Ventricle and Exercise Hemodynamics Rediscovered (Coral Sea)

6:00 PM – 7:15 PM
POSTER SESSION 3:
Heart Failure/Transplantation (Adult) (Hibiscus 1 & 2)
Lung Failure/Transplantation (Adult) (Banda Sea 1)
Mechanical Circulatory Support (Adult) (Timor Sea 1 & 2)
Pediatrics (Banda Sea 2)
Pulmonary Hypertension and CTEPH (Gardenia 2)

COUNCIL NETWORKING RECEPTIONS
Heart Failure and Transplantation (Hibiscus 1 & 2)
Pulmonary Transplantation (Banda Sea 1)
Pediatric Thoracic Transplantation and Heart Failure (Banda Sea 2)
Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension (Gardenia 2)

6:15 PM – 7:15 PM
MINI ORAL 13: Cardiac Donors and Recipients: Valuable Insights (Pacifica 1-2)
MINI ORAL 14: Unique Considerations for Special Heart Transplant Populations (Pacific 7)
MINI ORAL 15: Infectious Diseases and Basic Science (Pacific 3-5)
MINI ORAL 16: Lung Transplant Outcomes (Pacific 10-12)
MINI ORAL 17: LVAD Physiology: Effects on End Organs (Pacific 6)
MINI ORAL 18: MCS: Right Heart Failure (Coral Sea)

7:15 PM – 8:15 PM
Poster Session 3 Removal (Timor, Banda, Gardenia, Hibiscus)
SATURDAY, APRIL 6, 2019

6:00 AM – 12:15 PM
Speaker Ready Room Open (Pacifica 8-9)

7:00 AM – 12:15 PM
Annual Meeting Registration Open (Registration South & China Sea)

7:00 AM – 8:00 AM
SUNRISE 13: A Fork in the Road: How Can We Compare Interventional Therapies in CTEPH? (Coral Sea)
SUNRISE 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation (Pacifica 7)
SUNRISE 15: Lung Transplant Candidate Selection: Challenging Cases (Pacifica 10-12)
SUNRISE 16: Fragility: Not Necessarily Failure (Pacifica 6)
SUNRISE 17: A Brand-New Day: The New Normal in Pediatric Thoracic Transplantation (Pacifica 1-2)
SUNRISE 18: So Your Patient is on ECMO... Now What? Considerations for Drug Dosing and Anticoagulation in ECMO (Pacifica 3-5)

8:00 AM – 10:00 AM
PLENARY SESSION (Pacifica 6)

10:00 AM – 10:15 AM
Coffee Break (Pacifica Foyer)

10:15 AM – 12:00 PM
SESSION 72 (SYMPOSIUM): Seeing the Light: Antibodies in Thoracic Transplantation (Pacifica 3-5)
SESSION 73 (ORAL): Life on the Cutting Edge: CTEPH and Surgical Management of Pulmonary Hypertension (Pacifica 1-2)
SESSION 74 (ORAL): Frontiers of Cost-Efficacy and Policy in Transplant and MCS (Coral Sea)
SESSION 75 (SYMPOSIUM): Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter (Pacifica 7)
SESSION 76 (SYMPOSIUM): Location, Location, and Allocation: Worldwide Application of Broader Sharing in LTX (Pacifica 10-12)
SESSION 77 (ORAL): Thicker than Water? Bleeding and LVADs (Pacifica 6)

12:15 PM – 2:00 PM
SESSION 78 (ORAL): The Beginning of the End in Lung Transplantation: PGD, AMR and CLAD (Pacifica 3-5)
SESSION 79 (ORAL): Go with the Flow: Hemodynamic Guiding Therapies in Heart Failure (Pacifica 1-2)
SESSION 80 (ORAL): Heart Transplant Long-Term Outcomes: In It for the Long Haul (Pacifica 7)
SESSION 81 (ORAL): Primary Graft Dysfunction and Acute Lung Rejection (Coral Sea)
SESSION 82 (ORAL): Donor Lung Management: Can We Do Better? (Pacifica 10-12)
SESSION 83 (ORAL): What’s Holding Me Back? Exercise in LVAD Patients (Pacifica 6)

2:00 PM
MEETING ADJOURNS
WEDNESDAY, APRIL 3, 2019
8:00 AM - 10:00 AM

OPENING PLENARY SESSION
Room: Grand Caribbean 1-7
Target Audience: ALL

Chairs: Jeffrey J Teuteberg, MD, and Lara Danziger-Isakov, MD, MPH

8:00 AM  Welcome/Program Chair Report
           Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, USA

8:10 AM   Thoracic Registry Report
           Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

8:20 AM   IMACS Registry Report
           Daniel J Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

8:30 AM   Journal Editor's Report
           Mandeep R Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, USA

8:40 AM   President's Report
           Jeffrey J Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA

8:55 AM   (1) Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Clinical Trial: Final Analysis of the 1028 Patient Full Cohort; D. Goldstein1, M. R. Mehra2, - M. MOMENTUM 3 Investigators3. 1 Dept of Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 2 Brigham and Women's Hospital, Boston, MA

9:10 AM   Q&A with Interactive Discussant
           Robert L Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

9:15 AM   (2) INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) (Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil NCT03399604); N. S. Hill1, J. P. Feldman2, S. Sahay3, D. J. Levine4, R. F. Roscigno5, T. A. Vaughn6, T. M. Bull6. 1Tufts Medical Center, Boston, MA, 2Arizona Pulmonary Specialists, Ltd, Phoenix, AZ, 3Weill Cornell Medicine, Institute of Academic Medicine, Houston Methodist Lung Center, Houston Methodist, Houston, TX, 4University of Texas Health Sciences Center at San Antonio, San Antonio, TX, 5Liquidia Technologies, Morrisville, NC, 6Anschutz Medical Campus, Univ of Colorado Denver, Aurora, CO

9:30 AM   Q&A with Interactive Discussant
           Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

9:35 AM   Introductory Remarks to Lifetime Achievement Award Recipient
           Keith McNeil, MD, Papworth Hospital NHS Trust, Papworth Everard, United Kingdom

9:40 AM   Lifetime Achievement Award Recipient Lecture
           Prof. John Wallwork, FRCS, FmedSci, CBE, Royal Papworth Hospital, Cambridge, United Kingdom
SESSION 01 (ORAL): The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies
Room: Pacifica 1-2
Target Audiences: BSTR, LTX, PEDS, PATH

Chairs: Marilia Cascalho, MD, PhD, and Matthew G Hartwig, MD

10:30 AM

10:45 AM
(6) Distinct Heart Failure Phenotypes Identified by Myocardial Transcriptome Sequencing: Targets for Reverse Remodeling; P. Shah1, W. Zhu2, S. Navankasattusas1, D. K. Ramadurai1, S. S. Desai1, I. Taleb3, I. Efimov4, R. Singh5, N. Aliyev6, R. K. Iyer7, O. Wever-Pinzon8, S. McKellar9, W. T. Caine8, C. R. deFilippi9, J. Zhu10, S. Drakoš11. Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2Inova Translational Medicine Institute, Falls Church, VA, 3University of Utah, Salt Lake City, UT, 4George Washington University, Washington, DC, 5Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, 6Heart Failure and Transplantation, University of Utah, Salt Lake City, UT, 5Cardiac Surgery, University of Utah, Salt Lake City, UT, 7Cardiac Surgery, Intermountain Medical Center, Salt Lake City, UT, 8Inova Heart and Vascular Institute, Falls Church, VA, 9Mokobio, Rockville, MD

11:00 AM
(315) Exosome Proteomics and Machine Learning Identify Novel Biomarkers of Primary Graft Dysfunction; N. Giangreco1, G. Lebreton1, S. Restaino1, M. Farr3, P. C. Colombo1, E. Zorn1, N. Tatonetti1, P. Leprince2, J. Kobashigawa2, B. Fine1. Biomedical Informatics, Columbia University, New York, NY, 2Chirurgie Thoracique et Cardiovasculaire, Pitié-Salpêtrière University Hospital, Paris, France, 3Division of Cardiology, Columbia University, New York, NY, 4Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

11:15 AM
(8) Engineered Mesenchymal Stromal Cell Therapy during Pig Ex Vivo Lung Perfusion and Transplant; A. Estrada1, T. Martinu1, S. Juvet1, J. Yeung1, T. K. Waddell1, M. Cypel1, M. Liu1, J. E. Davies3, S. Keshavjee1. Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 2Tissue Regeneration Therapeutics, Toronto, ON, Canada, 3Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada

11:30 AM
(9) Hydrogen-Rich Preservation Solution Attenuates Lung Ischemia-Reperfusion Injury after Prolonged Cold Ischemia in a Canine Left Lung Transplant Model; H. Kayawake1, T. F. Chen-Yoshikawa1, M. Saito1, S. Hirano2, R. Kurokawa2, H. Yamagishi1, R. Okabe1, F. Gochi1, J. Tokuno1, S. Ueda1, Y. Yokoyama1, M. Ikeda1, H. Oda1, Y. Yamada1, Y. Yutaka1, D. Nakajima1, A. Ohsumi2, M. Hamaji1, H. Date1. Department of Thoracic Surgery, Kyoto University, Kyoto, Japan, 2MiZ Company Limited, Kamakura, Japan

11:45 AM
(10) Atorvastatin Preserves Cardiac Contractility via Reducing Matrix Metalloproteinase-2 Isoforms Expression in a Diabetic Heart Model; H. Lee1, S. Lee1, S. Song2, S. Bae3, S. Kim3, J. Choi3. Cardiology Department, Pusan National University Hospital, Busan, Korea, Republic of, 2Nephrology Department, Pusan National University Hospital, Busan, Korea, Republic of, 3MRC for Ischemic Tissue Regeneration and Department of Pharmacology, Medical Research Institute, Pusan National University Hospital, Busan, Korea, Republic of, 4Endocrinology Department, Pusan National University Hospital, Busan, Korea, Republic of, 5Department of Cardiology, Pusan National University Hospital, Busan, Korea, Republic of

12:00 PM
(11) Triptolide Attenuates Graft Inflammation During Ex Vivo Lung Perfusion; S. Burki, K. Noda, B. Philips, P. G. Sanchez, A. Kumar, J. D'Cunha. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
WEDNESDAY, APRIL 3, 2019
10:30 AM - 12:15 PM

SESSION 02 (SYMPOSIUM): Future Shock: Great Debates in Cardiogenic Shock
Room: Pacifica 7
Target Audiences: HF/HTX, MCS

Chairs: Teresa De Marco, MD, and Richard Cheng, MD

Session Summary: The incidence of cardiogenic shock is increasing, leading to an emerging focus on refining our approach to shock. This symposium will provide a framework for understanding goals of treatment, defining phenotypes and profiles of shock, exploring geographical differences in management, and reviewing trends in use of temporary MCS. A 10-min panel discussion with all speakers will conclude this session.

10:30 AM CASE PRESENTATION: ‘Gimme Gimme Shock Treatment’: Acute cardiogenic shock patient transferred for advanced heart failure therapy
Adriana Torres, MD, LosCobos Medical Center, Bogota, Colombia

10:35 AM DEBATE 1: ‘Culture Shock’: Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (PRO)
Daniel J Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

10:50 AM DEBATE 1: ‘Culture Shock’: Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (CON)
Jennifer Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, USA

11:05 AM DEBATE 2: ‘Shock Rock’: One Treatment Fits All in Cardiogenic Shock (PRO)
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

11:20 AM DEBATE 2: ‘Shock Rock’: One Treatment Fits All in Cardiogenic Shock (CON)
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

Pascal Leprince, MD, Hôpital de La Petite Salpetriere, Paris, France

David A Baran, MD, Sentara Heart Hospital, Norfolk, VA, USA

12:05 PM 10-min Panel Discussion
SESSION 03 (ORAL): Chronic Lung Allograft Dysfunction: Anything New?
Room: Pacifica 10-12
Target Audiences: LTX, BSTR, PATH

10:30 AM
(12) Diffusing Capacity for Carbon Monoxide (DLCO): A Predictor of CLAD and Death after Lung Transplantation in a 20-Year Longitudinal Study; D. R. Darley¹, J. Ma², E. Huszti², R. Ghany¹, M. Hutcheon¹, C. Chow¹, J. Tikkkanen¹, S. Keshavjee¹, L. G. Singer¹, T. Martinu¹. ¹Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, ²Biostatistics Research Unit, University Health Network, Toronto, ON, Canada

10:45 AM
(13) Molecular Analysis of Transbronchial and Mucosal Biopsies in Patients with CLAD; M. Parkes¹, P. F. Halloran¹, J. Chang¹, K. S. Famulski¹, J. Reeve¹, R. Hachem³, P. Jaksch³, S. Juver⁴, W. Klepetko⁵, S. Keshavjee⁴, D. Kreisel⁶, A. Roux⁶, G. I. Snell⁶, E. Trulock⁶, I. L. Timofte⁶, G. P. Westall⁶, K. M. Halloran¹. ¹University of Alberta, Edmonton, AB, Canada, ²Washington University School of Medicine, St. Louis, MO, ³Medical University of Vienna, Vienna, Austria, ⁴University Health Network, Toronto, ON, Canada, ⁵Hôpital Foch, Suresnes, France, ⁶Monash University, Melbourne, Australia, ⁷University of Maryland, Baltimore, MD

11:00 AM
(14) Predictive Biomarkers for Bronchiolitis Obliterans; V. Kaza¹, C. Zhu¹, L. Feng¹, A. Reddy², C. Lacelle³, L. Terada¹, M. Manish¹, S. Bollineni¹, A. Banga¹, F. Torres¹, J. Mullins¹, Q. Li¹. ¹UT SW Med Ctr, Dallas, TX, ²Southwest Pulmonary Associates, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴Ut SW Med Ctr, Dallas, TX

11:15 AM
(15) Chest CT Has Prognostic Value at BOS Diagnosis after Lung Transplantation; A. Van Herck¹, A. Sacreas¹, T. Heigl¹, J. Kaes¹, A. Vanstapel¹, S. E. Verleden¹, B. M. Vanaudenaeede¹, W. De Wever⁴, G. M. Verleden¹, R. Vos¹. ¹Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing, University of Leuven, Leuven, Belgium, ²Department of Radiology, University Hospitals Leuven, Leuven, Belgium

11:30 AM
(16) Regulatory T Cells in Asymptomatic ISHLT Grade A1 Rejection and the Risk of Chronic Lung Allograft Dysfunction; M. White, L. Levy, S. Moshkelgosha, G. Zehong, S. Keshavjee, T. Martinu, S. Juver. ¹Toronto Lung Transplant Program, Toronto General Research Institute, Toronto, ON, Canada

11:45 AM
(17) Emergence of a Specific Intrapulmonary CD4+ T Cell Subset Prior to the Onset of Lung Allograft Dysfunction; S. Moshkelgosha¹, L. Levy¹, T. Martinu¹, R. Zamel¹, C. Guidos½, S. Keshavjee¹, J. Yeung¹, S. C. Juver¹. ¹Toronto Lung Transplant Program, Lutner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, ²The Hospital for Sick Children (SickKids), Toronto, ON, Canada

12:00 PM
(18) Increased Hazard of Chronic Lung Allograft Dysfunction in the Presence of Persistent and Complement Fixing Donor-Specific Antibodies; C. J. Iasella¹, C. R. Ensor², M. Marrari², M. Mangiola³, C. A. Moore⁴, M. R. Morrell⁵, J. M. Pilewski⁵, J. D’Cunha⁶, P. Sanchez⁶, J. F. McDyer⁶, A. Zeevi³. ¹Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Department of Pharmacy, Florida Hospital, Orlando, FL, ³Department of Pathology, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA
SESSION 04 (ORAL): So Wrong It's Right: The Right Ventricle and MCS
Room: Pacifica 6
Target Audiences: MCS, PH, PHARM

Chairs: Bastian Schmack, MD, and Brent Lampert, MD

10:30 AM
(19) Right Ventricular Strain as a Predictor of Post-LVAD Early Right Ventricular Failure; L. W. Liang, E. Y. Birati, C. Justice, Y. Han. Hospital of the University of Pennsylvania, Philadelphia, PA

10:45 AM
(20) Serial Assessment of Pulmonary Artery Pulsatility Index Provides Incremental Risk Assessment for Early Right Ventricular Failure after Left Ventricular Assist Device Implantation; M. H. Gonzalez, J. Wagener, A. Aggarwal, T. Buda, V. Menon, M. Jacob, W. Tang, E. Hirsch, M. Tong, E. Soltész, R. Starling, J. Estep, E. Joyce. Cardiology, Cleveland Clinic Foundation, Cleveland, OH, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH

11:00 AM
(21) Bridging BiVentricular Failure to Successful Heart Transplants: HVAD BiVAD versus TAH; A. Salimbangon, R. Chaudhri, C. Lum, D. Vucicevic, E. DePasquale. UCLA, Los Angeles, CA, Newark Beth Israel, Newark, NJ

11:15 AM

11:30 AM
(23) Early and Late Right Heart Failure Following LVAD Implantation: Epidemiology, Natural History and Outcomes. An Analysis of the STS INTERMACS Database; C. J. Kapelios, L. H. Lund, C. H. Selzman, S. L. Meyers, A. Koliopoulos, J. Stehlik, O. Wever-Pinzon, A. G. Kfoury, J. C. Fang, J. K. Kirklin, S. G. Drakos. National and Kapodestrian University of Athens, Athens, Greece, Karolinska University Hospital, Stockholm, Sweden, University of Utah Health & School of Medicine, Salt Lake City, UT, Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, AL, Intermountain Medical Center, Salt Lake City, UT

11:45 AM
(24) Pectoralis Muscle Attenuation Improves the Prediction of Right Ventricular Failure after LVAD Implantation; H. Shah, T. Murray, J. Estep, R. Araujo, A. El Rafei, B. Trachtenberg, L. Teigen, J. Schultz, R. John, C. Martin, R. Cogswell. Cardiology, University of Minnesota, Minneapolis, MN, Biostatistics, University of Minnesota, Minneapolis, MN, Cardiology, Cleveland Clinic, Cleveland, OH, Cardiology, Houston Methodist, Houston, TX, Internal Medicine, University of Minnesota, Minneapolis, MN, Gastroenterology Hepatology and Nutrition, University of Minnesota, Minneapolis, MN, Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

12:00 PM
SESSION 05 (SYMPOSIUM): Limiting the Invasiveness of the VAD Therapy: Alternative to Limited Surgical Approaches
Room: Grand Caribbean 1-7
Target Audience: MCS

Chairs: George M. Wieselthaler, MD, and Marian Urban, MD

Session Summary: The ISHLT 2018 Annual Meeting included the highest number of abstracts on less invasive VAD implantation approach. This symposium will evaluate the potential advantages of minimal invasive approaches for VAD implantation, the usage of ECMO instead of CPB, and the feasibility and advantages of adding minimal invasive and off-pump techniques.

10:30 AM  Influence of the Surgical Technique on Post-Operative Outcome: Is Minimal Invasive Approach the Way to Go?
            Victor Pretorius, MD, UCSD Medical Center, La Jolla, CA, USA

10:45 AM  Q&A

10:50 AM  The Alternative Approach: Should We Be Using ECMO Instead of CPB?
            Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria

11:05 AM  Q&A

11:10 AM  Going 'Off-Pump': Does It Make a Difference?
            Diyar Saeed, MD, PhD, Leipzig Heart Center, Leipzig, Germany

11:25 AM  Q&A

11:30 AM  Going 'BIVAD': Acute Pitfalls and Long-Term Threats
            Evgenij V Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany

11:45 AM  Q&A

11:50 AM  Out with the Old: Pump Replacement/Upgrade Decommissioning Explant
            Carmelo A Milano, MD, Duke University Medical Center, Durham, NC, USA

12:05 PM  Q&A
SESSION 06 (ORAL): Pediatric Donor Utilization, MCS, Readmissions and More
Room: Pacifica 3-5
Target Audiences: PEDS, HF, HTX, MCS

Chairs: Jonathan N Johnson, MD, and Francesco Parisi, MD

10:30 AM  
(26) Donor Utilization in the Australian National Paediatric Heart Transplant Program: Stretching the Limits; J. Wacker1, A. Shipp1, I. Konstantinov2, J. Brink2, R. Weintraub1, J. Mathew1. 1Cardiology, The Royal Children's Hospital Melbourne, Parkville, Australia, 2Cardiac Surgery, The Royal Children's Hospital Melbourne, Parkville, Australia

10:45 AM  
(27) Regional Variation in Donor Refusal Rates Correlates with Poor Wait List Outcomes; R. R. Davies1, R. Butts2, M. Bano2, R. D. Jaquiss3, R. C. Kirk1. 1Pediatric Cardiothoracic Surgery, UT Southwestern - Children's Health Dallas, Dallas, TX, 2Pediatrics (Cardiology), UT Southwestern - Children's Health Dallas, Dallas, TX

11:00 AM  
(417) Toward a New Strategy for Pediatric Heart Allocation: High Risk Organs for Less Ill Patients?; A. K. Morrison1, C. Gowda2, R. Gajarski1, D. Nandi1. 1The Heart Center, Nationwide Children's Hospital, Columbus, OH, 2Department of Pediatrics, Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, OH

11:15 AM  
(29) Anti-Coagulation Management in Pediatric Ventricular Assist Device: A Quality Improvement Target; C. VanderPluym1, M. O'Connor2, A. Lorts3, M. Ploutz4, D. Peng5, S. Law6, M. Zinn7, R. Niebler8, D. Rosenthal9, J. Conway10, S. Auerbach11, D. Sutcliffe12, M. Mehegan13. 1Boston Children's Hospital, Boston, MA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Cincinnati Children's Hospital, Cincinnati, OH, 4Phoenix Children's Hospital, Phoenix, AZ, 5C.S. Mott Children's Hospital, Ann Arbor, MI, 6Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY, 7Children's Hospital of Pittsburgh, Pittsburgh, PA, 8Children's Hospital of Wisconsin, Milwaukee, WI, 9Lucile Packard Children's Hospital, Palo Alto, CA, 10Stollery Children's Hospital, Edmonton, AB, Canada, 11Children's Hospital Colorado, Aurora, CO, 12Children's Health Dallas, Dallas, TX, 13Children's Hospital St. Louis, St. Louis, MO

11:30 AM  
(30) Role of ECMO as Bridge to VAD Therapy in Critically Ill Pediatric Patients - An Analysis of the STS Pedimacs Database; S. M. Peer1, D. A. Koehi2, R. S. Cantor2, R. A. Jonas1, P. Sinha1. 1Cardiac Surgery, Children's National Health System, Washington, DC, 2Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, AL

11:45 AM  
(31) Hospital Readmission Following Pediatric Heart Transplantation; W. T. Mahle1, K. Mason2, A. Dipchand3, M. Richmond4, C. Canter5, D. Hsu6, T. P. Singh7, R. Shaddy8, B. Armstrong2, A. Zeevi9, D. Ikle2, H. Diop10, J. Odim10, S. Webber11. 1Children's Healthcare of Atlanta, Atlanta, GA, 2Rho, Chapel Hill, NC, 3Hospital for Sick Children, Toronto, ON, Canada, 4Columbia Presbyterian, New York, NY, 5St. Louis Children's, St. Louis, MO, 6Montefiore Children's Hospital, New York, NY, 7Boston Children's Hospital, Boston, MA, 8Los Angeles Children's Hospital, Los Angeles, CA, 9Children's Hospital of Pittsburgh, Pittsburgh, PA, 10NIH, Bethesda, MD, 11Vanderbilt University School of Medicine, Nashville, TN

12:00 PM  
(32) Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus; A. Putscheogl1, L. Pyle1, M. Everitt1, S. Miyamoto1, B. Pietra2, S. Auerbach1. 1Children's Hospital Colorado, Aurora, CO, 2University of Florida Health, Gainesville, FL
Room: Coral Sea
Target Audiences: PHARM, HF/HTX, LF/LTX

Chairs: Patricia Ging, PharmD, and Nicole L Casciello, PharmD, MBA

Session Summary: This symposium will review management of comorbidities and primary care needs that affect heart and lung transplant recipients before and after transplant including diabetes, dyslipidemia, osteoporosis, psychiatric disorders, complimentary/alternative medicine, and immunizations/travel. Best practices and recent guideline recommendations will be presented for each topic. New and novel medications available and any pros or cons for use in the transplant population will be discussed. A 15-min panel discussion with all speakers will conclude this session.

10:30 AM  What to Do When the A1C is ‘BIGLY’: An Update on the Management of Post-Transplant Diabetes
Jennifer L Day, PharmD, Baptist Health Heart Failure and Transplant Institute, Little Rock, AR, USA

10:45 AM  Good Lipoproteins on Both Sides: Optimizing Treatment of Dyslipidemia and Obesity
Jill C Krisl, PharmD, Houston Methodist Hospital, Houston, TX, USA

11:00 AM  'Skeletons in the Closet': Diagnosis, Prevention and Treatment of Osteoporosis
David Iturbe, MD, Hospital Universitario Marques de Valdecilla, Santander, Spain

11:15 AM  'Stable Genius': Managing Mental Health After Transplant
Melissa Sanchez, BSc Hons, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom

11:30 AM  Combating 'Alternative Facts': Complementary and Alternative Medicine in Transplant
Teena Sam, PharmD, Baylor University Medical Center, Dallas, TX, USA

11:45 AM  'Fake News': Immunization Practices and Travel Prophylaxis
Michele Estabrook, MD, St. Louis Children's Hosp, St Louis, MO, USA

12:00 PM  15-min Panel Discussion
SESSION 08 (ORAL): ISHLT Spotlight: Heart Transplantation in Latin America

Room: Pacifica 7
Target Audiences: HF/HTX, EEP, ID, PATH

Chairs: Are M Holm, MD, PhD, Howard Eisen, MD, and Victor Rossel, MD

12:45 PM  (33) Sequential Measurement of Trypanosoma cruzi Parasitic Load in Endomyocardial Biopsies for Early Detection and Follow-up of Chagas Disease Reactivation After Heart Transplantation; L. A. Benvenuti¹, A. Roggério¹, A. S. Nishiya², S. Mangini¹, J. E. Levi². ¹Heart Institute (InCor), Hospital das Clínicas da FMUSP, São Paulo, Brazil, ²Fundação Pró-Sangue, Hospital das Clínicas da FMUSP, São Paulo, Brazil

12:57 PM  (34) The Paradigm of Gender: Mismatch and Its Influence on Short and Long-Term Outcomes after Heart Transplantation; M. D. Gilbert¹, P. A. Morejón², M. F. Renedo², E. F. Giordanino², L. E. Favaloro², R. D. Ratto², D. O. Absi¹, R. R. Favaloro¹, A. M. Bertolotti¹. ¹Cardiovascular, Thoracic Surgery, and Intrathoracic Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina, ²Heart Failure and Heart Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina


1:21 PM  (36) The Effect of Donor-Recipient Heart Mass and Size Matching in Primary Graft Dysfunction Development after Heart Transplantation; M. D. Gilbert¹, P. A. Morejón², M. F. Renedo², E. F. Giordanino², L. E. Favaloro², R. D. Ratto², D. O. Absi¹, R. R. Favaloro¹, A. M. Bertolotti¹. ¹Cardiovascular, Thoracic Surgery, and Intrathoracic Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina, ²Heart Failure and Heart Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

SESSION 09 (SYMPOSIUM): Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection
Room: Pacifica 1-2
Target Audiences: BSTR, HF/HTX, LF/LTX

Chairs: Daniel Kreisel, MD, PhD, and Tereza Martinu, MD

Session Summary: The goal of this symposium is to review advances in molecular diagnostic assessments and novel biomarkers in thoracic (both heart and lung) organ transplantation. This will include approaches that are being applied clinically and others that are investigational but that can provide greater insight into the pathophysiology and immunology of allograft rejection.

2:00 PM  
*Donor-Derived Cell Free DNA as a Marker of Allograft Injury*
Hannah Valantine, MD, National Institutes of Health, Bethesda, MD, USA

2:15 PM  
Q&A

2:20 PM  
*Monitoring Immune Responses*
Glen Westall, MD, PhD, Alfred Hospital, Melbourne, Australia

2:35 PM  
Q&A

2:40 PM  
*MicroRNA and Exosomes*
P. Christian Schulze, MD, PhD, University Hospital, Jena, Germany

2:55 PM  
Q&A

3:00 PM  
*Through the Looking Glass: Advances in Histology*
Martin J Goddard, FRCS MRCPa, Papworth Hospital, Cambridge, United Kingdom

3:15 PM  
Q&A

3:20 PM  
*Gene Expression Signatures to Monitor Graft Rejection*
Jean-Paul Duong Van Huyen, MD, Hospital Necker, Paris, France

3:35 PM  
Q&A
SESSION 10 (ORAL): Heart Donor Management and Allocation: Setting It Up For Success
Room: Pacifica 7
Target Audiences: HTX, HF

Chairs: Victor Rossel, MD, and Jamila Kremer, MD

2:00 PM  
(38) Non Ischemic Heart Preservation – Results from the Safety Study; J. Nilsson1, V. Jernryd2, G. Qin3, A. Paskevicius1, T. Sjöberg3, P. Höglund4, S. Steen3. 1Skane University Hospital Cardiothoracic Surgery, Lund, Sweden, 2Clinical Sciences Lund, Cardiothoracic Surgery, Lund University, Skane University Hospital, Lund, Sweden, 3Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, 4Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund University and Skane University Hospital, Lund, Sweden

2:15 PM  
(39) Donation after Circulatory Death in Heart Transplantation May Increase the Donor Pool by 20% in the U.S; O. K. Jawitz1, V. Raman1, A. Devore2, R. Mentz2, C. B. Patel2, M. Hartwig1, M. Daneshmand1, J. Schroder1, C. Milano1. 1Department of Surgery, Duke University School of Medicine, Durham, NC, 2Department of Medicine, Duke University School of Medicine, Durham, NC

2:30 PM  
(40) DCD Donor Hearts Recipients Compared to DBD Donor Heart Recipients Present with Comparable Systolic Left Ventricular Function and Better Myocardial Strain at 1 Year Follow Up; A. Ciarka1, A. Page2, S. Messer2, E. Pavlushkov2, S. Colah2, R. Axel12, B. Parizkova2, S. Tsui2, J. Parameshwar2, S. Large2. 1Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, 2of Transplantation, Papworth Hospital, NHS Foundation Trust, Cambridge, United Kingdom

2:45 PM  
(41) A Data-Driven Framework for Monitoring and Improving Organ Donation Awareness among Minorities Using Optimal Social Network Intervention; D. Pinheiro1, M. Murphy2, R. Iyengar2, J. Lazareff3, J. Choi4, R. Menezes5, M. Cadeiras1. 1Department of Internal Medicine, University of California, Davis, Sacramento, CA, 2Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 3Center for World Health, University of California, Los Angeles, Los Angeles, CA, 4Department of Sociology, State University of San Diego, San Diego, CA, 5Department of Computer Science, University of California, Davis, Exeter, United Kingdom

3:00 PM  
(42) The Impact of DCD Heart Transplantation on the Waiting List: A Single Centre Experience; A. Page, R. Duchmke, S. Messer, S. Barra, M. Berman, S. Bhagra, J. Parameshwar, S. Tsui, P. Catarino, S. Pettit, S. Large. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

3:15 PM  
(43) The Benefit of Heart Transplant Among Candidates Assigned Lower Priority in the New 6-Status US Heart Allocation System; W. F. Parker1, E. S. Huang1, R. D. Gibbons2, A. S. Anderson3, M. M. Churpek1. 1University of Chicago Medicine, Chicago, IL, 2Public Health Sciences, University of Chicago Medicine, Chicago, IL, 3Northwestern Medicine, Chicago, IL

3:30 PM  
(44) Clinical Factors Associated with Left Ventricular Recovery in Brain Dead Cardiac Donors; J. R. Peacock, J. Ji, A. Bhatia, J. C. Hartupee, G. A. Ewald. Washington University in St. Louis, St. Louis, MO
SESSION 11 (ORAL): Chronic Lung Allograft Dysfunction: Overcoming the Hurdle?
Room: Pacifica 10-12
Target Audiences: LF/LTX, BSTR, PATH

Chairs: Edward R Garrity, MD, and Cynthia J. Gries, MD, MSc

2:00 PM

(45) Increased Frequency Of regulatory CD127low T Cells and of IL2+ T Cells Early after Lung Transplant is Associated with Improved Graft Survival; E. Ius1, J. Salman1, A. Knöfel1, T. Nakagiri1, W. Sommer1, T. Siemeni1, C. Kühn1, T. Welte2, C. S. Falk3, A. Haverich4, I. Tudorache4, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 3Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

2:15 PM

(46) Prognostic Significance of Mesenchymal Cell Colony Forming Units in Bronchoalveolar Lavage Fluid for Restrictive Chronic Lung Allograft Dysfunction; M. P. Combs1, M. Xia2, D. S. Wheeler1, E. A. Belloli1, D. M. Lyu1, N. M. Walker1, S. Murray2, V. N. L. A. Chen3, 1Department of Medicine, University of Michigan, Ann Arbor, MI, 2Department of Biostatistics, University of Michigan, Ann Arbor, MI

2:30 PM

(47) Intragraft IgG Levels and Donor-Specific anti-HLA Antibodies in Different Phenotypes of Chronic Lung Allograft Dysfunction; A. Sacreas1, J. Taupin2, A. Van Herck1, J. Kaes1, T. Heigl1, A. Vanstapel1, M. Emonds1, L. Daniëls3, R. Vos1, G. M. Verleden1, B. M. Vanaudenaerde1, A. Roux4, S. E. Verleden1. 1Leuven Lung Transplant Unit, Department of Chronic Diseases, Metabolism, and Ageing (CHROMETA), KU Leuven, Leuven, Belgium, 2Laboratoire d’Immunologie et Histocompatibilité, Saint-Louis Hospital, Paris, France, 3Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross, Brussels, Belgium, 4Service de Transplantation Pulmonaire, Foch Hospital, Suresnes, France

2:45 PM

(48) Airway Transcriptome Analysis and Immune Proteome Profiling of the Lung Allograft Reveals Novel Immune Signatures in Chronic Lung Allograft Dysfunction; C. J. Iasella1, A. Hojí2, Y. Zhang2, W. Xu2, K. Chen2, M. Brown2, E. Lendermon2, B. A. Johnson2, S. Kilaru2, M. R. Morrell1, J. M. Pilewski2, J. F. McDyer2. 1Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh, Pittsburgh, PA

3:00 PM

(49) Host miRNA Profile of Aspergillus Colonization Resulting in CLAD in Lung Transplant Recipients; W. Gohir1, W. Klement3, L. G. Singer3, S. M. Palmer4, S. Keshavjee3, S. Hussain1. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Organ Donor and Transplantation, Canadian Blood Services, Ottawa, ON, Canada, 3Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 4Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC

3:15 PM

(50) Identification and Characterization of Patients With a Mixed Phenotype of CLAD; S. E. Verleden1, J. Von der Thüsen2, A. Van Herck3, B. Weynand1, E. Verbeken1, J. Verschakelen1, A. Dubbeldam2, B. Vanaudenaerde1, D. Van Raemdonck1, R. Vos1, G. Verleden1. 1KU Leuven, Leuven, Belgium, 2Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands

3:30 PM

(51) Exploring Chronic Lung Transplant (LTX) Allograft Dysfunction (CLAD): The Potential Clinical Prognostic Relevance of Single Bite Transbronchial Biopsy (TBB) Microarray; G. I. Snell1, G. Westall1, Y. Cristiano1, B. J. Levvey1, L. Sullivan1, K. Halloran2, P. Halloran3. 1Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 2Lung Transplant and Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Medicine, University of Alberta, Edmonton, AB, Canada
SESSION 12 (ORAL): When Short-Term Becomes Long-Term: Transition from Temporary to Permanent Mechanical Support
Room: Pacifica 6
Target Audience: MCS

Chairs: Maria M. Mountis, DO, and Christopher T Salerno, MD

2:00 PM

(52) Outcomes of Patients Supported with ECMO as a Bridge to Durable Mechanical Circulatory Support: An Analysis of the STS Intermacs Database; R. Y. Lovaga-Rendon1, T. Boeve2, J. Tallaj3, S. Lee1, M. Leachec3, D. A. Koehl1, R. S. Cantor4, K. Lotun5, D. Ackarya5. 1Cardiology Division, Spectrum Health, Grand Rapids, MI, 2Cardiothoracic Surgery Division, Spectrum Health, Grand Rapids, MI, 3Cardiovascular Division, University of Alabama at Birmingham, Birmingham, AL, 4Kirklin Institute for Research in Surgical Outcomes, University of Alabama at Birmingham, Birmingham, AL, 5Cardiovascular Diseases Division, University of Arizona Sarver Heart Center, Tucson, AZ

2:15 PM

(53) Comparison of ECMO Patients Bridged to LVAD vs Bridged to Transplantation; C. Lui, C. D. Fraser, A. Suarez-Pierre, X. Zhou, K. J. Zehr, C. W. Choi, A. Kilic. Johns Hopkins University, Baltimore, MD

2:30 PM

(54) Short and Long-Term Adverse Events in Patients on Temporary Circulatory Support before LVAD: An IMACS Registry Analysis; V. Ton1, J. A. Hernandez-Montfort2, R. Xie3, B. P. Meyns4, T. Nakatani5, M. Yanase6, S. Shaw7, S. Pettiti8, I. Netuka9, J. Kirklin10, D. J. Goldstein11, J. Cowger12. 1University of Maryland School of Medicine, Baltimore, MD, 2The University of Texas Medical Branch-Galveston, Galveston, TX, 3The University of Alabama at Birmingham, Birmingham, AL, 4Gasthuisberg University Hospital, Leuven, Belgium, 5National Cardiovascular Center, Osaka, Japan, 6National Cerebral and Cardiovascular Center, Osaka, Japan, 7Wythenshawe Hospital, Manchester, United Kingdom, 8Royal Papworth Hospital, Cambridge, United Kingdom, 9IKEM - Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 10University of Alabama at Birmingham, Birmingham, AL, 11Montefiore Medical Center, New York, NY, 12Henry Ford Health System, Detroit, MI

2:45 PM

(55) Longitudinal Impact of Temporary Mechanical Circulatory Support on Durable Left Ventricular Assist Device Outcomes: An IMACS Registry Analysis; J. A. Hernandez-Montfort1, V. Khue Ton2, R. Xie3, A. Fisher4, B. Meyns5, T. Nakatani6, I. Netuka7, S. Pettiti8, S. Shaw9, M. Yanase10, J. K. Kirklin11, A. Rowe12, D. J. Goldstein13, J. Cowger14. 1The University of Texas Medical Branch - Galveston, Galveston, TX, 2University of Maryland, Baltimore, MD, 3IMACS, Birmingham, AL, 4Newcastle University, Newcastle, United Kingdom, 5UZ Leuven, Leuven, Belgium, 6Maki Hospital, Osaka, Japan, 7Institut Clinical and Experimental Medicine, Prague, Czech Republic, 8Papworth, Cambridge, United Kingdom, 9Manchester University NHS Foundation Trust, Manchester, United Kingdom, 10National Cerebral and Cardiovascular Center, Osaka, Japan, 11University of Alabama- Birmingham, Birmingham, AL, 12ISHLT Headquarters, Addison, TX, 13Montefiore, Bronx, NY, 14Cardiology, Henry Ford Hospital, Detroit, MI

3:00 PM

(56) Transition from Short-Term to Durable Mechanical Circulatory Support Systems. Outcome and Patient Selection. On Behalf of ECMO-VAD Study Group; D. Saeed1, E. Potapov2, A. Loforte3, M. Morchius4, D. Schibisky5, D. Zimpfer6, J. Riebandt6, F. Pappalardo7, M. Attisani8, A. Haneya9, F. Ramjankhan10, D. Donker10, U. Jorde11, R. Wieloch4, Osaka, Japan, 7Institut Clinical and Experimental Medicine, Prague, Czech Republic, 8Royal Papworth Hospital, Cambridge, United Kingdom, 9University of Alabama- Birmingham, Birmingham, AL, 12ISHLT Headquarters, Addison, TX, 13Montefiore, Bronx, NY, 14Cardiology, Henry Ford Hospital, Detroit, MI

3:15 PM

(57) Risk Factors for Bleeding and Thrombosis Events on Veno-Arterial Extracorporeal Life Support: An ELSO Analysis; F. R. Cabezas1, E. W. Grandin2, R. Kociol3, M. R. Mehra1. 1Beth Israel Deaconess Medical Center, Boston, MA, 2Advanced Heart Failure, Brigham and Women’s Hospital, Boston, MA

3:30 PM

(58) Impact of Temporary Mechanical Circulatory Support Prior to Implantation of a Ventricular Assist Device with a Follow-Up of 1 Year- A EUROMACS Analysis; D. Schibisky1, T. de By2, J. Gummert2, F. Ramjankhan3, J. Wolfinger4, E. Potapov5, I. Netuka6, F. Beyersdorf7, M. Siepe1. 1Department of Cardiovascular...
Surgery, University Heart Center Freiburg • Bad Krozingen, Freiburg Germany and Medical Faculty of the Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany, 2EUROMACS, Windsor, Germany, 3Department of Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany, 4Department of Cardiovascular Surgery, University Medical Center Utrecht, Utrecht, Germany, 5Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany, 6Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
SESSION 13 (SYMPOSIUM): They Tell Me I Am Irregular: Why Do They Care? Arrhythmias in LVAD Recipients
Room: Grand Caribbean 1-7
Target Audience: MCS

Chairs: Michael M. Givertz, MD, and Stephan Schueler, MD, PhD, FRCS

Session Summary: CF-LVAD patients are living longer, and cardiac implantable electronic devices and arrhythmia management have assumed a significant role. More data is available to guide management, and expert speakers including MCS and EP specialists will discuss existing data & provide recommendations regarding appropriate management of ICD/CRT and arrhythmias in LVAD recipients.

2:00 PM  Atrial Fibrillation and Flutter in LVAD Patients: Incidence, Significance and Management
Sean P Pinney, MD, Mount Sinai Medical Center, New York, NY, USA

2:15 PM  Q&A

2:20 PM  Optimal Device Programming and Role of Catheter and Surgical Ablation in Arrhythmia Management Post-LVAD
Joshua D Moss, MD, UCSF Medical Center, San Francisco, CA, USA

2:35 PM  Q&A

2:40 PM  DEBATE: All VAD Patients Should Have ICD and All VT Should Be Ablated (PRO)
Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

2:55 PM  DEBATE: All VAD Patients Should Have ICD and All VT Should Be Ablated (CON)
Shashank S Desai, MD, Inova Fairfax Hospital, Falls Church, VA, USA

3:10 PM  DEBATE: BiV Pacing Improves Outcomes in LVAD Patients (PRO)
Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

3:25 PM  DEBATE: BiV Pacing Improves Outcomes in LVAD Patients (CON)
Jens Garbade, MD, University of Leipzig Medical Center, Leipzig, Germany
WEDNESDAY, APRIL 3, 2019
2:00 PM - 3:45 PM

SESSION 14 (SYMPOSIUM): Part of (Their) World: Discharging Patients Home with a New Device
Room: Pacifica 3-5
Target Audiences: NHSAH, MCS, PEDS

Chairs: Sarah E Schroeder, ACNP-BC, MSN, RN, AACC, and Mark E Puhlman, DNP, ANP-C

Session Summary: A successful discharge for patients with VAD or other supportive therapies (continuous infusions for pulmonary hypertension and heart failure patients) requires thoughtful planning and education. This symposium addresses topics geared towards helping patients successfully discharge to (and remain) home, including self-management/self-efficacy, discharge medications, avoiding readmission, preparing caregivers of patients with devices, and addressing the issues most important to patients: driving, showering, drinking, sex and traveling.

2:00 PM I Can Go the Distance: Building Self Care and Self-Empowerment in Patients
Jesus Casida, PhD, RN, Johns Hopkins University, Baltimore, MD, USA

2:15 PM Q&A

2:20 PM You’ve Got a Friend in Me: Preparing Caregivers
Jodie Lantz, MSN, RN, PCNS-BC, Children’s Health Dallas, Richardson, TX, USA

2:35 PM Q&A

2:40 PM A Spoonful of Sugar Makes the Discharge Medications Go Down
Cassandra Vale, PharmD, The Prince Charles Hospital, Queensland, Australia

2:55 PM Q&A

3:00 PM How Far I’ll Go: Preventing Returns to the Hospital
Nicola Robinson Smith, RN, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

3:15 PM Q&A

3:20 PM The Bare Necessities: The Do’s and Don’ts of Living with a New Device
Wendy Gin-Sing, CNS, Hammersmith Hospital, London, United Kingdom

3:35 PM Q&A
SESSION 15 (ORAL): Pharmacotherapy in Transplantation: Reading the Tea Leaves to Improve Outcomes
Room: Coral Sea
Target Audiences: PHARM, HF/HTX, MCS

Chairs: Adam B Cochrane, PharmD, and Keyur B. Shah, MD


2:15 PM (60) *Effect of Methylene Blue Administration on Vasoplegia Following Left Ventricular Assist Device Implantation*; A. Saha, D. L. Jennings, J. Sanchez, A. Melehy, M. Yuzefpolskaya, P. C. Colombo, M. A. Farr, H. Takayama, Y. Naka, K. Takeda. *Columbia University Vagelos College of Physicians and Surgeons, New York, NY, Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, NY, Department of Surgery, Division of Cardiac, Thoracic & Vascular Surgery, Columbia University Irving Medical Center, New York, NY*

2:30 PM (61) *Comparative Efficacy of Bortezomib and Carfilzomib Desensitization Protocols in Highly Sensitized Cardiac Transplant Candidates*; M. Sobhanian, J. Saltarrelli, P. Weeks, S. Nathan, R. Radovancevic, B. Kar, I. Gregoric. *Memorial Hermann Hospital - Texas Medical Center, Houston, TX, The University of Texas Health Science Center at Houston, Houston, TX*


3:00 PM (63) *Association between Cumulative Pre-Transplant Amiodarone Dose and Post-Transplant Outcomes after Heart Transplantation*; L. M. Lourenco, K. Lang, P. Simone, S. Patel, J. Powers, T. Riley, C. Murks, B. Smith, S. Kalantari, J. Raikhelkar, N. Sarswat, G. Kim, G. Sayer, N. Uriel. *Pharmacy Services, University of Chicago Medicine, Chicago, IL, Cardiology, University of Chicago Medicine, Chicago, IL*


3:30 PM (65) *Past is Not Prologue - Immune Function Assay Results as a Predictor of Malignancy Post-Heart Transplant (HT)*; T. Khu, M. Kamath, M. Moore, A. Salimbangon, T. Daun, A. Chang, L. Sweet, E. DePasquale, A. Nsair, R. Ardehali, A. Baas, M. Deng, M. Cadeiras, A. Ardehali. *Transplant Services, UCLA, Los Angeles, CA, Medicine, Cardiology, UCLA, Los Angeles, CA, Medicine, Cardiology, UC Davis, Davis, CA, Surgery, UCLA, Los Angeles, CA*
WEDNESDAY, APRIL 3, 2019
4:15 PM - 6:00 PM

SESSION 16 (ORAL): Junior Faculty and Trainees Clinical Case Dilemmas: The Best of the Best
Room: Coral Sea
Target Audience: ALL
Chairs: Ryan Butts, MD, and Lavanya Bellumkonda, MD

4:15 PM  (66) Stop the Leak! Transcatheter Aortic Valve Replacement in Pediatric VAD Patient
H. P. Tunuguntla¹, I. Adachi², A. Khan³, B. A. Elias², S. Choudhry¹, A. G. Cabrera¹, J. F. Price¹, W. J. Dreyer¹, S. W. Denfield¹, J. A. Spinner¹, A. Jeewa¹, A. M. Qureshi¹. ¹Pediatric Cardiology, Texas Children's Hospital, Houston, TX, ²Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, ³Pediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

4:20 PM  Expert Discussant, Christopher Almond, MD, Stanford University, Stanford, CA, USA

4:25 PM  Discussion

4:32 PM  (67) The Utility of CardioMEMS Implantable Hemodynamic Monitoring Device in Heartware HVAD Patient with Recurrent Gastrointestinal Bleeding; H. Singh¹, V. Kittipibul², R. Flowers², S. V. Chaparro³. ¹University of Miami Miller School of Medicine, Miami, FL, ²Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ³Cardiovascular Medicine Division, University of Miami Miller School of Medicine, Miami, FL

4:37 PM  Expert Discussant, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

4:42 PM  Discussion

4:49 PM  (68) Inverted Lung Transplantation: Interposition of Pericardial Conduit for Pulmonary Venous Anastomosis; H. Yamamoto¹, K. Miyoshi¹, T. Kurokaki¹, S. Otani¹, M. Okazaki¹, S. Sugimoto¹, M. Yamane¹, S. Toyooka¹, T. Oto¹. ¹General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan, ²General Thoracic Surgery, Okayama Medical Center, Okayama, Japan

4:54 PM  Expert Discussant, Christopher H. Wigfield, MD, FRCS, Advocate Christ Medical Center, Chicago, IL, USA

4:59 PM  Discussion

5:06 PM  (69) Successful Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection in a Cystic Fibrosis Patient; N. Law¹, C. Logan¹, C. Furr², S. Lehman², S. Morales², F. Rosas², A. Gaidamaka², I. Bilinsky², P. Grín², R. Schooley¹, S. Aslam¹. ¹University of California, San Diego, San Diego, CA, ²AmpliPhi Biosciences Inc, San Diego, CA

5:11 PM  Expert Discussant, Nicolas Mueller, MD., University Hospital Zurich, Zurich, Switzerland

5:16 PM  Discussion

5:23 PM  (70) Tocilizumab for Antibody-Mediated Rejection in the Setting of Cardiac Allograft Vasculopathy; S. January¹, A. Pottebaum¹, D. Raymer¹, K. Lavine². ¹Barnes-Jewish Hospital, St Louis, MO, ²Washington University School of Medicine, St Louis, MO

5:28 PM  Expert Discussant, Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

5:33 PM  Discussion

5:40 PM  (71) Expanding Benefits from Cardiac Resynchronization Therapy to Exercise-Induced Left Bundle Branch Block in the Setting of Advanced Heart Failure: A Case Report; F. L. Scolari, W. R. Menegazzo, A. D. Silveira, A. C. Mendes, M. Pimentel, N. Clausell, L. Goldraich. Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil

5:45 PM  Expert Discussant, Sharon A. Hunt, MD, Stanford University Medical Center, Stanford, CA, USA

5:50 PM  Discussion
SESSION 17 (ORAL): Tolerance Is All We Need in Thoracic Transplantation
Room: Pacifica 1-2
Target Audiences: BSTR, HTX, LTX, PATH

Chairs: Fabio Ius, MD, and Thalachallour Mohanakumar, PhD

4:15 PM

(72) 31 Day Xeno Lung Recipient Survival - Progress towards the Clinic; L. Burdorf1, C. Laird2, S. Sendil2, N. O'Neill2, T. Zhang2, D. Parsell2, I. Tatarov3, Z. Abady1, B. M. Cerel1, S. Pratts1, C. J. Phelps4, D. L. Ayares4, A. M. Azimzadeh1, R. N. Pierson III1. 1Surgery, Center for Transplantation Sciences, MGH, Charlestown, MA, 2Surgery, University of Maryland, Baltimore, MD, 3Surgery, University of Maryland, Baltimore, MA, 4Revivicor, Blacksburg, VA

4:30 PM

(73) Tolerance Induction by Myeloid Progenitor Cells Does Not Require Lethal Preconditioning or Hematopoietic Stem Cell Transplantation; Y. Li1, A. Sedello2, J. Domen1. 1Ward Family Heart Center, Children’s Mercy Hospital and Clinics, Kansas City, MO, 2Cellerant Therapeutics, San Carlos, CA

4:45 PM

(74) IL-22 Regulates Induction of Foxp3-Rich Tertiary Lymphoid Organs in Tolerant Lung Allografts; S. Tanaka1, J. M. Gauthier1, A. Fuchs1, W. Li1, R. Higashikubo1, A. Y. Tong1, A. S. Krupnick2, A. E. Gelman1, D. Kreisel1. 1Department of Surgery, Washington University in St. Louis, St. Louis, MO, 2Department of Surgery, The University of Virginia, Charlottesville, VA

5:00 PM


5:15 PM

(76) PI3-Kinase Inhibition Promotes Tolerogenic CD8+ T Cell Function in Lung Transplant Recipients with a History of Cigarette Smoke Exposure; K. J. Patel1, Q. Cheng1, D. P. Allen1, C. Li1, C. Wallace1, A. Alawieh1, L. Cardenas1, J. Kilkenny1, S. N. Nadig1, M. Goddard4, J. Christie4, C. Krieg3, C. Atkinson1. 1Surgery, Medical University of South Carolina, Charleston, SC, 2Department of Surgery, Tongji Hospital, Wuhan, China, 3Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 4Pathology, Royal Papworth Hospital NHS Trust, Cambridgeshire, United Kingdom, 5Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

5:30 PM

(77) Donor T and NK Cells are Derived from the Donor Lung Parenchyme and Represent Tissue-Resident Memory Cells - An Important Feature for Tolerance Development; R. Bellmàs Sanz1, A. Hitz1, B. Wiegmann2, K. Bläsing1, F. Ius2, A. Knöfel2, I. Tudorache2, M. Avsar2, D. Jonigk3, A. Haverich2, G. Warnecke2, C. Falk1. 1Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, 2Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 3Institute of Pathology, Hannover Medical School, Hannover, Germany

5:45 PM

WEDNESDAY, APRIL 3, 2019
4:15 PM - 6:00 PM

SESSION 18 (ORAL): Ex-Vivo Heart Perfusion and Preservation: Some Like It Hot - or Not!
Room: Pacifica 7
Target Audiences: HTX, HF

Chairs: Luanda P Grazette, MD, and Maryl R Johnson, MD

4:15 PM
(79) Successful Utilization of Extended Criteria Donor (ECD) Hearts for Transplantation - Results of the OCS™ Heart EXPAND Trial to Evaluate the Effectiveness and Safety of the OCS Heart System to Preserve and Assess ECD Hearts for Transplantation; J. N. Schroeder1, D. D’Alessandro2, F. Esmailian3, T. Boeve4, P. Tang5, K. Liao6, I. Wang7, A. Anyanwu8, A. Shah9, K. Mudy10, E. Soltesz11, J. W. Smith12. 1Duke University Medical Center, Durham, NC, 2Massachusetts General Hospital, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4Spectrum Health, Grand Rapids, MI, 5University of Michigan, Ann Arbor, MI, 6University of Minnesota, Minneapolis, MN, 7Indiana University, Indianapolis, IN, 8Mount Sinai, New York, NY, 9Vanderbilt University, Nashville, TN, 10Minneapolis Heart Institute, Minneapolis, MN, 11Cleveland Clinic Foundation, Cleveland, OH, 12University of Washington, Seattle, WA

4:30 PM
(80) Ex-vivo Perfusion on Marginal Donors in Heart Transplantation: Clinical Results and Pathological Findings; S. Sponga1, V. Ferrara1, A. P. Beltrami2, A. Bonetti2, C. Cantarutti2, A. Caragnano2, F. Ortolani2, A. Lechiancole1, R. Esposito1, C. Di Nora1, V. Tursi1, C. Nalli1, U. Liv1, Cardiothoracic Department, Udine University Hospital, Udine, Italy, 2Medical Area Department (DAME), Udine University Hospital, Udine, Italy, 3Udine University Hospital, Udine, Italy

4:45 PM

5:00 PM
(82) Cardiac Transplantation in Higher Risk Patients: Is Ex Vivo Heart Perfusion a Safe Preservation Technique? A Two Center Experience; S. V. Rojas1, F. Ius1, D. Schibiliisky2, T. Kaufeld1, W. Sommer1, C. Benk2, T. Goecke1, T. Siemens1, R. Poyanmehr1, S. Rühke1, A. Mogaldea1, D. Bobylev1, J. Salman1, M. Avsar1, I. Tudorache1, C. Bara1, F. Beyerdsorf2, A. Haverich1, M. Siepe2, G. Warnecke1. 1Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Thoracic and Cardiovascular Surgery, University of Freiburg, Freiburg, Germany

5:15 PM
(83) Keeping It Cool: Extended Myocardial Protection with Topical Cooling to Reduce PGD; S. Avtaar Singh1, S. Das De1, K. Morcos1, Y. Hegazy1, H. Al-Haideri1, S. Nair1, J. Dalzell2, H. Doshi1, N. Al-Attar1, P. Curry1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

5:30 PM
(84) The First Clinical Use of a Novel Cold Storage System of Donor Hearts; N. Naito1, M. Funamoto1, R. Pierson1, M. Villavicencio1, W. Riley2, G. Lewis3, D. D’Alessandro4. 1Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Perfusion Services, Massachusetts General Hospital, Boston, MA, 3Cardiology, Massachusetts General Hospital, Boston, MA

5:45 PM
(85) Heart Ablation Avoiding Asystolia with an Always- Beating Heart; L. G. Berra1, M. L. Berra2, M. A. Lewis3, S. Berra4, A. O. Irusta5, G. Berra6, P. A. Takeuchi7. 1Heart, Lung and Kidney Transplant Team, Hospital Nacional de Pediatría JP Garrahan, Moron, Argentina, 2Clínica Medica, Hospital Nacional Alejandro Posadas, Morón, Argentina, 3Vice President, Lew Insuimos e Innovaciones, Moron, Argentina, 4Facultad de Ingeniería, Universidad de Buenos Aires, Buenos Aires, Argentina, 5Design Team, Lew Insuimos e Innovaciones, Moron, Argentina, 6President, Lew Insuimos e Innovaciones, Moron, Argentina
SESSION 19 (SYMPOSIUM): Chronic Lung Allograft Dysfunction (CLAD): The End of the Beginning?
Room: Pacifica 10-12
Target Audiences: LF/LTX, BSTR, PATH

Chairs: Christian Benden, MD, and Sofya Tokman, MD

Session Summary: The recognition that not all cases of lung allograft dysfunction could be described accurately within the bronchiolitis obliterans syndrome (BOS) terminology led to the development of a new overarching descriptor (CLAD) to embrace both obstructive and restrictive allograft dysfunction. How to detect, diagnose, and manage suspected cases is described based on sound physiological and radiological principles. Exclusion criteria are discussed as well as special circumstances. A 15-min panel discussion with all speakers will conclude this session.

4:15 PM  
**CLAD: Definition and Beyond**  
Geert Verleden, MD, Univ Hospital Gasthuisberg, Belgium, Belgium

4:30 PM  
**CLAD Phenotypes: Why Split?**  
Jamie Todd, MD, Duke University, Durham, NC, USA

4:45 PM  
**Restrictive Allograft Syndrome: Definition and Diagnosis**  
Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

5:00 PM  
**Restrictive Allograft Syndrome: Pathology**  
Jan H von der Thüsen, MD PhD, Erasmus Medical Center, Rotterdam, Netherlands

5:15 PM  
**Risk Factors and Prognosis of Restrictive Allograft Syndrome**  
Gregory I. Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia

5:30 PM  
**CLAD Treatment: The Kingdom of the Near Dead?**  
Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, ON, Canada

5:45 PM  
**15-min Panel Discussion**
SESSION 20 (ORAL): The Beat Goes On: Arrhythmias and Pacing During MCS
Room: Pacifica 6
Target Audiences: MCS, NHSAH

Chairs: Melana Yuzefpolskaya, MD, and Joseph Rogers, MD

4:15 PM
(86) Atrial Fibrillation is a Predictor of Poor Physical Capacity 6 Months after Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis from ELEVATE; K. K. Mirza1, F. Gustafsson1, Y. Pya1, S. Shaw1, A. Diegeler1, I. Netuka4, J. Lavee3, J. Garbade6, M. Morshuis5, J. Heatley8, D. Saeed9, E. V. Potapov10, J. Schimtt11, D. Zimpfner12. 1Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, 2National Research Center for Cardiovascular Surgery, Astana, Kazakhstan, 3Southmoor Road, M23 9LT, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 4Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 5Heart Transplantation Unit, Levie Heart Center, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Straumellstrasse 39, 4289, Department of Cardiac Surgery, Heart Center Leipzig, University of Leipzig, Leipzig, Germany, 7Georgstrasse 11, 32545, Department of Cardiothoracic Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, 8Abbott, Chicago, IL, 9Straumellstrasse 39, 40289, University Department for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany, 10Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany, 11Department of Cardiothoracic, Transplantation and Vascular Surgery, Medizinische Hochschule Hannover, Hannover, Germany, 12Department of Surgery, Waehringer Guertel 18–20, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

4:30 PM
(87) Impact of Atrial Fibrillation on Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation; V. Blumer1, M. Ortiz2, G. Hernandez3, V. Kittipibul1, A. Gage4, E. Joyce5, S. Chaparro1. 1University of Miami, Miami, FL, 2University of Iowa, Iowa City, IA, 3Univ. of Miami, Miami, FL, 4Cleveland Clinic, Cleveland, OH, 5Mater Misericordiae University Hospital, Dublin, Ireland

4:45 PM
(88) Peak Left Atrial Appendage Emptying Velocity Remains Reduced in Atrial Fibrillation during Continuous Flow Left Ventricular Assist Device Support; A. Rahman1, E. Tam1, L. Zhang1, J. Fontes1, S. Forest1, S. Vukelic1, D. Sims1, J. Shin1, S. Patel1, D. J. Goldstein2, U. P. Jorde1, O. Saeed1. 1Medicine (Cardiology), Montefiore Medical Center, Bronx, NY, 2Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

5:00 PM
(89) Comparison of Amiodarone and Beta Blockers to Suppress Tachyarrhythmias in Patients with Left Ventricular Assist Devices; B. El-Sabawy1, J. V. Hull2, H. Tun3, A. S. Vaidya3, J. E. Rahman1, K. A. Pandya3, L. Grizette1, M. W. Fong1. 1Department of Medicine, Mayo Clinic, Rochester, MN, 2Keck School of Medicine of the University of Southern California, Los Angeles, CA, 3Division of Cardiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA

5:15 PM
(90) Functional Status, Quality of Life and Ventricular Tachyarrhythmias Improve with Right Ventricular Pacing Compared to Biventricular Pacing in LVAD Patients; B. Chung1, J. Grinstein2, S. Weatherford3, S. Tayazime4, D. Rodgers1, A. Nguyen5, N. Narang6, G. Kim7, J. Raikhelkar8, U. Jorde9, C. LaBuhn1, V. Jeevanandam1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2MedStar Health, Washington, DC, 3Montefiore Medical Center, New York, NY

5:30 PM
(91) Acute Hemodynamic Effects of Different Pacing Strategies in LVAD Recipients; G. Gulati1, M. Brisco-Bacak2, C. Madias3, S. Joseph4, A. Kilić5, J. Rich5, I. Gosev6, M. Kiernan1. 1Cardiology, Tufts Medical Center, Boston, MA, 2Cardiology, Temple University Hospital, Philadelphia, PA, 3Cardiology, Baylor University Medical Center, Dallas, TX, 4Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, 5Cardiology, Northwestern University, Chicago, IL, 6Surgery, University of Rochester, Rochester, NY

5:45 PM
(92) Ventricular Arrhythmias in Patients with Biventricular Assist Devices; A. Lin1, H. Tran, J. Hsu, K. Hoffmayer, G. Feld, E. Adler, V. Pretorius, D. Krummen, G. Ho. 1University of California San Diego, San Diego, CA
SESSION 21 (SYMPOSIUM): Short Term Mechanical Support: Taking the Next Leap Forward  
Room: Grand Caribbean 1-7  
Target Audiences: MCS, HF/HTX

Chairs: Bart Meyns, MD, PhD, and Luciano Potena, MD, PhD  

Session Summary: This symposium will focus on short term mechanical support with a view to optimizing results, whether as a bridge to recovery, long term mechanical support or transplant. Current and future management trends will be discussed to identify best practices for these complex patients.

4:15 PM  IABP's Work, But in Whom?  
Jerry D Estep, MD, Cleveland Clinic, Cleveland, OH, USA

4:30 PM  Q&A

4:35 PM  In It for the Long Haul? What is the Role of ECMO in Short-Term Support?  
Martin Strueber, MD, Beth Israel Medical Center, Newark, NJ, USA

4:50 PM  Q&A

4:55 PM  DEBATE: Six Months After the Change in the US Allocation System: It Still Makes Sense to Transplant Patients Off ECMO (PRO)  
Danny Ramzy, MD, PhD, Cedars-Sinai Med Ctr, Los Angeles, CA, USA

5:10 PM  DEBATE: Six Months After the Change in the US Allocation System: It Still Makes Sense to Transplant Patients Off ECMO (CON)  
Jose Gonzalez-Costello, MD, Belvitge Hospital, Barcelona, Spain

5:25 PM  Debate Rebuttal (PRO)  
Danny Ramzy, MD, PhD, Cedars-Sinai Med Ctr, Los Angeles, CA, USA

5:30 PM  Debate Rebuttal (CON)  
Jose Gonzalez-Costello, MD, Belvitge Hospital, Barcelona, Spain

5:35 PM  Do All Roads Lead to Rome? Access Strategies for Temporary Percutaneous Mechanical Support  
Jennifer A Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, USA

5:50 PM  Q&A
SESSION 22 (SYMPOSIUM): What Do We Do? Burning Platforms in Pediatric Thoracic Transplant
Room: Pacifica 3-5
Target Audiences: PEDS, HF/HTX, NHSAH

Chairs: Melanie D Everitt, MD, and Tajinder P Singh, MD, MSc

Session Summary: The goal of the symposium is to address the challenges we are currently facing within the field of pediatric thoracic transplant. From donor selection to indications for transplant in the failing Fontan population, a potpourri of topics will be covered. A 15-min panel discussion with all speakers will conclude this session.

4:15 PM  Pediatric Heart Donors with Low Ejection Fraction - How Low Can You Go?
Claire A Irving, MBChB, MRCPCH, MD, Children's Hospital Westmead, Sydney, Australia

4:30 PM  But It's Legal Here: Addressing Legalized Marijuana and Illicit Drug Use with Thoracic Transplant Patients
Carol K Conrad, MD, Lucille Packard Children's Hospital, Palo Alto, CA, USA

4:45 PM  How Low Should We Go? Outcomes of Infant VAD and Transplant
Kathleen Simpson, MD, Washington University/St. Louis Children's Hospital, St. Louis, MO, USA

5:00 PM  Practical Strategies for Transitioning Our GenZ Patients
Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom

5:15 PM  Routine Use of mTOR inhibitors in Pediatric Thoracic Transplant Recipients: Show Me the Evidence
Kevin P Daly, MD, Boston Children's Hospital, Boston, MA, USA

5:30 PM  When to Refer: Advanced Cardiac Support for the Failing Fontan
Kurt R Schumacher, MD, CS Mott Children's Hospital, Ann Arbor, MI, USA

5:45 PM  15-min Panel Discussion
WEDNESDAY, APRIL 3, 2019
6:15 PM - 7:15 PM

MINI ORAL 01: Deciphering the Role of Antibodies and Inflammation in Thoracic Rejection
Room: Pacifica 1-2
Target Audiences: BSTR, HTX, LTX, PATH

Chairs: Yoshito Yamada, MD, PhD, and Sebastian G A Michel, MD

6:15 PM  (357) Downregulation of Alloimmunity in Lung Allograft by Eosinophils is Orchestrated by PD-L1 Dependent Contact with CD8+ T Cells; O. O. Onyema1, Y. Guo1, B. Mahgoub1, A. Manafi1, Q. Wang1, S. Criswell2, J. Lannigan3, E. A. Jacobsen4, A. E. Gelman5, D. Kreisel5, A. S. Krupnick1. 1Department of Surgery and Carter Immunology Center, University of Virginia, Charlottesville, VA. 2Department of Cell Biology and Advanced Microscopy Core Laboratory, University of Virginia, Charlottesville, VA. 3Flow Cytometry Core Facility, University of Virginia, Charlottesville, VA. 4Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ. 5Department of Surgery, Washington University, St Louis, MO

6:20 PM  (358) Donor-Derived Factors Influence NK Cell Effector Activity in a Model of Antibody-Mediated Chronic Rejection; C. M. Lin1, B. Mehrad2, R. G. Gill3. 1Medicine, University of Florida, Gainesville, FL. 2Surgery, University of Colorado, Aurora, CO


6:45 PM  (363) Alpha1-Antitrypsin Therapy Suppresses Acute Rejection in an Orthotopic Murine Lung Transplantation Model; T. Nakagiri1, A. Knöfel1, S. Janciauskiene2, P. Zardo1, S. Wrenger1, T. Welte2, A. Haverich1, G. Warnecke1. 1Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany. 2Respiratory Medicine, Hannover Medical School, Hannover, Germany

6:50 PM  (364) Circulating Exosomes with Lung Self-Antigens, Kα1Tubulin and Collagen V, and Immune Responses to Lung Self-Antigens Precedes Histological Evidence of Chronic Rejection Following Orthotopic Murine Lung Transplantation; M. Rahman, M. Sharma, W. Liu, M. A. Smith, R. M. Bremner, T. Mohanakumar. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

6:55 PM  (365) Reconstruction of Transcriptional Programs of Monocyte to Macrophage Sequential Cell Fate Transition Using Single Cell RNA Sequencing in Sex Mis-Matched Lung Transplantation; B. O'Sullivan1, J. Powell2, S. Lukowski2, M. Tan1, P. Hopkins1, D. Chambers1. 1Queensland Lung Transplant Research, Brisbane, Australia. 2Garvan Institute, Sydney, Australia. 3Institute for Molecular Bioscience, Brisbane, Australia

7:00 PM  (366) Clonal Composition and Single-Cell Characterization of T-Cell Infiltrates in Cardiac Allograft Vasculopathy; M. V. Habal1, A. Myung2, S. Rao2, S. See2, R. R. Shihab2, P. Roy2, C. Marboe3, S. Restaino1, A. S. Han2, M. Givertz2, J. C. Madsen2, L. J. Addonizio2, M. Farr1, E. Zorn2. 1Cardiology, Columbia University, New York, NY. 2Columbia Center for Translational Immunology, Columbia University, New York, NY. 3Pathology & Cell Biology, Columbia University, New York, NY. 4Cardiology, Brigham and Women's Hospital, Boston, MA. 5Surgery, Massachusetts General Hospital, Boston, MA. 6Pediatric Cardiology, Columbia University, New York, NY
(367) The Frequency of Tissue-Resident Donor T and NK Cells in Peripheral Blood after Lung Transplantation is Modulated by Normothermic Ex Vivo Lung; C. Falk¹, B. Wiegmann², A. Hitz¹, R. Bellmas-Sanz¹, K. Bläsing¹, F. Ius², C. Kühn², M. Avsar², I. Tudorache², A. Haverich², G. Warnecke². ¹Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ²Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

(368) Persisting Donor Alveolar Macrophages Have Increased Expression of Scavenger Receptor CD206 Compared to Graft-Infiltrating Recipient-Derived Macrophages Following Lung Transplantation; M. E. Snyder¹, S. P. Weisberg², T. Connors³, L. Benvenuto⁴, L. Shah⁴, H. J. Robbins⁴, J. L. Hook⁴, F. D'Ovidio⁵, J. Sonett¹, S. Arcasoy⁴, D. L. Farber⁵. ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Pathology, Columbia University, New York, NY, ³Pediatrics, Columbia University, New York, NY, ⁴Medicine, Columbia University, New York, NY, ⁵Surgery, Columbia University, New York, NY

6:20 PM  (370) Label-Free Proteomics Approach Characterizes Plasma Protein Signature of Donor Brain Death; J. Lukac1, M. Saraswata2, S. Joenväärää3, E. Holmström1, K. Dhaygude4, R. Krebs1, A. Nykänen1, R. Renkonen2, K. Lemström1. 1Cardiopulmonary Research Group, Transplantation Laboratory University of Helsinki, Helsinki, Finland, 2Mass Spectrometry Group, Transplantation Laboratory University of Helsinki, Helsinki, Finland, 3Cardiovascular Research Group, Transplantation Laboratory, University of Helsinki, Helsinki, Finland

6:25 PM  (371) Donor Hormonal Thyroid Therapy is Associated with Increased Risk of Primary Graft Dysfunction after Heart Transplantation; Y. Peled, J. Lavee, E. Nachum, Y. Kassif, M. Arad, A. Kogan, D. Freimark, E. Ram. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel


6:35 PM  (373) Oversizing Donors - Is It Necessary for ACHD Patients?: An Analysis of the United Network for Organ Sharing Registry; D. E. Clark1, R. D. Byrne2, D. S. Burnstein2, M. R. Danter1, R. Fowler1, B. P. Frischhertz1, J. Lindenfeld1, J. A. Mazurek2, B. A. Mettler2, A. Opotowsky3, T. L. Richardson3, E. M. Sandhu1, K. H. Schendorf1, J. Schmeckpeper1, A. S. Shah4, A. J. Weingarten5, S. Zalawadiya1, J. N. Menachem1. 1Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Internal Medicine-Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 3Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 4Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 5Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 6Pediatric Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 7Cardiology, Harvard Medical School, Boston, MA, 8Cardiovascular Medicine, Vanderbilt University, Nashville, TN

6:40 PM  (374) Mitigating the Impact of Gender Mismatch in Heart Transplantation Using BMI and BSA Ratios; Y. D. Barac1, O. Jawitz, V. Raman, M. Hartwig, J. Klapper, J. Schroder, M. Daneshmand, C. Patel, C. Milano. Duke University Medical Center, Durham, NC


6:50 PM  (376) Heart Transplant Recipient and Donor Age: Should the Younger Recipient Be Matched with the Younger Donor?; Y. Ravì1, N. Srikanth3, I. W. Paul3, B. A. Whitson2, S. Emani2, C. B. Sai-Sudhakar1. 1Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, 2Medical Student, Saveetha Institute of Medical Sciences, Chennai, India, 3Medical Student, Sree Mookambika Institute of Medical Sciences, Kulasekaram, India, 4Cardiac Surgery, The Ohio State University, Columbus, OH, 5Internal Medicine, The Ohio State University, Columbus, OH

6:55 PM  (377) Impact of Donor to Recipient Size Match on Survival after Heart Transplant Bridged with Continuous Flow Left Ventricular Assist Device; R. Yanaigida1, A. Okoh2, S. Fugar3, M. Camacho4, M. Strueber4, M. J. Zucker2. 1Newark Beth Israel Medical Center, Newark, NJ, 2Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ, 3Department of Medicine, Rush University Medical Center, Chicago, IL, 4Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ
(378) Older Donors Portend Worse Survival in Older and Younger Recipients after Heart Transplant: A UNOS Database Analysis; V. Raman, O. K. Jawitz, C. White, M. Daneshmand, J. Schroder, C. Milano, M. Hartwig. Duke University Medical Center, Durham, NC

(379) Cardiac Allografts from Overdosed Donors: An Underutilized Resource?; N. K. Ranganath¹, K. G. Phillips¹, J. Malas¹, B. E. Lonze², D. E. Smith¹, Z. N. Kon¹, C. G. Gidea³, A. Reyentovich³, N. Moazami¹. ¹Cardiothoracic Surgery, NYU Langone Health, New York, NY, ²Surgery, NYU Langone Health, New York, NY, ³Medicine, NYU Langone Health, New York, NY

(380) Donors after Circulatory Death at the Medical College of Wisconsin and Potential for Increased Volume in Cardiac Transplantation; A. Cole¹, A. Mohammed², L. Durham¹, N. Gaglianello², D. Ishizawar², L. Joyce¹, R. Kursel², M. Saltberg², D. Joyce¹. ¹Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, ²Advanced Heart Failure, Medical College of Wisconsin, Milwaukee, WI
Mini ORAL 03: Chronic Lung Allograft Dysfunction
Room: Pacifica 10-12
Target Audiences: LF/LTX, BSTR, PATH, PHARM

Chairs: Joshua Mooney, MD, and Tanya J. McWilliams, MD, PhD

6:15 PM (1030) Early Shift of Lung Perfusion to the Unilateral Lung Predicts the Development of Unilateral Chronic Lung Allograft Dysfunction after Bilateral Living-Donor Lobar Lung Transplantation; H. Yamamoto, S. Sugimoto, T. Kurosaki, S. Otani, M. Okazaki, M. Yamane, S. Toyooka, T. Oto. General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

6:20 PM (382) Bronchoalveolar Lavage Pentraxin 3 Levels during Clinically-Stable Minimal Acute Rejection are Associated with CLAD and Death Risk; L. Levy1, E. Huszti2, R. Ghany3, M. Ahmed1, S. Hunter1, K. Zhang4, K. Boonstra1, W. Klement1, S. Moshkelgosha1, J. Tikkanen1, L. Singer1, S. Keshavjee1, S. Juvet1, T. Martinu1. 1Toronto Lung Transplant Program, Toronto, ON, Canada, 2Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada

6:25 PM (383) Impact of mir21 Expression in Chronic Lung Allograft Dysfunction after Lung Transplantation; N. Miyahara1, A. Benazzo1, F. Oberndorfer2, P. Jaksh1, W. Klepetko1, K. Hoetzenecker1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Pathology, Medical University of Vienna, Vienna, Austria

6:30 PM (384) Quantiferon®-Monitor: A Potential Biomarker of Immunosuppression in Lung Transplantation; B. J. Gardiner1, Y. Cristiano2, B. J. Levey2, G. I. Snell3, A. Y. Peleg4, G. P. Westall5. 1Infectious Diseases, Alfred Hospital & Monash University, Melbourne, Australia, 2Respiratory Medicine & Lung Transplantation, Alfred Hospital & Monash University, Melbourne, Australia

6:35 PM (385) Lung Bacterial Burden is Increased Following the Onset of Chronic Rejection; M. P. Combs, D. S. Wheeler, J. Luth, N. M. Walker, R. P. Dickson, V. N. Lama. Department of Medicine, University of Michigan, Ann Arbor, MI

6:40 PM (386) The Impact of Pharmacogenomics on Tacrolimus Dosing and Levels among Lung Transplant Recipients; A. W. Brown1, J. Peterson1, M. Fregoso1, M. Nayyar1, A. Cochrane1, J. Pluhacek1, M. Lemma1, S. Aryal1, O. A. Shlobin1, C. S. King1, R. Iyer2, J. F. Deeken2, S. D. Nathan1. 1Inova Advanced Lung Disease & Transplant, Fairfax, VA, 2Inova Translational Medicine Institute, Fairfax, VA

6:45 PM (387) Extracorporeal Photorhesis (ECP) in the Management of Chronic Lung Allograft Dysfunction; Y. Furuuya1, C. Witt1, E. P. Trulock1, D. Byers1, H. Kulkarni1, L. K. Tague1, P. Aguilar1, D. Kreisel1, V. Puri1, A. Gelmann2, R. Hachem1. 1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, MO, 2Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO

6:50 PM (388) Five-Year Results of an IgA and IgM-Enriched Human Immunoglobulin G-Based Therapy for Early Anti-HLA Donor Specific Antibodies in 158 Lung-Transplanted Patients; F. Jus1, M. Verboom2, W. Sommer1, C. Muller1, M. Hallensleben1, J. Salman1, T. Siemen1, C. Kuhn1, M. Avars1, D. Bobylev1, N. Schwerk1, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Department of Paediatrics, Hannover Medical School, Hannover, Germany

6:55 PM (389) Donor-Specific Antibodies and Antibody-Mediated Rejection after Alemtuzumab Induction Therapy: A Retrospective Analysis of a High-Volume Lung Transplant Center; A. Benazzo1, S. Schwarz1, S. Geleff2, D. Weber3, G. Murakozy1, C. Lambers3, B. Moser1, J. Matilla1, G. Lang3, S. Taghavi1, W. Klepetko1, K. Hoetzenecker1, P. Jaksh1. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, 3Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria

7:00 PM (390) Extravascular Lung Water Quantification in Donor Lungs; K. S. Ayvat1, T. Okamoto1, H. Niikawa1, Y. Itoda1, S. Dugar1, S. Q. Latifi1, D. J. Lebovitz2, A. Moghekar1, K. R. McCurry1. 1Cleveland Clinic, Cleveland, OH, 2Lifebanc, Cleveland, OH
7:05 PM  (391) Precision Proteomics as Protein Biomarker Discovery in Detecting Chronic Lung Allograft Dysfunction; H. Ghaider, M. Fakhro, S. Lindstedt. Cardiothoracic Surgery, Lund University Hospital, Lund, LUND, Sweden

7:10 PM  (392) Mid-Term Results of Lung Transplantation (LTx) after Bridging with Extracorporeal Membrane Oxygenation - Influence of Concomitant Invasive Mechanical Ventilation (iMV); M. Monteagudo Vela¹, D. Garcia Saez¹, P. Mohite², A. Reed², F. De Robertis¹, U. Stock¹, B. Mahesh¹, M. Carby², A. Simon¹, B. Zych¹. ¹Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom, ²Respiratory Medicine, Harefield Hospital, London, United Kingdom
MINI ORAL 04: MCS: A Focus on Stroke
Room: Coral Sea
Target Audience: MCS

Chairs: Paolo C Colombo, MD, and Anique Ducharme, MD, MSC


6:25 PM (395) Hemocompatibility in HeartMate III: Is Anticoagulation Alone a Safe Strategy?; V. Tarzia1, C. Tessari2, A. Fabozzo3, C. Cavalli4, T. Bocca1, C. Pagnin1, B. Volpe5, T. Bottio6, G. Gerosa1. 1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy, 2Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Chiara Tessari, Padova, Italy, 3Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Assunta Fabozzo, Padova, Italy, 4Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Chiara Pagnin, Padova, Italy, 5Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Biancarosa Volpe, Padova, Italy, 6Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Tomas Bottio, Padova, Italy,


6:35 PM (397) Digoxin is Associated with Decreased Survival Free from Hemocompatibility-Related Adverse Events in LVAD Patients - A Propensity Score Matched Analysis; A. Pinsino1, A. Gaudig2, K. L. Hoffman3, D. D’Angelo2, E. A. Rozyman3, G. M. Mondellini3, F. Castagna3, A. M. Zuver3, A. R. Garan3, H. Takayama4, K. Takeda4, Y. Naka4, R. T. Demmer5, M. Yuzeapkolskaya1, P. C. Colombo1. 1Jacobi - Albert Einstein College of Medicine, Bronx, NY, 2Department of Medicine, Columbia University Medical Center, New York, NY, 3Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 4Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, 5Department of Surgery, Columbia University Medical Center, New York, NY, 6Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

6:40 PM (398) Influence of Device Type on Stroke Risk in Women Undergoing LVAD Implantation; R. J. Vela1, J. Pruszynsk1, A. Amin2, M. Drazner2, L. C. Huffman1, M. Peltz1, 1Cardiovascular & Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, 2Internal Medicine, UT Southwestern Medical Center, Dallas, TX

6:45 PM (399) Concentrated Factor Administration and Subsequent Stroke Rates on HeartMate II LVAD Support; J. Schultz1, A. Shaffer2, J. Misialek1, H. Shah1, R. John2, C. Martin1, T. Thenappan1, T. Alexy1, F. Kamdar1, R. Cogswell1, 1Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 2Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

6:50 PM (400) Current Smoking and Increased Risk of Stroke in Patients with Left Ventricular Assist Device; S. Sherazi1, I. Goldenberg1, S. McNitt1, V. Kutyifa1, J. Gosev2, K. Wood2, L. Chen1, S. Polonsky1, H. Vidula1, J. Alexis1. 1Cardiology, University of Rochester Medical Center, Rochester, NY, 2Cardiothoracic Surgery, University of Rochester Medical Center, Rochester, NY

6:55 PM (401) Carotid Artery Blood Flow and Its Association with Stroke during Left Ventricular Assist Device Support; M. E. Kiyatkin1, A. M. Zuver1, A. Gaudig2, M. Tiburcio1, B. J. McDonnell1, M. Yuzeapkolskaya1, P. C. Colombo1, E. J. Stöhr2, J. Z. Willey1. 1Columbia University Irving Medical Center, New York, NY, 2University of Münster, Münster, Germany, 3Cardiff Metropolitan University, Cardiff, United Kingdom, 4Cardiff Metropolitan University, Cardiff, United Kingdom
7:00 PM (402) Different Risk Factors for Ischemic and Hemorrhagic Stroke on Continuous Flow Left Ventricular Assist Device Support; H. K. Lamba¹, M. Kim¹, L. Hart¹, B. Chou¹, C. Rao¹, S. Chatterjee¹, S. Sattee², F. Cheema¹, A. Civitello¹, R. Delgado¹, A. Nair¹, A. Shafii¹, G. Loor¹, T. Rosengart¹, O. Frazier¹, J. Morgan³.
¹Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Texas Heart Institute at Baylor College of Medicine, Houston, TX

7:05 PM (403) Strokes in LVADS. Insights from Modelling Flow in the Circle of Willis; K. Balakrishnan¹, R. Krishnakumar², S. Krishna². ¹Fortis Malar Hospital, Chennai, India, ²Engineering Design, Indian Institute of Technology, Madras, Chennai, India

7:10 PM (404) Does Left Atrial Appendage Occlusion in LVAD Patients Impact Outcomes: A Single Centre Study; E. Yu¹, J. Alvarez¹, R. Ribeiro¹, M. B. Adamson¹, F. Amin¹, M. Degen¹, F. Foroutan², J. Duero Posada², T. Yau¹, R. Cusimano¹, F. Billia², C. Alba², M. Badiwala¹, V. Rao¹. ¹Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, ²Cardiology, Toronto General Hospital, Toronto, ON, Canada
WEDNESDAY, APRIL 3, 2019
6:15 PM - 7:15 PM

MINI ORAL 05: Do It Quick and Do It NOW: ECMO Update
Room: Pacifica 6
Target Audience: MCS

Chairs: Hiroo Takayama, MD, and Alastair Proudfoot, MBChB

6:15 PM
(405) Use of Extracorporeal Membrane Oxygenation (ECMO) in Acute Myocarditis - Insights from a National Inpatient Database; M. S. Panhwar¹, A. Karim¹, M. Ginwalla². ¹Internal Medicine, Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH, ²Division of Cardiology, Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH

6:20 PM
(406) Assessing Left Ventricular Unloading and Wall Tension to Predict the Need for Durable Mechanical Circulatory Support after Peripheral VA-ECMO; A. Prasad¹, C. E. Brehm², M. Goldenberg³, A. Ghodsizad⁴, M. M. Koerner⁵, A. El Banayosy⁶, K. Singbartl⁷. ¹Anesthesiology and Perioperative Medicine, PennState Health, Hershey, PA, ²Heart and Vascular Institute, PennState Health, Hershey, PA, ³PennState College of Medicine, Hershey, PA, ⁴Division of Interventional Cardiology, University of Miami/JFK Medical Center, West Palm Beach, FL, ⁵Department of Cardiovascular Surgery, Ege University Medical Center, Izmir, Turkey, ⁶Department of Cardiovascular Surgery, Siyami Ersek Hospital, Istanbul, Turkey, ⁷Department of Cardiovascular Surgery, University Hospital Luebeck, Luebeck, Germany

6:25 PM

6:30 PM
(408) Hematological Complications of Impella as an Unloading Device in Patients with Cardiogenic Shock and Veno-Arterial ECMO. A Systematic Review and Metaanalysis; J. E. Pino, E. Grajeda, F. Ramos-Tuarez, S. Sundaravell, S. Sehatbakhsh, E. Donath, R. Chair. ¹Medicine, University of Miami/JFK Medical Center, West Palm Beach, FL, ²Medicine, University of Miami/JFK Medical Center, Atlantis, FL

6:35 PM

6:40 PM

6:45 PM
(411) Differences in Post-Thoracotomy Outcomes in Patients Implanted off ECMO; J. D. Schmitto, M. Ozbaran, C. Engin, A. Simon, V. Horvath, J. Roussel, M. Pac, U. Kervan, S. Klotz, F. Wagner, T. Schloeghofer, D. Zimpfer. ¹Cardiac Surgery, Hannover Medical School, Hannover, Germany, ²Cardiac Surgery, Ege University Medical Center, Izmir, Turkey, ³Cardiac Surgery, Royal Brompton and Harefield Hospital, London, United Kingdom, ⁴Cardiac Surgery, Center for Cardiovascular and Transplant Surgery, Brno, Czech Republic, ⁵Cardiac Surgery, University of Nantes, Nantes, France, ⁶Cardiac Surgery, Turkey, ⁷Cardiac Surgery, University of Rochester, Rochester, NY

6:50 PM
(412) Mid Term Survival after VA ECMO Weaning; A. Vincentelli, N. Rousse, V. Loobuyck, M. Moussa, A. Mugnier, J. Soquet, E. Robin, F. Juthier, C. Goeminne, C. Banfi. ¹Cardiac Surgery, Centre Hospitalier Universitaire Regional de Lille, Lille, France, ²Cardiac Surgery, Anesthesiology, Centre Hospitalier Universitaire Regional de Lille, Lille, France

6:55 PM
(413) Does Transport Time or Distance from Hospital Affect Survival in Extracorporeal Membrane Oxygenation (ECMO) Patients?; J. S. Nelson, A. Eisenbeiss, E. Stauder, K. Graham, R. Alharethi, W. Caine, H. Smith, B. Reid, M. McCulloch, B. Rasmusson, V. Hebl, B. Kfouri. Intermountain Medical Center, Murray, UT

7:00 PM
7:05 PM  

(415) Effect of Time from Cardiogenic Shock to Initiation of Complete Cardiovascular Support on Survival: “Shock to Support Time”; A. Scatola¹, A. Singh¹, K. Singh², N. Singh², P. Meraj¹. ¹Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, ²New York Institute of Technology, New York, NY

7:10 PM  

(416) Risk and Causes of 30-Day Readmissions Following Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock; N. Tashtish¹, S. Al-Kindi², M. Karnib¹, C. Di Felice³, E. Zanath⁴, G. Oliveira², F. Lytle⁴, C. Elamm². ¹Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, ²Cardiovascular Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, ³Pulmonary and Critical Care, University Hospitals Cleveland Medical Center, Cleveland, OH, ⁴Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH
WEDNESDAY, APRIL 3, 2019
6:15 PM - 7:15 PM

MINI ORAL 06: Pediatrics
Room: Pacifica 3-5
Target Audiences: Peds, HTX, MCS

Chairs: Jacob Mathew, MD, and Beth Kaufman, MD

6:15 PM
(1203) Expanding the Donor Pool for Transplant Candidates with Congenital Heart Disease: Use of Recipient Total Cardiac Volumes; S. B. Shush1, N. A. Szugye1, C. R. Villa1, F. Zafar2, R. Bryant III2, A. Lorts1, D. L. Morales2, R. A. Moore1. 1Pediatric Cardiology, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cardiothoracic Surgery, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

6:20 PM
(418) Transplant Center Refusal Rate and Waitlist Outcomes in Pediatric Heart Transplantation; N. Baez, R. Davies, R. Kirk, M. Bano, D. Sutcliffe, R. Jaquiss, R. Butts. University of Texas Southwestern Medical Center, Dallas, TX

6:25 PM
(419) Pediatric Heart Transplant Recipients Bridged with Biventricular Assist Device Have Worse One-Year Graft Survival: An Analysis of the United Network of Organ Sharing Database; K. Watanabe1, A. Joong1, P. T. Thrush1, N. Srdanovic2, M. C. Monge1, E. Pahl1. 1Ann and Robert Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL

6:30 PM
(420) Variability in Donor Selection among Pediatric Heart Transplant Providers - Results from an International Survey; J. Godown1, R. Kirk2, A. Joong3, A. Lal4, M. McCulloch5, D. M. Peng6, J. Scheel7, R. Davies8, A. I. Dipchand9, O. Miera10, J. G. Gossett11. 1Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2Pediatric Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, 3Pediatric Cardiology, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL, 4Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT, 5Pediatric Cardiology, University of Virginia Children's Hospital, Charlottesville, VA, 6Pediatric Cardiology, C.S. Mott Children's Hospital, Ann Arbor, MI, 7Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO, 8Pediatric Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 9Pediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, 10Deutsches Herzzentrum Berlin, Berlin, Germany, 11UCSF Benioff Children's Hospitals, San Francisco, CA

6:35 PM
(421) Non-Infant, Single Ventricle Patients Enjoy the Same Post-Transplant Survival as Other Congenital Heart Patients; K. W. Riggs1, J. T. Broderick1, F. Zafar1, C. Chin2, R. Bryant III1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH

6:40 PM
(422) Lifetime Achievement and Quality of Life in Adult Survivors of Pediatric Heart Transplant; N. T. Stanford1, J. McAllister2, L. Addonizio2, M. Richmond2, S. Law2, T. Lee2, M. Farr2, M. Gibbons2, K. Jensen2, H. Lee2, A. Rothkopf2, R. Jackson3, W. Zuckerman2. 1Department of Pediatrics, Columbia University Medical Center, New York, NY, 2Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY, 3Division of Cardiology, Columbia University Medical Center, New York, NY

6:45 PM
(423) De Novo Development of Antibodies to Cardiac Myosin and Vimentin in Pediatric Heart Transplant Recipients: A Single Center Pilot Study; S. Zangwill1, M. Ploutz1, S. Bansal2, T. Mohanakumar2. 1Cardiology, Phoenix Children's Hospital, Phoenix, AZ, 2Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

6:50 PM
(1185) Antithymocyte Globulin Induction is Associated with Complement Deposition in Pediatric Cardiac Transplant Biopsies; S. Ghaleb1, H. Martinez1, S. Wittekind1, D. Witte2, T. Hengehold3, C. Chin1. 1Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

6:55 PM
(425) Retransplantation: An Underutilized Resource or Only for a Select Few?; M. Vazquez Alvarez1, E. Pruitt2, D. Nandi3, M. S. Kemna4, S. Urschel5, S. C. West6, K. Y. Lin7, H. M. Lim8, T. Allain-Rooney1, A. I. Dipchand1. 1Labatt Family Heart Center, Hospital for the Sick Children, Toronto, ON, Canada, 2University of
7:00 PM  
(426) First Clinical Experience of Jarvik 2015 in North America: The New Era of Pediatric-Specific VAD Support; I. Adachi¹, J. A. Spinner², Z. Spigel¹, H. Tunuguntla³, B. Elias¹, E. O. McCullum¹, A. G. Cabrera³, S. Tume⁴, W. J. Dreyer³, H. Justino³, J. S. Heinle¹, C. A. Caldarone¹. ¹Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, ²Pediatrics, Baylor College of Medicine, Houston, TX, ³Pediatric Cardiology, Texas Children's Hospital, Houston, TX, ⁴Critical Care, Texas Children's Hospital, Houston, TX

7:05 PM  
(1204) Heterogeneous Outcomes of Liver Disease after Heart Transplantation for a Failed Fontan Procedure; A. M. Ybarra¹, G. Khanna², Y. P. Turmelle¹, J. M. Stoll¹, C. D. Castleberry¹, J. N. Scheel¹, V. Exil³, R. Ameduri¹, C. E. Canter¹, K. E. Simpson¹. ¹Pediatrics, Washington University in Saint Louis School of Medicine, St Louis, MO, ²Radiology, Washington University in Saint Louis School of Medicine, St Louis, MO, ³Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, ⁴Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN

7:10 PM  
(428) Real World Data from the ACTION Quality Improvement Network - Preliminary Experience with a Magnetically Levitated Ventricular Assist Device in US Pediatric Centers; M. J. O'Connor¹, A. Lorts², C. Mascio³, D. Sutcliffe⁴, R. Davies⁴, S. Law⁵, P. Chai⁵, D. Rosenthal⁶, K. Maeda⁶, D. Nandi⁷, P. McConnell⁷, D. Morales². ¹Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Cincinnati Children's Hospital, Cincinnati, OH, ³The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Medical Center Dallas, Dallas, TX, ⁵Morgan Stanley Children's Hospital, New York, NY, ⁶Lucile Packard Children's Hospital Stanford, Palo Alto, CA, ⁷Nationwide Children's Hospital, Columbus, OH
THURSDAY, APRIL 4, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 01: In the Thick of It: Hypertrophic and Amyloid Cardiomyopathies
Room: Pacifica 7
Target Audience: HF/HTX

Chairs: Jignesh K. Patel, MD, PhD, and Marta Farrero Torres, MD

Session Summary: Hypertrophic and infiltrative cardiomyopathies are often underrecognized. There has been increasing understanding of HCM and cardiac amyloidosis with rapid development of diagnostic modalities and treatment strategies. This symposium will begin with a case and then review recent advances, highlighting key therapeutics that are available and being developed. The role of heart transplant and advanced therapies in these entities will be outlined. A 10-min panel discussion with all speakers will conclude this session.

7:00 AM  CASE PRESENTATION of HCM: Gasping and Dizzy - Please Help!
Imad Hussain, MD, Houston Methodist Hosp, Houston, TX, USA

7:05 AM  Veni, Vidi, Vici: Pathophysiology and Therapeutic Options in Hypertrophic Cardiomyopathy
Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain

7:25 AM  CASE PRESENTATION of Cardiac Amyloidosis: I Can't Breathe and My Tongue is Too Big!
Song Li, MD, University of Washington, Seattle, WA, USA

7:30 AM  Double Double Toil and Trouble: Physiology and Therapeutic Options for Cardiac Amyloidosis
Margot Davis, MD, University of British Columbia, Vancouver, BC, Canada

7:50 AM  10-min Panel Discussion
THURSDAY, APRIL 4, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 02: Immunobiology of the Older Lung Transplant Recipient
Room: Pacifica 10-12
Target Audiences: LF/LTX, BSTR, PHARM

Chairs: Jonathan P. Singer, MD, MS, and Hanneke Kwakkel-van Erp, MD, PhD

Session Summary: As the number of older transplant patients continues to grow it becomes more important to understand age-associated immune changes, which may influence the impact of immunosuppression. Older lung transplant patients experience increased rates of infection, malignancy, and death, but decreased rates of rejection, suggesting over immune suppression. Yet at the same time, older transplant recipients experience increased levels of inflammation.

7:00 AM Frailty and Pro-Inflammatory Cytokines: Potential Biomarkers for Poor Outcomes?
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA

7:15 AM Q&A

7:20 AM Immune Senescence and Transplantation: Balance Between Infection and Rejection
Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

7:35 AM Q&A

7:40 AM Challenges in Medication Administration in Older Transplant Patients
Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

7:55 AM Q&A
SUNRISE SYMPOSIUM 03: From Isolated to Mainstream: Evolving ECMO Strategies That Are Reshaping Outcomes
Room: Pacifica 6
Target Audiences: MCS, HF/HTX

Chairs: Feras Khaliel, MD, PhD, and Ivan Knezevic, MD

Session Summary: The aim of this symposium is to update attendees on cutting edge techniques and experiences in the realm of ECMO, related both to BTT and non-BTT populations. Therapies and strategies that used to seem very isolated (mobilizing on ECMO, etc.) are likely more mainstream than previously thought. An understanding of the data and outcomes may lead to expanded international adoption of some useful practices.

7:00 AM  Pressure Volume Loops: What Insight Can They Give Us on Device Strategy?
Jiri Maly, MD, PhD, IKEM, Prague, Czech Republic

7:15 AM  Q&A

7:20 AM  The Future of ECMO: It’s All About Hemocompatibility
Omar Saeed, MD, Montefiore Medical Center, Bronx, NY, USA

7:35 AM  Q&A

7:40 AM  When the Bridge Has Termites: The Impact of ECMO-Related Infections on Post-Transplant Outcomes in Bridged Patients
Priya Nair, MD, St Vincent's Hospital, Sydney, Australia

7:55 AM  Q&A
SUNRISE SYMPOSIUM 04: Nobody is CLAD to See AMR in Lung Transplantation
Room: Coral Sea
Target Audiences: PATH, BSTR, LF/LTX, PEDS

Chairs: Monique Malouf, MD, and Desley Neil, FRCPath

Session Summary: Clinical and pathologic definitions for chronic rejection in lung transplantation - antibody-mediated rejection (AMR) and chronic lung allograft dysfunction (CLAD) - have undergone rapid changes over the past decade. This session will provide an update on the two major areas of discussion and acquisition over the recent years (AMR, CLAD) and potential areas for future development.

7:00 AM Clinical Review of Antibody Mediated Rejection and Chronic Lung Allograft Dysfunction
Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland

7:15 AM Pathology of Antibody Mediated Rejection
Fiorella Calabrese, MD, University of Padua, Padua, Italy

7:30 AM Pathology of Chronic Lung Allograft Dysfunction
David M. Hwang, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

7:45 AM 15-min Panel Discussion
THURSDAY, APRIL 4, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 05: I Want to Ride My Bicycle: Cardiopulmonary Exercise Testing (CPET) for PAH and CTEPH
Room: Pacifica 1-2
Target Audiences: PH, CTEPH

Chairs: Marco Guazzi, MD, PhD, and William Auger, MD

Session Summary: Exercise testing plays a key role in the management of PAH and CTEPH, diseases with exercise-induced symptoms. In contrast with 6MWD, CPET provides unique insights in the pathophysiology of PAH and CTEPH. In addition, the role of key variables derived from CPET on outcome may be useful in assessing treatment efficacy in clinical practice and maybe clinical trials. This symposium will review the various aspects of this technique, from pathophysiology to outcome prediction. A 15-min panel discussion with all speakers will conclude this session.

7:00 AM       Bicycle Race: Basic Principles of CPET
               Lisa Mielniczuk, MD, Univ of Ottawa Heart Institute, Ottawa, ON, Canada

7:15 AM       Under Pressure: CPET in PAH and CTEPH
               Marco Guazzi, MD, PhD, IRCCS Pol San Donato, Milan, Italy

7:30 AM       Don’t Stop Me Now: CPET to Predict Outcome in PAH - Time for a Change!
               Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

7:45 AM       15-min Panel Discussion
THURSDAY, APRIL 4, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 06: Making Deals with the Devil: Substances of Abuse from Pre- to Post-Transplant
Room: Pacifica 3-5
Target Audiences: PHARM, HF/HTX, LF/LTX, NHSAH

Chairs: Martin Zamora, MD, and Vincent G. Valentine, MD

Session Summary: The purpose of this symposium is to review substances of abuse pre- and post-transplant. The symposium will focus on use of medications for pain and anxiety, smoking (nicotine and marijuana), and alcohol use. Speakers will present available evidence describing why these substances are harmful when used before and after transplant and offer guidance for cessation or therapeutic alternatives.

7:00 AM    'Hurts So Good': Analgesia Beyond Opioids
Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, USA

7:15 AM    Q&A

7:20 AM    So, Light 'em if You've Got 'em - or Don't! Smoking Pre- and Post-Transplant
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

7:35 AM    Q&A

7:40 AM    How Much is Too Much? Alcohol Use and Cessation Pre- and Post-Transplant
Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

7:55 AM    Q&A
SESSION 23 (ORAL): Hepatitis C+ Cardiac Donors: Do They Get an A+?
Room: Pacifica 6
Target Audiences: HTX, ID

Chairs: JoAnn Lindenfeld, MD, and Sanjeet Singh Avtaar Singh, MRCS, MSc

8:00 AM (93) Early Utilization Trends and Outcomes of Hepatitis C Donor Hearts in the Era of Nucleic Acid Amplification Testing (NAT) and Direct Acting Antivirals (DAAs); S. Madan, S. R. Patel, O. Saeed, S. Forest, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Bronx, NY

8:15 AM (94) Use of Donor HCV NAT Positive Hearts: Expanding the Donor Pool?; E. C. DePasquale¹, C. J. Lum¹, R. Chand¹, W. Ragalie¹, A. Chang¹, A. Salimbangon¹, M. Deng¹, M. Cadeiras², T. Khullu¹, D. Vucicevic³, K. Pandya¹, A. Ardehali¹. ¹UCLA, Los Angeles, CA, ²UC Davis, Sacramento, CA, ³Newark Beth Israel, Newark, NJ, ⁴USC, Los Angeles, CA

8:30 AM (95) Clinical Experience with Heart Transplantation from Hepatitis C Positive Donors; A. Reyentovich¹, C. Gidea¹, D. Smith², B. Lonze³, J. Pavone¹, S. Katz¹, S. Pan¹, S. Rao¹, T. Saraon¹, N. Moazami². ¹Heart Transplant, NYU Langone Medical Center, New York, NY, ²CardioThoracic Surgery, NYU Langone Medical Center, New York, NY, ³Transplant Surgery, NYU Langone Medical Center, New York, NY, ⁴Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY


9:00 AM (97) Regional Variation in Utilization of Hepatitis C-Positive Organs for Heart Transplantation in the United States; E. M. DeFilippis¹, A. R. Garan¹, R. C. Givens¹, L. K. Truby², F. Latifi³, S. W. Restaino¹, K. Takeda¹, H. Takayama¹, Y. Naka¹, P. C. Colombo¹, M. A. Farr¹, V. K. Topkara¹. ¹Columbia University Medical Center, New York, NY, ²Duke University Medical Center, Durham, NC

9:15 AM (98) Trends in Renal Function among Heart-Transplant Recipients of Donor-Derived Hepatitis C Virus; S. Zalawadiya¹, J. Lindenfeld¹, A. Shah², M. Wigger¹, M. Danter², D. Brinkley¹, J. Menachem¹, L. Punnoose¹, S. Brown Sacks¹, H. Ooi¹, K. Balsara², R. Perri², J. Awad¹, S. Smith¹, R. Fowler¹, H. O'Dell³, C. Darragh³, S. Ruzevich-Scholl¹, K. Schlendorf¹. ¹Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, ²Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, ³Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN

9:30 AM (99) Acceptance of HCV-Positive Donor Hearts Improves Organ Acceptance Selectivity: Single Center Experience; K. J. Gaj¹, D. A. D'Alessandro², E. D. Bethea³, J. L. Gustafson¹, M. A. Villavicencio-Theodoloz², R. T. Chung³, G. D. Lewis³. ¹Cardiac Transplantation, Massachusetts General Hospital, Boston, MA, ²Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, ³Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, ⁴Advanced Heart Disease, Massachusetts General Hospital, Boston, MA
THURSDAY, APRIL 4, 2019
8:00 AM - 9:45 AM

SESSION 24 (ORAL): Molecular Diagnostics in Heart Transplantation: It's All in the Genes
Room: Pacifica 7
Target Audiences: HTX, BSTR, PATH

Chairs: Pradeep P. A. Mammen, MD, FACC, FAHA, and Markus Johannes Barten, MD, PhD

8:00 AM

(100) Increase in Donor Fraction Cell-Free DNA Correlates with Cellular and Antibody Mediated Rejection (ACR/AMR) in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study; M. E. Richmond, S. J. Kindel, J. N. Schroeder, S. R. Deshpande, D. P. Bichell, M. A. Wigger, K. R. Knecht, E. Pahl, N. A. Gaglianello, P. M. Simpson, W. T. Mahle, A. T. Mitchell, S. D. Zangwill, M. E. Mitchell. 1Pediatrics, Columbia University, New York, NY; 2Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI; 3Surgery, Duke University, Durham, NC; 4Children's National, Washington, DC; 5Surgery, Vanderbilt University, Nashville, TN; 6Medicine, Vanderbilt University, Nashville, TN; 7Pediatrics, Arkansas Children's Hospital, Little Rock, AR; 8Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL; 9Medicine, Medical College of Wisconsin, Milwaukee, WI; 10Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 11Emory University, Atlanta, GA; 12Surgery and Biomedical Engineering, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI; 13Pediatrics, Phoenix Children's Hospital, Phoenix, AZ; 14Surgery, Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Milwaukee, WI

8:15 AM

(101) Increase in Total Cell-Free DNA Correlates with Death in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study; S. D. Zangwill, S. J. Kindel, J. N. Schroeder, D. P. Bichell, S. R. Deshpande, M. A. Wigger, M. E. Richmond, K. R. Knecht, N. A. Gaglianello, E. Pahl, P. M. Simpson, W. T. Mahle, A. T. Mitchell, M. E. Mitchell. 1Pediatrics, Phoenix Children's Hospital, Phoenix, AZ; 2Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI; 3Surgery, Duke University, Durham, NC; 4Surgery, Vanderbilt University, Nashville, TN; 5National Children's Hospital, Washington, DC; 6Medicine, Vanderbilt University, Nashville, TN; 7Pediatrics, Columbia University, New York, NY; 8Pediatrics, Arkansas Children's Hospital, Little Rock, AR; 9Medicine, Medical College of Wisconsin, Milwaukee, WI; 10Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL; 11Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 12Pediatrics, Emory University, Atlanta, GA; 13Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI; 14Surgery, Pediatric Cardiothoracic Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI

8:30 AM

(102) Correlation of Human Myocardial Apoptosis with Pathology Rejection Grade and Levels of Donor-Derived Cell-Free DNA in Heart Transplantation; S. Pattar, F. Iqbal, D. Isaac, N. Fine, S. C. Greenway. 1Biochemistry & Molecular Biology, University of Calgary, Calgary, AB, Canada; 2Health Sciences, University of Calgary, Calgary, AB, Canada; 3Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; 4Pediatrics, Cardiac Sciences, Biochem & Molecular Bio/Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada

8:45 AM

(103) Distinct Patterns of Gene Expression Identified Longitudinally and within AlloMap Score Ranges are Associated with Clinical Outcomes; A. Loupy, R. N. Woodward, M. Machrus, S. P. Pinney, J. A. Kobashigawa. 1Hospital Necker, Paris, France; 2CareDx, Brisbane, CA; 3Mt Sinai Health System, New York, NY; 4 Cedars-Sinai Heart Institute, Los Angeles, CA

9:00 AM

(104) Molecular Microscope Determinants of Graft Survival in the INTERHEART Study; J. Reeve, D. H. Kim, M. G. Crespo-Leiro, J. Kobashigawa, L. Potena, M. Deng, M. Cadeiras, E. C. Depasquale, A. Loupy, P. Macdonald, A. Zuckermann, A. Z. Aliabadi, J. Goekler, M. Parkes, P. F. Halloran. 1University of Alberta, Edmonton, AB, Canada; 2Complexo Hospitalario Universitario A Coruña, A Coruña, Spain; 3Cedars-Sinai Medical Center, Los Angeles, CA; 4University of Bologna, Bologna, Italy; 5Ronald Reagan UCLA Medical Center, Los Angeles, CA; 6Hôpital Necker, Paris, France; 7The Victor Chang Cardiac Research Institute, Sydney, Australia; 8Medical University of Vienna, Vienna, Austria

9:15 AM

(105) mir-208a-5p and miR-135a-5p in Formalin Fixed Paraffin Embedded Endo-Myocardial Monitoring Biopsies Discriminate Rejection from Cardiac Infection; A. Di Francesco, M. Fedrigo, C. Castellani, D. Gregori, D. Santovito, L. Natarelli, G. Toscano, T. Bottio, G. Thiene, M. Valente, M. Valente, A. Schober, C. Basso, G. Gerosa, A. Angelini. 1Department of Cardiac, Thoracic, Vascular Sciences and
¹Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, ²National Heart, Lung and Blood Institute, Bethesda, MD, ³Inova Translational Medicine Institute, Falls Church, VA, ⁴Mokobio, Rockville, MD, ⁵Heart Failure and Transplantation, Johns Hopkins University, Baltimore, MD, ⁶Heart Failure and Transplantation, Washington Hospital Center, DC, DC, ⁷Heart Failure and Transplantation, University of Maryland, Baltimore, MD, ⁸Heart Failure and Transplantation, Virginia Commonwealth University, Richmond, VA
SESSION 25 (SYMPOSIUM): The Magic Kingdom of the Bronchoscopy: Pathogens with Real Implications and Those to Disregard
Room: Pacifica 3-5
Target Audiences: ID, LF/LTX, PATH

Chairs: Are Holm, MD, and Stephanie M Pouch, MD

Session Summary: This symposium will review the evidence and discuss the utility of detection of pathogens from surveillance bronchoscopies after lung transplantation. Evidence will be presented regarding the interpretation and treatment of positive culture results from surveillance bronchoscopy. We will review and analyze the management/treatment of bacteria, fungi, atypical mycobacteria and CMV in asymptomatic patients.

8:00 AM ‘Critter Country’: Treatment and Eradication of Bacteria and Bacterial Biome
Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland

8:15 AM Q&A

8:20 AM ‘Fungal Frontierland’: Pathogens or Colonizers?
Me-Linh Luong, MD, St. Luc Hospital, Montréal, QC, Canada

8:35 AM Q&A

8:40 AM ‘Off Main Street’: Atypical Mycobacteria - What, When and How to Manage
Fernanda Silveira, MD, University of Pittsburgh, Pittsburgh, PA, USA

8:55 AM Q&A

9:00 AM ‘CMV Square’: Lung Transplant Recipients with CMV Positivity in a Bronchoscopy without CMV DNAemia
Jutta K Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada

9:15 AM Q&A

9:20 AM ‘Tomorrowland’: A Case-Based Approach to Managing Bronchoscopy Results
Shalika B Katugaha, MD, InovaFairfax Hospital, Annandale, VA, USA

9:40 AM Q&A
THURSDAY, APRIL 4, 2019
8:00 AM - 9:45 AM

SESSION 26 (ORAL): Mechanical Lung Support for Isolated Organs and Patients
Room: Pacifica 10-12
Target Audience: LF/LTX

Chairs: Alexis Slama, MD, and Daniel F Dilling, MD

8:00 AM (107) Validation of an EVLP Perfusate Diagnostic Test for the Prediction of Lung Transplant Outcomes; A. T. Sage1, M. Richard-Greenblatt2, K. J. Zhong3, M. B. Snow4, M. Babits1, M. Chen5, H. Gokhale5, M. Galasso1, H. Shan1, M. Cypel1, M. Liu1, K. C. Kain2, S. Keshavjee1. 1Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada

8:15 AM (108) A Clinical Trial Evaluating the Effects of Ultra-Violet C treatment (UVC) during Ex Vivo Lung Perfusion (EVLP) as a Method of Inactivating Hepatitis C Infection in Donor Lungs; M. Cypel1, M. Galasso1, R. Ribeiro1, B. Wilson1, V. Bagnato2, C. Kurachi2, M. Chen1, D. Kumar1, T. K. Waddell1, L. G. Singer1, S. Keshavjee1, A. Humar1, J. Feld1. 1Toronto General Hospital, Toronto, ON, Canada, 2Sao Paulo University, Sao Carlos, Brazil


8:45 AM (110) Ex-Vivo Lung Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus; T. J. Ku1, M. Cypel2, R. V. Ribeiro2, V. H. Ferreira3, D. Kumar1, A. Humar1. 1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada


9:15 AM (112) Increasing Use of EVLP in the United States: Data from the OPTN/UNOS; R. R. Lehman1, K. Uccellini1, E. Lease2, R. Daly3, K. M. Chan4. 1United Network for Organ Sharing, Richmond, VA, 2University of Washington, Seattle, WA, 3Mayo Clinic, Rochester, MN, 4University of Michigan, Ann Arbor, MI

9:30 AM (113) Central Ambulatory Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation; P. Downey1, W. Ragalie1, D. Ross2, A. Ardehali1. 1Cardiothoracic Surgery, UCLA, Los Angeles, CA, 2Pulmonary and Critical Care Medicine, UCLA, Los Angeles, CA
SESSION 27 (SYMPOSIUM): Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins
Room: Grand Caribbean 1-7
Target Audience: MCS

Chairs: Marco Masetti, MD, PhD, and Garrick C. Stewart, MD

Session Summary: This symposium will examine state of the art knowledge on device programming and medical management of LVAD patients. Current controversies such as the utility of platelet function monitoring and invasive hemodynamic testing will be reviewed and debated. A 10-min panel discussion with all speakers will conclude this session.

8:00 AM  What are We Treating with Heart Failure Therapy after MCS: the LV, the RV, the Periphery or Ourselves?
Gabriella Masciocco, MD, Niguarda Hospital, Milan, Italy

8:20 AM  Antiplatelet Therapy: Fixed Dose or Functional Assays?
Jeffrey J Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA

8:35 AM  Time in Therapeutic Range: Is There an Optimal Way to Manage INR?
Douglas L Jennings, PharmD, New York-Presbyterian Hospital, New York, NY, USA

8:50 AM  Pump Data: Do We Need It to Decide Changes in Therapy?
Thomas Schloglhofer, MSc, Medical University of Vienna, Vienna, Austria

9:05 AM  DEBATE: You Need Information From Invasive Hemodynamics to Properly Manage an LVAD (PRO)
Nir Uriel, MD, University of Chicago, Chicago, IL, USA

9:20 AM  DEBATE: You Need Information From Invasive Hemodynamics to Properly Manage an LVAD (CON)
Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA

9:35 AM  10-min Panel Discussion
THURSDAY, APRIL 4, 2019
8:00 AM - 9:45 AM

SESSION 28 (ORAL): Tissue is Not the Only Issue: Advances in Thoracic Transplant Pathology
Room: Coral Sea
Target Audiences: PATH, BSTR, HTX, LTX, PEDS

Chairs: Patrick Bruneval, MD, and Brandon T Larsen, MD, PhD

8:00 AM (114) Gene Expression in Formalin-Fixed Paraffin-Embedded Lung Transplant Biopsies: Correlation between Molecular and Histologic Phenotypes; B. Adam, K. Du, S. Rotich, M. Mengel. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada

8:15 AM (115) Occurrence and Risk Factors for Acute Lung Injury (ALI) and Organizing Pneumonia (OP) after Lung Transplant; E. N. Pavlisko1, M. L. Neely1, H. Kopetskie2, D. Hwang3, C. F. Farver4, A. V. Arrossi5, W. D. Wallace6, P. Illei7, M. Sever7, J. Kirchner7, C. W. Frankel1, L. D. Snyder1, T. Martinu4, M. Y. Shino9, N. Williams10, M. A. Robien11, L. G. Singer8, M. Budev4, W. Tsuang8, P. D. Shah8, J. M. Reynolds4, S. Weigt6, J. A. Belperio9, S. M. Palmer1, J. L. Todd1. 1Duke University Medical Center, Durham, NC, 2Rho Federal Systems Division, Chapel Hill, NC, 3Sunnybrook Health Sciences Center, Toronto, ON, Canada, 4Cleveland Clinic, Cleveland, OH, 5University of California, Los Angeles, CA, 6Johns Hopkins University, Baltimore, MD, 7Rho Federal Systems Division, Chapel Hill, NC, 8University of Toronto, Toronto, ON, Canada, 9University of California Los Angeles, Los Angeles, CA, 10National Institute of Allergy and Infectious Disease, Bethesda, MD, 11National Institute of Allergy and Infectious Disease, Bethesda, MD

8:30 AM (116) The Prognostic Value of Fibrin and Organizing Pneumonia in Transbronchial Biopsies from Lung Transplant Patients; A. Vanstapel1, S. E. Verleden1, A. Van Herck1, J. Kaes1, T. Heigl1, A. Sacreas1, E. Verbeken2, B. Weynand2, B. M. Vanaudenaerde1, G. M. Verleden1, R. Vos1. 1Leuven Lung Transplant Unit, KU Leuven - UH Leuven, Leuven, Belgium, 2Department of Imaging and Pathology, KU Leuven - UH Leuven, Leuven, Belgium

8:45 AM (117) Sarcoidosis Associated Pulmonary Hypertension: Correlation of Vascular Morphologic Changes with Hemodynamic Data in Explanted Lungs; P. Chung, K. Warrior, M. Reid, R. Nigdelioglu, S. Boyes, V. Ananthnarayanan, S. Quddus. Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL

9:00 AM (118) What are the Histopathologic Findings in Pulmonary Allografts with Graft Failure?; R. E. White, A. P. Burke. Pathology, University of Maryland, Baltimore, MD

9:15 AM (119) Endomyocardial Biopsy Findings in Pediatric Heart Transplant Recipients with Positive HLA Associated Antibodies: Review of a Cohort with Poor Outcomes; A. Shenoy1, A. K. Enukula2, S. S. Goldstein2, B. A. Pietra3, M. S. Bleiweis3, F. J. Fricker3, D. Gupta3. 1Departments of Pathology, Immunology and Laboratory Medicine & Pediatrics, University of Florida, Gainesville, FL, 2Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, 3Congenital Heart Center, University of Florida, Gainesville, FL

9:30 AM (120) Accelerated Cardiac Allograft Vasculopathy: A Clinical and Pathologic Correlation Study; D. V. Miller1, M. Revelo1, E. Hammond1, B. Kloury2, K. Afshar2, K. Molina3, R. Alharethi3. 1Pathology, UTAH Cardiac Transplant Program, Salt Lake City, UT, 2Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT, 3Pediatric Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT
8:00 AM (121) Pediatric Patients with Pulmonary Vascular and Restrictive Lung Disease Suffer Disproportionately High Waitlist Mortality; K. W. Riggs1, D. B. Colohan1, R. Rizwan1, C. Towe2, M. Schecter2, F. Zafar1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH

8:15 AM (122) Outcomes of Cystic Fibrosis and Non-Cystic Fibrosis Pediatric Lung Transplants: An ISHLT Registry Study; J. S. Nelson1, T. M. Maul1, C. G. Hurtado2, P. D. Wearden1. 1Cardiovascular Services, Nemours Children's Hospital, Orlando, FL, 2University of Central Florida College of Medicine, Orlando, FL

8:30 AM (123) Pediatric Lung Transplantation: Fit for Split?; T. Martens1, M. Kanakis2, H. Spencer3, N. Muthialu4. 1Cardiothoracic Surgery, University Hospital, Ghent, Belgium, 2Cardiothoracic Surgery, Onassis Cardiothoracic Surgery Centre, Athens, Greece, 3Transplantation, Great Ormond Street Hospital, London, United Kingdom, 4Cardiothoracic Surgery, Great Ormond Street Hospital, London, United Kingdom

8:45 AM (124) Etiology of Failure Predicts Heart-Lung Transplant Candidate's Waitlist Survival; K. W. Riggs1, J. L. Chapman1, M. Schecter2, C. Towe2, R. Bryant1, F. Zafar1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH

9:00 AM (125) Is the Current Era Better for Pediatric Heart-Lung Transplantation?; K. W. Riggs1, J. L. Chapman1, M. Schecter2, C. Towe2, R. Bryant1, F. Zafar1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH

9:15 AM (126) Proinflammatory Cytokines as Biomarkers for BOS, Death, or Re-transplantation after Lung Transplantation; C. K. Conrad. Pediatrics, Lucile Packard Children's Hospital, Palo Alto, CA

9:30 AM (127) Five-Year Experience with Treatment of Early Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients; F. Ius1, N. Schwerk2, C. Müller2, W. Sommer1, M. Verboom2, M. Hallensleben3, J. Salman1, T. Siemens1, C. Kühn1, M. Avsar1, D. Bobylev1, J. Carlens2, L. Bayir2, G. Hansen2, R. Blasczyk2, A. Haverich1, I. Tudorache1, G. Warneckel. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Paediatric Pulmonology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany, 3Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany
THURSDAY, APRIL 4, 2019
10:15 AM - 12:00 PM

SESSION 30 (ORAL): Get Up and Go! Predicting Survival in Heart Failure
Room: Pacifica 7
Target Audiences: HF, HTX, NHSAH

Chairs: George G Sokos, DO, and Wandy Chan, PhD, FRACP

10:15 AM
(128) Genomic Prediction of One Year Survival Status Related to Functional Recovery Potential in Advanced Heart Failure Patients Undergoing Mechanical Circulatory Support; G. Bondar1, T. Bao1, M. Kurani1, D. L. Bhaskar1, A. Le1, R. Dod1, Y. Khachatooorian1, A. Aliyari1, E. Higuchi1, E. Oh1, K. Patel1, M. Cadeiras3, J. Schaeinan1, L. Masukawa1, S. Kupiec-Weglinski3, V. Groysberg1, M. Bakir1, E. Depasquale1, M. Kamath1, D. Liem1, J. Meltzer1, M. Kwon1, M. Rossetti1, D. Elashoff1, X. Li1, E. Reed1, P. Ping1, M. C. Deng1.
1David-Geffen Sch Med, Los Angeles, CA, 2University of California Davis School of Medicine, Sacramento, CA, 3Cornell University, Ithaca, NY

10:30 AM
(129) Impact of Frailty on Health-Related Quality of Life from before to 6 Months after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study; K. Ghaforian1, A. C. Andrei2, Y. Xu2, C. W. Yancy1, H. Adam2, D. T. Pham2, K. L. Grady2. 1Cardiology, Northwestern University, Chicago, IL, 2Surgery, Northwestern University, Chicago, IL

10:45 AM
(130) Leg Muscle Strength Independently Predicts Clinical Outcome in Patients with Acute Decompensated Heart Failure; J. Youn3, E. Yoon1, H. Choi2, I. Kim3, J. Lee4, S. Lee1, S. Han1, S. Kang4. 1Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea, Republic of, 2Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of, 3Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, 4Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

11:00 AM
(131) Comparison of Percutaneous Ventricular Assist Device and Intra-Aortic Balloon Pump for Cardiogenic Shock; A. Y. Lee1, C. Y. Guerrero-Miranda1, T. Nisar2, A. K. Jamil2, A. Perez2, D. Tangellamundi1, J. Felius1, S. A. Hall1, D. Wencker1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX

11:15 AM
(132) Characteristics and Outcomes of Patients with Cardiogenic Shock Complicated by Acute Kidney Injury Requiring Hemodialysis; C. Inampudi1, O. Adegbala2, E. Akintoye1, P. Alvarez1, A. Briasoulis1. 1Internal Medicine - Cardiology, Univ of Iowa Hospital, Iowa City, IA, 2Internal Medicine, Englewood Hospital and Medical Center, Seton Hall University-Hackensack Meridian School of Medicine, Englewood, New Jersey, NJ

11:30 AM
(133) LVAD Survival May Be Predicted by Preoperative Lymphopenia; K. Stawiarski1, O. Agboola2, D. Jacoby3, L. Bellumkonda3, L. Sugeng3, T. Ahmad3, M. Chen3, G. McCloskey2, A. Geirsson1, M. Anwar2, P. Bonde2. 1Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, 2Yale School of Medicine, New Haven, CT, 3Yale School of Medicine, Bridgeport, CT

11:45 AM
(134) Differences in Health-Related Quality of Life by Socio-Demographic Characteristics: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study; L. Uppalapati1, A. Andrei2, C. Yancy3, Y. Xu2, H. Adam2, D. Pham2, K. L. Grady2. 1Northwestern University, Chicago, IL, 2Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, 3Medicine, Northwestern University, Chicago, IL
10:15 AM (135) Routine Utilization of NAT Negative PHS Increased Risk Thoracic Organs Appears Safe and Effective in Increasing Organ Supply for Transplantation; K. J. Gaj1, L. Irwin1, A. Leifer1, M. A. Villavicencio-Theoduloz2, K. Turvey1, G. D. Lewis3, C. Kotton4, D. A. D'Alessandro1. 1Transplant Surgery, Massachusetts General Hospital, Boston, MA, 2Transplant Surgery, Massachusetts General Hospital, Boston, MA, 3Advanced Heart Disease, Massachusetts General Hospital, Boston, MA, 4Infectious Disease Division, Massachusetts General Hospital, Boston, MA


11:00 AM (138) Magnitude of Recipient Viremia after Heart Transplantation from HCV Viremic Donors and Time to Clearance with Therapy; C. G. Gidea1, A. Reyentovich1, D. Smith2, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami2. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY

11:15 AM (139) The Impact of Utilizing Hepatitis C Virus Nucleic Acid Test-Positive Donor Heart on Heart Transplant Waitlist Time; Y. K. Gernhofer1, M. Brambatti2, B. H. Greenberg2, E. Adler2, S. Aslam3, V. Pretorius1. 1Cardiothoracic Surgery, UC San Diego, San Diego, CA, 2Cardiology, UC San Diego, San Diego, CA, 3Infectious Diseases, UC San Diego, San Diego, CA

11:30 AM (140) The Impact of HCV Viremia in Heart Transplant Recipients from Donors with HCV Infection on Acute and Humoral Cellular Rejection; C. G. Gidea1, N. Narula2, A. Reyentovich1, D. Smith3, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami3. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2Pathology, NYU Langone Medical Center, New York, NY, 3Infectious Diseases, NYU Langone Medical Center, New York, NY

11:45 AM (141) Outcomes of Heart and Heart-Kidney Transplantation from Hepatitis C Virus (HCV) Positive Donors into HCV Negative Recipients; S. Aslam1, I. Yumul2, M. Mariski1, V. Pretorius1, E. Adler1. 1University of California, San Diego, San Diego, CA, 2University of Iowa, Iowa City, IA
SESSION 32 (SYMPOSIUM): Ex-Vivo Lung Perfusion (EVLP) in 2019: From Research to Implementation

Room: Pacifica 10-12
Target Audiences: LF/LTX, MCS

Chairs: John Dark, MB, FRCS, and Tiago Machuca, MD, PhD

Session Summary: This symposium will bring experts in Ex-Vivo Lung Perfusion and donor lung management from all over the world. Current practices, different models, ongoing clinical trials with EVLP and added therapeutics will be discussed. The attendee will increase his or her understanding of the technique, its applications and future directions. A 15-min panel discussion with all speakers will conclude this session.

10:15 AM  Implementation of High Volume Clinical EVLP: The Toronto Model
            Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

10:30 AM  Rationale for Portable EVLP
            Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany

10:45 AM  Benefits and Barriers of a Do-It-Yourself EVLP Program
            Peter Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia

11:00 AM  Organ Procurement Organization-Based EVLP Program
            Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA

11:15 AM  Experience with a Third-Party EVLP Program
            Kenneth R. McCurry, MD, FACS, Cleveland Clinic, Cleveland, OH, USA

11:30 AM  The Role of Biomarkers in EVLP
            Andrew J Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:45 AM  15-min Panel Discussion
THURSDAY, APRIL 4, 2019
10:15 AM - 12:00 PM

SESSION 33 (ORAL): Brain Attack: Strokes and MCS
Room: Pacifica 6
Target Audience: MCS

Chairs: Sai Bhagra, MBBS, and Erin Coglianese, MD

10:15 AM
(142) Understanding Risk Factors for Stroke Subtypes in the ENDURANCE Trials; S. Cho1, R. Starling2, J. Teuteberg3, J. Rogers4, F. Pagani5, P. Shah6, K. Uchino3, T. Vassiliades4. 1John Hopkins University, Baltimore, MD. 2Cardiology, Cleveland Clinic, Cleveland, OH. 3Cardiology, Stanford University, Stanford, CA. 4Duke University, Durham, NC. 5University of Michigan, Ann Arbor, MI. 6Cardiology, Inova Fairfax, Falls Church, VA. 7Cleveland Clinic, Cleveland, OH. 8Medtronic, Framingham, MA

10:30 AM
(143) Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort; N. Uriel1, M. Mehr2. 1University of Chicago, Chicago, IL. 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

10:45 AM
(144) Two-Year Outcomes in Real World Patients Treated with Heartmate 3™ Left Ventricular Assist Device for Advanced Heart Failure: Data from the ELEVATE Registry; D. Saeed1, J. Garbade1, F. Gustafsson2, J. Lavee3, M. Morshuis4, D. Zimpfer5, E. Potapov6, Y. Pya7, J. Schmitto8, S. M. Shaw9. 1Department for Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany. 2The Heart Centre, Rigshospitalet, Copenhagen, Denmark. 3Heart Transplantation Unit, Leive Heart Center, Tel Aviv, Israel. 4Department of Cardiothoracic Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany. 5Department of Surgery, Medical University of Vienna, Vienna, Austria. 6Deutsches Herzzentrum Berlin, Berlin, Germany. 7National Research Center for Cardiac Surgery, Astana, Kazakhstan. 8Medizinische Hochschule Hannover, Hannover, Germany. 9Heart and Lung Transplant Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom

11:00 AM
(145) Impact of Stroke Onset Severity on 2-Year Survival in Destination Therapy Patients Supported by Centrifugal Flow versus Axial Flow Ventricular Assist Devices; P. Shah1, C. Mahr2, J. Rogers3, M. Kiernan4, S. Boyce5, N. A. Mokadam6, F. Pagani7, T. Vassiliades8, J. Teuteberg9. 1Cardiology, Inova Fairfax, Falls Church, VA. 2Cardiology, University of Washington, Seattle, WA. 3Cardiology, Duke University, Durham, NC. 4Cardiology, Tufts University, Boston, MA. 5Cardiac Surgery, Washington Hospital Center, Washington, DC. 6Cardiac Surgery, University of Washington, Seattle, WA. 7Cardiac Surgery, University of Michigan, Ann Arbor, MI. 8Medtronic, Framingham, MA. 9Cardiology, Stanford University, Stanford, CA

11:15 AM
(146) Apixaban in HVAD Patients Non-Compliant to Standard Vitamin-K-Antagonism; S. Schulte-Eistrup1, N. Mayer-Wingert1, N. Reiss2, J. Sindermann3, H. Warnecke1. 1Cardiac Surgery, Schuechtermann Klinik, Bad Rothenfelde, Germany. 2Clinical Research, Schuechtermann Klinik, Bad Rothenfelde, Germany. 3Rehabilitation, Schuechtermann Klinik, Bad Rothenfelde, Germany

11:30 AM
(147) Presence of Left Atrial or Left Ventricular Thrombus at the Time of CF-LVAD Implantation is Associated with Increased Post-Operative Risk of Stroke or Death; J. A. Fried1, H. Lumish1, A. M. Zuver1, A. R. Garan1, V. K. Topkara1, B. Caglistro1, G. Parkis2, M. Cevasco2, M. T. Pineda2, G. M. Mondellini1, K. Ross2, L. Witer2, H. Takayama2, K. Takeda2, Y. Naka2, M. Yuzefpolskaya1, R. T. Demmer1, P. C. Colombo1. 1Cardiology, Columbia University Medical Center, New York, NY. 2Department of Surgery, Columbia University Medical Center, New York, NY. 3Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

11:45 AM
SESSION 34 (ORAL): Never Mind the Leaks: Addressing Valvular Disease with LVADs
Room: Grand Caribbean 1-7
Target Audience: MCS

Chairs: William Hiesinger, MD, and J. Eduardo Rame, MD

10:15 AM
(149) Course and Clinical Impact of Tricuspid Regurgitation after LVAD Implantation: An Analysis of the EUROMACS Registry; K. Veen¹, M. M. Mokhles¹, O. I. Soliman¹, T. M. de By², P. Mohacsi³, F. Schoenrath⁴, L. Palusziewicz⁵, A. J. Bogers⁵, J. J. Takkenberg⁵, K. Caliskan⁵. ¹Erasmus MC, Rotterdam, Netherlands, ²EUROMACS Registry, Windsor, United Kingdom, ³University Hospital Zurich, Zurich, Switzerland, ⁴German Heart Centre Berlin, Berlin, Germany, ⁵Heart and Diabetes Centre NRW, Bad Oeynhausen, Germany

10:30 AM

10:45 AM
(151) Impact of Pre-Op Mitral Regurgitation Following Left Ventricular Assist Device Implant; G. N. Coyan¹, B. Pierce², Z. Rhinehart², F. Thoma², W. Katz², A. Kilic¹, R. Kormos¹, C. M. Sciortino¹. ¹Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, ²Cardiology, University of Pittsburgh, Pittsburgh, PA, ³Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA

11:00 AM

11:15 AM

11:30 AM

11:45 AM
(155) Impact of Concomitant Valvular Surgery on Patients Undergoing LVAD Implantation; K. Y. Mulumba¹, P. Kasinipila¹, R. Fong¹, S. Kong¹, L. Hecker¹, R. Nissan¹, D. Banerjee², J. Teuteberg², Y. Shudo¹, Y. Woo¹, W. Hiesinger¹. ¹Cardiothoracic Surgery, Stanford University, Palo Alto, CA, ²Cardiology, Stanford University, Palo Alto, CA
SESSION 35 (SYMPOSIUM): Bring Out Your Dead: The Postmortem Evaluation in the Thoracic Transplant Setting
Room: Coral Sea
Target Audiences: PATH, HF/HTX, LF/LTX

Chairs: Lorriana E Leard, MD, and Carmela D Tan, MD

Session Summary: The postmortem examination ("autopsy") is underutilized in modern medicine, but provides critical information to the clinicians, families and loved ones of the decedent to help them understand the decedent's clinical course. Data obtained from autopsies may be used by hospital quality personnel, researchers, policy makers, registries and device manufacturers to improve the state of thoracic transplantation and mechanical circulatory support therapy. A 15-min panel discussion with all speakers will conclude this session.

10:15 AM The Autopsy in the Modern Era: What the Clinician Still Would Like to Gain from an Autopsy
Stephen C Clark, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

10:30 AM What the Pathologist Can Tell: More Than Just Cause of Death
Anja C Roden, MD, Mayo Clinic, Rochester, MN, USA

10:45 AM How is a Postmortem Examination Performed: Frequently Asked Questions
Billie S. Fyfe-Kirschner, MD, Robert Wood Johnson School of Medicine, New Brunswick, NJ, USA

11:00 AM The Autopsy in the Mechanical Circulatory Support Patient
Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, USA

11:15 AM The Autopsy in the Thoracic Transplant Patient
Ornella Leone, MD, S. Orsola Hospital, Bologna, Italy

11:30 AM The ‘Rapid Autopsy’: A Tool for Scientific Inquiry
Dylan V. Miller, MD, Intermountain Central Lab, Murray, UT, USA

11:45 AM 15-min Panel Discussion
SESSION 36 (SYMPOSIUM): Learning from the Children: Important Lessons from the Pediatric and Congenital Heart Disease VAD Experience

Room: Pacifica 3-5

Target Audiences: PEDS, HTX, MCS

Chairs: Angela Lorts, MD, and Ulrich Jorde, MD

Session Summary: Pediatric and congenital heart disease VAD support is a challenge because the population is heterogenous, VADs were not designed for complex anatomy and physiology, and compared with adults, the numbers, data and collective experience are extremely limited. Despite these challenges, pediatric centers have successfully adapted and utilized VADs to improve outcomes. This symposium will provide an opportunity for the pediatric community to share their experience with the broader MCS community. A 15-min panel discussion with all speakers will conclude this session.

10:15 AM  
Not Just Small Adults: Outcomes of Pediatric Patients with Continuous Flow Devices  
Christina J VanderPluym, MD, Boston Children's Hospital, Boston, MA, USA

10:30 AM  
Not Just Small Adults: Novel Antithrombosis Strategies Used in Pediatric VADs  
Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

10:45 AM  
Not-So Temporary Circulatory Support  
Aamir Jeewa, MD, Hospital for Sick Children, Toronto, ON, Canada

11:00 AM  
Optimizing Hemodynamics of Continuous Flow VADS for Small Patients  
Lucas Eastaugh, MBBS, Royal Children's Hospital, Melbourne, Australia

11:15 AM  
One Size Fits All? Strategies for Using Implantable VADs in Small Patients  
Antonio Amodeo, MD, Bambino Gesu Ped Hosp, Rome, Italy

11:30 AM  
Building Bridges: Collaborative Learning to Improve Outcomes in VAD Care  
David M Peng, MD, University of Michigan, Ann Arbor, MI, USA

11:45 AM  
15 min Panel Discussion
THURSDAY, APRIL 4, 2019
1:45 PM - 3:30 PM

SESSION 37 (SYMPOSIUM): JHLT at ISHLT: The Year in a Capsule
Room: Pacifica 10-12
Target Audiences: HF/HTX, ID, LF/LTX, MCS, PEDS, PH

Chairs: Manreet Kanwar, MD, and Martin Schweiger, MD

Session Summary: This symposium will highlight the most exciting publications in JHLT over the past year, each paper followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

1:45 PM  JHLT Best Papers of 2018
Patricia A. Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

1:50 PM  Highlights of Heart Transplantation and MCS
Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany

2:05 PM  Invited Discussant in Heart Transplantation and MCS
Francis D Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

2:15 PM  Highlights of Lung Transplantation and Pulmonary Hypertension
Peter Riddell, MBBS, Mater Misericordiae University Hospital, Dublin, Ireland

2:30 PM  Invited Discussant in Lung Transplantation and Pulmonary Hypertension
Jason D Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

2:40 PM  Highlights of Pediatric Heart and Lung Transplantation
Ann R Punnoose, MD, Children's Hospital of Wisconsin, Milwaukee, WI, USA

2:55 PM  Invited Discussant in Pediatric Heart and Lung Transplantation
Stuart C Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

3:05 PM  Highlights of Infectious Disease
Jonathan M Hand, MD, Ochsner Medical Center, New Orleans, LA, USA

3:20 PM  Invited Discussant in Infectious Diseases
Emily A Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA
THURSDAY, APRIL 4, 2019
1:45 PM - 3:30 PM

SESSION 38 (ORAL): Early Career Scientist Award Candidate Presentations
Room: Coral Sea
Target Audiences: BSTR, HTX, LTX, PATH

Chairs: Andrew E Gelman, PhD, and Frank D'Ovidio, MD, PhD

1:45 PM

(156) Mitochondrial DNA Mismatches in Thoracic Transplantation: Potential Triggers of Allograft Immunogenicity; A. Marishta1, Y. Yang1, X. Hu2, M. Jang1, K. Cuttin1, A. Jackson3, H. Luikart4, K. Bhatti1, U. Fidel1, T. Deuse2, K. Khush1, S. Schrepfer2, S. Agbor-Enoh1, H. Valantine1. 1Genomic Research Alliance for Transplantation (GRAfT), Laboratory of Transplantation Genomics, National Heart, Lung, and Blood Institute, Bethesda, MD, 2Department of Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco (UCSF), San Francisco, CA, 3Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, 4Department of Medicine, Stanford University School of Medicine, Palo Alto, CA

2:05 PM

(157) Effects of Nissen Fundoplication on Markers of Microaspiration and Inflammation after Lung Transplantation; K. C. Zhang1, S. E. Hunter1, E. Huszti2, M. Ahmed3, L. Levy4, K. M. Boonstra5, A. T. Sage1, S. Azad1, R. Zamel1, C. Frankel3, M. Budev4, P. Shah5, L. D. Snyder1, J. Belperio6, L. G. Singer1, S. S. Weigt6, J. L. Todd3, S. Keshavjee1, S. M. Palmer3, T. Martinu1, * for the CTOT-20 Investigators. 1Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 2Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, 3Duke University Medical Center, Durham, NC, 4Cleveland Clinic, Cleveland, OH, 5Johns Hopkins University Hospital, Baltimore, MD, 6UCLA Medical Center, Los Angeles, CA

2:25 PM

(158) ABO Tolerance Following Treatment of Infant Mice with A-Expressing MHC-Identical Erythrocytes; J. Fersovich1, B. Motyka1, I. Adam1, J. Pearcey1, K. Tao1, C. W. Cairo2, P. J. Cowan3, L. J. West1. 1Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, 2Dept Chemistry, University of Alberta, Edmonton, AB, Canada, 3Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia

2:45 PM

(159) Modulating Mitochondrial Fusion/Fission Induces Immunoprotective Effects in Models of Cardiac Transplantation; D. T. Tran1, Z. Tu2, C. Atkinson1, S. N. Nadig1. 1Microbiology & Immunology, Surgery, Medical University of South Carolina, Charleston, SC, 2Microbiology & Immunology, Medical University of South Carolina, Charleston, SC

3:05 PM

THURSDAY, APRIL 4, 2019
1:45 PM - 3:30 PM

SESSION 39 (ORAL): Walking a Tightrope: The Double-Edged Sword of Drugs after Heart Transplant
Room: Pacifica 3-5
Target Audiences: HTX, ID, PHARM

**Chairs:** Darko Vucicevic, MD, and Monica Colvin, MD

### 1:45 PM

(161) **Late-Breaking Clinical Trial: 10-Year Follow-Up of the Everolimus versus Azathioprine Multi-National Study:** J. A. Kobashigawa1, R. Starling2, E. Passano1, P. Bernhardt3, B. Arzarbal1, R. Cheng1, F. Esmailian1, K. Khush4, D. Mancini5, J. Patel1, T. Sato1, S. Varnous6. 1Smidi Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cleveland Clinic, Cleveland, OH, 3Novartis Pharmaceuticals, Basel, Switzerland, 4Stanford University, Palo Alto, CA, 5Mount Sinai, New York, NY, 6APHP, Pitie#8208;Salp#233;trie, Sorbonne University, Paris, France

### 2:00 PM

(162) **Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Ischemia-Reperfusion Injury:** R. Krebs1, M. Kankainen2, E. Holmström3, K. Dhaygude1, J. Lukac1, T. Ojala2, P. Mattila2, A. Nykänen1, K. Lemström1. 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland, 2Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

### 2:15 PM

(163) **Higher Intensity Statin Therapy Reduces Clinical Endpoints after Heart Transplantation Independent of Lipid Levels:** L. R. Golbus1, S. Adie1, S. Hanigan1, M. Dorsch1, B. Rooks2, K. D. Aaronson1, M. C. Konerman. 1Internal Medicine, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI

### 2:30 PM

(164) **Everolimus in the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy in Heart Transplantation (RAD-TAC Study):** C. Anthony, M. Imran, S. Emmanuel, J. Iliff, E. Kotlyar, K. Muthiah, A. M. Keough, C. S. Hayward, P. S. Macdonald, A. Jabbour. Heart and Lung Transplant, St Vincent’s Hospital Sydney, Sydney, Australia

### 2:45 PM


### 3:00 PM

(166) **Early Infection Risk Associated with Induction Immunosuppression after Cardiac Transplant in Patients with Left Ventricular Assist Devices:** J. Batra1, D. L. Jennings1, A. R. Garan1, L. K. Truby1, K. Takeda2, H. Takayama2, S. Restaino1, F. Lati1, J. Haythe1, M. Yuzefpolskaya1, P. C. Colombo1, Y. Naka2, M. A. Farr1, V. K. Topkara1. 1Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

### 3:15 PM

(167) **Specific Immune Tolerance Response Triggered by Extracorporeal Photopheresis after Heart Transplantation:** K. Klaeske1, M. Dieterlen1, J. Wittke1, M. Borger1, J. Garbade1, S. Lehmann1, H. Reichenspurner2, M. Barten2. 1Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, 2University Heart Center Hamburg, Hamburg, Germany
THURSDAY, APRIL 4, 2019
1:45 PM - 3:30 PM

SESSION 40 (SYMPOSIUM): Heart Failure in Adult Congenital Heart Disease: Unique Problems Need Unique Solutions
Room: Pacifica 7
Target Audiences: HF/HTX, MCS, PEDS

Chairs: Maryjane Farr, MD, and Heather J. Ross, MD, MHSc, FRCPC

Session Summary: The aim of this symposium is to describe the pathophysiology and management of heart failure syndromes that are unique to ACHD patients.

1:45 PM  
Too Sick to Live, Too Well to Die: When Do You Transplant a Failing ACHD Patient?
Daphne Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA

2:00 PM  
Q&A

2:05 PM  
Is Two Really Better Than One? Heart-Liver Transplantation in ACHD
Clive J Lewis, MB BChir PhD FRCP, Papworth Hospital, Cambridge, United Kingdom

2:20 PM  
Q&A

2:25 PM  
Under Pressure: Managing Pulmonary Hypertension in ACHD
Robert Weintraub, MD, Royal Children's Hospital, Parkville, Australia

2:40 PM  
Q&A

2:45 PM  
I've Got Options: VADs in Patients with ACHD
David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

3:00 PM  
Q&A

3:05 PM  
The Failing Sub-Pulmonic RV in Congenital Heart Disease: Forgotten, But Not Gone
Wendy M Book, MD, Emory University, Atlanta, GA, USA

3:20 PM  
Q&A
THURSDAY, APRIL 4, 2019
1:45 PM - 3:30 PM

SESSION 41 (ORAL): Perfecting the Graft: LVAD Pump Management, Outcomes and Medications
Room: Pacifica 6
Target Audience: MCS

Chairs: Nader Moazami, MD, and Emma Birks, MD, PhD

1:45 PM
(168) Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life: The RAMP-IT-UP Multicenter Study: N. Uriel1, D. Burkhoff2, J. Rich3, S. Drakos4, D. Banerjee4, J. Teuteberg5, G. Sayer1. 1University of Chicago, Chicago, IL, 2Columbia University, New York, NY, 3Northwestern University, Chicago, IL, 4University of Utah, Salt Lake City, UT, 5Stanford University, Palo Alto, CA

2:00 PM
(169) HeartMate 3 Surgical Implant Technique and Outcomes in the MOMENTUM 3 Trial: C. Salerno1, Y. Naka2, S. C. Silvestry3, D. J. Goldstein4, J. C. Cleveland5, A. Bansal6, N. A. Mokadam7, J. N. Schroder8, V. Jeewanandam9, A. J. Tatooles10, J. Chuang11, J. W. Long12. 1St. Vincent Heart Center, Indianapolis, IN, 2Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, NY, 3Florida Hospital, Orlando, FL, 4Montefiore Einstein Center for Heart and Vascular Care, New York, NY, 5University of Colorado School of Medicine, Aurora, CO, 6Ochsner Clinic Foundation, New Orleans, LA, 7Ohio State University Medical Center, Columbus, OH, 8Duke University Medical Center, Durham, NC, 9University of Chicago School of Medicine and Medical Center, Chicago, IL, 10Advocate Christ Medical Center, Oak Lawn, IL, 11Abbott, Abbott Park, IL, 12Integris Baptist Medical Center, Oklahoma City, OK

2:15 PM
(170) Poor Left Ventricular Unloading is Associated with Increased Mortality after Continuous Flow Left Ventricular Assist Device Implantation: V. Maharaj1, R. Cogswell1, J. Schultz2, R. John2, C. Martin1, T. Thenappan1, T. Alexy1. 1Division of Cardiology, University of Minnesota Medical Center, Minneapolis, MN, 2Division of Cardiothoracic Surgery, University of Minnesota Medical Center, Minneapolis, MN

2:30 PM
(171) Effect of Anesthesia on Cardiac Hemodynamics in patients undergoing durable LVAD Implantation: The EACH LVAD Study: T. C. Hanif1, P. A. Patel2, K. L. Kurcik1, S. Rao1, S. E. Kimmel1, M. E. Putt3, P. Atluri2, C. A. Bermudez4, M. A. Acker4, E. Y. Birati1, J. E. Rame1, J. W. Wald1. 1Division of Cardiology, University of Pennsylvania, Philadelphia, PA, 2Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, 3Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 4Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

2:45 PM
(172) Evaluation of Anticoagulation Bridging Strategies in LVAD Patients: A. D. Rabon1, D. J. Taber2, W. E. Uber1, B. A. Houston3, H. Meadows1. 1Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC, 2Department of Surgery, Medical University of South Carolina, Charleston, SC, 3Division of Cardiology, Medical University of South Carolina, Charleston, SC

3:00 PM
(173) Concentrated Factor Administration and Subsequent Pump Thrombosis on HeartMate II LVAD Support: H. Shah1, R. Cogswell1, J. Misialek2, J. Schultz1, A. Nitzkowskii3, R. John1, C. Martin1, M. Pritzker1, A. Shaffer4. 1Cardiology, University of Minnesota, Minneapolis, MN, 2Epidemiology & Community Health, University of Minnesota, Minneapolis, MN, 3Pharmacology, University of Minnesota, Minneapolis, MN, 4Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

3:15 PM
(174) Regional Outcomes after Continuous-Flow Left Ventricular Assist Device: An IMACS Analysis: K. K. Mirza1, R. Rongbing Xie2, J. K. Kirklin3, B. Meyns3, J. A. Cowger4, J. Pennington2, F. Gustafsson1, D. Goldstein5. 1Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, 2Department of Surgery, University of Alabama, Birmingham, AL, 3Katholieke Universiteit Leuven, Leuven, Belgium, 4Henry Ford Hospital, Detroit, MI, 5Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY
SESSION 42 (ORAL): Too Much or Two Little? Obesity and Frailty in MCS
Room: Grand Caribbean 1-7
Target Audiences: MCS, NHSAH

Chairs: Gene H Kim, MD, and Mary E Keebler, MD

1:45 PM
(175) Complete Sternal-Sparing LVAD Implantation is a Safe and Effective Technique for Obese Patients; K. Wood, B. C. Ayers, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. University of Rochester, Rochester, NY

2:00 PM
(176) Continuous-Flow Left Ventricular Assist Devices and Bariatric Surgery in Patients with Morbid Obesity and Heart Failure - A Systematic Review; J. Challapalli¹, D. Cross², M. P. Weber³, J. Choi², E. J. Maynes², R. Aggarwal¹, A. J. Boyle³, J. W. Entwistle², H. T. Massey³, R. J. Morris², V. Tchantchaleishvili². 
¹College of Medicine, Drexel University, Philadelphia, PA, ²Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, ³Department of Surgery, Thomas Jefferson University, Philadelphia, PA

2:15 PM
(177) Impact of Diabetes Mellitus on Mortality and In-Hospital Outcomes after Left Ventricular Assist Device Implantation; V. Blumer¹, M. Ortiz², G. Hernandez³, S. Chaparro¹, A. Vest⁴. ¹University of Miami, Miami, FL, ²University of Iowa, Iowa, IA, ³Univ. of Miami, Miami, FL, ⁴Tufts Medical Center, Boston, MA

2:30 PM
(178) The Combination of Left Ventricular Assist Device and Laparoscopic Sleeve Gastrectomy May Promote Myocardial Recovery in Obese Advanced Chronic Heart Failure Patients; G. Poglajen¹, S. Kumar¹, B. Akkanti¹, R. Radovancevic¹, S. Nathan¹, M. Jumean¹, M. H. Akay¹, M. Patel¹, B. Vrtovec², B. Kar¹, I. D. Gregoric¹. ¹Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, ²Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia

2:45 PM

3:00 PM
(180) The Impact of Frailty on Survival in Patients Undergoing Advanced Therapies for Heart Failure; M. Stein¹, K. T. O'Brien¹, F. Foroutan¹, V. Rao¹, H. J. Ross², A. C. Alba³. ¹Toronto General Hospital, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital, University Health Network, Toronto, ON, Canada

3:15 PM
(181) Frailty and Clinical Outcomes Following Left Ventricular Assist Device Implantation; H. G. Uzun¹, E. Demir², E. Simsek³, T. Capanoglu³, H. Karapolat³, C. Engin², T. Yagdi³, P. Ozturk³, M. Ozbaran³, S. Nalbantgil². ¹Cardiology, Can State Hospital, Canakkale, Turkey, ²Cardiology, Ege University, Izmir, Turkey, ³Physical Medicine and Rehabilitation, Ege University, Izmir, Turkey
SESSION 43 (SYMPOSIUM): Changes in the World of Pulmonary Hypertension: Nice or Not Nice  
Room: Pacifica 1-2  
Target Audiences: PH, CTEPH, PATH  

Chairs: Colin Church, MD PhD, and Marc A. Simon, MD  

Session Summary: This symposium, in collaboration with the Pulmonary Vascular Research Institute (PVRI), will focus on controversies and new proposed developments under review since the recent World Symposium on Pulmonary Hypertension, exploring the concept of changing the definition to mean pulmonary artery pressure of 20mmHg and the implications for future management of patients, risk stratification of patients with PAH and best approach, and which best clinical trial endpoint should be adopted.

1:45 PM    Feeling the Pressure: New Hemodynamic Classification of Pulmonary Vascular Disease  
Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA  

2:00 PM    Q&A  

2:05 PM    The Drugs Don’t (or might not) Work Anymore! Implications for Treatments in PAH with the New Hemodynamic Definition  
Mardi Gomberg-Maitland, MD, Inova Fairfax Hospital, Falls Church, VA, USA  

2:20 PM    Q&A  

2:25 PM    Too Risky for PAH? Patient Stratification and Implications for Treatment  
Paul Hassoun, MD, Johns Hopkins University, Baltimore, MD, USA  

2:40 PM    Q&A  

2:45 PM    DEBATE: Quality Over Quantity? Future Trial Primary Endpoints Should Be QOL Focused (PRO)  
Ioana R Preston, MD, Tufts Medical Center, Boston, MA, USA  

3:00 PM    DEBATE: Quality over Quantity? Future Trial Primary Endpoints Should be QOL Focused (CON)  
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom  

3:15 PM    Debate Rebuttal (PRO)  
Ioana R Preston, MD, Tufts Medical Center, Boston, MA, USA  

3:20 PM    Debate Rebuttal (CON)  
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
SESSION 44 (ORAL): Philip K. Caves Award Candidate Presentations
Room: Coral Sea
Target Audience: ALL

Chairs: Hermann Reichenspurner, MD, PhD, and Christopher H Wigfield, MD, FRCS

4:00 PM (182) B Cells Drive Chronic Lung Allograft Rejection after Ischemia-Reperfusion Injury in Mouse Lung Transplantation; T. Watanabe, T. Martinu, K. Boonstra, M. Horie, Z. Guan, B. Joe, K. Bei, A. Chruscinski, D. Hwang, M. Liu, S. Keshavjee, S. Juvet. University Health Network, Toronto, ON, Canada

4:15 PM (183) Microbiome Dependent Regulatory T Cell Generation Correlates with Acute and Chronic Lung Allograft Rejection in a Murine Model; Y. Guo1, Q. Wang1, D. Li1, A. Manafi1, Z. Mei1, O. Onyema1, A. E. Gelman2, D. Kreisel2, A. S. Krupnick1. 1Surgery, University of Virginia, Charlottesville, VA, 2Surgery, Washington University in St. Louis, St. Louis, MO

4:30 PM (184) Right Ventricular Dysfunction Correlates with Decreased Endothelial Progenitor Cell Mobilisation and Impaired Angiogenesis in Patients with Dilated Cardiomyopathy; S. Frljak1, M. Jaklic1, G. Zemljic1, A. Cerar1, G. Poglajen1, F. Haddad2, B. Vrtovec1. 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Stanford Cardiovascular Institute, Stanford, CA

4:45 PM (185) Host miRNA Profile of Invasive Aspergillosis in Lung Transplant Recipients; W. Gohir1, W. Klement2, L. G. Singer3, S. M. Palmer4, S. Keshavjee3, S. Husain1. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Organ Donation and Transplantation, Canadian Blood Services, Ottawa, ON, Canada, 3Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 4Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC


5:15 PM (187) Hemodynamic Parameters That Predict Success with an Ambulatory Counterpulsation Heart Assist System in Advanced Congestive Heart Failure; T. Symalla1, T. Song1, D. Onsager1, T. Ota1, C. LaBuhn1, P. Combs1, T. Lammy1, S. Patel-Raman2, G. Sayer3, G. Kim4, J. Raikhelkar3, N. Uriel1, V. Jeevanandam1. 1Cardiac Surgery, University of Chicago, Chicago, IL, 2NuPulseCV, NuPulseCV, Chicago, IL, 3Cardiology, University of Chicago, Chicago, IL

5:30 PM (188) A Novel Tool to Quantify Immune Suppression after Pediatric Transplantation: Flow Cytometric Activation Assays; R. E. Penner1, L. Ionescu1, S. Mitai2, B. Foster1, P. Birk4, V. Phan1, T. Blydt-Hansen6, U. Allen2, L. Hamiwka1, C. Morgan4, S. Urschel1. 1University of Alberta, Edmonton, AB, Canada, 2Hospital for Sick Children, Toronto, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Manitoba, Winnipeg, MB, Canada, 5CHU Sainte-Justine, Montreal, QC, Canada, 6BC Children's Hospital, Vancouver, BC, Canada, 7Alberta Children's Hospital, Calgary, AB, Canada
SESSION 45 (ORAL): Acute Cardiac Rejection: New Approaches to an Old Problem
Room: Pacifica 7
Target Audiences: HTX, BSTR, PATH

Chairs: David Schibilsky, MD, and Ravikumar Ratnagiri, MD

4:00 PM

(189) Clinical and Pathological Insights of Myocardial Molecular Profiling: Time to Revise ISHLT Grading System?; L. Potena, V. Agostini, L. Borgese, E. Rinaldi, L. Giovannini, J. Reeve, M. Parkes, M. Masetti, A. Russo, O. Leone, P. Halloran. 1Bologna University Hospital, Bologna, Italy, 2University of Alberta, Edmonton, AB, Canada

4:15 PM

(190) HLA Epitope Mismatching is Associated with Rejection and Worsened Graft Survival in Heart Transplant Recipients; E. Osorio-Jaramillo, G. W. Haasnoot, A. Kaida, A. Zuckermann, A. Schaefer, T. Haberl, J. Goekler, P. Angleitner, R. Moayedifar, G. F. Fischer, G. Laufer, F. H. Claas, A. Z. Aliabadi-Zuckermann. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, 3Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria, 4Department for Blood Group Serology and Transplant Medicine, Medical University of Vienna, Vienna, Austria

4:30 PM


4:45 PM

(704) Heart Transplant Patients with Histologic Normal and Molecular Microscope Abnormal Biopsies: An Exploratory Analysis; K. Shah, J. A. Kobashigawa, J. Patel, M. Kittleson, D. H. Chang, S. Dimbil, R. Levine, S. Sana, L. Czer, R. Azarbal, F. Esmailian, P. Halloran. 1Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 2University of Alberta, Alberta, AB, Canada

5:00 PM

(193) Racial Differences in Risk of Acute Rejection after Cardiac Transplantation; R. C. Patel, L. B. Cooper, R. T. Cole, S. Sinha, L. J. Bogar, S. D. Barnett, A. Cochrane, M. Psotka, P. Shah. 1Virginia Commonwealth University School of Medicine, Richmond, VA, 2Department of Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA, 3Department of Heart Failure and Transplant, Emory University, Atlanta, GA, 4Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA

5:15 PM


5:30 PM

THURSDAY, APRIL 4, 2019
4:00 PM - 5:45 PM

SESSION 46 (SYMPOSIUM): FUN and Games with FUNgal Infections in Lung Transplantation
Room: Pacifica 3-5
Target Audiences: ID, LF/LTX, PATH, PHARM

Chairs: Orla Morrissey, MD, and Gregory A Fishbein, MD

Session Summary: Fungal infections after thoracic transplantation are associated with high mortality. Prophylaxis and treatment come with various complications including drug-drug interactions, toxicities, treatment failure and emerging resistance. This symposium will provide insights regarding the epidemiology, prevention, diagnosis and treatment approaches to take when faced with the challenges of fungal infections in thoracic transplantation. A 15-min panel discussion with all speakers will conclude this session.

4:00 PM  Defining Fungal Infection: Not a TRIVIAL PURSUIT
          Erika D Lease, MD, University of Washington, Seattle, WA, USA

4:15 PM  DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (PRO)
          John W Baddley, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA

4:30 PM  DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (CON)
          Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

4:45 PM  Don’t Be SORRY! Tips and Tricks for Managing Azole Antifungal Agents
          Tara Veasey, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA

5:00 PM  Not a MONOPOLY: Antifungal Drug Administration Via the Inhaled Route
          Antonio B Roman, MD, PhD, Hospital General Vall D'Hebron, Barcelona, Spain

5:15 PM  Are We in TROUBLE? Emergence of Azole-Resistant Molds
          Minh-Hong Nguyen, MD, University of Pittsburgh, Pittsburgh, PA, USA

5:30 PM  15 minute Panel Discussion
THURSDAY, APRIL 4, 2019
4:00 PM - 5:45 PM

SESSION 47 (ORAL): Back to the Basics: Physiological Alterations During Continuous Flow VAD Support
Room: Pacifica 6
Target Audiences: MCS, BSTR, PATH

Chairs: Ahmet Kilic, MD, and Carlo Banfi, MD, PhD, FCCP

4:00 PM  
(196) Evaluation of the Effect of Artificial Pulsatility in Continuous Flow Assist Device on Peripheral Vascular Reactivity: P. Ivak1, J. Pišťař1, J. Pích1. 1Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

4:05 PM  
(197) Long-Term Changes in Kidney Function after Left Ventricular Assist Device Implant: An Analysis of the STS Intermacs Database: D. D. Franz1, M. R. Stedman1, S. L. Myers2, D. C. Naftel3, S. A. Silver4, D. Banerjee5, T. I. Chang1. 1Medicine, Stanford University, Palo Alto, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3Kingston General Hospital, Kingston, ON, Canada

4:30 PM  
(198) Functional Assessment of Decellularized Extracellular Matrix in Patients Undergoing LVAD Implantation: D. Yu1, M. Vaičiūnas2, A. Nguyen1, D. Rodgers1, N. Narang1, H. Holzhauser1, I. Ebbing1, A. Kanelidis1, G. Sayer1, J. Raikhelkar1, N. Sarswat1, B. Smith1, S. Kalantari1, B. Chung1, J. Georgiadis2, N. Urie1, G. H. Kim1. 1Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL, 2College of Engineering, Illinois Institute of Technology, Chicago, IL

4:45 PM  

5:00 PM  
(200) A Comparison of Middle Cerebral Artery and Central Retinal Artery Hemodynamics in HM II Patients: E. J. Stöhr1, R. Ji2, K. Akiyama3, F. Castagna4, A. Pinsino5, J. R. Cockcroft6, M. Yuzefpolskaya7, A. R. Garan6, V. K. Topkara2, R. T. Te-Frey5, H. Takayama1, K. Takeda3, Y. Naka4, P. C. Colombo2, J. Z. Willey4, B. J. McDonnell1. 1Physiology & Health, Cardiff Metropolitan University, Cardiff, United Kingdom, 2Medicine, Columbia University Medical Center, New York, NY, 3Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 4Neurology Stroke, Columbia University Medical Center, New York, NY

5:15 PM  
(201) Risk of dnDSA with Various MCS Devices as Bridge-to-Transplant: R. T. Cole1, M. Flattery2, J. Minto3, A. Parikh4, T. Dong5, R. Roy1, L. Bogar1, A. Smith1, J. Vega1, A. Morris1, S. Laskar1, K. Bhatt1, D. Gupta1, A. Lala2, K. Shah3, P. Shah3. 1Cardiology, Emory Univ Sch of Med, Atlanta, GA, 2Cardiology, Virginia Commonwealth University, Richmond, VA, 3George Washington University School of Medicine, Washington, D.C., 4Cardiology, Mount Sinai Hospital, New York, NY, 5Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, 6Cardiology, Emory University School of Medicine, Atlanta, GA, 7Mount Sinai Hospital, New York, NY, 8Virginia Commonwealth University, Richmond, VA, 9Inova Heart and Vascular Institute, Falls Church, VA

5:30 PM  
(202) Associations among Biomarkers of Congestion, Inflammation and Oxidative Stress in Heart Failure, LVAD and Heart Transplant: E. A. Royzman1, G. M. Mondellini1, A. M. Zuver1, C. A. Bravo2, D. L. Brunjes3, D. Onat1, M. Mabasa1, J. C. Hupf1, A. R. Garan1, H. Takayama1, K. Takeda3, Y. Naka3, R. T. Demmer4, P. C. Colombo5, M. Yuzefpolskaya7. 1Department of Medicine, Columbia University Medical Center, New York, NY, 2Department of Medicine, Montefiore Medical Center, Bronx, NY, 3Department of Surgery, Columbia University Medical Center, New York, NY, 4Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
THURSDAY, APRIL 4, 2019
4:00 PM - 5:45 PM

SESSION 48 (SYMPOSIUM): Advances in Short- and Long-Term Mechanical Circulatory Support - What’s Next
Room: Grand Caribbean 1-7
Target Audience: MCS

Chairs: Ulrich Jorde, MD, and Simon Maltais, MD PhD

Session Summary: Following a brief update on the state of the art of short and long term MCS, this symposium will focus on innovation and improvement opportunities. Specifically, issues of device size, deployment / implantation, hemodynamic properties and hemocompatibility will be reviewed. Presenters will discuss current capabilities as well as ongoing research and development efforts with 2- and 5-year targets. This symposium is not CME accredited.

4:00 PM  
STATE OF THE ART Durable MCS and Unmet Needs  
Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA

4:05 PM  
The Future of Durable MCS - Medtronic Perspective  
Eric Corndorf, PhD, Medtronic, Framingham, MA, USA

4:20 PM  
The Future of Durable MCS - Abbott Perspective  
Kevin Bourque, DVP, Abbott, Burlington, MA, USA

4:35 PM  
STATE OF THE ART and Unmet Needs Total Heart Replacement (THR)  
Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria

4:40 PM  
The Future of THR - Syncardia Perspective  
Steven R. Langford, BSEE, Syncardia Systems, Tucson, AZ, USA

4:55 PM  
The Future of THR - CarMat Perspective  
Piet G. Jansen, MD, PhD, Carmat SA, Velizy-Villacoublay Cedex, France

5:10 PM  
STATE OF THE ART Acute MCS and Unmet Needs  
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

5:15 PM  
The Future of Acute MCS - Abiomed Perspective  
Daniel H. Raess, MD, FACC, FACS, Abiomed, Danvers, MA, USA

5:30 PM  
15-min Panel Discussion
4:00 PM  (203) Intravenous Methamphetamine Does Not Appear to Be a Contraindication for Heart Donation in Heart Transplantation; A. Velleca, T. Kao, B. Kearney, J. Patel, M. Kittleson, R. Levine, S. Dimbil, S. Mersola, M. Hamilton, F. Esmailian, J. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA

1Faculty of Community Services, School of Social Work, Ryerson University, Toronto, ON, Canada, 2Tema Genus, Tema Institute, Linkopings Universitet, Linkopings, Sweden, 3Department of Psychiatry, University Health Network, Toronto, ON, Canada, 4Department of Studio Arts, Faculty of Fine Arts, Concordia University, Montreal, QC, Canada, 5Winchester School of Art, Southampton University, Winchester, United Kingdom, 6Department of Cardiology, University Health Network, Toronto, ON, Canada, 7Department of Art History, Faculty of Fine Arts, Concordia University, Montreal, QC, Canada, 8Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, 9Department of English, Linguistics and Cultural Studies, University of Westminster, London, United Kingdom

4:30 PM  (205) Universal Depression Screen of Ambulatory Cardiac Transplant Recipients is Feasible and Identifies a Subset of Patients That May Benefit from Mental Health Intervention; L. Peters, L. Rosenthal, H. Monroe, M. Dierks, A. Ambardekar, C. McIlvnnan. University of Colorado, Aurora, CO

4:45 PM  (206) Depressive Symptoms, Physical Activity, and Post-Transplant Outcomes: The ADAPT Prospective Study; P. J. Smith, C. Frankel, D. Bacon, E. Bush, L. Snyder. Duke University Medical Center, Durham, NC

5:00 PM  (207) PTSD in Tx ICU Nurses; M. Sanchez1, A. Simon2, D. Ford1. 1Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom, 2MCS and Cardiothoracic Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom


5:30 PM  (209) The Value of Licensed Clinical Social Worker Pre-Implant Assessment in Predicting Non-Compliance in Durable Mechanical Circulatory Support Device Patients; H. Barone1, M. Olman2, A. Fishman2, L. Olanisa2, C. Runyan1, J. Haji1, N. Huie1, M. Lindsay1, E. Passano1, J. Kobashigawa1, J. Moriguchi1, R. Cole1, F. Esmailian1, J. Chung1, D. Ramzy1. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA
SESSION 50 (ORAL): Pulmonary Hypertension in Translation: From Novel Biomarkers to Cutting Edge Clinical Results
Room: Pacifica 1-2
Target Audiences: PH, PHARM

Chairs: C. Dario Vizza, MD, and Amresh Raina, MD

4:00 PM  
(210) Treatment with Oral Treprostinil Delays Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension - Results from FREEDOM-EV; V. F. Tapson1, C. J. Sanchez Diaz2, G. M. Bohns Meyer3, T. Pulido4, P. Sepulveda5, K. Y. Wang6, C. Q. Deng7, R. Grover7, D. Solum7, A. Ousmanou8, R. J. White8, 1Cedars Sinai, Los Angeles, CA, 2Unidad De Inv Clinica En Medicina, Monterrey, Mexico, 3Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Brazil, 4Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico, 5Hospital San Juan De Dios, University of Chile, Santiago, Chile, 6Taichung Veterans General Hospital, Taichung, Taiwan, 7United Therapeutics, Research Triangle Park, NC, 8University of Rochester Medical Center, Rochester, NY

4:15 PM  
(211) Risk Assessment in Functional Class (FC) II Pulmonary Arterial Hypertension (PAH) Patients: Comparison of Physician Gestalt with ESC/ERS-Guidelines and REVEAL 2.0; S. Sahay1, A. Tonelli2, T. Kung3, Z. Watson4, R. L. Benza5, 1Houston Methodist Hospital, Houston, TX, 2Cleveland Clinic, Cleveland, OH, 3Actelion Pharmaceuticals US, Inc., South San Francisco, CA, 4Putnam Associates, Boston, MA, 5Allegheny General Hospital, Pittsburgh, PA

4:30 PM  
(212) Clinical Surrogates of Right Ventricular-Pulmonary Arterial Arterial Uncoupling; C. G. Ireland1, R. L. Damico1, T. M. Kolb1, S. Mathai1, S. Zimmerman1, A. A. Shah1, M. Mukherjee1, F. Wigley1, P. M. Hassoun1, D. A. Kass1, R. J. Tedford2, S. Hsu1, 1The Johns Hopkins Hospital, Baltimore, MD, 2Medical University of South Carolina, Charleston, SC

4:45 PM  
(213) Relationship between Race/Ethnicity and Survival in Patients with Pulmonary Arterial Hypertension (PAH); S. Medrek1, S. Sahay2, T. Kung3, C. Zhao4, A. E. Frost5, 1Division of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, 2Houston Methodist Hospital, Houston, TX, 3Actelion, South San Francisco, CA

5:00 PM  
(214) Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study; R. L. Benza1, J. R. Klinger2, H. A. Ghofrani3, P. Jansa4, E. Grünig5, D. Vizza6, M. M. Hoeper7, 1The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 2Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, 3University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany, 4Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Centre for Pulmonary Hypertension, Thorax Clinic at the University Hospital, Heidelberg, Germany, 6Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy, 7Clinical for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany

5:15 PM  
(215) Long-Term Outcomes in Pulmonary Arterial Hypertension by Functional Class: A Meta-Analysis of Randomized Controlled Trials and Observational Registries; N. H. Kim1, M. Fisher2, D. S. Poch1, C. Zhao3, M. Shah1, S. Bartolome4, 1University of California, San Diego, La Jolla, CA, 2Emory School of Medicine, Atlanta, GA, 3Actelion, South San Francisco, CA, 4University of Texas, Southwestern Medical Center, Dallas, TX

5:30 PM  
(216) Beta Receptor Blockade Fails to Recover Ventricular Function Despite Increased Pre-Synaptic Sympathetic Nervous System Function in Experimental Pulmonary Arterial Hypertension; J. Zeh1, A. Ahmadi, J. Renaud, R. deKemp, R. Beanlands, L. Mielniczuk, University of Ottawa Heart Institute, Ottawa, ON, Canada
THURSDAY, APRIL 4, 2019
6:00 PM - 7:00 PM

MINI ORAL 07A & 07b: Basic Science and Translational Research / Heart Transplantation (Adult)
Room: Coral Sea
Target Audiences: BSTR, HTX, PATH, PEDS

Chairs: Alexander M Bernhardt, MD, and Karl B Lemstrom, MD, PhD

6:00 PM  (429) Functional Assessment of DCD Hearts Following Normothermic Regional Perfusion Can Predict Post-Transplantation Contractility; R. Ribeiro, J. S. Alvarez, E. Paradiso, F. Yu, M. B. Adamson, F. Foroutan, V. Bissoondath, M. Meineri, V. Rao, M. V. Badiwala. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

6:05 PM  (430) Hi1a, an ASIC1a Inhibitor, Significantly Improves the Tolerance of Donor Allografts to Ischaemia in a Rodent Model of DCD Heart Transplantation; S. E. Scheuer1, L. Gao2, M. Hicks1, H. Chew1, A. Doyle3, J. Villanueva2, A. Jabbour1, G. King3, P. Macdonald1, K. Dhill1. 1St Vincent's Hospital, Darlinghurst, Australia, 2Victor Chang Cardiac Research Institute, Darlinghurst, Australia, 3Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia

6:10 PM  (431) In Vivo Resuscitation, Perfusion and Transplantation of a Porcine Cardiac Allograft Donated after Cardiac Death; A. Grant1, R. R. Gonzalez2, A. Klima1, A. Badiye1, A. Gardiner1, M. Thomas2, I. hernandez Schuman3, J. Hare2, A. Ghodsizad2, M. Loebe1. 1Miami Transplant Institute University of Miami, Miami, FL, 2Surgery, Miami Transplant Institute University of Miami, Miami, FL, 3Cardiology, Miami Transplant Institute University of Miami, Miami, FL, 4Veterinary Resources, University of Miami, Miami, FL, 5Department Veterinary Resources, University of Miami, Miami, FL, 6Interdisciplinary Stem Cell Institute, Department of Medicine, Division of Nephrology, Katz Family Division of Nephrology and Hypertension, University of Miami Leonard M Miller School of Medicine, Miami, FL, 7Interdisciplinary Stem Cell Institute, Cardiovascular Division, University of Miami Leonard M Miller School of Medicine, Miami, FL

6:15 PM  (432) Conditioned Medium from Mesenchymal Stem Cells Protects Vascular Grafts of Brain-Dead Rats against In Vitro Ischemia/Reperfusion Injury; S. Korkmaz-Içöz1, P. Zhou1, Y. Guo1, S. Loganathan1, P. Brlecic1, T. Radovits2, M. Ruppert1, A. A. Sayour1, M. Karck1, G. Szabó1. 1Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany, 2Heart and Vascular Center, Semmelweis University, Budapest, Hungary

6:20 PM  (433) Gene Expression in Ex Vivo Perfused Porcine Hearts: Identification of a Molecular Injury-Repair Response; S. Rotich1, N. Herbs1, S. Hatami2, M. Mengel1, J. Nagendran2, D. H. Freed1, B. Adam1. 1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, 2Department of Surgery, University of Alberta, Edmonton, AB, Canada

6:25 PM  (434) Ghrelin, a Novel Growth Hormone-Releasing Peptide, Inhibits Inflammatory Response and Apoptosis during Ischemic Reperfusion Injury Following Murine Heart Transplantation; N. Fukunaga1, R. V. Ribeiro1, V. Bissoondath1, F. Billia2, M. V. Badiwala1, V. Rao1. 1Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Cardiology, Toronto General Hospital, Toronto, ON, Canada

6:30 PM  (435) Survival Outcomes in Heart Transplant Patients; Specific Focus on ACHD Patients and Their Outcomes as Compared to Dilated and Ischemic Cardiomyopathy Patients; A. Kinsella1, V. Rao1, C. Fan2, C. Manlhiot2, J. Stehlik2, H. Ross2, A. C. Alba2. 1Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada

6:35 PM  (436) Candidate Selection and the Survival Benefit of Heart Transplantation in the United States; W. F. Parker1, E. S. Huang1, R. D. Gibbons2, A. S. Anderson3, M. M. Churpek1. 1University of Chicago Medicine, Chicago, IL, 2Public Health Sciences, University of Chicago Medicine, Chicago, IL, 3Northwestern Medicine, Chicago, IL

6:40 PM  (437) Does Pre-Existing Donor Heart Coronary Artery Disease Impact Survival after Orthotopic Heart Transplantation?; J. Jahanyar1, J. M. Liao2, N. Zhang3, R. J. Butterfield III4, R. W. Hardaway5, R. L. Scott6, E. D. Steidley7. 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Medicine, University of Washington, Seattle, WA, 3Health Sciences Research, Mayo Clinic, Phoenix, AZ, 4Biostatistics, Mayo Clinic, Phoenix, AZ, 5Cardiology, Mayo Clinic, Phoenix, AZ


6:55 PM  (440) Survival after Primary Graft Dysfunction in Heart Transplantation: Outcomes of the National UK Data; S. Avtaar Singh1, S. Das De1, S. Rushton2, N. Banner3, C. Berry4, N. Al-Attar1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Statistics, National Health Service Blood and Transplant, Bristol, United Kingdom, 3Advanced Heart Failure and Transplantation, Harefield Hospital, London, United Kingdom, 4Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
THURSDAY, APRIL 4, 2019
6:00 PM - 7:00 PM

MINI ORAL 08: Lung Donor Management and Organ Allocation
Room: Pacifica 10-12
Target Audiences: LF/LTX

Chairs: David R Darley, MBBS BSc (Hons II) and Erika D. Lease, MD

6:00 PM  
(441) The Accuracy of LAS in Predicting Post-Transplant Risk of ECMO Recipients; J. Katsis, W. F. Parker, M. Churpek, E. Garrity. Pulmonary and Critical Care, University of Chicago, Chicago, IL

6:05 PM  
(442) The Protective Effect of Prone Positioning on Human Rejected Donor Lungs during Cellular Ex Vivo Lung Perfusion; H. Niikawa1, T. Okamoto1, K. S. Ayyat1, Y. Itoda1, C. F. Farver2, K. R. McCurry1. 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 2Anatomic Pathology, Cleveland Clinic, Cleveland, OH

6:10 PM  

6:15 PM  
(444) Donor Lung Weight at Lung Procurement; Predictive Value for Transplant Suitability during Ex Vivo Lung Perfusion; T. Okamoto, H. Niikawa, D. Wheeler, B. Soliman, K. S. Ayyat, Y. Itoda, K. R. McCurry. Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

6:20 PM  
(445) Impact of Lung Allograft Oversizing on Pleural Cavity Expansion in Transplant Recipients with Idiopathic Pulmonary Fibrosis; S. H. Roberts1, S. L. Miter1, B. Shukrullah2, B. C. Keller1, M. E. Lee1, T. Yurjevic1, S. Carter1, A. Pope-Harman1, P. Lee1, B. A. Whitson1. 1The Ohio State University Wexner Medical Center, Columbus, OH, 2Minnesota Heart Institute, Minneapolis, MN

6:25 PM  
(446) Single Lung Transplant Compared with Double Lung Transplant in Older Adults with Interstitial Lung Disease; L. J. Benvenuto1, M. Aversa1, L. Shah1, M. Carroll1, F. D’Ovidio2, B. P. Stanifer2, J. R. Sonett2, H. Y. Robbins1, S. Arcasoy1. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY

6:30 PM  
(447) Right Single and Double Lung Transplant Outperform Left Single Lung Transplant in Chronic Obstructive Pulmonary Disease: A UNOS Analysis; L. J. Benvenuto1, J. Costa2, D. Piloni2, M. Aversa1, H. Y. Robbins1, L. Shah1, B. P. Stanifer2, S. Arcasoy1, J. R. Sonett2, F. D’Ovidio2. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY

6:35 PM  
(448) Initial Experience with Non-Perfused Organ Donors for Lung Transplantation; Y. Watanabe1, A. Healey2, M. Scott2, S. Lavery2, K. Johnson2, C. Mills2, M. Galasso1, M. Chen1, J. Yeung1, L. Donahoe1, A. Pierre1, M. de Perrot1, K. Yasufuku1, T. K. Waddell1, S. Keshavjee1, M. Cypel1. 1Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada, 2Trillium Gift of Life Network, Toronto, ON, Canada

6:40 PM  
(449) Time from Lung Transplant Donor Brain Death to Cross Clamp: An Analysis of the UNOS Registry; O. K. Jawitz, V. Raman, Y. Barac, M. Mulvihill, C. Moore, A. Choi, M. Hartwig, J. Klapper. Department of Surgery, Duke University School of Medicine, Durham, NC

6:45 PM  
(450) Living-Donor Lobar Lung Transplantation with Undersized Lobar Grafts Can Provide Comparable Long-Term Pulmonary Function and Exercise Capacity to Cadaveric Lung Transplantation; D. Nakajima, T. F. Chen-Yoshikawa, T. Menju, T. Sato, M. Sonobe, Y. Yamada, Y. Yutaka, A. Ohsumi, M. Hamaji, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan

6:50 PM  
(451) Predicted Total Lung Capacity Ratio between Donors and Recipients Does Not Predict Outcomes in Non-Volume Reduced Lung Transplantation; R. Poyanmehr1, W. Sommer1, F. Ius1, J. Salman1, T. Siemen1, M. Aversa1, C. Kühn1, M. Greer2, J. Gottlieb2, T. Welte2, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Departement of Cardiothoracic Surgery, Medizinische Hochschule Hannover, Hannover, Germany, 2Departement of Pneumology, Medizinische Hochschule Hannover, Hannover, Germany

Department of Surgery, Trauma and Surgical Critical Care Grady Memorial Hospital Emory University School of Medicine, Atlanta, GA, Surgery, Miami Transplant Institute University of Miami, Miami, FL, Miami Transplant Institute, Memorial Jackson Health System, University of Miami Leonard M Miller School of Medicine, Miami, FL, Comprehensive Care Services, Inc., Livonia, MI, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, Comprehensive Care Services, Inc., Livonia, MI, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, Department of Surgery, Liver, Intestinal and Multivisceral Transplant, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, Dewitt Daughtry Family Department of Surgery, Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Miami Leonard M Miller School of Medicine, Miami, FL, Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL.
6:00 PM  (453) Early Anticoagulation Bridging to Therapeutic International Normalized Ratio after Left Ventricular Assist Device Implantation is Not Associated with Thromboembolic and Bleeding Complications: A Systematic Review and Meta-Analysis; V. Kittipibul, N. Angsubhakorn, J. Kewchareon, N. Prasitlumkum, P. Rattanawong, Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, Department of Internal Medicine, University of Minnesota, Minneapolis, MN, Department of Internal Medicine, University of Hawaii, Honolulu, HI

6:05 PM  (454) Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices; P. Namdaran, T. A. Zikos, J. Y. Pan, D. Banerjee, Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, Division of Cardiovascular Medicine, Stanford University, Stanford, CA


6:15 PM  (456) Diagnostic Yield of Endoscopy Procedures in the Management of Left Ventricular Assist Device Recipients Presenting with Gastrointestinal Bleeding; A. Y. Lee, K. M. Tecson, H. E. Sheffield, Michael E. Marcom, A. Z. Jacob, S. Patiolla, N. H. Kwak, B. L. Da, J. Felius, S. A. Hall, H. Kale, P. Kale, Baylor Heart and Vascular Hospital, Dallas, TX, Baylor Heart and Vascular Institute, Baylor Scott & White Research Institute, Dallas, TX, College of Medicine, Texas A&M Health Science Center, Dallas, TX, Department of Internal Medicine, Baylor Scott and White, Dallas, TX, Department of Gastroenterology, SUNY Health Science Center, Brooklyn, NY, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, Dallas, TX, Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott and White, Dallas, TX, Digestive Health Associates of Texas, Baylor Scott and White, Dallas, TX

6:20 PM  (457) Serotonergic Antidepressants and Hospitalization for Bleeding in Patients with LVAD; K. Behrend, M. P. Lillyblad, P. Skelton, R. F. Gaberich, K. Wilson, P. M. Eckman, B. Sun, K. Hryniewicz, Abbott Northwestern Hospital, Minneapolis, MN, Minneapolis Heart Institute Foundation, Minneapolis, MN, Minneapolis Heart Institute, Minneapolis, MN

6:25 PM  (458) Correlation of Thromboelastography Parameters with Bleeding Episodes of Post-LVAD Surgery; P. Tantrakoti, P. Pacharyanon, V. Vuithikraivit, B. Hirsch, N. Nair. Texas Tech University Health Sciences Center, Lubbock, TX


6:35 PM  (460) Pre-Operative Ventilatory Inefficiency is Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices; M. D. Yu, J. Newman, Y. Brailovsky, M. Liebo, R. Zolty, B. Lowes, A. Heroux, E. Raichlin, Loyola University Medical Center, Maywood, IL, University of Nebraska Medical Center, Omaha, NE

6:40 PM  (461) Pulmonary Artery Pulsatile Index (PAPi) Score May Predict Risk of Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device; L. Cunningham, S. George, A. M. El Banayosy, D. Horstmannhof. Advanced Heart Failure and Transplant Cardiology, Integris Baptist Medical Center, Oklahoma City, OK

6:45 PM  (462) Gastrointestinal Hemorrhage among LVAD Recipients. A Nationwide Inpatient Sample Study; D. C. Voruganti, G. P. Shantha, C. Inampudi, P. Alvarez, M. C. Giudici, A. Briasoulis. Internal Medicine,
6:50 PM  (463) Microbiome-Derived TMAO Exhibits No Protective Effect against GIB in LVAD Patients; A. M. Zuver1, K. L. Hoffman2, D. D'Angelo3, D. Onat3, E. A. Royzman1, J. C. Hupf3, D. L. Brunjes1, G. M. Mondellini4, C. A. Bravo3, M. Tiburcio4, A. R. Garan1, H. Takayama4, K. Takeda4, Y. Naka4, P. C. Colombo1, R. T. Demmer3, M. Yuzefpolskaya1. 1Department of Medicine, Columbia University Medical Center, New York, NY, 2Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, 3Department of Medicine, Montefiore Medical Center, Bronx, NY, 4Department of Surgery, Columbia University Medical Center, New York, NY, 5Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

6:55 PM  (464) Gastrointestinal Bleeding Ceases after Heart Transplantation in Patients Bridged on Continuous-Flow LVAD Support; A. Critsinelis1, J. Kraus2, H. Lamba1, F. Cheema1, A. Civitello1, R. Delgado1, A. Nair1, A. Shafii1, G. Loor1, T. Rosengart1, O. Frazier1, J. Morgan1. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, TX
THURSDAY, APRIL 4, 2019
6:00 PM - 7:00 PM

MINI ORAL 10A & 10B: Nursing, Health Sciences, Allied Health / Pharmacy and Pharmacology
Room: Pacifica 3-5
Target Audiences: NHSAH, PHARM, HTX, LTX, MCS, PEDS

Chairs: Donna Hickling, and Kyle L Dawson, PharmD, MBA, BCPS

6:00 PM  
(465) Associations between Self-Reported Physical Function and Exercise Capacity in De Novo Heart Transplant Recipients; K. Rolid1, A. K. Andreassen1, M. Yardley1, E. Gude1, E. Bjørkelund1, A. R. Authen1, I. Grov1, K. I. Pettersen1, C. Dal12, E. Prescott2, K. Karason3, L. Gullestad1, K. Nytrøen1. 1Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, 3Department of Cardiology, Sahlgrenska University Hospital, Gothenborg, Sweden

6:05 PM  
(466) Effect of High Intensity Interval Training on Health Related Quality of Life in De Novo Heart Transplant Recipients-The HITTS Study; K. Rolid1, A. K. Andreassen1, M. Yardley1, E. Gude1, E. Bjørkelund1, A. R. Authen1, I. Grov1, K. I. Pettersen1, C. H. Dal12, E. Prescott2, K. Karason3, L. Gullestad1, K. Nytrøen1. 1Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, 3Department of Cardiology, Sahlgrenska University Hospital, Gothenborg, Sweden

6:10 PM  
(467) Pre Transplant Quadriceps Strength is a Modifiable Predictor of Functional Outcomes Following Lung Transplantation; J. R. Walsh1, D. C. Chambers2, S. T. Yerkovich2, N. R. Morris3, P. M. Hopkins2. 1Physiotherapy, The Prince Charles Hospital, Brisbane, Australia, 2Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, 3School of Allied Health Sciences, Griffith University, Gold Coast, Australia

6:15 PM  
(468) What Happens to Frailty in the First Year after Lung Transplantation?; L. M. Fuller1, H. Whitford2, Y. Cristiano3, R. Robinson1, R. Steward1, M. Poulsen1, W. Shi3, G. M. Snell1. 1Physiotherapy, Alfred Hospital, Melbourne, Australia, 2Respiratory Unit, Alfred Hospital, Melbourne, Australia, 3Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia, 4Lung Transplant Unit, Alfred Hospital, Melbourne, Australia

6:20 PM  
(469) QOLVAD Detects Changes in Emotional, Social, Cognitive and Physical Wellbeing after Continuous-Flow LVAD Implant; J. A. Cowger1, C. S. Lee2, P. Eckman3, R. Garberich4, C. Weaver5, S. Joseph6, S. Hall6, S. Carrie7, S. Chaudhry8, S. E. Schroeder9, R. O. Hoffman, III10, D. Feldman11, G. Conway12, E. Y. Birati13, M. Soni14, J. Marble15, K. M. Faulkner2, K. E. Sandau16, 1Cardiovascular Medicine, HF/Transplant/MCS, Henry Ford Hospital, Detroit, MI, 2Boston College Connell School of Nursing, Boston, MA, 3Cardiovascular Medicine, HF/Transplant/MCS, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, 4Minneapolis Heart Institute Foundation, Minneapolis, MN, 5Cardiovascular Medicine, HF/Transplant/MCS, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, 6Cardiovascular Medicine, HF/Transplant/MCS, Baylor University Medical Center, Dallas, TX, 7Baylor University Medical Center, Dallas, TX, 8Cardiovascular Medicine, HF/Transplant/MCS, Ascension Hospital/St Vincent, Indianapolis, IN, 9Bryan Heart Center, Lincoln, NE, 10University of Cincinnati Medical Center, Cincinnati, OH, 11Cardiovascular Medicine, HF/Transplant/MCS, University of Cincinnati Medical Center, Cincinnati, OH, 12Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Cincinnati, OH, 13Cardiovascular Medicine, HF/Transplant/MCS, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 14Department of Medicine, University of Pennsylvania, Philadelphia, PA, 15Cardiovascular Medicine, HF/Transplant/MCS, University of Pennsylvania, Philadelphia, PA, 16Cardiovascular Medicine, Bethel University; Allina Health, Minneapolis, MN

6:25 PM  
(470) Lack of Social Support is Not a Contraindication to VAD Therapy; N. Robinson Smith1, E. Sowerby2, J. Meadows2, S. Tovey Brown1, A. Woods1, G. MacGowan1, S. Schueler1. 1MCS Service Cardio Thoracic, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, 2Social Work, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, 3MCS Service Cardiothoracic, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom

6:30 PM  
(471) It Takes a Village: Pediatric Ventricular Assist Device Training and Education Practices among ACTION Centers; K. Fields1, B. Hawkins2, J. Lantzi2, M. Mehegan3, J. Murray2, L. Burkhart1, C. Villa3. 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Boston Children’s Hospital, Boston, MA,
6:35 PM  
(472) Lung Transplant Clinicians’ Perceptions of Pocket PATH Synergy, an Interactive Health Technology (IHT) to Monitor Patients Remotely; A. J. Devito Dabbs¹, T. Irizarry¹, M. Alrawashdeh¹, J. M. Pilewski², M. Morrell², J. D’Cunha², M. Dew². ¹University of Pittsburgh School of Nursing, Pittsburgh, PA, ²University of Pittsburgh School of Medicine, Pittsburgh, PA

6:40 PM  
(473) Pre-Lung Transplant Waitlist Mortality Rate Reduction Using Remote Video Monitoring Technology; M. Zubrinic¹, N. Marks², L. Brzozowski³, J. Qiu³, D. Lin³, K. Wang³, J. De Romana¹, L. Singer¹, S. Keshavjee¹. ¹Department of Surgery, University Health Network, Toronto, ON, Canada, ²Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ³Techna Institute & University Health Network, Toronto, ON, Canada, ⁴Division of Respirology, Department of Medicine, University Health Network, Toronto, ON, Canada

6:45 PM  
(474) A Pilot Randomized Placebo Controlled Trial of Inhaled Beclomethasone after Community-Acquired Respiratory Viral (CARV) Infection in Lung Transplant Recipients (LTR); K. B. Bain¹, K. A. Fester¹, J. Iuppa², K. Bakos¹, B. Mittler³, K. Richardson³, P. Aguilar³, J. Alexander-Brett³, D. Byers³, H. Kulkarni³, E. Trulock³, C. Witt³, R. Yusen³, V. Puri⁴, D. Kreisel⁴, R. Hachem³. ¹Pharmacy, Barnes Jewish Hospital, Saint Louis, MO, ²Pharmacy, University of Rochester Medical Center, Rochester, NY, ³Pulmonary & Critical Care, Washington University, Saint Louis, MO, ⁴Surgery, Washington University, Saint Louis, MO

6:50 PM  
(475) Effects of INR Variability and Time in the Therapeutic Range on the Rates of Gastrointestinal Bleeding in Patients Supported by Left Ventricular Assist Devices; A. Mardis¹, M. Freiter², B. Mierzewski², M. Adams³. ¹Department of Pharmacy, Palmetto Health, Columbia, SC, ²College of Pharmacy, University of South Carolina, Columbia, SC, ³Department of Family and Preventive Medicine, University of South Carolina College of Medicine, Columbia, SC

6:55 PM  
(476) Appropriate Management of Drug Interactions Results in Safe Use of Hepatitis C Therapies in Heart Transplant Recipients; K. Boyle, R. E. Fowler, A. Pollack, C. Edmonds, J. Gray, J. Lindenfeld, K. Schlendorf. Vanderbilt University Medical Center, Nashville, TN
THURSDAY, APRIL 4, 2019
6:00 PM - 7:00 PM
MINI ORAL 11A & 11B: Pediatrics / Heart Failure (Adult)
Room: Pacifica 1-2
Target Audiences: Peds, HF, LTX

Chairs: Jennifer Conway, MD, and Tomasz Zielinski, MD

6:00 PM
(477) Genetic Testing Outcomes in Pediatric Dilated Cardiomyopathy; R. Khan1, E. Pahl1, L. Dellefave-Castillo2, K. Rychlik1, E. McNally2, G. Webster1. 1Cardiology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 2Cardiology, Northwestern Memorial Hospital, Chicago, IL

6:05 PM
(478) Cardiac Resynchronization Therapy in Congenital Heart Disease and Pediatric Patients with Heart Failure is Associated with Improved Survival; H. Chubbi1, C. S. Almond2, D. N. Rosenthal2, A. V. Trela2, D. Hanisch2, K. S. Motonaga3, S. R. Ceresnak2, D. B. McElhinney2, A. M. Dubin2. 1Stanford University, Palo Alto, CA, 2Pediatric Cardiology, Stanford University, Palo Alto, CA

6:10 PM
(479) A Simple Pediatric Heart Failure Symptom Score for Children Hospitalized with Acute Decompensated Heart Failure; C. S. Almond, D. Rosenthal, J. Kwong, J. Dykes, V. Yarlagadda, S. Chen, C. Chen. Stanford University, Palo Alto, CA

6:15 PM
(480) Distinction of Serum Biomarker Profiles between Adults and Children with Dilated Cardiomyopathy; M. R. Gropler1, K. J. Lavine2, S. E. Lipshultz3, J. D. Wilkinson4, S. Colan3, J. Towbin5, L. Si1, C. E. Canter1, K. E. Simpson1. 1Pediatrics, Washington University in Saint Louis School of Medicine, St Louis, MO, 2Medicine, Washington University in Saint Louis School of Medicine, St Louis, MO, 3Pediatrics, Wayne State University School of Medicine, Detroit, MI, 4Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, 5Pediatrics, Harvard Medical School, Boston, MA, 6Pediatrics, University of Tennessee Health Science Center, Memphis, TN, 7New England Research Institute, Watertown, MA

6:20 PM

6:25 PM
(482) Broadening ABO Incompatibility Pediatric Heart Transplantation, Even in Children 2 Years and Older; R. Daulton, K. Riggs, F. Zafar, C. Villa, R. Bryant, D. L. Morales. Cardiothoracic Surgery, Children's Hospital Med Ctr, Cincinnati, OH

6:30 PM
(483) Efficacy of Tafamidis in Patients with Hereditary or Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Results from the ATTR-ACT Trial; M. Gropler1, R. Witteles2, S. J. Shah3, J. H. Schwartz4, B. Gundapaneni5, T. A. Patterson6, M. B. Sultan7, M. S. Maurer7. 1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Stanford University School of Medicine, Stanford, CA, 3Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Pfizer Inc, New York, NY, 5Department of Cardiovascular Diseases, Syneos Health, Raleigh, NC, 6Pfizer Inc, Groton, CT, 7Columbia University College of Physicians and Surgeons, New York, NY

6:35 PM
(484) The Rising Epidemic of Resource Utilization for Adult Congenital Heart Disease-Related Heart Failure in the United States; D. S. Burstein1, J. W. Rossano1, H. Griffis1, X. Zhang1, R. Fowler2, B. P. Frischhertz2, Y. Y. Kim1, J. Lindenfeld2, J. A. Mazurek3, J. N. Menachem2. 1Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Cardiology, Vanderbilt University Medical Center, Nashville, TN, 3Cardiology, Hospital of University of Pennsylvania, Philadelphia, PA

6:40 PM
(970) Comparison of Long-Term Effects of Cell Therapy in Patients with Ischemic and. Nonischemic Heart Failure; G. Poglajen, G. Zemljic, S. Frljak, A. Cerar, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Heart Medical Center Ljubljana, Ljubljana, Slovenia

6:45 PM
(485) Myocardial Ischemia Correlates with Left Ventricular Systolic Dysfunction in Patients with Noncompaction Cardiomyopathy; A. Cerar1, M. Jaklič1, M. Dolenc Novak2, B. Guzic Salobir3, R. Zbancik3, M. Kozelj1, B. Vrtovec1. 1Department of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, Slovenia, 3Department of Radiology, UMC Ljubljana, Ljubljana, Slovenia
(487) Absence of Pre-Transplant Pulmonary Features of Sarcoidosis is of Low Negative Predictive Value in End-Stage Cardiac Sarcoidosis; H. K. Rokadia1, A. K. Jamil2, R. El Tomi2, H. Zafar3, T. Nisar3, M. Petrozzi1, R. L. Gottlieb1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX

(488) Undiagnosed Cardiac Sarcoidosis Has a Significant First Presentation as Sudden Cardiac Death: An Autopsy Review; D. Pedrotty1, A. Rosenbaum2, S. Kapa2, L. Blauwet2, J. Maleszewski3. 1Heart Failure Cardiology, University of Pennsylvania, Philadelphia, PA, 2Cardiology, Mayo Clinic, Rochester, MN, 3Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
THURSDAY, APRIL 4, 2019
6:00 PM - 7:00 PM

MINI ORAL 12A & 12B: Pulmonary Hypertension / Heart Transplantation (Adult)
Room: Pacifica 7
Target Audiences: PH, HTX

Chairs: John Granton, MD and Joanna Pepke-Zaba, MD

6:00 PM

(489) Demographic, Hemodynamic, and HRQL Differences between Methamphetamine-Associated and Idiopathic PAH: The Pulmonary Hypertension Association Registry; N. A. Kolaitsi1, R. T. Zamanian2, V. A. de Jesus Perez2, D. B. Badesch3, R. L. Benza4, C. D. Burger5, M. M. Chakinala6, J. Feldman7, M. R. Lammi8, S. C. Mathai9, K. W. Presberg10, J. C. Robinson11, J. S. Sager12, O. A. Shlobin13, M. A. Simon14, S. M. Kavut15, J. P. Singer1, T. De Marco1. 1University of California, San Francisco, San Francisco, CA, 2Stanford University, Palo Alto, CA, 3University of Colorado Denver, Aurora, CO, 4Allegheny General Hospital, Pittsburgh, PA, 5Mayo Clinic Florida, Jacksonville, FL, 6Washington University in St. Louis, St. Louis, MO, 7Arizona Pulmonary Specialists, Phoenix, AZ, 8Louisiana State University, New Orleans, LA, 9Johns Hopkins University, Baltimore, MD, 10Medical College of Wisconsin, Milwaukee, WI, 11The Oregon Clinic, Portland, OR, 12Cottage Pulmonary Hypertension Center, Santa Barbara, CA, 13Inova Fairfax Medical Campus, Falls Church, VA, 14University of Pittsburgh, Pittsburgh, PA, 15University of Pennsylvania, Philadelphia, PA

6:05 PM


6:10 PM

(491) Do Pulmonary Hypertensive Patients Have Worse Post Transplant Survival Than Non-Pulmonary Hypertensive Patients? An ISHLT Registry Analysis; J. Lasky1, K. Tsui2, C. Alex2, M. Dia2, E. Jweied3, P. Pappas3, C. Wigfield4. 1Rosalind Franklin University of Medicine and Science, Chicago, IL, 2Lung Transplant, Advocate Christ Medical Center, Chicago, IL

6:15 PM

(492) Exercise Pulmonary Hypertension and Progression to Resting Pulmonary Hypertension - Is TPR the Best Predictor?; K. Kearney, N. Bart, V. Shah, P. Jain, E. Kotlyar, A. Keogh. St Vincents Hospital, Darlinghurst, Australia

6:20 PM

(1228) Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor; M. Simon1, M. Gomberg-Maitland2, R. J. Oudiz3, R. Machado4, F. Rischart5, J. M. Elinoff6, B. Grigorian7, A. N. Schmid1, S. Hou1, N. Desai8, M. Gladwin1. 1Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 2MSc. Inova Heart and Vascular Institute, VCU Medicine, Falls Church, VA, 3LA Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, CA, 4Indiana University, Indianapolis, IN, 5Department of Medicine, University of Arizona, Tucson, AZ, 6The NIH Clinical Center, Bethesda, MD, 7Aardi Bioscience, Pacific Palisades, CA

6:25 PM

(495) Two Polymorphic Gene Loci Associated with Treprostinil Dose in Pulmonary Arterial Hypertension; M. A. Psoetka1, V. Thomeas-McEwing2, E. R. Gamazon3, T. Hirota4, P. N. Friedman5, A. Konkashbaev5, M. Kubo5, Y. Nakamura6, M. J. Ratain7, R. L. Benza8, N. J. Cox9, M. I. Gomberg-Maitland10, M. L. Maitland11. 1Inova Heart and Vascular Institute, Falls Church, VA, 2Center for Personalized Health, Inova Schar Cancer Institute, Falls Church, VA, 3Division of Genetic Medicine, Vanderbilt University School of Medicine, Nashville, TN, 4Center for Integrative Medical Sciences, RIKEN, Tokyo, Japan, 5Feinberg School of Medicine, Northwestern University, Chicago, IL, 6Cancer Precision Medicine Research Center, Japanese Foundation for Cancer Research, Tokyo, Japan, 7Department of Medicine, University of Chicago, Chicago, IL, 8Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

6:30 PM

(496) Raltepag Plasma Levels Correlate with Improvements in Functional and Hemodynamic Parameters in Patients with Pulmonary Arterial Hypertension; H. W. Farber1, N. Sood2, I. R. Preston3, J. Adams3, J. Grundy3, C. King3, P. Klassn3, V. F. Tapson4, V. McLaughlin2, R. J. Oudiz5. 1Professor of Medicine, Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, 2University of Texas Health Science Center of Houston, Houston, TX, 3Arena Pharmaceuticals, Inc, San Diego, CA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Director of Pulmonary Hypertension Program, University of Michigan, Ann Arbor, MI, 6Department of Medicine, Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrence, CA
6:35 PM  
**(497) The Effects of Inhaled Sodium Nitrite on Pulmonary Vascular Impedance in Patients with Pulmonary Hypertension Associated with HFpEF;** M. J. Bashline¹, T. N. Bachman², N. L. Helbling³, M. T. Gladwin⁴, M. A. Simon⁵. ¹Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, ³Vascular Medicine Institute, UPMC Heart and Vascular Institute, Pittsburgh, PA, ⁴Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

6:40 PM  
**(498) Association between Serial Measurements of Tricuspid Annular Plane Systolic Excursion and Mortality Post Heart Transplant;** J. K. Vishram-Nielsen¹, F. Foroutan², H. J. Ross², F. Gustafsson³, T. A. Buchan², A. Alba². ¹The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, & Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, ²Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, ³The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, Copenhagen, Denmark

6:45 PM  
**(499) Prognostic Value of Cardiac Magnetic Resonance Acquired at One Year after Heart Transplantation;** P. Pedrotti¹, O. Rimoldi², G. Masciocco¹, L. D’Angelo¹, G. Foti¹, G. Quattrocchi¹, A. Milazzo¹, R. Facchetti¹, C. Giannattasio¹, M. Frigerio¹. ¹Cardiothoracic and Vascular DPT, ASST Niguarda, Milan, Italy, ²CNR, IBFM, Segrate (MI), Italy, ³Health Science DPT, Bicocca University, Milan, Italy

6:50 PM  
**(500) Can CT Measures of Thoracic Muscle Provide Prognostication among Heart Transplant Recipients?;** A. J. Kuchnia¹, J. Lortie¹, N. Stabo², N. Tsuchiya², T. Hess³, N. Binkley⁴, C. Francois⁵, M. L. Schiebler², J. Hermsen³, R. Dhingra⁴. ¹Nutritional Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Radiology, University of Wisconsin-Madison, Madison, WI, ³Department of Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Department of Surgery, University of Wisconsin-Madison, Madison, WI, ⁵Advanced Heart Failure and Transplantation section, Department of Medicine, University of Wisconsin-Madison, Madison, WI
FRIDAY, APRIL 5, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 07: Highways to Hell: Chronic Lung Allograft Dysfunction
Room: Pacifica 1-2
Target Audiences: BSTR, LF/LTX, PATH

Chairs: Sangeeta M. Bhorade, MD, and Stijn E. Verleden, MD, PhD

Session Summary: The pathologies of Chronic Lung Allograft Dysfunction (CLAD) have been recognized since 1984, yet their mechanisms and definitive treatments remain enigmatic. Indeed, there are multiple rival hypotheses as to the cause of CLAD. Is CLAD a final common pathway, an integration of pathobiologies, or are some pathways overriding? This symposium will describe the scientific evidence for some of these pathways. A 15-min panel discussion with all speakers will conclude this session.

7:00 AM Immune Responses Cause CLAD
Federica Meloni, MD, University of Pavia, Pavia, Italy

7:15 AM CLAD is a Disease of Accelerated Aging
John R. Greenland, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

7:30 AM Mesenchymal Stem Cells are the Cause of CLAD
Vibha N. Lama, MD, MS, University of Michigan, Ann Arbor, MI, USA

7:45 AM 15-min Panel Discussion
FRIDAY, APRIL 5, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 08: Print, Replace or Innovate: Alternative Strategies to Cardiac Transplantation
Room: Pacifica 7
Target Audiences: HF/HTX, MCS

Chairs: Mrinalini Krishnan, MD, and Ulrich Steinseifer, MD

Session Summary: This symposium will provide an overview of the potential alternatives to and fresh ideas for organ transplantation. Each speaker will provide an overview of the “state of the art” in their respective area of organ repair, regeneration or replacement, and will give insight into successes, challenges and potential of their respective areas, incorporating discussion of the clinical feasibility, ethics and potential of the respective therapies. A 15-min panel discussion with all speakers will conclude this session.

7:00 AM Copy and Paste vs. Renovate: Cardiac 3D Printing and Its Future Direction
Doris A. Taylor, PhD, FAHA, FACC, Texas Heart Institute, Houston, TX, USA

7:15 AM ‘When Pigs Fly’: Where Are We Now With Xenotransplantation?
Richard Pierson, MD, Massachusetts General Hospital, Boston, MA, USA

7:30 AM Hitting Reset: Utility of Stem Cells to Regenerate the Heart
Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

7:45 AM 15-min Panel Discussion
SUNRISE SYMPOSIUM 09: MCS Infections: New Twists in an Old Saga
Room: Pacifica 3-5
Target Audiences: ID, MCS

Chairs: Saima Aslam, MD, MS, and Jan D. Schmitto, MD, PhD, MBA

Session Summary: Infections are a leading cause of death in VAD recipients, and are associated with morbidity, readmissions and healthcare costs. This symposium will focus on state of the art updates on the prevalence of VAD infections and their consequences including neurologic complications. Infection control and quality practices can impact the rate of infections. The recent ISHLT consensus document discussing the prevention and management of MCS infections will be reviewed.

7:00 AM  What are the Consequences of a VAD Infection?
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA

7:15 AM  Q&A

7:20 AM  Infection Prevention for Patients with Mechanical Circulatory Support
Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

7:35 AM  Q&A

7:40 AM  Molecular Pathogenesis and Diagnostic Strategies for MCS Infections
Anton Peleg, MD, PhD, MPH, The Alfred Hospital and Monash University, Melbourne, Australia

7:55 AM  Q&A
FRIDAY, APRIL 5, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 10: Cardiac Reverse Remodeling in MCS: State of the Art
Room: Pacifica 6
Target Audiences: MCS, BSTR, PATH

Chairs: Ivan Netuka, MD, PhD, and Joyce W. Wald, DO

Session Summary: Mechanical unloading of the left ventricle is a potent platform through which to study reverse remodeling. While we now understand that sufficient “recovery” to allow for device explantation is realistic in only a select population, the concept of reverse remodeling during LVAD still has much broader application. This symposium will highlight reverse remodeling during MCS starting with basic physiology and moving through clinical topics and commencing with a view to the future.

7:00 AM Cardiac Recovery on Acute Mechanical Support - When to Wean and When to Transition
Anna L. Meyer, MD, Leipzig Heart Center, Leipzig, Germany

7:15 AM Q&A

7:20 AM LVAD Explantation for Cardiac Recovery – Who, When, and How
Snehal R. Patel, MD, Montefiore Medical Center, Bronx, NY, USA

7:35 AM Q&A

7:40 AM Present and Future of Cardiac Recovery and Durable MCS
Stavros G. Drakos, MD, PhD, FACC, University of Utah School of Medicine, Salt Lake City, UT, USA

7:55 AM Q&A
SUNRISE SYMPOSIUM 11: The Mission IS Possible If You Choose to Accept it: The Processes of Performing Research
Room: Pacifica 10-12
Target Audience: NHSAH

Chairs: Sarah Schettle, PA-C, and Mary Amanda Dew, PhD

Session Summary: Research has led to incredible advancements in organ failure/transplant outcomes. Despite its significance, not all transplant professionals have training or experience in the conduct of research. Launching (or continuing) a program of research can be intimidating for many. Experts in the field will provide guidance on the conduct of research from study development to dissemination findings. Tips for funding one's research will also be shared. A 15-min panel discussion with all speakers will conclude this session.

7:00 AM  
Don't Go Rogue: Planning and Launching a Research Study
Pamela Combs, PhD, RN, University of Chicago, Chicago, IL, USA

7:15 AM  
The Fallout: Dissemination and Sharing your Results
Desiree Robson, RN BSc (Hons), St Vincent's Hospital, Sydney, Australia

7:30 AM  
The Ghost Hunt: Funding Your Research
Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA

7:45 AM  
15-min Panel Discussion
FRIDAY, APRIL 5, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 12: A Bloody Mess: Management of Hematologic Complications in Transplantation and MCS
Room: Coral Sea
Target Audiences: PHARM, MCS

Chairs: Bastian Schmack, MD, and Kyle L. Dawson, PharmD, MBA, BCPS

Session Summary: This symposium will aim to review pharmacotherapy management of hematologic complications in transplant and MCS including neutropenia, thrombocytopenia, anticoagulation with direct oral anticoagulants (DOACs), hemoglobin optimization, and bleeding reversal.

7:00 AM  I've Got Friends with Low Platelets (and Neutrophils): Management of Cytopenias After Transplant
Jennifer McDermott, PharmD, Spectrum Health, Grand Rapids, MI, USA

7:15 AM  Q&A

7:20 AM  Thicker than Blood: Using DOACs in Transplantation and MCS
Sara Strout, PharmD, Johns Hopkins, MD, USA

7:35 AM  Q&A

7:40 AM  Ain't No Hemoglobin High Enough: Approaches to Hemoglobin Optimization and Bleeding Reversal Pre- and Post-Surgery
Ian B. Hollis, PharmD, BCPS, University of North Carolina Medical Center, Chapel Hill, NC, USA

7:55 AM  Q&A
PLENARY SESSION
Room: Grand Caribbean 1-7
Target Audience: ALL

Chairs: David O. Taylor, MD, and Maryl R. Johnson, MD

Session Summary: Changing our Vantage Point: Incorporating New Ideas to Improve Care and Research in Transplantation

8:00 AM  
New Perspectives on Tolerance  
Sing Sing Way, MD, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, USA

8:20 AM  
Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, AmpliPhi Biosciences, San Diego, CA, Adaptive Phage Therapeutics, Gaithersburg, MD, Naval Medical Research Center, Fort Detrick, MD, Department of Infectious Diseases, UC San Diego, San Diego, CA

8:35 AM  
Q&A with Interactive Discussant  
Fernanda P Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

8:40 AM  
Department of Surgery, Uniformed Services University, Bethesda, MD, Cardiothoracic Surgery, Thoracic Transplant Consultants, San Francisco, CA, Department of Surgery, Johns Hopkins University, Baltimore, MD

8:55 AM  
Q&A with Interactive Discussant  
Andreas Zuckermann, MD, Medical Univ of Vienna, Vienna, Austria

9:00 AM  
Transplant From Every Angle - An Interview  
Interviewee: Susan Hou, MD, Loyola University Medical Center, Maywood, IL, USA  
Interviewer: Daniel F Dilling, MD, Loyola University Medical Center, Maywood, IL, USA

9:20 AM  
Countdown to Teamwork  
Colonel Mike Mullane, Astronaut, Albuquerque, NM, USA
10:30 AM (217) Identification of Latent Classes of Cardiac Allograft Vasculopathy Trajectories after Heart Transplantation and Their Determinants; G. Coutance\textsuperscript{1}, M. Racapé\textsuperscript{2}, G. Bonnet\textsuperscript{3}, M. Raynaud\textsuperscript{2}, J. Van Keer\textsuperscript{2}, M. Bories\textsuperscript{3}, P. Bruneval\textsuperscript{1}, J. Duong Van Huyen\textsuperscript{4}, J. Taupin\textsuperscript{4}, S. Varnous\textsuperscript{4}, R. Guillemain\textsuperscript{1}, X. Jouven\textsuperscript{3}, A. Loupy\textsuperscript{4}. \textsuperscript{1}Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France, \textsuperscript{2}Paris Transplant Group, Paris, France, \textsuperscript{3}Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France, \textsuperscript{4}Paris Transplant Group, Necker Hospital, Paris, France, \textsuperscript{5}Saint Louis Hospital, Paris, France, \textsuperscript{6}Pitié-Salpêtrière Hospital, Paris, France, \textsuperscript{7}Hôpital Européen Georges Pompidou, Paris, France

10:45 AM (218) Leukotriene B4 Contributes to Development of Cardiac Allograft Vasculopathy; K. K. Khush\textsuperscript{1}, D. Wang\textsuperscript{2}, G. Tediashvili\textsuperscript{3}, H. Luikart\textsuperscript{1}, N. D’Emilio\textsuperscript{1}, Y. Moayedi\textsuperscript{1}, S. Schrepfer\textsuperscript{2}. \textsuperscript{1}Stanford University, Stanford, CA, \textsuperscript{2}University of California San Francisco, San Francisco, CA

11:00 AM (219) Novel Descriptors of Coronary Wall Properties Measured by OCT at Baseline Are Associated with CAV-Related Intimal Thickening One Year after Heart Transplant; Z. Chen\textsuperscript{1}, M. Pazdernik\textsuperscript{2}, A. Wahle\textsuperscript{1}, H. Zhang\textsuperscript{1}, V. Melinovsky\textsuperscript{2}, J. Kautzner\textsuperscript{2}, V. Karmazin\textsuperscript{2}, H. Bedanova\textsuperscript{3}, A. Tomasek\textsuperscript{3}, E. Ozabalova\textsuperscript{3}, M. Sonka\textsuperscript{1}. \textsuperscript{1}University of Iowa, Iowa City, IA, \textsuperscript{2}Institute of Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, \textsuperscript{3}Cardiovascular and Transplantation Surgery Center, St. Annes University Hospital and Masaryk University Brno, Brno, Czech Republic

11:15 AM (220) Low Serum Magnesium is Associated with Increased Mortality and Cardiac Allograft Vasculopathy Following Heart Transplantation; Y. Peled\textsuperscript{1}, J. Lavev\textsuperscript{1}, N. Shlomo\textsuperscript{2}, T. Cohen\textsuperscript{2}, A. Kogan\textsuperscript{1}, E. Maor\textsuperscript{1}, M. Shechter\textsuperscript{1}, D. Freimark\textsuperscript{2}, R. Klempern\textsuperscript{2}. \textsuperscript{1}Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel, \textsuperscript{2}Israeli Association for Cardiovascular Trials, Ramat Gan, Israel

11:30 AM (221) Increased Platelet Aggregation in Heart Transplant Recipients with Cardiac Allograft Vasculopathy; K. P. Bierre\textsuperscript{1}, K. Berg\textsuperscript{1}, T. S. Clemmensen\textsuperscript{2}, S. H. Poulsen\textsuperscript{1}, S. D. Kristensen\textsuperscript{1}, A. Hvas\textsuperscript{1}, E. L. Grove\textsuperscript{1}, H. Eiskjær\textsuperscript{1}. \textsuperscript{1}Aarhus University Hospital, Aarhus N, Denmark, \textsuperscript{2}Horsens Regional Hospital, Horsens, Denmark

11:45 AM (222) Mild Acute Cellular Rejection is Not Associated with Development of Cardiac Allograft Vasculopathy Assessed by Intravascular Ultrasound and Coronary Angiography in Heart Transplant Recipients - A Substudy of the SCHEDULE Trial; L. M. Nelson\textsuperscript{1}, A. K. Andreassen\textsuperscript{2}, S. Arora\textsuperscript{2}, B. Andersson\textsuperscript{3}, E. Gude\textsuperscript{2}, H. Eiskjær\textsuperscript{1}, G. Rådegran\textsuperscript{2}, G. Dellgren\textsuperscript{2}, L. Gullestad\textsuperscript{2}, F. Gustafsson\textsuperscript{1}. \textsuperscript{1}Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, \textsuperscript{2}Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, \textsuperscript{3}Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, \textsuperscript{4}Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark, \textsuperscript{5}The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, \textsuperscript{6}Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, \textsuperscript{7}Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Oslo, Norway

12:00 PM (223) Are Gene Expression Profile Testing Scores Associated with New Onset Cardiac Allograft Vasculopathy?; A. Lala\textsuperscript{1}, D. Hiller\textsuperscript{2}, J. Yee\textsuperscript{2}, K. Khush\textsuperscript{1}, R. Alharethi\textsuperscript{2}, S. Pinney\textsuperscript{5}. \textsuperscript{1}Medicine, Cardiology, Population Health Science, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, \textsuperscript{2}CareDx, Brisbane, CA, \textsuperscript{3}Stanford University School of Medicine, Stanford, CA, \textsuperscript{4}University of Utah School of Medicine, Salt Lake City, UT, \textsuperscript{5}Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY
SESSION 52: JOINT ISHLT/SCMR SYMPOSIUM: Cardiac MRI and the World of Heart Failure: When Two Disciplines Harmonize
Room: Pacifica 7
Target Audience: HF/HTX

Chairs: Daniel Kim, MD, and Sonya Babu-Narayan, MBBS, BSc, PhD

Session Summary: In collaboration with the Society for Cardiovascular Magnetic Resonance (SCMR), this symposium will address how CMR advances in structural and functional imaging techniques have led to better cardiac tissue and anatomical characterization in complex patients. We will address its clinical role in the management of cardiomyopathies and heart transplant and explore pathological and imaging relationships while addressing standard and novel CMR based diagnostic approaches including contrast free imaging and imaging in patients with pacemakers. A 15-min panel discussion with all speakers will conclude this session.

10:30 AM       MRI Sequences and Pathologic Correlates: The First Face of Janus
Annalisa Angelini, MD, University of Padua, Padua, Italy

10:45 AM       MRI Sequences and Pathologic Correlates: The Second Face of Janus
Timothy C Wong, MD, MS, University of Pittsburgh, Pittsburgh, PA, USA

11:00 AM       5 min Q&A

11:05 AM       CMR and Cardiomyopathies: A World Beyond Speckles
Victor A Ferrari, MD, Perelman School of Medicine, Philadelphia, PA, USA

11:20 AM       CASE PRESENTATION: A Post-Transplant Patient with New Worsening of LV Function
Mandar Aras, MD, UCSF Medical Center, San Francisco, CA, USA

11:25 AM       CMR and Heart Transplantation: One Stop Shop?
Sofia C Masri, MD, University of Washington, Seattle, WA, USA

11:40 AM       CASE PRESENTATION: Patient with CHD and New Echocardiographic Findings: What Next?
Chesney Castleberry, MD, Washington University in St. Louis, St. Louis, MO, USA

11:45 AM       CMR and Congenital Heart Disease: Not as Baffling as You Thought
Sonya Babu-Narayan, MBBS, BSc, PhD, Imperial College London, London, United Kingdom

12:00 PM       15-min Panel Discussion
FRIDAY, APRIL 5, 2019
10:30 AM - 12:15 PM

SESSION 53 (ORAL): Chasing the Golden Snitch: Optimizing Outcomes of MCS Infections
Room: Pacifica 1-2
Target Audiences: ID, MCS

Chairs: Margaret M Hannan, MD, and Christine E Koval, MD

10:30 AM
(224) Increased Risk of Stroke and Death in Ventricular Assist Device Patients Varies by ISHLT Infection Category: An INTERMACS Analysis; P. Shah1, S. E. Birk2, L. B. Cooper1, M. A. Psotka1, J. K. Kirklin1, S. D. Barnett1, S. B. Katugaha1, S. Phillips1, M. M. Looby4, F. D. Pagani6, J. A. Cowger3, 1Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2School of Public Health, George Washington University, Washington, DC, 3Cardiac Surgery, University of Alabama, Birmingham, AL, 4Transplant Infectious Diseases, Inova Heart and Vascular Institute, Falls Church, VA, 5Department of Pharmacy, Inova Heart and Vascular Institute, Falls Church, VA, 6Cardiac Surgery, University of Michigan, Ann Arbor, MI, 1Heart Failure and Transplantation, Henry Ford Hospital, Detroit, MI

10:45 AM
(225) Epidemiology, Outcomes, and Effects of Device Flow Type on Ventricular Assist Devices (VAD) Infections: An IMACS Registry Analysis; R. Xie1, J. Cowger2, J. K. Kirklin1, M. M. Hannan3, D. J. Goldstein4, S. Aslam2, 1Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 2Henry Ford Hospitals, Farmington Hills, MI, 3Mater Misericordiae University Hospital, Dublin, Ireland, 4Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 5Division of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA

11:00 AM
(226) A Comprehensive In Vitro Evaluation of Medihoney as an Anti-Biofilm Agent in Preventing Ventricular Assist Device Driveline Infections; Y. Qu1, D. McGiffin2, C. Kure3, J. McLean2, C. Duncan2, A. Y. Peleg3, 1Infectious Diseases, The Alfred Hospital and Monash University, Clayton, Australia, 2Cardiothoracic Surgery, The Alfred Hospital and Monash University, Melbourne, Australia

11:15 AM
(227) Efficacy of Pump Exchange with a Left Ventricular Assist Device Associated Infection; L. Coyle, C. Gallagher, W. Cotts, P. Pappas, A. Tatooles. Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL

11:30 AM
(228) Primary versus Delayed Sternal Closure in Left Ventricular Assist Device Implantation Patients: Impact on Infection; M. H. Akay3, M. Cakici1, M. Alagoz1, M. K. Patel1, M. K. Jezovnik1, M. Ilic1, I. Salas De Armas2, K. Rajagopal1, R. Radovancevic1, S. Kumar1, M. Junean1, B. Kar1, I. D. Gregoric1, 1Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, 2Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center-Houston, Houston, TX

11:45 AM
(229) Comparing the Incidence of Surgical Site Infections (SSI) Using Narrow versus Broad-Spectrum Perioperative Antibiotic Prophylaxis in Mechanical Circulatory Support (MCS) Patients; L. D. Lam1, M. Payne-Cardona2, M. Fang2, R. Herra2, E. Coria Mondragon2, C. Runyan1, J. Moriguchi3, J. A. Kobashigawa3, L. S. Czer3, F. Arabia4, R. Zabner4, 1Mechanical Circulatory Support, Cedars Sinai Comprehensive Transplant Center, Los Angeles, CA, 2University of California, School of Pharmacy, San Francisco, CA, 3Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 4Advanced Heart Program, Banner/University of Arizona, Phoenix, AZ, 1Infectious Disease, Cedars Sinai Health System, Los Angeles, CA

12:00 PM
(230) A Study of Infected Drivelines from Ventricular Assist Device Patients: The Presence of Microbial Biofilms and Micro-Gaps in the Driveline Tunnel; Y. Qu1, D. McGiffin2, C. Hayward3, D. Robson3, A. Peleg4, 1Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia, 2Cardiothoracic Surgery, The Alfred Hospital and Monash University, Melbourne, Australia, 3Department of Cardiology, St Vincent’s Public Hospital, Sydney, Darlinghurst, Australia, 4CSIRO, Melbourne, Australia, 1Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia
SESSION 54 (ORAL): Swipe Right or Swipe Left? Matching Donors and Recipients in Lung Transplantation
Room: Pacifica 10-12
Target Audiences: LF/LTX, ID, PATH

Chairs: Stephane Collaud, MD, and Walter Klepetko, MD

10:30 AM
1University Hospitals Leuven, Leuven, Belgium, 2University of Toronto, Toronto, ON, Canada, 3Alfred Hospital, Melbourne, Australia, 4UNOS, Richmond, VA, 5University Medical Center Groningen, Groningen, Netherlands, 6Harefield Hospital, London, United Kingdom, 7St Vincent’s Hospital, Sydney, Australia, 8Freeman Hospital, Newcastle upon Tyne, United Kingdom, 9Columbia University Presbyterian Hospital, New York, NY, 10Royal Papworth Hospital, Cambridge, United Kingdom, 11Cleveland Clinic, Cleveland, OH, 12University of Minnesota, Minneapolis, MN, 13Wythenshawe Hospital, Manchester, United Kingdom, 14The Prince Charles Hospital, Brisbane, Australia, 15University Hospital Zurich, Zurich, Switzerland, 16St. Joseph’s Hospital & Medical Center, Phoenix, AZ, 17Washington University, St Louis, MO, 18University Hospitals Birmingham, Birmingham, United Kingdom, 19Loyola University Medical Center, Chicago, IL, 20Brigham and Women’s Hospital, Boston, MA, 21Baylor University Medical Center, Dallas, TX, 22Fiona Stanley Hospital, Perth, Australia, 23Great Ormond Street for Children, London, United Kingdom, 24University of Utah, Salt Lake City, UT

10:45 AM
(232) Estimated Impact of Hepatitis C Positive Lung Donor Utilization on US Donor Lung Supply; J. Mooney, N. Purinton, P. Mohabir, G. Dhillon. Department of Medicine, Stanford University School of Medicine, Stanford, CA

11:00 AM
(233) Center Variability in Organ Offer Acceptance and Waitlist Mortality in Lung Transplantation; A. Y. Choi1, M. S. Mulvihill2, J. Weber3, H. Lee4, M. L. Cox2, B. A. Yerokun2, M. Kuchibhatla2, J. A. Klapper2, M. G. Hartwig2, 1Duke University School of Medicine, Durham, NC, 2Department of Surgery, Duke University Medical Center, Durham, NC, 3Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC

11:15 AM
(234) Donation after Circulatory Death (DCD): A 10-Year Experience in Bilateral Lung Allograft Survival at a Single Australian Center; D. R. Darley, M. Benzmira, R. Pearson, M. Malouf, A. Glanville, A. Havryk, M. Plit. Lung Transplantation, St Vincent’s Hospital, Sydney, Australia

11:30 AM
(235) The Impact of the Calculated Panel Reactive Antibody Value on Wait List Outcomes for Lung Transplant Candidates; M. Aversa1, L. Benvenuto1, H. Kim1, L. Shah1, H. Robbins1, B. P. Stansifer1, F. D’Ovidio1, E. Vasilescu2, J. Sonetti2, S. Arcasoy1. 1Lung Transplant Program, Columbia University Medical Center, New York, NY, 2Pathology and Cell Biology, Columbia University Medical Center, New York, NY

11:45 AM
(236) Utilization of PHS Increased Risk Donors in Lung Transplant Reduces Median Waitlist Time without Reducing Survival; T. Khoo1, R. Chand2, C. Lum2, A. Salimbangon2, A. Chang3, D. Ross4, A. Ardehali5, E. DePasquale1. 1Transplant Services, UCLA, Los Angeles, CA, 2Medicine, Cardiology, UCLA, Los Angeles, CA, 3Transplant Service, UCLA, Los Angeles, CA, 4Medicine, Pulmonology, UCLA, Los Angeles, CA, 5Surgery, UCLA, Los Angeles, CA

12:00 PM
(237) Donor-Recipient Size Matching via Chest X-ray Measurements and Primary Graft Dysfunction Risk in Lung Transplantation; D. Li, J. Weinkauf, D. Lien, A. Kapasi, A. Hirji, K. Halloran. Department of Medicine, University of Alberta, Edmonton, AB, Canada
10:30 AM  
(238) **Sequential Chains of Adverse Events Post LVAD Implantation**; F. Movahedi, R. L. Kormos, L. Lohmueller, L. Seese, M. Kanwar, S. Murali, Y. Zhang, R. Padman, J. F. Antaki.  
*Electrical Engineering, University of Pittsburgh, PA; Medicine, Heart and Vascular Institute, Pittsburgh, PA; School of Computer Science, Carnegie Mellon University, Pittsburgh, PA; Electrical Engineering, Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA; Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA; Weill Cornell Medicine, Pittsburgh, NY; Heinz College of Information Systems and Public Policy, Pittsburgh, PA; Meining School of Biomedical Engineering, Cornell University, Pittsburgh, PA*

10:45 AM  
*MedStar Heart and Vascular Institute, Washington, DC; MedStar Washington Hospital Center, Washington, DC; University of Chicago, Chicago, IL; Georgetown University School of Medicine, Washington, DC*

11:00 AM  
(240) **Features for Success: Factors Associated with Successful LVAD Outcomes at 1-Year Post Implant**; L. C. Lohmueller, M. Kanwar, S. Murali, J. F. Antaki.  
*Language Technologies Institute, Carnegie Mellon University, Pittsburgh, PA; Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA; Biomedical Engineering, Cornell University, Ithaca, NY*

11:15 AM  
(241) **Derivation and Validation of the EUROMACS Left Ventricular Assist Device Score for Long-Term Outcome - The EUROMACS-LVAD-Score**; B. Schrage, N. Rübsamen, C. Magnussen, J. Gummert, F. Schönhart, T. de By, B. Meyns, D. Westermann, S. Blankenberg, H. Reichenspurner, A. Bernhardt.  
*University Heart Center Hamburg, Hamburg, Germany; University Heart Centre Hamburg, Hamburg, Germany; Heart and Diabetes Center Bad Oeynhausen, Bad Oeynhausen, Germany; German Heart Center Berlin, Berlin, Germany; EUROMACS, Windsor, United Kingdom; Cardio Heelkunde, Leuven, Belgium*

11:30 AM  
*Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN; School of Public Health, Department of Biostatistics, University of Minnesota, Minneapolis, MN; Department of Medicine, Division of Cardiology, Houston Methodist, Houston, TX; Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN; Department of Medicine, Division of Cardiology, Cleveland Clinic, Cleveland, OH*

11:45 AM  
*Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN; Department of Medicine, Division of Cardiology, Cleveland Clinic, Cleveland, OH; Department of Medicine, Division of Cardiology, Houston Methodist, Houston, TX; Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN*

12:00 PM  
*Tufts Medical Center, Boston, MA; Tufts University School of Medicine, Boston, MA*
SESSION 56: JOINT ISHLT/IPTA SYMPOSIUM: EBV and CMV are Not as Easy as 1-2-3 When Caring for Pediatric Thoracic Transplant Recipients
Room: Pacifica 3-5
Target Audiences: PEDS, HTX, ID, LTX, NHSAH, PHARM

Chairs: Brian Feingold, MD, MS, and Klara Posfay-Barbe, MD, MS

Session Summary: In collaboration with the International Pediatric Transplant Association (IPTA), this symposium will focus on EBV and CMV in pediatric thoracic transplantation. We will cover monitoring, prevention, current and emerging therapies for these entities in pediatric thoracic transplant candidates and recipients. The session will appeal to the following groups: pediatric heart and lung transplant physicians, advance practice nurses, nursing, transplant coordinators, infectious disease clinicians, pharmacists, and translational virologists. A 15-min panel discussion with all speakers will conclude this session.

10:30 AM  The A-B-C’s of EBV Monitoring in Pediatric Thoracic Transplant Recipients
Upton Allen, MBBS, MSc, FAAP, FRCPC, University of Toronto/Sick Kids, Toronto, ON, Canada

10:45 AM  EBV Prevention in Pediatrics: Fantasy or Reality?
Michael Green, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

11:00 AM  First Line, Advanced, and Emerging Therapies for the Treatment of EBV Disease/PTLD in Pediatrics
Steven A Webber, MBChB, Vanderbilt University, Nashville, TN, USA

11:15 AM  Implications of EBV Disease on Long-Term Outcomes in Thoracic Transplant Recipients
Matthew J. Bock, MD, Loma Linda University, Loma Linda, CA, USA

11:30 AM  PCRs, Cellular Immunity and Immunogenetic Biomarkers: We’ve Got You Now CMV!
Klara Posfay-Barbe, MD, MS, Hopitaux Universitaires de Genève, Genève, Switzerland

11:45 AM  CMV Prevention and Treatment: Do It Yourself?... or Current Guidelines
Lara Danziger-Isakov, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

12:00 PM  15-min Panel Discussion
SESSION 57 (SYMPOSIUM): Take These Broken Lungs and Learn to Fly: Great Debates for Patients with PAH Awaiting Transplant
Room: Coral Sea
Target Audiences: PH, CTEPH, LF/LTX

Chairs: Paul A. Corris, MB, FRCP, and Oksana A. Shlobin, MD

Session Summary: This symposium will explore the complex decision making in the care of patients with end stage pulmonary hypertension awaiting lung transplantation. Should patients with pulmonary hypertension ever be offered combined heart and lung transplantation? Should patients with Group 3 pulmonary hypertension be offered vasodilators as they become sicker before transplantation? Can urgency-based allocation systems be fair to patients with pulmonary hypertension?

10:30 AM CASE PRESENTATION: PAH Patient with Severe RV Dysfunction Prior to Transplant
Nicholas Kolaitis, MD, UCSF Medical Center, San Francisco, CA, USA

10:35 AM DEBATE: ‘All You Need is Lungs’: Lung Transplantation Alone is the Only Type of Organ Transplantation that Should Be Offered in Patients With End Stage PAH
Jerome Le Pavec, MD, Hôpital Marie Lannelongue, Le Plessis Robinson, France

10:50 AM DEBATE: ‘All You Need is Lungs’: Combined Heart/Lung Transplant Should Be Offered in Patients with End Stage PAH
Fernando Torres, MD, UT Southwestern Medical Center, Dallas, TX, USA

11:05 AM CASE PRESENTATION: Patient with Group 3 Disease and RV Dysfunction Awaiting Transplant
Caroline M Patterson, MD, Papworth Hospital, Cambridge, United Kingdom

11:10 AM DEBATE: Severe PH in Advanced Lung Disease (Group 3) Should Be Treated with Vasodilators (PRO)
Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

11:25 AM DEBATE: Severe PH in Advanced Lung Disease (Group 3) Should Be Treated with Vasodilators (CON)
Adaani Frost, MD, Baylor College of Medicine, Houston, TX, USA

11:40 AM CASE PRESENTATION: Patient with PAH Listed for Lung Transplant Who is Getting Sicker
Errol L Bush, MD, Johns Hopkins, Baltimore, MD, USA

11:45 AM DEBATE: Let It Be, Let It Be, Speaking of Urgency Allocation, Let It Be: Urgency-Based Allocation Can Be Fair for Patients with PAH (PRO)
Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC, USA

12:00 PM DEBATE: Let It Be, Let It Be, Speaking of Urgency Allocation, Let It Be: Urgency-Based Allocation Can Be Fair for Patients with PAH (CON)
Helen M Whitford, MBBS, FRACP, Alfred Hospital, Melbourne, Australia
SESSION 58 (SYMPOSIUM): Resilience in the Face of Calamity: The Art of Preventing PTE Disasters
Room: Coral Sea
Target Audiences: CTEPH, PH

Chairs: Elie Fadel, MD, and John Cannon, MD

Session Summary: The success of Pulmonary Thromboendarterectomy (PTE) has improved over the years due to better understanding of the pathophysiological mechanisms leading to major complications. This knowledge has translated into better ability to prevent them, recognize them early on and manage them more appropriately. This symposium will review specific complications related to PTE and discuss how to manage them to achieve a successful outcome. A 15-min panel discussion with all speakers will conclude this session.

2:00 PM Diagnosed with CTEPH and Decompensated Right Heart Failure: What are the Options?
Marc de Perrot, MD, Toronto General Hospital, Toronto, ON, Canada

2:15 PM ECMO as a Rescue: When, Why and How?
David P Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom

2:30 PM Major Hemoptysis After PTE: How to Assess It and Treat It?
David McGiffin, MD, Alfred Hospital and Monash University, Melbourne, Australia

2:45 PM Severe Reperfusion Pulmonary Edema After PTE: Can We Prevent It?
Kim M Kerr, MD, UCSD Medical Center, La Jolla, CA, USA

3:00 PM Residual PH after PTE: When Should I Start to Worry and What Should I Do?
Joanna Pepke-Zaba, MD, Papworth Hospital, Cambridge, United Kingdom

3:15 PM Diagnosed with CTEPH and Heparin Induced Thrombocytopenia (HIT): How to Proceed?
Olaf Mercier, MD, Centre Chirurgical Marie Lannelongue, Fontenay aux Roses, France

3:30 PM 15-min Panel Discussion
FRIDAY, APRIL 5, 2019
2:00 PM - 3:45 PM

SESSION 59 (ORAL): Heart Transplant Short-Term Outcomes: Getting it Right From the Start
Room: Pacifica 7
Target Audiences: HTX, MCS

Chairs: Sung-Ho Jung, MD, and Marian Urban, MD

2:00 PM  (245) LVAD Patients with RV Failure Pre-Heart Transplant Have Reduced Post-Transplant Survival; Y. D. Barac, O. Jawitz, J. Schroder, M. Daneshmand, C. Patel, C. Milano. Duke University Medical Center, Durham, NC

2:15 PM  (246) Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices; M. Yin1, O. Wever-Pinzon1, M. R. Mehra2, C. G. Selzman3, A. E. Toll4, W. S. Cherikh4, J. Nativi-Nicolau1, J. C. Fang1, A. G. Kfoury5, E. M. Gilbert1, L. Kemeyou1, S. H. McKellar1, A. Kolipolou1, M. Vaduganathan2, S. Drakos1, J. Stehlik1. 1Cardiovascular Services, University of Utah, Salt Lake City, UT, 2Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA, 3Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, 4United Network for Organ Sharing, Richmond, VA, 5Intermountain Healthcare, Salt Lake City, UT

2:30 PM  (247) In Hospital Outcomes in Adult Congenital Heart Disease Patients with Fontan Undergoing Heart Transplantation - A Decade Nationwide Analysis from 2004 until 2014; G. A. Hernandez1, A. Lemor2, D. Clark3, V. Blumer1, R. Byrne3, R. Fowler3, E. Sandhaus3, A. Weingarten3, B. Frischhertz3, K. Schlendorf3, S. Zalawadiya3, J. Lindenfeld3, J. Menachem3. 1University of Miami, Miami, FL, 2Henry Ford Hospital, Detroit, MI, 3Vanderbilt University, Nashville, TN

2:45 PM  (248) Development and Validation of a Risk Model for Primary Graft Failure after Heart Transplantation and Comparison to the RADIAL Risk Score; D. Reichart1, L. Castro2, N. Ruebsamen1, S. Blankenberg1, H. Reichenspurner2, A. Bernhardt2. 1Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany, 2Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

3:00 PM  (249) Outcomes with Heartsize Matching among Cardiac Transplant Recipients with Pulmonary Hypertension; M. Shah1, O. Saeed1, J. Shin1, S. Murthy1, D. B. Sims1, S. Vukelic1, D. Goldstein2, S. J. Forest2, U. P. Jorde1, S. R. Patel1. 1Advanced HF/Transplant Cardiology, Montefiore Medical Center, Bronx, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY

3:15 PM  (250) Insights from High-Performing Heart Transplant Centers across the Recipient Risk-Spectrum; T. P. Singh1, M. R. Mehra2, K. Gauvreau3. 1Pediatrics, Harvard Medical School, Boston, MA, 2Medicine, Harvard Medical School, Boston, MA, 3Biostatistics, Harvard School of Public Health, Boston, MA

3:30 PM  (251) A Direct Heart-Transplantation Strategy in Selected Patients on Extra-Corporeal Membrane Oxygenation Achieved Favorable Post-Transplant Outcomes; G. Coutance1, G. Lebreton1, N. Jacob1, N. Bréchot2, P. Demondion1, A. Bouglé2, L. Nguyen1, S. Varnous1, A. Combes2, P. Leprince1. 1Cardiac Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 2Intensive Care Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 3Anaesthesiology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
SESSION 60: JOINT ISHLT/ABTO SYMPOSIUM: Combining Experiences to Enhance Thoracic Organ Transplantation Worldwide
Room: Pacifica 3-5
Target Audiences: ID, HF/HTX, LF/LTX

Chairs: Paulo M. Pego-Fernandes, MD, PhD, and Fernanda P Silveira, MD

Session Summary: This joint symposium with the Associação Brasileira de Transplante de Órgãos (ABTO: Brazilian Association of Organ Transplants) will provide the opportunity to exchange experiences between heart and lung transplant centers in Brazil and other centers around the world. Important topics regarding aspects of thoracic organ procurement in different countries and health systems as well as the regional variations in disease burden will be discussed. A 15-min panel discussion with all speakers will conclude this session.

2:00 PM  The Largest Public Kidney Transplant Program in the World: What Lessons Should We Learn to Improve Thoracic Organ Transplantation?
Jose Osmar Medina Pestana, MD, Hospital do Rim e Hipertensão of Universidade Federal de São Paulo, São Paulo, Brazil

2:15 PM  Few Potential Donors and One of the Largest (Lung) Transplant Systems of the World: How is it Possible?
Jonathan Yeung, MD, Toronto General Hospital, Toronto, ON, Canada

2:30 PM  Tuberculosis and Thoracic Organ Transplantation: Pre- and Post-Transplant Management in Endemic Areas
Luís Fernando Aranha Camargo, MD, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil

2:45 PM  Tuberculosis and Thoracic Organ Transplantation: Pre- and Post-Transplant Management in Non-Endemic Areas
Amparo Sole, MD, Hospital Universitario La Fe, Valencia, Spain

3:00 PM  Heart Transplant and Chagas Disease: Lessons Learned After 30 Years of Experience
Tania Mara Varejão Strabelli, MD, Heart Institute São Paulo Medical School, São Paulo, Brazil

3:15 PM  Chagas Disease and Heart Failure Management in Non-Endemic Areas
Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA

3:30 PM  15-min Panel Discussion
SESSION 61 (SYMPOSIUM): Making Them Count: Enhancing Lung Donor Utilization
Room: Pacifica 10-12
Target Audiences: LF/LTX, ID

Chairs: Aleem Siddique, MBBS, and Sakhee Kotecha, MBBS (Hons)

Session Summary: Patients with end stage heart and lung disease outnumber the annual thoracic transplants. Maximizing donor utilization is a key factor to addressing this imbalance, but donor management varies greatly across regions leading to significant heterogeneity in donor utilization. This symposium will describe proven and developing strategies for donor management to increase organ utilization as well as identify future directions and opportunities for improvement. A 15-min panel discussion with all speakers will conclude this session.

2:00 PM    Yin and Yang? Goal Directed Thoracic Organ Optimization Does Not Compromise Abdominal Organs
            Arne Neyrinck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

2:15 PM    Practical Steps to Optimize the Heart and Lungs: The UK Experience
            Rajaminiyer Venkateswaran, FRCS, Wythenshawe Hospital, Manchester, United Kingdom

2:30 PM    Carpe Diem - On the Cusp of an Explosion? Research in Donor Management
            George B. Mallory, MD, Texas Children's Hospital, Houston, TX, USA

2:45 PM    Impact of Using Infection Risk Donors Including NAT + HCV
            Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada

3:00 PM    Making the Most in DCD Lung Transplant
            Dirk Van Raemdonck, MD, PhD, University Hospitals, Leuven, Belgium

3:15 PM    Use of Older Donors for Lung Transplantation: How Old is Too Old?
            Jonathan Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA

3:30 PM    15-min Panel Discussion
2:00 PM  
(252) High Afterload Driving Poor Cardiac Output in LVAD Patients is Rectified with Nitrate Therapy; A. Rosenbaum, A. Behfar. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN

2:15 PM  

2:30 PM  
(254) A Trial of Complete Withdrawal of Anticoagulation Therapy in the Heartmate 3 Pump; I. Netuka, P. Ivak, Z. Tucanova, S. Gregor, O. Szarszo, J. Rimsans, J. Connors, D. Crandall, P. Sood, M. Mehra. Institute for Clinical & Experimental Medicine, Prague, Czech Republic, Brigham and Women's Hospital, Boston, MA, Abbott, Burlington, MA

2:45 PM  
(255) A Long-Term Counterpulsation Heart Assist System Used as a Bridge to Decision in Advanced Congestive Heart Failure; T. Symalla, T. Song, D. Onsager, T. Ota, C. LaBuhn, P. Combs, T. Lammy, S. Patel-Raman, G. Sayer, G. Kim, J. Raikhelkar, N. Uriel, V. Jeevanandam. Cardiac Surgery, University of Chicago, Chicago, IL, NuPulseCV, University of Chicago, Chicago, IL, Cardiology, University of Chicago, Chicago, IL

3:00 PM  
(256) Calculation of VAD Cardiac Cycle Volume Using HeartWare Waveform; K. L. Kiehl, B. N. Butzler, M. T. Saltzberg, D. Ishizawar, A. A. Mohammed, R. L. Kursel, N. A. Gaglianello. Advanced Heart Failure, Froedtert Hospital, Milwaukee, WI, Advanced Heart Failure and Transplant Cardiology, The Medical College of Wisconsin, Milwaukee, WI

3:15 PM  

3:30 PM  
(258) Outcomes of Obese Patients Bridged to Heart Transplantation with Continuous-Flow Left Ventricular Assist Devices; A. K. Okoh, S. Fugar, M. Schulthes, M. Russo, K. Rivandra, R. Yanagida, M. Camacho. RWJ Barnabas Health Newark Beth Israel Medical Center, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ, Division of Cardiology, Rush University Medical Center, Chicago, NJ, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ
FRIDAY, APRIL 5, 2019
2:00 PM - 3:45 PM

SESSION 63: JOINT ISHLT/ICCAC SYMPOSIUM: Faster, Higher, Stronger: Monitoring Exercise in Cyberspace
Room: Pacifica 6
Target Audiences: MCS, NHSAH

Chairs: Peggy S. Blood, RN, MSN, and Simon Maltais, MD, PhD

Session Summary: Patient and healthcare provider partnerships can enhance patient outcomes. Remote care support and monitoring of MCS patients can improve patient independence and positively impact patient care. This joint symposium with the International Consortium of Circulatory Assist Clinicians (ICCAC) will discuss integration of self-care strategies, educational preparation, new technologies maximizing MCS patient management, strategies to reduce morbidity and mortality, the future of MCS support, and challenges and opportunities that advancing technology poses to current practice.

2:00 PM  
*Under Pressure: Continuous Pulmonary Artery Monitoring and LVAD*
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

2:15 PM  
*Q&A*

2:20 PM  
*Care Anywhere: Remote Patient Monitoring*
Michele C Kassemos, BSN, UCSF Medical Center, San Francisco, CA, USA

2:35 PM  
*Q&A*

2:40 PM  
*There’s an App for That: Preparing the EMS*
Thomas Schloeglhofer, MSc, Medical University of Vienna, Vienna, Austria

2:55 PM  
*Q&A*

3:00 PM  
*Frailty and Exercise Tolerance: How Are They Related?*
Kavitha Muthiah, MBchB, PhD, St. Vincent's Hospital, Sydney, Australia

3:15 PM  
*Q&A*

3:20 PM  
*Let the Pacer Do the Work! Conduction Abnormalities in Heart Failure and Their Role in Exercise During VAD Support*
Van-Khue Ton, MD PhD, University of Maryland School of Medicine, Baltimore, MD, USA

3:35 PM  
*Q&A*
SESSION 64 (ORAL): Highlights of Challenging Topics in Pediatric Heart Transplant and MCS

Room: Pacifica 1-2
Target Audiences: PEDS, HF/HTX, MCS

Chairs: Estela Azeka, MD, and David L. Sutcliffe, MD

2:00 PM
(259) Simultaneous Pediatric Heart-Kidney Transplant Outcomes in the US: A 25 Year National Cohort Study; S. Choudhry1, S. W. Denfield1, V. R. Dharnidharka2, Y. Wang3, J. F. Price1, A. G. Cabrera1, H. P. Tunuguntla1, W. J. Dreyer1, 1Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, 2Washington University School of Medicine, Saint Louis, MO

2:15 PM
(260) Development and Validation of a Pediatric Heart Failure Risk-Prediction Model for Children Listed for Heart Transplantation in the Current Era; C. Chen1, Y. Zhang2, E. Profita3, J. C. Dykes1, E. Liu1, K. Maeda3, C. S. Almond4, 1Pediatric Cardiology, Stanford University, Palo Alto, CA, 2Cardiothoracic Surgery, Clinical and Translational Research Program, Stanford University, Palo Alto, CA, 3Cardiothoracic Surgery, Stanford University, Palo Alto, CA

2:30 PM
(261) Cardiac Transplantation in Fontan Patients Has Equally Excellent Results as Biventricular Congenital Heart Disease Patients; K. W. Riggs1, J. T. Broderick1, C. Chin2, R. Bryant III3, F. Zafar4, D. L. Morales1, 1Cardiothoracic Surgery, Cincinnati Children’s Hospital, Cincinnati, OH, 2Pediatric Cardiology, Cincinnati Children’s Hospital, Cincinnati, OH

2:45 PM
(262) Speaking the Same Language? Assessing Blood Pressure Measurement and Effectiveness in Pediatric VAD Patients; C. Villa1, D. Peng2, S. Auerbach3, S. Kindel4, S. Law5, A. Lorts1, M. Mehegan6, M. O’Connor7, M. Ploutz8, D. Rosenthal9, C. VanderPluym10, M. Zinn11, D. Sutcliffe12, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2C. S. Mott Children’s Hospital, Ann Arbor, MI, 3Children’s Hospital of Colorado, Aurora, CO, 4Children’s Hospital of Wisconsin, Milwaukee, WI, 5New York Presbyterian/Morgan Stanley Children’s Hospital, New York, NY, 6St. Louis Children’s Hospital, Saint Louis, MO, 7Children’s Hospital of Philadelphia, Philadelphia, PA, 8Phoenix Children’s Hospital, Phoenix, AZ, 9Lucille Packard Children’s Hospital, Palo Alto, CA, 10Children’s Hospital of Boston, Boston, MA, 11Children’s Hospital of Pittsburgh, Pittsburgh, PA, 12Children’s Medical Center Dallas, Dallas, TX

3:00 PM
(263) Extracorporeal Membrane Oxygenation Use within 24 Hours of Heart Transplantation in Children: Incidence, Risk Factors, and Outcomes; J. Godown1, D. W. Bearl1, C. Thurm2, M. Hall2, B. Feingold3, J. H. Soslowsky1, B. A. Mettler4, A. H. Smith5, E. Profita6, T. P. Singh7, D. A. Dodd8, 1Pediatric Cardiology, Monroe Carell Jr. Children’s Hospital, Nashville, TN, 2Children’s Hospital Association, Lenexa, KS, 3Pediatric Cardiology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, 4Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children’s Hospital, Nashville, TN, 5Pediatric Critical Care, Monroe Carell Jr. Children’s Hospital, Nashville, TN, 6Pediatric Cardiology, Lucile Packard Children’s Hospital, Palo Alto, CA, 7Pediatric Cardiology, Boston Children’s Hospital, Boston, MA

3:15 PM
(264) Risk Factors for Pediatric Causes of Death in Males with Duchenne Muscular Dystrophy; C. A. Wittlieb-Weber1, K. K. Knecht2, C. R. Villa3, C. Cunningham4, M. J. Bock5, K. E. Gambetta6, A. K. Lai7, K. R. Schumacher8, S. P. Law9, S. R. Deshpande10, S. C. West11, J. M. Friedland-Little12, I. D. Lytrivi13, M. A. McCulloch13, R. J. Butts14, D. R. Weber1, J. N. Johnson15, 1University of Rochester Medical Center, Rochester, NY, 2University of Arkansas, Little Rock, AR, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Chentel.cunningham@albertahealthservices.ca, Edmonton, AB, Canada, 5Loma Linda University Children’s Hospital, Loma Linda, CA, 6Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 7Primary Children’s Hospital, Salt Lake City, UT, 8C.S. Mott Children’s Hospital, Ann Arbor, MI, 9Morgan Stanley Children’s Hospital of New York Presbyterian, New York, NY, 10Children’s National, Washington, DC, 11Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 12Seattle Children’s Hospital, Seattle, WA, 13University of Virginia Children’s Hospital, Charlottesville, VA, 14Children’s Medical Center of Dallas, Dallas, TX, 15Mayo Clinic Children’s Center, Rochester, MN

3:30 PM
(265) ABO Incompatible Listing in Early Childhood Results in Earlier Transplantation and Equal Post-Transplant Survival Despite Predominant Use in Sicker Patients; S. Urschel1, M. McCoy2, Z. Reinhardt2, A. Dipchand3, R. S. Cantor4, D. A. Koehler5, J. K. Kirklin6, J. A. Ballweg7, K. R. Kanter8, W. Zuckerman9, J. Sparks9, W. F. Carlo8, 1Pediatrics, University of Alberta, Edmonton, AB, Canada, 2Pediatrics, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 3Pediatrics, Hospital for Sick Children, Toronto, ON,
Canada, 4Kirklin Institute for Research in Surgical Outcomes (KIRSO), Birmingham, AL, 5Pediatrics, Children’s Hospital & Medical Center, Omaha, Omaha, NE, 6Pediatrics, Emory University School of Medicine, Atlanta, GA, 7Pediatrics, Columbia University Medical Center, New York, NY, 8Pediatrics, University of Louisville, Louisville, KY, 9Pediatrics, University of Alabama, Birmingham, AL
FRIDAY, APRIL 5, 2019
4:15 PM - 6:00 PM

SESSION 65 (SYMPOSIUM): All Talk, No Action? New Strategies and Best Practices to Maximize Donor Heart Utilization
Room: Pacifica 7
Target Audiences: HF/HTX, LF/LTX

Chairs: Kiran K Khush, MD, and James K. Kirklin, MD

Session Summary: The paucity of donors is still the primary limitation for heart transplantation across the world. Too many donor hearts are not accepted for concerns over particular risk factors. This symposium will explore novel ways to expand the donor pool. In a time when the waiting lists grow exponentially, our field must find ways to maximize donor utilization. A 15-min panel discussion with all speakers will conclude this session.

4:15 PM  
*Perfect is the Enemy of Good: Using Marginal Donor Hearts*
David Rabkin, MD, Loma Linda University, Loma Linda, CA, USA

4:30 PM  
*Riding the Epidemic: Hepatitis C + Donors Should Become Standard of Care*
Kelly Schlendorf, MD, Vanderbilt University, Nashville, TN, USA

4:45 PM  
*Distance Makes the Heart Grow Fonder: Miles Should Not Limit Donor Acceptance*
Christopher S Hayward, MD, St. Vincent's Hospital, Sydney, Australia

5:00 PM  
*Love It or Levophed It: High Dose Catecholamine Donor Support and Outcomes After Heart Transplantation*
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

5:15 PM  
*DEBATE: All Nations Should Have an Opt Out System (PRO)*
Maria Dolores Cosio, MD, Hospital 12 Octubre, Madrid, Spain

5:30 PM  
*DEBATE: All Nations Should Have an Opt Out System (CON)*
Peter J Bergin, MBBS, FRACP, Alfred Hospital, Melbourne, Australia

5:45 PM  
15-min Panel Discussion
FRIDAY, APRIL 5, 2019
4:15 PM - 6:00 PM

SESSION 66 (ORAL): Between the Devil and the Deep Blue Sea: Fungus or CMV?
Room: Pacifica 1-2
Target Audiences: ID, HTX, LTX, PEDS, PHARM

Chairs: Shahid Husain, MD, MS, and Erik Verschuuren, MD, PhD

4:15 PM
(266) Pentraxin-3 Polymorphisms are Associated with Invasive Pulmonary Aspergillosis after Lung Transplantation; A. Van Herck, A. Sacreas, T. Heigl, J. Kaes, A. Vanstapel, S. E. Verleden, D. Lambrechts, B. M. Vanaudenaerde, G. M. Verleden, R. Vos. 1Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing, University of Leuven, Leuven, Belgium. 2Laboratory of Translational Genetics (VIB Center for Cancer Biology), Department of Human Genetics, University of Leuven, Leuven, Belgium

4:30 PM

4:45 PM
(268) A Comparison of Aspergillus Prophylaxis with Voriconazole versus Isavuconazole in Lung Transplant Recipients; D. D. Nanayakkara, E. Blodget, S. Ganesh. 1Infectious Diseases, University of Southern California, Los Angeles, CA, 2Pulmonary and Critical Care Medicine, University of Southern California, Los Angeles, CA

5:00 PM
(269) Quantiferon-CMV Guided Virostatic Prophylaxis after Heart Transplantation; G. Poglajen, G. Zemljic, S. Frljak, R. Okrajšek, M. Sebeštjen, A. Cerar, V. Andro, E. B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia

5:15 PM
(270) Does the Use of Serum Ganciclovir Levels to Adjust Valganciclovir Dosing Prevent the Development of CMV Resistance in CMV Mismatched Heart Transplant Recipients? The Mid America Experience; J. Linard, C. Knutson, R. Wells, A. M. Borkon, A. Kao. 1Cardiac Transplant, Saint Luke’s Mid America Heart Institute, Kansas City, MO, 2Cardiothoracic Surgery, Saint Luke’s Mid America Heart Institute, Kansas City, MO, 3Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO

5:30 PM

5:45 PM
(272) Impact of Prolonging CMV Prophylaxis in High-Risk (CMV D+/R-) Lung Transplant Recipients; S. Herrera, B. Khan, S. Husain, M. Binnie, C. Chow, T. Martinu, C. Chaparro, S. Keshavjee, L. G. Singer, J. Tikkanen. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
SESSION 67 (ORAL): Diagnostics and Immunosuppression in Lung Transplantation
Room: Pacifica 10-12
Target Audiences: LF/LTX, NHSAH, PHARM

Chairs: Robert D Levy, MD, FRCPC, and Jonathan P Singer, MD, MS

4:15 PM

(273) ISHLT Consensus on Standardization of Bronchoalveolar Lavage in Lung Transplantation; T. Martini1, A. Koutsokera2, C. Benden3, E. Cantu4, D. Chambers5, M. Cypel6, J. Edelman7, A. Emiaizjoo8, A. J. Fisher9, J. R. Greenland10, D. Hayes11, D. M. Hwang12, B. C. Keller13, E. D. Lease14, M. Perch15, M. Sato16, J. L. Todd17, S. Verleden18, J. von der Thüsen19, S. S. Weigt20, S. Keshavjee1, *. On Behalf of ISHLT BAL Standardization Workgroup1. 1Toronto Lung Transplant Program, Toronto, ON, Canada, 2University Hospital Zurich, Zurich, Switzerland, 3University Hospital of Pennsylvania, Philadelphia, PA, 4The Prince Charles Hospital, Brisbane, Australia, 5Puget Sound VAMC, Seattle, WA, 6University of Florida, Gainesville, FL, 7Fremantle Hospital, Newcastle, United Kingdom, 8University of California San Francisco, San Francisco, CA, 9Nationwide Children’s Hospital, Columbus, OH, 10Toronto General Hospital Research Institute, Toronto, ON, Canada, 11The Ohio State University, Columbus, OH, 12University of Washington, Seattle, WA, 13Rigshospitalet, Copenhagen, Denmark, 14University of Tokyo, Tokyo, Japan, 15Duke University Medical Canter, Durham, NC, 16Katholieke Universiteit Leuven, Leuven, Belgium, 17Erasmus Medical Center, Rotterdam, Netherlands, 18University of California Los Angeles, Los Angeles, CA.

4:30 PM


4:45 PM


5:00 PM

(276) Ten-Year-Experience with Alemtuzumab as Induction Therapy: A Single-Center Analysis of More Than 500 Patients; A. Benazzo1, S. Schwarz2, D. Weber3, G. Murakozy4, C. Lambers5, B. Moser6, J. Matilla7, G. Lang8, S. Taghavi9, W. Klepetko10, K. Hoetzenecker11, P. Jakshch12. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 3University Hospital of Pennsylvania, Philadelphia, PA, 4Medical University of Vienna, Vienna, Austria, 5University of Washington, Seattle, WA, 6Toronto Lung Transplant Program, Toronto, ON, Canada, 7University of Tokyo, Tokyo, Japan, 8Duke University Medical Canter, Durham, NC, 9Katholieke Universiteit Leuven, Leuven, Belgium, 10Erasmus Medical Center, Rotterdam, Netherlands, 11University of California San Francisco, San Francisco, CA, 12University of California San Francisco, San Francisco, CA.

5:15 PM

(277) Extracorporeal Photopheresis Improves Survival Probability and Lowers Hospital-Related Expenses In Lung Transplant Recipient's With Bronchiolitis Obliterans Syndrome; C. Joukhadar1, R. Knobler2, A. Cho3, U. Just4, G. Murakozy5, P. Jakshch6. 1J&P Medical Research Ltd, Vienna, Austria, 2Department of Dermatology, Medical University of Vienna, Vienna, Austria, 3Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.

5:30 PM

(278) Sirolimus + Tacrolimus Maintenance with No Induction Therapy May Maximize Survival in Lung Transplant Recipients; M. Wijesinha1, J. Hirshon, M. Terrin, L. Magder, C. Brown, K. Stafford, A. Iacono. University of Maryland School of Medicine, Baltimore, MD.

5:45 PM

SESSION 68 (ORAL): LV Recovery after MCS: From Promise to Reality?
Room: Pacifica 6
Target Audience: MCS

Chairs: Ioannis Dimarakis, PhD, FRCS, and Amanda R Vest, MBBS MPH

4:15 PM

4:30 PM

4:45 PM
(282) Does Indication for LVAD at Time of Implant Matter in Younger Patients?; A. Lala, J. Rowland, A. Gelijns, E. Bagiella, A. Moskowitz, B. Ferket, S. Pinney, M. Miller, F. Pagani, D. Mancini. 1Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, 2Population Health Science, Icahn School of Medicine at Mount Sinai, New York, NY, 3Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, 4NHLBI, Bethesda, MD, 5Cardiothoracic Surgery, University of Michigan, Ann Arbor, NY, 6Medicine, Cardiology, Population Health Science, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY

5:00 PM

5:15 PM

5:30 PM

5:45 PM
(286) Long-Term Outcome of Patients after Successful LVAD Explant: A EUROMACS Study; C. Antonides, F. Schoenrath, K. Veen, R. Muslem, I. Netuka, I. Gummert, B. Meyns, M. Özbaran, D. Schibiisky, T. de By, K. Caliskan. 1Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany, 3DZHK (German Center for Cardiovascular Research), partner site, Berlin, Germany, 4Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 5Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW, Ruhr University Bochum, Bad Oeynhausen, Germany, 6Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, 7Department of Cardiovascular Surgery, Ege Üniversitesi T&#305;Fakültesi, Izmir, Turkey, 8Department of Cardiovascular Surgery, Universitäts-Herzzentrum Freiburg - Bad Krozingen, Freiburg, Germany, 9EACTS, EUROMACS, Windsor, United Kingdom, 10Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands
SESSION 69 (ORAL): Tricks of the Trade: Management Considerations with Continuous Flow LVADs
Room: Grand Caribbean 1-7
Target Audiences: MCS, EEP

Chairs: Minoru Ono, MD, PhD, and Ivan Knezevic, MD

4:15 PM

(287) Predictors and Impact of Vasoplegia after Continuous-Flow Left Ventricular Assist Device Implantation; M. Kim, H. Lamba, R. Miller, J. George, S. Sattee, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan, S. Chatterjee. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX

4:30 PM

(288) Longitudinal Trends in Gut Microbial Community Diversity among HF Patients Undergoing LVAD; M. Yuzefpolskaya1, B. Bohn D.F.2, D. Onat1, A. Zuver1, D. L. Brunjes1, E. A. Royzman1, A. Pinsino1, K. L. Antler1, J. C. Hupf1, M. B. Dominguez1, A. R. Garan1, H. Takayama1, K. Takeda1, Y. Naka1, P. C. Colombo1, R. T. Demmer4. 1Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, 2Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, 3Medicine, Jacobs AECOM, Bronx, New York, NY, 4Medicine, Division of Cardiology, Columbia University, New York, NY, 5Surgery, Columbia University Medical Center, New York, NY, 6Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

4:45 PM

(289) Novel Approach to Assess Intraventricular Pressure Difference in Patients with Left Ventricular Assist Device during Ramp Study; K. Akiyama1, E. J. Stöhr2, R. Ji3, O. G. Jimenez4, I. Wu5, K. Itatani6, S. Miyazaki7, T. Furusawa7, T. Nishino7, B. J. McDonnell8, A. R. Garan1, M. Yuzefpolskaya1, P. C. Colombo1, Y. Naka1, H. Takayama1, K. Takeda1. 1Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Cardiac Physiology and Health, Cardiff Metropolitan University, Cardiff, United Kingdom, 3Cardiology, Columbia University Medical Center, New York, NY, 4Surgery, Columbia University Medical Center, New York, NY, 5Anesthesiology, Columbia University Medical Center, New York, NY, 6Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan, 7Cardio Flow Design, Tokyo, Japan, 8Cardiff Metropolitan University, Cardiff, United Kingdom

5:00 PM

(554) Post-Implant Phosphodiesterase-5 Inhibitor Use is Associated with Increased Rates of Late Right Heart Failure after LVAD: An INTERMACS Analysis; E. Grandin1, G. Gulati1, K. Kennedy1, E. Cabezas1, E. Y. Birati2, J. Rame3, P. Atluri3, F. D. Pagani3, J. K. Kirklin3, D. C. Naftel4, R. L. Kormos5, J. Teuteberg6, M. Kiernan7. 1Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 2Division of Cardiovascular Medicine, Tufts Medical Center, Boston, MA, 3BIDMC Smith Center for Outcomes Research in Cardiology, St. Luke’s Mid-America Heart Institute, Kansas City, MO, 4Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 5Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 6Division of Cardiovascular Surgery, University of Michigan, Ann Arbor, MI, 7Division of Cardiothoracic Surgery, University of Alabama Birmingham, Birmingham, AL, 8Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 9Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA

5:15 PM


5:30 PM

(292) Does Low-Intensity Anticoagulation Using Vitamin K Antagonists Correlate with Factor X Activity in Patients Implanted with the HeartMate 3 Pump? A Validation Analysis of the MAGENTUM 1 Study; J. M. Connors4, I. Netuka2, P. Ivák2, Z. Tu&#269;anová1, S. Gregor4, P. Sood6, D. Crandall6, M. R. Mehra7. 1Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Institute for Clinical & Experimental Medicine, Prague, Czech Republic, 3Department of Cardiovascular Surgery, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, 4Department of Pharmacy, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, 5Global Clinical Affairs, Heart Failure, Abbott, Burlington, MA, 6Global Clinical, Heart Failure, Abbott, Burlington, MA, 7Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

5:45 PM

(293) Impact of Socioeconomic Status on Outcomes Post-Ventricular Assist Device Implantation; J. J. Han1, A. Iyengar1, W. L. Patrick1, J. Goldenring2, M. Molina1, A. Ameer1, M. Helmers1, E. Y. Birati1, P. Atluri1.
1Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA. 2Perelman School of Medicine, Philadelphia, PA. 3Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA
FRIDAY, APRIL 5, 2019
4:15 PM - 6:00 PM

SESSION 70 (SYMPOSIUM): Matters of Life and Death: Palliative and End of Life Care in Transplant Medicine
Room: Pacifica 3-5
Target Audiences: NHSAH, PEDS, PH, PHARM

Chairs: Melissa Cousino, PhD, and Rachel M Crackett, MSc

Session Summary: This symposium will include novel talks to advance the ways in which we care for organ failure/transplant patients at end of life (EOL). Covered topics will include: emotional support for patients at EOL, collaboration with ethics and palliative care teams, pharmacological management of patients at EOL, palliative care for the pediatric and adult congenital heart disease population, religious/cultural diversity in EOL, and addressing provider burn-out/self-care. A 15-min panel discussion with all speakers will conclude this session.

4:15 PM  
**Beyond Life Support: Emotional Support for Patients at End of Life**  
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia

4:30 PM  
**It's Complicated: Collaboration and Integration Between Palliative Care, Ethics and Transplant Teams**  
Andrew Courtwright, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

4:45 PM  
**Pharmacological Management of the MCS/Transplant Patient at End of Life**  
Steven P Ivulich, BPharm, Alfred Hospital, Melbourne, Australia

5:00 PM  
**Bringing PC to PEDS: Palliative Care for Pediatric Transplant and MCS Patients**  
Elizabeth Blume, MD, Children's Hospital, Boston, MA, USA

5:15 PM  
**Bridging the Gaps: Cultural and Regional Diversity and End of Life Care**  
Rachel Hadler, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

5:30 PM  
**Self-Care for Us! Provider Heartbreak in Organ Failure/Transplant Care**  
Julie Bidwell, PhD, UC Davis, Davis, CA, USA

5:45 PM  
**15-min Panel Discussion**
SESSION 71 (SYMPOSIUM): Breaking Bad: The Right Ventricle and Exercise Hemodynamics Rediscovered
Room: Coral Sea
Target Audiences: PH, CTEPH, MCS

Chairs: Arun Jose, MD, and Marc Simon, MD

Session Summary: In collaboration with the Pulmonary Vascular Research Institute (PVRI), this symposium will provide an overview into the mechanisms, clinical diagnosis and management of chronic right heart failure in left heart disease, scleroderma, and pulmonary hypertension. There will be a focus on the identification of maladaptive remodeling with discussion of the mechanisms contributing to maladaptive remodeling in right heart failure. We will explore the relationship of right ventricular function to functional capacity and highlight a debate on exercise challenge during right heart catheterization. A 15-min panel discussion with all speakers will conclude this session.

4:15 PM    Back to the Future 1: Mechanisms of Chronic RV Failure
            Ryan J Tedford, MD, Medical University of South Carolina, Charleston, NC, USA

4:30 PM    Back to the Future 2: Metabolic Changes in the Failing Right Heart
            Evangelos Michelakis, MD, University of Alberta, Alberta, AB, Canada

4:45 PM    Don't Go Breaking My Heart: Scleroderma Related - a Specific Entity
            Steven Hsu, MD, Johns Hopkins University, Baltimore, MD, USA

5:00 PM    When the Going Gets Tough, the Tough Get Going: Management of Acute RV Failure
            John Granton, MD, University of Toronto, Toronto, ON, Canada

5:15 PM    DEBATE: We Should Exercise Our PH Patients During Right Heart Catheterization (PRO)
            Susanna Mak, MD, PhD, Mount Sinai Hospital, Toronto, ON, Canada

5:30 PM    DEBATE: We Should Exercise Our PH Patients During Right Heart Catheterization (CON)
            Ivan Robbins, MD, Vanderbilt University, Nashville, TN, USA

5:45 PM    15-min Panel Discussion
MINI ORAL 13: Cardiac Donors and Recipients: Valuable Insights  
Room: Pacifica 1-2  
Target Audiences: HF/HTX, PHARM

Chairs: Rami Alharethi, MD, and Hye Won Lee, PhD

6:15 PM  
(501) Risk Stratification of Inotropic Therapy for Heart Transplant Candidates in the Era of Ventricular Assist Device Support; L. K. Truby1, V. K. Topkara2, S. D. Russell1, C. B. Patel1, R. Agarwali. 1Duke University Medical Center, Durham, NC, 2Columbia University Medical Center, New York, NY

6:20 PM  

6:25 PM  

6:30 PM  
(504) Elevated Pre-Transplant Neutrophil to Lymphocyte Ratio is Associated with Increased Vasoplegia Syndrome in Cardiac Transplantation; N. Ahmed, H. Gandhi, K. Rahgozar, S. Guo, E. Sun, O. Saeed, S. Patel, S. Murthy, J. J. Shin, S. Vukelic, S. Forest, D. J. Goldstein, U. P. Jorde, D. B. Sims. Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY

6:35 PM  
(505) Utility of Routine versus Triggered Evaluations of Rejection Greater Than Two Years Following Heart Transplant; J. R. Golbus, M. C. Konerman, K. D. Aaronson. Internal Medicine, University of Michigan, Ann Arbor, MI

6:40 PM  
(506) Protocol Endomyocardial Biopsy beyond Six Months - It's Time to Move On; K. Oh1, M. H. Mustehsan1, D. B. Sims1, O. Saeed1, S. Vukelic1, J. J. Shin1, S. Murthy1, A. Luke1, S. J. Forest2, D. Goldstein2, U. Jorde1, S. R. Patel1. 1Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

6:45 PM  
(507) Clinical Utility of the IMPACT Score for Mortality Prediction after Heart Transplantation: External Validation Study; C. D. Ortiz Bautista1, J. Muniz Garcia2, F. Gonzalez-Vilchez3, J. Segovia Cubero4, M. G. Crespo Leiro5, R. Lopez Vilella6, J. Gonzalez Costelo7, E. Roig Minguell8, J. M. Arizon Del Prado9, J. M. Sobrino Marquez10, I. P. Garrido Bravo11, J. F. Delgado Jimenez12. 1Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Instituto de Investigación Biómédica (INIBIC), Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, 3Cardiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 5Cardiology, Hospital Universitario Puertollano, Cuenca, Spain, 6Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain, 7Cardiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 8Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 9Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain

6:50 PM  
(508) One but Not the Same: Risk Factors for Early Post-Transplant Mortality Differ between Medically Managed Patients and Those Bridged to Transplant with Left Ventricular Assist Devices; L. K. Truby1, M. Farr2, V. K. Topkara2. 1Duke University Medical Center, Durham, NC, 2Columbia University Medical Center, New York, NY

6:55 PM  
(509) Cardiac Transplantation across Preformed HLA-Antibody Barriers: Results of a Peritransplant Desensitization Protocol; F. Ius1, S. V. Rojas1, T. Kauffeld1, W. Sommer1, C. Bara1, J. Salman1, T. Siemeni1, R. Poyanmehr1, D. Bobylev1, M. Avsar2, I. Tudorache1, C. S. Falk2, A. Haverich1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
(510) Treatment of Therapy-Resistant Hyperlipidaemia after Heart Transplant with PCSK9-Inhibitors; K. Uyanik-Uenal, M. Stoegerer-Lanzenberger, K. Auersperg, A. Aliabadi-Zuckermann, G. Laufer, A. Zuckermann. 1Department of Cardiac Surgery, Medical University of Vienna (AKH), Vienna, Austria, 23rd Medical Department for Metabolic Disorders and Nephrology, Hospital Hietzing, Vienna, Austria

(511) Change in Health-Related Quality of Life from Before to Early after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study; K. L. Grady, A. Kao, M. Dew, R. Kormos, A. Andrei, H. Adam, Y. Xu, D. Pham, L. Pollan, C. Yancy, E. Hsich, W. Cotts, S. LaRue, M. Petty, S. V. Pamboukian, F. Pagani, B. Lampert, M. Johnson, M. Murray, K. Tekeda, M. Yuzefpolskaya, S. Silvestry, J. Kirklin, S. Collum, J. Spertus. 1Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, 2Medicine, University of Missouri - Kansas City, Kansas City, MO, 3Psychiatry, University of Pittsburgh, Pittsburgh, PA, 4Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, 5Medicine, Northwestern University, Chicago, IL, 6Medicine, Cleveland Clinic, Cleveland, OH, 7Medicine, Advocate Christ Medical Center, Oak Lawn, IL, 8Medicine, Washington University, St. Louis, MO, 9Surgery, University of Minnesota Medical Center, Minneapolis, MN, 10Medicine, University of Alabama, Birmingham, AL, 11Surgery, University of Michigan, Ann Arbor, MI, 12Medicine, Ohio State University, Columbus, OH, 13Medicine, University of Wisconsin, Madison, WI, 14Surgery, Columbia University, New York, NY, 15Medicine, Columbia University, New York, NY, 16Surgery, Florida Hospital, Maitland, FL, 17Surgery, University of Alabama - Birmingham, Birmingham, AL

(512) Intraoperative Perfusion Strategies during Heart Transplantation: Are We Optimizing Renal Protection?; N. M. Foley, M. Kuzemchak, Y. Tipograf, C. White-Dzuro, K. Balsara, K. Schlendorf, M. Danter, A. Shah. Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN
MINI ORAL 14: Unique Considerations for Special Heart Transplant Populations
Room: Pacifica 7
Target Audiences: HF/HTX, NHSAH

Chairs: Alejandro M. Bertolotti, MD, and Van N Selby, MD


6:20 PM  (514) Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation; K. Alexander¹, C. Barrett², K. Dobos¹, P. Cheng¹, R. Liao¹, M. Wheeler¹, M. Liedtke¹, D. Weisshaar³, R. Witteles³. ¹Stanford University Medical Center, Stanford, CA, ²University of Colorado, Aurora, CO, ³Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA


6:30 PM  (979) Heart Transplantation in Cardiac Amyloidosis: A Ten Year Experience; J. P. Donnelly¹, E. G. Soltesz², M. Z. Tong³, S. A. Hall³, P. Kale¹, J. D. Estep¹, M. Hanna¹.¹Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ²Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ³Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, Dallas, TX

6:35 PM  (516) Differential Gene Expression by Race and Impact on Risk after Heart Transplantation; Y. Moayed³, C. S. Fan², R. J. Miller¹, D. Hillier¹, M. Tremblay-Gravel¹, M. A. Shullo³, R. Woodward², J. Yee³, C. Manlihot⁶, S. Pinney⁷, S. A. Hall⁶, K. K. Khush⁶, H. J. Ross⁸, J. J. Teuteberg³.³Medicine, Stanford University, Stanford, CA, ²Biosciences and Epidemiology, University Health Network, University of Toronto, University of Toronto, ON, Canada, ³Medicine, Division of Cardiology, Stanford University, Palo Alto, CA, ⁴CareDx, CareDx, Brisbane, CA, ⁵Pharmacy, West Virginia University, Morgantown, WV, ⁶Biosciences, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷Medicine, Division of Cardiology, Mount Sinai New York, NYC, NY, ⁸Medicine, Division of Cardiology, Baylor Health Care, Dallas, TX, ⁹Medicine, Division of Cardiology, Stanford University, Stanford, CA, ¹⁰Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada

6:40 PM  (517) Comparison of Patients Undergoing Multiorgan Transplantation with or without Prior Ventricular Assist Device; M. E. Currie¹, D. Banerjee², Y. Shudo¹, B. Lingala¹, Y. Zhu¹, F. Haddad², J. Woo¹.¹Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Medicine, Stanford University, Stanford, CA


6:50 PM  (520) Improving Nutrition Practices for Critically Ill Postoperative Heart Transplant and Ventricular Assist Device Implant Patients; R. Modir¹, V. Rao¹, J. Teuteberg¹, D. Banerjee³, P. Oyer¹, Z. Tulu³, E. Hadhazy⁶, W. Hiesinger⁴, S. Jimenez⁴, L. Tu¹, C. Hill⁴.¹Heart Transplant/Clincial Nutrition, Stanford University Hospital, Stanford, CA, ²Anesthesia - Cardiac, Stanford University Hospital, Stanford, CA, ³Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, ⁴Cardiothoracic Surgery - Adult Cardiac Surgery, Stanford University Hospital, Stanford, CA, ⁵Solid Organ Transplant, Stanford Health Care, Stanford, CA, ⁶Stanford Health Care, Stanford, CA

6:55 PM  (521) The BRIGHT Study Shows Geographical Disparities in Body Mass Index among Heart Transplant Recipients; M. Alrawashdeh¹, M. R. Molina¹, S. Beckmann¹, K. Denhaerynck³, F. Dobbels¹, S. De Geest³.¹Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³Institute of Nursing Science, University of Basel, Basel, Switzerland, ⁴Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
(522) Weight Gain Post Heart Transplantation is Associated with an Increased Risk for Allograft Vasculopathy and Rejection; Y. Peled, D. Freimark, E. Nachum, M. Arad, D. Elian, Y. Kassif, N. Shlomo, R. Klempfner, J. Lavee. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel

(523) The Gift That Keeps on Giving? The Impact of Donor Coronary Atherosclerosis on the Development of Coronary Allograft Vasculopathy by IVUS; Y. Moayedi1, C. S. Fan2, R. J. Miller3, M. Tremblay-Gravel1, M. Kawana1, H. I. Luikart1, N. D'Emilio3, J. Gordon3, J. T. Parizo3, G. Oro3, R. Wainwright1, W. Hiesinger4, C. Manlhiot2, K. K. Khush3, J. J. Teuteberg1. 1Medicine, Stanford University, Stanford, CA, 2Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada, 3Medicine, Division of Cardiology, Stanford University, Stanford, CA, 4Cardiovascular Surgery, Stanford University, Stanford, CA, 5Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada

(524) Induction with Rabbit-Thymoglobulin (r-ATG) is Associated with Lower Cardiac Allograft Vasculopathy (CAV); S. Madan, S. R. Patel, O. Saeed, S. Forest, W. A. Jakobleff, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Bronx, NY
6:15 PM
(525) Cytomegalovirus Infection among Pediatric Heart Transplant Recipients in the Current Era of Valganciclovir Prophylaxis: Impact on Post-Transplant Outcomes; B. B. Das1, J. Niu2, P. K. Sue3, B. K. Prusty3, 1Joe DiMaggio Children’s Heart Institute, Hollywood, FL, 2Memorial Healthcare System, Hollywood, FL, 3UT Southwestern Medical Center, Dallas, TX, 4University of Wuerzburg, Wuerzburg, Germany

6:20 PM
(526) KPC Klebsiella Identification Significantly Increases Risk of Bronchial Dehiscence in Lung Transplant Recipients; J. Suh1, W. Yu1, S. Song1, J. Lee1, M. Park2, S. Kim2, J. Song2, S. Jeong2, H. Paik1, 1Thoracic Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, 2Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

6:25 PM
(527) Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients Treated with a Preemptive/Targeted Antifungal Therapy Strategy: 4 Year Follow Up; S. Herrera1, A. Faroq1, S. Davoudi1, T. Martinu2, D. Kumar1, A. Humar1, C. Rotstein1, L. G. Singer2, S. Keshavjee2, S. Husain1, 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

6:30 PM
(528) Pre Transplant Interleukin 10 Levels are Higher in Lung Recipients with Post Transplant Infections; L. Calahorra1, E. Sarmiento1, J. Cifrian2, C. Bravo3, R. Laporta4, M. Ussetti4, A. De Pablos4, A. Soler4, L. Carbone1, 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Pneumology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Pneumology, Hospital Universitario Valle de Hebron, Barcelona, Spain, 4Pneumology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 5Pneumology, Hospital Universitario Doce de Octubre, Madrid, Spain, 6Pneumology, Hospital Universitario La Fe, Valencia, Spain

6:35 PM

6:40 PM
(530) IgG2 Insufficiency before Heart Transplantation as a Risk Factor of Early Deadly Infections; L. Carbone1, J. Navarro1, I. Sousa1, E. Zatarain2, J. Fernandez-Yañez2, P. Muñoz3, M. Valerio3, E. Sarmiento1, 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Microbiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

6:45 PM
(531) Effective Reduction of Postoperative Infections through Routine Preoperative Decolonization with Chlorhexidine and Mupirocin Prior to Left Ventricular Assist Device Implantation; S. George1, R. Leasure2, A. McGovern1, H. Setidadi1, D. A. Horstmannshof1, 1INTEGRIS Baptist Medical Center, Oklahoma City, OK, 2College of Nursing, University of Oklahoma, Oklahoma City, OK

6:50 PM
(532) Novel Bacteriophage Therapy for Treatment of Ventricular Assist Device Infections; S. Aslam1, V. Pretorius1, E. Adler1, S. Lehman2, S. Morales2, A. Gaidamaka2, C. Furr2, F. Rosas2, K. Bishop-Lilly3, B. Biswas3, B. Sisson4, J. Fackler4, M. Trigg5, R. Schooley1, 1University of California, San Diego, San Diego, CA, 2AmpliPhi Biosciences, San Diego, CA, 3Naval Medical Research Center, Fort Detrick, MD, 4Adaptive Phage Therapeutics, Gaithersburg, MD

6:55 PM
(790) Role of Gallium-SPECT-CT in Predicting Outcomes of Patients with Ventricular Assist Device-Specific Percutaneous Driveline Infection; Y. Kimura1, O. Seguchi1, H. Mochizuki1, K. Iwasaki1, K. Toda1, Y. Kumai1, K. Kuroda1, S. Nakajima1, T. Watanabe1, Y. Matsumoto2, S. Fukushima3, M. Yanase1, T. Fujita1, J. Kobayashi2, N. Fukushima3, 1Department of Transplant Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan, 2Department of Cardiac Surgery, National Cerebral and Cardiovascular Centre, Osaka, Japan
7:00 PM  (534) The Impact of Biomarkers in Predicting the Response to CD34+ Cell Therapy in Non-Ischemic Dilated Cardiomyopathy Patients; G. Zemljic, M. Jaklic, A. Cerar, S. Frlija, G. Poglajen, B. Vrtovec. Advanced Heart Failure and Transplantation Centre, University Medical Centre Ljubljana, Ljubljana, Slovenia

7:05 PM  (535) LVAD Therapy Induces Changes in Myocardial Glucose Metabolism and Clock Genes; K. Dhar1, A. KC1, F. Qiu2, H. Basma1, J. Um1, D. Anderson1, B. Lowes1. 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Bio Statistics, University of Nebraska Medical Center, Omaha, NE

7:10 PM  (536) Sphingosine-1-Phosphate Receptor Agonist Fingolimod Reduces Myocardial Ischemia-Reperfusion Injury and Apoptosis Increasing Long-Term Left Ventricular Function after Heart Transplantation; A. Rungatscher, D. Linardi, A. Naseer, R. Mani, S. Hoxha, G. B. Luciani, G. Faggian. Division of Cardiac Surgery, Department of Surgery, University of Verona, Verona, Italy
MINI ORAL 16: Lung Transplant Outcomes
Room: Pacifica 10-12
Target Audiences: LTX, NHSAH, PHARM

Chairs: Jussi Tikkanen, MD, PhD, and Ramsey Hachem, MD

6:15 PM  
(537) Reconsidering Indication of Lung Transplantation for Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation; M. Noguchi, T. F. Chen-Yoshikawa, H. Kayawake, Y. Yamada, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto City, Japan

6:20 PM  

6:25 PM  
(539) CLAD Phenotypes Determined by Change in Spirometric Index Associate with Quantitative Image Analyses; S. S. Weigt1, G. Kim1, F. Abtin1, H. Jones2, Y. Shino1, A. DerHovanesian1, D. Sayah1, R. Saggar1, J. P. Lynch III1, J. A. Belperio1, D. J. Ross1, J. Goldin1. 1UCLA, Los Angeles, CA; 2Cedars Sinai, Los Angeles, CA

6:30 PM  
(540) Single versus Double Lung Transplantation for Chronic Obstructive Lung Disease(COPD); I. Timofte1, R. Vesselinov2, M. Terrin2, M. Wijesinha2, D. Kaczorowski2, R. Mandathil2, R. Wise3, A. Sternberg3, B. Griffith1, A. Iacono2. 1Pulmonary and Critical Care, UMMC, Baltimore, MD; 2UMMC, Baltimore, MD

6:35 PM  
(541) Risk Factors Associated with Airway Complications after Lung Transplantation; A. Bery1, P. Aguilar1, D. Byers1, D. Kreisef2, H. Kulkarni1, R. Nava2, V. Purri2, E. Trulock1, C. Witt2, R. Yusen1, R. Hachem1. 1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO; 2Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

6:40 PM  
(542) Pushing the Envelope in Single Lung Transplantation for Secondary Pulmonary Hypertension: Identifying an Upper Limit of Pressures; G. Sunagawa1, M. Kashem1, E. Leotta1, F. Kromah1, S. Brann1, J. Gomez-Abraham1, S. Keshavamurthy1, K. Minakata1, F. Cordova2, Y. Toyoda1, N. Shigemura1. 1Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA; 2Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA

6:45 PM  
(543) Predicting Survival for Lung Retransplantation Patients at One and Five Years; E. S. Clausen1, J. M. Weber2, M. L. Neely2, S. M. Palmer1. 1Pulmonary and Critical Care Medicine, Duke University, Durham, NC; 2Biostatistics and Bioinformatics, Duke University, Durham, NC

6:50 PM  
(544) Do the Pretransplant Use of Statins in a Recipient Reduce the Incidence of Primary Graft Dysfunction after Lung Transplant?; I. Bello1, E. Coll2, A. Sandiumenge3, L. Romero1, A. Jauregui1, J. Pérez1, J. Ochoa1, S. Peñafiel1, L. Sánchez1, F. Ascanio1, M. Montoya1, E. San Ginés1, J. Sacanell1, C. Berastequi1, C. Vázquez1, I. Los Arcos2, M. Deu1. 1Thoracic Surgery, Vall d’Hebron University Hospital, Barcelona, Spain; 2Organización Nacional de Trasplantes (ONT), Madrid, Spain; 3Transplant Coordination, Vall d’Hebron University Hospital, Barcelona, Spain; 4Intensive Unit Care, Vall d’Hebron University Hospital, Barcelona, Spain; 5Pulmonologist, Vall d’Hebron University Hospital, Barcelona, Spain; 6Anesthesiologist, Vall d’Hebron University Hospital, Barcelona, Spain

6:55 PM  
(545) Single and Double Lung Transplantation Have Equivalent Functional Status Outcomes at One Year; N. K. Ranganath1, T. C. Geraci1, J. Malas1, K. G. Phillips1, D. E. Smith1, B. E. Lonze2, M. B. Lesko3, L. F. Angel1, Z. N. Kon1. 1Cardiothoracic Surgery, NYU Langone Health, New York, NY; 2Surgery, NYU Langone Health, New York, NY; 3Medicine, NYU Langone Health, New York, NY

7:00 PM  
(546) Frailty is Associated with Greater Impairments in Health-Related Quality of Life after Lung Transplantation Than Before; N. A. Kolaitis1, A. Soong1, Y. Gao1, R. J. Shah1, A. Venado1, S. R. Hays1, J. Kukreja2, J. Golden1, L. E. Leard1, J. R. Greenland1, M. Kleinhenz1, P. P. Katz1, P. D. Blanc1, J. P. Singer1. 1Medicine, University of California, San Francisco, San Francisco, CA; 2Surgery, University of California, San Francisco, San Francisco, CA

(548) Less Delayed Chest Closure, Systemic Edema, and Postoperative Bleeding in Lung Transplantation Using ECMO, Compared with CPB; M. Ikeda¹, A. Aoyama¹, H. Oda¹, Y. Yokoyama¹, H. Kayawake¹, J. Tokuno¹, S. Ueda¹, F. Gochi¹, R. Okabe¹, M. Saito¹, J. Fukuyama², M. Okuda², K. Yamazaki³, K. Minatoya³, Y. Yamada¹, Y. Yutaka¹, D. Nakajima¹, M. Hamaji¹, A. Ohsumi¹, T. Menju¹, T. Sato¹, M. Sonobe¹, T. F. ChenYoshikawa¹, H. Date¹. ¹Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Medical Equipment, Kyoto University Hospital, Kyoto, Japan, ³Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
FRIDAY, APRIL 5, 2019
6:15 PM - 7:15 PM

MINI ORAL 17: LVAD Physiology: Effects on End Organs
Room: Pacifica 6
Target Audience: MCS

Chairs: Snehal R. Patel, MD, and Josef Stehlik, MD, MPH

6:15 PM  (561) Unexpected Contribution of Pulsatility to Pump Thrombosis; J. Engelman, K. Muthiah, P. Jain, D. Robson, P. Jansz, C. Hayward. Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia

6:20 PM  (562) CCR5 Expression is Lower in Women, and Mediates Sex-Based Differences in Post-LVAD Right Ventricular Failure; A. Nayak1, A. A. Morris1, C. M. Sciortino2, C. Neill1, R. L. Kormos2, C. McTiernan4, J. Larsen1, T. N. Bachman4, K. Hanley-Yanez1, D. M. McNamara2, M. A. Simon2. 1Emory University, Atlanta, GA, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pittsburgh Vascular Medicine Institute, Pittsburgh, PA

6:25 PM  (563) Impact of Left Ventricular Assist Device Placement on Chronic Kidney Diseases: A Multicenter Longitudinal Study; Y. C. Yalcin1, R. Muslem1, K. Veen1, R. J. Tedford2, B. Tomashitis2, Y. Al Najam1, A. Kilic1, B. Houston2, J. J. Brugts1, A. C. Constantinescu1, O. C. Manintveld1, S. Hsu4, A. J. Bogers1, K. Caliskan1, 1Thoraxcenter, Erasmus University, Rotterdam, Netherlands, 2Cardiology, University of South Carolina, Charleston, SC, 3Cardiothoracic Surgery, Johns Hopkins School of Medicine, Baltimore, MD, 4Cardiology, Johns Hopkins School of Medicine, Baltimore, MD

6:30 PM  (564) Elevated Shear Associated with MCS Devices Yields Unique Platelet Membrane Lipid Species: Pro-Thrombotic Agonists?; A. Sweedo1, L. M. Wise2, Y. Roka-Moia3, J. Sheriff4, D. Bluestein4, J. G. Purdy5, M. J. Slepian1. 1Biomedical Engineering, Arizona, Tucson, AZ, 2Immunobiology, University of Arizona, Tucson, AZ, 3Medicine, University of Arizona, Tucson, AZ, 4Biomedical Engineering, Stony Brook University, Stony Brook, NY


6:40 PM  (566) Metabolic Vasoreactivity in the Middle Cerebral Artery of Heart Failure Patients with and without Continuous-Flow Left Ventricular Support; R. Ji1, K. Akiyama2, F. Castagna1, A. Pinsino3, J. R. Cockcroft2, M. Yuzeffolskaya1, A. Garan1, V. K. Topkara1, M. T. Pineda4, H. Takayama1, K. Takeda4, Y. Naka4, P. C. Colombo1, B. McDonnell3, E. J. Stöhr3, J. Z. Willey4. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY, 3Physiology & Health, Cardiff Metropolitan University, Cardiff, CF5 2YB, United Kingdom, 4Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 5Neurology Stroke, Columbia University Medical Center, New York, NY

6:45 PM  (567) Incidence and Predictors of Long-Term Renal Function Deterioration after Implantation of a Centrifugal, Continuous-Flow Device for Bridge to Transplant; N. Kikuchi, A. Yoshimura, H. Hattori, A. Suzuki, T. Shiga, H. Niinami, N. Hagiwara, S. Nunoda. Tokyo Women's Medical University, Tokyo, Japan

6:50 PM  (568) Baseline LVAD Flow is an Important Risk for Hemoresponse to Blood Stream Infection in LVAD Patients with Fixed Cardiac Output; N. Bart1, S. Emmanuel2, D. Andresen3, K. Muthiah1, C. S. Hayward1. 1Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, 2Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, 3Infectious Disease, St Vincents Hospital, Sydney, Australia

6:55 PM  (569) What Happens to Right Ventricular Strain and Function Following Tricuspid Valve Repair in Patients Undergoing Implantation of a Left Ventricular Assist Device?; O. N. Kisliatsina1, A. S. Anderson1, J. D. Thomas1, J. D. Rich1, J. E. Wilcox1, E. E. Vorovich1, A. Zhou2, A. C. Andrei3, R. Harap1, P. M. McCarthy4, C. W. Yancy1, D. T. Pham1. 1Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2CTU, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Cardiac Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL

7:00 PM  (570) Cystatin C is Superior to Creatinine for Prediction of Adverse Events in Heart Failure Patients Undergoing LVAD Implant; A. Pinsino1, A. Gaudig2, E. A. Royzman2, M. B. Dominguez2, J. Radhakrishnan2,
7:05 PM  (571) Trends and Predictors of Acute Kidney Injury in Patients with and without Chronic Kidney Disease Undergoing Left Ventricular Assist Device Implantation: A Nationwide Inpatient Sample Analysis; S. Ranka1, M. Pahuja2, S. Mony3, T. Akhtar1, O. Chahab2, H. Abubakar4, A. Yassen5, T. Ando2, P. Alvarez5, L. Afonso5, A. Brisoulis5. 1John H Stroger Hospital of Cook County, Chicago, IL, 2Detroit Medical Center Wayne State University, Detroit, MI, 3University of South Florida, Tampa, FL, 4Detroit Medical Center Wayne State University, Chicago, IL, 5University of Iowa, Iowa City, IA

MINI ORAL 18: MCS: Right Heart Failure
Room: Coral Sea
Target Audience: MCS

Chairs: Cristiano Amarelli, MD, and Pavan Atluri, MD

6:15 PM  

6:20 PM  
**(550) The Effect of Right Ventricular Arterial Uncoupling on Mortality in Cardiogenic Shock;** V. Nguyen¹, J. McCabe¹, C. Mahr¹, T. Jones², M. Tan³, R. Cheng¹, T. Dardas¹, S. Masri¹. ¹Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA. ²Department of Medicine, Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT

6:25 PM  
**(1119) The Model for End-Stage Liver Disease Score and Survival after the Total Artificial Heart;** A. Jahangiri¹, M. Smallfield¹, A. Andreae², K. Desai², T. Johnson², J. Hillaryd², E. Sawey¹, J. Cook³, D. Tang¹, V. Kasirajan¹, K. B. Shah¹. ¹Pauley Heart Center, Virginia Commonwealth University, Richmond, VA. ²Virginia Commonwealth University School of Medicine, Richmond, VA. ³Internal Medicine, Virginia Commonwealth University, Richmond, VA. ⁴Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, TN

6:30 PM  
**(552) Timing of Right Heart Failure after Left Ventricular Assist Device is Associated with Survival after Heart Transplantation;** E. M. Senser¹, F. Cabezas², E. W. Grandin². ¹Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA. ²Cardiology, Beth Israel Deaconess Medical Center, Boston, MA

6:35 PM  
**(1117) Relationship between Length of Hospital Stay Post LVAD Implant and Survival: The Potential for Understanding a Less Sick Population;** S. Silvestry¹, J. Rogers², W. Cotts³, M. Slaughter³, S. Prasad³, M. Jacoski⁴, F. Pagani⁵, L. Stein⁶. ¹Cardiac Surgery, Florida Hospital Transplant Hospital, Orlando, FL. ²Cardiology, Duke University, Durham, NC. ³Cardiology, Advocate Christ Medical Center, Oak Lawn, IL. ⁴Cardiac Surgery, University of Louisville, Louisville, KY. ⁵Cardiac Surgery, University of Rochester, Rochester, NY. ⁶Medtronic, Framingham, MA.

6:40 PM  
**(1118) Safety of Mechanical Circulatory Support for Left Ventricular Non-Compaction: Single Center Experience;** A. Bansal¹, F. Akhtar¹, M. Bansal², S. Desai³, D. Jacks¹, Y. Gilliland¹. ¹Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA. ²Pathology, Ochsner Clinic Foundation, New Orleans, LA. ³Heart Transplant Med, Ochsner Clinic Foundation, New Orleans, LA

6:45 PM  
**(895) Tricuspid Regurgitation Predicts Late Onset Right Heart Failure after Left Ventricular Assist Device Implantation;** O. Gonzalez Fernandez, N. Bouzas Cruz, C. Ferrera Duran, A. Woods, N. Robinson-Smith, S. Tovey, G. Parry, K. Booth, G. MacGowan, S. Schueler. ¹Freeman Hospital, Newcastle upon Tyne, United Kingdom

6:50 PM  
**(556) Utilization of Combined Mechanical Circulatory Support Devices in Cardiogenic Shock: Insights from the National Inpatient Sample;** M. Pahuja¹, S. Ranka², S. Mony³, O. Chahab³, T. Ando³, H. Abubakar³, A. Yassen³, P. Alvarez³, L. Afonso³, A. Brisolides³. ¹Detroit Medical Center/Wayne State University, Detroit, MI. ²John H Stroger Hospital of Cook County, Chicago, IL. ³University of South Florida, Tampa, FL.

6:55 PM  

7:00 PM  
**(558) Temporary Mechanical Circulatory Support as a Bridge to Heart Transplantation: Insights from the UNOS Database;** A. K. Okoh¹, S. Fugar², M. Schultbies³, M. Russo¹, R. Karanam¹, M. Zucker¹, R. Yanagida¹,
M. Camacho¹, ¹RWJ Barnabas Health Newark Beth Israel Medical Center, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ, ²Division of Cardiology, Rush University Medical Center, Chicago, IL, ³RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ


7:10 PM (560) Direct Cavo-Pulmonary Stent Mounted Right Ventricular Assist Device; J. Park, P. Bonde. Yale School of Medicine, New Haven, CT
SUNRISE SYMPOSIUM 13: A Fork in the Road: How Can We Compare Interventional Therapies in CTEPH?
Room: Coral Sea
Target Audiences: CTEPH, PH

Chairs: Isabelle Opitz, MD, and Gustavo A. Heresi, MD

Session Summary: Interventional options for the treatment of CTEPH are expanding with BPA recently emerging as an option, in addition to PTE surgery. Yet, how can we compare the two therapies when there are differences in patient populations, procedures performed, and variability in reporting of risks and outcomes? This symposium will address these issues and facilitate discussion on how we can move toward more uniform reporting of outcomes.

7:00 AM  Challenges in Risk Stratification of CTEPH Patients  
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

7:15 AM  Therapeutic Outcomes: Beyond Mortality, What Are The Other Important Endpoints?  
Marion Delcroix, MD, University Hospital Leuven, Leuven, Belgium

7:30 AM  Balloon Pulmonary Angioplasty: Defining Essential Differences in Procedure Technique and Uniform Definitions of Complications  
Aiko Ogawa, MD, Okayama Medical Center, Okayama, Japan

7:45 AM  Can We Compare Apples to Oranges? How Can We Design a Meaningful Trial to Compare PTE and BPA?  
William Auger, MD, UCSD Medical Center, La Jolla, CA, USA
SUNRISE SYMPOSIUM 14: One Size Does Not Fit All: Personalized Medicine in Heart Transplantation
Room: Pacifica 7
Target Audiences: HF/HTX, PHARM

Chairs: Douglas Greig, MD, and Christina Aquilante, PharmD

Session Summary: Immunosuppression management balances the risks of under-immunosuppression and allograft rejection with the risks of over-immunosuppression and infection. Recent studies have demonstrated the efficacy of tacrolimus monotherapy, the utility of gene-expression profiling and the T-cell immune monitoring assay for minimization of immunosuppression. This symposium will serve to review approaches to minimization of immunosuppression as well as the pros and cons. A 15-min panel discussion with all speakers will conclude this session.

7:00 AM  The ABCs of Immunosuppression: Patient Profiles and Personalized Therapy
Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, USA

7:15 AM  The Nuts and Bolts of Tailoring Immunosuppression: Impact on Long-Term Issues in Heart Transplantation
Marisa G. Crespo-Leiro, MD, Hospital University A Coruña, La Coruña, Spain

7:30 AM  Minimizing Immunosuppression: Do All Roads Lead Home?
Satish Arora, MD, Oslo University Hospital, Oslo, Norway

7:45 AM  15-min Panel Discussion
SATURDAY, APRIL 6, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 15: Lung Transplant Candidate Selection: Challenging Cases
Room: Pacifica 10-12
Target Audiences: LF/LTX, ID, NHSAH, PEDS

Chairs: Edward Cantu, III, MD, and Mark Benzimra, MD

Session Summary: Guidelines for lung transplant candidacy were last updated in 2014 and include significant numbers of absolute and strong relative contraindications. In the last 5 years there has been a dramatic increase in the willingness of transplant programs to push the boundaries of transplant candidacy and a concomitant increase in the published literature regarding extended criteria recipients. This symposium focuses on several potential avenues for increased lung transplant candidate access. A 15-min panel discussion with all speakers will conclude this session.

7:00 AM  Is HIV a Contra-Indication for Lung Transplant?
Paolo Grossi, MD, PhD, University of Insubria, Varese, Italy

7:15 AM  Scleroderma: The Ability to Swallow is Optional
Maria M. Crespo, MD, University of Pennsylvania, Philadelphia, PA, USA

7:30 AM  So Many Antibodies...
Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

7:45 AM  15-min Panel Discussion
SUNRISE SYMPOSIUM 16: Fragility: Not Necessarily Failure
Room: Pacifica 6
Target Audiences: NHSAH, HF/HTX, LF/LTX, MCS

Chairs: Louise M. Fuller, PT, and Rose DeRosa, PA-C

Session Summary: A multi-disciplinary approach to the assessment and treatment of a complex frail patient will be highlighted. A case study describing a patient with end stage disease will be presented who is experiencing nutritional, cognitive, and mental health concerns. Individual talks addressing these issues will be from a physician, psychologist, and dietitian. The symposium will conclude by involving the audience in an open discussion on issues raised in one's clinical experience with frail patients.

7:00 AM  
*Dying, Not Necessarily Doomed*  
Oscar Gonzalez Fernandez, MD, Hospital Universitario La Paz, Madrid, Spain

7:15 AM  
*Cognitive Deficits, Not Necessarily Crazy*  
Patrick J. Smith, PhD, MPH, Duke University Medical Center, Durham, NC, USA

7:30 AM  
*Withered, Not Necessarily Wasted*  
Kirsten Diegel, RD, LDN, Temple University Hospital, Philadelphia, PA, USA

7:45 AM  
*15-min Panel Discussion*
SATURDAY, APRIL 6, 2019
7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 17: A Brand-New Day: The New Normal in Pediatric Thoracic Transplantation
Room: Pacifica 1-2
Target Audiences: PEDS, LF/LTX, PATH

Chairs: Melinda P. Solomon, MD, FRCPC, and Marc G. Schecter, MD

Session Summary: With improvements in the care of children with cystic fibrosis and pulmonary hypertension, the demographics of pediatric lung and heart lung transplantation are changing. This symposium will focus on the new demographics of pediatric lung and heart lung transplant recipients, the new challenges, and the impacts of these changes on pediatric transplant programs.

7:00 AM  The Changing Pediatric Lung Transplant Recipient
Samuel B. Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

7:15 AM  Q&A

7:20 AM  Childhood Interstitial Lung Disease (ChiLD) and Transplant
Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

7:35 AM  Q&A

7:40 AM  When One is Not Enough - Indications for Heart Lung Transplant
Maria C. Gazzaneo, MD, Texas Children's Hospital, Houston, TX, USA

7:55 AM  Q&A
**SUNRISE SYMPOSIUM 18: So Your Patient is on ECMO ... Now What? Considerations for Drug Dosing and Anticoagulation in ECMO**

**Room:** Pacifica 3-5  
**Target Audiences:** PHARM, MCS

**Chairs:** Patricia Uber, PharmD, and Charles Hoopes, MD

**Session Summary:** ECMO presents unique drug dosing and medication management challenges. This symposium will discuss the approach to optimal pharmacotherapy management for ECMO patients with a focus on anti-infectives and anticoagulation. Anecdotes and clinical pearls for ECMO in special populations will also be discussed.

7:00 AM  
*Keeping Things Moving: Anticoagulation on ECMO*
Christopher Michaud, PharmD, BCPS, Spectrum Health, Grand Rapids, MI, USA

7:15 AM  
*Q&A*

7:20 AM  
*What's My Vd Again? Drug Dosing on ECMO with a Focus on Anti-Infectives*
Haifa Lyster, MSc, Royal Brompton, Middlesex, United Kingdom

7:35 AM  
*Q&A*

7:40 AM  
*ECMO and What Else? Approach to Management of ECMO in Special Populations*
Konrad Hoetzenecker, MD, PhD, Medical University of Vienna, Vienna, Austria

7:55 AM  
*Q&A*
SATURDAY, APRIL 6, 2019
8:00 AM - 10:00 AM

PLENARY SESSION
Room: Pacifica 6
Target Audience: ALL

Chairs: Stuart C Sweet, MD, PhD, and Stephan M. Ensminger, MD, DPhil

8:00 AM  
Awards Presentations
Kathleen L Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA

8:30 AM  
What's Hot, What's New: Basic Science Overview
Stijn E Verleden, PhD, KU Leuven, Leuven, Belgium

8:50 AM  
What's Hot, What's New: Clinical Science Overview
Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

9:10 AM  
PRESIDENT'S DEBATE: Resource Limits: It's Time to Abandon Retransplantation (PRO)
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

9:30 AM  
PRESIDENT'S DEBATE: Resource Limits: It's Time to Abandon Retransplantation (CON)
Andrew J Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom

9:50 AM  
Debate Rebuttal (PRO)
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

9:55 AM  
Debate Rebuttal (CON)
Andrew J Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom
SESSION 72 (SYMPOSIUM): Seeing the Light: Antibodies in Thoracic Transplantation
Room: Pacifica 3-5
Target Audiences: BSTR, HF/HTX, LF/LTX, PHARM

Chairs: Jon A. Kobashigawa, MD, and Edward Horn, PharmD, BCPS

Session Summary: The goal of this symposium is to provide the audience with a deeper understanding of antibody-mediated mechanisms and potential downstream consequences of antibodies in transplantation. Presentations will discuss the basic science of immunology, the role of donor specific antibodies and emerging management strategies. A 15-min panel discussion with all speakers will conclude this session.

10:15 AM The Pre-Transplant Alphabet Soup – MFI, C1Q, HLA
Christine Falk, MD, Hannover Medical School, Hannover, Germany

10:30 AM Seeing Ghosts? The Role of Non-DSA and Non-HLA in the Transplant Recipient
Antoine Roux, MD, Hôpital Foch, Paris, France

10:45 AM The Needles in the Haystack: Diagnostic Challenges in Antibody-Mediated Rejection
Agnieszka Ciarka, MD, PhD, Catholic University of Leuven, Leuven, Belgium

11:00 AM The Transplant Toolbox: Dealing with DSA Now and in the Future
Miae Kim, PharmD, Brigham & Women's Hospital, Boston, MA, USA

11:15 AM DEBATE: Photopheresis is Useful for Rejection Management (PRO)
Peter Jaksch, MD, Medical University of Vienna, Vienna, Austria

11:30 AM DEBATE: Photopheresis is Useful for Rejection Management (CON)
Michael Shullo, PharmD, University of West Virginia, Morgantown, WV, USA

11:45 AM 15-min Panel Discussion
SESSION 73 (ORAL): Life on the Cutting Edge: CTEPH and Surgical Management of Pulmonary Hypertension  
Room: Pacifica 1-2  
Target Audiences: CTEPH, PH

Chairs: Andrea M D'Armini, and Michael M. Madani, MD

10:15 AM  
(294) Preoperative C-Reactive Protein Predicts Early Postoperative Outcomes after Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension; J. Arthur¹, M. Amsallem¹, J. Guihaire², F. Haddad³, L. Lamrani¹, S. Feuillet¹, F. Stephan⁴, X. Jais⁵, M. Humbert⁷, G. Simonneau¹, O. Mercier⁴, E. Fadel⁴. ¹Research and Innovation Unit, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, ²Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, ³Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, ⁴Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, ⁵Advanced Care Unit, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, ⁶Respiratory Medicine, Kremlin Bicêtre Hospital, Paris Sud University, Kremlin Bicêtre, France, ⁷Respiratory Medicine, Kremlin Bicêtre Hospital, Paris Sud University, Kremlin Bicêtre, France

10:30 AM  
(295) Right Ventricular Reverse Remodeling after Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension; S. Guimaron¹, J. Guihaire¹, M. Amsallem¹, A. Potier², A. Amatgauberville³, L. Mobile⁴, M. Isorni³, L. Lamrani¹, E. Fadel⁴, O. Mercier⁵. ¹Research and Innovation Unit Research Lab, Marie Lannelongue Hospital, Le Plessis Robinson, France, ²Marie Lannelongue Hospital, Le Plessis Robinson, France, ³Adult Cardiac Surgery, Marie Lannelongue Hospital, Le Plessis Robinson, France, ⁴Respiratory Medicine, Marie Lannelongue Hospital, Le Plessis Robinson, France, ⁵Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France

10:45 AM  
(296) Outcome after Pulmonary Endarterectomy for Segmental Chronic Thromboembolic Pulmonary Hypertension; M. de Perrot¹, K. McRae¹, L. Donahoe¹, M. McInnis¹, J. Thenganatt¹, A. Bykova¹, K. Tan¹, J. Moric¹, S. Mak², J. Granton¹. ¹Toronto General Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada

11:00 AM  
(297) Pulmonary Endarterectomy in CTEPH: The Pavia Experience; M. Pin, A. Sciortino, A. Celentano, L. J. Masiglat, E. Borrelli, V. N. Merli, B. Vanini, C. Klersy, G. Silvaggio, C. Monerossi, A. M. D'Armini. Policlinico San Matteo, Policlinico San Matteo, Pavia, Italy

11:15 AM  
(298) Characteristics and Management of Patients Following Pulmonary Embolism: A Focus on Screening for Chronic Thromboembolic Pulmonary Hypertension; M. Kanwar¹, M. Cole², M. Gauthier-Loiselle³, A. M. Manceur², C. Lickert², M. Greenberg³, P. Lefebvre³, W. Drake⁴, R. Benza³. ¹Allegheny General Hospital, Pittsburgh, PA, ²Actelion Pharmaceuticals Inc., San Francisco, CA, ³Analysis Group Inc., San Francisco, CA

11:30 AM  
(299) Correlation of Surgical and Computed Tomography Pulmonary Angiographic Level of Disease in Chronic Thromboembolic Pulmonary Hypertension; M. C. McInnis¹, M. de Perrot², D. C. Wang³, L. Donahoe³, K. T. Tan¹, J. Kavanagh¹. ¹Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ²Department of Surgery, University of Toronto, Toronto, ON, Canada

11:45 AM  
(300) Medical and Surgical Management of ECLS as Bridge to Recovery and Transplantation for Pulmonary Hypertension: A Large Single Center Experience; E. B. Rosenzweig¹, W. D. Gannon², C. L. Agerstrand³, D. Abrams³, D. Brodie³, M. D. Bacchetta³. ¹Pediatrics and Medicine, Columbia University Medical Center - NYP, New York, NY, ²Surgery, Vanderbilt University Medical Center, Nashville, TN, ³Medicine, Columbia University Medical Center - NYP, New York, NY
10:15 AM  
(301) Costs Associated with the First Clinical Trial Evaluating the Safety and Efficacy of the Thoracotomy Approach for Implantation of a Small Intrapericardial Centrifugal LVAD; N. A. Mokadam
1, E. McGee
2, G. Wieselthaler
3, D. T. Pham
4, S. Bailey
5, G. Pretorius
6, T. Boeve
7, E. Ismyrloglou
8, M. Struerer
9. 1The Ohio State University Wexner Medical Center, Columbus, OH, 2Loyola University Medical Center, Maywood, IL, 3University of California San Francisco, San Francisco, CA, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Allegheny Health Network, Pittsburgh, PA, 6University of California San Diego, La Jolla, CA, 7Spectrum Health, Grand Rapids, MI, 8Medtronic, Maastricht, Netherlands, 9Newark Beth Israel Medical Center, Newark, NJ

10:45 AM  
(303) Cost Effectiveness of Using Hepatitis C Virus (HCV)-Viremic Hearts for Transplantation into HCV-Negative Recipients; C. Logan
1, I. Yumul
2, S. Aslam
3, N. Martin
4. 1University of California, San Diego, San Diego, CA, 2University of Iowa, Iowa City, IA

11:15 AM  

11:45 AM  
(307) Commercial Airlines as a Viable, Safe and Cost Effective Way for Transporting the Donor Hearts across the Country: Single Center Experience; K. Bala Krishnan
1, K. Suresh Rao
2, M. K. Tanguturu
2, M. Rajam
1, A. Aravind
2, J. Dushyanthan
2, R. Subramanian
2, V. Ramanan
2. 1Cardiac Surgery, Fortis Malar Hospital, Chennai, India, 2Cardiac Anesthesia & Critical Care, Fortis Malar Hospital, Chennai, India
SESSION 75 (SYMPOSIUM): Cardiac Allograft Vasculopathy: Have Hope, Ye Who Enter
Room: Pacifica 7
Target Audience: HF/HTX

Chairs: Kyung-Hee Kim, MD, PhD, and Stephan Ensminger, MD, DPhil

Session Summary: This symposium will focus on changing disease epidemiology and outcomes; role of noninvasive surveillance, particularly novel approaches such as PET; advanced coronary imaging for early CAV including intracoronary imaging, plaque characterization and intracoronary haemodynamics; pharmacologic therapy including mTORi and non-immune based strategies such as antiplatelet and lipid lowering therapies, and end with a captivating debate on the role of revascularization and defibrillators for CAV treatment. A 10-min panel discussion with all speakers will conclude this session.

10:15 AM  Shifting CAV Landscape: Definitions, Epidemiology, and Pathophysiology
Michael Pham, MD, California Pacific Medical Center, San Francisco, CA, USA

10:30 AM  Resisting Invasion: Traditional and Novel Non-Invasive Imaging Surveillance for CAV
Sharon Chih, MBBS, PhD, University of Ottawa Heart Institute, Ottawa, ON, Canada

10:45 AM  New Tricks for an Old Dog: Intracoronary Imaging and Hemodynamics - A New Classification for CAV?
Tor SClemmensen, MD, Aarhus University Hospital, Skejby, Denmark

11:00 AM  If I Knew Then What I Know Now: Old and New Drugs for CAV Prevention and Regression
Yael Peled, MD, Sheba Medical Center, Tel Hashomer, Israel

11:15 AM  CASE PRESENTATION: Young Man s/p AMR Treatment Who Later Died Suddenly - What Should Have Been Done?
Livia Goldraich, MD, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

11:20 AM  DEBATE: Preventing the Invasion of the Body Snatchers: All Patients with CAV Should Have Revascularization and Defibrillators (PRO)
Howard Eisen, MD, Pennsylvania College of Medicine, Hershey, PA, USA

11:35 AM  DEBATE: Preventing the Invasion of the Body Snatchers: All Patients with CAV Should Have Revascularization and ICDs (CON)
Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, USA

11:50 AM  10-min Panel Discussion
SESSION 76 (SYMPOSIUM): Location, Location, and Allocation: Worldwide Application of Broader Sharing in Lung Transplant
Room: Pacifica 10-12
Target Audiences: LF/LTX, PH

Chairs: Duane M Davis, MD, and James L. Lordan, MB, FRCP

Session Summary: Lung allocation in the United States recently moved to broader geographic sharing. This symposium will review lung allocation throughout the world as it relates to this concept. Topics will include an overview of international lung allocation, the US lung allocation system, review of modeled data on this principle, updated US data available since policy implementation, and a review of this concept as it affects allocation over greater distances in Canada and Australia.

10:15 AM  Lung Allocation Systems: Similarities and Differences
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

10:30 AM  Q&A

10:35 AM  Changes in US Lung Allocation: Support for Broader Sharing
Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH, USA

10:50 AM  Q&A

10:55 AM  Implementation of 250 Nautical Miles as the First Region of Lung Allocation in the US: Early Results
Kevin Chan, MD, University of Michigan, Ann Arbor, MI, USA

11:10 AM  Q&A

11:15 AM  Effects of Distance on Lung Allocation in Australia/New Zealand
Dan Chambers, MBBS, FRACP, The Prince Charles Hospital, Brisbane, Australia

11:30 AM  Q&A

11:35 AM  Effects of Distance on Lung Allocation in Canada
Alim Hirji, MD, University of Alberta, Edmonton, AB, Canada

11:50 AM  Q&A
SATURDAY, APRIL 6, 2019
10:15 AM - 12:00 PM

SESSION 77 (ORAL): Thicker than Water? Bleeding and LVADs
Room: Pacifica 6
Target Audience: MCS

Chairs: Emil Najjar, MD, and Ulrich Jorde, MD

10:15 AM (308) Prospective Validation of the First Endoscopic Management Algorithm for Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices; J. Axelrad1, A. S. Faye2, A. Pinsino3, B. Cagliostro3, A. Thanataveerat4, L. Effner1, F. M. Pineda1, A. R. Garan1, H. Takayama4, K. Takeda5, Y. Naka5, P. C. Colombo5, T. Gonda2, M. Yuzefpolskaya1. 1Gastroenterology, NYU Langone, NYC, NY, 2Gastroenterology, Columbia University Medical Center, NYC, NY, 3Cardiology, Columbia University Medical Center, NYC, NY, 4Biostatistics, Columbia University Medical Center, NYC, NY, 5CT Surgery, Columbia University Medical Center, NYC, NY


11:00 AM (311) Prediction of GIB Using R², CHA²DS²; VASc Risk Score; A. Critsinelis1, H. Lamba1, S. Chatterjee1, F. Cheema1, A. Civitello1, R. Delgado1, A. Nair1, A. Shafii2, G. Loor3, T. Rosengart1, O. Frazier1, J. Morgan1. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, TX

11:15 AM (312) Experimental Venous Congestion Causes Peripheral Release of Angiopoietin-2 and Tissue Necrosis Factor-a - A New Insight into the Pathophysiology of Gastrointestinal Bleeding in CF-LVAD Patients; P. C. Colombo1, F. Castagna1, D. Onati1, S. M. Laganà2, W. Y. Ka1, E. A. Rozyzman1, A. S. Faye2, J. E. Axelrad4, T. A. Gonda3, A. R. Garan5, H. Takayama6, K. Takeda6, Y. Naka6, G. Parkis7, M. Yuzefpolskaya1, R. Demmer8. 1Cardiology, Columbia University Medical Center, New York, NY, 2Pathology & Cell Biology, Columbia University Medical Center, New York, NY, 3Digestive & Liver Diseases, Columbia University Medical Center, New York, NY, 4Gastroenterology, New York University, New York, NY, 5Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, 6Surgery, Columbia University Medical Center, New York, NY, 7Gastroenterology, Columbia University Medical Center, New York, NY, 8Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

11:30 AM (313) Digoxin Restores Angiogenic Equilibrium in CF-LVAD Patients; S. Vukelic1, S. Patel1, P. Vlismas1, T. Chinnadurai1, D. Sims1, S. Murthy1, J. Shin1, O. Saeed1, N. Sibinga2, S. Forest3, D. Goldstein2, U. Jorde1. 1Cardiology, Montefiore MC AECOM, New York, NY, 2Cardiology, AECOM, New York, NY, 3Cardiothoracic & Vascular Surgery, Montefiore MC AECOM, New York, NY

11:45 AM (314) Gastrointestinal Angiodysplasia is Part of the Vascular Pathophysiology of Advanced Heart Failure; S. R. Patel, S. Vukelic, J. Kwah, T. Chinnadurai, O. Saeed, D. Goldstein, U. P. Jorde. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
SESSION 78 (ORAL): The Beginning of the End in Lung Transplantation: PGD, AMR and CLAD
Room: Pacifica 3-5
Target Audiences: BSTR, LTX, PEDS, PATH

Chairs: Bart M. Vanaudenaerde, MSc, PhD, and Stephen C Juvet, MD, PhD, FRCPC

12:15 PM (320) Development of a New Local Therapeutic Approach for BOS: Efficacy of Imatinib Loaded -antiCD44 Coated Gold Nanoparticles In Vitro and In Vivo; F. Meloni1, R. Di Paola2, P. Morbini3, L. Pandolfi4, V. Frangipane4, E. Gugliandolo2, E. Cova4, M. Colombo6, D. Proserpi6, P. Vitulo7, G. Ferrarri6, R. Fusco8, C. Pacini8, R. Siracusa2, S. Cuzzocrea2. 1Internal Medicine, University of Pavia, Pavia, Italy, 2Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy, 3Molecular Medicine, University of Pavia, Pavia, Italy, 4Respiratory Diseases, IRCCS San Matteo Foundation, Pavia, Italy, 5Pathology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 6Department of Biotechnology and Bioscience, University of Milano Bicocca, Milan, Italy, 7Respiratory Disease Unit, IRCCS ISMETT, Palermo, Italy, 8Pathology Section Department of Molecular Medicine, University of Pavia, Pavia, Italy

12:30 PM (316) B Cells Drive iBALT Formation in a Mouse Model of Chronic Lung Allograft Dysfunction; N. F. Smirnova1, T. M. Conlon2, C. Morrone2, A. O. Yildirim2, O. Eickelberg1. 1PSCCM, University of Colorado - Anschutz Medical Campus, Aurora, CO, 2Comprehensive Pneumology Center, Munich, Germany

12:45 PM (317) Linking CLAD in Lung Transplant Recipients after 3 Years Follow Up with Transplant Arteriosclerosis in Humanized Mice; T. Siemen1, A. Knöfel1, F. Ius1, J. Salmon1, W. Sommer1, M. Avsar1, R. Poyanmehr1, C. Kühn1, C. Falk2, I. Tudorache1, A. Haverich1, G. Warnecke1. 1Hannover HTTG, Hannover, Germany, 2Hannover Transplant Immunology, Hannover, Germany

1:00 PM (318) Pulmonary Antibody-Mediated Rejection (AMR) Accelerates Aging-Evidence from Whole Genome DNA Methylation Sequencing; S. Agbor-Enoh1, F. Seifuddin1, M. Pirooznia2, M. Jang1, H. Valantine1. 1Genomic Research Alliance for Transplantation (GRAfT), Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD, 2Genomic Research Alliance for Transplantation (GRAfT), Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, MD

1:15 PM (319) Increased NKG2C+ Natural Killer Cells in Bronchoalveolar Lavage Precede CMV Viremia and Are Associated with CLAD or Death in Lung Transplant Recipients; D. R. Calabrese1, T. Chong1, A. S. Wang1, J. P. Singer1, M. Gottschall1, S. R. Hays1, J. A. Golden1, J. Kukreja2, Q. Tang1, J. R. Greenland4. 1Department of Medicine, University of California San Francisco, San Francisco, CA, 2Department of Clinical Lab Medicine, University of California San Francisco, San Francisco, CA, 3Department of Surgery, University of California San Francisco, San Francisco, CA, 4Medical Service, VA Health Care System, San Francisco, CA

1:30 PM (7) A Novel Injury Site-Targeted Complement Inhibitor Which Protects against Lung Transplant Ischemia Reperfusion Injury; C. Li1, K. Patel1, P. Allen2, Z. TU1, J. Kilkenney1, C. Wallace1, S. Nadig1, S. Tomlinson1, C. Atkinson1. 1Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC, 2Department of Surgery, Medical University of South Carolina, Charleston, SC

1:45 PM (321) Receptor Tyrosine Kinase Inhibitor Nintedanib as Treatment Option in Bronchiolitis Obliterans after Airway Transplantation; C. Heim1, J. Mauer1, A. Kuckhahn1, J. Distler1, B. Spriewald1, M. Ramspger-Gleixner1, M. Weyand7, S. M. Ensminger2. 1University of Erlangen, Erlangen, Germany, 2University of Luebeck, Luebeck, Germany
SESSION 79 (ORAL): Go with the Flow: Hemodynamic Guiding Therapies in Heart Failure
Room: Pacifica 1-2
Target Audiences: HF, HTX

12:15 PM (322) PH in Heart Transplant (HT) Candidates: Don’t Look at Ghosts, Search the Evil in the Details; M. Masetti, A. Moretta, A. Russo, F. Dardi, M. Palazzini, S. Martin Suarez, A. Loforte, F. Grigioni, N. Galié, L. Potena. Cardiovascular Department, Bologna University Hospital, Bologna, Italy


12:45 PM (324) Association between Central Hemodynamics and Glomerular Filtration Rate in Patients with Advanced Heart Failure; E. Bobbio, S. Esmaily, E. Bollano, S. Bartfay, P. Dahlberg, G. Dellgren, K. Karason. 1Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden

1:00 PM (325) Use of Remote Dielectric Sensing (ReDS) as Point-of-Care Testing Following Heart Failure Hospitalization and Risk of 30-Day Readmission; M. H. Barghash, A. Lala, G. Giustino, A. Parikh, J. Ullman, S. S. Mitter, S. Konje, B. Keith, N. Moss, D. Mancini, M. G. Trivieri, S. Pinney. 1The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, NY, 2Department of Medicine, Mount Sinai Hospital, New York, NY, 3Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY


1:30 PM (327) Cardiac Autonomic Nerves Stimulation Improves Hemodynamics: A Pilot Study in Advanced Heart Failure Patients; T. Diaz, C. Marin y Kall, J. Boehmer, M. Cowie, A. Mebazaa, M. Cuchiara. 1Pacifica Salud Hospital Punta Pacífica, Panama City, Panama, 2International Medicine Institute, University of Miami, Miami, FL, 3Penn State Hershey Heart and Vascular Institute, Hershey, PA, 4National Heart and Lung Institute, Imperial College London, London, United Kingdom, 5University Paris Diderot, Paris, France, 6NeuroTronik Inc, Durham, NC

1:45 PM (328) Cell Therapy is Associated with Reduction of Functional Mitral Regurgitation in Cardiomyopathy Patients with High End-Diastolic Volumes; S. Frljak, G. Zemljic, G. Poglajen, A. Cerar, M. Jaklic, F. Haddad, B. Vrtovec. 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Stanford Cardiovascular Institute, Stanford, CA
SESSION 80 (ORAL): Heart Transplant Long-Term Outcomes: In It for the Long Haul
Room: Pacifica 7
Target Audiences: HTX, PATH

Chairs: Eugene C DePasquale, MD, and Marta Farrero Torres, MD, PhD


12:30 PM  (330) HLA-G 14BP Polymorphism Matching Protects against Development of Post-Transplant Malignancy Following Heart Transplantation; M. B. Adamson¹, R. V. Ribeiro¹, F. Yu¹, J. Lazarte¹, K. Runeckles², C. Manlihot², V. Rao¹, D. Delgado¹. ¹Peter Munk Cardiac Centre, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada

12:45 PM  (331) The Impact of New Onset Post-Transplant Diabetes on Outcomes after Heart Transplantation; A. R. Vest¹, W. S. Cherikh², S. M. Noreen², J. Stehlik³, K. K. Khush⁴. ¹Tufts Medical Center, Boston, MA, ²United Network for Organ Sharing (UNOS), Richmond, VA, ³University of Utah, Salt Lake City, UT, ⁴Stanford University, Stanford, CA

1:00 PM  (332) Severe Acute Kidney Injury after Cardiac Transplantation is a Marker of Poor Early Outcome and Impacts on Late Renal Function - A UK Cohort Study; L. Wang¹, T. Wang², S. N. Rushton³, A. J. Fisher¹, N. S. Sheerin¹, J. H. Dark¹. ¹Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ²Univeristy College London, London, United Kingdom, ³Statistics and Clinical Studies, National Health Service Blood and Transplant, Bristol, United Kingdom, ⁴Renal Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom


1:30 PM  (439) Heart Transplantation Survival and the Use of Traumatically Brain-Injured Donors; Y. D. Barac, O. Jawitz, J. Krapper, J. Schroder, M. Daneshmand, C. Patel, C. Milano, M. Hartwig. Duke University Medical Center, Durham, NC

1:45 PM  (335) Association between AT1R Autoantibody with Adverse Outcomes in Patients Bridged to Heart Transplant Using Continuous Flow Ventricular Assist Device; V. Q. Chau¹, K. Nicholson¹, M. Flattery¹, F. McDougan², K. Desai¹, P. Uber¹, G. Gupta¹, P. Kimball², K. B. Shah¹. ¹Division of Cardiology and Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ²Division of Transplant Surgery, Virginia Commonwealth University, Richmond, VA.
SESSION 81 (ORAL): Primary Graft Dysfunction and Acute Lung Rejection
Room: Coral Sea
Target Audiences: LF/LTX, BSTR, PATH

Chairs: Alejandro M Bertolotti, MD, and MD Aigner, MD

12:15 PM  
(336) The New View of Pre-Lung Transplant Determinants for Predicting De Novo Donor Specific Antibody and Transplant Rejection: A. Zhang¹, D. Thomas¹, J. Allen¹, K. McCurry², M. Budev², ¹Allograft Laboratories, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH

12:30 PM  
(337) Inflammatory Events Precede Development of De Novo DSA after Lung Transplantation: J. L. Ponor¹, A. Jackson², A. Cochrane³, I. Tunc⁴, M. Jang⁵, J. Mathew⁶, N. De’Emilio⁷, H. I. Luikart⁸, I. Timofe⁹, A. Brown¹⁰, P. Shah¹¹, S. Nathan¹¹, A. Iacono¹², J. B. Orens¹³, C. Marboe¹⁴, G. J. Berry¹⁵, K. Khush¹⁶, H. Valantine¹³, S. Agbor-Enoh¹⁷. ¹Medicine, Johns Hopkins SoM, Baltimore, MD, ²Medicine-Immunogenetics and Transplantation Immunology, Johns Hopkins Univ, Baltimore, MD, ³Medicine, Inova Fairfax Hospital, Fairfax, VA, ⁴Div of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD, ⁵Palm and Critical Care, Johns Hopkins SoM, Baltimore, MD, ⁶Div of Cardiology, Stanford Univ SoM, Stanford, CA, ⁷Palm and Critical Care Medicine, Univ of Maryland Medical Center, Baltimore, MD, ⁸Inova Heart and Vascular Institute, Inova Fairfax Hospital, Fairfax, VA, ⁹Palm and Critical Care Medicine, Johns Hopkins SoM, Baltimore, MD, ¹⁰Pathology, New York Presbyterian Univ Hospital of Cornell and Columbia, New York, NY, ¹¹Pathology, Stanford Univ SoM, Palo Alto, CA, ¹²Cardiology, Stanford Univ SoM, Palo Alto, CA, ¹³Div of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD, ¹⁴Div of Intramural Research, National Heart, Lung, and Blood Institute-NIH, Bethesda, MD

12:45 PM  
(338) Transcriptome Profiles of the Circulating Extracellular Vesicles in Acute Lung Allograft Rejection: S. Joo¹, M. Pulka², R. Krebs³, P. Mattila³, M. Kankaenen³, K. Dhaygude⁴, E. Rouvinen⁴, P. Ravio³, K. Lemström⁵. ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland, ²EV core, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ³Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ⁴Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland

1:00 PM  
(339) Profiling Pre-Existing Autoantibodies for Prediction of Primary Graft Dysfunction: V. Kaza¹, C. Zhu¹, L. Feng¹, A. Reddy², L. Terada¹, M. Mohanka¹, C. Lacelle³, S. Bollineni¹, A. Banga¹, J. Mullins¹, F. Torres¹, Q. Li¹. ¹Internal Medicine, UT Southwestern Medical Center, Dallas, TX, ²Internal Medicine, Southwest Pulmonary Associates, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX

1:15 PM  
(340) Correlation between Early B and NK Cell Frequencies and in Relation to CLAD Development and PGD 24h after Lung Transplantation: A. Knoeffel¹, F. Ius¹, T. Nakagiri¹, J. Salaman¹, T. Siemeni¹, W. Sommer¹, C. Kuehn¹, M. Avas¹, T. Wette¹, I. Tudorache¹, C. S. Falk¹, A. Haverich¹, G. Warnecke¹, ¹HTTG, MHH, Hannover, Germany, ²Pneumology, MHH, Hannover, Germany, ³Transplant Immunology, MHH, Hannover, Germany

1:30 PM  
(341) miRNAs in Lung Transplantation: Small Things That Make Big Differences: V. Vaira¹, S. V. Musso², A. Terrasi¹, G. Gaudioso¹, S. Ferreo¹, V. Rossetti¹, L. C. Morlacchi¹, D. Tosi¹, A. Palleschi¹. ¹Università degli Studi di Milano, Milan, Italy, ²Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, ³Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy

1:45 PM  
(342) Risk Factors for Primary Graft Dysfunction in Patients with Cystic Fibrosis Receiving Lung Transplants: J. A. Martin¹, M. K. Pertoues¹, E. Cantu², D. J. Lederer³, L. Snyder³, A. Weinacker³, J. B. Orens⁴, P. D. Shah⁵, V. N. Lama⁵, J. McDyer⁵, K. M. Wille⁶, C. A. Hage⁷, J. Singer¹¹, L. B. Ware¹², M. Oyster¹, M. Brown¹, J. D. Christie¹, J. M. Diamond¹. ¹Medicine, University of Pennsylvania, Philadelphia, PA, ²Surgery, University of Pennsylvania, Philadelphia, PA, ³Medicine, Columbia University, New York, NY, ⁴Medicine, Duke University, Durham, NC, ⁵Medicine, Stanford University, Palo Alto, CA, ⁶Medicine, Johns Hopkins University, Baltimore, MD, ⁷Medicine, University of Michigan, Ann Arbor, MI, ⁸Medicine, University of Pittsburgh, Pittsburgh, PA, ⁹Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Medicine, Indiana University, Indianapolis, IN, ¹¹Medicine, University of California San Francisco, San Francisco, CA, ¹²Medicine, Vanderbilt University, Nashville, TN
SESSION 82 (ORAL): Donor Lung Management: Can We Do Better?
Room: Pacifica 10-12
Target Audiences: LF/LTX, EEP, PATH

Chairs: Sara J. Shumway, MD, and Ahmed Menaouar, PhD

12:15 PM (343) High Calculated Panel Reactive Antigen (cPRA) is Associated with Decreased Rates of Transplantation and Increased Waitlist Mortality in Lung Transplantation: A UNOS/OPTN Registry Analysis; Y. D. Barac, M. Mulvihill, O. Jawitz, J. Haney, J. Klapper, M. Daneshmand, M. Hartwig. Duke University Medical Center, Durham, NC


12:45 PM (345) Despite Growing Utilization, the Use of Public Health Service Increased Risk Donors for Lung Transplantation is Not Associated with Increased Mortality; D. J. Hall, E. I. Jeng, J. A. Gregg, A. Pelaez, A. Emtiazjoo, S. Chandrashekaran, M. Pipkin, T. Beaver, T. N. Machuca. 1Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, 2Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL, 3Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL

1:00 PM (346) Donor-Bound Predictors for Primary Graft Function in Lung Transplantation - Results from a Prospective Multicenter Study; A. Benazzo, S. Schwarz, M. Muckenhuber, T. Schweiger, R. Vamos Ferenc, S. Taghavi, G. Lang, S. Azad, P. Jaksch, M. Cypel, W. Klepetko, S. Keshavjee, K. Hoetzenecker. 1Thoracic Surgery, Medical University of Vienna, Vienna, Austria, 2Thoracic Surgery, Medical University of Budapest, Budapest, Hungary, 3Division of Thoracic Surgery, University of Vienna, Vienna, Austria, 4Toronto Lung Transplant Program Toronto General Hospital, University Health Network University of Toronto, Toronto, ON, Canada, 5Toronto Lung Transplant Program Toronto General Hospital, University Health Network, University of Toronto, Ontario, ON, Canada, 6Toronto Lung Transplant Program Toronto General Hospital, Toronto General Hospital University Health Network University of Toronto, Toronto, ON, Canada

1:15 PM (347) Unfavorable Donor after Cardiac Death Characteristics in Lung Transplantation: An Analysis of the UNOS Registry; A. Y. Choi, O. K. Jawitz, V. Raman, Y. Barac, M. S. Mulvihill, C. Moore, M. G. Hartwig. 1Duke University School of Medicine, Durham, NC, 2Department of Surgery, Duke University Medical Center, Durham, NC

1:30 PM (348) The Impact of Removing the Donor Service Area (DSA) as the First Unit of Allocation for Lungs in the United States; R. R. Lehman, K. Uccellini, E. Lease, R. Daly, K. M. Chan. 1United Network for Organ Sharing, Richmond, VA, 2University of Washington, Seattle, WA, 3Mayo Clinic, Rochester, MN, 4University of Michigan, Ann Arbor, MI

1:45 PM (349) Donor-Recipient Weight Mismatch and Primary Graft Dysfunction Risk Post-Lung Transplantation; A. Hirji, D. Li, A. Kapasi, J. Weinkauf, D. Lien, K. Halloran. Lung Transplant Program, University of Alberta, Edmonton, AB, Canada
12:15 PM (350) Routine Right Heart Catheterization in LVAD Patients Awaiting Heart Transplant: What is the Appropriate Surveillance Interval?; D. Ruan1, M. Farr2, V. Topkara2, A. R. Garan3, J. Sanchez1, P. Kurlansky3, M. Yuzeftolskaya2, P. Colombo2, H. Takayama4, Y. Naka4, K. Takeda4. 1Columbia University Vagelos College of Physicians & Surgeons, New York, NY, 2Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 3Department of Surgery, Columbia University Irving Medical Center, New York, NY, 4Division of Cardiothoracic Surgery, Columbia University Irving Medical Center, New York, NY

12:30 PM (351) Cardiac and Cerebrovascular Response to Exercise in the Setting of Mechanical Circulatory Support among Individuals with Advanced Heart Failure; T. Tran1, G. Coe1, M. Bradley1, K. O’Gean1, M. Spotts1, M. Ostertag1, S. Laing1, L. C. Prado1, C. Cornwell1, J. Paul1, W. Cornwell1. 1University of Colorado, Aurora, CO, 2Ohio State University, Columbus, OH

12:45 PM (352) Echocardiographic Predictors of Left Ventricle Unloading after LVAD Implantation; A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, N. Salam, F. Hussain, I. Hussain. Houston Methodist Hospital, Houston, TX

1:00 PM (353) Comparison of Exercise Hemodynamics in Patients Supported with Centrifugal and Axial Flow Left Ventricular Assist Devices; N. Moss1, A. Parikh1, V. Rakita2, A. Lala1, S. Mitter1, J. Roldan1, A. Cuca1, M. Barghash1, J. Contreras1, S. Pinney1, A. Anyanwu1, D. M. Mancini1. 1Mount Sinai Hospital, New York, NY, 2Temple University Hospital, Philadelphia, PA

1:15 PM (354) High Right Venticular Afterload is Associated with Impaired Exercise Tolerance in LVAD Patients; V. Ton1, L. Dees1, E. Sorensen1, E. Feller1, R. Madathil1, D. Kaczorowski1, B. Griffith1, R. J. Tedford2, G. Ramani1. 1University of Maryland School of Medicine, Baltimore, MD, 2Medical University of South Carolina, Charleston, SC

1:30 PM (355) Exercise-Induced Hypoxemia Predicts Heart Failure Hospitalization and Death in Patients Supported with Left Ventricular Assist Devices; D. M. Koerber1, A. N. Rosenbaum2, T. P. Olson2, S. Kushwaha2, J. Stulak1, S. Maltais1, A. Behfar1. 1Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, 2Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 3Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN

1:45 PM (356) Prospective Evaluation of LVAD Risk Scores’ Capacity to Predict Cardiopulmonary Exercise Parameters; A. Dorken1, P. Öztürk2, E. Demir2, Ç. Engin2, S. Nalbantgil3, T. Yagdı2, M. Özbaran2. 1Ege University Faculty of Medicine, Izmir, Turkey, 2Cardiovascular Surgery, Ege University Faculty of Medicine, Izmir, Turkey, 3Cardiology, Ege University Faculty of Medicine, Izmir, Turkey
**Poster Session 1: Basic Science & Translational Research**

**Room: Hibiscus 1**

**Poster Discussants:**
- Christian Heim, MD, University of Erlangen, Erlangen, Germany
- Daniel Pauly, MD, PhD, University of Missouri, Kansas City, MO, USA
- Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA
- Akira Shimamoto, MD, PhD, Mie Univ Graduate School of Medicine, Tsu, Japan
- Nikolaos Skartsis, MD, PhD, UCSF Medical Center, San Francisco, CA, USA
- Poyanmehr, Medical School, Hannover, Germany
- Falk, University of Montréal, Montréal, QC, Canada
- Cailhier, Toronto, ON, Canada
- J. S. Alvarez, Medical University of South Carolina, Charleston, SC
- C. Wallace, Mannheim, Mannheim, Germany
- Rats, Toronto, ON, Canada
- Nakao, D. H. Freed
- Hamed, D. H. Freed
- Freeland, J. Nagendra

---

**(573) Sub-Normothermic Ex-Vivo Lung Perfusion Attenuates Ischemia Reperfusion Injury from Donation after Circulatory Death Donors:**
T. Maeyashiki, S. Arni, I. Iskender, W. Weder, I. Inci. Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

**(574) Metabolic Alterations in Myocardial Metabolism during Ex Situ Heart Perfusion:**

**(575) Continuous Hemodialysis during Ex Vivo Lung Perfusion Allows for Improved Maintenance of Perfusate Composition, without Compromising Functional Performance:**
M. T. Buchko, S. Himmat, C. J. Stewart, S. Hatami, P. Dromparis, B. Adam, D. H. Freed, J. Nagendra. 1Department of Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, 2Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada

**(576) Recombinant Thrombomodulin Reduce Histone-Induced Rat Lung Transplant Model of Primary Graft Dysfunction:**
K. Nakao, M. Anraku, T. Murayama, A. Hosoi, K. Kakimi, J. Nakajima. University of Tokyo, Tokyo, Japan

**(577) Recipient Treatment with n-octanoyl Dopamine Improves Post Transplant Graft Function from Brain-Dead Heart Donor in Rats:**
S. Loganathan, Y. Guo, S. Korkmaz-Icöz, P. Zhou, P. Brlecic, T. Radovits, M. Ruppert, A. A. Sayour, B. Yard, M. Karck, G. Szabó. 1Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany, 2Heart and Vascular Center, Semmelweis University, Budapest, Hungary, 3Medicine V (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, Mannheim, Germany

**(578) Endothelial Stabilization Reduces the Effects of Brain Death Induced Acute Lung Injury Post-Transplant:**
Z. Tu, P. Allen, C. Wallace, C. Li, J. Kilkenny, K. Patel, S. Nadig, C. Atkinson. 1Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, SC

**(579) Ex Situ Heart Perfusion Improves Preservation of Endothelial Function in Both DBD and DCD Hearts:**
R. Ribeiro, F. Yu, J. S. Alvarez, M. B. Adamson, L. Paradiso, L. Xin, B. Gellner, V. Bissoondath, M. Meineri, M. V. Badiwala. 1Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Mechanical Engineering, University of Toronto, Toronto, ON, Canada, 3Cardiovascular Anesthesia, Toronto General Hospital, Toronto, ON, Canada

**(580) Assessment of Predictive Biomarkers Associated with Ischemia/Reperfusion Injury and Primary Graft Dysfunction in Lung Transplants:**
C. Landry, A. Privé, A. Menaouar, D. Adam, A. Dagenais, M. Merjaneh, J. F. Germain, N. Noisieux, J. F. Caillier, Y. Berthiaume, C. Poirier, P. Ferraro, E. Brochiero. 1CRCHUM/CHUM/Faculty of Medicine, University of Montréal, Montréal, QC, Canada, 2CRCHUM/CHUM/Faculty of Medicine, University of Montréal, Montréal, QC, Canada, 3IRCM, Montréal, QC, Canada, 4CRCHUM/CHUM, Montréal, QC, Canada, 5CRCHUM/CHUM/Department of Surgery, University of Montréal, Montréal, QC, Canada, 6CHUM, IRCM, Faculty of Medicine, University of Montréal, Montréal, QC, Canada

**(581) Effects of Ex Vivo Perfusion and II-6 Receptor Blockade on Ischemia Reperfusion Injury in Cardiac Transplantation:**

**(582) Contractility versus Metabolic Cardiac Assessment during Ex Situ Heart Perfusion: A Pre-Clinical Transplant Study:**
R. Ribeiro, J. Alvarez, B. Gellner, L. Xin, E. Paradiso, F. Yu, M. B. Adamson, F. Foroutan, V. Bissoondath, M. Meineri, M. V. Badiwala. 1Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, 3Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada
(583) **Influence of Various Perfusion Temperatures on Lung Graft Preservation during Ex Vivo Lung Perfusion:** S. Burki, K. Noda, A. Kumar, B. Philips, P. G. Sanchez, J. D'Cunha. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

(584) **Reperfusion Inflammatory State of Human Lungs during Cellular Ex-Vivo Perfusion:** K. S. Ayvat, T. Okamoto, H. Niikawa, H. Elgharably, Y. Itoda, R. Fairchild, K. R. McCurry. Cleveland Clinic, Cleveland, OH

(585) **The Effect of Prostaglandin E1 on Pulmonoplegia before and after Ex Vivo Lung Perfusion:** K. Noda, A. Kumar, S. Burki, B. Philips, P. G. Sanchez, J. D'Cunha. Department of Cardiothoracic Surgery, Univ of Pittsburgh Medical Center. Pittsburgh, PA


(588) **Human Hearts Declined for Transplant Were Resuscitated on the Visible Heart® Apparatus:** A. Shaffer, E. Schinstock, M. Bateman, T. Iles, P. Iaizzo. Department of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.

(589) **Prolonged Cold-Ischemia Increases Reactive Oxygen Species and Activates Autophagy by Enhancing Glycolysis in the Graft through the mTOR Signaling Pathway in Orthotopic Lung Transplantation of Rats:** H. Lin, S. Dai, W. Liu, X. Liu, B. Yu, J. Tang. Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

(590) **Prolongation of the Agonal Phase in the DCD Donor Results in Impairment of Myocardial Contractility Following DCD Heart Resuscitation:** A. A. Ali, P. Downey, M. Anwer, P. Bonde, Z. Ali. Cardiothoracic Surgery, Yale University, New Haven, CT.


(592) **Hypoxia-Reperfusion in a Rodent Model of DCD Cardiac Resuscitation Leads to Improved Myocyte Function Compared to Conventional Ischemia Reperfusion Injury:** A. A. Ali, P. Downey, M. Anwer, P. Bonde, Z. A. Ali. Cardiothoracic Surgery, Yale University, New Haven, CT.


(594) **Clinical Parameters of Right Ventricular Dysfunction Predict Depressed RV Myofilament Function:** M. I. Aslam, B. Lin, D. Kass, S. Hsu. Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD

(595) **Acute Metabolomic Changes after Implantation of a Left Ventricular Assist Device:** N. Clendenen, W. Cornwell, J. Pal, N. Weitzel. Anesthesiology, University of Colorado, Aurora, CO.

(596) **Characteristics of Urine Cell-Free DNA in Heart and Lung Transplant:** K. Bhatti, S. Agbor-Enoh, I. Tunc, A. Marishta, Y. Yang, U. Fidelio, J. Mathew, A. Iacono, J. Zhu, M. Pirooznia, M. Jiang, H. Valantine. Laboratory of Transplant Genomics, National Heart, Lung, and Blood Institute, Bethesda, MD.

(580) **Acute Metabolomic Changes after Implantation of a Left Ventricular Assist Device:** N. Clendenen, W. Cornwell, J. Pal, N. Weitzel. Anesthesiology, University of Colorado, Aurora, CO.
(597) Stimulation of Cardiac Angiogenesis through Growth Factors with a Fibrin Gel Delivery Platform; L. Melly\(^1\), A. Grosso\(^2\), C. Stanciu Pop\(^1\), M. Nollevaux\(^1\), N. Di Maggio\(^2\), A. Banfi\(^2\), B. Rondelet\(^1\). \(^1\)CHU UCL Namur, Yvoir, Belgium, \(^2\)Cell and Gene Therapy, Department of Biomedicine, Basel, Switzerland

(598) Hyaluronic Acid Decorated-Liposome are Good Biocompatible Nano-Carrier for Drug Delivery to Mesenchymal Cells Derived from BAL of Bronchiolitis Obliterans Patients; F. Meloni\(^1\), L. Pandolfi\(^1\), V. Frangipane\(^1\), E. Cova\(^2\), S. Arpicco\(^3\), A. Marengo\(^3\), C. Bocca\(^4\), M. Monti\(^5\). \(^1\)Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, \(^2\)Pathology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, \(^3\)Department of Department of Drug Science and Technology, University of Turin, Turin, Italy, \(^4\)Department Clinical and Biological Sciences, University of Turin, Turin, Italy, \(^5\)Laboratori di Biotecnologie, Centro Ricerche di Medicina Rigenerativa, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

(599) Influence of CYP2C9 and VKORC1 on Warfarin Dose and Complications in Kazakhstani Patients with Left Ventricular Assist Device; A. R. Akilzhanova\(^1\), M. R. Zhalbinova\(^1\), S. E. Rakhimova\(^1\), S. A. Andosova\(^2\), Z. S. Zhumadilov\(^3\), M. S. Bekbossynova\(^2\). \(^1\)Laboratory of Genomic and Personalised Medicine, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, \(^2\)National Research Cardiac Surgery Center, Astana, Kazakhstan, \(^3\)University Medical Center, Nazarbayev University, Astana, Kazakhstan

(600) Modeling Right Ventricular Heart Failure in Congenital Heart Disease; A. Azakie\(^1\), M. J. Doyle\(^2\), C. M. Martin\(^2\). \(^1\)Cardiac Surgery, Children’s Heart Center at St. Vincent, Indianapolis, IN, \(^2\)Medicine, University of Minnesota, Minneapolis, MN

(601) Comparison of Endothelin-1 Level in Group I Pulmonary Hypertension vs. Group II Pulmonary Hypertension Both at Rest and at Peak Exercise; A. Albulushi, A. Patel, D. Stoller, M. Hyden, A. Burdorff, L. Brian, R. Zolty. University of Nebraska Medical Center, Omaha, NE

(602) Galectin-3 Expression in the Left Ventricular Interstitium of Dogs with Chronic Heart Failure: Association with Interstitial Fibrosis; H. N. Sabbah, V. Singh-Gupta, R. C. Gupta. Medicine, Henry Ford Health System, Detroit, MI

Wednesday, April 3, 2019
6:00 PM - 7:15 PM

POSTER SESSION 1: BASIC SCIENCE AND TRANSLATIONAL RESEARCH
Room: Hibiscus 2

Poster Discussants:
Laurens J. Ceulemans, MD, PhD, University Hospitals Leuven, Leuven, Belgium
Wayne W. Hancock, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA
James L. Lordan, MB, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Pradep P. A. Mamman, MD, FACC, FAHA, UT Southwestern Medical Center, Dallas, TX, USA
Natalia Smirnova, PhD, University of Colorado, Denver, CO, USA
Nicole M. Valenzuela, PhD, D(ABHI), UCLA Immunogenetics Center, Los Angeles, CA, USA

(604) Reproducible Model for Chronic Stable Heart Failure in Ovine Species; N. Sadat1, C. Torregroza1, D. Scheiber1, C. Gomez4, R. Westenfeld1, J. von der Beek2, I. J. Knorr2, P. Akhary1, M. Sager2, A. Lichtenberg1, D. Saeed1. 1Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Department of Animal Research and Animal Protection, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany


(607) Dynamic BCMA Expression by Alloreactive B Cells Coupled with Donor Specific Antibody Production during De Novo Alloantibody Responses; I. Kim, G. D. Wu, N. Chai, S. Jordan, A. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

(608) ZFYVE21 is a Novel Complement-Induced Rab5 Effector Protein Mediating Cardiac Allograft Vasculopathy; D. Jane-Wit, C. Fang, L. Liu, L. Qin, G. Li, G. Tellides, J. S. Pober. Dept of Cardiology, Yale School of Medicine, New Haven, CT

(609) miR-155 Plays an Essential Role in Anti-MHC-Induced Obliterative Airway Disease; R. Ravichandran, Y. Itabashi, W. Liu, T. Mohanakumar. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

(610) Elevetad Cysteine-Protease Activity in Bronchiolitis Obliterans Syndrome; C. Morrone1, N. Smirnova2, N. Kneidinger3, H. Schiller4, O. Eickelberg2, A. Yildirim1. 1Comprehensive Pulmonary Center, CPC/ILBD and Helmholtz Zentrum Munich, Munich, Germany, 2University of Colorado Denver, Denver, Colorado, CO, 3Department of Internal Medicine V, Comprehensive Pneumology Munich, Munich, Germany


(612) Circulating Exosomes from Lung Transplant Recipients Diagnosed with Bronchiolitis Obliterans Syndrome Induces Immune Responses in C57BL/6 Mice Leading to Obliterative Airway Disease and miRNA 155 Plays an Essential Role in Immune Activation; S. Bansal, M. Sharma, M. A. Smith, R. M. Bremmer, T. Mohanakumar. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

(613) Pioglitazone Induces Infiltations of Regulatory T Cells in the Tracheal Graft and Attenuates Allograft Rejection; T. Shigenobu1, T. Ohtsuka2, M. Shimoda1. 1Thoracic Surgery, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan, 2Thoracic Surgery, Jikei University School of Medicine, Tokyo, Japan, 3Pathology, Keio University School of Medicine, Tokyo, Japan

(614) Donor Brain Death Affects Tolerance Induction in Non-Human Primates; W. Sommer4, J. M. O2, K. B. Pruner2, J. T. Paster2, A. Bean2, A. Dehnadi2, M. Hanekamp2, L. Rosales3, R. N. Smith3, R. B. Colvin3, G. Benichou2, J. S. Allan2, T. Kawai3, J. C. Madsen2. 1Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, 2Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 3Department of Pathology, Massachusetts General Hospital, Boston, MA

(615) B1Ux2x2: N. Diakos1, I. Taleb1, O. Wever Pinzon1, H. Javan1, A. Kfouri2, J. Stenhilix, W. Caine2, J. Nativi1, A. Koliopoulou1, M. Yin1, L. McCreath1, A. Thodou1, T. Sankar1, E. Gilbert1, C. Selzman1, S. Drakos1. 1Cardiology, University of Utah, Salt Lake City, UT, 2Cardiology, Intermountain Medical Center, Salt Lake City, UT
(616) Complement (C3a) Levels are Increased in the Bronchoalveolar Lavage Fluid of Patient with All Chronic Lung Allograft Dysfunction Phenotypes; M. P. Combs, R. Vittal, D. S. Wheeler, N. M. Walker, V. N. Lama. Department of Medicine, University of Michigan, Ann Arbor, MI


(618) Cytokine Expression and Alloreactivity in a Humanized Mouse Transplant Arteriosclerosis Model Reflects Primary Graft Dysfunction in Lung Transplant Recipients; A. Knoefel1, T. Siemen1, N. Madrahimov1, W. Sommer1, M. Avsar1, F. Ius1, I. Tudorache1, C. Kuehn2, K. Daemen2, A. Haverich1, C. S. Falk3, G. Warnecke1. 1TTG, MHH, Hannover, Germany, 2MHH, Hannover, Germany, 3Transplantation medicine, MHH, Hannover, Germany

(619) A Longitudinal Study of ϕT Cell Subsets Post Lung Transplant: Potential Players in CMV Immunity; L. Sullivan1, E. Shaw2, G. Snell1, A. Brooks2, G. Westall1. 1Lung Transplant Service, The Alfred, Melbourne, Australia, 2Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia

(620) Mechanisms of Antibody Mediated Rejection in the Absence of Donor Specific Antibodies; S. B. See1, B. S. Mantell2, K. J. Clerkin1, B. Ray3, R. E. Vasilescu4, C. C. Marboe5, Y. Naka6, S. Restaino7, P. C. Colombo8, L. J. Addonizio9, M. A. Farr10, E. Zorn1. 1Columbia Center for Translational Immunology, Columbia Univ Medical Center, New York, NY, 2Pediatric Cardiology, Columbia Univ Medical Center, New York, NY, 3Immucor, Inc., Norcross, GA, 4Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 5Department of Pathology and Cell Biology, Columbia Univ Medical Center, New York, NY, 6Cardiothoracic Surgery, Columbia Univ Medical Center, New York, NY, 7Cardiology, Columbia University Medical Center, New York, NY

(621) Standard Drug Immunosuppression Eliminates Peripheral Transitional B Cells but Does Not Create a Distinct Genetic Signature in Non-Human Primates; A. Bean1, J. T. Paster1, K. B. Pruner1, J. O.1, W. Sommer2, K. Robinson3, I. M. Hanekamp1, G. Benichou1, J. C. Madsen1. 1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 2Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany, 3Beth Israel Deaconess Medical Center, Boston, MA

(622) Comparative Behaviour of Allogeneic Spleen versus Bone Marrow Cells in Non-Conditioned Neonatal Mice: Insights into Robust Heart Transplant Tolerance; R. A. Bascom, K. Tao, L. J. West. University of Alberta, Edmonton, AB, Canada


(625) Lung Bile Acid as Biomarker of Microaspiration and Its Relationship to Lung Inflammation; M. Ahmed1, L. Levy1, S. E. Hunter1, K. C. Zhang1, E. Husztí2, K. M. Boonstra1, A. T. Sage1, S. Azad1, R. Zamel1, R. Ghany1, J. C. Yeung1, O. M. Crespin2, C. Frankel1, M. Budev3, P. Shah4, L. D. Snyder5, J. Belperio5, L. G. Singer1, S. S. Weigt1, J. L. Todd1, S. M. Palmer1, S. Keshavjee1, T. Martinu1. 1* For CTOT-20 Investigators. 2Toronto Lung Transplant Program, Toronto, ON, Canada, 3Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5Duke University Medical Center, Durham, NC, 6Cleveland Clinic, Cleveland, OH, 7Johns Hopkins University Hospital, Baltimore, MD, 8University of California Los Angeles, Los Angeles, CA

(626) Myeloid-Derived Suppressor Cells in Lung Transplant Recipients; T. Heigl1, A. Singh2, B. Saez1, J. Kae1, A. Van Herck1, A. Sacre1, H. Beeckmans1, S. Verleden1, D. Van Raemdonck1, G. Verleden1, B. Vanaudenaerde1, D. Hart1, R. Vo1. 1Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 2Universitatsklinik für Kinder- und Jugendmedizin, Tubingen, Tubingen, Germany

(627) Heart-Associated Cytokine and Endothelial Patterns Dominate the Ischemia Reperfusion Response in Recipients of Combined Heart/Lung Transplant in Comparison to Lung Transplantation; B. Wiegmans1, N. Ledwoch2, R. Bellmas-Sanz2, F. Ius1, W. Sommer1, S. Rojas-Hernandez3, I. Tudorache1, C. Kühn1, M. Avsar1, A. Haverich1, G. Warnecke1, C. Falk1. 1Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

(628) Lung T Cell Activation in an Outbred Pig Transplant and Ischemia-Reperfusion Injury Model; A. Duong, L. Caldareone, A. Mariscal, L. Huang, C. Xu, S. Keshavjee, M. Liu, S. Juvet, T. Martinu. Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
(629) Orthotopic Implantation with Immature Mouse Fetal Lung Did Not Self-Organize Airways Structures, but Improved Prognosis of Mice with Paraquat-Induced Severe Lung Injury; R. Okabe1, T. Chen-Yoshikawa1, A. Yoshizawa1, T. Hirashima1, F. Gochi1, H. Yamagishi1, A. Takahagi1, M. Saito1, A. Ohsumi1, D. Nakajima1, M. Hamaji1, H. Date1, T. Takebe2. 1Thoracic Surgery, Kyoto University, Kyoto City, Japan, 2Thoracic Surgery, Kyoto University, Kyoto City, Japan, 3Pathology, Kyoto University, Kyoto City, Japan, 4Pathology and Biology of Diseases, Kyoto University, Kyoto City, Japan, 5Pediatrics, Cincinnati College of Medicine, Cincinnati, OH


(631) Impact of Severe Tricuspid Valve Insufficiency on the Performance of the Left Ventricular Assist Devices. Acute and Chronic Animal Studies; C. Gomez1, C. Torregroza1, N. Sadat1, D. Scheiber1, J. von der Beek2, R. Westenfeld1, I. J. Knorr1, P. Akhyari1, M. Sager2, A. Lichtenberg3, D. Saeed1. 1Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Department of Animal Research and Animal Protection, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

(632) Stem Cells Transplantation Improves Kidney Function in Cardio-Renal Syndrome Type II: Insight into Pathophysiological Mechanisms; G. Vescovo1, C. Castellani2, M. Fedrigo2, A. Di Francesco2, G. M. Virzi3, G. M. Vescovo2, R. Tavano4, M. Pozzobon5, A. Angelini5. 1Internal Medicine, S.Antonio Hospital, Padova, Italy, 2Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy, 3Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy, 4Dept. Biomedical Sciences, University of Padova, Padova, Italy, 5Dept. Women and Children Health Institute of Pediatric Research Città della Speranza, University of Padova, Padova, Italy

(633) The Case for Pig Heart Xenotransplantation in Infants with Complex Congenital Heart Disease; H. Hara1, Q. Li1, C. A. Banks1, T. Yamamoto1, D. Ayares2, D. C. Cleveland3, D. K. Cooper1. 1Surgery, University of Alabama at Birmingham, Birmingham, AL, 2Revivicor, Blacksburg, VA, 3Cardio Thoracic Surgery, University of Alabama at Birmingham, Birmingham, AL

(634) Improvement of Left Ventricular Ejection Fraction by a Novel Electrical Microcurrent Therapy in a Sheep Model of Chronic Heart Failure; L. Napp1, C. Baum2, G. Dogan1, J. S. Hanke1, T. Meyer1, P. Goettel1, K. Brandes5, S. Sarikouch1, C. Bara1, J. Bauersachs1, A. Haverich1, J. Mueller3, J. D. Schmitt1. 1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany, 2University of Veterinary Medicine, Hannover, Germany, 3Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 4MedImplant, Hannover, Germany, 5BerlinHeals, Zug, Switzerland
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

**POSTER SESSION 1: PATHOLOGY**
Room: Hibiscus 2

**Poster Discussants:**
Marny Fedrigo, MD, University of Padua, Padua, Italy
Brandon T. Larsen, MD, PhD, University of Arizona Medical Center, Tucson, AZ, USA

*(605) Mast Cell Expression in Heart Transplant Acute Cellular Rejection (ACR): A Retrospective Single Institution Analysis; S. Boyes¹, R. Nigdelioglu¹, S. Mehrotra¹, S. Pambuccian¹, M. Walsh², V. Ananthanarayanan¹. ¹Loyola University Medical Center, Maywood, IL, ²University of Illinois at Chicago, Chicago, IL*
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

POSTER SESSION 1: ECONOMICS, ETHICS, PUBLIC POLICY
Room: Gardenia 2

Poster Discussants:
Nancy P. Blumenthal, CRNP, Hospital of University of Pennsylvania, Philadelphia, PA, USA
Jay D. Pal, MD, PhD, University of Colorado, Aurora, CO, USA

(635) Heart Allocation in France Since the Introduction of the New Allocation System; B. Audry, C. Jasseron, C. Legeai, L. Sebbag, C. Goeminne, O. Bastien, C. Jacquelinet, R. Doreni, Agence de la Biomedecine, Saint-Denis la Plaine, France, CHU Lyon, Lyon, France, CHU Lille, Lille, France

(636) Behavioural Economic Nudge Policy, Organ-Donation and Heart Transplant Conversion Rates in Alberta, Canada. A Ten-Year Retrospective Analysis; P. F. Kantor, A. Yong, D. J. Kutsogiannis, Pediatrics, Stollery Children's Hosp, Edmonton, AB, Canada, 2Transplant Services, Alberta Health Services, Edmonton, AB, Canada, 3Critical Care Medicine, University of Alberta, Edmonton, AB, Canada

(637) Regional and Socioeconomic Distribution, Healthcare Utilization, and In-Hospital Mortality of Heart Transplantation; L. Newman, C. Mullan, M. Geib, G. Stevens, D. Majure, S. Hussain, H. Fernandez, A. Hartman, B. Lima, 1Cardiovascular and Thoracic Surgery, Northwell Health, Manhasset, NY, 2Cardiac and Thoracic Surgery, Yale School of Medicine, New Haven, CT, 3University of Texas Health Science Center, San Antonio, San Antonio, TX, 4Cardiology, Northwell Health, Manhasset, NY

(638) Quantifying the Effects of Training in Lung Transplantation: Lessons from NASA; N. Chilvers, A. W. Clark, M. I. Mydin, S. Clark, Cardi thoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

(639) Validity and Reliability of the Quality of Life with a Left Ventricular Assist Device (QOLVAD) Questionnaire; K. E. Sandau, C. S. Lee, K. M. Faulkner, P. Eckman, R. Garberich, B. Pozehl, C. Y. Jurgens, C. E. Weaver, S. Joseph, S. A. Hall, S. Carey, J. A. Cowger, S. P. Chaudhry, S. E. Schroeder, R. O. Hoffman, III, D. Feldman, G. Conway, E. Birati, M. Soni, J. Marble, M. S. Kunz, K. M. Storey, B. A. Hoglund, Bethel University, St. Paul, MN, 2Boston College Connell School of Nursing, Chestnut Hill, MA, 3Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, 4Minneapolis Heart Institute Foundation, Minneapolis, MN, 5University of Nebraska Medical Center College of Nursing, Omaha, NE, 6Stony Brook University, School of Nursing, Stony Brook, NY, 7Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, 8Baylor University Medical Center, Dallas, TX, 9Henry Ford Hospitals, Detroit, MI, 10St. Vincent Heart Center/St. Vincent, Indianapolis, IN, 11Bryan Heart Center, Lincoln, NE, 12University of Cincinnati Medical Center, Cincinnati, OH, 13Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 14Department of Medicine, University of Pennsylvania, Philadelphia, PA, 15University of Pennsylvania, Philadelphia, PA, 16Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, 17Metropolitan State University, St. Paul, MN


(641) Hospitalization Rate among LVAD Patients during the Last Decade in the United States; S. Shore, Z. Geng, S. Adusumalli, M. Seigerman, J. Mazurek, J. Wald, M. Tanna, P. Atluri, P. Groeneveld, E. Y. Birati, Cardiology, University of Michigan, Ann Arbor, PA, 2Cardiology, University of Pennsylvania, Philadelphia, PA, 3Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

(642) Cost Comparison between Subclavian-Artery Intra-Aortic Balloon Pump and Intravascular Ventricular Assist System as a Bridge to Transplant Therapy; T. Lammy, C. LaBuhn, P. Combs, E. Gonzales, T. Ota, T. Song, D. Onsager, V. Jeevanandam, Cardiac Surgery, University of Chicago, Chicago, IL
**POSTER SESSION 1: HEART TRANSPLANTATION (ADULT)**

Room: Timor Sea 2

**Poster Discussants:**
Natasha Altman, MD, University of Colorado, Denver, CO, USA
Richard Cheng, MD, University of Washington, Seattle, WA, USA
Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, Canada
Amy Hackmann, MD, University of Southern California, Los Angeles, CA, USA
Tomoko Kato, MD, PhD, National Cardiovascular Center, Tokyo, Japan
Anthony Lemaire, MD, Robert Wood Johnson Med Ctr, Princeton, NJ, USA
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
Andreas Zuckermann, MD, Medical Univ of Vienna, Vienna, Austria

---

(643) **Frequent Use of Organs after Rescue Allocation for Heart Transplantation: Can We Still Achieve Adequate Results?**; U. Boeken¹, A. Mehdiani², C. Boettger¹, D. Saeed¹, R. Westenfeld², B. Sowinski¹, H. Aubin¹, H. Dalyanoglu¹, P. Akhyari¹, A. Lichtenberg¹. ¹Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, ²Cardiology, University Hospital, Duesseldorf, Germany

(644) **Echocardiographic Characteristics Associated with Left Ventricular Recovery in Donor Hearts**; A. Bhatia¹, J. Ji², J. Peacock², J. Hartupel¹, G. Ewald¹. ¹Division of Cardiology, Washington University School of Medicine, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO

(645) **Application of Predicted Heart Mass Difference in a Canadian Cohort of Heart Transplant Recipients**; V. M. Molinero¹, F. Foroutan¹, J. G. Duero Posada¹, S. Chih², M. Badiwala¹, H. J. Ross¹, A. C. Alba¹. ¹Cardiology, UHN, Toronto, ON, Canada, ²Cardiology, Ottawa Heart Institute, Ottawa, ON, Canada

(646) **What Antigens to Avoid in Heart Transplant to Optimize Outcome via the Virtual Crossmatch**; E. Kransdorf, J. Patel, M. Kittleston, D. Chang, S. Dimbil, R. Levine, A. Shen, A. Jain, M. Olymbios, L. Czer, X. Zhang, J. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA

(647) **Thyroid Hormone Improved Heart Transplant Recipient Survival**; K. Carter¹, S. Lirette¹, R. P. Cochran¹, L. Creswell¹, A. Panos¹, D. A. Baran², H. Copeland¹. ¹University of MS Medical Center, Jackson, MS, ²Sentara Healthcare, Norfolk, VA

(648) **Impaired Outcome after Heart Transplantation: Impact of Donor Age and Ischemic Time**; C. Boettger, A. Mehdiani, P. Akhyari, A. Albert, H. Dalyanoglu, R. Westenfeld, D. Saeed, H. Aubin, A. Lichtenberg, U. Boeken. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany

(649) **Specialized Thoracic Adapted Recovery (STAR) Team Model for Heart Transplantation: 1000 Recoveries**; H. Tetteh¹, P. Brandenhoff², R. S. Higgins³. ¹Department of Surgery, Uniformed Services University, Bethesda, MD, ²Cardiothoracic Surgery, Thoracic Transplant Consultants, San Francisco, CA, ³Department of Surgery, Johns Hopkins University, Baltimore, MD

(650) **Single Center Experience of Hepatitis C Donor Viremic Cardiac Transplantation**; K. L. Morris¹, J. P. Adlam², M. Bochan³, M. Padanilam¹, A. Patel¹, R. Garcia-Cortes¹, S. Chaudhry¹, S. Tompkins¹, C. Salerno³, A. Ravichandran¹. ¹Cardiology, St. Vincent Hospital, Indianapolis, IN, ²Internal Medicine, St. Vincent Hospital, Indianapolis, IN, ³Infectious Disease, St. Vincent Hospital, Indianapolis, IN, ⁴Cardiovascular Surgery, St. Vincent Hospital, Indianapolis, IN


(652) **Analysis of Discrepancy between Expected and Actual Donor-Recipient Matching in Heart Transplantation**; C. R. Chen¹, M. Connellan², E. Granger², Y. Kawanishi², A. Jabbour², P. Macdonald², K. Muthiah², C. Hayward², K. Dhillon². ¹Faculty of Medicine, The University of New South Wales, Sydney, Australia, ²Heart and Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia

(653) **Donor and Recipient Racial Mismatch Impacts Thoracic Organ Transplant Survival**; K. Cox¹, K. Carter¹, S. Lirette¹, R. Cochran¹, L. Creswell¹, A. Panos¹, D. Baran², H. Copeland¹. ¹Cardiothoracic Surgery, University of Mississippi Medical Center, Jackson, MS, ²Sentara Healthcare, Norfolk, VA
(654) Does Donor-Recipient Age Difference Matter in the Outcome of Heart Transplantation?; E. Ram, J. Lavee, Y. Kassif, D. Elian, M. Katz, R. Klempfner, D. Freimark, Y. Peled. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel


(657) Effect of Recipient Race on Quality of Donors Allocated to Heart Transplant Recipients; B. Smith1, W. Parker1, S. Kalantari1, J. Raikhelkar1, G. Kim1, N. Sarswat1, G. Sayer1, A. Nguyen1, B. Chung1, L. Holzhauser1, N. Narang1, I. Ebong1, J. Rich2, A. Anderson2, N. Uriel1, E. Vorovich2. 1University of Chicago, Chicago, IL, 2Northwestern Memorial Hospital, Chicago, IL

(658) Achievement of Donor Management Goals and Primary Graft Dysfunction after Heart Transplant; L. Benck1, E. Kransdorf1, J. Patel1, D. Malinoski2, R. Levine1, C. Neimann3, J. A. Kobashigawa1. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Division of Surgery, Oregon Health & Science University, Portland, OR, 3Department of Anesthesiology, University of California San Francisco, San Francisco, CA


(661) Heart Transplantation with Older Donors Age: Single Centre Experience; C. Di Nora1, S. Sponga1, A. Lechiancole1, C. Nalli1, G. Guzz1, V. Tursi2, U. Livi2. 1Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, 2Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata, Udine, Italy

(662) Short and Stout Female Donors in Heart Transplantation: Do They Make a Difference?; D. H. Chang, M. Kittleson, J. Patel, D. Geft, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

(663) Heart Transplant Candidates Perceptions of the Newly Implemented United Network for Organ Sharing Heart Allocation System: An Eye Opener; N. T. Rivera, B. Bednar, O. Wu, M. Loebe, A. Badiye. Miami Transplant Institute, Jackson Health System in affiliation with University of Miami Health System, Miami, FL

(664) Coronary Angiography and Intravascular Ultrasound in an Ex-Vivo Perfused Heart Using the Organ Care System (OCS); D. Schibilsky1, Q. Zhou2, T. Wengenmayer2, S. Maier1, C. Benk1, M. Berchtold-Herz2, F. Beyersdorf1, M. Siepe1. 1Department Cardiovascular Surgery, University Heart Center Freiburg • Bad Krozingen, Faculty of Medicine, Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany, 2Department of Cardiology, University Heart Center Freiburg • Bad Krozingen, Faculty of Medicine, Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany, 3Department Cardiovascular Surgery, University Heart Center Freiburg • Bad Krozingen; Freiburg, Germany Faculty of Medicine, Albert-Ludwigs-University Freiburg, Germany, Freiburg, Germany

(665) Successful Use of Female Donors in Heart Transplantation: A Single Center Experience; N. Rajagopalan, D. R. Dennis, J. Akhtarekhavari, M. E. Sekela. University of Kentucky, Lexington, KY

(666) Short-Term Outcome after Heart Transplantation is Comparable When Using Extended-Criteria Donors; G. Poglajen, G. Zemljic, S. Frlijak, R. Okrajsk, M. Šebeštjen, A. Cerar, V. Andročec, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia

(667) Can Donor Step Up Pressure Predict Primary Graft Dysfunction in Recipients Post Heart Transplantation?; S. Das De1, S. Avtaar Singh1, K. Morcos1, Y. Hegazy1, A. Barton2, M. McGowan2, A. Smyth2, J. Dalzell2, P. Curry4, N. Al-Attar1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(668) Impact of the New Heart Allocation System in France on Candidates’ Profile and Waitlist Outcomes; C. Jasseur1, C. Legée1, G. Lébreton2, M. Kindo1, B. Audry1, C. Jacquelinet1, O. Bastien1, R. Dorent1. 1Agence de la Biomedecine, Saint-Denis la Plaine, France, 2Hôpital La Salpêtrière, Paris, France, 3Hôpital de Strasbourg, Strasbourg, France
(683) **De-Novo Malignancy in Cardiac Transplant Recipients - Single Centre Experience**; L. Saiva, B. Parlon, T. Baby, C. Halley, L. Nolke, N. Mahon, J. O'Neill. 1Heart and Lung Transplant, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2Cardiology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 3Consultant Transplant Cardiologist, Mater Misericordiae University Hospital, Dublin 7, Ireland

(684) **Effect of Bortezomib Desensitization Therapy on Levels of AT1R Antibody**; X. Zhang, J. Patel, J. Kobashigawa. 1HLA and Immunogenetics Laboratory, Cedars-Sinai Health System, Los Angeles, CA, 2Cardiology, Cedars-Sinai Health System, Los Angeles, CA


(686) **Characteristics of Cardiopulmonary Exercise Tests in Heart Transplantation Patients: The Importance of Chronotropic Incompetence in Predicting Exercise Capacity**; Y. Peled, E. Ram, H. Patal, J. Lavee, J. Buber, R. Klempfner. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel

(687) **EVOLVD: Cholesterol Lowering with EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Rationale and Design of a Randomized, Controlled Trial**; K. Broch, F. Gustafsson, G. Rådegran, L. B. Karl, H. Eiskjær, K. Karason, G. Dellgren, J. Lommi, M. Pentikäinen, S. Arora, E. Gude, A. K. Andreassen, L. Gullestad. 1Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Cardiology, Rigshospitalet, Copenhagen, Denmark, 3The Section for Heart Failure and Valvular Disease, VO. Heart and Lung Medicine, Skåne University Hospital, Oslo, Sweden, 4Cardiology, Helsinki University Hospital Heart and Lung Center, Helsinki, Finland, 5Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark, 6Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

(688) **Metformin Therapy is Associated with Reduced Risk of Vasculopathy and Cardiovascular Mortality after Heart Transplantation**; Y. Peled, E. Ram, Y. Har-Zahav, N. Shlomo, Y. Kassif, A. Kogan, E. Maor, D. Freimark, R. Klempfner, J. Lavee. 1Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel, 2Israeli Association for Cardiovascular Trials, Ramat Gan, Israel.
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

**POSTER SESSION 1: HEART TRANSPLANTATION (ADULT)**
Room: Timor Sea 1

**Poster Discussants:**
Markus Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Brian Clarke, MD, Libin Cardiovascular Institute/University of Calgary, Calgary, Canada
Robert Cole, MD, Emory University School of Medicine, Atlanta, GA, USA
Mahazarin Ginwalla, MD, University Hospital Cleveland Medical Center, Cleveland, OH, USA
Eileen Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH, USA
George Javorsky, MBBS, FRACP, Prince Charles Hospital, Brisbane, Australia
Karl Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland
Donna Mancini, MD, Mount Sinai Medical Center, New York, NY, USA
Ravikumar Ratnagiri, MD, Gleneagles Global Hospital, Chennai, India

(689) **Everolimus Immunosuppression in De Novo Heart Transplant Recipients: Clinical and Intravascular Ultrasound Study;** H. Choi, J. Hong, M. Kim, S. Lee, J. Kim. Cardiology, Asan Medical Center, Seoul, Korea, Republic of

(690) **Effect of High-Intensity Interval Training on Progression of Coronary Artery Vasculopathy in De Novo Heart Transplant Recipients;** K. Nytrøen1, K. Rolld2, E. Bjørkelund3, K. Karason4, F. Gustafsson4, O. Solberg1, L. Gullestad4, S. Arora2. 1Department of Cardiology, Oslo Univ Hosp Rikshospitalet, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Sahlgrenska University Hospital, Gothenburg, Sweden, 4Rigshospitalet University Hospital, Copenhagen, Denmark, 5Oslo University Hospital Rikshospital, Oslo, Norway

(691) **Intensity of Statin Therapy Affects Progression of Coronary Artery Vasculopathy;** J. Power1, M. Patarroyo2. 1Allegheny Health Network, Pittsburgh, PA. 2University of Texas Houston Memorial Hermann Hospital, Houston, TX

(692) **Deep Learning Facilitates Automation of Wall Layer Quantification in Heart Transplant Coronary OCT;** S. Mullan1, Z. Chen1, M. Pazdernik2, H. Zhang1, A. Wahle1, V. Melenovsky2, J. Kautzner3, V. Karmazin2, H. Bedanova3, A. Tomasek3, E. Ozabalova3, M. Sonka1. 1Institute for Biomedical Imaging, University of Iowa, Iowa City, IA, 2Institute of Clinical and Experimental Medicine, Prague, Czech Republic, 3Department of Cardiovascular Diseases, St. Annes University Hospital and Masaryk University, Brno, Czech Republic

(693) **Intracoronary Intimal Thickness in Transplant Recipients of Hepatitis C-Positive Donor Hearts;** S. Zalawadiya1, J. Lindenfeld1, E. Haddad2, A. Shah3, M. Wigger4, S. Negrotto5, M. Danner6, D. Brinkley6, J. Menachem1, L. Punnoose1, S. Brown Sacks1, H. Ooi1, K. Balsara2, R. Perril3, J. Awad4, S. Smith5, R. Fowler6, H. O'Dell4, C. Darrahy4, S. Ruzevich-Scholl1, K. Schleendorf1. 1Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, 2Cardiology, Vanderbilt University Medical Center, Nashville, TN, 3Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 4Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN

(694) **Myocardial Flow Reserve Using 13N Ammonia PET for Detection of Cardiac Allograft Vasculopathy;** N. Kikuchi, E. Yamamoto, H. Hattori, M. Nagao, M. Momose, T. Shiga, N. Hagiwara, H. Niinami, S. Nunoda. Tokyo Women's Medical University, Tokyo, Japan

(695) **Silent Ischemia and Arrhythmia after Heart Transplantation: Relation to Cardiac Allograft Vasculopathy;** K. Berg, K. Bjerre, T. Clemmensen, S. Poulsen, H. Eiskjaer. Cardiology, AUH, Aarhus University Hospital, Aarhus, Denmark

(696) **Does Aspirin Reduce the Rate of Early Cardiac Allograft Vasculopathy (CAV) Following Heart Transplant?;** J. E. Bloom1, C. Pereira Kessler Iglesias2, J. Moskovitch1, D. Letchford1, E. Kotlyar3, S. Offen4, A. Keogh4, A. Jabbour5, C. Hayward4, D. M. Kaye5, K. Muthiah4, P. Macdonald4. 1Department of Cardiology, Alfred Health, Melbourne, Australia, 2Cardiology, St Vincent's Hospital, Sydney, Australia, 3Department of Cardiology, St Vincent's Hospital, Saturday, Australia, 4Department of Cardiology, St Vincent's Hospital, Sydney, Australia, 5Department of Cardiology, Alfred Health, Baker Institute, Melbourne, Australia

(698) Effect of Heart Rate on Early Progression of Cardiac Allograft Vasculopathy: A Prospective Study Using Highly Automated 3-D Optical Coherence Tomography Analysis; M. Pazdernik, D. Wichterle1, Z. Chen2, H. Zhang2, A. Wahle2, J. Kautzner1, V. Melenovsky1, I. Malek1, V. Karmazin1, H. Bedanova1, E. Ozabalova1, A. Tomasek1, T. Kovarník3, M. Sonka2. 1IKEM, Prague, Czech Republic, 2Iowa Institute for Biomedical Imaging, University of Iowa, Iowa City, IA, 3Cardiovascular and Transplantation Surgery, Brno, Czech Republic, 4General University Hospital in Prague, Prague, Czech Republic


(701) 1-Year Coronary IVUS in Heart Transplant Recipient Fails to Predict 10-Year Cardiovascular Mortality; A. Verde1, I. Bossi1, A. Iconelli2, G. Masciocco1, L. D’Angelo1, M. Varrenti1, C. Santolamazza1, A. Giglio1, E. Perna1, G. Foti1, A. Garascia1, M. Cipriani1, E. Ammirati1, M. Frigerio1. 1De Gasperis Cardio Center, ASST Big Metropolitan Hospital Niguarda, Milano, Italy, 2Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Roma, Italy

(702) Novel Intravascular Ultrasound Measurements to Assess for Coronary Allograft Vasculopathy in Patients after Orthotopic Heart Transplant; T. J. Fendler1, D. M. Safley1, A. Kao2, B. A. Austin1, A. Borkon3, H. Brandt4, K. F. Kennedy5, B. W. Sperry6. 1Cardiovascular Diseases, St. Luke’s Mid America Heart Institute / UMKC, Kansas City, MO, 2Cardiovascular Diseases, St. Luke’s Mid America Heart Institute / UMKC, Kansas City, MO, 3Cardiothoracic Surgery, St. Luke’s Mid America Heart Institute, Kansas City, MO, 4Cardiovascular Diseases, St. Luke’s Mid America Heart Institute, Kansas City, MO

(705) The Role of Transpulmonary Gradient and Mean Pulmonary Artery Pressure in Risk Stratification of Heart Transplant Candidates with Pulmonary Hypertension; L. K. Truby, R. Agarwal, S. D. Russell, C. B. Patel, J. G. Rogers. Duke University Medical Center, Durham, NC

(706) High Intra-Patient Variability of Echocardiographic Parameters is Associated with Heart Transplantation Outcomes: Report of a Real-World Experience; Y. Peled1, M. Feinberg1, J. Lave1, O. Vatury1, I. Hay1, S. Ben Zekry1, N. Shlomo2, R. Koperstein1, E. Schwammenthal1. 1Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel, 2Israeli Association for Cardiovascular Trials, Ramat Gan, Israel

(707) Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients (IronIC): Rationale and Design of a Randomized, Controlled Trial; K. V. Brautaset, C. M. Østby, T. Vartdal, K. Rolid, E. Gude, A. K. Andreassen, L. Gullestad, K. Broch. Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway

(708) Implantable Cardioverter-Defibrillators in Heart Transplant Recipients with Allograft Failure; E. M. DeFilippis1, A. R. Garan1, R. C. Givens1, L. K. Truby2, F. Latifi3, S. W. Restaino1, K. Takeda1, H. Takayama1, Y. Naka3, P. C. Colombo1, M. A. Farr1, Y. K. Topkara1. 1Columbia University Medical Center, New York, NY, 2Duke University Medical Center, Durham, NC

(709) Outcome after Heart Transplantation in High-Urgent Listed Patients on LVAD: Impact of Type of Complication; U. Boeken, C. Boekiger, A. Mehdiani, A. Albert, B. Sowinski, D. Saeed, H. Aubin, R. Westenfeld, P. Akhyari, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany

(710) Impact of High-Urgent Status on Outcome after Use of Undersized Donors for Orthotopic Heart Transplantation; U. Boeken, P. Akhyari, A. Albert, B. Sowinski, H. Dalyanoglu, R. Westenfeld, D. Saeed, H. Aubin, A. Mehdiani, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany


(712) Prevalence of Iron Deficiency in Heart Transplant Recipients; K. Brautaset, C. M. Østby, G. Tjonnås, E. Gude, A. K. Andreassen, L. Gullestad, K. Broch. Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway

(713) Does Cell-Free DNA Detect the Development of De Novo Donor Specific Antibodies; J. A. Kobashigawa1, J. Patel1, E. Kransdorf2, D. Chang2, M. Kittleson3, S. Dimbil1, R. Levine1, S. Sana1, A. Wolfson1, L. Czer4, M. Hamilton5, R. Woodward6, F. Esmailian1. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2CareDx, Inc., Brisbane, CA
(714) Efficacy and Safety of Idarucizumab for Rapid Reversal from Dabigatran in Patients Undergoing Orthotopic Heart Transplantation; I. Kim1, H. Kim1, W. Chang1, J. Kim1, N. Park1, J. Youn2, S. Choi1, S. Jun1, Y. Cho1, H. Yoon1, C. Nam1, S. Han1, S. Hur1, H. Park1. 1Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, 2Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Daegu, Korea, Republic of

(715) Use of dd-cfDNA in Real World Practice: Single Center Experience; J. Smith1, J. Fuentes1, T. Khuu1, W. Carpenter1, D. Cruz1, M. Cadeiras2, M. C. Deng1, E. C. DePasquale1. 1UCLA, Los Angeles, CA, 2UC Davis, Sacramento, CA

(716) Heart Transplantation Outcomes in Liver Cirrhosis: Influence of Ascites on Post-Transplantation Survival; H. Kim, J. Kim, S. Lee, H. Joo, K. Yoo, Y. Yoon. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

(717) Trends in Post-Heart Transplant Biopsies for Graft Rejection versus Non-Rejection; A. K. Jamil1, T. Nisar1, A. Afzal2, A. Y. Kluger3, J. Felius1, D. Wencker2, P. Kale2, S. A. Hall2. 1Baylor Scott & White Research Institute, Dallas, TX, 2Baylor University Medical Center, Dallas, TX, 3Baylor Heart and Vascular Institute, Dallas, TX

(718) Back to ECG in Predicting Graft Dysfunction in the Era of Molecular Assays: Einthoven’s Revenge?; M. Masetti, E. Presta, F. Corazza, N. Laganà, S. Boschi, L. Giovannini, A. Russo, F. Grigioni, L. Potena. Cardiovascular Department, Bologna University Hospital, Bologna, Italy

(719) Early Detection of Immune Morbidity after Heart Transplantation (htx) by Means of Procalcitonin (PCT) combined with Highly Sensitive Cardiac Troponin T (hs-cTNT); U. Boeken, A. Mehdiani, A. Albert, H. Aubin, H. Dallyanoglu, R. Westenfeld, B. Sowinski, D. Saeed, P. Akhyari, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany

(720) Non-Invasive Venous Waveform Analysis (NIVA) for Monitoring Pulmonary Capillary Wedge Pressure Post-Orthotopic Heart Transplantation: A Proof of Concept Study; B. D. Alvís1, T. S. Hopper2, M. Polez3, K. M. Hocking3, J. Whitfield4, C. Brophy3, S. Eagle1, J. Lindenfeld5. 1Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, 2Medical School, Vanderbilt University College of Medicine, Nashville, TN, 3Surgery, Vanderbilt University Medical Center, Nashville, TN, 4Volumetrix, LLC, Nashville, TN, 5Cardiology, Vanderbilt University Medical Center, Nashville, TN


(722) Efficacy and Safety of Ivabradine Application in the Early Period after Heart Transplantation; U. Boeken, A. Albert, A. Mehdiani, B. Sowinski, R. Westenfeld, H. Aubin, D. Saeed, P. Akhyari, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany

(723) Inflammatory Cardiomyopathy (ICM): Long-Term Survival after Heart Transplantation or Implantation of Mechanical Circulatory Support; S. Esmailiy1, E. Bobbio1, E. Bollano2, P. Dahlberg2, S. Bartfay3, G. Dellgren3, K. Karason1. 1Sahlgrenska Academy, Institute of Medicine, Gothenburg, Sweden, 2Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Department of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden

(724) Use of dd-cfDNA in Multiorgan Transplantation; E. C. DePasquale, J. Smith, J. Fuentes, T. Khuu, M. C. Deng. UCLA, Los Angeles, CA


(726) Incidence and Effect of VA-ECMO Use in Primary Graft Failure Patients after Heart Transplantation; M. Kawabori1, M. A. Mastroiannii, J. A. Reich1, Y. Zhan1, K. G. Warner1, H. Rastegar2, A. Vest1, D. Denofrio1, F. Y. Chen1, G. S. Couper1. 1Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA


(728) International Society for Heart and Lung Transplantation Defined Primary Graft Dysfunction in Heart Transplant Recipients Predicts 30-Day Mortality; N. F. Smith1, S. Salehi Omrani2, M. V. Genuardi2, E. Horn3, M. Keebler3, G. Hickey4, R. Kormos4. 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 4University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center, Pittsburgh, PA
(729) Cardiac Transplantation Primary Graft Dysfunction Incidence and Predictors; L. Xie, S. S. Nathan, R. Radovancevic, M. Jumean, B. Kar, I. D. Gregoric. Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX

(730) The Interaction of Amiodarone and LVAD in Severe Primary Graft Dysfunction; T. Chinnadurai1, W. Hanif, S. R. Patel1, D. Sims1, O. Saeed1, S. Murthy1, J. Shin1, S. Vukelic1, S. Forest2, W. Jakobleff2, D. Goldstein2, U. P. Jorde1. 1Cardiology, Montefiore Medical Center, Bronx, NY; 2Cardiothoracic, Montefiore Medical Center, Bronx, NY

(731) Treatment with a Statin or Spironolactone is Associated with a Reduced Risk for Primary Graft Dysfunction and Mortality; Y. Peled, E. Ram, D. Freimark, Y. Kassif, N. Shlomo, A. Kogan, E. Maor, R. Klempfner, J. Lavee. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel

(732) Cardiac Biomarkers for Early Identification of Primary Graft Dysfunction; V. Jernryd1, C. Metzch2, G. J. Smith3, B. Andersson4, J. Nilsson5. 1Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden; 2Clinical Sciences Lund, Anesthesiology, Lund University and Skane University Hospital, Lund, Sweden; 3Clinical Sciences Lund, Cardiology, Lund University and Skane University Hospital, Lund, Sweden; 4Clinical Sciences Lund, Surgery, Lund University and Skane University Hospital, Lund, Sweden; 5Skanes University Hospital Cardiothoracic Surgery, Lund, Sweden

(733) Preoperative Amiodarone and Primary Graft Dysfunction in Heart Transplantation; A. Servais1, S. Bowman1, S. Lundgren2, D. Klepser2, H. Brink1. 1Nebraska Medicine, Omaha, NE; 2University of Nebraska Medical Center, Omaha, NE

(734) Graft Recovery Estimation at Transplantation (GREAT) Algorithm Identifies the Most Important Risk Factors for Primary Graft Dysfunction for Heart Transplantation; M. Leacche1, P. Wilton2, G. Marco1, S. Fitch1, N. Manandhar Shrestha1, M. Dickinson1, T. Boeve1, S. Jovinge2. 1Fredrik Meijer Heart and Vascular Institute, Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI; 2Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI


(736) 1-Year Graft Function and Hemodynamics in Heart Transplant Patients Who Experienced Severe Primary Graft Dysfunction; K. Takeda1, M. A. Farr1, A. R. Garan1, V. Topkara1, C. Marisa2, L. Witer1, S. Restaino1, M. Yuzefpolskaya1, P. C. Colombo1, H. Takayama1, Y. Naka1. 1Columbia University, NY, NY; 2Columbia, New York, NY

Wednesday, April 3, 2019
6:00 PM - 7:15 PM

**POSTER SESSION 1: NURSING, HEALTH SCIENCES, ALLIED HEALTH**
Room: Gardenia 2

**Poster Discussants:**
Flavio Epstein, PhD, Kaiser Permanente, San Francisco, CA, USA
Margaret Fregoso, NP, Inova Fairfax Hospital, Falls Church, VA, USA
Donna Hickling, Queensland Health, Brisbane, Australia
Angela Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA

(738) *Review of Lung Transplantation for Patients 65 Years and Older with Idiopathic Pulmonary Fibrosis in Ireland*; I. Byrne, P. Grehan. Physiotherapy, Mater Misericordiae University Hospital, Dublin, Ireland

(739) *The Importance of Physiotherapy in Promoting Bone Health for Children Supported by VAD: Early Mobilisation and Weight Bearing Guidelines*; K. Caulfield. Paediatric Physiotherapy, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(740) *Distal Intestinal Obstruction Syndrome and Constipation Following Lung Transplantation, Incidence and Nutritional Consequences*; S. Murphy, J. O'Mahony, M. McKiernan, S. Doyle, J. J. Egan. Nutrition and Dietetics, Mater University Hospital, Dublin, Ireland, 2Dublin Institute of Technology, Dublin, Ireland, 3Mater University Hospital, Dublin, Ireland

(741) *Anticholinergic Burden and Cognitive Impairment in Patients with Heart Failure*; J. Salyer, L. Sargent, C. Tirado, M. P. Flattery, K. B. Shah. 1Adult Health, Virginia Commonwealth University, Richmond, VA, 2Psychology, Virginia Commonwealth University, Richmond, VA, 3Pauley Heart Center, VCUHealth, Richmond, VA

(742) *Showering with the Driveline Exit Site Exposed to Well Water Does Not Increase Rates of Driveline Exit Site Infection*; C. Ballew, M. Young, E. Burns, S. Mazimba. 1University of Virginia Health System, Ivy, VA, 2University of Virginia Health System, Charlottesville, VA

(743) *International Practices for Driveline Exit Site Care and Infection Prevention in Ventricular Assist Devices*; S. E. Schroeder, B. Shay, T. Schlöglhofer, J. Casida. 1MCS Team, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE, 2Advanced Heart Failure/MCS, Christiana Care Health System, Newark, DE, 3Division of Cardiac Surgery, Center of Medical Physics and Biomedical Engineering, Medical Univ of Vienna, Vienna, Austria, 4School of Nursing, Faculty Associate, John Hopkins Univ, Baltimore, MD

(744) *The Organ Care System Training Manual for Hearts Donated after Circulatory Death: The Experience of One UK Centre after 50 Successful DCD Heart Transplants*; C. Ellis, J. Baxter, R. Quigley, S. Messer, A. Page, E. Pavlushkov, S. Large, S. Tsui, P. Catarino, M. Berman, K. Morley. Transplant Unit, Royal Papworth Hospital, Cambridge, United Kingdom

(745) *Ventricular Assist Device Therapy Evaluation and Implantation Timing: A Destination Therapy Center’s Perspective*; S. E. Schroeder, J. A. Steuter. 1MCS Team, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE, 2Division of Cardiology, Bryan Heart, Lincoln, NE

(746) *A Qualitative Analysis of Adolescent and Young Adult Decision Making about Heart Transplant*; C. Smith, V. Miller, K. Uzark, R. Lowery, K. R. Schumacher, M. K. Cousino. 1Pediatrics, C.S. Mott Children’s Hospital, Ann Arbor, MI, 2Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA

(747) *Establishing a Nursing-Led Ex-Vivo Lung Perfusion Program: A Primer*; D. Miller, N. Wrenn, M. Tran, J. Muraka, K. Gaskie, A. Banga, F. Torres, M. Wait. UT Southwestern Medical Center, Dallas, TX

(748) *Professional Employment Following Thoracic Transplantation*; C. Kugler, S. Jobst, J. Schaefer, H. Spaderna, C. Kleiser. 1Faculty for Medicine, Albert-Ludwigs-Univ Freiburg, Freiburg, Germany, 2Health Psychology, Univ Trier, Freiburg, Germany
(749) Relationship of Spiritual Wellbeing and Depressive Symptoms for Patients with a Left-Ventricular Assist Device (LVAD); K. E. Sandau1, C. S. Lee2, R. Garberich3, C. E. Weaver4, S. Joseph5, S. A. Hall6, S. Carey7, J. A. Cowger8, S. P. Chaudhry9, S. E. Schroeder8, R. O. Hoffman, III10, D. Feldman11, G. Conway12, E. Y. Birati10, M. Soni11, J. Marble12, M. S. Kunz13, K. M. Storey13, K. M. Faulkner14, P. Eckman1. 1Bethel University, St. Paul, MN, 2Boston College Connell School of Nursing, Boston, MA, 3Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, 4Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, 5Baylor University Medical Center, Dallas, TX, 6Henry Ford Hospitals, Detroit, MI, 7St. Vincent Heart Center/St. Vincent Indianapolis, Indianapolis, IN, 8Bryan Heart Center, Lincoln, NE, 9University of Cincinnati Medical Center, Cincinnati, OH, 10Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 11Department of Medicine, University of Pennsylvania, University of Pennsylvania, PA, 12University of Pennsylvania, Philadelphia, PA, 13Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, 14Boston College Connell School of Nursing, Chestnut Hill, MA

(750) Describing the End of Life Experience of Patients Supported with a Life-Sustaining Left Ventricular Assist Device (LVAD) as Bridge to Transplantation in a UK Centre; D. Weiand, M. McKenna. Specialist Palliative Care Team, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(751) Vanishing MCS Caregiver: Insights into the Impact of Machines on the Caring Relationship; B. Coleman1, B. Martinez1, H. Barone2, M. Williams3, H. Aronow1, K. Sandau1, L. Ansryan1, J. Felice1, J. Hajj1, L. Olanisa1, N. Huie1, A. Fishman1, M. Olman1, M. White2, J. Pamu1, D. H. Chang2. 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

(752) Assessment of Pre-Transplant Perceptions during Transition to Lung Transplant; L. N. Fessler1, K. W. Wright1, G. Pace1, S. Andrews2, M. Davis1, K. Raffensperger1, J. Seymour1, M. Lagergren2, N. West4, C. Merlo6, P. Shah6. 1Surgery, Johns Hopkins Hospital, Baltimore, MD, 2Psychiatry, Johns Hopkins Hospital, Baltimore, MD, 3Nutrition, Johns Hopkins Hospital, Baltimore, MD, 4Johns Hopkins Hospital, Baltimore, MD, 5Social Work, Johns Hopkins Hospital, Baltimore, MD, 6Pulmonary, Johns Hopkins Hospital, Baltimore, MD

(753) Self-Care Management after Ventricular Assist Device Implantation: Recipient Needs and Experiences after Hospital Discharge; W. Alonso1, E. Mollard1, L. Zimmerman1, S. Lundgren4, A. Clark3, B. Pozehl1. 1College of Nursing, University of Nebraska Medical Center, Omaha, NE, 2College of Medicine, University of Nebraska Medical Center, Omaha, NE, 3Cardiothoracic Surgery, Nebraska Medicine, Omaha, NE

(754) Using Patient Feedback to Drive Psychological Care in Awake Extracorporeal Life Support; M. Sanchez1, A. Simon2, M. Carby3, A. Reed4. 1Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom, 2Director, MCS and Cardiothoracic Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom, 3Lung Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

POSTER SESSION 1: PHARMACY AND PHARMACOLOGY
Room: Gardenia 1

Poster Discussants:
Edward Horn, PharmD, University of Pittsburgh, Pittsburgh, PA, USA
Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, USA

(755) Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Cardiothoracic Transplant Recipients; T. Pasley, A. Logan, A. Brueckner, L. Bowman-Anger, A. Silverman, A. Rumore. Tampa General Hospital, Tampa, FL

(756) Outcomes Associated with Opioid Use in Cardiothoracic Transplant Recipients; A. J. Brueckner, A. T. Logan, A. L. Rumore, L. J. Bowman. Pharmacy, Tampa General Hospital, Tampa, FL

(757) Effect of Glecaprevir-Pibrentasvir on Tacrolimus Dosage Requirements in Cardiac Transplant Recipients; T. C. Lewis, C. Gidea, A. Reyentovich, N. Moazami. Transplant Institute, NYU Langone Health, New York, NY

(758) The Efficacy of Intensive Monitoring of SerumTacrolimus Level Post Itraconazole Cessation in Preventing Rejection after Heart Transplant; N. Song, K. Muthiah, J. Phan, K. Kearney, C. Pereira Kessler, Iglesias, F. Burrows, L. Carlos, C. Hayward, A. Keogh, A. Jabbour, E. Kotlyar, P. Macdonald. 1Heart Transplant Unit, St Vincent's Hospital, Sydney, Darlinghurst, Australia, 2Pharmacy, St Vincent's Hospital, Sydney, Darlinghurst, Australia


(760) Kidney Function in Lung Transplant Patients Receiving IV Tacrolimus; G. Waldman, A. Feist, L. Awdishu, G. Yung, K. Afshar. 1Massachusetts General Hospital, Boston, MA, 2UC San Diego Health, San Diego, CA

(761) Evaluation of Outpatient Anticoagulation Bridging after Left Ventricular Assist Device (LVAD) Implantation; R. Rainess, L. Alderman, A. Butler, T. Cicci, M. Yoder, B. Pisanii. 1Wingate University School of Pharmacy, Wingate, NC, 2Campbell University College of Pharmacy & Health Science, Buies Creek, NC, 3Acute Care Services Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC, 4Professor of Medicine, Cardiology, Wake Forest Baptist Medical Center, Winston-Salem, NC

(762) Use of Cangrelor during Venoarterial Extracorporeal Membrane Oxygenation Following Percutaneous Coronary Intervention; A. M. Ciolek, K. Ma, D. L. Jennings, A. R. Garan, A. Eisenberger. 1Pharmacy, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, 2Medical Cardiology, Columbia University, New York, NY, 3Hematology, Columbia University, New York, NY

(763) An Evaluation of Warfarin Dose Changes after Discharge from Mechanical Circulatory Support Device Implantation; R. H. Cosgrove, R. L. Basken, J. R. Finger, J. L. Deangelo, R. G. Smith, T. Kazui, Z. Khalpey. 1Department of Pharmacy Services, Banner University Medical Center - Tucson, Tucson, AZ, 2Artificial Heart Department, Banner University Medical Center - Tucson, Tucson, AZ, 3Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: INFECTION DISEASES
Room: Banda Sea 2

Poster Discussants:
Shalika Katugaha, MD, INOVA Fairfax Hospital, Falls Church, VA, USA
Me-Linh Luong, MD, St. Luc Hospital, Montreal, Canada
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

(1245) Letermovir for Prevention of CMV Infection after Lung Transplantation; B. C. Keller1, P. Burcham2, S. Kirkby1, D. R. Nunley3, I. Poojary4, M. Howsare5, B. A. Whitson1, M. Lustberg1. 1Internal Medicine, The Ohio State University, Columbus, OH, 2Pharmacology, The Ohio State University, Columbus, OH, 3Cardiac Surgery, The Ohio State University, Columbus, OH

(1246) Previous Contaminant, Now Emerging Pathogen; A. Ariuna, S. Chandrashekaran, E. Rodriguez, A. Pelaez. Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL

(1247) Cardiac Transplantation as Salvage Therapy Following Bartonella henselae Infective Endocarditis; W. Kuan1, K. Dulnuan2, M. Guglin1, A. Kolodziej1, H. El Haddad1, N. Rajagopalan1. 1University of Kentucky Healthcare, Lexington, KY, 2University of Louisville, Louisville, KY


(1252) Is PJP Prophylaxis Sufficient to Prevent Acute Toxoplasmosis in Solid Organ Transplant World?; S. Nandavaram1, L. Benninger2, S. Chandrashekaran3, A. Emiriazoo3, H. Alnuaimat4, T. Machuca1, M. Pipkin4, A. Shahmohammadi5, C. Lim1, V. Scheuble2, A. Pelaez2. 1Surgery, University of Kentucky, Lexington, KY, 2Medicine, University of Florida, Gainesville, FL, 3Surgery, University of Florida, Gainesville, FL

(1253) Donor-Derived Strongyloides Hyperinfection Syndrome in a Lung Transplant Recipient; K. Ahmad1, O. Shlobin1, S. Aryal1, S. Nathan1, C. King1, A. Brown2, S. Katugaha2. 1Transplant, Inova Fairfax Medical Center, Falls Church, VA, 2Infectious Disease, Inova Fairfax Medical Center, Falls Church, VA

(1254) Fatal Scedosporium apiospermum Complex Left Ventricular Assist Device (LVAD) Infection Precipitating Pump Thrombosis; S. J. Chung1, F. Y. Chan1, T. Tan2, J. Soon3, L. L. Teo3, D. K. Sim4, Y. Tan4, T. Tan5, B. Tan1, C. Sivathasan2. 1Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore, 2Department of Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore, 3Department of Cardiology, National Heart Centre, Singapore, Singapore, 4Department of Microbiology, Singapore General Hospital, Singapore, Singapore

(1255) Cryptococcus laurentii Hip Infection after Lung Transplant; M. K. Kim1, W. Brown2, O. Shlobin2, C. King2, S. Aryal2, K. Ahmad2, A. Cochran2, L. Marinak2, S. B. Katugaha3. 1Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, 2Inova Advanced Lung Disease and Transplant, Inova Fairfax Hospital, Falls Church, VA, 3Infectious Diseases Physicians, Inc., Inova Fairfax Hospital, Falls Church, VA

(1256) A Stealth Invader under CMV Cover; N. Pempalung1, R. A. Miller2, B. D. Alexander2. 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Duke University Medical Center, Durham, NC

(1258) **Feline Fevers!**; A. Arjuna, S. Chandrashekaran, H. Alnuaimat, A. Pelaez, D. Schain. *Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL*

(1259) **Cardiac Aspergillosis in a Lung Transplant Recipient**; T. K. Rajab, S. Singh, H. Mallidi, H. Goldberg, A. E. Woolley. *Bridgham and Women’s Hospital, Boston, MA*

(1260) **Acute Myocarditis after Lung Transplantation**; J. E. Afonso1, I. Wozniak2, R. Carraro1, R. H. Teixeira2, L. T. Pires2, P. L. Camargo1, S. Mangini2. 1Lung Transplant, Albert Einstein Jewish Hospital, Sao Paulo, Brazil, 2Heart Transplant, Albert Einstein Jewish Hospital, Sao Paulo, Brazil

(1261) **A Case of Aspergillus Mural Endocarditis after Liver-Kidney Transplantation**; H. Choi1, G. Kim1, J. Youn3, Y. Yoon1, Y. Cho2, G. Cho2. 1Hallym Sacred Heart Hospital, Anyang, Korea, Republic of, 2Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, 3Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of

(1262) **Carbapenem-Resistant Enterobacteriaceae Pneumonia Early after Single Lung Transplant**; S. El Hajj1, R. El-Lababidi1, M. Mooty2, M. Balkis2, F. Hamed3. 1Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 2Infectious Diseases, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 3Transplant Pulmonology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates


(1264) **Cardiac Aspergillosis - 1 Year after Cardiac Transplant**; A. E. Woolley1, T. K. Rajab2, M. R. Mehra3, A. Coppolino4, E. L. Woodcome1, D. S. Page3, L. R. Baden1, S. K. Singh2. 1Infectious Diseases, Brigham and Womens Hospital, Boston, MA, 2Cardiac Surgery, Brigham and Womens Hospital, Boston, MA, 3Cardiology, Brigham and Womens Hospital, Boston, MA, 4Thoracic Surgery, Brigham and Womens Hospital, Boston, MA
Wednesday, April 3, 2019
6:00 PM - 7:15 PM
POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: MECHANICAL CIRCULATORY SUPPORT
Room: Banda Sea 2

Poster Discussants:
Stephane Collaud, MD, Essen, Germany
Adam Putschoegl, DO, Mayo Clinic, Rochester, MN, USA


(1267) Hypoxia on Venous-Venous Extracorporeal Membrane Oxygenation after Uncomplicated Single Lung Transplant; D. P. Logsdon, A. Kiankhooy, P. McFadden, A. Hackmann. 1University of Southern California, Los Angeles, CA, 2Cardiothoracic Surgery, University of Southern California, Los Angeles, CA

(1269) Prophylactic Percutaneous Circulatory Support in High Risk Transcatheter Aortic Valve Replacement (TAVR); J. Castrodeza, A. Serrador Frutos, I. Amat-Santos, I. Sayago Silva, J. San Román. Hospital Clinico Universitario Valladolid, Valladolid, Spain

(1270) Fulminant GCM Bridged to Transplant with Heartware HVADs in Biventricular Configuration; P. Pirlamarla, A. Anyanwu, A. Pawale, G. Larocca, D. M. Mancini, N. Moss. 1Thomas Jefferson University Hospital, Philadelphia, PA, 2Mount Sinai Hospital, New York, NY

(1271) Percutaneous Temporary RVAD Support via Protek-Duo TandemLung to Treat Right Heart Failure Secondary to Scleroderma Severe Pulmonary Artery Hypertension; J. A. Gomez-Abraham, S. Brann, K. Minakata, S. Keshavamurthy, G. Sunagawa, M. Kashi, B. O'Neill, Y. Toyoda. 1Surgery, Temple University School of Medicine. Division of Cardiovascular Surgery, Philadelphia, PA, 2Medicine, Temple University School of Medicine. Division of Interventional Cardiology, Philadelphia, PA


(1273) Implantation of a Left Ventricular Assist Device (HeartMate 3) as Destination Therapy in a Patient with Antiphospholipid Syndrome; A. Z. Pinatto, S. R. Siqueira, F. Scussel, M. S. Lira, L. C. Sampaio, P. P. Fernandes, M. S. Avila, L. A. Hajjar, E. A. Bocchi, S. M. Ayub-Ferreira. 1Insuficiência Cardíaca e Transplante, Instituto do Coração, Faculdade de Medicina de São Paulo, São Paulo, Brazil, 2Instituto do Coração, Faculdade de Medicina de São Paulo, São Paulo, Brazil

(1274) Rescue Therapy for Acute Pulmonary Hypertension Related to Sickle Cell Disease; P. Mudigonda, V. Cotlar, J. M. Elwing. 1Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH, 2Advanced Heart Failure and Transplant, University of Cincinnati, Cincinnati, OH, 3Pulmonary Hypertension Program, Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, OH

(1275) Cholecystitis after Left Ventricular Assist Device Implantation; a Case Series; K. Ahmad, D. Mehta, K. Meehan, N. Krause, S. Pauwaa, A. Tatooles, P. Pappas, G. Macaluso, W. Cotts, C. Sciamanna, A. Joshi, A. Andrade. 1Brown University, Providence, RI, 2Advocate Christ Medical Center, Oak Lawn, IL

(1276) VA-ECMO Use in Staged Combined Heart-Kidney Transplant; T. Al Saadi, A. Joshi, A. Andrade, W. Cotts, G. Macaluso, S. Pauwaa, M. Dia, A. Tatoole, P. Pappas, C. Sciamanna. Advocate Christ Medical Center, Oak Lawn, IL

(1277) Implantation of Implantable Left Ventricular Assist Device for Bridging to Transplantation in Patients with Female Dystrophinopathy: Two Case Reports; H. Mochizuki, K. Iwasaki, Y. Kimura, K. Toda, Y. Kumai, K. Kuroda, S. Nakajima, T. Watanabe, O. Seguchi, M. Yanase, T. Fujita, J. Kobayashi, N. Fukushima. 1Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
(1278) **It Takes a Village to Take Care of a Left Ventricular Assist Device**: D. Tang\(^1\), A. Ghaly\(^2\), M. Huang\(^3\), K. Mody\(^1\), D. Iyer\(^1\).
\(^1\)Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, \(^2\)Cardiothoracic Surgery, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, \(^3\)Cardiology, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ

(1279) **Veno-Arterial Extracorporeal Membrane Oxygenation with Chemotherapy in B-Cell Lymphoma Which Induced Tracheal Collapse**: X. Xu, M. Huang. General ICU, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China

(1280) **Left Axillary Artery Side Graft ECMO Cannulation and Direct Pre-Oxygenator Heparin Infusion**: O. Altas, O. Yerlikhan, T. Özer, S. Sarikaya, K. Kirali. Cardiovascular Surgery, Kosuyolu Heart Training and Research Hospital, Istanbul, Turkey
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: PEDIATRICS
Room: Banda Sea 2

Poster Discussants:
Chesney Castleberry, MD, St. Louis Children's Hospital, St. Louis, MO, USA
Michelle Ploutz, MD, MPH, Phoenix Children's Hospital, Phoenix, AZ, USA
Ann Punnoose, MD, Children's Hospital of Wisconsin, Milwaukee, WI, USA

(1281) Successful Treatment of Adenoviremia with Bricidofovir in a Pediatric Heart Transplant Recipient; S. M. Lyon, J. J. Parent. Pediatric Cardiology, Indiana University, Indianapolis, IN

(1282) Increased VAD Flow is Required in Fontans with Significant AP Collaterals; E. K. Bedzra¹, A. C. Nutting², M. N. Kavarana¹. ¹Surgery, Medical University of South Carolina, Charleston, SC, ²Pediatrics, Medical University of South Carolina, Charleston, SC

(1283) Anamnestic Response Treated with Total Lymphoid Irradiation after Pediatric Heart Transplantation; A. M. Ybarra¹, J. Scheel¹, D. Phelan², K. E. Simpson¹, A. Abarbanell², C. E. Canter¹, P. Eghtesady², C. D. Castleberry¹. ¹Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis, MO

(1284) "Acquired" Brugada Syndrome in a Cardiac Allograft; A. Power¹, S. Lévesque², A. I. Dipchand¹, E. Jean-St-Michel¹, E. A. Stephenson¹, S. Mital¹, A. Jeewa¹. ¹Hospital for Sick Children, Toronto, ON, Canada, ²Sherbrooke Genomic Medicine, Sherbrooke, QC, Canada

(1285) Relieving Bronchial Compression Due to Cardiomegaly; the Role of Aortopexy When LVAD Support Just Isn't Enough; J. A. Laks¹, M. Haranal², P. Purcell³, S. L. Cushing³, M. Mazwi⁴, O. Honjo⁵, A. Jeewa¹. ¹Division of Cardiology, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Cardiovascular Surgery, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Otolaryngology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada

(1286) Left Ventricular Assist Device as a Bride-to-Decision in a Williams Syndrome Child with Dilated Cardiomyopathy; Y. Shin¹, Y. Shin¹, J. Jung², H. Park¹. ¹Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea, Republic of

(1287) BK Virus as a Rare Cause of Native Kidney Failure after Pediatric Heart Transplantation; D. W. Bearl¹, J. Godown¹, K. Jabs², D. E. Dulek³, D. A. Dodd¹. ¹Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Pediatric Nephology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ³Pediatric Infectious Diseases, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN

(1288) First Pediatric HeartMate3 Implantation: US Experience; N. Zwintscher¹, S. Desai², A. Bansal¹. ¹Cardiothoracic Surgery, Ochsner Medical Center, New Orleans, LA, ²Heart Transplant, Ochsner Medical Center, New Orleans, LA

(1289) Successful Heart Transplant in an Infant with Noonan Syndrome; R. L. Shih¹, D. Gupta¹, A. Kimbro¹, B. A. Pietra¹, J.Phillip², F. J. Fricker¹. ¹Pediatric Cardiology, University of Florida College of Medicine, Gainesville, FL, ²University of Florida, Gainesville, FL
Wednesday, April 3, 2019
6:00 PM - 7:15 PM

POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: MECHANICAL CIRCULATORY SUPPORT
Room: Banda Sea 1

Poster Discussants:
Mustafa Ahmed, MD, University of Florida, Gainesville, FL, USA
Sai Bhagra, MRCP (UK), Toronto General Hospital, Toronto, Canada
Robert Hooker, MD, South Florida Hospital, Tampa, FL, USA
Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland
Maryse Palardy, MD, University of Michigan, Ann Arbor, MI, USA
Martin Strueber, MD, Beth Israel Medical Center, Newark, NJ, USA

(1290) Double Sequential Defibrillation for LVAD Patient in Refractory Ventricular Fibrillation; M. DiVita, M. Montgomery, M. Zucker, L. Letarte. Newark Beth Israel Med Ctr, Newark, NJ


(1292) Use of an Implantable Pulmonary Artery Pressure Monitor to Guide Hemodynamic Echocardiogram-Based LVAD Ramp Testing for Presumed Pump Thrombosis; S. Sharma1, A. Oseran1, M. E. Afari2, T. Lebeis3, L. Arrighi2, J. Camuso3, K. Milley3, J. Ruckel3, M. Swan2, D. Sullivan2, G. D. Lewis2, S. Thomas2. 1Medicine, Massachusetts General Hospital, Boston, MA, 2Cardiology, Massachusetts General Hospital, Boston, MA, 3Cardiac Surgery, Massachusetts General Hospital, Boston, MA

(1293) Colonic Mass and Gastrointestinal Bleeding after Left Ventricular Assist Device Implant: A Rare Case of Cytomegalovirus Colitis; M. F. Sullivan1, M. A. Psotka1, L. B. Cooper1, C. W. May1, S. S. Desai1, R. Singh2, M. Abedi1, S. B. Katugaha3, H. Mani2, P. Shah1. 1Cardiovascular Disease, Inova Heart and Vascular Institute, Falls Church, VA, 2Thoracic and Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, 3Gastroenterology, Inova Fairfax Medical Campus, Falls Church, VA


(1295) Applying Heart String Anastamotic Device for Left Ventricular Assist Device Outflow Graft Anastomosis; A. Mehdian1, N. Kalampokas1, A. Albert1, U. Boeken1, P. Akhyari1, R. Westenfeld2, H. Aubin1, A. Lichtenberg1, D. Saeed1. 1Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

(1296) A Novel Approach to Aortic Root Thrombus and Left Main Coronary Artery Occlusion in a Patient with a Left Ventricular Assist Device; B. DeMoss1, D. Markham, G. Chang, A. Thobani, R. Cole, J. Miller. Emory University School of Medicine, Atlanta, GA

(1297) First Percutaneous Right Ventricular Assist Device Placement through Persistent Left Superior Vena Cava; G. Sunagawa1, S. Brann1, B. O’Murchu2, J. Pelberg2, A. Singh2, A. Vaidya2, E. Hamad2, Y. Toyoda1. 1Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, 2Cardiology, Temple University Hospital, Philadelphia, PA

(1298) HeartWare LVAD in Adult Patients with Complex Single Ventricle Physiology and Failed Systemic Ventricle; J. M. Griffin1, M. J. Lewis1, M. Yuzefpolskaya1, M. Cevasco1, R. Te-Frey1, M. Tiburcio1, J. Ginn2, R. W. Elder3, M. Rosenbaum1, M. A. Farr1, P. C. Colombo1, H. Takayama1, K. Takeda1, K. M. Axsom1, Y. Naka1. 1Columbia University Medical Center, New York, NY, 2Weill Cornell Medical Center, New York, NY, 3Yale - New Haven Hospital, New Haven, CT

(1299) Impact of A-V Synchrony on LVAD Flow and Pulsatility; R. I. Goldberg1, A. Sridharan1, A. Vest1, D. DeNofrio1, G. Couper2, M. Kawabori2, M. S. Kieman1. 1Cardiology, Tufts Medical Center, Boston, MA, 2Cardiac Surgery, Tufts Medical Center, Boston, MA

(1300) An Unusual Case of Acquired Hypoxemia Following LVAD; S. N. Purohit1, A. L. Strobel1, A. A. Desai1, M. T. Marsala1, T. M. Bull2, D. Vargas2, J. D. Kay2, N. L. Altman1. 1Cardiology, University of Colorado, Denver, CO, 2Pulmonology, University of Colorado, Denver, CO

(1301) HeartMate III Outflow Graft Thrombosis; J. Eulert-Grehn1, C. Klein2, V. Falk1, E. Potapov1, C. T. Starck1. 1Cardiac, Thoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany
(1302) Innumerable Systemic-Pulmonary Shunt Formation during ECMO Support; D. Yoshioka, K. Toda, A. Satoh, S. Miyagawa, Y. Yoshihikawa, H. Hata, Y. Sawa. Osaka University Graduate School of Medicine, Osaka, Japan

(1303) Trimming the Waistline as a Bridge to Transplant in LVAD Patients; O. Ali, R. Donovan, H. Eisen. Penn State Hershey Medical Center, Hershey, PA

(1304) A Twist of Fate: Diagnosing LVAD Flow Obstruction from Late Twisting of the Outflow Graft; I. T. Tei, D. Miranda, I. Hussain, S. Chang, C. Lin, F. Beg, J. Bhatt, A. Guha, E. Suarez. 1Cardiology, Houston Methodist Hospital, Houston, TX, 2Cardiothoracic Surgery, Houston Methodist Hospital, Houston, TX

(1305) Utilization of Cardiac MRI for Risk Stratification of Right Ventricular Failure Post Left Ventricular Assist Device Implantation. A Case Series; A. Mahmoud, M. Al-Ani, D. Mahatta, J. Vilaro, M. Ahmed. 1Internal Medicine, University of Florida, Gainesville, FL, 2Internal Medicine - Cardiology, University of Florida, Gainesville, FL

(1306) Successful HVAD Left Ventricular Assist Device Implantation after ACORN Corcap Placement; M. Kawabori, E. Wang, M. Rambukwella, B. Deng, N. J. Toomey, C. Cassidy, Y. Zhan, F. Y. Chen, G. S. Couper. 1Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA

(1307) Simple, Effective and Inexpensive Distal Embolic Protection in Removing Impella 5.0 "Vessel Loop" Technique; M. Kawabori, Y. Pramill, N. K. Kapur, Y. Zhan, K. Ohlrich, E. Wang, M. Rambukwella, P. Shindigkar, F. Y. Chen, G. S. Couper. 1Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA

(1308) Minimally-Invasive Single Incision Temporary Biventricular Assist Device Insertion; E. Sandoval, A. Fernandez-Cisneros, R. Pruna, D. Pereda. Cardiovascular Surgery, Hospital Cliníc, Barcelona, Spain

(1309) Heart Mate 3 LVAD Implant with Left Subcostal Approach as a BTT Replacing HMII LVAD (DT) Complicated with Recurrent Pump Thrombosis in a Patient with Non Ischemic Cardiomyopathy Ultimately on Heart Transplant List; J. A. Gomez-Abraham, K. Minakata, S. Keshavamurthy, S. Brann, F. Kromah, M. Kashem, E. Hamad, R. Alvarez, Y. Toyoda. 1Surgery, Temple Univ School of Medicine. Division of Cardiothoracic Surgery, Philadelphia, PA, 2Medicine, Temple Univ School of Medicine. Division of Cardiology, Philadelphia, PA, 3Medicine, Temple Univ School of Medicine. Division of Cardiology, Philadelphia, PA


(1311) Permanent Dialysis Access in a Total Artificial Heart Patient; B. B. Hair, L. Kirksey, M. Z. Tong, N. Smedira, M. Hanna. 1Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH, 2Department of Vascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 3Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 4Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH

(1312) LVAD Decommission with Percutaneous Outflow Graft Occlusion: A Word of Caution; K. Oh, O. Saeed, J. Wiley, R. H. Pass, N. J. Sutton, S. Madan, M. Shah, K. Rahgozar, S. R. Patel, S. Vukelic, D. B. Sims, D. Goldstein, U. P. Jorde. 1Medicine, Div of Cardiology, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY, 2Pediatric Cardiology, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY, 3Medicine, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY, 4Cardiovascular and Thoracic Surgery, Montefiore Med Center/Albert Einstein College of Medicine, Bronx, NY

(1313) Enoxaparin in a Dialysis-Dependent LVAD Patient with Presumed Pump Thrombosis; A. Mardis, S. Blandy, S. Branham, J. Barham, A. Poole, P. McCann, J. Martin, R. Napier. 1Department of Pharmacy, Palmetto Health, Columbia, SC, 2Cardiothoracic Surgery, Palmetto Health, Columbia, SC, 3Cardiology, Palmetto Health, Columbia, SC

(1314) Case Report on Interventional Treatment of HeartMate 3 LVAD Outflow Graft Twisting with a Bare Metal Stent Insertion; A. Juraszek, J. Szymański, M. Demkow, M. Sobieszczańska-Malek, M. Kuśmierczyk. 1Dept of Cardiac Surgery and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland, 2Dept of Coronary and Structural Heart Disease, Warsaw Institute of Cardiology, Warsaw, Poland, 3Dept of Heart Failure and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland

(1315) Computed Tomography in Diagnosing Thrombosis of the LVAD’s Outflow-Graft: Still a Challenge; A. Addas, J. Fischer, S. Lehmann, J. Garbade, M. Borger. 1Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany

(1316) Intracardiac Echocardiography a Novel Approach in the Evaluation Total Artificial Heart Function; C. Buto-Colletti, J. N. Konuru. Virginia Commonwealth University, Virginia Commonwealth University, Richmond, VA
(1317) Left Ventricular Assist Device Support in a Patient with Ischemic Cardiomyopathy from Untreated Homocystinuria; A. M. Shah1, N. Bansal2, D. Hsu1, J. Lamour2, D. Sims1, J. Shin1, U. Jorde1, D. Goldstein3, W. Jakobleff6, G. Peek1. 1Division of Cardiology, Montefiore Medical Center, Bronx, NY, 2Pediatric Cardiology, Montefiore Medical Center, Bronx, NY, 3Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY

(1318) Caught in the Act: Left Ventricular Assist Device Suction Event Diagnosed with Electrocardiogram Gated Computed Tomography Angiography; M. Kawabori1, M. Rambukkawella2, E. Wang2, C. Cassidy2, K. Barry2, A. Soin2, S. Lofftus2, V. Pramil2, F. Y. Chen1, G. S. Couper1. 1Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA

(1319) An Unusual Cause of Outflow Graft Thrombosis; M. Veerasamy, T. Boeve, D. Fermin. Spectrum Health, Grand Rapids, MI

(1320) Changes in Pulmonary Vascular Resistance and the Incidence of Right Heart Failure in Post Cardiac Transplant Patients Bridged with Biventricular Assist Devices; S. Adhikari1, G. Rubin2, K. Meehan3, A. Andrade3, W. Cotts3, S. Pauwaa3, A. Joshi3, C. Sciamanna3, P. Pappas3, A. Tatooles3, G. Macaluso3. 1University of Illinois-Christ, Oak Lawn, IL, 2Advocate Lutheran General Hospital, Park Ridge, IL, 3Advocate Christ Medical Center, Oak Lawn, IL

(1321) A Case of Beta Blocker Therapy for Harlequin Syndrome in Venoarterial ECMO; S. Kaur1, R. Hussain1, B. Maffre1, I. Gregorie1, B. Kar1, B. Akkanti1, K. Dinh1, S. Nathan2, M. Jumean2, S. Kumar2, I. Salas de Armas2, J. Patel2, M. Patel2. 1Pulmonary Critical Care and Sleep Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 2University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX

(1322) Beating the Odds: ECMO CPR to Rescue Patient with Cardiogenic Shock Due to Non-Hodgkin Lymphoma; I. Saba, M. Loebe, R. Cifuentes, N. Thakkar, A. Badiye, A. Ghodsizad, S. Chaparro, N. Brozzi. University of Miami, Miami, FL

(1323) Evolving Indications of Left Ventricular Assist Device Therapies: Long-Term LVAD Support for Chagas Cardiomyopathy; N. A. Brozzi, I. C. Saba1, S. Chaparro2, C. Franco Mesa3, T. Patricelli1, A. Ghodsizad4, N. Rivera Takkar2, A. Badiye5, M. Loebe6. 1Surgery, University of Miami, Miami, FL, 2Medicine, University of Miami, Miami, FL, 3Universidad CES, Medillin, Colombia

(1324) Minimally Invasive Approach of Left Ventricular Assist Device Implantation: Friend or Foe?; N. T. Rivera, N. Brozzi, M. Loebe, S. Chaparro, A. Badiye. Miami Transplant Institute, Jackson Health System in affiliation with University of Miami Health System, Miami, FL

(1325) Mechanical Circulatory Support for Right Ventricular Failure in Idiopathic Pulmonary Fibrosis Patient Who is Waiting for Lung Transplantation with VV ECMO: VVA ECMO or RVAD?; S. Lee1, D. Kim2. 1Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, 2

(1326) A Bailout Approach with Heart Mate-III in Deteriorating Heart Transplant Patient with Graft Dysfunction; F. Khaliel, F. Alshamdim, U. Kjellman. Cardiac Surgery, King Faisal Specialist Hospital & RC, Riyadh, Saudi Arabia

(1327) North-North Syndrome: Regional Differential Hypoxia in Patients with Centrally Cannulated Veno-Arterial Extracorporeal Membrane Oxygenation; M. Tsai. ECMO, AdventHealth, Orlando, FL

(1328) The Opportunistic Use of the Continuous Renal Replacement Therapy Circuit as a Physiologically Friendly Rapid Infuser during Catastrophic Bleeding; M. Tsai. ECMO, AdventHealth, Orlando, FL

(1329) Extended Infusion Alteplase for Refractory Left Ventricular Assist Device Pump Thrombosis; A. Mardis1, S. Frye1, A. Poole2, S. Branham2, J. Barham3, R. Napier3, P. McCann3, J. Martin3. 1Department of Pharmacy, Palmetto Health, Columbia, SC, 2Cardiothoracic Surgery, Palmetto Health, Columbia, SC, 3Cardiology, Palmetto Health, Columbia, SC

(1330) Application of VA ECMO in Patients with a High MELD-XI Score as a Bridge to VAD Implantation: Fact or Motion Sickness; A. Badiye1, R. R. Gonzalez2, J. Bauerlein3, A. Grant3, M. Loebe2, P. Rusconi3, A. Ghodsizad2. 1Cardiology, Miami Transplant Institute University of Miami, Miami, FL, 2Surgery, Miami Transplant Institute University of Miami, Miami, FL, 3Miami Transplant Institute University of Miami, Miami, FL

(1331) Plasma Leakage-Induced Outflow Graft Obstruction in a Jarvik 2000 Patient; T. Ushijima1, K. Hirayama1, Y. Tanoue1, T. Hashimoto2, T. Higo2, H. Tsutsui2, A. Shiode1. 1Cardiovascular Surgery, Kyushu University Hospital, Fukuoka, Japan, 2Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

(1332) With and without You: LVAD Unplugged; F. Loiacono, S. Vazquez, J. M. Dominguez, M. Farrero, M. Castel, F. Perez Villa. Heart Failure and Transplant Unit, Hospital Clinic, Barcelona, Spain
POSTER SESSION 1: JUNIOR FACULTY CASE REPORTS: PULMONARY HYPERTENSION
Room: Banda Sea 1

Poster Discussants:
Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada
Laurent Godinas, MD, PhD, University Hospitals Leuven, Leuven, Belgium

(1333) Management of Right Ventricular Failure through Pulmonary Thromboendarterectomy: A Role for Percutaneous Ventricular Support?; A. M. Schurman¹, M. T. Cain¹, D. L. Joyce², L. D. Joyce², L. A. Durham², A. Mohammed³; ¹Medical College of Wisconsin, Milwaukee, WI, ²Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, ³Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI

(1334) Salvage Therapy for Pulmonary Arterial Hypertension with Single Anomalous Pulmonary Vein Return via VV ECMO and Atrial Septostomy; V. Y. Parikh, L. Simpson, D. Parekh, C. Castillo, R. Reddy, A. Nair. Baylor St. Luke's Medical Center/Texas Heart Institute, Houston, TX

(1335) Injected Buprenorphine Tablets as Cause of Pulmonary Hypertension; S. D. Khodjaev, C. Alpert, R. L. Benza, S. Mirza, K. Hoffman, A. Hadi. Advanced Heart Failure and Transplant Cardiology, Allegheny Health Network, Pittsburgh, PA

(1336) Management of an Anomalous Right Coronary Artery with Underlying Pulmonary Arterial Hypertension; S. Bhattacharya, N. Colaco, A. Schnell Heringer, N. Tarango, M. Aras, V. Selby, L. Klein, T. De Marco. Cardiology, University of California, San Francisco, San Francisco, CA
POSTER SESSION 2: INFECTIOUS DISEASES

Room: Gardenia 2

Poster Discussants:
Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA
Ricardo La Hoz, MD, UT Southwestern Medical Center, Dallas, TX, USA
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia
Joanna Schaanman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA
Cameron Wolfe, MBBS MPH, Duke University Medical Center, Durham, NC, USA


(767) Simultaneous Assessment of Plasma and Peripheral Mononuclear Cells for Multiple Viral Load Quantification in Peripheral Blood of Patients after Heart Transplantation; N. Fukushima1, H. Sakaguchi2, K. Toda3, S. Kogaki3, J. Narita4, H. Ishida4, Y. Hashii5, T. Miyamura5, K. Imadome5. 1Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan, 2Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan, 3Department of Pediatrics, Osaka General Medical Center, Osaka, Japan, 4Department of Pediatrics, Osaka University, Suita, Japan, 5Department of Advanced Medicine for Infections, National Center for Child Health and Development, Tokyo, Japan


(769) Hepatitis E Virus after Heart Transplantation, Single Center Experience; M. Hegarová1, S. Fraňková2, P. Trunečka2, I. Málek1, V. Melenovský1. 1Clinic of Cardiology, IKEM, Prague, Czech Republic, 2Clinic of Hepatogastroenterology, IKEM, Prague, Czech Republic


(771) Impact of Mycophenolate Dosing on CMV Rates in Heart Transplant Recipients; H. Brink, M. Hyden. Nebraska Medicine, Omaha, NE

(772) Human Cytomegalovirus Immunoglobulin as an Early Adjunctive Therapy Increased CMV-Free Survival after Heart Transplantation; M. J. Barten1, C. Neumaier2, A. Bernhardt2, M. Rybczynski2, H. Reichenspurner2. 1Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, 2University Heart Center Hamburg, Hamburg, Germany

(773) Does Thymoglobulin Induction Lead to Increased CMV Infection after Heart Transplantation in the Current Tacrolimus Era?; M. Kittleson1, J. Patel1, R. Cole1, D. Geft1, S. Dimbil1, R. Levine1, S. Mersola1, L. Czer1, B. Azarbal1, R. Zabner2, P. Zakowski2, J. A. Kobashigawa1. 1Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA

(774) Undue Infection Risk from Proliferation Signal Inhibitors When Initiated Later after Heart Transplantation; M. Kittleson1, J. Patel1, E. Kransdorf1, D. Geft1, S. Dimbil1, R. Levine1, A. Velleca1, L. Czer1, A. Hage1, R. Zabner2, P. Zakowski2, J. Kobashigawa3. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA


(777) Cytomegalovirus Infection and Disease in Lung Transplant Recipients; B. L. Lynch¹, P. Ding², A. Ronayne³, C. De Gascun³, J. Kleinerova³, J. J. Egan³, M. M. Hannan¹. ¹Clinical Microbiology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Department of Pharmacy, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³National Virus Reference Laboratory, Dublin 4, Ireland, ⁴Department of Respiratory and Transplant, Mater Misericordiae University Hospital, Dublin 7, Ireland

(778) Impact of Respiratory Syncytial Virus Infection on Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients; N. Permpalung¹, T. Thaniyavarn², J. H. Saullo³, S. Arif³, R. A. Miller³, J. M. Reynolds³, B. D. Alexander³. ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC


(780) Kaposi's Sarcoma in Lung Transplantation; A Decade's Single-Centre Case Series; V. Rossetti¹, L. Morlacchi¹, L. Rosso², A. Palleschi², P. Mendogni², E. Benazzi³, M. Corbellino³, P. Tarsia¹. ¹Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ³Transplant Coordination (NITp); Dept. of Services and Preventive Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy


(782) Antifungal Prophylaxis in Lung Transplant Recipients: A Network Meta-Analysis; S. Herrera¹, E. Foroutan², S. Husain¹. ¹Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, ²Ted Rogers Center of Excellence in Heart Function, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada

(783) Analysis of Risk Factors for Invasive Mold Infections in Lung Transplant Recipients; J. Sullivan¹, N. Sharma², K. Patel², A. Logan². ¹Jackson Memorial Hospital, Miami, FL, ²Tampa General Hospital, Tampa, FL

(784) Lung Transplantation for Patients with Cystic Fibrosis and Achromobacter xylosoxidans in the Lung Allocation Score Era; E. Nolley¹, K. Robinson¹, J. Pilewski², P. Sanchez², J. DCunha², M. Morrall¹. ¹Pulmonary Allergy and Critical Care, University of Pittsburgh, Pittsburgh, PA, ²Division of Lung Transplantation and Lung Failure, University of Pittsburgh, Pittsburgh, PA

(785) Risk of Skin Cancers with Long-Term Itraconazole in Lung Transplant Recipients; K. Pennington, R. Razonable, S. Peters, R. Daly, J. Scott, M. Brutinel, H. Sekiguchi, M. Wylam, C. Kennedy. Mayo Clinic, Rochester, MN

(786) Donor to Host Transmission of Infection in Lung Transplantation; E. J. Wainstein¹, A. Smud¹, N. Mañez¹, M. L. Orazi¹, L. Barcan¹, G. N. Svetliza¹, C. Quinteros¹, A. Dietrich², A. Da Lozzo³, E. Beveraggi³, D. E. Smith³, H. M. Castro¹. ¹Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

(787) Susceptibility Testing of Exophiala dermatitidis to Inform Peri-Operative Prophylaxis at Time of Lung Transplantation; A. Perry¹, S. Mattu¹, S. Pearl¹, A. Hague¹, G. Meachery¹, A. Fisher¹, K. Gould¹, J. Samuel¹, A. Robb¹. ¹Microbiology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK, ²Institute of Transplantation, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK

(788) MSSA Bacteraemia Can Be Eliminated in LVAD Patients; N. Robinson Smith¹, A. Woods¹, S. Tovey Brown¹, G. A. MacGowan¹, S. Schueler¹, J. Samuel². ¹I HELP Service, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, ²Microbiology Department, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom

(789) Cold Atmospheric Plasma as an Additional Tool for Successful Therapy of Left Ventricular Assist Device Related Infections; L. Hilker¹, T. von Woedtke², K. Weltmann³, H. Wollert³, H. Reichenspurner³, M. Barten³. ¹Cardiovascular Surgery, Klinikum Karlsruhe, Karlsruhe, Germany, ²Cardiovascular Surgery, Leibniz Institute for Plasma Science and Technology, Greifswald, Germany, ³Leibniz Institute for Plasma Science and Technology, Greifswald, Germany

(790) Cold atmospheric plasma as an additional tool for successful therapy of left ventricular assist device related infections; L. Hilker¹, T. von Woedtke², K. Weltmann³, H. Wollert³, H. Reichenspurner³, M. Barten³. ¹Cardiovascular Surgery, Klinikum Karlsruhe, Karlsruhe, Germany, ²Cardiovascular Surgery, Leibniz Institute for Plasma Science and Technology, Greifswald, Germany, ³Leibniz Institute for Plasma Science and Technology, Greifswald, Germany

(791) Pre-LVAD Blood-Borne Infection is a Harbinger of Poor Prognosis after LVAD Implantation; B. Cugliostro¹, A. M. Zuver¹, L. Effner¹, G. Parkis¹, G. M. Mondellini¹, E. A. Roymanz¹, C. A. Bravo¹, R. Te-Frey¹, E. F. Lin¹, A. R. Garan¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Department of Medicine, Columbia University Medical Center, New York, NY, ²Department of Medicine, Montefiore Medical Center, Bronx, New York, NY, ³Department of Surgery, Columbia University Medical Center, New York, NY
(792) Etiology of Continuous-Flow LVAD (CF-LVAD) Infections; N. Wang¹, J. K. Ho², F. I. Musfee³, H. K. Lamba², F. H. Cheema², D. A. Taylor⁴, L. C. Sampaio⁴, J. A. Morgan⁴, G. Loor², O. H. Frazier², G. V. Letsou². ¹Heart Intensive Care Unit, First Affiliated Hospital of Dalian Medical University, Dalian, China, ²Surgery, Baylor College of Medicine, Houston, TX, ³Epidemiology, University of Texas School of Public Health, Houston, TX, ⁴Research, Texas Heart Institute, Houston, TX

(793) Total Replacement of Implantable Left Ventricular Assist Device for Pump Pocket/Device Infection; Y. Itoda, M. Kimura, O. Kinoshita, H. Yamauchi, K. Nawata, M. Ono. Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan

(794) Blood Stream Infection in Patients with Permanent Mechanical Circulatory Support: Risk Factors for On-Pump Mortality; N. K. Bart¹, S. Malik¹, S. Emmanuel², D. Andresen³, K. Muthiah¹, C. S. Hayward⁴. ¹Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, ²Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, ³Infectious Disease, St Vincents Hospital, Sydney, Australia, ⁴Heart Transplant and Failure, St Vincent's Hospital, Sydney, Australia
Thursday, April 4, 2019
5:45 PM - 7:00 PM

POSTER SESSION 2: LUNG TRANSPLANTATION (ADULT)
Room: Hibiscus 1

Poster Discussants:
Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria
Bronwyn Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia
Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany
Vincent Valentine, MD, University of Alabama, Birmingham, USA
Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia
Chad Witt, MD, Washington University School of Medicine, St. Louis, MO, USA

(795) Sequential Single Lung Transplant (SLT) with or without Ex-Vivo Lung Perfusion Maximizes on Donor to Transplant Conversion Rates; B. Gadallah, A. Hudson, J. Egan, L. Nolke, K. Redmond. Cardiothoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland

(796) Lung Transplantation from Donation after Circulatory Death Donors Following Portable Ex-Vivo Lung Perfusion: Post-Hoc Analysis of OCS Lung EXPAND Trial; L. J. Ceulemans1, A. Neyrinck2, G. Grooten3, G. Warnecke4, M. Villavicencio5, J. C. Madsen6, J. Kukreja6, M. Hartwig7, A. Ardehali8, S. Huddleston9, M. Hertz10, D. Van Raemdonck11. Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, Anesthesiology, University Hospitals Leuven, Leuven, Belgium, University of Minnesota Medical Center, Minneapolis, MN, Hannover Medical School, Hannover, Germany, Massachusetts General Hospital, Boston, MA, University of California San Francisco Medical Center, San Francisco, CA, Duke University, Durham, NC, University of California Los Angeles Medical Center, Los Angeles, CA

(797) Long (>6h) versus Short (<6h) Clinical Normothermic Ex-Vivo Lung Preservation: Post-Hoc Analysis of OCS Lung EXPAND Trial; L. J. Ceulemans1, A. Neyrinck2, G. Grooten3, G. Warnecke4, M. Villavicencio5, J. C. Madsen6, J. Kukreja6, M. Hartwig7, A. Ardehali8, S. Huddleston9, M. Hertz10, D. Van Raemdonck11. Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, Anesthesiology, University Hospitals Leuven, Leuven, Belgium, University of Minnesota Medical Center, Minneapolis, MN, Hannover Medical School, Hannover, Germany, Massachusetts General Hospital, Boston, MA, Univ of California San Francisco Medical Center, San Francisco, CA, Duke Univ, Durham, NC, Univ of California Los Angeles Medical Center, Los Angeles, CA

(798) Better Oxygenation in Upper Lobes Than in Whole Lungs in Marginal Human Donor Lungs Utilized for Cellular Ex Vivo Lung Perfusion; H. Niikawa1, T. Okamoto1, K. S. Ayyat1, Y. Itoda1, C. F. Farver2, K. R. McCurry1. Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, Anatomic Pathology, Cleveland Clinic, Cleveland, OH


(800) Factors That Predict the Successful Utilization of Donor Lungs after Ex-Vivo Lung Perfusion; P. H. Lemaître, E. Patel, K. Brar, R. J. Jeagal, J. C. Yeung, L. Donahoe, T. K. Waddell, S. Keshavjee, M. Cypel. Division of Thoracic Surgery and Lung Transplantation, Toronto General Hospital, Toronto, ON, Canada

(801) Arrhythmias Following Lung Transplantation: A Single Centre Experience; J. Dutton1, J. McLoughlin1, D. Garcia-Saez2, N. Lees1, A. Simon2, A. Hurtado-Doce1. Department of Anaesthesia and Critical Care, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom


(803) Constrictive Pericarditis after Lung Transplant: Zebra or Horse?; C. M. Wojnarowski1, A. Y. Choi2, M. G. Hartwig1, J. A. Klapper1, J. C. Haney1, C. A. Milano1, M. A. Daneshmand1. Thoracic and Cardiovascular Surgery, Duke University, Durham, NC, Duke University Medical School, Durham, NC

(804) Fractional Flow Reserve Guided Coronary Revascularization in Lung Transplant Recipients; J. Shin1, M. Suryapalam2, K. Shenoy3, B. O'Neill4, R. Bashir5, V. Lakhter4, B. O'Murchu4, V. Aggarwal5. Internal Medicine, Temple University Hospital, Philadelphia, PA, Biophysics and Computer Science, Temple University, Philadelphia, PA, Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA, Cardiology, Temple University Hospital, Philadelphia, PA, Cardiology, Michigan University, Ann Arbor, MI
Long-Term Outcomes are Worse in Patients Hospitalized Prior to Lung Transplantation; X. Zhou\(^1\), A. Suarez-Pierre\(^1\), C. Lui\(^1\), P. D. Shah\(^2\), B. S. Kim\(^2\), J. S. Ha\(^1\), C. A. Merlo\(^3\), E. L. Bush\(^1\). \(^1\)Surgery, Johns Hopkins Hospital, Baltimore, MD, \(^2\)Medicine, Johns Hopkins Hospital, Baltimore, MD

Extra-Operative Transfusions are Associated with Worse Outcomes after Lung Transplantation; O. Zou\(^4\), E. Granger\(^2\).

Not All Lungs are Dirty: Positive Sputum Culture in a Candidate with Pulmonary Fibrosis (PF) Should Not Always Deny the Option of Single Lung Transplant; M. I. Mohamed Mydin\(^1\), A. Perry\(^2\), J. Trevis\(^3\), N. Chilvers\(^1\), J. Samuel\(^2\), K. Gould\(^2\), G. Parry\(^4\), O. Senbaklavaci\(^1\), S. C. Clark\(^1\), J. H. Dark\(^1\). \(^1\)Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom, \(^2\)Department of Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, \(^3\)Newcastle University Medical School, Freeman Hospital, Newcastle upon Tyne, United Kingdom, \(^4\)Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Characteristics and Outcomes after Lung Transplantation among Patients with Advanced Lung Disease with Secondary Pulmonary Hypertension; H. Ali\(^1\), J. Mullins, M. Mohanka, S. Bollineni, V. Kaza, J. Joerns, F. Torres, M. Wait, M. Peltz, J. Murala, A. Banga. UT Southwestern Medical Center, Dallas, TX

Comparison of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) between Living-Donor Lobar Lung Transplantation and Cadaveric Lung Transplantation; T. Chen-Yoshikawa\(^1\), F. Gochi\(^2\), A. Ohsumi\(^2\), Y. Yamada\(^2\), Y. Yutaka\(^2\), D. Nakajima\(^2\), M. Hamaji\(^2\), H. Date\(^2\). \(^1\)Kyoto University, Kyoto, Japan, \(^2\)Thoracic Surgery, Kyoto University, Kyoto, Japan


Point of Care Management of Perioperative Coagulopathy Reduces Blood Loss and Consumption of Blood Transfusion Products (Preliminary Results); M. Durila\(^1\), J. Vajter\(^1\), R. Lischke\(^2\), J. Berousek\(^1\), T. Vymazal\(^2\). \(^1\)Anesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, \(^2\)3rd Department of Surgery, 1st Faculty of Medicine, Charles University, Motol University Hospital, Prague, Prague, Czech Republic

Progression of Mitral Valve Regurgitation after Lung Transplantation; W. Y. Shi, B. Levvey, A. D. Zimmet, S. F. Marasco, G. Snell, D. C. McGiffin. Alfred Hospital, Melbourne, Australia

Alternative Therapeutic Approach for the Management of Symptomatic Hyperammonemia Syndrome after Lung Transplantation; A. M. Emtiazioojoo\(^1\), S. Chandrashekar\(^1\), C. Lin\(^1\), H. Alnuaimat\(^1\), A. Shahmohammadi\(^1\), A. Kame\(^2\), T. Veasey\(^2\), T. Machuca\(^2\), M. Pipkin\(^3\), A. Pelaez\(^1\). \(^1\)Medicine, University of Florida, Gainesville, FL, \(^2\)Pharmacy, University of Florida, Gainesville, FL, \(^3\)Surgery, University of Florida, Gainesville, FL

Association between Allograft Ischemic Time and Adverse Outcomes Following Lung Transplantation; L. K. Tague\(^1\), W. Cherikh\(^2\), R. R. Lehman\(^2\), D. Chambers\(^3\), R. Yusen\(^1\), R. Hachem\(^2\). \(^1\)Internal Medicine, Pulmonary and Critical Care Medicine, Washington University in St. Louis, Saint Louis, MO, \(^2\)United Network for Organ Sharing, Richmond, VA, \(^3\)School of Medicine, University of Queensland, Brisbane, Queensland, Australia

Alpha 1-Antitrypsin Deficiency: Diagnosis and Replacement in the Lung Transplantation Phase of Life: Survey among Lung Transplant Specialists; A. M. Emtiazioojoo\(^1\), S. Chandrashekar\(^1\), A. Pelaez\(^2\), H. Alnuaimat\(^1\), A. Shahmohammadi\(^1\), T. Machuca\(^2\), M. Pipkin\(^2\), E. Golts\(^2\), G. Yung\(^3\), T. Floreth\(^3\), C. Lin\(^1\), K. Afshar\(^4\). \(^1\)Medicine, University of Florida, Gainesville, FL, \(^2\)Surgery, University of Florida, Gainesville, FL, \(^3\)Surgery, UCSD, La Jolla, CA, \(^4\)Medicine, UCSD, La Jolla, CA

Factors Associated with Prolonged Survival (>15 Years) after Lung Transplantation: Analysis of the ISHLT Registry; H. A. Ali\(^1\), M. Neely\(^2\), A. Long\(^3\), W. Cherikh\(^4\), D. Chambers\(^5\), J. Stehlik\(^6\), L. Snyder\(^1\). \(^1\)Internal Medicine, Duke University, Durham, NC, \(^2\)Dept of Biostatistics & Bioinformatics, Duke University, Durham, NC, \(^3\)DCRI, Duke University, Durham, NC, \(^4\)Internal Medicine, ISHLT, ISHLT, VA, \(^5\)Heart and Lung Transplantation, The Prince Charles Hospital, Brisbane, Australia, \(^6\)Internal Medicine, Univ of Utah Sch of Med, Salt Lake City, UT
(818) Improvements in Health-Related Quality of Life with Lung Transplantation: A Prospective Multicenter Cohort Study; L. D. Snyder¹, M. Neely¹, H. Kopetskie², M. Sever¹, J. Kirchner¹, C. Frankel¹, J. Todd¹, P. Smith¹, N. Williams¹, M. Robien¹, J. Belperio⁴, D. Ross⁴, D. Rozenberg⁵, M. Budev⁶, W. Tsuang⁶, P. Shah⁷, J. Reynolds¹, S. Palmer¹, L. Singer⁵, *. for CTOT-20 Investigators². ¹Duke University Med Ctr, Durham, NC, ²Rho Federal Systems Division, Chapel Hill, NC, ³NIAID, Bethesda, MD, ⁴UCLA, Los Angeles, CA, ⁵University of Toronto, Toronto, ON, ⁶Cleveland Clinic, Cleveland, OH, ⁷Johns Hopkins, Baltimore, MD.

(819) Morbidity and Mortality in Hospitalized versus Outpatient Lung Transplant Recipients; D. Rudym¹, L. Benvenuto¹, H. Kim², L. Shah¹, M. Aversa¹, H. Robbins¹, J. Hook¹, F. D’Ovidio³, M. Bacchetta¹, J. Sonett³, S. Arcasoy¹. ¹Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, NY, ²NewYork-Presbyterian Hospital, New York, NY, ³Department of Surgery, Columbia University Medical Center, New York, NY

(820) Return to Work in Lung Transplant Recipients: An Australian Perspective - Predictors, Health Status and Outcomes; M. Munsif, K. Levin, G. Snell, M. Paraskeva. Lung Transplant Service, Alfred Health, Melbourne, Australia

(821) Point of Care Management of Perioperative Bleeding or Coagulopathy and Volume Replacement Strategy with Albumin 5% Seems to Reduce Primary Graft Dysfunction after Lung Transplantation (Preliminary Results); J. Vajter¹, M. Durila¹, J. Berousek¹, T. Vymazal¹, Z. Prikrylova¹, R. Lischke². ¹Anesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University, Prague, CZ, Prague, Czech Republic, ²Department of Surgery, 1st Faculty of Medicine, Charles University, Motol University Hospital, Charles University, Prague, CZ, Prague, Czech Republic

(822) Obesity Leads to Increased IL-18, Treg Impairment and Increased Risk of PGD; T. Akimova¹, T. Zhang¹, U. H. Beier², A. Samanta³, R. Han¹, L. Wang¹, J. Jiao¹, J. M. Diamond³, D. S. Wilkes³, D. J. Lederer³, R. A. Simmons⁶, J. D. Christie⁷, W. W. Hancock¹. ¹Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, ²Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, ³Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Medicine, University of Virginia, Charlottesville, VA, ⁵Pulmonary, Allergy and Critical Care Medicine, Columbia University, New York, NY, ⁶Neonatology, Children’s Hospital of Philadelphia, Philadelphia, PA, ⁷Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA


(824) Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction after Lung Transplantation; T. Harano¹, J. D’Cunha¹, M. R. Morrell², J. D. Luketich¹, P. Sanchez¹. ¹Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
(825) Do Long Term Outcomes Justify Third Time Redo Lung Transplantation?; W. Ragalie. P. Downey, D. Ross, E. Depasquale, A. Ardehali. UCLA, Los Angeles, CA

(826) Predicting Long Term Survival in Lung Transplant: Analysis of United Network for Organ Sharing (UNOS) Database; J. Sethi1, G. A. Garrido Rosa2, K. Patel3, N. Sharma. 1Pulmonary and Critical Care Medicine, University of South Florida, Tampa, FL, 2Advanced Lung Diseases & Lung Transplantation, University of South Florida, Tampa, FL

(827) A Real-Life Evaluation of Criteria for Listing for Lung Transplant: A Single-Center, Five-Year Experience; L. Morlacchi1, S. Henchi1, V. Rossetti1, A. Palleschi2, D. Tosi2, S. Aliberti1, G. Sotgiu1, P. Tarsia1, L. Rosso2. 1Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Italy, 2Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

(828) Frailty is Highly Prevalent in Lung Transplant Candidates and Varies by Frailty Tool; A. O'Boye, K. Leitner, M. Kelly, J. Wright, J. Lee, R. Tomic, S. Bhorade. Northwestern Memorial Hospital, Chicago, IL

(829) Surgical and Endoscopic Lung Volume Reduction (LVR) Prior to Lung Transplantation (LuTX); A. Slama1, C. Raber1, C. Hedederich1, V. Besa2, D. Valdivia1, K. Darwiche2, A. Koch2, M. Kamler2, C. Taube2, C. Aigner1. 1Department of Thoracic Surgery, University Medicine Essen - Ruhrlandklinik, Essen, Germany, 2Department of Pneumology, University Medicine Essen - Ruhrlandklinik, Essen, Germany

(830) Lung Transplant Referral Consensus Guidelines for Individuals with Cystic Fibrosis: An Opportunity for Partnerships between CF and Lung Transplant Centers; K. J. Ramos1, P. J. Smith2, E. F. McKone2, J. M. Pilewski2, A. Lucy2, S. E. Hempstead6, E. Talarico6, A. Faro6, D. B. Rosenbluth6, A. L. Gray6, J. M. Dunitz6, C. F. Lung Transplant Referral Guidelines Committee6. 1Medicine, University of Washington, Seattle, WA, 2Duke University, Durham, NC, 3Medicine, University College, Dublin, Ireland, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5.., 6MD, 4Cystic Fibrosis Foundation, Bethesda, MD, 7Medicine, Washington University School of Medicine in St Louis, St. Louis, MO, 8Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado – Anschutz Medical Campus, Denver, CO, 7Medicine, University of Minnesota, Minneapolis, MN

(831) Predictors of Mortality Post Lung Transplantation: Systematic Review and Meta-Analysis; F. Foroutan1, K. Clark1, A. Malik1, T. A. Buchan1, A. Akhtar2, A. Rigobon1, M. Stein1, J. Yepes Nuñez2, K. Quach3, D. C. Birriel4, A. Sidhu4, G. H. Guyatt5, M. O. Meade6. 1Cardiology, Toronto General Hospital, Toronto, ON, Canada, 2Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, 3Toronto General Hospital, Toronto, ON, Canada, 4Lung Transplantation, Toronto General Hospital, Toronto, ON, Canada, 5Department of Health Research Methods, Evidence, and Impact, McMaster, Hamilton, ON, Canada, 6Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

(832) Single-Center Study Evaluating the Impact of Sarcopenia on Outcomes after Lung Transplantation; P. S. Garcha1, T. Nisar2, A. K. Jamil2, M. O. Edens2, V. L. Flores2, J. Felius2, G. Schwartz1, D. P. Mason1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX

(833) Is Combined Lung-Liver Transplantation Justified? 30-Year Review of UNOS Database; W. Ragalie, P. Downey, D. Ross, E. Depasquale, A. Ardehali. UCLA, Los Angeles, CA

(834) Outcomes and Long-Term Survival after Pulmonary Retransplantation: A Single Center Experience; A. Wallinder1, J. Magnusson1, C. Danielsson2, G. C. Riise2, G. Dellgren2. 1Dep. of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden
(835) Survival Analysis Evaluating Extracorporeal Membrane Oxygenation and Mechanical Ventilation as a Bridge to Lung Transplantation; Y. Xia, J. Lee, H. Seetharamu, S. Scheinin, S. J. Forest. Montefiore Medical Center, Bronx, NY

(836) Lung Transplant Listing of Idiopathic Pulmonary Fibrosis Patients at Pulmonary Fibrosis Care Centers; J. Mooney1, J. Moore2, R. Raj3, G. Dhillon1. 1Department of Medicine, Stanford University School of Medicine, Stanford, CA, 2Department of Biostatistics, University of Michigan, Ann Arbor, MI

(837) Outcomes of Lung Transplant Recipients 70 and Over; S. Elnahas1, P. Kang2, S. Biswas Roy1, M. Olson3, M. A. Smith1, R. Walia1. 1Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ, 2University of Arizona - Phoenix Campus, Phoenix, AZ, 3Grand Canyon University, Phoenix, AZ

(838) Waitlist Mortality and Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation; J. Hayanga1, S. D. Holmes1, H. K. Hayanga2, J. H. Fugett, II3, N. Shigemura4, V. Badhwar5, G. Abbas1. 1Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, WV, 2Anesthesiology, West Virginia University, Morgantown, WV, 3Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, 4Cardiovascular Surgery, Temple University Health System, Philadelphia, PA

(839) EMPROVING Outcomes: Evaluating the Effect of an Ultra-Lung Protective Strategy for Patients with ARDS Treated with ECMO; A. A. Grant1, A. Badiye2, C. Mehta3, Z. Wu4, M. Koerner5, R. Viana6, M. Loebe6, A. Ghodsizad7. 1Department of Surgery, Emory University School of Medicine/Emory Transplant Institute, Atlanta, GA, 2University of Miami/MIAMI Transplant Institute, Miami, FL, 3Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta, GA, 4Emory University Rollins School of Public Health, Atlanta, GA, 5Integris Baptist Medical Center, Oklahoma City, OK, 6Department of Surgery, University of Miami/MIAMI Transplant Institute, Miami, FL, 7Heart and Lung Transplant and Mechanical Circulatory Support, University of Miami/MIAMI Transplant Institute, Miami, FL

(840) Feasibility and Safety of Systemic Anticoagulation-Free Veno-Venous Extracorporeal Membrane Oxygenation in Adults Respiratory Failure Patients; C. Kurihara, J. M. Walter, A. Karim, R. Wunderink, G. S. GR Scott Budinger, A. Bharat. Northwestern University Feinberg School of Medicine, Chicago, IL

(841) Effect of PEEP-Induced Alveolar Recruitment on Lung Injury during Extracorporeal Membrane Oxygenation for ARDS; B. M. Gomes1, R. V. Ribeiro2, K. Ramadan3, M. Galasso4, A. Ali5, Y. Watanabe6, E. Paradiso7, M. Meineri8, H. Chan9, Y. Zhang10, D. Hwang11, A. Slutsky12, E. Fan13, M. Liu14, S. Keshavjee15, M. Cypel16, L. del Sorbo17. 1Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

(842) Perioperative Extracorporeal Membrane Oxygenation-Based Protocol for Massive Acute Pulmonary Embolism; F. Ius1, C. Fulgheutel1, C. Kühn1, I. Tudorache1, G. Warnecke1, K. Olsson2, M. M. Hoepfer3, A. Haverich4, S. Cebotari1. 1Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

(843) New Technique Which Was Combined Living Donor Lower Lobe with Cadaveric Marginal Lung as Called “Hybrid Lung Transplant”; T. Kurosaki, S. Otani, K. Miyoshi, M. Okazaki, S. Sugimoto, M. Yamane, T. Oto. Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(844) Including Cystic-Fibrosis-Specific Variables Improves Accuracy of the Lung Allocation Score; C. J. Lehr1, M. Skeans2, E. Dassenbrook1, A. Faro3, A. Fink3, G. Fernandez4, M. Valapour5. 1Pulmonary, Cleveland Clinic, Cleveland, OH, 2Scientific Registry of Transplant Recipients, Minneapolis, MN, 3Cystic Fibrosis Foundation, Bethesda, MD

(846) Excellent Long-Term Outcome with Lungs Obtained from Uncontrolled Donation after Circulatory Death; E. Miñambres, J. M. Cifrian, C. Alvarez, B. Suberviola, B. Fernandez, L. Sanchez, D. Iturbe, M. A. Ballesteros. Hospital Univ Marques Valdecilla, Santander, Spain

(847) Characteristics & Outcomes of Second Time Lung Re-Transplant Patients: Retrospective Cohort Analysis of the United Network for Organ Sharing Database; G. K. Dubey1, C. Dobrescu1, S. Bhalla1, H. H. Nguyen2, S. Kanangat3, I. C. Beulaygue4, D. S. Nath1. 1Pediatric Cardiotoracic Surgery, Rush University Medical Center, Chicago, IL, 2Pediatric Cardiology, Rush University Medical Center, Chicago, IL, 3Pathology, Rush University Medical Center, Chicago, IL, 4Education & Human Development, Boston University, Boston, MA

(848) Should High Risk Donors Be Restricted to High Volume Lung Transplant Centers?; J. Rice, J. Trivedi, V. VanBerkel, M. Fox. Department of Cardiothoracic Surgery, The University of Louisville School of Medicine, Louisville, KY
(849) The Use of Polytrauma Donor Organs Does Not Impair Long-Term Outcome after Lung Transplantation; S. Schwarz, N. Rahimi, M. Muckenhuber, A. Benazzo, B. Moser, J. R. Matilla, G. Lang, S. Taghavi, P. Jaksch, W. Klepetko, K. Hoetzenecker. Thoracic Surgery, Medical University of Vienna, Vienna, Austria

(850) Bigger is Better - Oversizing May Improve Survival in Single Lung Transplantation for Pulmonary Fibrosis; K. Freystaetter¹, J. Mehew², S. Tait¹, O. Senbaklavaci¹, J. Dark¹. ¹Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ²Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom

(851) One-Year Outcome after Lung Transplantation from Controllo DCD with Long WIT. Initial Experience; A. Palleschi¹, D. Tosi¹, L. Rosso¹, P. Mendogni¹, I. Righi¹, A. Zanella², P. Tarsia², M. Nosotti¹. ¹Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, ²Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy

(852) Outcome of Lung Transplantation Using Organ Donors with Evidence of Aspiration; S. Schwarz, M. Muckenhuber, N. Rahimi, A. Benazzo, B. Moser, J. R. Matilla, G. Lang, S. Taghavi, P. Jaksch, W. Klepetko, K. Hoetzenecker. Thoracic Surgery, Medical University of Vienna, Vienna, Austria

(853) Longer Duration of Donor Ventilation Does Not Impact Long-Term Lung Function after Lung Transplantation; A. Hirji, D. Li, A. Kapasi, J. Weinkauf, D. Lien, K. Halloran. Lung Transplant Program, University of Alberta, Edmonton, AB, Canada
**Thursday, April 4, 2019**

**5:45 PM - 7:00 PM**

**POSTER SESSION 2: MECHANICAL CIRCULATORY SUPPORT (ADULT)**

**Room:** Timor Sea 2

**Poster Discussants:**

Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, USA  
Kavitha Muthiah, MBchB, PhD, St. Vincent's Hospital, Sydney, Australia  
Stuart Russell, MD, Duke University, Durham, USA  
Elena Sandoval, MD, Hosp Clinic De Barcelona, Barcelona, Spain  
Tahir Yagdi, MD, Ege University Hospital, Izmir, Turkey  
Rashad Zayat, MD, RWTH University Hospital, Aachen, Germany

**(854) Corwave LVAD Development Update;** T. Snyder, A. Bourquin, F. Cornat, J. Biasetti, C. Botterbusch. Corwave SA, Clichy, France

**(856) A 4-Chamber Model Heart with 3D Printed Silicone Aorta and Peripheral Arteries to Simulate the Human Cardiovascular System in a Mock Circulatory Loop;** Y. Wang1, P. A. Smith1, J. R. Wheeler1, M. M. John2, C. R. Broda3, O. H. Frazier4, D. A. Taylor4, L. C. Sampao1. 1Cardiovascular Surgery Research, Texas Heart Institute, Houston, TX, 2Texas Heart Institute, Houston, TX, 3Department of Pediatrics, Section of Adult Congenital Heart Disease, Baylor College of Medicine/Texas Children’s Hospital, Houston, TX, 4Regenerative Medicine Research, Texas Heart Institute, Houston, TX


**(858) A Novel Rotary Blood Pump for HFpEF;** E. Gude1, A. Fiane2. 1Dept of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Dept of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway


**(860) Evaluation of New Left Ventricular Assist Device for Transapical Insertion Using Virtual Mock Loop Model;** Y. Kado1, W. A. Smith2, T. Miyamoto1, N. Byram1, J. Adams1, A. R. Polakowski1, R. Dessoffy1, D. J. Horvath2, K. Fukamachi1, J. H. Karimov1. 1Cleveland Clinic Foundation, Cleveland, OH, 2Perfusions Solutions Inc., South Euclid, OH, 3RI Engineering, Euclid, OH

**(861) Novel Extracorporeal Continuous-Flow Ventricular Assist System for Patients with Advanced Heart Failure;** O. Seguchi1, T. Fujita2, Y. Kuami1, K. Kuroda1, S. Nakajima1, T. Watanabe1, M. Yanase1, Y. Matsumoto2, S. Fukushima2, T. Tsukiya3, T. Mizuno4, N. Katagiri1, Y. Kakuta1, Y. Takeawa1, T. Hamasaki1, H. Yamamoto2, E. Tatsumi1, J. Kobayashi1, N. Fukushima1. 1Dept of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Dept of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan, 3Dept of Artificial Organs, National Cerebral and Cardiovascular Center, Osaka, Japan, 4Office of Biostatistics and Data Management, National Cerebral and Cardiovascular Center, Osaka, Japan, 5Dept of Advanced Medical Technology Development, National Cerebral and Cardiovascular Center, Osaka, Japan


**(863) Preoperative Computational Fluid Dynamics Simulation of the Best Anastomosis Site and Angle of the Outflow Graft and Ascending Aorta in Continuous Flow Mechanical Assist Devices;** A. Giacomini1, A. Esposito2, T. Nisi1, E. Lapenna1, S. Bartsaghi3, D. Redaelli1, F. Pappalardo4, G. Colombo3, M. De Bonis1. 1Cardio-Thoracic and Vascular Surgery, San Raffaele Scientific Institute, Milan, Italy, 2Experimental Imaging Center, San Raffaele Scientific Institute, Milan, Italy, 3Department of Mechanical Engineering, Politecnico di Milano, Milan, Italy, 4Cardio-Vascular Intensive Care Unit, San Raffaele Scientific Institute, Milan, Italy


**(865) Effects of Residential Distance from LVAD Implanting Center on Survival;** T. Nelson, S. George, A. Phancao, A. El Banayosy, J. W. Long. IACC/NZTI, Integris Baptist Medical Center, Oklahoma City, OK
(881) Tricuspid Clipping during LVAD Support: First in Human Report; S. Schulte-Eistrup, N. Reiss, J. Sindermann, T. Schmidt, H. Warnecke, F. Ritter, N. Franz, M. Kowalski. 1Department for Cardiac Surgery, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany; 2Department for Cardiovascular Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany; 3Department for Cardiac Rehabilitation, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany; 4Department for Cardiology, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany

(882) Role of Immunocompetent Cells in Functional Recovery Post-Implantation of Ventricular Assist Device in Non-Ischemic Dilated Cardiomyopathy; A. Koga, S. Fukushima, Y. Matsumoto, K. Otani, N. Fukushima, H. Ishibashi-Ueda, M. Harada-Shiba, J. Kobayashi, K. Suzuki, T. Fukui, T. Fujita. 1Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 2Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 3Department of Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 4Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 5Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 6William Harvey Research Institute, Bart's and The London School of Medicine and Dentistry, Queen Mary, University of London, London, United Kingdom; 7Department of Cardiovascular Surgery, Kumamoto University, Kumamoto, Kumamoto, Japan

(883) Minimally Invasive LVAD Implantation: Early and Mid-Term Results at a Single Center; U. Kervan, S. S. Kocabeyoglu, D. E. Sert, M. Karahan, A. Temizhan, B. Demirkan, Y. Akin, M. Pac. 1Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey; 2Cardiology, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey; 3cardiology, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey

(884) Education and Decision-Making in Patients and Caregivers Considering Left Ventricular Assist Devices; A. Oehler, A. J. Kanelidis, S. Kalantari, B. Smith, G. Sayer, N. Narang, H. L. Holzhauser, A. Nguyen, B. Chung, M. Quinn, C. Rhee, M. Siegler, N. Uriel. 1Cardiovascular Disease, University of Chicago, Chicago, IL; 2Internal Medicine, University of Chicago, Chicago, IL; 3Geriatric Medicine, University of Chicago, Chicago, IL


(886) Improved Survival Trend Following the Introduction of Heartmate 3. A Single Centre Experience; S. M. Shaw, P. Callan, S. Kore, R. Venkateswaran. Heart and Lung Transplant, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(887) INTERMACS Profile Does Not Predict Required Flow Rate of CF-LVAD at Discharge; A. Critsinelis, H. Lamba, S. Oberton, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loo, T. Rosengart, O. Frazier, J. Morgan. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX; 2Baylor College of Medicine, Houston, TX

(888) Hypoalbuminemia in Patients Post LVAD Implantation; C. Falls, M. K. Rayens, M. Guglin. University of Kentucky, Lexington, KY

(889) Predictors of Change in Mitral Regurgitation Severity after Left Ventricular Assist Device Implantation; W. Lin, J. Bullen, E. Soltész, J. Estep, W. Tang, M. Sabe, E. Joyce, D. Kwon. 1Section of Heart Failure and Cardiac Transplantation, Cleveland Clinic, Cleveland, OH; 2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; 3Department of Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; 4Beth Israel Deaconess Medical Center, Boston, MA; 5Section of Cardiovascular Imaging, Cleveland Clinic, Cleveland, OH
POSTER SESSION 2: MECHANICAL CIRCULATORY SUPPORT (ADULT)
Room: Timor Sea 1

Poster Discussants:
Cristiano Amarelli, MD, Monaldi, Azienda dei Colli, Naples, Italy
Pavan Atluri, MD, University of Pennsylvania, Philadelphia, PA, USA
Jay Bhama, MD, University of Iowa Health Care, Iowa City, IA, USA
Sandra Chaparro, MD, University of Miami, Miami, FL, USA
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA
Ioannis Dimarakis, PhD, FRCS, University Hospital of S. Manchester, Manchester, United Kingdom
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France
Jerry Estep, MD, Cleveland Clinic, Cleveland, OH, USA
Anna Meyer, MD, Leipzig Heart Center, Leipzig, Germany
Sarah Schettle, PA-C, Mayo Clinic, Rochester, NY, USA

(890) Delineating Pathways to Death by Multisystem Organ Failure in Patients with a Left Ventricular Assist Device (LVAD); L. Seese¹, F. Movahedii, J. Antaki², R. Padman³, S. Murali⁴, Y. Zhang⁶, A. Kilić¹, C. Sciortino¹, M. Keebler¹, R. Kormos¹, ¹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Electrical and Computer Engineering, University of Pittsburgh, Pittsburgh, PA, ³Meining School of Biomedical Engineering, Cornell University, New York, NY, ⁴The H. John Heinz III College of Information Systems and Public Policy, Carnegie Mellon University, Pittsburgh, PA, ⁵Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ⁶Weill Cornell Medical, Cornell University, New York, NY

(891) External Assessment of EUROMACS Right-Sided Heart Failure Risk Score; H. Shah¹, T. Murray², A. El Rafei³, J. Schultz³, T. Thenappan¹, T. Alexy¹, R. John⁴, C. Martin⁴, M. Pritzker⁵, R. Cogswell¹. ¹Cardiology, University of Minnesota, Minneapolis, MN, ²Biostatistics, University of Minnesota, Minneapolis, MN, ³Internal Medicine, University of Minnesota, Minneapolis, MN, ⁴Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

(892) Reduced Adverse Events with Heartmate 3. The Manchester Experience; P. D. Callan, S. M. Shaw, R. Venkateswaran, S. Kore. Heart and Lung Transplant Centre, Wythenshawe Hospital, Manchester, United Kingdom


(894) Continuous-Flow Left Ventricular Assist Devices Have Very Low Rates of Mechanical Failure; G. V. Letsou¹, N. Wang², G. Loor³, F. I. Musfee³, L. Sampaio⁴, D. A. Taylor¹, F. Cheema¹, J. A. Morgan¹, H. K. Lamba¹, J. K. Ho³, O. H. Frazier¹. ¹Surgery, Baylor College of Med, Houston, TX, ²Heart Intensive Care Unit, First Affiliated Hospital of Dalian, Dalian, China, ³Surgery, Baylor College of Medicine, Houston, TX, ⁴Epidemiology, University of Texas School of Public Health, Houston, TX, ⁵Research, Texas Heart Institute, Houston, TX

(896) Valvular Disease Management in Patients with Continuous-Flow Left Ventricular Assist Device; S. Maeda, K. Toda, H. Hata, S. Miyagawa, Y. Yoshikawa, S. Kainuma, T. Kawai, A. Kawamura, S. Yoshida, T. Ueno, T. Kuratani, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan

(897) Predicting Post LVAD Acute Severe Right Heart Failure Using Bayesian Analysis; M. Kanwar¹, C. Khoo², L. Lohmueller², S. Bailey¹, S. Murali¹, J. Antaki². ¹Allegheny General Hospital, Pittsburgh, PA, ²Carnegie Mellon University, Ithaca, NY, ³Carnegie Mellon University, Pittsburgh, PA

(898) Trend in Pulmonary Artery Pulsatility Index Pre- to Post-LVAD Implantation; S. Kumar¹, A. Rahman¹, J. S. Josephs¹, O. Saeed², S. Patel², S. Murthy², J. J. Shin², S. Forest³, S. Vukelic², D. J. Goldstein³, U. P. Jorde², D. Sims². ¹Internal Medicine, Montefiore Medical Center (Moses/Weiler Division), New York, NY, ²Cardiology, Montefiore Medical Center (Moses/Weiler Division), New York, NY, ³Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), New York, NY

(899) Pulmonary Artery Pulsatility Index Early Post-LVAD Implantation Predicts Severe Right Ventricular Failure; S. Kumar¹, A. Rahman¹, J. S. Josephs¹, O. Saeed², S. Patel², S. Murthy², J. J. Shin², S. Forest³, S. Vukelic², D. J. Goldstein³, U. P. Jorde², D. Sims². ¹Internal Medicine, Montefiore Medical Center (Moses/Weiler Division), New York, NY, ²Cardiology, Montefiore Medical Center (Moses/Weiler Division), New York, NY, ³Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), New York, NY

(901) Right Ventricular Failure Risk Prediction Models in Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review; C. Frankfurter, M. Molinero, F. Foroutan, J. Visham, A. Alba. 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Heart Failure and Transplant Program, University Health Network, Toronto, ON, Canada, 3Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada


(903) Long-Term Outcomes in HeartMate 2 Short-to-Shield Patients on an Ungrounded Cable; L. Coyle, N. Graney, C. Gallagher, R. Paliga, G. Yost, G. Macaluso, A. Tatooles. Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL

(904) The Effect of Postoperative Vasoposaglia to the Survival of LVAD Recipients; M. Kawabori, J. Soffer, M. Mastorianni, Y. Zhan, K. G. Warner, H. Rastegar, M. S. Kiernan, D. Denofrio, F. Y. Chen, G. S. Couper. 1Cardiothoracic Surgery, Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA

(905) Length of Stay in the Intensive Care Unit during Index Admission for Left Ventricular Assist Device and Total Artificial Heart Insertion is a Risk Factor for Infection; N. K. Bart, S. Emmanuel, P. C. Jansz, K. Muthiah, C. S. Hayward. 1Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, 2Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, 3Heart Transplant and Failure, St Vincent’s Hospital, Sydney, Australia

(906) Characteristics of Left Ventricular Assist Device (LVAD) Supported Patients Who Experience Indication Changes during Time on Support; D. McGrath, B. Nsiraiyya, L. Berube, J. Camuso, K. Milley, M. Villavicencio-Theoduloz, D. D’Alessandro, E. Coglianese. 1Cardiology, Massachusetts General Hospital, Boston, MA, 2Cardiac Surgery, Massachusetts General Hospital, Boston, MA

(907) Rehospitalization in Patients Implantated with the Total Artificial Heart and Discharged with a Portable Driver; C. W. Lee, E. J. Sawey, K. Shah, K. Desai, D. Tang, V. Kasirajan, M. Quader. 1Internal Medicine, Virginia Commonwealth Univ Health System, Richmond, VA, 2Cardiology, Virginia Commonwealth Univ Health System, Richmond, VA, 3Virginia Commonwealth Univ School of Medicine, Richmond, VA, 4Cardiothoracic Surgery, Virginia Commonwealth Univ Health System, Richmond, VA

(908) Characterizing Sex-Specific Baseline Characteristics and Outcomes in Left Ventricular Assist Device (LVAD) Support; B. Nsiraiyya, D. McGrath, L. Berube, J. Camuso, K. Milley, M. Villavicencio-Theoduloz, D. D’Alessandro, E. Coglianese. 1Cardiology, Massachusetts General Hospital, Boston, MA, 2Cardiac Surgery, Massachusetts General Hospital, Boston, MA

(909) MELD Score: A Predictor of Mortality for Patients Receiving RVAD after LVAD Implantation; A. Bansal, F. Akhtar, D. Jacks, S. Desai. 1Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA, 2Heart Transplant Med, Ochsner Clinic Foundation, New Orleans, LA

(910) ICD Therapy in LVAD: Rates and Predictors of Appropriate and Inappropriate Shock; N. Dharmavaram, R. Kipp, T. Hess, R. Dhingra. 1Department of Medicine, University of Wisconsin, Madison, WI, 2Division of Cardiovascular Medicine, University of Wisconsin, Madison, WI, 3Advanced Heart Failure and Transplantation, University of Wisconsin, Madison, WI

(911) Once Bitten Twice Not So Shy: Outcomes of Left Ventricular Assist Device Pump Exchange; N. A. Brozzi, I. C. Saba, T. Patricelli, S. Thakkar Rivera, A. Ghodsizad, A. Badiye, S. Chaparro, M. Loebe. 1Surgery, University of Miami, Miami, FL, 2Medicine, University of Miami, Miami, FL, 3University of Miami & Jackson Memorial Hospital in the city of Miami, Miami, FL

(912) How Do Mechanical Circulatory Support Patients Die? Autopsy Findings for Bridge to Transplant LVAD/TAH Patients Who Do Not Survive to Transplant; N. K. Bart, K. Muthiah, P. C. Jansz, C. S. Hayward. 1Heart Transplant and Failure, St Vincents Hospital, Sydney, Australia, 2Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia

(913) Psychosocial Evaluation of Candidates for Mechanical Circulatory Support and Risk for Adverse PostImplantation Medical Outcomes; M. A. Dew, J. Hollenberger, L. L. Obregon, G. W. Hickey, C. M. Sciortino, K. L. Lockard, N. M. Kunz, M. A. Mathier, R. N. Ramani, A. Kilic, D. M. McNamara, M. A. Simon, R. L. Kornmos. 1University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA, 2Grove City College, Grove City, PA and University of Pittsburgh Medical Center, Pittsburgh, PA, 3Heart and Vascular Institute, University of Pittsburgh Medical Center, and Carnegie Mellon University, Pittsburgh, PA, 4Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA
(914) Magnitude of Bleeding and Blood Product Utilization Predict Early Right Ventricular Implantation in LVAD Recipients; J. Conroy, H. Lamba, J. Ho, J. Kraus, S. Chatterjee, S. Fedson, S. Satte, F. Cheema, A. Civitello, R. Delgado, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan, A. Nair. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support. Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, TX


(918) Relationship between Inflow Malposition and Clinical Outcomes in HVAD Recipients; E. N. Sorensen, E. D. Feller, D. J. Kaczorowski, L. M. Dees, V. Ton, R. J. Madathil, Z. N. Kon, B. P. Griffith. 1University of Maryland, Baltimore, MD, 2NYU Langone Medical Center, New York, NY

(919) Patient-Tailored Silicone Plug for HeartMate 3™ Left Ventricular Assist Device Explantation; C. Heim, N. Ebel, D. W. Schuberth, S. Werner, M. Kondruweit, R. Tandler, M. Weyand. University of Erlangen, Erlangen, Germany

(920) “The Right Stuff”: Using a Caval Stent Valve to Mitigate the Effect of Right Heart Failure in LVAD Patients; R. R. Gonzalez, A. A. Grant, E. DeMarchena, A. Klime, M. Armor, A. Badiye, M. Loeb, M. Cohen, A. Ghodsizad. 1Surgery, Miami Transplant Institute Univ of Miami, MI, 2Miami Transplant Institute, Miami, FL, 3Div of Cardiology, Dept of Medicine, Univ of Miami Leonard M Miller School of Medicine, Miami, FL, 4Comprehensive Care Services, Inc., Livonia, MI, 5Dept of Medicine, Div of Cardiology, Div of Heart and Lung Transplant and Mechanical, Miami Transplant Institute, Univ of Miami Leonard M Miller School of Medicine, Miami, FL, 6Div of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Dept of Surgery, Div of Cardiothoracic Surgery, Univ of Miami Leonard M Miller School of Medicine, Miami, FL, 7Dept of Medicine, Cardiovascular Div, Univ of Miami Leonard M Miller School of Medicine, Miami, FL

(921) Results of Minimally Invasive HVAD Insertion in a Large Cohort of Unselected Patients; D. J. Kaczorowski, Z. N. Kon, E. N. Sorensen, S. M. Pham, C. Pasrija, L. M. Dees, R. J. Madathil, V. Ton, E. D. Feller, B. P. Griffith. 1University of Maryland, Baltimore, MD, 2NYU Langone Medical Center, New York, NY, 3Mayo Clinic Florida, Jacksonville, FL

(922) Less Invasive HeartMate 3 Implantation is Safe and Reproducible with Excellent Outcomes; I. Gosev, K. Wood, B. C. Ayers, H. Vidula, J. Alexis, N. Kumar, J. Delehanty, B. Barrus, P. Knight, L. Chen, S. Prasad. University of Rochester, Rochester, NY

(923) Approaches to Repairing Outflow Graft Stenosis in Left Ventricular Assist Devices; V. Kagan, C. Mehta, E. Michel, A. Ward, A. Jivan, M. Ricciardi, A. Anderson, D. T. Pham, J. Rich. 1Division of Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL, 2Division of Cardiology, Northwestern Memorial Hospital, Chicago, IL

(924) Left Thoracotomy Upper Hemisternotomy Left Ventricular Assist Device (LVAD) Implantation Offers Safe, Durable Option for Patients with Prior Sternotomy Undergoing LVAD Implantation; N. M. Foley, S. Zalawadiya, M. Kuzemchak, K. Balsara, J. Menachem, K. Schlenдорf, S. Maltais, A. Shah, M. Danter. 1Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 2Cardiology, Vanderbilt University Medical Center, Nashville, TN, 3Cardiac Surgery, Mayo Clinic, Rochester, MN


(927) Impact of Previous Sternotomy on Outcome after Left Ventricular Assist Device Implantation; K. Zhigalov, A. Mashhour, M. Szczecowicz, S. Mkalalulah, J. Ennker, H. Eichstaedt, A. Weymann. Department of Cardiac Surgery, Carl von Ossietzky University Oldenburg, Oldenburg, Germany


(930) Experience with Long-Term Continuous Flow Ventricular Assist Devices Bridge to Recovery Concept; R. Wieloch, A. Albert, A. Mehdiani, U. Boeken, H. Aubin, R. Westenfeld, P. Akhyari, A. Lichtenberg, D. Saeed. Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

(931) Implantation of a HeartMate 3 Left Ventricular Assist Device in a Patient with Congenitally Corrected Transposition of the Great Arteries; H. Kirov, G. Faerber, T. Doenst. University Clinic Jena, Jena, Germany

(932) A New Less Invasive Technique of RVAD Insertion - Time to Lower the Threshold around LVAD Insertion; S. Madassery1, D. O’Leary4, S. Schueller2, G. Macgowan5, N. Robinson4, A. Woods4, A. Samuel1. 1Cardiothoracic Anaesthesia, Freeman Hospital, Newcastle Upon Tyne, UK, 2Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, UK, 3Cardiology, Freeman Hospital, Newcastle Upon Tyne, UK, 4Heart Transplantation, Freeman Hospital, Newcastle Upon Tyne, UK

(933) Effect of Preoperative Cardiac Anatomy and Surgical Approach on HVAD Inflow Position; E. N. Sorensen1, D. J. Kaczorowski1, E. D. Feller1, L. M. Dees1, V. Ton1, R. J. Madathil1, Z. N. Kon2, B. P. Griffith1. 1University of Maryland, Baltimore, MD, 2NYU Langone Medical Center, New York, NY

(934) INTERMACS 3 and 4 Patients Have Excellent Outcomes after Complete Sternal-Sparing HeartMate 3 Implantation; K. Wood, B. Ayers, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. University of Rochester, Rochester, NY


(936) P2Y12 Receptor Antagonists: Do They Really Inhibit Shear-Mediated Platelet Activation within MCS?; Y. Roka-Moia1, J. Sheriff5, D. Bluestein2, M. J. Slepian1. 1Department of Medicine, Sarver Heart Center, University of Arizona, Tucson, AZ, 2Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY


(938) Impact of Concomitant Valve Surgery at the Time of HeartMate II Implantation; Japanese Multicenter Study; H. Hata1, K. Toda1, Y. Saiki2, M. Ono3, A. Shiose4, D. Yoshioka1, Y. Sawa1. 1Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 2Cardiovascular Surgery, Tohoku University, Sendai, Japan, 3Cardiovascular Surgery, University of Tokyo, Tokyo, Japan, 4Cardiovascular Surgery, Kyusyu University, Fukuoka, Japan

(939) Hemodynamic Improvement with Application of Mechanical Circulatory Support in Heart Failure with Preserved Ejection Fraction in a Mock Circulation Loop; C. Broda4, P. A. Smith2, Y. Wang2, O. H. Frazier5, W. J. Dreyer4, I. Adachi2, D. A. Taylor4, L. C. Sampaio2. 1Pediatrics; Section of Adult Congenital Heart Disease, Baylor College of Medicine, Houston, TX, 2Cardiovascular Surgical Research Laboratory, Texas Heart Institute, Houston, TX, 3Surgery, Section Cardiothoracic Transplantation & Circulatory Support, Baylor College of Medicine, Houston, TX, 4Pediatrics; Section of Pediatric Cardiology, Baylor College of Medicine, Houston, TX, 5Surgery; Section of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, 6Regenerative Medicine Research, Texas Heart Institute, Houston, TX

(940) Outcomes of Continuous-Flow Left Ventricular Assist Devices with No Antiplatelet Therapy: Systematic Review; V. Kittipibul1, N. Angsubhakorn2, J. Kewchareon1, N. Prasitlumkum3, P. Rattanawong4. 1Department of Internal Medicine, University of Miami Miller School of Medicine, MIAMI, FL, 2Department of Internal Medicine, University of Minnesota, Minneapolis, MN, 3Department of Internal Medicine, University of Hawaii, Honolulu, HI


(943) Efficacy and Safety of Ferric Carboxymaltose Therapy in Continuous Flow LVAD Patients; E. Demir1, S. Nalbantgil1, P. Özütrük2, E. Simsek1, C. Engin2, T. Yagdi2, M. Özbaran2. 1Cardiology, Ege University Medicine Faculty, İzmir, Turkey, 2Cardiovascular Surgery, Ege University Medicine Faculty, İzmir, Turkey
POSTER SESSION 2: JUNIOR FACULTY CASE REPORTS: HEART FAILURE/TRANSPLANTATION
Room: Banda Sea 1

Poster Discussants:
Lavanya Bellumkonda, MD, Yale School of Medicine, New Haven, CT, USA
Alejandro Bertolotti, MD, University Hospital Favaloro Foundation, Buenos Aires, Argentina
Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA
Robert Chen, MD, MPH, Indiana University Methodist Hospital, Indianapolis, IN, USA
Justin Godown, MD, Nashville, TN, USA
Douglas Greig, MD, University Health Network, Toronto, Canada
Jeremy Mazurek, MD, University of Pennsylvania, Philadelphia, PA, USA
Bruno Meiser, MD, University Munich/Grosshadern, Munich, Germany

(1338) A Fatal Case of Bortezomib-Induced Lung Toxicity in a Young Heart Transplant Recipient; E. L. Frandsen¹, J. Otero², J. C. Rutledge¹, M. S. Kemna¹, E. L. Albers¹, B. J. Hong¹, Y. M. Law¹, J. M. Friedland-Little¹. ¹Division of Cardiology, Seattle Children’s Hospital, University of Washington, Seattle, WA, ²Division of Pharmacy, Seattle Children’s Hospital, University of Washington, Seattle, WA, ³Division of Pathology, Seattle Children’s Hospital, University of Washington, Seattle, WA


(1340) Initial Experience with Alemtuzumab as a Salvage Therapy for Refractory Cardiac Cellular Allograft Rejection; M. E. Afari¹, T. A. Lebeis¹, K. J. Gaj¹, K. Turvey¹, J. K. Steiner¹, R. V. Shah¹, N. E. Ibrahim¹, S. Shao¹, T. Gift², M. G. Nayor¹, E. Coglianese¹, J. E. Ho³, S. S. Thomas¹, C. Newton-Cheh¹, W. D. Carlson¹, M. Villavicencio-Theoduloz², D. D’Alessandro³, G. Lewis¹. ¹Division of Advanced Heart Failure and Transplant Cardiology, Massachusetts General Hospital, Boston, MA, ²Department of Pharmacy, Massachusetts General Hospital, Boston, MA, ³Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

(1341) A Novel Therapy for an Unusual Problem: IL-1 Receptor Antagonist for Recurrent Post-Transplant Pericarditis; J. Parizo¹, Y. Moayed³, K. Nieman³, K. Town³, J. Teuteberg¹, K. Khush¹. ¹Cardiovascular Medicine, Stanford University, Stanford, CA, ²Peter Munk Cardiac Center, University Health Network, Toronto, ON, Canada, ³Departments of Cardiovascular Medicine and Radiology, Stanford University, Stanford, CA


(1343) De Novo Esosinophilic Myocarditis in a Transplanted Heart; J. R. Vilano¹, B. D. Stewart², G. Rojas¹, A. Shenoy¹, R. Rogers¹, J. Aranda¹. ¹Cardiology, University of Florida, Gainesville, FL, ²Pathology, University of Florida, Gainesville, FL

(1344) Catastrophic Sickleling Crisis in Patient Undergoing Cardiac Transplantation with Sickle Cell Trait; J. Ali, S. Bhagra, M. Goddard, M. Besser, P. Catario, Y. Abu-Omar, M. Berman. Papworth Hospital, Cambridge, United Kingdom

(1345) Eculizumab for the Treatment of Severe Antibody-Mediated Rejection in an Adult Heart Transplant Recipient; J. P. Feliberti¹, J. Huang², J. E. Finan³, M. Lopez-Cepero³, D. A. Rinde-Hoffman¹. ¹Cardiology, Tampa General Hospital, Tampa, FL, ²Cardiology, University of South Florida, Tampa, FL, ³Pathology, Tampa General Hospital, Tampa, FL. 4Immunology, Lifelink, Tampa, FL

(1346) Protein Losing Enteropathy (PLE) with Severe Gastrointestinal (GI) Bleeding: Safe to Transplant?; B. S. Mantell, M. Richmond, W. Zuckerman, S. Law, T. Lee, L. Addonizio. Pediatric Cardiology, Columbia University Medical Center, New York, NY

(1347) An Unusual Case of Infectious Mycotic Aneurysm in a Heart Transplant Patient; W. G. Willeford¹, E. Orozco-Hernandez¹, J. Talla², C. Hope², J. Baddley¹. ¹Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL

(1348) Two Cases of Giant Cell Myocarditis with Complete Remission after Treatment with Rituximab; J. Lundgren, O. Braun, B. Kornhall, Ö. Reitan, O. Gidlöf, J. Smith. Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden
(1349) A Dual Targeting Approach to Desensitization with Belatacept & Bortezomib; M. V. Habal1, D. Jennings1, K. Clerk1, N. Geo2, E. Vasilescu1, G. Far1, S. Restaino1. 1Cardiology, Columbia University, New York, NY; 2Pathology & Cell Biology, Columbia University, New York, NY

(1350) Successful Treatment of Donor-Derived Hepatitis C Virus Infection with Glecaprevir/Pibrentasvir Following Cardiac Re-Transplantation; K. Martits-Chalangeri1, S. Y. Wada1, J. T. Trotter2, P. P. Kale2, S. A. Hall2, R. L. Gottlieb5. 1Baylor Scott & White Research Institute, Dallas, TX; 2Baylor University Medical Center, Dallas, TX

(1351) Safe and Successful Implantation of Micro in Post-Heart Transplantation as a Strategy to Reduce Infectious Complications in the Immunocompromised Population; J. Maning1, N. T. Rivera2, S. Chaparro3, I. Mendoza4. 1Internal Medicine, Jackson Memorial Hospital, Miami, FL; 2Department of Medicine, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL; 3Department of Cardiac Electrophysiology, Jackson Memorial Hospital, Miami, FL

(1352) Implantable Pulmonary Artery Pressure Sensor as a Guide to the Management of Bridge to Transplant Left Ventricular Assist Device Patient; M. Afari1, T. Lebeis1, K. Milley2, J. M. Camuso2, D. Sullivan1, L. Arrighi1, M. Swan1, G. Lewis1, S. S. Thomas1. 1Division of Advanced Heart Failure and Transplant Cardiology, Massachusetts General Hospital, Boston, MA; 2Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA


(1355) Isolated IgG4-RD Myocarditis Treated with Heart Transplantation; F. F. Lin, J. R. Cook, J. E. Diamond, N. O. Palmeri. Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY

(1356) Primary Cardiac ALK-Negative Anaplastic Large Cell Lymphoma Diagnosed in the Explanted Heart; J. Newman1, Y. Brailovsky2, A. Haryani1, V. Ananthanarayanan2, A. Kim2, S. Nand2, E. Jaffe3, K. Mirza2, M. Liebo1. 1Cardiology, Loyola University Medical Center, Chicago, IL; 2Pathology, Loyola University Medical Center, Chicago, IL; 3Hematology, Loyola University Medical Center, Chicago, IL

(1357) Orthotopic Heart Transplantation in Recipients with Persistent Left Superior Vena Cava: Anterior Rerouting Technique; Y. Koda, N. Uriel, V. Jeevanandam, T. Ota. The University of Chicago, Chicago, IL

(1358) Wireless PA Monitoring during Acute Cardiac Allograft Rejection; D. Corbally, N. Wettersten, V. Pretorius, E. Adler, H. Tran. UCSD, San Diego, CA

(1359) Amyloid Cardiomyopathy Heart-Liver Transplantation with Domino Liver Transplantation; C. I. Tugulan, J. Mena, M. J. Bates, P. G. Parrino, A. Bansal. Cardiothoracic Surgery, Ochsner Medical Center, New Orleans, LA

(1360) Antibody Mediated Rejection Causing LV Systolic Dysfunction with Improvement on Initiation of Sacubitril/Valsartan; K. Morris1, K. Grant1, S. Chaudhry1, A. Patel1, T. Schleeter1, R. Garcia-Cortes1, A. Ravichandran1. 1Cardiology, St. Vincent Hospital, Indianapolis, IN; 2Internal Medicine, St. Vincent Hospital, Indianapolis, IN

(1361) Successful Heart-Lung Transplant for a Patient on Continuous Flow Left Ventricular Assist Device Support Complicated with Amiodarone-Induced Pulmonary Fibrosis; M. E. Currie, Y. Shudo, J. Mooney, J. Woo. Cardiothoracic Surgery, Stanford University, Stanford, CA

(1362) A Case of Severe Necrotizing Pancreatitis in a Patient Who Received a Heart from a Hepatitis C Positive Donor; M. Chowdhury, K. Schlendorf, S. Zalawadiya, J. Menachem, M. Brinkley, M. Wigger, H. Ooi, A. Shah, K. Balsara, M. Danter, J. Lindenfeld. Vanderbilt University Medical Center, Nashville, TN

(1363) CardioMems to Guide Heart Transplant Timing in a Total Artificial Heart Patient; V. Parikh1, L. Simpson1, J. Morgan1, M. Ono2, O. Frazier2, A. Civitello1, A. Naik1. 1Baylor St. Lake’s Medical Center/Texas Heart Institute, Houston, TX; 2Methodist Hospital, San Antonio, TX
(1364) A Case of Heart Transplantation Using a Distantly Procured Brain Dead Donor Heart That Was Preserved in a Novel Cold Storage System; N. Naito1, M. Funamoto1, R. Pierson1, M. Villavicencio1, W. Riley2, G. Lewis3, D. D'Alessandro1. 1Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Perfusion Services, Massachusetts General Hospital, Boston, MA, 3Cardiology, Massachusetts General Hospital, Boston, MA

(1365) Williams Beuren Syndrome with Diffuse Arteriopathy, a Case of Successful Heart Transplantation; N. Baez, R. Kirk, R. Butts, R. Davies. University of Texas Southwestern Medical Center, Dallas, TX

(1366) Multiple Micro-Neo-Vessels Detected by Optical Coherence Tomography (OCT) Can Predict a Progression of Cardiac Allograft Vasculopathy in a 15-Year Post Transplant Recipient; K. Shibata, T. S. Kato, T. Nishikura, N. Ikeda, C. Sato, K. Wakabayashi, K. Tanno. Division of Cardiology, Cardiovascular Center, Showa University Koto Toyosu Hospital, Tokyo, Japan

(1367) Giant Cell Myocarditis as a Late Complication of DRESS Syndrome; K. Murphy1, D. Steidley1, A. E. McCullough2, O. E. Pajaro3, J. L. Rosenthal1, B. W. Hardaway1, D. E. Jaroszewski3, R. L. Scott1, L. LeMond1. 1Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ, 2Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, 3Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ

(1368) Recurrence of Giant Cell Myocarditis after Successful LVAD Explantation; R. Bhatt1, A. Borczuk2, M. Karas1, E. Horn1, I. Sobol1. 1Division of Cardiology Perkin Center for Heart Failure, Weill Cornell Medical College, New York, NY. 2Department of Pathology, Weill Cornell Medical College, New York, NY

(1369) CardioMEMS Guides Successful CAR T-Cell Therapy; A. J. Kanelidis1, J. Raikhelkar2, L. Holzhauser2, A. B. Nguyen2, B. B. Chung2, B. Smith2, G. Kim3, N. Narang2, G. Sayer2, T. S. Polonsky2, N. Uriel1. 1Internal Medicine, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL

(1370) Open Repair of a Juxtarenal Abdominal Aortic Aneurysm in a Left Ventricular Assist Device Patient; S. R. LeJeune1, J. M. Titus2, K. Mudy2, R. Siddiqui3, P. M. Eckman2. 1University of Minnesota, Minneapolis, MN, 2Minneapolis Heart Institute, Minneapolis, MN, 3Abbott Northwestern Hospital, Minneapolis, MN

(1371) LVAD Deactivation after Cardiac Recovery and Pump Thrombosis; R. C. Flowers1, V. Kittipibul1, S. Chaparro2. 1Internal Medicine, University of Miami, Miami, FL, 2Cardiovascular Medicine, University of Miami, Miami, FL


(1373) End-Stage Cardiomyopathy Due to Hydroxychloroquine Therapy; A. M. Wolfson1, D. Chang1, S. Bannykh2, M. Kittleson1, E. Kranstorf1, J. Kobashigawa1. 1Medicine - Devison of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, 2Pathology, Cedars-Sinai Medical Center, Los Angeles, CA

(1374) Eculizumab as a Bridge to Re-Transplantation for Chronic Antibody Mediated Rejection in a Heart Transplant Patient; K. Kearney, J. Phan, N. Song, N. Bart, A. Jabbour, E. Kotlyar, C. Hayward, P. Macdonald, K. Muthiah. St Vincents Hospital, Darlinghurst, Australia

(1375) Cardiac Arrest and Wilson’s Disease; E. Bobbio1, M. Lingbrant2, E. Bollano2, S. Esmaily3, A. Oldfors3, B. Andersson2, N. Bergh2, C. L. Polte4, K. Karason2. 1Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden


(1377) Fever of Unknown Origin in Orthotopic Heart Transplant; M. Erlich. Yale New Haven Hospital, New Haven, MA

(1378) A Case Series of Three Hepatitis C Donor Heart Transplant Recipients and 1-Year Cardiac Allograft Vasculopathy Follow-Up; Q. M. Bui, N. Wettersten, E. Adler, S. Aslam, H. A. Tran. UCSD, San Diego, CA

(1379) Resynchronization as an Early Therapeutic Target in Cardiac Amyloidosis: Time for a Clinical Trial?; A. J. Kadado1, S. Atallah-Yunes1, A. Turk2, J. Hernandez-Montfort1. 1University of Massachusetts Medical School - Baystate Medical Center, Springfield, MA, 2Cardiology, University of Massachusetts Medical School - Baystate Medical Center, Springfield, MA, 3Cardiology, University of Texas Medical Branch, Galveston, TX
(1380) A Heart-Lung Transplantation Case for Refractory Diffuse Alveolar Hemorrhage after ST Segment Elevation Myocardial Infarction; S. Lee1, J. Kim1, M. Ju2, G. Kim3. 1Cardiology, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of; 2Thoracic Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of; 3Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of

(1381) Improvement in Cognitive Assessment Score Following Left Ventricular Assist Device Implantation for End-Stage Heart Failure; K. Rankin, F. Foroutan, M. Rodger, J. Kobulnik. Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada

(1383) Severe Hypertriglyceridemia without Pancreatitis Following Treatment with Everolimus after Heart Transplant; P. Lo1, K. Kearney1, C. Muir2, N. Song1, J. Eisman2, P. Macdonald1. 1Heart and Lung Transplantation, St Vincent's Hospital, Sydney, Australia, 2Diabetes and Endocrinology, St Vincent's Hospital, Sydney, Australia

(1385) Extreme Orthostatic Hypotension in a Veteran Heart Transplant Patient Treated for Tongue Squamous Cell Carcinoma; E. Ram1, Y. Sharabi2, M. Wolf2, J. Lavee1, Y. Peled1. 1Cardiac Surgery, Sheba Medical Center, Ramat Gan, Israel, 2Sheba Medical Center, Ramat Gan, Israel

(1386) The Meddling Infiltrate That Never Went Away; A. A. Arjuna1, M. Mody2, C. Migliore2, P. S. Patel2, T. Anandarangam2. 1Pulmonary and Critical Care Medicine, University of Florida, Gainesville, NJ, 2Pulmonary and Critical Care Medicine, Robertwood Johnson Newark Beth Israel Medical Center, Newark, NJ

(1387) Dual Oral and Continuous Intravenous Chelation Therapy Recovers End-Stage Iron Overload Cardiomyopathy; M. Aras, V. Selby, N. Colaco, S. Bhattacharya, L. Klein, T. De Marco. Cardiology, University of California, San Francisco, San Francisco, CA
POSTER SESSION 2: JUNIOR FACULTY CASE REPORTS: HEART FAILURE/TRANSPLANTATION
Room: Banda Sea 2

Poster Discussants:
Maria Crespo-Leiro, MD, Hospital Univ A Coruna, La Coruna, Spain
Maryjane Farr, MD, Columbia University Medical Center, New York, NY, USA
Farhan Zafar, MD, Children's Hospital Medical Center, Cincinnati, OH, USA

(1388) Hemophagocytic Lymphohistiocytosis after Heart Transplantation: C. Danielsson, E. Bobbio, S. Esmaily, G. Dellgren, K. Karason. Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

(1389) Left Ventricular Assist Device as a Bridge to Successful Heart-Liver Transplantation: A Case Report: D. Rinewalt, J. W. MacArthur, W. Hiesinger, M. E. Currie, F. Haddad, W. Concepcion, Y. J. Woo, D. Banerjee. 1Cardiac Surgery, Stanford University, Palo Alto, CA, 2Cardiovascular Medicine, Stanford University, Palo Alto, CA, 3Surgery, Stanford University, Palo Alto, CA

(1390) Blood and IvIg Causing Takotsubo Cardiomyopathy: Chicken or Egg Dilemma?: A. Arjuna, A. Emmitagoo, A. Shahmommadi, M. Pipkin, M. Massoomi. Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL


(1392) A Case of Heart Transplantation from a Donor with Atrial Septal Defect Secondum: H. Lee, J. Shin, S. Song, S. Kim, M. Kim. 1Cardiology Department, Pusan National University Hospital, Busan, Korea, Republic of, 2Thoracic Surgery Department, Pusan National University Hospital, Busan, Korea, Republic of

(1393) To Explant or Not to Explant - That is the Question: A. Alam, A. Mukherjee, A. Ghaly, M. Huang, K. Mody, D. Iyer, J. Almendral. 1Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, 2Jersey Shore Medical Center, Neptune City, NJ

(1394) Left Ventricular Assist Device as Rescue Therapy for Giant Cell Myocarditis: P. Mudigonda, S. Jaganathan, J. Vierecke, D. Sharma, D. S. Feldman. 1Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH, 2Advanced Heart Failure and Transplant, University of Cincinnati, Cincinnati, OH, 3Division of Pathology, University of Cincinnati, Cincinnati, OH


(1396) Heart Transplantation as Salvage Therapy for Intractable Prosthetic Valve Endocarditis: K. Rankin, C. McGuinty, V. M. Molinero, A. Luk, H. J. Ross, R. J. Cusimano, M. Ouzounian, M. McDonald. Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada


(1400) An Unusual Case of Syncope after Heart Transplant: F. Al-Saffar, D. Jaroszewski, P. DeValeria, E. Steidley, L. LeMond. 1Cardiology, Mayo Clinic, Scottsdale, AZ, 2Cardiothoracic Surgery, Mayo Clinic, Scottsdale, AZ

(1401) A Coronary Cameral Fistula Treated with Coil Embolization: E. D. Hinds, M. J. Marin III, J. George, R. M. Delgado III. 1University of Texas Medical Branch, Galveston, TX, 2Texas Heart Institute, Houston, TX

(1402) Abrupt Onset of Chest Pain and Fever in a Young Man: A Case Report: G. L. Leonor Lopez, A. Badiye, S. Chaparro, D. Rao, N. A. Brozzi. Internal Medicine, Jackson Memorial Hospital/ University of Miami, Miami, FL

(1403) Fulminant Myocarditis: Should We Wait for Recovering? Biopsy Says No!: S. Vazquez, F. Loiacono, J. M. Domínguez, G. Frigola, M. Farrero, M. Castel, F. Perez Villa. 1Heart Failure and Transplant Unit, Hospital Clinic, Barcelona, Spain, 2Department of Pathology, Hospital Clinic, Barcelona, Spain
(1405) Lamin Heart Disease: One Approach to Treating Conduction Disease and Progressive Arrhythmias; D. Pedrotty1, L. Goldberg1, G. Supple2, A. Owens3. 1Heart Failure Cardiology, University of Pennsylvania, Philadelphia, PA, 2Cardiology, Electrophysiology, University of Pennsylvania, Philadelphia, PA


(1407) A Case of Acute Heart Failure Due to Immune Checkpoint Blocker- Nivolumab; M. Sharma, D. Silber, B. Kim. Heart Failure and Pulmonary Hypertension, Hackensack University Medical Center, Hackensack, NJ

(1409) Atypical Pattern of Danon Disease with Advanced Heart Failure; E. Anegawa1, K. Kuroda1, Y. Kimura1, K. Iwasaki1, Y. Kumai1, K. Toda1, Y. Matsumoto2, T. Watanabe1, O. Seguchi1, S. Nakajima1, S. Fukushima1, H. Ueda3, M. Yanase1, T. Fujita2, J. Kobayashi2, N. Fukushima1. 1Heart Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan, 2Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, 3Pathology, National Cerebral and Cardiovascular Center, Suita, Japan

(1410) Coronary Artery By-Pass Grafting in a Patient 4 Days Post Orthotropic Heart Transplantation: A Case Review; L. Saiva1, J. O'Neil1, L. Nolke1. 1Heart and Lung Transplant, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2Consultant Transplant Cardiologist, Mater Misericordiae University Hospital, Dublin 7, Ireland

(1411) Maintaining Immunosuppression in the Setting of Posterior Reversible Encephalopathy Syndrome and Status Epilepticus in High-Risk Multi-Organ Transplantation; N. T. Rivera, A. Badiye, N. Brozzi, M. Loebe, S. Chaparro. Miami Transplant Institute, Jackson Health System in affiliation with University of Miami Health System, Miami, FL

(1412) Benefits and Challenges of Robotic Pelvic Surgery in a Cardiac Transplant Recipient; W. A. Parker1, V. L. Parker2, H. J. Ramshaw1, E. K. D'Arcy1, A. Al-Mohammad1, O. Mateszko1, F. M. Kew2, P. C. Braidley1. 1The Heart & Lung Transplant Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, 2Department of Obstetrics & Gynaecology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, 3Department of Anaesthesia, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

(1413) Mechanism of Sustained Action: Milrinone-Induced Priapism; M. Ignaszewski1, N. Ejaz2, S. Bar3, M. Toma3, A. Ignaszewski3. 1Cardiology, Cooper University Hospital, Camden, NJ, 2Cardiology, Toronto General Hospital, Toronto, ON, Canada, 3Cardiology, St. Paul's Hospital, Vancouver, BC, Canada

(1414) Chronic Lymphocytic Myocarditis Confirmed by Electrogram-Guided Endomyocardial Biopsy; J. Oh, H. Kim, J. Jang, S. Kang. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

(1415) Differences in Dynamics of Alterations in Frailty and Sarcopenia Assessment Tools; L. Roehrich1, J. Knierim1, M. Hajduczenia1, J. Mulzer1, M. Mueller1, P. Pergantis1, M. Hummel1, V. Falk1, E. Potapov1, S. Suendermann2, F. Schoenrath1. 1Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany, 2Department of Cardiothoracic Surgery, Chariite - Universitätsmedizin Berlin, Berlin, Germany

(1416) Stress Cardiomyopathy Induced by Dobutamine Stress Echocardiogram; K. Sawalha1, H. Mahmaljy2, M. Al-Akchar3, A. Battisha1, A. Alsaid2. 1Internal Medicine, University of Massachusetts Medical School-Baystate Medical Center, Springfield, MA, 2Cardiology, Geisinger Medical Center, Danville, PA, 3Internal Medicine, Southern Illinois University, Springfield, IL

(1417) Hiding in Plain View: Antibody-Mediated Cardiac Allograft Rejection Presenting as Unilateral Pleural Effusion and Atrial Flutter; B. Rasmussen, L. Stone, T. O'Neill. Cardiology, Wake Forest Baptist Health, Winston Salem, NC
Thursday, April 4, 2019
5:45 PM - 7:00 PM

POSTER SESSION 2: JUNIOR FACULTY CASE REPORTS: LUNG FAILURE/TRANSPLANTATION
Room: Banda Sea 2

Poster Discussants:
Michiel Erasmus, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands
Jennifer Gray, PharmD, Vanderbilt University Medical Center, Nashville, TN, USA
Hanneke Kwakkel-van Erp, MD, PhD, Lung Transplantation Center, Antwerp, Belgium
Amit Parulekar, MD, Baylor College of Medicine, Houston, TX, USA

(1418) Extracorporeal Liver Assist Device (MARS®) for Treatment of Hyperammonemia after Lung Transplantation; M. Kwon1, A. Patel2, J. Canabal2, P. Moreno Franco3, T. J. Haddad3, F. Alvarez3, D. B. Erasmus2, J. M. Mallea2, T. Narula2. 1Pulmonary and Critical Care, Mayo Clinic, Jacksonville, FL, 2Transplant Medicine, Mayo Clinic, Jacksonville, FL

(1419) A Successful Lung Transplant from a 3-Year-Old Donor after Controlled Cardiac Death Followed by Ex-Vivo Lung Perfusion: A Case Report; M. Galasso1, R. D. Vanderlaan2, M. Solomon3, S. Keshavjee1, M. Cypel1, M. De Perrot1. 1Latter Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada, 2Division of Cardiac Surgery, University of Toronto, Toronto, ON, Canada, 3Lung Transplant Program, The Hospital for Sick Children (SickKids), University Health Network, Toronto, ON, Canada

(1420) Lung Positioning during Ex-Vivo Lung Perfusion: Impact of Prone Ventilation; A. Banga, J. Murala. UT Southwestern Medical Center, Dallas, TX

(1421) Treatment of HLA Antibody Negative Acute Antibody-Mediated Lung Allograft Rejection with Eculizumab; C. Kurihara, A. Bharat. Northwestern University Feinberg School of Medicine, Chicago, IL

(1422) Donor Derived Lymphangioleiomyomatosis in a Lung Transplant Recipient; B. Buddhdev, R. Walia, T. Panchabhai, A. Omar, S. Tokman. Norton Thoracic Institute, St Joseph Hospital and Medical Center, Phoenix, AZ

(1423) Percutaneous RVAD and Oxygenator Support as an Alternative to VV ECMO in Pulmonary Graft Failure; M. T. Cain1, D. L. Joyce1, L. D. Joyce1, L. A. Durham1, A. Mohammed2. 1Surgery - Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, 2Department of Medicine - Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI

(1425) Sildenafil Improved Refractory Reflux and Gastroparesis Symptoms in a Lung Transplant Recipient; A. Arjuna1, A. Pelaez1, A. Ouni2, T. Machuca2, M. Pipkin2, S. Chandrashekaran1, A. Emtiazjoo1, H. Alnuaimat1, A. Shahmohammadi1, M. Amaris2. 1Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, 2Internal Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL

(1426) Successful Use of Cangrelor as a Bridge to Lung Transplant; P. Chung, E. Mancl, S. Quddus, D. Dilling. Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL

(1427) End Stage Lung Disease with Severe Aortic Stenosis: Transcatheter Aortic Valve Replacement (TAVR) as a Bridge to Transplant; A. Arjuna, A. Shahmohammadi, T. Machuca, M. Pipkin, G. Arnaoutakis. Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL

(1428) Extracorporeal Membrane Oxygenation to Facilitate Chest Closure of Open Chest after Lung Transplantation with Oversized Allograft; T. Harano1, J. D'Cunha3, S. Kilaru2, M. R. Morrell2, J. D. Luketich1, P. Sanchez1. 1Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA


(1430) An Incidental Finding at Transplant Assessment; J. Wallis, M. Mallouppas, I. Okpala, C. Sudarshan, J. S. Parmar. Royal Papworth Hospital, Cambridge, United Kingdom
(1431) Use of ProtekDuo® as Venoarterial and Venovenous Extracorporeal Membrane Oxygenation during Bilateral Lung Transplantation; C. Kurihara, A. Budd, A. Bharat, A. Kretzer. Northwestern University Feinberg School of Medicine, Chicago, IL


(1433) Lung Transplantation for Posttraumatic Acute Respiratory Distress Syndrome; K. Hanlon, L. Allenspach, L. Stagner, J. Pinto, H. Nemeh. Pulmonary and Critical Care Medicine, Henry Ford Hospital, Detroit, MI

(1434) Calcineurin Associated Sensorimotor Polyneuropathy after Lung Transplant Partly Recovered after Switching to Everolimus; V. Verplancke1, S. K. Yogeswaran2, P. Lauwers2, P. Van Schil2, J. M. Hendriks2, J. P. Van Meerbeeck1, J. M. Kwakkel-van Erp1. 1Pulmonology, University Hospital Antwerp, Antwerp, Belgium, 2Thoracic Surgery, University Hospital Antwerp, Antwerp, Belgium, 3Pulmonology & Thoracic Oncology, Antwerp University and University Hospital, Antwerp, Belgium

(1435) Pleuroparenchymal Fibroelastosis; C. Rutherford, J. Kleinerova, O. MacEneaney, P. Ging, S. Winward, K. Redmond, M. Murray, J. J. Egan. National Heart and Lung Transplant Centre, Mater Misericordiae University Hospital, Dublin, Ireland

(1436) Lung Allograft Assessed by Acellular Ex-Vivo Lung Perfusion with Dramatic Improvement in Severe Primary Graft Dysfunction Following Double-Lung Transplant; I. Sakanoue, T. Okamoto, S. Unai, K. R. McCurry. Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

(1437) Atypical Presentation of Tacrolimus-Induced Posterior Reversible Encephalopathy Syndrome in Lung Transplantation; S. El Hajj1, J. Dibu2, F. Hamed1. 1Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 2Neurocritical Care, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 3Transplant Pulmonology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

(1438) Respiratory Failure after Epidural Analgesia; P. Shah, A. Arjuna, S. Chandrashekaran. Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL

(1439) A Case of Constrictive Pericarditis after Bilateral Lung Transplantation; N. Donthi1, J. L. Della-Santina2, H. Mani3, L. J. Bogar4, S. Aryal5. 1Internal Medicine, INOVA Fairfax Medical Center, Falls Church, VA, 2INOVA Fairfax Medical Center, Falls Church, VA, 3Inova Pathology Institute, INOVA Fairfax Medical Center, Falls Church, VA, 4Inova Cardiac and Thoracic Surgery, INOVA Fairfax Medical Center, Falls Church, VA, 5Inova Heart and Lung Transplant, INOVA Fairfax Medical Center, Falls Church, VA


(1441)Tacrolimus Associated Thrombotic Microangiopathy Presenting with Renal Failure and Hemolysis Following Lung Transplant; J. B. Smith1, J. Carney2, L. Morrison1. 1Department of Medicine, Duke University, Durham, NC, 2Department of Pathology, Duke University, Durham, NC

(1442) First Bilateral Lobar Lung Transplantation in Poland; B. Kubisa1, M. Nieborak-Raczkowska2, M. Piotrowska3, T. Grodzki3, A. Kubisa2, J. Pieróg3, M. Wojtyś1, M. Bielewicz1, M. Czarnecka1, J. Wójcik1, N. Wójcik1, P. Sielicki4, M. Bryczyński4. 1Thoracic Surgery and Transplantation Department, Pomeranian Medical University of Szczecin, Szczecin, Poland, 2Department of Internal Medicine and Hypertension, SPWSZ Sokólskiego, Szczecin, Poland, 3Thoracic Surgery and Transplantation Department, SPWSZ Sokolowskiego, Szczecin, Poland, 4Cardiac Surgery Department, Pomeranian Medical University of Szczecin, Szczecin, Poland
POSTER SESSION 3: HEART FAILURE/TRANSPLANTATION (ADULT)
Room: Hibiscus 2

Poster Discussants:
Emanuele Bobbio, MD, Sahlgrenska University Hospital, Gothenburg, Sweden
Monica Colvin, MD, University of Michigan, Ann Arbor, MI, USA
Sofia Carolina Masri, MD, University of Washington, Seattle, WA, USA
Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA
Hao Tran, MD, UCSD Medical Center, San Diego, CA, USA

(944) Deep Learning for Diagnosing Heart Failure from ECG Signals; K. Kim, J. Kwon. Sejong General Hospital, Kyunggi do, Korea, Republic of


(946) Differences in Swan-Ganz Hemodynamics from Catheterization Lab Insertion to the Cardiac Care Unit: A Prospective Study; M. Husaini, A. Bhatia, C. Lin, J. LeClair, N. Becker, A. Scott, E. De Togni, J. Acevedo-Cintron, J. Schilling. Washington University in Saint Louis, St. Louis, MO

(947) Importance of a Partnered Heart Failure Network to Increase Access to Advanced Heart Failure Therapies; S. Rodriguez, E. Melrose, S. George, M. Duke, D. A. Horstmanshof. INTEGRIS Baptist Medical Center, Oklahoma City, OK

(948) Early- and Late-Onset Arrhythmias after Bioelectrical Impedance Analysis in End-Stage Heart Failure Patients under Inotropic Support; L. Roehrich, J. Knierim, M. Hajduczenia, J. Mulzer, M. Mueller, P. Pergantis, M. Hummel, V. Falk, E. Potapov, S. Suendermann, F. Schoenrath. 1Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany, 2Department of Cardiothoracic Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

(949) Correlation of Initial Echocardiographic Parameters and Emergency Room Admission Rates in Heart Failure Clinic Patients; X. Cai, S. Jia, S. J. Smith, S. De, R. McKelvie, R. A. Davey. 1Medicine, London Health Sciences Centre, London, ON, Canada, 2Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 3Cardiology, London Health Sciences Centre, London, ON, Canada

(950) Use of Intra-Aortic Balloon Pump in Heart Failure Admissions Requiring Inotropic Support in the United States between 2004-2014; A. Afzal, T. Nisar, A. K. Jamil, A. Y. Kluger, J. Felius, S. A. Hall, P. Kale. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX, 3Baylor Heart and Vascular Institute, Dallas, TX

(951) The Obesity Paradox and Predictors of Thirty Day Mortality in a Single Center Heart Failure Population; C. P. Boyd, K. Luskin, D. Eastwood, M. Conti, A. Mohammed. 1Cardiology, Medical College of Wisconsin, Milwaukee, WI, 2Allergy and Immunology, Scripps Health, San Diego, CA, 3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, 4Cardiology, Froedtert Health, Milwaukee, WI

(952) How Dynamic are Hemodynamics?: Short-Term Changes in Hemodynamic Measures and Indices among Heart Failure Patients; A. Bhatia, M. Husaini, C. Lin, J. LeClair, N. Becker, A. Scott, M. Terng, J. Acevedo-Cintron, J. Schilling. 1Division of Cardiology, Washington University School of Medicine, St. Louis, MO, 2Washington University School of Medicine, St. Louis, MO

(953) The Effect of Preload Change on QRS Amplitude in Advanced Heart Failure Patients; P. Pergantis, S. A. Dual, M. Schmid Daners, J. Kezniick-Pulst, F. Schoenrath, V. Falk. 1German Heart Center Berlin, Berlin, Germany, 2ETH Zurich, Zurich, Switzerland

(954) N-Terminal Pro-B Type Natriuretic Peptide Imly Left Ventricular Diastolic Function but is a Low Sensitivity Marker; H. Choi, S. Lee, C. Park, W. Chung. Cardiology, Gachon University Gil Medical Center, Incheon, Korea, Republic of

(955) Validating the Newly Reported ASA Score; A. Alam, A. Mukherjee, J. Xu, E. Pagan, E. Hiltner, E. Rios, S. Pollack, D. Iyer, K. Mody, J. Kassotis, D. James, R. Jermy, J. Almendral. 1Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, 2St. Francis University Hospital, Roslyn, NY, 3Jersey Shore Medical Center, Neptune, NJ
(956) Positive Correlation between P Wave Analysis and Severity of Heart Failure with Preserved and Reduced Ejection Fraction; H. Patel, B. Allen, S. Almahmoud. Cardiology, University of Texas Medical Branch, Galveston, TX

(957) Diagnostic Accuracy of D-dimer is Comparable to NT-proBNP in Decompensated Heart Failure; N. Nair1, S. Yang2, C. Marzban1, C. Cole1, P. Tantrachoti1, E. Gongora1. 1Division of Cardiology, Dept of Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX. 2Dept of Internal Medicine, Texas Tech HSC, Lubbock, TX. 3Cardiothoracic Surgery, Memorial Cardiovascular Institute, Hollywood, FL

(958) The Impact of Hand Carried Ultrasound on the Management of Acute Heart Failure with Chronic Kidney Disease; W. Khalife, A. Albaeni, V. R. Mukku, M. Almahmoud. Cardiology, University of Texas Medical Branch, Galveston, TX

(959) The Role of Hand Carried Ultrasound in Guiding Management of Challenging Heart Failure Patients; W. Khalife, A. Albaeni, V. R. Mukku, M. Almahmoud. Cardiology, University of Texas Medical Branch, Galveston, TX

(960) Hand Carried Ultrasound Utilization in Acute Heart Failure Patients, Does It Correlate with Physical Examination?; W. Khalife, A. Albaeni, V. Mukku, M. Almahmoud. Cardiology, University of Texas Medical Branch, Galveston, TX

(961) Physician Prediction versus Model Predicted Prognosis in Ambulatory Patients with Heart Failure; T. A. Buchan1, H. J. Ross2, M. McDonald3, F. Billia4, D. Delgado1, J. G. Duero Posada1, A. Luk5, G. H. Guyatt6, A. C. Alba1. 1Cardiology, Ted Rogers Centre for Heart Research, University Health Network, Toronto, ON, Canada. 2Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

(962) Outpatient Weaning of Inotropes is Achievable in Patients with Advanced Heart Failure; A. Afzal, A. Y. Lee, A. S. Bindra, P. Kale. Baylor University Medical Center, Dallas, TX

(963) Multidisciplinary Care for End-Stage HF: How to Improve Care?; S. Mirabet1, A. Pascual2, P. Fluvia3, M. Pirla1, N. Mesado1, I. Lumillo1, E. Villegas1, M. Llauger2, E. Roig1. 1Cardiology, Hospital Sant Pau, Barcelona, Spain. 2Palliative Care, Hospital Sant Pau, Barcelona, Spain. 3Cardiology, Hospital Josep Trueta, Girona, Spain. 4Intern Medicine, Creu Roja, Barcelona, Spain. 5Primary Care, Sant Pau, Barcelona, Spain

(964) Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients; K. Stawiarcki1, O. Agboola2, D. Jacoby2, L. Bellumkonda2, T. Ahmad2, L. Sugeng2, M. Chen2, G. McCloskey3, A. Geirsson4, M. Anwar5, P. Bonde5. 1Yale New Haven Health Bridgeport Hospital, New Haven, CT. 2Yale School of Medicine, New Haven, CT

(965) Home Inotropic Therapy as a Bridge and as Destination: Intended and Unintended Outcomes in a Single Center Contemporary Cohort; C. S. Grubb1, M. S. Bohnen, A. Kleet, V. K. Topkara, A. R. Garan, R. Bijou, M. S. Maurer, H. Garan, M. Farr. Columbia University Medical Center, New York, NY

(966) Bariatric Surgery in Patients with Systolic and Diastolic Heart Failure: Insights from the Nationwide Inpatient Sample; Y. Blumer1, M. Ortiz2, G. A. Hernandez1, A. Vest1. 1University of Miami, Miami, FL. 2University of Iowa, Iowa City, IA. 3Tufts Medical Center, Boston, MA

(967) To Exchange or Not: Defibrillators, Ventricular Assist Devices and Hematomas; R. Khedrak1, M. Rajeev2, J. Rogers1, J. T. Heywood2, A. Srivastava2. 1Cardiology, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA. 2Division of Cardiology, Section of Advanced Heart Failure, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA

(968) Safety and Efficacy of Home Inotropes as Bridge to LVAD and Transplant; J. Pillarella1, L. Albers1, P. Katrapati1, D. Abramov2, E. Birks1, R. Vijayakrishnan1. 1University of Louisville, Louisville, KY. 2Loma Linda, Loma Linda, CA

(969) Positive Familial History Poses a Higher Risk for No Spontaneous Recovery in Patients with Peripartum Heart Failure: Left Ventricular Assist Device Implantation and Transplantation with Bromocriptine as Novel Therapeutic Options in These Patients; K. Jawad1, J. Erdmann5, M. Borger1, S. Eifert1. 1Leipzig, Heart Center, Leipzig, Germany. 2University to Lübeck, Lübeck, Germany

(971) Cell-Free DNA in Different Clinical Scenarios after Heart Transplantation: Shedding Light or Obscuring the Picture?; L. Bohmer1, A. Ricksten2, J. Asp3, C. Wasslavič2, A. Stahlberg3, K. Karason4, H. Wahlander1, J. Sunnegardh1, G. Dellgren3. 1Pediatric Heart Center, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden. 2Laboratory for Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden. 3Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden. 4Transplant Center, Sahlgrenska University Hospital, Gothenburg, Sweden


(974) Immunoadsorption for Acute Symptomatic Antibody-Mediated Rejection after Heart Transplantation; A. Schaef1, G. Böhmig2, A. Zuckermann1, G. Fischer3, G. Laufer1, A. Kaider4, A. Aliabadi-Zuckermann1. 1Department of Surgery, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Medical University of Vienna, Vienna, Austria, 3Department for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria, 4Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria

(975) Combination of Cell-Free DNA with Gene-Expression Profiling in the Diagnosis of Acute Rejection; E. Depasquale1, S. Hall2, M. Crespo-Leiro3, A. Kao4, J. Teuteberg5, D. Hiller6, J. Yee6. 1Department of Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA, 2Baylor Scott & White Research Institute, Dallas, TX, 3Hospital Universitario A Coruña, La Coruña, Spain, 4Saint Luke’s Mid America Heart Institute, Kansas, MO, 5Stanford University, Stanford, CA, 6CareDx, Inc., Brisbane, CA

(976) Effects of Induction on the Risk of Post-Transplant De Novo DSA; R. T. Cole1, J. Minto2, M. Flattery3, A. Parikh4, T. Dong1, R. Roy1, L. Boga3, A. Morris1, J. Vega4, D. Gupta1, K. Bhatt1, A. Smith1, S. Laskar2, A. Lala4, K. Shah3, P. Shah4. 1Cardiology, Emory Univ Sch of Med, Atlanta, GA, 2George Washington University School of Medicine, Washington DC, GA, 3Virginia Commonwealth University, Richmond, VA, 4Mount Sinai Hospital, New York, NY, 5Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, 6Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA, 7Cardiology, Emory University School of Medicine, Atlanta, GA, 8Inova Heart and Vascular Institute, Falls Church, VA


POSTER SESSION 3: HEART TRANSPLANTATION (ADULT)
Room: Hibiscus 1

Poster Discussants:
Jaime-Juergen Eulert-Grehn, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
Kristjan Karason, MD, Sahlgrenska Hospital, Goteborg, Sweden
Jamila Kremer, MD, University Hospital Heidelberg, Heidelberg, Germany
Farhana Latif, MD, Columbia University New York Presbyterian Hospital, New York, NY, USA
Marco Masetti, MD, PhD, University of Bologna, Bologna, Italy
Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain

(981) Directly to a DOAC? Safety of Alternatives to Warfarin for Anticoagulation in Heart Transplantation; M. Tremblay-Gravel, K. M. Alexander, P. Czobor, R. Lee, F. Foroutan, W. A. Yang, A. Hayes, W. Hiesinger, H. J. Ross, K. K. Khush, J. J. Teuteberg, Y. Moayed, Medicine, Division of Cardiology, Stanford University, Palo Alto, CA, 2Medicine, Division of Cardiology, Stanford University, Stanford, CA, 3Biostatistics, University of Toronto, Toronto, ON, Canada, 4Cardiovascular Surgery, Stanford University, Stanford, CA, 5Cardiovascular Surgery, Stanford University, Palo Alto, CA, 6Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada, 7Medicine, Stanford University, Stanford, CA

(983) Transpulmonary Gradient as a Predictor of Outcomes after Heart Transplantation; J. Jahanyar, J. M. Liao, R. J. Butterfield, III, N. Zhang, B. W. Hardaway, E. D. Steidley, R. L. Scott, 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Medicine, University of Washington, Seattle, WA, 3Biostatistics, Mayo Clinic, Phoenix, AZ, 4Health Sciences Research, Mayo Clinic, Phoenix, AZ, 5Cardiology, Mayo Clinic, Phoenix, AZ


(985) Risk Factors and Early Outcomes of Vasoplegia Syndrome (VS) after Heart Transplantation in CF-LVAD Patients; T. Chinnadurai, F. Jahufar, O. Moussa, A. Rahman, S. Rangasamy, E. Borukhov, A. Miller, O. Saeed, D. Goldstein, U. P. Jorde, S. R. Patel, 1Cardiology, Montefiore Medical Center, Bronx, NY, 2Cardiothoracic, Montefiore Medical Center, Bronx, NY

(986) En-Block Heart-Liver Transplantation in Adults - Technique and Mid Term Outcomes; N. A. Brozzi, R. Vianna, F. Souki, I. C. Saba, A. Ghodzisad, A. Tekin, G. Selvaggi, T. Beduschi, A. Badiye, S. Chaparro, O. Aljure, A. Nicolaou-Raduclu, M. Loebe, 1Thoracic Transplantation and Mechanical Circulatory Support, University of Miami, Miami, FL, 2Liver Transplantation, University of Miami, Miami, FL, 3Anesthesia, University of Miami, Miami, FL

(987) Cervical Abnormalities and Gynecological Neoplasms in Heart Transplanted Recipients; S. Mirabet, V. Brossa, C. Vanrell, L. Lopez, E. Roig, 1Cardiolog, Hospital Sant Pau, Barcelona, Spain, 2Ginecology, Hospital Sant Pau, Barcelona, Spain

(988) Factors Influencing Access to Transplant, Waitlist Mortality, and Post-Transplant Survival in the Italian National Heart Transplant Database; M. Frigerio, M. Varrenti, C. Santolamazza, D. P. Bernasconi, A. Nanni Costa, A. Oliveti, F. Puoti, T. Bottio, G. Gerosa, C. F. Russo, C. Giannattasio, V. Tursi, U. Livi, C. Maiello, C. Amarelli, L. Potena, S. Martin Suarez, M. Boffini, C. Pace Napoleon, F. Clemenza, F. Musumeci, M. Maccherini, G. Faggian, C. Pellegrini, A. Terzi, C. Tramontin, D. De Angelis, A. D. Milano, M. Valsecchi, 1DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy, 2Center of Biostatistics for Medical Epidemiology, School of Medicine and Surgery, Milano-Bicocca University, Milan, Italy, 3CNT-National Transplant Center, Rome, Italy, 4Dept of Cardiac, Thoracic and Vascular Sciences, Padua University Medical School, Padua, Italy, 5Cardiovascular Medicine and Emergency Medicine School, School of Medicine and Surgery, Milano-Bicocca University, Milan, Italy, 6University Hospital, Udine, Italy, 7Dept of Cardiovascular Surgery and Transplants, AORN Ospedale dei Colli, Naples, Italy, 8Heart Transplant Program, Bologna University Hospital, Bologna, Italy, 9Dept of Surgical Sciences, Turin University, ASOU Città della Salute e della Scienza, Turin, Italy, 10Pediatric Cardiosurgery, OIRM Sant’Anna, OAU Città della Salute e della Scienza, Turin, Italy, 11IRCCS-ISMETT, Palermo, Italy, 12Cardiac Surgery Unit and Heart Transplantation Center, S. Camillo-Forlanini Hospital, Rome, Italy, 13AOU Siena, Siena, Italy, 14Verona University Hospital, Verona, Italy, 15Dept of Surgical, Clinical and Surgical, Diagnostic and Pediatric Sciences, Pavia Study University, Pavia, Italy, 16ASST Papa Giovanni XXIII, Bergamo, Italy, 17G Brotzu Hospital, Cagliari, Italy, 18Thoracic Transplantation Unit, Bambino Gesu Children’s Hospital, Rome, Italy, 19Dep of Emergency and Organ Transplants, University of Bari Medical School, Bari, Italy

(989) Trends in Exercise Capacity Following Heart Transplantation; S. Lundgren, E. Lyden, M. Hyden, A. Burdorf, R. Zolty, B. Lowes, J. Um, D. Stoller, University of Nebraska Medical Center, Omaha, NE
(990) A Conformational Anastomotic Device for Heart Transplantation; J. Park, P. Bonde. Yale School of Medicine, New Haven, CT

(991) Outcomes in Combined Heart-Liver Transplantation: A Single-Center Experience; A. Akhmerov1, Q. Chen1, M. DeRobertis2, L. Czer2. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, 2Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

(992) Orthotopic Heart Transplant Volume Can Be Aggressively Increased While Maintaining Outcomes; A. Ivengar, J. Han, M. Helmers, W. Patrick, J. Chung, N. Goel, P. Atluri. University of Pennsylvania, Philadelphia, PA

(993) Impact of Blood Group A Subtyping on Heart Transplantation: A Single Center Experience; H. Ilias Basha, S. Hussain, E. Raichlin, S. Gudipati, M. Liebo, E. McGee, P. De Christopher, A. Heroux. Loyola University Medical Center, Maywood, IL

(994) Multimodal Prehabilitation in Patients Listed for Heart Transplantation: A Pilot Study; M. J. Arguis1, M. A. Castel1, E. Gimeno1, R. Navarro1, M. Coca1, A. Lopez-Hernández1, M. Montane-Muntane1, B. Romano1, M. Farrero1, E. Sandoval1, F. Perez-Villa2, A. García2, G. Martinez-Palli1. 1Anesthesiology, Hospital Clinic of Barcelona, Barcelona, Spain, 2Cardiology, Hospital Clinic of Barcelona, Barcelona, Spain

(995) Impact of Center Volume on Post Heart Transplant Survival; J. Rice1, M. Slaughter1, E. Birk2, J. Trivedi1. 1Department of Cardiovascular Surgery, The University of Louisville School of Medicine, Louisville, KY, 2Department of Cardiology, The University of Louisville School of Medicine, Louisville, KY


(998) Is There a Mortality “Weekend Effect” in Cardiac Transplantation?; R. Chand1, C. J. Lum1, A. Chang1, A. Salimbangon1, M. Deng1, M. Cadeiras2, T. Khuu1, K. Pandya1, D. Vucicevic2, A. Ardehali1, E. DePasquale1. 1UCLA, Los Angeles, CA, 2UC Davis, Sacramento, CA, 3USC, Los Angeles, CA, 4Newark Beth Israel, Newark, NJ

(999) Impact of Heart Rate and Left Ventricular Mass on Survival Following Heart Transplantation; S. Lundgren, E. Lyden, M. Hyden, A. Burdorff, R. Zolty, B. Lowes, J. Um, D. Stoller. University of Nebraska Medical Center, Omaha, NE

(1000) Gender Differences in Pre-Transplant Characteristics and Short-Term Clinical Outcomes Post Heart Transplantation; A. Almufleh1, S. Fazelpour2, A. Merdad1, J. Marbach1, R. Davies1, L. Mielenzuk1, S. Chih1, E. Stadnick1. 1Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada, 2The Ottawa Hospital, Ottawa, ON, Canada

(1001) Is There a Mortality “Weekend Effect” in Cardiac Transplantation - A Single Center Experience?; A. Salimbangon1, D. Vucicevic2, C. Lum1, A. Chang1, T. Khuu1, M. Moore1, R. Chand1, M. Cadeiras2, M. Kwon1, M. Deng1, M. Kamath1, E. DePasquale1. 1UCLA, Los Angeles, CA, 2Newark Beth Israel, Newark, NJ, 3UC Davis, Sacramento, CA

(1002) Post-Transplant Trends in BNP Levels among Recipients of Heart versus Heart-Kidney Transplantation; K. Schleendorff1, P. Hanner2, M. Wigger1, D. Brinkley1, J. Menachem1, A. Shah1, M. Dantzer4, K. Balsara3, L. Punnose1, S. Brown Sacks1, H. Ooi1, J. Lindenfeld1, S. Zalawadiya1. 1Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, 2Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, 3Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN

(1003) Interactive Maps for UNOS Data Visualization; A. Rivard1, M. Gentili1, N. Koizumi1. 1Department of Radiology, Cleveland Clinic, Abu Dhabi, United Arab Emirates, 2University of Louisville, Louisville, KY, 3George Mason University, Arlington, VA

(1004) Heart and Heart-Lung Transplantation in Adult Congenital Heart Disease (ACHD): A 4-Year Single-Centre Experience; A. Verzelloni1, H. Hassan2, H. Smail1, D. Garcia-Saez3, T. Aw4, A. Simon1. 1Department of Anaesthesia and Critical Care, Harefield Hospital, Harefield, United Kingdom, 2Cardiothoracic Surgery, Menoufia University Hospital, Menoufia, Egypt, 3Cardiothoracic Transplantation and Mechanical Support, Harefield Hospital, Harefield, United Kingdom, 4Department of Anaesthesia, Royal Brompton Hospital, London, United Kingdom
Comparison of Mortality Rate after In-Hospital Cardiac Arrest in Heart Transplant Recipients versus Non-Transplant Patients; S. Sulaiman1, N. Yousef2, M. Asim3, N. Gagliannello1. 1Medical College of Wisconsin, Milwaukee, WI, 2Kalamoon University, Damascus, Syrian Arab Republic, 3Department of Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI


The Impact of Insurance Type on Listing Status and Mortality on the Waiting List: Insights from the United Network for Organ Sharing (UNOS); A. Briasoulis1, E. Akintoye1, E. Ruiz Duque1, C. Inampudi1, J. Bhama2, P. Alvarez1. 1University of Iowa, Iowa City, IA, 2Cardiovascular Surgery, University of Iowa, Iowa City, IA

Comparison of Ambulatory, and Central Blood Pressure in Heart Transplant Recipients; C. Lee, J. Oh, S. Park, S. Lee, S. Kang. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Denovo Malignancy in Chinese Patients Post-Heart Transplant in Current Era-A “Not So Bad Prognosis”?; K. Fan, M. Wong, K. Cheng. Cardiac Medical Unit, Grantham Hospital, Aberdeen, Hong Kong


A Higher Need for Permanent Pacing after Orthotopic Heart Transplantation Due to Increased Donor Age; S. Roest1, F. Akca1, M. A. Kolff4, J. F. Veenis1, A. A. Constantinescu1, J. J. Brugts1, O. Birim2, O. C. Manintveld1, T. Szili-Torok1, K. Caliskan1. 1Cardiology, Erasmus MC, University Medical Center, Thoraxcenter, Rotterdam, Netherlands, 2Cardiothoracic Surgery, Erasmus MC, University Medical Center, Thoraxcenter, Rotterdam, Netherlands


POSTER SESSION 3: LUNG FAILURE/TRANSPLANTATION (ADULT)
Room: Banda Sea 1

Poster Discussants:
Andrew Courtwright, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA
Peter Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia
Lorriana Leard, MD, UCSF Medical Center, San Francisco, CA, USA
Deborah Levine, MD, UT Health Science Center, San Antonio, TX, USA
Sebastian Michel, MD, Ludwig Maximilian University/Munich University, Munichen, Germany
Caroline Patterson, MD, Papworth Hospital, Cambridge, United Kingdom
Aida Venado, MD, UCSF Medical Center, San Francisco, CA, USA
Robin Vos, MD, PhD, University Hospitals Leuven, Leuven, Belgium

(1014) Time to Therapeutic Tacrolimus Serum Concentrations and the Impact on Early Acute Cellular Rejection in Adult Lung Transplant Recipients; K. Mecadon1, J. Scheffert2, L. Shah3, H. Robbins3, M. Aversa3, S. Arcasoy3, L. Benvenuto3. 1Department of Pharmacy, Rhode Island Hospital, Providence, RI, 2Department of Pharmacy, NewYork-Presbyterian Hospital, New York, NY, 3Department of Medicine, Columbia University Irving Medical Center, New York, NY

(1015) Acute Rejection (AR) and Lymphocytic Bronchiolitis (LB) in a Multicenter Lung Transplant Cohort; J. L. Todd1, M. L. Neely1, H. Kopetskie2, M. Sever3, J. Kirchner1, C. W. Frankel1, L. D. Snyder1, E. N. Pavlisko1, T. Martinu1, W. Tsuang4, M. Shino5, N. Williams6, M. A. Robien6, L. G. Singer6, M. Budev4, P. D. Shah2, J. M. Reynolds1, S. M. Palmer1, J. A. Belperio2, S. S. Weigt3. 1Duke Univ Med Ctr, Durham, NC, 2Rho Federal Systems Division, Chapel Hill, NC, 3University of Toronto, Toronto, ON, Canada, 4Cleveland Clinic, Cleveland, OH, 5University of California Los Angeles, Los Angeles, CA, 6National Institute of Allergy and Infectious Disease, Bethesda, MD, 7Johns Hopkins University, Baltimore, MD


(1017) Peripheral Blood Eosinophil Count as a Marker of Pulmonary Allograft Rejection; S. Aguado Ibáñez, J. Carrillo, M. Aguilar, R. Laporta, C. López, G. Diaz, C. Salas, M. Ussetti. Hospital Univ Puerta de Hierro, Majadahonda, Majadahonda, Spain

(1018) Clinical Antibody Mediated Rejection of Lung is Not One Disease, but Includes Distinct Obstructive, Restrictive and Indolent Phenotypes; D. Abelson1, S. Garnett2, A. Awford3, A. Kwok3, N. Watson4, J. Colgan5, A. Rigby5, M. Plit5, A. R. Glanville5. 1Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia, 2Integrative Biomedical Sciences, University of Capetown, Capetown, South Africa, 3Department of Radiology, St. Vincent’s Hospital, Sydney, Australia, 4Solid Organ Transplantation, Australian Red Cross Blood Service, Sydney, Australia

(1019) Anti-HLA Antibodies before and after Lung Transplantation: A Role on Medium-Long Term Outcomes?; E. Benazzi1, L. Morlacchi2, A. Cannovà1, L. Rosso1, A. Palleschi3, V. Rossetti1, I. Righi1, S. Passamonti1, B. Dalpedri1, E. Longhi1, M. Cardillo1, P. Tarsia1. 1Transplant Coordination (NItp); Dept. of Services and Preventive Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, 2Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 3Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

(1020) Evaluating Novel Graft Failure Thresholds after Lung Transplantation; J. Liu, D. Li, K. Jackson, J. Weinkauf, A. Kapasi, D. Lien, A. Hirji, K. Halloran. Department of Medicine, University of Alberta, Edmonton, AB, Canada

(1021) Impact for Survival and Chronic Lung Allograft Dysfunction of ISHLT Consensus of Antibody Mediated Rejection after Lung Transplantation; Y. Ito1, M. Sato2, L. Thuita2, H. Nikiwa2, K. S. Ayyat3, T. Okamoto4, C. F. Farver4, A. Zhang5, M. Budev3, E. H. Balckstone3, K. R. McCurry1. 1Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan, 2Thoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 5Anatomic Pathology, Cleveland Clinic, Cleveland, OH, 6Allogren Department, Cleveland Clinic, Cleveland, OH, 7Respiratory Institute, Cleveland Clinic, Cleveland, OH

(1022) COMBINATION Therapies Including TOCILIZUMAB Decrease the Progression of CLAD: Initial Clinical Experience; D. J. Ross1, A. Der Hovanessian2, B. Kubak1, E. Reed3, C. Natori4, J. Schaenman4, A. Ardehali5. 1Medicine, David Geffen - UCLA School of Medicine, Los Angeles, CA, 2Medicine, David Geffen - UCLA School of Medicine, Los Angeles, CA, 3Immunogenetics, David
(1023) Impact of Donor-Recipient Sex Mismatch on the Incidence of Allograft Rejection in Clinical Lung Transplantation: A Review of the United Network of Organ Sharing Database; E. H. Cheema, A. Al-najjar, P. Loyalka, K. Rajagopal. 1Surgery, Baylor College of Medicine, Houston, TX, 2Cardiology, HCA Healthcare - Park Plaza Hospital, Houston, TX, 3Surgery, University of Texas, Houston, TX


(1026) Decreased Serum Levels of Irisin are Associated with the Development of Chronic Lung Allograft Dysfunction after Bilateral Living-Donor Lobar Lung Transplantation; T. Shiotani, S. Sugimoto, H. Yamamoto, T. Kurosaki, S. Otani, M. Okazaki, M. Yamane, S. Toyoooka, T. Oto. Department of General Thoracic Surgery, Organ Transplant Center, Okayama University, Okayama, Japan

(1027) Quantitative CT Imaging Analysis for Chronic Lung Allograft Dysfunction in Single Lung Transplant Recipients; M. Horie, T. Saito, L. Levy, P. Salazar, C. Houbois, S. Keshavjee, N. Paul, T. Martinu. 1Toronto Lung Transplant Program, Toronto, ON, Canada, 2Vital Images, Minnetonka, MN, 3Department of Medical Imaging, London Health Sciences, London, United Kingdom


(1029) Risk Factors for the Development of Antibody-mediated Rejection (AMR) after Lung Transplantation; S. Sunder, C. Witt, D. Byers, R. Hachem. Pulmonary and Critical Care, Washington University, St Louis, MO

(1031) Differences in Onset of Chronic Lung Allograft Dysfunction between Living Donor and Cadaveric Lung Transplantation; S. Sugimoto, H. Yamamoto, T. Kurosaki, S. Otani, M. Okazaki, M. Yamane, S. Toyoooka, T. Oto. 1General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, 2Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(1032) Outcomes Following Antithymocyte Globulin (ATGAM) for Chronic Lung Allograft Dysfunction Post Lung Transplantation; S. Kotecha, E. Paul, J. Fuller, B. J. Levey, G. I. Snell, G. P. Westall. 1Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 2Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

(1033) Liposomal Cyclosporine A (L-CsA) via Inhalation to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improves Tolerability; N. Henig, J. Teichmann, J. Paulukat, D. Kappeler, O. Denk, G. Boerner. Breath Therapeutics, Menlo Park, CA

(1034) Immunosuppression and Outcomes in Elderly Lung Transplant Recipients; J. K. McDermott, P. Nguyen, J. L. Parker, R. J. Hadley, A. Kumar, G. Sathiyamoorthy, M. Leacche, E. T. Murphy, R. E. Girgis. Spectrum Health Hospitals, Grand Rapids, MI

(1035) Correlation of Tacrolimus Levels and Metabolizer Status Based on CYP3A5 Polymorphism in Indian Lung Transplant Recipients; A. Jindal, V. Rahulan, S. Sagadevan, P. Dutta, S. Attawar. 1Pulmonary Critical Care and Sleep Medicine, Institute of Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, 2Pulmonary Critical Care and Sleep Medicine, Institute of Heart & Lung Transplant, Gleneagles Global Health City, Chennai, India


1Medicine, University of California, San Francisco, CA, 2Medicine, VA Health Care System, San Francisco, CA, 3Life Sciences Solutions Group, Thermo Fisher Scientific, Carlsbad, CA, 4Surgery, University of California, San Francisco, CA

(1038) A Phase II, Prospective, Open Label, Standard of Care (SOC) Controlled, Study to Evaluate the Safety and Efficacy of Glassia® in Lung Transplantation during the First 6 Months; M. R. Kramer1, Y. Rosen-Krauss1, D. Rosengarten1, O. Shtriechman2, A. Avron3, S. Gai-Castro4, N. Jaffe4, N. Tov1. 1Pulmonary Institute, Rabin Medical Center, Petah Tikva, Israel, 2Pulmonary Institute, Rabin Medical Center, Beachinon Hospital, Petah Tikva, Israel, 3Clinical Development, Kamada, Rehovot, Israel, 4Clinical Development, Kamada Ltd, Rehovot, Israel

(1039) Steroid Dosing and Delirium after Lung Transplant Surgery; G. N. Mody1, K. Townsend2, C. Kerwin3, D. Larios Chavez4, S. Boukedes1, A. Coppolino6, S. Singh6, G. Jin4, D. Wolfe4, H. Madli6, H. Goldberg1. 1Surgery, University of North Carolina, Chapel Hill, NC, 2Pharmacy, Brigham and Women’s Hospital, Boston, MA, 3Medicine, University of Colorado School of Medicine, Denver, CO, 4Medicine, Harvard Medical School, Boston, MA, 5Medicine, Brigham and Women’s Hospital, Boston, MA, 6Surgery, Brigham and Women’s Hospital, Boston, MA


(1043) The Need for Haemofiltration after Lung Transplantation is a Marker of Poor Early Outcomes, but Has No Deleterious Long-Term Renal Effect - A UK Cohort Study; L. Wang, T. Wang, S. N. Rushton, G. Parry, N. S. Sheerin, J. H. Dark. 1Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, UK, 2University College London, London, UK, 3National Health Service Blood and Transplant, Bristol, UK, 4Renal Services, Freeman Hospital, Newcastle upon Tyne, UK


(1045) Developing DSA Post-Lung Transplant - Identifying Risk Factors; L. Wang, A. Andreasson, C. Straughan, A. J. Sims, K. J. Brennan, A. J. Fisher, S. C. Clark, G. Parry, K. L. Booth, J. H. Dark. 1Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(1046) Incisional Negative Pressure Wound Therapy Use to Reduced Surgical Site Complications in Lung Transplant Patients; R. Anderson, M. Weder, S. Kilbourne. Lung Transplant, University of Virginia, Charlottesville, VA

(1047) Risk Factors for Cancer after Lung Transplantation; L. Fernandez, M. Delgado, A. Pinto, D. Cruz, E. Fieira, M. Peradelo, J. Ovalle, R. Fernández, M. Trabazo, M. De La Torre. 1Thoracic Surgery Department, A Coruña University Hospital, A Coruña, Spain, 2Pneumology Department, Vila Nova de Gaia Espinho Hospital, Gaia, Portugal, 3Pneumology Department, Ourense University Hospital, Ourense, Spain

(1048) The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation - A Retrospective Analysis; E. Ng, D. Topliss, M. Paraskeva, E. Paul, S. Ształ-Mazer. 1Department of Medicine, Alfred Health, Melbourne, Australia, 2Department of Endocrinology and Diabetes, Department of Medicine, Alfred Health, Melbourne, Australia, 3Department of Allergy, Immunology & Respiratory Medicine, Alfred Health, Melbourne, Australia, 4School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, 5Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia

(1049) A New 3D CT Method to Analyze Bronchial Stenosis after Lung Transplantation; Y. T. Nunes Dias, R. C. Chate, J. M. Nogueira Filho, G. G. Cirillo, P. M. Pégio-Fernandes, M. N. Samano. 1Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 2Radiology Division, Heart Institute (InCor), Sao Paulo, Brazil, 3Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 4Thoracic Surgery Division, Heart Institute (InCor), Sao Paulo, Brazil
(1050) **Pre-Transplant Opioid Use is Not Associated with Overall Graft Survival in Lung Transplant Recipients:** S. Vahidy, D. Li, A. Hirji, J. Weinkauf, A. Kapasi, D. C. Lien, K. Halloran. *Department of Medicine, University of Alberta, Edmonton, AB, Canada*

(1051) **Comparison of Bronchial Anastomotic Techniques in Lung Transplantation by 3D CT Analysis:** G. G. Cirillo¹, R. C. Chate², J. M. Nogueira Filho³, Y. N. Dias¹, P. M. Pêgo-Fernandes¹, M. N. Samano¹. ¹Faculdade de Medicina da USP, São Paulo, Brazil, ²Radiology Div, Heart Institute (InCor), São Paulo, Brazil, ³Thoracic Surgery Div, Heart Institute (InCor), São Paulo, Brazil

(1052) **Outcomes of Donor-Recipient Gender Mismatched Lung Transplantation in the Eurotransplant Area:** J. M. Kwakkel-van Erp¹, J. M. Smits², V. Verplancke³, P. Evrard¹, G. Lang¹, R. Schramm¹, R. Vos¹, G. M. Verleden², B. Rondelet², D. Hoeffe², E. A. Verschuuren³, W. van der Bijk³, R. A. Hoek³, G. Laufer¹, K. Hoetzenecker¹², C. Knoop⁴, R. Buhl⁴, C. Witt⁴, J. Gottlieb⁴, E. A. van de Graaf⁴. ¹Pulmonology, Univ Hosp Antwerpen, Antwerpen, Belgium, ²Eurotransplant, Leiden, Netherlands, ³Intensive Care, UCL, Namur Godinne, Belgium, ⁴Thoracic Surgery, Medical Univ of Vienna, Vienna, Austria, ⁵Cardiothoracic Surgery, Univ Muenich, Bad Oeynhausen, Germany, ⁶Dept of Respiratory Diseases, Univ Hosp Leuven, Leuven, Belgium, ⁷Dept of Thoracic Surgery, UCL, Namur Godinne, Belgium, ⁸Thoracic Surgery, Univ Hosp Innsbruck, Innsbruck, Austria, ⁹Lung Transplantation, Univ Med Ctr Groningen, Groningen, Netherlands, ¹⁰Pulmonary Medicine, Erasmus Univ Med Ctr, Rotterdam, Netherlands, ¹¹Cardiac Surgery, Univ Hosp, Vienna, Austria, ¹²Thoracic Surgery, Univ Hosp, Vienna, Austria, ¹³Respiratory Medicine, Hospital Erasme, Brussels, Belgium, ¹⁴Respiratory Medicine, Univ Hosp Mainz, Mainz, Germany, ¹⁵Pulmonology, Univ Hosp Charite, Berlin, Germany, ¹⁶Respiratory Medicine, Hannover Med Sch, Hannover, Germany, ¹⁷Pulmonology, Univ Med Ctr Utrecht, Utrecht, Netherlands

(1053) **Sequential Lung Transplantation:** A. Hirji, J. Weinkauf, A. Kapasi, D. C. Lien, K. Halloran. *Department of Anesthesiology, Duke University, Durham, NC*

(1054) **Sternum Sparing Bilateral Anterolateral Thoracotomy Approach Improves Early Respiratory Function after Bilateral Sequential Lung Transplantation:** G. K. Mathew¹, G. J. Valooran¹, M. C. Mathew¹, G. Hariprasad¹, J. Cho¹, A. Mc George¹, D. Haydock¹, A. K. Sibal¹. ¹Greenlane Cardiothoracic Surgery Unit, Auckland City Hospital, Auckland, New Zealand

(1055) **Institutional Algorithm for the Optimal Treatment Strategy for the Patients with Severe Coronary Artery Disease in Lung Transplantation:** S. H. Brann, N. Shigemura, B. O'Murchu, G. Sunagawa, F. Kromah, J. Gomez-Abraham, S. Keshavamurthy, K. Minakata, F. Cordova, Y. Toyoda. *Temple University Hospital, Philadelphia, PA*

(1056) **Institutional Algorithm for the Optimal Treatment Strategy for the Patients with Severe Coronary Artery Disease in Lung Transplantation:** S. H. Brann, N. Shigemura, B. O'Murchu, G. Sunagawa, F. Kromah, J. Gomez-Abraham, S. Keshavamurthy, K. Minakata, F. Cordova, Y. Toyoda. *Temple University Hospital, Philadelphia, PA*

(1057) **Assessing Levels of Frailty in a Cohort of Lung Transplant Candidates Using Pre-Transplant Frailty Assessments:** S. Jaladanki¹, L. Shih¹, D. D. Nanayakkara¹, O. Kwon¹, V. Dobaria¹, N. Ventigan¹, S. Weigt¹, J. Singer², A. Ardehali¹, R. Biniwale¹, D. Goldwater¹, J. Schaenman¹. ¹Univ of California Los Angeles, Los Angeles, CA, ²Univ of California San Francisco, San Francisco, CA

(1058) **The Incidence of Acute Kidney Injury Following Lung Transplantation Performed on Cardiopulmonary Bypass; Risk Factors, Effect on Short and Long-Term Mortality:** C. Carlheim¹, A. M. Holm², J. F. Bugge³. ¹Anesthesiology and Critical Care, Oslo University Hospital, Oslo, Norway, ²Respiratory Medicine, Oslo University Hospital, Oslo, Norway

(1059) **Anticoagulation Strategies in the Perioperative Period for Lung Transplant: 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal:** Y. D. Barac¹, J. Klapper¹, J. Poisson², L. Zaffir², A. Pollack³, T. Seay³, O. Jawitz³, J. Haney¹, M. Daneshmand¹, I. Welsby¹, M. G. Hartwig¹, B. Bottiger¹. ¹Department of Surgery, Cardiothoracic Division, Duke University, Durham, NC, ²Department of Pathology, Duke University, Durham, NC, ³Department of Pulmonary, Allergy and Critical Care, Duke University, Durham, NC

(1060) **Various Anastomotic Techniques for Size Mismatch in Pulmonary Artery during Lung Implantation:** Y. Yokoyama, T. Chen Yoshikawa, Y. Yamada, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto Univ, Kyoto, Japan*

(1061) **‘Side-Mismatched’ Single Lung Transplantation Does Not Compromise the Transplant Outcomes:** G. Sunagawa¹, M. Kashem¹, E. Leotta¹, F. Kromah¹, S. Brann¹, J. Gomez-Abraham¹, S. Keshavamurthy¹, K. Minakata¹, F. Cordova², Y. Toyoda¹, N. Shigemura¹. ¹Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, ²Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA

(1062) **Comparison of Oto, MALT and ET-Score in Predicting Outcome after Lung Transplantation - A Large Single-Center Cohort Study:** S. Schwarz, N. Rahimi, M. Muckenhuber, A. Benazzo, B. Moser, J. R. Matilla, G. Lang, S. Taghavi, P. Jaksh, W. Klepetko, K. Hoetzenecker. *Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

(1063) **Survival for Combined Heart-Lung Transplant (HLT) Recipients over the Past 30 Years:** C. J. Lum¹, W. Ragalie¹, R. Chand¹, A. Salimbangon¹, A. Chang¹, T. Khui¹, M. Cadeiras², M. Deng¹, D. Vucicevic¹, K. Pandya², A. Ardehali¹, E. DePasquale¹. ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Davis, Davis, CA, ³Newark Beth Israel, Newark, NJ, ⁴University of Southern California, Los Angeles, CA
**POSTER SESSION 3: MECHANICAL CIRCULATORY SUPPORT (ADULT)**
**Room: Timor Sea 2**

**Poster Discussants:**
Peggy Blood, RN, MSN, University of Alabama, Birmingham, AL, USA
Paolo Colombo, MD, Columbia University, New York, NY, USA
Jaime Hernandez-Montfort, MD, MPH, University of Texas Medical Branch, Galveston, TX, USA
Colleen Juricek-LaBuhn, RN, MSN, University of Chicago, Chicago, IL, USA
Christiane Kugler, PhD, Albert-Ludwigs-University Freiburg, Dortmund, Germany
Brent Lampert, DO, Ohio State University, Columbus, OH, USA
Bhavadharini Ramu, MD, Medical University of South Carolina, Charleston, SC, USA
Thomas Schöllhofer, MSc, Medical University of Vienna, Vienna, Austria
Nicola Robinson Smith, RN, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom

(1064) **Intracranial Hemorrhage in Patients with Continuous Flow LVAD:** E. Demir, S. Nalbantgil, P. Özütk, E. Simsek, C. Engin, T. Yağdı, M. Özbaran. 1Cardiology, Ege University Medicine Faculty, İzmir, Turkey, 2Cardiovascular Surgery, Ege University Medicine Faculty, İzmir, Turkey

(1065) **Comorbidities and Biomarkers Vary between United States and Japanese LVAD Patients:** T. Imamura, A. Nguyen, D. Nitta, T. Fujino, L. Holzhauser, D. Rodgers, S. Kalantari, B. Smith, J. Raikhelkar, N. Narangi, B. Chung, I. Ebong, C. Juricek, P. Combs, D. Onsager, T. Song, T. Ota, V. Jeevanandum, G. Kim, G. Sayer, M. Ono, N. Uriel. 1University of Chicago, Chicago, IL, 2University of Tokyo, Tokyo, Japan


(1067) **Aspirin: Therapy or Trouble for LVAD Patients?**; R. Khedraki, C. Vanichsarn, A. Moitoza, R. Mohan, J. T. Heywood, A. Srivastava. 1Cardiology, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA, 2Division of Cardiology, Section of Advanced Heart Failure, Scripps Clinic, Prebys Cardiovascular Institute, La Jolla, CA


(1070) **Wall Shear Stress in the Middle Cerebral Artery of HM II Patients - A Prospective, Mechanistic Study Using Vector Flow Mapping:** K. Akiyama, R. Ji, F. Castagna, A. Pinsino, J. R. Cockcroft, M. Yusefpolskaya, A. R. Garan, V. K. Topkara, K. Ross, H. Takayama, K. Takeda, Y. Naka, B. J. McDonnell, P. C. Colombo, J. Z. Willey, E. J. Stöhrl. 1Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Medicine, Columbia University Medical Center, New York, NY, 3Physiology & Health, Cardiff Metropolitan University, Cardiff, United Kingdom, 4Neurology Stroke, Columbia University Medical Center, New York, NY

(1071) **Recurrent Pump Thrombosis is Common after Axial Continuous Flow LVAD Exchange:** C. Macdonald, M. Urban, M. Moulton, N. McCain, D. Stoller, R. Zolty, J. Um, A. Siddique. 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE

(1072) **Novel Oral Anticoagulants in Patients with Continuous Flow Left Ventricular Assist Devices:** V. Parikh, U. Parikh, A. M. Ramirez, H. Lamba, J. George, S. Fedson, F. Cheema, A. Civitello, A. Nair, A. Shafi, G. Loo, T. Rosengart, O. Frazier, J. Morgan, R. Delgado. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Baylor College of Medicine, Houston, TX
Institute, Kansas City, MO, Hofstra/Northwell, Manhasset, NY, K. Kennedy
Extracorporeal Membrane Oxygenation Support (1086)
City, OK
Chicago, IL

Ischemic Cardiomyopathy in LVAD Patients (1084)
Pathogenesis, Nat’l Cerebral CV Ctr, Suita, Japan
(1083)
University of Minnesota, Minneapolis, MN,
Institute, Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI
Treatment (1081)

Assist Device (HVAD) or HeartMate (1079)
1
El Banyosy, D. Horstmanshof, Netherlands,
Egnaczyk
Ventricular Assist Device Thrombosis (1074)
1
Cardiothoracic, Newcastle upon Tyne NHS Foundations Trust, Newcastle upon Tyne, United Kingdom, 2Freeman Hospital,
Newcastle upon Tyne, United Kingdom

Argatroban Bridging in the Immediate Post-Operative Period in Recipients of Durable Left Ventricular Assist Devices; G.
Cincinnati, OH

Aortic Root Thrombus after LVAD Implantation and Aortic Valve Replacement; J. F. Veenis1, J. J. Brugts1, Y. C. Yalcin1, S.
Roe3t, J. A. Bekkers2, O. C. Manintveld1, A. A. Constantinescu1, A. J. Bogers1, K. Caliskan1. 1Cardiology, Erasmus MC, Rotterdam,
Netherlands, 2Cardio-Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands

Association of Post Implant Thromboelastogram and Left Ventricular Assist Device Thrombosis; C. L. Eshelbrenner, A. M.
El Banyosy, D. Horstmanhoff, S. George. Integris Baptist Medical Center, Oklahoma City, OK

Surgical Device Exchange is Favorable to Treat Device Thrombosis Compared to Medical Therapy; Y. Koda1, H. Kitahara1, G.
Kim2, N. Saraswat1, S. Kalantari2, B. Smith3, J. Raikhelkar2, G. Sayer2, D. Onsager1, T. Song1, N. Uriel5, V. Jeevanandam1, T. Ota1.
1Surgery, The University of Chicago, Chicago, IL, 2Medicine, The University of Chicago, Chicago, IL

Minimally Invasive Exchange of the HeartMate 2 (HM2) Left Ventricular Assist Device (LVAD) to HeartWare Ventricular
Assist Device (HVAD) or HeartMate 3 (HM3); I. Aljabban1, B. Hendriksen2, J. Conte3, B. Soleimani3. 1Pennsylvania State University
College of Medicine, Hershey, PA, 2Department of Surgery, Pennsylvania State University College of Medicine, Hershey, PA,
3Department of Cardiac Surgery, Pennsylvania State University College of Medicine, Hershey, PA

The Implication of HeartWare HVAD Inflow Cannula Angle on Stroke and Thrombus Rate; S. Emmanuel, D. Aktuerk, A.
Chowdhury, C. Hurwitz, L. Beiglari, P. Jansz, C. Hayward. St Vincent’s Hospital (Sydney), Darlinghurst, Australia

Primary Exchange of Heart Mate II Comes with Less Mortality/Treatment Failure within Six Months Than Eptifibatide
Treatment; M. Dickinson, M. Leache, N. Manandhar Shrestha, T. Boeve, S. V. Jovinge, S. Lee. Fredrik Meijer Heart and Vascular
Institute, Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI

Surgical Outcomes of HeartMate2 to HeartMate3 Pump Exchange: A Single Center Experience; A. Shaffer1, K. Goodwin2,
R. Cogswell3, H. Shah1, J. M. Schultz3, C. M. Martin8, R. M. John1. 1Department of Surgery, Division of Cardiothoracic Surgery,
University of Minnesota, Minneapolis, MN, 2Department of Surgery, University of Minnesota, Minneapolis, MN, 3Department of
Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN

Cleavage and Re-Supply of von Willebrand Factor in Continuous Flow Blood Pump; T. Mizuno1, Y. Eura2, K. Kokame2, T.
Tsukiyami4, Y. Takewa1, E. Tatsumi1, 1Dept. of Artificial Organs, Nat’l Cerebral CV Ctr, Suita, Japan, 2Dept. of Molecular
Pathogenesis, Nat’l Cerebral CV Ctr, Suita, Japan

Ischemic Cardiomyopathy is Associated with Increased Hemocompatibility Related Adverse Events Compared to Non-
Ischemic Cardiomyopathy in LVAD Patients; J. Raikhelkar, T. Fujino, T. Imamura, L. Holzhauser, I. Ebong, N. Narang, A. Nguyen,
B. Chung, D. Rodgers, B. Smith, N. Saraswat, G. Kim, C. Juricek, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago,
Chicago, IL

Postcardiomyoty Cardiogenic Shock: Initial Results of Oklahoma Hub-and-Spoke Model; A. M. El Banayosy, M. D. Harper,
City, OK

Reduction in Plasma Macrophage Migration Inhibitory Factor and Angiopoietin-2 Levels during Venoarterial Extracorporeal
Membrane Oxygenation Support; J. Navarro1, E. Miller2, C. Heaney1, R. Vuthoori1, D. Majure1, K. Lin2, P. Wang2,
K. Kennedy2, H. Fernandez2, B. Lima3, S. Maybaum3. 1Cardiology, Donald and Barbara Zacker School of Medicine at Hofstra/Northwell,
Manhasset, NY, 2Feinstein Institute, Feinstein Institute for Medical Research, Manhasset, NY, 3Mid America Heart Institute,
Kansas City, MO, 4Cardiovascular and Thoracic Surgery, North Shore University Hospital, Manhasset, NY
(1088) Our Experience with the "Hub and Spoke" Model in Spain: Results from the First 4 Years; M. Jimenez-Blanco Bravo, F. Hernandez Perez, J. Vazquez Lopez Ibor, M. Gomez Bueno, L. Alonso Pulpon, J. Segovia Cubero. 1Cardiology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 2Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 3Hospital Puerta de Hierro Majadahonda, Madrid, Spain


(1090) Single Center Percutaneous Right Ventricular Assist Device Experience - 100% In-Hospital Survival Post-Left Ventricular Assist Device; S. K. Sundararajan, M. Cain, B. Badu, L. Durham, L. Joyce, N. Gaglianello, M. Saltzberg, D. Ishizawar, D. Joyce, A. Mohammed. Medicine, Medical College of Wisconsin, Milwaukee, WI

(1091) Single Center Experience with a Percutaneous Right Ventricular Assist Device in the Management of Right Ventricular Failure; B. Badu, M. Cain, Z. Laste, N. Gaglianello, D. Ishizawar, M. Saltzberg, L. Durham, L. Joyce, A. Mohammed, D. Joyce. 1Medical College of Wisconsin, Wauwatosa, WI, 2Surgery, Medical College of Wisconsin, Milwaukee, WI, 3Radiology, Medical College of Wisconsin, Milwaukee, WI, 4Cardiology, Medical College of Wisconsin, Milwaukee, WI, 5Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI

(1092) Upgrading of ECLS (ECMO versus STCF-VAD): Is It a Matter of Time?; V. Tarzia, L. Bagozzi, R. Bianco, G. Bortolussi, E. Bellanti, G. Folino, T. Bottio, G. Gerosa. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy

(1093) Extracorporeal Cardiopulmonary Resuscitation (E-CPR) - 8 Years of Experience; S. Liem, N. C. Cavarocchi, H. Hirose. Surgery, Thomas Jefferson University, Philadelphia, PA


(1096) Association of Time on Temporary Circulatory Support with Resolution of Hemometabolic Shock; M. Cikes, J. Rocek, N. Jakus, D. Milicic, I. Netuka, J. Maly. 1Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia, 2Department of Cardiovascular and Transplant Surgery, IKEM, Prague, Czech Republic

(1097) Use of a Formal Stepwise Weaning Protocol to Assess Cardiac Recovery during Venoarterial ECMO; R. Vuthoori, B. Lima, J. Navarro, C. Heaney, K. Bocchieri, K. Kennedy, D. Majure, G. Stevens, H. Fernandez, S. Maybaum. 1Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, 2Cardiovascular and Thoracic Surgery, North Shore University Hospital, Manhasset, NY, 3Mid America Heart Institute, Kansas City, MO

(1098) Impact of Veno-Arterial Membrane Oxygenation on Outcome of “Crash and Burn” Patients Transitioned to Durable Left Ventricular Assist Device; M. Urban, H. Merritt-Genore, A. Siddique, M. Moulton, T. Ryan, J. Um. University of Nebraska Medical Center, Omaha, NE

(1099) Model for End-Stage Liver Disease (MELD) Does Not Predict Mortality after Veno-Arterial Extracorporeal Membrane Oxygenation Support; M. Karmi, N. Tashthi, S. Al-Kindi, E. Zanath, A. M. Johnson, J. Sohn, L. Chaaban, T. Schwab, M. A. Alaiti, H. Bezerra, M. Zacharias, G. H. Oliveira, B. Sareyyupoglu, Y. Elgudin, B. Medalion, S. Park, S. Deo, F. Lyttle, C. Elammi. 1Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, 2Cardiovascular Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, 3Department of Anesthesia, University Hospitals Cleveland Medical Center, Cleveland, OH, 4Cardiovascular Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH


(1101) Outcomes of Weaning Trial from Veno-Arterial Extracorporeal Membrane Oxygenation Using Inflow-Outflow Bridging; M. Kawabori, C. Cassidy, Y. Zhan, J. A. Reich, K. G. Warner, H. Rastegar, A. Vest, D. Denofrio, F. Y. Chen, G. S. Couper. 1Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA
Younger LVAD Recipients Fare Worse on Emotional and Spiritual Wellbeing Scores: P. Mudigonda¹, K. E. Sandau², R. O. Hoffman III¹, S. P. Jaganathan³, P. Eckman¹, R. Garberich⁴, C. E. Weaver⁵, S. Joseph⁶, S. Hall⁶, S. Carey¹, J. Cowger⁸, S. P. Chaudhry⁴, S. E. Schroeder⁹, G. Conway¹⁰, E. Y. Birati¹¹, M. Soni¹, J. Marble¹³, C. S. Lee¹⁴, K. M. Faulkner¹⁵, M. S. Kunz¹³, K. M. Storey¹⁶, D. S. Feldman¹. ¹Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Cincinnati, OH, ²Professor of Nursing, Bethel University; Allina Health, Minneapolis, MN, ³Section Head - Heart Failure, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ⁴Senior Biostatistician, Minneapolis Heart Institute Foundation, Minneapolis, MN, ⁵Lead VAD Coordinator, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, ⁶Advanced Heart Failure and Transplant Cardiology, Baylor University Medical Center, Dallas, TX, ⁷Baylor University Medical Center, Dallas, TX, ⁸Henry Ford, Detroit, MI, ⁹Mechanical Circulatory Support, Bryan Heart Center, Lincoln, NE, ¹⁰Director, Advanced Heart Failure, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ¹¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ¹²Department of Cardiovascular Health and Disease, University of Pennsylvania, Philadelphia, PA, ¹³Professor and Associate Dean for Research, Boston College Connell School of Nursing, Chestnut Hill, MA, ¹⁴Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN

Digoxin is Associated with Higher Quality of Life in LVAD Recipients: M. S. Kiernan¹, G. Couper², D. DeNofrio¹, J. Cowger³, U. Jorde⁴. ¹Cardiology, Tufts University, Boston, MA, ²Cardiac Surgery, Tufts University, Boston, MA, ³Cardiology, Henry Ford Hospital, Detroit, MI, ⁴Cardiology, Albert Einstein School of Medicine, New York, NY

Gender and Spirituality Influence Patient Care Decisions after LVAD: M. Soni¹, E. Y. Birati², J. Marble², P. Eckman³, R. Garberich⁴, C. Weaver⁵, S. Joseph⁶, S. Hall⁶, S. Carey¹, J. Cowger³, S. Chaudhry⁴, S. Schroeder⁹, R. Hoffman III¹⁰, D. Feldman¹⁰, G. Conway¹⁰, C. Lee¹¹, K. M. Faulkner¹², M. S. Kunz¹³, K. M. Storey¹⁴, K. E. Sandau¹⁵. ¹Cardiology, University of Pennsylvania, Philadelphia, PA, ²Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ³Cardiovascular Medicine, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ⁴Biostatistics, Minneapolis Heart Institute, Minneapolis, MN, ⁵Cardiovascular Medicine, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, ⁶Cardiovascular Medicine, Baylor University Medical Center, Dallas, TX, ⁷Cardiovascular Medicine, Henry Ford Health System, Detroit, MI, ⁸Cardiovascular Medicine, St. Vincent Heart Center/St. Vincent Indianapolis, Indianapolis, IN, ⁹Cardiovascular Medicine, Bryan Heart Center, Lincoln, NE, ¹⁰Cardiovascular Medicine, University of Cincinnati Medical Center, Cincinnati, OH, ¹¹Research, Boston College Connell School of Nursing, Chestnut Hill, MA, ¹²Cardiovascular Medicine, Boston College Connell School of Nursing, Chestnut Hill, MA, ¹³Biostatistics, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, ¹⁴Biostatistics, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ¹⁵Nursing, Bethel University, St. Paul, MN


(1121) Subjective Assessment Underestimates Frailty in Patients with Heart Failure Referred for Advanced Therapies; C. Heaney1, H. Fernandez2, B. Lima2, J. Taylor2, R. Vuthoori1, J. Navarro1, K. Davidson2, Y. Jelcic2, D. Majure1, K. Kennedy1, G. Stevens1, S. Maybaum1. 1Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, 2Cardiovascular & Thoracic Surgery, North Shore University Hospital, Manhasset, NY, 3Mid America Heart Institute, Kansas City, MO

(1122) Readmission Rates and Outcomes at 90 Days in Patients with Perioperative Use of Temporary Circulatory Support at the Time of Heart Transplantation; G. A. Hernandez1, A. Lemor2, V. Blumer1, S. Chaparro1, S. Zalawadiya1, J. Cowger2, J. Lindenfeld3. 1University of Miami, Miami, FL, 2Henry Ford Hospital, Detroit, MI, 3Vanderbilt University, Nashville, TN

(1123) Impaired Spirometry, but Not DLCO, is Associated with Risk of Death or Right Heart Failure Following LVAD Implantation; G. Gulati1, N. Sutaria1, A. Vest1, D. DeNofrio1, M. Kawabori2, G. Couper1, M. Kiernan1. 1Cardiology, Tufts Medical Center, Boston, MA, 2Cardiac Surgery, Tufts Medical Center, Boston, MA

(1124) Measurement of Pectoralis Muscle Quantity and Attenuation by Computed Tomography Using Routinely Available Software is Feasible and predicts Mortality after LVAD Implantation; R. Cogswell1, L. Teigen1, T. Allen2, J. Estep1, R. Araujo1, J. Schultz1, R. John3, C. Martin1, B. Trachtenberg4. 1Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 2Department of Radiology, University of Minnesota, Minneapolis, MN, 3Department of Medicine, Division of Cardiology, Cleveland Clinic, Cleveland, OH, 4Department of Medicine, Division of Cardiology, Houston Methodist, Houston, TX, 5Department of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

(1125) Gender Bias in LVAD Referral Patterns - A Survey of Patients and Providers; H. Lumish1, J. C. Hupf1, F. Latif1, J. H. Haythe1, M. A. Farr1, A. M. Zuver1, K. L. Antler2, A. R. Garan1, H. Takayama2, K. Takeda2, Y. Naka2, P.C. Colombo1, M. Yuzefpolskaya1. 1Department of Medicine, Columbia University Medical Center, New York, NY, 2Department of Surgery, Columbia University Medical Center, New York, NY


(1127) Impact of Peripheral Artery Disease on Long-Term Outcomes Following Ventricular Assist Device Placement; A. Ip, J. Roldan, N. Moss. Icahn School of Medicine at Mount Sinai, New York, NY
(1128) Transthoracic Echocardiogram Can Accurately Assess Left Ventricular Thrombus in Patients Who Receive an LVAD: Comparison with Intraoperative Intraventricular Visualization; I. D. Gregorie1, M. K. Jezovnik1, M. Illic1, S. Shoukat1, R. Radovancevic1, T. Sharma1, S. S. Nathan1, I. A. Salas de Armas2, S. Plavljancic1, M. K. Patel1, M. H. Akay1, B. Kar1. 1Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, 2Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center-Houston, Houston, TX


(1130) SIPAT Scores Do Not Correlate with Outcomes in Patients with Ventricular Assist Devices; K. L. Morris1, S. Wagner1, Y. Reddy2, C. Salerno1, A. Ravichandran1, R. Garcia-Cortes1, A. Patel1, S. Plotner1, J. Hart1, K. Neawedde1, M. N. Walsh1, S. P. Chaudhry1. 1St. Vincent Heart Center of Indiana, Indianapolis, IN, 2The Mayo Clinic, Rochester, MN

(1131) Psychosocial Characteristics and Outcomes in Patients with Ventricular Assist Device; C. Morreale1, R. Paliga2, S. Kothari1, K. Meehan1, L. Coyle2, M. Morack2, S. Pauwai2, G. Macaluso2, A. Joshi2, C. Sciamaanana2, A. Tatooles2, P. Pappas3, W. Cotts2, A. Andrade2. 1Medicine, UIC/Advocate Christ Medical Center, Oak Lawn, IL, 2Cardiology, Advocate Christ Medical Center, Oak Lawn, IL, 3Cardiovascular and Thoracic Surgery, Advocate Christ Medical Center, Oak Lawn, IL

(1132) Lower Pre-Implantation Psychosocial Risk Scores Do Not Correlate with Better Survival Following Left Ventricular Assist Device (LVAD) Placement; N. Grigoryan, L. Brobst, H. Zhao, E. Hamad. Temple University School of Medicine, Philadelphia, PA

(1133) Impact of Elevated Preoperative Blood Urea Nitrogen (BUN) Levels on Outcomes in CF-LVAD Patients; A. Critsinelis1, H. Lamba2, W. Etheridge2, C. Walther2, S. Oberton2, F. Cheema1, A. Civitello1, R. Delgado2, A. Nair2, T. Rosengart2, O. Frazier2, J. Morgan2. 1Baylor College of Medicine, Houston, TX, 2Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, BCM, Houston, TX

(1134) Outcomes of LVAD Implantation in Ischemic versus Nonischemic Cardiomyopathy; B. Chou1, H. K. Lamba2, G. Long1, V. Parikh2, S. Chatterjee1, J. George1, F. Cheema1, A. Civitello1, R. Delgado2, A. Nair2, A. Shafigi1, G. Loo1, T. Rosengart2, O. Frazier2, J. Morgan1. 1Baylor College of Medicine, Houston, TX, 2Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Baylor College of Medicine, Houston, TX

(1135) Exploring Sex Differences in Gut Microbial Diversity, Endotoxemia, Inflammation and Oxidative Stress in Heart Failure, Left Ventricular Assist Device, and Heart Transplant Patients; A. M. Zuver1, E. A. Royzman1, B. Bohn D.F.2, D. L. Brunjes1, M. Nasiri Ahmadabadi1, F. Latifi1, M. A. Farr1, S. W. Restaino1, A. R. Garan1, H. Takayama1, K. Takeda1, P. C. Colombo1, Y. Naka3, R. T. Demmer3, M. Yuzefpolskaya1. 1Department of Medicine, Columbia University Medical Center, New York, NY, 2Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, 3Department of Surgery, Columbia University Medical Center, New York, NY, 4Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

(1136) Blood Flow Kinetic Energy of Right Ventricular Outflow Tract: A Marker for Right Ventricular Global Systolic Function; K. Akiyama1, P. C. Colombo2, E. J. Stöhr3, R. Ji2, O. G. Jimenez4, I. Wu1, S. Shamess2, K. Itatani5, S. Miyazaki1, T. Furusawa7, T. Nishino2, B. J. McDonnell6, A. R. Garan2, Y. Naka1, K. Takeda1, H. Takayama1, M. Yuzefpolskaya1. 1Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Cardiology, Columbia University Medical Center, New York, NY, 3Cardiology, Vanderbilt University Medical Center, Nashville, TN, 4Cardiac Physiology and Health, Cardiff Metropolitan University, Cardiff, United Kingdom, 5Anesthesiology, Columbia University Medical Center, New York, NY, 6Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan, 7Cardio Flow Design, Tokyo, Japan, 8Cardiff Metropolitan University, Cardiff, United Kingdom

(1137) Inspiratory Breath-Hold - A Simple Clinical Intervention to Assess Risk Threshold for Suction Events in Stable LVAD Outpatients; D. Robson, K. Muthiah, P. Jain, J. Engelman, M. Connellan, P. Jansz, C. Hayward. Heart Lung Transplant Unit, St Vincent’s Hospital, Sydney, Australia


(1139) Hyponatremia after LVAD Implantation is Associated with Adverse Outcomes; A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, F. Hussain, N. Salam, I. Hussain. Houston Methodist Hospital, Houston, TX
(1152) **Benefits of Ultra-Fast-Track Anaesthesia after HeartMate 3 Implantation: A Pilot Study**; R. Zayat, U. Ahmad, L. Tewarie, G. Schaelte, A. Moza, R. Autschbach. 1Department of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany, 2Department of Anesthesiology, RWTH University Hospital, Aachen, Germany

(1153) **What Should Be Done for Improving the Outcomes of Salvage from Cardiogenic Shock on ECMO Support?**; T. Mizuno, T. Fujiwara, H. Kuroki, K. Oishi, M. Takeshita, M. Yashima, K. Oi, H. Arai. Dep. of Cardiovascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan

(1154) **Carboxyhemoglobinemia and Anemia are Associated with Unreliable Pulse Oximetry in the LVAD Population**; M. T. Hassanein, S. S. Najjar, N. Shah. 1Surgery, MedStar Georgetown/Washington Hospital Center, Washington, DC, 2Advanced Heart Failure, Mechanical Circulatory Support, and Cardiac Transplantation, MedStar Washington Hospital Center, Washington, DC, 3Surgical Cardiovascular Intensive Care Unit, MedStar Washington Hospital Center, Washington, DC

(1155) **High-Intensity Interval Training Induces Reverse Left Ventricular Remodeling in Patients with LVAD**; M. Alvarez Villela, T. Chimnadurai, A. Furlani, K. Salkey, J. Shin, S. Drakos, U. Jorde, S. Patel. 1Cardiology, Montefiore Medical Center, New York, NY, 2Cardiology, University of Utah, Salt Lake City, UT


(1157) **Outcomes Associated with Complete versus Partial LV Unloading in Patients with LVAD**; A. Duran, A. Guha, A. Bhimaraj, B. Trachtenberg, M. H. Park, J. Estep, F. Hussain, N. Salam, I. Hussain. Houston Methodist Hospital, Houston, TX

(1158) **Impact of Distance from Implant Center on Mechanical Circulatory Device Patient Outcomes**; C. J. Park, M. Murray, T. Kohmoto, E. Lushaj. Cardiothoracic Surgery, University of Wisconsin, Madison, WI

(1159) **Resolution of Right Atrial Congestion before LVAD Implantation is Associated with Improved Outcomes**; G. Gulati, N. Sutaria, A. Vest, D. DeNofrio, M. Kawabori, G. Couper, M. Kiernan. 1Cardiology, Tufts Medical Center, Boston, MA, 2Cardiac Surgery, Tufts Medical Center, Boston, MA

(1160) **Cardiac CT Provides Complementary Parameters of Right Ventricle Function in LVAD Patients**; A. Scott, P. J. Kim, H. Tran, M. Brambatti, Y. Ignatyeva, S. Rosenberg, S. Kligerisman, A. Hsiao, V. Pretorius, E. Adler, F. Contijoch. University of California, San Diego, San Diego, CA

(1161) **Invasive Hemodynamic after LVAD Implantation and Association with Outcomes**; A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, N. Salam, F. Hussain, I. Hussain. Houston Methodist Hospital, Houston, TX

(1162) **The Physiological Effects of Percutaneous Right Ventricular Assist Device**; D. Quinn, S. Lim. 1Cardiac Surgery, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 2Cardiology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom

(1163) **Aortic Valve Opening Time, a Novel Parameter to Describe the Aortic Valve in Patients with Continuous Flow Devices**; X. Mai, A. Reyentovich, N. Moazami, C. Soria, D. Smith, S. Katz, S. Pan, S. Rao, T. Sauraon, C. Gidea. 1Cardiology, NYU Langone Medical Center, New York, NY, 2Heart Transplant, NYU Langone Medical Center, New York, NY, 3Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, 4Internal Medicine, NYU Langone Medical Center, New York, NY

(1164) **Does Type of Mechanical Circulatory Support as Bridge to Heart Transplant Affect Outcomes?**; F. Hussain, J. Newman, H. Basha, S. Morris, A. Waqar, A. Heroux, E. McGee, E. Raichlin, M. Liebo. 1Internal Medicine, Loyola University Medical Center, Maywood, IL, 2Cardiology, Loyola University Medical Center, Maywood, IL, 3Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

(1165) **Measurement of Frailty over Time in Ventricular Assist Device Patients: Use of the 5-Meter Walk Test**; S. E. Schroeder, W. S. Alonso, J. A. Steuter, B. J. Pozehl. 1MCS Team, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE, 2College of Nursing, Post-Doctoral Research Associate, University of Nebraska Medical Center, Omaha, NE, 3Division of Cardiology, Bryan Heart, Lincoln, NE, 4Department of Nursing/Cardiology, University of Nebraska Medical Center, Omaha, NE
(1166) REMEDIZER- An Innovative Program of Remote Home Care for Patients with Implanted Mechanical Heart Support. Single Centre Experience; J. Szymański¹, A. Juraszek¹, M. Jasińska², M. Sobieszczanka-Malek¹, T. Zieliński³, M. Kuśmierczyk¹. ¹Department of Cardiac Surgery and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland, ²Department of Anesthesia, Warsaw Institute of Cardiology, Warsaw, Poland, ³Department of Cardiac Failure and Transplantation, Warsaw Institute of Cardiology, Warsaw, Poland.

(1167) Preemptive Hemodynamic Transesophageal Echocardiography after Continuous Flow Ventricular Assist Device Implantation; M. Krause¹, J. Hastie², O. Panzer², P. C. Colombo³, M. Yuzefpolskaya¹, Y. Naka⁴, H. Takayama⁴, R. N. Sladen². ¹Anesthesiology, University of Colorado, Denver, Denver, CO, ²Anesthesiology, Columbia University Medical Center, New York, NY, ³Medicine, Columbia University Medical Center, New York, NY, ⁴Surgery, Columbia University Medical Center, New York, NY.

(1168) Lavare Cycle Does Not Induce Pulsatility in CF-LVAD Patients; J. Engelman, K. Muthiah, P. Jain, D. Robson, P. Jansz, C. S. Hayward. Heart Failure and Transplant Unit, St Vincent’s Hospital, Sydney, Australia.

(1169) Pathophysiologica Insights into Persistent Hyponatremia after LVAD Implantation; A. Duran, A. Guha, A. Bhimaraj, J. Estep, B. Trachtenberg, M. H. Park, F. Hussain, N. Salam, I. Hussain. Houston Methodist Hospital, Houston, TX.
(1170) Clinical Features and Outcomes for Danon Disease: Data from Global Registry; V. S. Escobedo1, N. Nguyen1, D. Teng2, Q. M. Bu3, G. S. Ma2, M. Brambatti4, E. Covarrubias2, M. Taylor3, E. A. Adler2,1 Biology, University of California, San Diego, La Jolla, CA, 2University of California, San Diego, La Jolla, CA, 3University of Colorado, Aurora, CO

(1171) Implantable Cardioverter Defibrillator Use in Males with Duchenne Muscular Dystrophy and Severe Left Ventricular Dysfunction; M. A. McCulloch1, K. R. Knecht2, R. J. Butts3, C. R. Villa4, J. N. Johnson5, J. Conway6, M. J. Bock7, A. K. Lal8, K. R. Schumacher8, S. P. Law9, J. M. Friedland-Little11, S. R. Deshpande12, S. C. West13, I. D. Lytrivi14, K. E. Gambetta15, C. A. Wittlieb-Weber16. Division of Pediatric Cardiology, University of Virginia Children's Hospital, Charlottesville, VA, 2Division of Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR, 3Division of Pediatric Cardiology, Children's Medical Center of Dallas, Dallas, TX, 4The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Division of Pediatric Cardiology, Mayo Clinic Children's Hospital, Rochester, MN, 6Stollery Children's Hospital, Edmonton, AB, Canada, 7Division of Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, 8Division of Pediatric Cardiology, Primary Children's Hospital, Salt Lake City, UT, 9Division of Pediatric Cardiology, C.S. Mott Children's Hospital, Ann Arbor, MI, 10Division of Pediatric Cardiology, Morgan Stanley Children's Hospital, New York, NY, 11Division of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, 12Division of Pediatric Cardiology, Children's National Hospital, Washington, DC, 13Division of Pediatric Cardiology, Children's Hospital of Pittsburgh, Pittsburgh, PA, 14Division of Pediatric Cardiology, Kravis Children's Hospital, New York, NY, 15Division of Pediatric Cardiology, Lurie Children's Hospital, Chicago, IL, 16Division of Pediatric Cardiology, Golisano Children's Hospital, Rochester, NY

(1172) Parent-Reported Symptoms and Effectiveness of Treatment in Children Hospitalized with Advanced Heart Disease; E. S. DeWitt1, E. M. Balkin2, J. R. Reichman3, K. M. Moynihan4, J. McDermott5, M. Miller6, J. Wolfe7, L. A. Sleeper8, C. Samsel7, E. D. Blume9. Cardiology, Boston Children's Hospital, Boston, MA, 2PEDIATRICS, UCSF, San Francisco, CA, 3Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA

(1173) Anemia is Associated with Greater Morbidity and Resource Utilization in Pediatric Patients with Systolic Heart Failure - A Multi-Institutional Analysis; K. Puri, R. Morales Demori, P. A. Checchia, M. M. Anders. Pediatric Critical Care Medicine, Baylor College of Medicine, Houston, TX

(1174) Electrocardiographic Trends in Boys with Duchenne Muscular Dystrophy; K. Gambetta1, C. W. Wittlieb-Weber2, C. R. Villa3, J. Conway4, J. N. Johnson5, M. J. Bock6, A. K. Lal7, K. R. Schumacher8, S. P. Law9, S. Deshpande10, S. C. West11, J. M. Friedland-Little12, J. M. Friedland-Little12, I. D. Lytrivi13, R. J. Butts14, K. J. Knecht15, M. A. Michael16. 1Lurie Children's Hospital, Chicago, IL, 2Pediatric Cardiology, University of Rochester Medical Center, Rochester, NY, 3Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, 4Pediatric Cardiology, University of Alberta Stollery Children's Hospital, Alberta, AB, Canada, 5Pediatric Cardiology, Mayo Clinic, Rochester, MN, 6Pediatric Cardiology, Loma Linda University, Loma Linda, CA, 7Pediatric Cardiology, University of Utah, Salt Lake City, UT, 8Pediatric Cardiology, Mott Children's Hospital, Ann Arbor, MI, 9Pediatric Cardiology, New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, 10Pediatric Cardiology, Emory University, Atlanta, GA, 11Pediatric Cardiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 12Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, 13Pediatric Cardiology, Mount Sinai Kravis Children's Hospital, New York, NY, 14Pediatric Cardiology, Children's Medical Center Dallas, Dallas, TX, 15Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR, 16Pediatric Cardiology, University of Virginia, Charlottesville, VA

(1175) Pediatric Hypertrophic Cardiomyopathy: Survival and Prognostic Indicators in the Current Era; J. Ashkanase, A. Jeewa, K. Arathoon, E. Cui, K. Dillon, S. Mital, E. Jean-St-Michel. Division of Cardiology, The Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada
(1176) Utilization of Heart Failure Medications in Duchenne Muscular Dystrophy Patients with Left Ventricular Systolic Dysfunction; A. K. Lal1, C. A. Wittlieb-Weber2, C. R. Villa3, C. Cunningham4, M. J. Bock5, K. E. Gambetta6, J. N. Johnson7, K. R. Schumacher8, S. P. Law9, S. R. Deshpande10, S. C. West11, J. M. Friedland-Little12, I. D. Lytrivi13, M. A. McCulloch14, Z. Ou15, A. P. Presson16, R. J. Butts16. 1University of Utah/Primary Children's Hospital, Salt Lake City, UT, 2Golisanos Children's Hospital, Rochester, NY, 3Cincinnati Children's Hospital, Cincinnati, OH, 4Stollery Children's Hospital, Edmonton, AB, Canada, 5Loma Linda University Medical Center, Loma Linda, CA, 6Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 7Mayo Clinic Children's Center, Rochester, MN, 8C.S. Mott Children's Hospital, Ann Arbor, MI, 9Morgan Stanley Children's Hospital, New York, NY, 10Children's National Medical Center, Washington, DC, 11Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 12Seattle Children's Hospital, Seattle, WA, 13Kravis Children's Hospital at Mount Sinai, New York, NY, 14University of Virginia Children's Hospital, Charlottesville, VA, 15University of Utah, Salt Lake City, UT, 16Children's Health at UT Southwestern Medical Center, Dallas, TX

(1177) The Role of Prophylactic Heart Failure Therapy in Duchenne Muscular Dystrophy; A. K. Lal1, C. A. Wittlieb-Weber2, C. R. Villa3, J. Conway4, M. J. Bock5, K. E. Gambetta6, K. R. Schumacher7, S. P. Law8, S. R. Deshpande9, S. C. West10, J. M. Friedland-Little11, I. D. Lytrivi12, M. A. McCulloch13, R. J. Butts14, K. R. Knecht15, Z. Ou16, A. P. Presson16, J. N. Johnson17. 1Pediatrics, University of Utah/Primary Children's Hospital, Salt Lake City, UT, 2Pediatrics, Golisanos Children's Hospital, Rochester, NY, 3Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH, 4Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada, 5Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, 6Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 7Pediatrics, C.S. Mott Children's Hospital, Ann Arbor, MI, 8Pediatrics, Morgan Stanley Children's Hospital, New York, NY, 9Pediatrics, Children's National Medical Center, Washington, DC, 10Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 11Pediatrics, Seattle Children's Hospital, Seattle, WA, 12Pediatrics, Kravis Children's Hospital at Mount Sinai, New York, NY, 13Pediatrics, UVA Children's Hospital, Charlottesville, VA, 14Pediatrics, Children's Health at UT Southwestern Medical Center, Dallas, TX, 15Pediatrics, Arkansas Children's Hospital, Little Rock, AR, 16University of Utah, Salt Lake City, UT, 17Mayo Clinic Children's Center, Rochester, MN

(1178) Outcomes in Pediatric Hypertrophic Cardiomyopathy Patients with Reduced Systolic Ventricular Function; J. Ashkanase, A. Jeewa, K. Arathoon, E. Cui, K. Dillon, S. Mital, E. Jean-St-Michel. Division of Cardiology, The Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada

(1179) Use of Pulmonary Arterial Catheters for Management of Acute Decompensated Heart Failure and Peri-Operative Monitoring in Children; P. Esteso1, E. D. Blume1, C. VanderPlym1, F. Fynn-Thompson2, K. P. Daly1. 1Cardiology, Boston Children's Hospital, Boston, MA, 2Cardiac Surgery, Boston Children's Hospital, Boston, MA

(1180) Antihypertensive Treatment in the Immediate Post-Operative Period and One-Year after Pediatric Heart Transplantation; J. S. Kerstein1, D. J. Donovan2, M. D. Zinn3, M. E. Richmond4, E. W. Cheung4, L. J. Addonizio5, W. A. Zuckerman1. 1Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2Department of Pediatrics, Columbia University Medical Center, New York, NY, 3Division of Pediatric Cardiology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 4Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY

(1181) Dose-Dependent Response to Desensitization in Pediatric Heart Transplant Candidates Assessed by Single Antigen Bead Technology; J. Edwards1, N. Seliktar2, S. Heron3, K. Lin4, D. Monos5, D. Sesok-Pizzini6, J. Rossano1, R. White1, M. O'Connorr. 1Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Technion - Israel Institute of Technology, Haifa, Israel, 3Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, 4Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, 5Blood Bank and Transfusion Medicine, Children's Hospital of Philadelphia, Philadelphia, PA

(1182) Use of Bortezomib in the Treatment of Antibody Mediated Rejection (AMR) in Pediatric Heart Recipients; J. Otero1, E. Albers1, J. Friedland-Little1, B. Hong1, M. Kemna1, I. Gimferrer2, Y. Law1. 1Seattle Children's Hospital, Seattle, WA, 2Bloodworks NW, Seattle, WA

(1183) Total Parenteral Nutrition Portends Worse One-Year Survival in Pediatric Heart Transplantation; M. F. Algham, F. Zafar, K. W. Riggs, J. T. Broderick, A. Lorts, D. L. Morales. Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH

(1184) Cardiovascular Health in Pediatric Heart Transplant Patients; C. Bogle1, A. Marma Perak1, S. Wilkens1, A. Aljiffry1, K. Rychlik1, J. M. Costello1, D. Lloyd-Jones2, E. Pahl1. 1Ann & Lurie Children's Hospital of Chicago, Chicago, IL, 2Northwestern Memorial Hospital, Chicago, IL

(1186) HLA Antibody Titer and CIQ Reactivity Reflect Response to Desensitization and Facilitate Donor Selection; M. Mangiola1, M. D. Zinn2, S. West2, S. A. Miller3, K. Rose-Felker2, B. Feingold2, A. Zeevi1. 1Transplant Pathology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Pediatrics, Univ of Pittsburgh Med Ctr, Pittsburgh, PA

1Pediatrics, Vanderbilt University, Nashville, TN; 2Children's Hospital Association, Lenexa, KS; 3Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

(1188) Physical Activity, Exercise Capacity and Quality of Life in Adolescent Heart Transplant Patients; N. Arora, A. De Souza, C. Galvin, T. Sueyoshi, S. Lui, A. Cote, D. Human, K. Armstrong. Pediatric Cardiology, British Columbia Children's Hospital, Vancouver, BC, Canada

(1189) The Major Adverse Transplant Events (MATE) Score Applied to a Cohort of Pediatric Heart Transplant Recipients; M. J. Bock, P. Chau, M. A. Kuhn, T. Martens, A. Razouk, R. E. Chinnock. 1Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA; 2Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA; 3Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA

(1190) Standardized Donor Acceptance Criteria: Impact on Pediatric Waitlist and Heart Transplant Outcomes; N. Baez, R. Kirk, R. Davies, D. Sutcliffe, M. Bano, R. Buts. University of Texas Southwestern Medical Center, Dallas, TX

(1191) The Use of Patient-Reported Outcomes to Screen for Underrecognized Psychiatric Co-Morbidities in Adolescent and Young Adult Cardiac Transplant Recipients; T. N. Brown, S. Chen, J. Stehlik, L. Bennett Murphy, D. Cox, A. Hoskoppal, L. M. Schneider, N. McDonald, L. Barkoff, L. J. May. 1Pediatrics, University of Utah, Salt Lake City, UT; 2Stanford University, Palo Alto, CA; 3Cardiology, University of Utah, Salt Lake City, UT; 4University of Utah, Salt Lake City, UT


(1193) MELD-XI Score Predicts Post-Heart Transplant Survival in Fontan Patients: A PHTS Analysis; S. Amdani, K. E. Simpson, P. T. Thrush, R. Shih, J. D. Simmonds, K. R. Knecht, D. Mogul, K. K. Hurley, D. A. Koehl, D. C. Naftel, J. K. Kirklin. 1Pediatric Cardiology, Cleveland Clinic Children's Hospital, Ohio, OH; 2Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO; 3Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; 4Pediatric Cardiology, University of Florida, Gainesville, FL; 5Paediatric Cardiology, Great Ormond Street Hospital for Children, London, United Kingdom; 6Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR; 7Pediatric Gastroenterology, Hepatology and Nutrition, Johns Hopkins University, Baltimore, MD; 8Transplant Services, St. Louis Children's Hospital, St. Louis, MO; 9Surgery, University of Alabama at Birmingham, Birmingham, AL; 10Pediatric Cardiology, Boston Children's Hospital & Harvard Medical School, Boston, MA

(1194) Routine Surveillance Biopsies after Pediatric Heart Transplantation - Are They Still Necessary?; T. P. Fleck, P. Nieratschker, B. Stiller. Congenital Heart Disease and Pediatric Cardiology, University Heart Centre Freiburg, Germany, Freiburg im Breisgau, Germany

(1195) Alloantibody Reduction in Pediatric Heart Transplant Recipients; K. Rose-Felker, M. Zinn, S. C. West, S. A. Miller, M. Mangiola, A. Zeevi, B. Feingold. 1Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA; 2Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA

(1196) Tracheostomy and Pediatric Heart Transplantation: The Loma Linda University Experience; J. Lee, K. Soltad, S. Abd-Allah, J. Fitts, M. Bock. 1Pediatric Critical Care, Loma Linda University Children's Hospital, Loma Linda, CA; 2School of Medicine, Loma Linda University, Loma Linda, CA; 3Cardiac Transplant, Loma Linda University, Loma Linda, CA; 4Pediatric Cardiology/Heart Failure/Transplant, Loma Linda University Children's Hospital, Loma Linda, CA

(1197) Over Sized Adult Hearts Can Be Used for Paediatric Transplant Recipients with Good Medium Term Outcomes; K. Balakrishnan, S. Rao, S. Vijayashekaran, G. Subramanian, R. Subramanian, M. Tungatru. 1Cardiac Surgery, Fortis Malar Hospital, Chennai, India; 2Cardiac Anaesthesia, Fortis Malar Hospital, Chennai, India

(1198) Combined Pediatric Heart-Liver Transplant Outcomes in the US: A 25 Year National Cohort Study; S. Choudhry, W. J. Dreyer, Y. Wang, A. G. Cabrera, K. D. Hope, J. F. Price, J. A. Spinner, H. P. Tunuguntla, S. W. Denfield. 1Texas Children's Hospital, Baylor College of Medicine, Houston, TX; 2Section of Pediatric Cardiology, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas, Houston, TX

(1199) Epidural Analgesia Reduces Total Inhospital Morphine Requirements Post Heart Lung / Lung Transplant in Paediatric Population; S. Karna, H. J. Sivakumar, P. Dhar, K. McLaughlin. Department of Anaesthesia and Perioperative Medicine, The Alfred, Melbourne, Australia
(1200) Analysis of Status 1A Exceptions in Children Listed for Heart Transplantation; D. W. Bearl¹, D. Dodd¹, B. A. Mettler², R. R. Davies³, J. Winslow⁴, J. Godown⁴. ¹Pediatric Cardiology, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN, ²Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN, ³Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center and Children’s Health, Dallas, TX, ⁴United Network for Organ Sharing, Richmond, VA


(1202) Pediatric Heart Transplantation in a National Pediatric Hospital J.P. Garrahan (Argentina); L. G. Bereta, H. Vogelfang, L. Quiroga, G. Sivori, G. Naiman, G. Abad. Heart, Lung and Kidney Transplant Team, National Pediatric Hospital J.P. Garrahan, Buenos Aires, Argentina


(1206) ABO Incompatible Heart Transplantation in Young Children: Less Rejection and Infection; S. Urschel¹, M. McCoy¹, R. S. Cantor², D. A. Koehl², W. A. Zuckerman³, A. Dipchand³, Z. Reinhardt³, K. R. Kanter³, J. A. Ballweg¹, J. Sparks⁴, J. K. Kirklin⁵, W. F. Carlo⁶. ¹Pediatrics, University of Alberta, Edmonton, AB, Canada, ²Kirklin Institute for Research in Surgical Outcomes (KIRSO), Birmingham, AL, ³Pediatrics, Columbia University Medical Center, New York, NY, ⁴Pediatrics, Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁶Emory University School of Medicine, Atlanta, GA


(1208) Novel Trans-Septal Left VAD Cannulation Technique for Hypertrophic/Restrictive Cardiomyopathy; K. Maeda¹, T. Nasirov¹, Y. V. Yarlagadda², S. A. Holland³, M. Nadarathnum³, D. N. Rosenthal³, S. Chen³, C. S. Almond³, B. D. Kaufman³, O. Reinhardt³, J. Murray³, J. C. Dykes³. ¹Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Pediatrics, Stanford University, Stanford, CA

(1209) End Stage Liver Disease Models and Outcomes in Pediatric Patients Supported with Short-Term Continuous Flow Ventricular Assist Devices; G. Malik¹, T. Pidboyochynski², H. Buchholz², D. H. Freed², M. Al-Aklabi³, S. J. Bozso³, S. Choudhry⁵, V. Anand⁵, P. Holinski⁶, J. Conway⁶. ¹University of Alberta, Edmonton, AB, Canada, ²Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Cardiac Surgery, Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, ⁴Pediatric Cardiac Surgery, Stollery Children’s Hospital, Edmonton, AB, Canada, ⁵Texas Children’s Hospital, Houston, TX, Canada, ⁶Pediatric Critical Care, University of Alberta, Edmonton, AB, Canada

(1210) Palliative Care Involvement in Pediatric VAD Patients - A Single Center Experience; C. Knoll¹, B. Kaufman¹, S. Chen¹, J. Murray¹, B. Sourkes², H. Cohen³, C. Almond⁴, D. Rosenthal⁴, S. A. Holland⁴. ¹Pediatric Cardiology, Lucile Packard Children’s Hospital Stanford, Palo Alto, CA, ²Psychology, Lucile Packard Children’s Hospital Stanford, Palo Alto, CA, ³Palliative Care, Lucile Packard Children’s Hospital Stanford, Palo Alto, CA

(1211) Continuous Flow Ventricular Assist Device Implantation in Non Dilated Cardiomyopathy Pediatric Patients Using Complimentary 3D Techniques; M. H. Desai¹, S. M. Peer¹, L. Oliveri², P. Mass², J. Opfermann², S. Boyce³, R. A. Jonas³, P. Sinha¹. ¹Department of Cardiovascular Surgery, Children’s National Medical Center, Washington, DC, ²Department of Cardiovascular Surgery, Children’s National Medical Center, Washington, DC, ³Department of Cardiovascular Surgery, MedStar Washington Hospital Center, Washington, DC

(1212) Patients with Surgical Corrected TGA or Congenital Corrected TGA Supported with Durable VAD; M. Schweiger¹, T. de By², E. Sandica², O. Miera³, T. Fleck³, M. Häbler³, I. Netuka³. ¹Children’s Hospital Zurich, Zurich, Switzerland, ²EUROMACS, EACTS, Windsor, United Kingdom, ³Center for Congenital Heart Defects, Heart and Diabetes Centre North Rhine Westphalia, Zurich, Germany, ⁴Dpt. of Congenital Heart Disease/Pediatric Cardiology, German Heart Centre, Berlin, Germany, ⁵Bad Krozingen, Department of Congenital Heart Disease and Pediatric Cardiology, University Heart Center Freiburg, Freiburg, Germany, ⁶Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Zurich, Czech Republic
Readmission to the Pediatric Cardiac Intensive Care Unit in Pediatric Patients with Durable Ventricular Assist Devices; J. J. Chacko, T. Pidborochynski, H. Buchholz, D. H. Freed, M. Al-Aklabi, V. Anand, P. Holinski, J. Conway. 1Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 2Department of Pediatric Cardiology, Stollery Children’s Hospital, Edmonton, AB, Canada, 3Division of Cardiac Surgery, Stollery Children’s Hospital, Edmonton, AB, Canada, 4Division of Pediatric Cardiac Surgery, Stollery Children’s Hospital, Edmonton, AB, Canada, 5Pediatric Critical Care, Stollery Children’s Hospital, Edmonton, AB, Canada


Use of Bivalirudin in Pediatric Patients on Ventricular Assist Device Support; K. Puri, H. P. Tunuguntla, T. J. Humlcek, W. J. Dreyer, S. W. Denfield, A. G. Cabrera, S. Hui, L. Hensch, J. F. Price, S. Choudhry, I. Adachi, J. Teruya. 1Pediatric Critical Care Medicine, Baylor College of Medicine, Houston, TX, 2Pediatric Cardiology, Baylor College of Medicine, Houston, TX, 3Pathology and Transfusion Medicine, Baylor College of Medicine, Houston, TX, 4Congenital Heart Surgery, Baylor College of Medicine, Houston, TX

Explantation of Mechanical Circulatory Support Devices to Recovery is Possible and Should Be Considered in Selected Conditions in Children; M. Ramaswamy, A. Khushnood, M. Kostolny, Z. Reinhardt, T. Chila, F. De Rita, M. Burch, A. Hasan, N. Muthialu. 1Great Ormond Street Hospital for Children, London, United Kingdom, 2Freeman Hospital, Newcastle upon Tyne, United Kingdom

Development of Continuous-Flow Total Artificial Heart for Use in Infants; J. H. Karimov, A. Polakowski, D. Horvath, N. Byram, Y. Kado, T. Miyamoto, M. Ahmad, H. Najm, R. Stewart, E. Saarel, B. Kuban, K. Fukamachi. The Cleveland Clinic, Cleveland, OH
**POSTER SESSION 3: PULMONARY HYPERTENSION AND CTEPH**

**Room:** Gardenia 2

**Poster Discussants:**
Marco Caccamo, DO, West Virginia University, Washington, PA, USA
Agnieszka Ciarka, MD, PhD, Catholic University of Leuven, Leuven, Belgium
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Anjali Vaidya, MD, Temple University, Philadelphia, PA, USA
Helen Whitford, MBBS, FRACP, Alfred Hospital, Melbourne, Australia


(1218) **Expression of MicroRNAs in Surgical Specimens of Patients with Chronic Thromboembolic Pulmonary Hypertension**; M. B. Kirschner1, M. Friess1, V. Orlowski1, B. Gray-Stockert1, W. Weder1, I. Inc1, R. Schüpbach2, D. Bettex3, S. Ulrich4, J. Opitz5.  
1Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, 2Department of Intensive Medicine, University Hospital Zurich, Zurich, Switzerland, 3Department of Anaesthesiology, University Hospital Zurich, Zurich, Switzerland, 4Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland

1University of California Los Angeles, Los Angeles, CA, 2University of Michigan, Ann Arbor, MI, 3UT Southwestern Medical Center, Dallas, TX, 4Kentuckiana Pulmonary Associates, Louisville, KY, 5University of California San Diego, La Jolla, CA, 6Actelion Pharmaceuticals Ltd, Allschwill, Switzerland, 7Actelion Pharmaceuticals US, Inc, South San Francisco, CA

1Hospital of University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2Internal Medicine, Mercy Catholic Medical Center, Drexel University College of Medicine, Philadelphia, PA, 3Johns Hopkins, Baltimore, MD, 4Hoffman Heart Institute, St Francis Hospital of the University of Connecticut, Hartford, CT


(1222) **Rest ET CO2 and VO2/VO2 are Superior to Exercise Gas Exchange Parameters with Invasive Cardiopulmonary Exercise Testing to Predict Pulmonary Vascular Disease in Patients with Dyspnea of Unclear Etiology**; F. Raza1, A. Vaidya2, P. Forfia2.  
1Dept of Medicine, Univ of Wisconsin School of Medicine and Public Health, Madison, WI, 2Temple Univ Hospital, Philadelphia, PA

(1223) **Determinants of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: Beyond Pulmonary Vascular Resistance**; A. Chaturvedi1, M. Naik1, A. A. Joshi1, J. PO2, T. Meeran3, A. Raina1.  
1Allegheny Health Network, Pittsburgh, PA, 2Ascension Borgess Hospital, Kalamazoo, MI, 3Advanced Heart Failure and Cardiac Transplant, Fortis Hospital, Mumbai, India

(1224) **Right Ventricular - Pulmonary Vascular Coupling at Rest and Exercise in Patients with Dyspnea and/or Suspected Pulmonary Hypertension**; S. P. Wright1, F. H. Valle1, L. Groves2, S. Esfandiari1, J. T. Granton3, S. Mak1.  
1Cardiology, Mount Sinai Hospital, Toronto, ON, Canada, 2School of Biomedical Engineering, Western University, London, ON, Canada, 3Respirology, University Health Network, Toronto, ON, Canada

(1225) **A New Strategy after Lung Transplantation for Pulmonary Hypertension: Tapering Epoprostenol Administration**; A. Ohsumi, A. Aoyama, H. Kinoshita, T. Yoneda, M. Okuda, K. Yamazaki, K. Minatoya, Y. Yamada, Y. Yutaka, D. Nakajima, M. Hamaji, T. F. Chen-Yoshikawa, H. Date. Kyoto University Hospital, Kyoto, Japan

1Univ of Texas, Southwestern Medical Center, Dallas, TX, 2Univ of Michigan Medical Center, Ann Arbor, MI, 3Univ of California, San Diego, La Jolla, CA, 4Washington Univ School of Medicine, St. Louis, MO, 5Vanderbilt Univ Medical Center, Nashville, TN, 6Boston Univ School of Medicine, Boston, MA, 7Actelion, South San Francisco, CA, 8Cleveland Clinic, Cleveland, OH
(1227) Secular Trends and Outcome of Isolated versus Combined Type 2 Pulmonary Hypertension in Patients with End-Stage Heart Failure; A. Nasri¹, J. Dupuis¹, L. Hausermann¹, M. Tremblay-Gravel¹, M. C. Parent¹, M. Carrier¹, N. Racine¹, S. de Denus¹, A. Ducharme¹, A. Fortier², M. White¹. ¹Montreal Heart Institute, Montreal, QC, Canada, ²Montreal Health Innovations Coordinating Centre, Montreal, QC, Canada

(1229) Clinical Impact of Right Ventricular Diastolic Patterns in Idiopathic Pulmonary Arterial Hypertension by Speckle Tracking; R. Badagliacca¹, F. Pezzuto¹, S. Papa¹, R. Poscia¹, G. Manzi¹, A. Pascaretta¹, R. Torre¹, G. Casu², S. Sciomer³, F. Fedele¹, R. Naeije¹, C. Vizza¹. ¹Dept. of Cardiovascular and Respiratory Science, Univ of Rome Sapienza, Rome, Italy, ²Dept. of Cardiology, Dept. of Cardiology, Nuoro, Italy, ³Dept. of Cardiology, Erasmus University Hospital, Brussels, Belgium

(1230) Derivation of a Bayesian Network Model from an Existing Risk Score Calculator for Pulmonary Arterial Hypertension: J. Kraisangka¹, L. C. Lohmueller², M. K. Kanwar³, C. Zhao⁴, M. J. Druzdzel⁵, J. F. Antaki⁶, M. A. Simon⁶, R. L. Benza⁶. ¹School of Computing and Information, University of Pittsburgh, Pittsburgh, PA, ²Language Technologies Institute, Carnegie Mellon University, Pittsburgh, PA, ³Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ⁴Actelion Pharmaceuticals US, Inc., South San Francisco, CA, ⁵Mening School of Biomedical Engineering, Cornell University, Ithaca, NY, ⁶Department of Medicine, University of Pittsburgh, Pittsburgh, PA

(1231) Pulmonary Hypertension in Rural Minnesota: Prevalence and Clinical Classification; E. R. Fenstad¹, N. Bonfig², L. Mirfakhraie³, S. Ebner², P. Eckman², B. Cabuy², R. Garberich², S. Reed¹, T. Dirks¹, P. Stokman¹. ¹Minneapolis Heart Institute, Baxter, MN, ²Minneapolis Heart Institute, Minneapolis, MN

(1232) Clinical Implications of Idiopathic Pulmonary Arterial Hypertension Phenotypes Defined by Cluster Analysis; R. Badagliacca¹, F. Rischard², S. Papa³, S. Kubba³, R. Vanderpoo³, J. Yuan³, J. Garcia³, S. Aihart³, R. Poscia¹, B. Pezzuto¹, G. Manzi¹, S. Sciomer³, R. Torre¹, F. Fedele¹, C. Vizza¹. ¹Dept. of Cardiovascular and Respiratory Science, Univ of Rome Sapienza, Rome, Italy, ²University of Arizona, Tucson, AZ, ³Univ of Arizona, Tucson, AZ

(1233) High Heart Rate and Pulmonary Vascular Resistance Predict Poor Prognosis after Referral for Lung Transplantation in Patients with Pulmonary Arterial Hypertension; T. Har¹, M. Hatano², A. Saito³, S. Minatsuki³, H. Maki¹, E. Amiya¹, Y. Hosoya¹, K. Nagayama¹, M. Sato¹, M. Anraku¹, J. Nakajima¹, I. Komuro¹. ¹Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan, Tokyo, Japan, ²Department of Therapeutic Strategy for Heart Failure, University of Tokyo, Tokyo, Japan, Tokyo, Japan, ³Department of Thoracic Surgery, University of Tokyo, Tokyo, Japan, Tokyo, Japan

(1234) Does Etiology of Pulmonary Hypertension Impact Survival? An ISHLT Registry Analysis; K. Tsui¹, J. Lasky², C. Alex¹, M. Dia¹, E. Jweied³, P. Pappas¹, C. Wigfield¹. ¹Lung Transplant, Advocate Christ Medical Center, Chicago, IL, ²Rosalind Franklin University of Medicine and Science, Chicago, IL

(1235) Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry; R. Channick¹, K. Chin², N. Kim³, M. Brand⁴, A. Morganti⁵, M. Selej⁵, V. McLaughlin⁶. ¹University of California Los Angeles, Los Angeles, CA, ²UT Southwestern Medical Center, Dallas, TX, ³University of California San Diego, La Jolla, CA, ⁴Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁵Actelion Pharmaceuticals US, Inc, South San Francisco, CA, ⁶University of Michigan, Ann Arbor, MI

(1236) Alteration of Right Ventricular to Pulmonary Artery Coupling in Systemic Sclerosis; A. Krokos, C. Dewachter, A. Rimouche, J. Vachiery. Department of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Académique Erasme, Bruxelles, Belgium, Brussels, Belgium

(1237) Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag; H. Klose¹, K. Chin², R. Ewert³, H. Gall³, J. Parambil⁴, D. Poch⁴, H. Seyfarth⁵, L. Axelsen⁵, S. Hsu Schnitz⁶, C. Stein⁷, J. Preston¹. ¹Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf, Center of Oncology, Hamburg, Germany, ²University of Texas Southwestern, Medical Centre, Dallas, TX, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Pulmonary Critical Care Medicine, University of California, San Diego, CA, ⁵Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany, ⁶Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁷Biostatistics, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁸Clinical Science, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁹Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, MA

(1238) Targeting CCL5 for Treatment of BMP-Mediated Pulmonary Hypertension; X. Nie¹, J. Chen¹, J. Bian². ¹Center of Clinical Research, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China, ²Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Feasibility of Exercise Hemodynamic Evaluation in the Clinical Cardiac Catheterization Laboratory; F. Valle, S. Esfandiari, S. Wright, J. Udell, C. Overgaard, S. Mak. 1Cardiology, Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada

The Effect of Left Ventricular Assist Devices (LVAD) on Pulmonary Hypertension: A Single Center Review; P. L. Tremblay, S. A. Stewart, R. J. Baskett. 1Department of Surgery, Dalhousie University, Halifax, NS, Canada, 2Department of Community Health & Epidemiology, Dalhousie University, Halifax, NS, Canada

Platelet Derived Growth Factor (PDGF) and Bone Morphogenetic Protein 4 (BMP4) Levels May Indicate Presence of Combined Pre and Post Capillary WHO Group II Pulmonary Hypertension; H. Marcos-Abdala, H. Karmouty-Quintana, K. Youker, A. Cruz-Solbes, J. Amione-Guerra, A. Ali, R. Araujo-Gutierrez, R. Thandavarayan, G. Ashrith. 1Heart Failure, Houston Methodist Research Institute, Houston, TX, 2Molecular Biology, UT Health and Medicine School, Houston, TX


Role of Extracorporeal Membrane Oxygenation Support as a Bridge to Medical Therapy in Decompensated Pulmonary Hypertension; M. Tsai, C. Hsu, P. Yang, T. Lin, D. Chen, C. Luo, Y. Hu, J. Roan. 1Cardiovascular Surgery, National Cheng Kung University Hospital, Tainan, Tainan, Taiwan, 2Cardiology, National Cheng Kung University Hospital, Tainan, Tainan, Taiwan, 3Cardiovascular Surgery, Division of Cardiovascular Surgery, Department of Surgery, E-Da Hospital/I-Shou University, Kaohsiung, Kaohsiung, Taiwan

Lower Socioeconomic Status Associated with Decreased Completion of Exercise Rehabilitation in Patients with Pulmonary Hypertension; T. Cascino, C. Ashur, C. Richardson, E. Jackson, V. McLaughlin. 1University of Michigan, Ann Arbor, MI, 2University of Alabama Birmingham, Birmingham, AL
POSTER MAPS

Poster Session 1, Wednesday – Banda Sea 1

BANDA SEA 1

POSTER SESSION 1

WEDNESDAY, APRIL 3, 2019

Junior Faculty Case Reports: MCS and PH
Poster Numbers: 1290-1336

START

END
Poster Session 1, Wednesday – Banda Sea 2
Poster Session 1, Wednesday – Gardenia 2

GARDENIA 2  POSTER SESSION 1
WEDNESDAY, APRIL 3, 2019

Economics/Ethics/Public Policy: Poster Numbers 635-642
Nursing/Health Science/Allied Health: Poster Numbers 738-754
Poster Session 1, Wednesday – Hibiscus 1
Poster Session 1, Wednesday – Hibiscus 2
Poster Session 1, Wednesday – Timor Sea 1

POSTER MAPS, cont.
Poster Session 1, Wednesday – Timor Sea 2
Poster Session 2, Thursday – Banda Sea 1
Poster Session 2, Thursday – Banda Sea 2
Poster Session 2, Thursday – Gardenia 2

GARDENIA 2
POSTER SESSION 2
THURSDAY, APRIL 4, 2019
Infectious Diseases
Poster Numbers: 765-794

START

765 766

767

768

769

770

771

772

773 774 775 776 777
Poster Session 2, Thursday – Hibiscus 1

HIBISCUS 1  POSTER SESSION 2
THURSDAY, APRIL 4, 2019

Lung Transplantation (Adult)
Poster Numbers: 795-824

START

795
796
797
798
799
800

821  820  811  810
822  819  812  809
823  818  813  808
824  817  814  807

816  815  806

END

801  802  803  804  805
Poster Session 2, Thursday – Hibiscus 2

HIBISCUS 2
POSTER SESSION 2
THURSDAY, APRIL 4, 2019

Lung Transplantation (Adult)
Poster Numbers: 825-833 and 1029

START

825
826
827
828
829
830

831
832
833
834
835

836 846
847

837 844
848

838 843
849 1029

END
Poster Session 2, Thursday – Timor Sea 1
Poster Session 3, Friday – Banda Sea 1
Poster Session 3, Friday – Banda Sea 2

BANDA SEA 2  POSTER SESSION 3
FRIDAY, APRIL 5, 2019

Pediatrics
Poster Numbers 1170-1217
Poster Session 3, Friday – Gardenia 2

Pulmonary Hypertension / CTEPH
Poster Numbers: 1218-1244
Poster Session 3, Friday – Hibiscus 1

HIBISCUS 1 POSTER SESSION 3
FRIDAY, APRIL 5, 2019

Heart Transplantation (Adult)
Poster Numbers: 981-1013

START

END
Poster Session 3, Friday – Timor Sea 1

TIMOR SEA 1  POSTER SESSION 3
FRIDAY, APRIL 5, 2019

Mechanical Circulatory Support (Adult)
Poster Numbers: 1116-1169

START

1116  1120  1121

END

1143  1156  1157  1159  1122
Poster Session 3, Friday – Timor Sea 2

TIMOR SEA 2  POSTER SESSION 3
FRIDAY, APRIL 5, 2019

Mechanical Circulatory Support (Adult)
Poster Numbers: 1064-1115

START  END
ISHLT ACADEMIES

ISHLT ACADEMY: CORE COMPETENCIES IN NURSING, HEALTH SCIENCES AND ALLIED HEALTH
Care of Patients Requiring Mechanical Circulatory Support and Transplantation

Scientific Program Chairs
Chair: Sarah Schettle, PA-C, Mayo Clinic College of Medicine, Rochester, MN, USA
Co-Chairs: Connie White-Williams PhD, RN, NE-BC, FAAN, Univ of Alabama at Birmingham Hospital, Birmingham, AL, USA
Patricia M. Leisfield, RN, The Prince Charles Hospital, Queensland, Australia

Faculty
Nancy P. Blumenthal, DNP, CRNP, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children's Hospital, Redwood City, CA, USA
Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada
Pamela S. Combs, PhD, RN, University of Chicago, Chicago, IL, USA
Margaret M. Fregoso, NP, Inova Transplant Center, Fairfax, VA, USA
Steven P. Ivulich, BPharm, Alfred Hospital, Melbourne, VIC, Australia
Colleen J. Juricek-LaBuhn, University of Chicago, Chicago, IL, USA
Jane MacIver, RN, NP, PhD, Toronto General Hospital, Toronto, ON, Canada
Tara E. Miller, FNP, Duke University Medical Center, Durham, NC, USA
Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA
Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA
Nicola Robinson Smith, RN, Newcastle Upon Tyne Hospitals NHS, Newcastle Upon Tyne, UK
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, NSW, Australia
Thomas Schloeghofer, BSc, Medical University of Vienna, Vienna, Austria
Sarah E. Schroeder, ACNP-BC, MSN RN, Bryan Heart, Lincoln, NE, USA
Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA
Jo Wray, PhD, Great Ormond Street Hospital, London, UK

Educational Goals
This Academy is intended to offer a concise synopsis of clinical knowledge to support mastery of the core competencies of the selection, pre-transplant, perioperative, and post-transplant management of the thoracic transplant organ recipient by Nursing, Health Sciences, and Allied Health professionals. In addition to basic knowledge, attention is also paid to patients with special needs who require transplantation and to the Nursing, Health Sciences, and Allied Health professionals caring for this unique population.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for Nursing, Health Sciences, and Allied Health professionals who are in the early stages of their careers, or who are in training and/or are part of a new program, or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of thoracic transplant and mechanical circulatory support, rather than as a detailed update for those who are already proficient experts in the field.

Learning Objectives
At the conclusion of this Course, participants will have improved competence and professional performance in their ability to:

1. Understand the role of the Transplant and MCS Coordinator and how to evaluate, manage, and care for patients for the short term and long term within this role.
2. Recognize and appreciate challenges with patients with special needs and identify strategies to implement quality care for all patients.
3. Identify patient needs at the end of life, how to meet these needs and how to practice self-care.

Accreditation & Credit Designation Statements
Physicians
Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the American Council for Continuing Medical Education
(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 8.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**Transplant Coordinators**  
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart & Lung Transplantation grants up to 8.25 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Provider Number: #907-000.

**Disclosure**  
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interests that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

### Scientific Program

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 7:45 AM</td>
<td><strong>REGISTRATION AND MORNING COFFEE</strong></td>
</tr>
<tr>
<td>7:45 AM - 8:00 AM</td>
<td><strong>WELCOME AND OVERVIEW</strong></td>
</tr>
</tbody>
</table>
| 8:00 AM - 8:30 AM | **SESSION 1 - ROLE OF THE TRANSPLANT AND MCS COORDINATOR: EVOLUTION AND CURRENT PRACTICE**  
**CHAIR:** Connie White-Williams, PhD, RN, NE-BC, FAAN |
| 8:00 AM         | **Evolution of the Heart and Lung Transplant and MCS Coordinator Role**       |
|                 | Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA          |
| 8:15 AM         | **Global Role Variations**                                                    |
|                 | Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria      |
| 8:30 AM – 9:30 AM | **SESSION 2 – EVALUATION AND MANAGEMENT OF THE ADVANCED THORACIC ORGAN FAILURE PATIENT**  
**CHAIR:** Patricia Leisfield, RN |
| 8:30 AM         | **When to Refer…and do They Meet Criteria?**                                  |
|                 | Colleen J. Juricek-LaBuhn, University of Chicago, Chicago, IL, USA            |
| 8:45 AM         | **Evaluation and Management**                                                 |
|                 | Nancy P. Blumenthal, DNP, CRNP, University of Pennsylvania Medical Center, Philadelphia, PA, USA |
| 9:00 AM         | **Psychosocial Issues pre-Transplant and pre-MCS**                            |
|                 | Sarah E. Schroeder, ACNP-BC, MSN RN, Bryan Heart, Lincoln, NE, USA           |
| 9:15 AM         | **Hot Topics in Evaluation**                                                  |
|                 | Jane MacIver, RN, NP, PhD, Toronto General Hospital, Toronto, ON, Canada     |
| 9:30 AM – 10:00 AM | **COFFEE BREAK**                                                              |
| 10:00 AM – 11:00 AM | **SESSION 3 – CARING FOR THE LISTED PATIENT**                                |
|                 | **CHAIR:** Connie White-Williams, PhD, RN, NE-BC, FAAN                        |
| 10:00 AM        | **Listing and Collaboration: Transplant/MCS Coordinators and Patients**      |
|                 | Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA          |
| 10:15 AM        | **Immunology 101**                                                            |
|                 | Tara E. Miller, FNP, Duke University Medical Center, Durham, NC, USA          |
10:30 AM
*Managing Patients with anti HLA Antibodies and Desensitization Therapies*
Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA

10:45 AM
*Case Scenario: Cannabis Legality and Patient Evaluation*
Nicola Robinson Smith, RN, Newcastle Upon Tyne Hospitals NHS, Newcastle Upon Tyne, UK

11:00 AM – 11:30 AM
SESSION 4 – TRANSPLANT MANAGEMENT
CHAIR: Patricia Leisfield, RN

11:00 AM
*The Heart and Lung Donor*
Margaret M. Fregoso, NP, Inova Transplant Center, Fairfax, VA, USA

11:15 AM
*Immunosuppression: Induction and Maintenance*
Steven P. Ivulich, BPharm, Alfred Hospital, Melbourne, VC, Australia

11:30 AM – 12:00 PM
SESSION 5 – MCS MANAGEMENT
CHAIR: Sarah Schettle, PA-C

11:30 AM
*Devices*
Nicola Robinson Smith, RN, Newcastle Upon Tyne Hospitals NHS, Newcastle Upon Tyne, UK

11:45 AM
*Complications Overview*
Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria

12:00 PM – 1:00 PM
LUNCH/NETWORKING BREAK (a box lunch is included in the registration fee)

1:00 PM – 1:45 PM
SESSION 6 – IMMEDIATE POST TRANSPLANT CARE
CHAIR: Connie White-Williams, PhD, RN, NE-BC, FAAN

1:00 PM
*Primary Graft Dysfunction: Definitions and Treatment*
Margaret M. Fregoso, NP, Inova Transplant Center, Fairfax, VA, USA

1:15 PM
*Management of Acute Cellular Rejection and Antibody Mediated Rejection*
Tara E. Miller, FNP, Duke University Medical Center, Durham, NC, USA

1:30 PM
*Post-Transplant Heart and Lung Recipient and Caregiver Education*
Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada

1:45 PM – 2:45 PM
SESSION 7 – CARE OF THE PATIENT WITH SPECIAL NEEDS
CHAIR: Sarah Schettle, PA-C

1:45 PM
*Poor Social Support and Low Socioeconomic Status*
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children’s Hospital, Redwood City, CA, USA

2:00 PM
*Low Health Literacy and Adherence*
Colleen J. Juricek-LaBuhn, University of Chicago, Chicago, IL, USA

2:15 PM
*Care of the Very Young, School Age and Adolescent*
Jo Wray, PhD, Great Ormond Street Hospital, London, UK

2:30 PM
*Care of the Older Aged Patient*
Patricia Leisfield, RN, The Prince Charles Hospital, Queensland, Australia

2:45 PM – 3:15 PM
COFFEE BREAK

3:15 PM – 4:15 PM
SESSION 8 – LONG TERM FOLLOW UP
CHAIR: Patricia Leisfield, RN

3:15 PM
*Chronic Rejection: BOS*
Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA
3:30 PM  
Chronic Rejection: CAV
Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA

3:45 PM  
Infection and Malignancy
Linda Ohler, MSN, FAAN, FAST, New York University, New York, NY, USA

4:00 PM  
Return to Work, School and Quality of Life
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, NW, Australia

4:15 PM – 4:45 PM  
SESSION 9 – QUALITY
CHAIR: Connie White-Williams, PhD, RN, NE-BC, FAAN

4:15 PM  
Quality Assurance and Interprofessional Collaborative Practice
Connie White-Williams, PhD, RN, NE-BC, FAAN, University of Alabama at Birmingham Hospital, Birmingham, AL, USA

4:30 PM  
Readmissions
Sarah Schettle, PA-C, Mayo Clinic College of Medicine, Rochester, MN, USA

4:45 PM - 6:00 PM  
SESSION 10 – CARING FOR OURSELVES AND OTHERS
CHAIR: Patricia Leisfield, RN

4:45 PM  
Collaboration Strategies
Pamela Combs, PhD, RN, University of Chicago, Chicago, IL, USA

5:00 PM  
Care for the Caregivers
Caron Burch, RN, MSN, FNP, CCTC, UCSF Benioff Children’s Hospital, Redwood City, CA, USA

5:15 PM  
Caring at the End of Life
Jane MacIver, RN, NP, PhD, Toronto General Hospital, Toronto, ON, Canada

5:30 PM  
Career Development Strategies for MCS and Transplant Professionals
Connie White-Williams, PhD, RN, NE-BC, FAAN, University of Alabama at Birmingham Hospital, Birmingham, AL, USA

5:45 PM  
Work-life Balance for the MCS and Transplant Professional – Making it all Work
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, NSW, Australia

6:00 PM  
SUMMARY / EVALUATION / Q&A
Sarah Schettle, PA-C, Mayo Clinic College of Medicine, Rochester, MN, USA
Connie White-Williams, PhD, RN, NE-BC, FAAN, University of Alabama at Birmingham Hospital, Birmingham, AL, USA
Patricia Leisfield, RN, The Prince Charles Hospital, Queensland, Australia

6:15 PM  
ADJOURN
ISHLT ACADEMY: CORE COMPETENCIES IN PEDIATRIC HEART FAILURE

Scientific Program Chairs
Chair: Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA
Co-Chair: Heather Henderson, MD, Medical University of South Carolina, Charleston, SC, USA

Scientific Program Committee
Rachel Andrews, FRCPCH, Great Ormond Street Hospital for Children, London, UK
Jennifer Conway, MD, University of Alberta/Stollery Children’s Hospital, Edmonton, AB, Canada
Claire Irving, FRACP, MD, Children’s Hospital Westmead, Sydney, Australia
Joseph Rossano, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

Faculty
Rachel Andrews, FRCPCH, Great Ormond Street Hospital for Children, London, UK
Michael P. Carboni, MD, Duke Children's Hospital, Durham, NC, USA
Jennifer Conway, MD, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada
Claire Irving, FRACP, MD, Children’s Hospital Westmead, Sydney, Australia
Robert Jaquiss, MD, Children's Medical Center, Dallas, TX, USA
Paul F. Kantor, MBChB, FRCP, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada
Richard Kirk, FRCP, FRCPCH, University of Texas Southwestern Medical Center, Dallas, TX, USA
Jodie Lantz, MSN, RN, PCNSBC, Children's Health Dallas, Dallas, TX, USA
Jack F. Price, MD, Texas Children’s Hospital, Houston, TX, USA
Joseph Rossano, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia
Robert Shaddy, MD, The Children's Hospital, Los Angeles, CA, USA
Jeffrey Towbin, MD, Le Bonheur Children's Hospital, Memphis, TN, USA

Course Summary
This course is designed for pediatric cardiologists, early career professionals and advance practice nurses with an interest in pediatric heart failure. Each section is designed with focused, didactic lectures followed by an interactive Q&A. The course will start by covering general topics of pediatric heart failure – epidemiology, pathophysiology and etiology of pediatric heart failure. The course will then move to the diagnostic approach and medical management of pediatric heart failure, including a section on acute decompensated heart failure. The course will then cover the topics of a multi-disciplinary approach to heart failure as well as activity restrictions, precautions and the management of co-morbidities. Next, the timing and outcomes of advanced heart failure therapies will be discussed. The course will conclude with a discussion on unique patient populations (including heart failure in congenital heart disease) as well as future directions of heart failure therapies and research topics to progress the field of pediatric heart failure.

Educational Goals
The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate the development of core skills, diagnostic approach and management interventions to provide comprehensive care to pediatric heart failure patients.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied health professionals who are in the early stages of their careers, or who are in training and/or are part of a new program, or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of pediatric heart failure, rather than as a detailed update for those who are already proficient experts in the field.

Learning Objectives
At the conclusion of this academy, participants will have improved competence and professional performance in their ability to:

1. Discuss the different etiologies, natural history, pathophysiology and prognosis of pediatric heart failure.
2. Understand diagnostic approaches and therapies for acute and chronic heart failure.
3. Recognize challenges, co-morbidities, and complications in the multidisciplinary care of pediatric heart failure.
Accreditation & Credit Designation Statements

Physicians
Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 7.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

Scientific Program

7:00 AM – 7:55 AM REGISTRATION AND MORNING COFFEE

7:55 AM – 8:00 AM WELCOME AND OVERVIEW
Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA

8:00 AM - 9:10 AM SESSION 1 – DEFINING THE PROBLEM: PEDIATRIC HEART FAILURE
CHAIR: Rachel Andrews, FRCPCH

8:00 AM What is Heart Failure & Who Gets It? Definitions, Etiologies and Natural History
Joseph Rossano, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

8:15 AM Symptoms, Signs & Staging of Pediatric Heart Failure
Ryan Butts, MD, University of Texas Southwestern, Dallas, TX, USA

8:30 AM Cellular and Genetic Basis of Pediatric Heart Failure
Jeffrey Towbin, MD, Le Bonheur Children's Hospital, Memphis, TN, USA

8:45 AM Q&A with Panel

9:00 AM – 10:00 AM SESSION 2 – DIAGNOSIS AND TESTING IN PEDIATRIC HEART FAILURE
CHAIR: Jennifer Conway, MD

9:00 AM What Can Laboratory Values Tell Me about My Patient in Heart Failure?
Claire Irving, FRACP, MD, Children’s Hospital Westmead, Sydney, Australia

9:15 AM What Imaging Should I Do in My Patient with Heart Failure?
Paul F. Kantor, MBBCh, FRCP, Stollery Children’s Hospital, Univ of Alberta, Edmonton, AB, Canada

9:30 AM What Testing is Useful in the Follow-up of Patients with Heart Failure?
Heather T. Henderson, MD, Medical University of South Carolina, Charleston, SC, USA

9:45 AM Q&A with Panel

10:00 AM – 10:30 AM COFFEE BREAK
10:30 AM – 11:30 AM  SESSION 3 – ACUTE HEART FAILURE IN PEDIATRICS  
CHAIR: Ryan Butts, MD

10:30 AM  Diagnosing and Managing Acute Decompensated Heart Failure  
Joseph Rossano, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

10:45 AM  Using Mechanical Circulatory Support in Acute Decompensated Heart Failure  
Robert Jaquiss, MD, Children's Medical Center, Dallas, TX, USA

11:00 AM  Myocarditis: More than just Whether or Not to Give IVIG---Case Presentation  
Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia

11:15 AM  Q&A with Panel

11:30 AM – 12:30 PM  LUNCH / NETWORKING BREAK (a box lunch is included in the registration fee)

12:30 PM – 1:45 PM  SESSION 4 – CHRONIC HEART FAILURE IN PEDIATRICS  
CHAIR: Claire Irving, FRACP, MD

12:30 PM  The Multidisciplinary Approach to Heart Failure Management  
Jodie Lantz, MSN, RN, PCNSBC, Children's Health Dallas, Dallas, TX, USA

12:45 PM  Medications for Chronic Heart Failure  
Rachel Andrews, FRCPCH, Great Ormond Street Hospital for Children, London, UK

1:00 PM  Recognizing and Managing Comorbidities  
Jack F. Price, MD, Texas Children’s Hospital, Houston, TX, USA

1:15 PM  Promotion of Healthy Lifestyle  
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

1:30 PM  Q&A with Panel

1:45 PM - 2:45 PM  SESSION 5 – ADVANCED HEART FAILURE THERAPIES  
CHAIR: Heather T. Henderson, MD

1:45 PM  Arrhythmia’s, Pacers, ICD’s and CRT  
Michael P. Carboni, MD, Duke Children's Hospital, Durham, NC, USA

2:00 PM  Advanced Circulatory Support  
Jennifer Conway, MD, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada

2:15 PM  When is it Time to Talk Transplant?  
Richard Kirk, FRCP, FRCPCH, University of Texas Southwestern Medical Center, Dallas, TX, USA

2:30 PM  Q&A with Panel

2:45 PM - 3:15 PM  COFFEE BREAK

3:15 PM – 4:15 PM  SESSION 6 – UNIQUE PATIENT POPULATIONS  
CHAIR: Heather T. Henderson, MD

3:15 PM  Managing Chemotherapy-Induced Cardiomyopathy  
Rachel Andrews, FRCPCH, Great Ormond Street Hospital for Children, London, UK

3:30 PM  Managing Neuromuscular Cardiomyopathy  
Claire Irving, FRACP, MD, Children’s Hospital Westmead, Sydney, Australia

3:45 PM  Heart Failure in the Single Ventricle Patient  
Jennifer Conway, MD, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada
4:00 PM    Q&A with Panel

4:15 PM - 5:15 PM    SESSION 7 – DEBATE: FUTURE DIRECTIONS AND RESEARCH IN PEDIATRIC HEART FAILURE: REGISTRY VS RANDOMIZED CONTROL TRIALS  
                      CHAIR: Joseph Rossano, MD

4:15 PM    Randomized Trials in Pediatric Heart Failure and Why We Need Them  
                   Robert Shaddy, MD, The Children's Hospital, Los Angeles, CA, USA

4:25 PM    Research from Registries in Heart Failure and Why We Need Them  
                   Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

4:35 PM    Rebuttal  
                   Robert Shaddy, MD, Children’s Hospital, Philadelphia, PA, USA

4:40 PM    Rebuttal  
                   Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

4:45 PM    Q&A with Panel

5:00 PM    SUMMARY / EVALUATION  
                   Heather T. Henderson, MD Medical University of South Carolina, Charleston, SC, USA

5:15 PM    ADJOURN
ISHLT ACADEMIES, Cont.

ISHLT ACADEMY: MASTER CLASS IN HEART FAILURE AND TRANSPLANTATION

Scientific Program Chairs
Chair: Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Co-Chair: Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

Case Moderators
Patricia Chang, MD, MHS, University of North Carolina, Chapel Hill, NC, USA
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA
Heather Ross, MD, MHSc, FRCP (C), FACC, University of Toronto, Toronto, ON, Canada
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

Case Discussants
Luke Burchill, MBBS, PhD, FRACP, Oregon Health and Science University, Portland, Oregon, USA
Maria Crespo-Leiro, MD, Hospital Universitario a Coruna, La Coruna, Spain
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Steven Tsui, MD, FRCS, Papworth Hospital NHS Trust, Cambridge, UK

Course Summary
The HFTX Master Class is designed for clinicians with higher levels of expertise in advanced heart failure and transplantation (completed the core curriculum course on HFTX and/or primary practice in advanced heart failure management (≥ 5 years)). The course format is intended to generate highly interactive discussion among experienced users of these technologies, in order to tackle the most complex nuances of managing these complex patients. Rather than didactic lectures, this course will employ the concept of “convergent discussion” composed of small groups. Faculty moderators and case discussants will engage the audience by focusing on areas with gaps in knowledge and absence of consensus in the field. The case-based format will allow moderators and discussants to use real-world complex situations in order to lead the group through active audience participation towards specific answers designed to address the practice gaps and learning objectives.

Practice Gaps
1. Transplant clinicians lack the immunology expertise required to effectively integrate the results of HLA antibody testing into patient management.
2. The diagnostic and therapeutic approaches to cardiac allograft rejection are evolving, and transplant clinicians face difficulties in incorporating newer diagnostic modalities such as MRI, molecular diagnostics, and newer immunosuppressive agents into current algorithms.
3. Specific approaches to optimize the matching of donor hearts to the most appropriate recipients are not well delineated for clinicians.
4. With the availability of multiple combinations of immunosuppressive agents, some transplant clinicians lack the expertise required to select the most effective agents for different subgroups of patients and to individualize immunosuppression to prevent or minimize long-term complications.

Target Audience
This course has been developed for cardiologists, cardiothoracic surgeons, nurses, advanced practice providers, and allied health professionals with at least 5 years of experience in the field of heart transplantation/advanced heart failure or who have attended a prior ISHLT core competency course in advanced heart failure and cardiac transplant medicine. While all members are invited to enroll, Master Classes are primarily designed to be of benefit for health care and allied professionals who are beyond the training stages of their careers. This may be professionals who are seeking additional proficiencies, who wish to understand current areas of controversy, or who desire an update on the current advanced topics of the field. The information presented is intended to provide insights beyond core competencies established in the specialty.

Objectives
After completion of this Class, participants will have improved competence and professional performance in their ability to:

1. Identify the risk of HLA sensitization on cardiac rejection and outcomes, management strategies for sensitized patients pre-transplant and approach to heart transplant recipients with antibody-mediated rejection.
2. Understand perioperative strategies for (a) assessing extended-criteria (marginal) heart donors and optimizing outcomes after transplantation and (b) identifying type and severity of primary graft dysfunction (PGD), including donor, procedural and recipient risk factors for PGD; signs of PGD during reperfusion and challenges with weaning off cardio-pulmonary bypass.
3. Evaluate the candidacy of adults with congenital heart disease for heart transplant, incorporating prognostic testing, and relative contraindications to transplant in this high-risk population. Develop insights into mechanisms of late graft
dysfunction, including (a) role of CAV and rejection, (b) diagnostic strategies including IVUS, OCT and MRI, and (c) treatment strategies including modification in immunosuppression and decision for re-transplant.

Accreditation & Credit Designation Statements

Physicians
Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Offered in the morning and repeated in the afternoon. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 4.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

Scientific Program – Morning Course

8:00 AM – 8:10 AM  WELCOME AND OVERVIEW
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

8:10 AM – 10:15 AM  SMALL GROUP INTERACTIVE DISCUSSION A: SENSITIZATION AND ANTIBODY MEDIATED REJECTION (AMR)
Moderator: Patricia Chang, MD, MHS
CASE SCENARIO A1: Sensitized LVAD Patient with Chronic Infection
Patricia Chang, MD, MHS, University of North Carolina, Chapel Hill, NC, USA
CASE SCENARIO A2: Asymptomatic AMR Management
Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain

SMALL GROUP INTERACTIVE DISCUSSION B: DONOR SELECTION AND PRIMARY GRAFT DYSFUNCTION
Moderator: Hannah Copeland, MD
CASE SCENARIO B1: Approach to the Extended Criteria (Marginal) Donor
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA
CASE SCENARIO B2: Identification and Diagnosis of Primary Graft Dysfunction
Steven Tsui, MD, FRCS, Papworth Hospital NHS Trust, Cambridge, UK

10:15 AM – 10:45 AM  COFFEE BREAK

10:45 AM – 12:50 PM  SMALL GROUP INTERACTIVE DISCUSSION C: RECIPIENT SELECTION (CONGENITAL HEART DISEASE)
Moderator: Heather Ross, MD, MHSc, FRCP (C), FACC
CASE SCENARIO C1: Timing of Transplantation in Adult Congenital Heart Disease
Heather Ross, MD, MHSc, FRCP (C), FACC, University of Toronto, Toronto, ON, Canada

CASE SCENARIO C2: Transplant as a Strategy for the Failing Fontan Patient
Luke Burchill, MBBS, FRACP, Oregon Health and Science University, Portland, Oregon, USA

SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM CHALLENGES IN TRANSPLANT (LATE GRAFT DYSFUNCTION, CANCER)
Moderator: Luciano Potena, MD, PhD

CASE SCENARIO D1: Late Graft Dysfunction
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

CASE SCENARIO D2: Malignancy in the Heart Transplant Patient
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

12:50 PM – 1:00 PM CLOSING REMARKS/EVALUATION
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

1:00 PM ADJOURN

Scientific Program – Afternoon Course

2:00 PM – 2:10 PM WELCOME AND OVERVIEW
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

2:10 PM – 4:10 PM SMALL GROUP INTERACTIVE DISCUSSION A: SENSITIZATION AND ANTIBODY MEDIATED REJECTION (AMR)
Moderator: Patricia Chang, MD, MHS

CASE SCENARIO A1: Sensitized LVAD Patient with Chronic Infection
Patricia Chang, MD, MHS, University of North Carolina, Chapel Hill, NC, USA

CASE SCENARIO A2: Asymptomatic AMR Management
Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain

SMALL GROUP INTERACTIVE DISCUSSION B: DONOR SELECTION AND PRIMARY GRAFT DYSFUNCTION
Moderator: Hannah Copeland, MD

CASE SCENARIO B1: Approach to the Extended Criteria (Marginal) Donor
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA

CASE SCENARIO B2: Identification and Diagnosis of Primary Graft Dysfunction
Steven Tsui, MD, FRCS, Papworth Hospital NHS Trust, Cambridge, UK

4:15 PM – 4:45 PM COFFEE BREAK

4:45 PM – 6:50 PM SMALL GROUP INTERACTIVE DISCUSSION C: RECIPIENT SELECTION (CONGENITAL HEART DISEASE)
Moderator: Heather Ross, MD, MHSc, FRCP (C), FACC

CASE SCENARIO C1: Timing of Transplantation in Adult Congenital Heart Disease
Heather Ross, MD, MHSc, FRCP (C), FACC, University of Toronto, Toronto, ON, Canada

CASE SCENARIO C2: Transplant as a Strategy for the Failing Fontan Patient
SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM CHALLENGES IN TRANSPLANT (LATE GRAFT DYSFUNCTION, CANCER)
Moderator: Luciano Potena, MD, PhD

CASE SCENARIO D1: Late Graft Dysfunction
Marta Farrero, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Luciano Potena Torres, MD, PhD, University of Bologna, Bologna, Italy

CASE SCENARIO D2: Malignancy in the Heart Transplant Patient
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

6:50 PM – 7:00 PM  CLOSING REMARKS/EVALUATION
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
Lynn Punnoose, MD, Vanderbilt University, Nashville, TN, USA

7:00 PM  ADJOURN
ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT

Scientific Program Chairs
Chair: Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA
Co-Chair: Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

Case Moderators
Jens Garbade, MD, PhD, MHBA, University of Leipzig, Leipzig, Germany
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Scott Silvestry, MD, Florida Hospital Transplant Network, Orlando, FL, USA
Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

Case Discussants
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA
Kelsey Flint, MD, University of Colorado, Aurora, CO, USA
P. Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

Course Summary
The MCS Master Class is designed for clinicians with higher levels of expertise in MCS (completed the core curriculum course on MCS and/or primary practice in MCS (≥ 5 years)). The course format is intended to generate highly interactive discussion among experienced users of these technologies, in order to tackle the most complex nuances of managing these complex patients. Rather than didactic lectures, this course will employ the concept of “convergent discussion” composed of small groups. Faculty moderators and case discussants will engage the audience by focusing on areas with gaps in knowledge and absence of consensus in the field. The case-based format will allow moderators and discussants to use real-world complex situations in order to lead the group through active audience participation, towards specific answers designed to address the practice gaps and learning objectives.

Practice Gaps
1. The outcomes of cardiogenic shock have remained poor, large randomized trials are scarce and the management of these patients remains challenging. Comprehensive clinical expertise of advanced usage of evolving MCS options including patient and device selection and transition to next step therapies continue to constitute major limitations in the care of these critically ill patients. Knowledge in this area is rapidly evolving and frequent updates are necessary.
2. The diagnosis and management of complex and combined adverse events such as cerebrovascular hemorrhagic accidents, device thrombosis and gastrointestinal bleeding is challenging and practitioners often face difficulties in developing effective strategies to appropriately identify and treat these adverse events. Recent improvements in device technology have eliminated thrombosis and new anticoagulation strategies continue to evolve.
3. The diagnostic and therapeutic approaches for early and late right ventricular failure in MCS patients have been evolving with the introduction of new diagnostic criteria and new technologies/therapeutic options. Such practice gaps in specialist knowledge and clinical skills constitute major limitations in the care of MCS patients.
4. The implantation of results from large clinical studies such as MOMENTUM 3 and ENDURENCE supplement into clinical practice is still lagging. The Master Academy will review the information from those studies and discuss their use in daily practice.

Target Audience
This course has been developed for cardiac and mechanical circulatory support surgeons, advanced heart failure cardiologists, VAD Coordinators, and allied health professionals with at least 5 years of experience in the field of mechanical circulatory support or who have attended a prior ISHLT core competency course in mechanical circulatory support. While all members are invited to enroll, Master Classes are primarily designed to be of benefit for health care professionals who are beyond the training stages of their careers. This may be professionals who are seeking additional proficiencies, who wish to understand current areas of controversy, or who desire an update on the current advanced topics of the field. The information presented is intended to provide insights beyond core competencies established in the specialty.

Educational Need
Mechanical circulatory support is a rapidly growing and rapidly evolving therapy for advanced heart failure. There are now several options approved for use to support patients both acutely in the short term, as well as for durable support. Optimizing outcomes and survival in these complex patients requires mastery of the identification of cardiogenic shock phenotypes, knowledge of device choice and timing, as well as pre-operative optimization of these patients. Multidisciplinary teams are an essential part of modern day
mechanical circulatory support management. This Class is designed to meet the target audience’s need for an advanced learning opportunity that explores and seeks to address the unique clinical challenges faced by specialists and developing experts in the field of MCS for treatment of heart failure patients.

Objectives
After completion of this Class, participants will have improved competence and professional performance in their ability to:
1. Identify patients with cardiogenic shock, including complex presentation, appropriate devices for short-term mechanical circulatory support, and factors impacting transition to longer term support platforms.
2. Understand the management of durable MCS patients with complex hemo-compatibility related adverse events, including recurrent GI bleed, bleeding in the setting of thrombosis, or the patient with a history of confounding events (i.e. bleeding and thrombosis).
3. Review predictors of early and late right ventricular failure post LVAD implantation, understand the utility of presently available risk scores, and identify management strategies.
4. Understand the implications of the Momentum 3 and Endurance clinical trials for clinical practice.

Accreditation & Credit Designation Statements
Physicians
Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement - ISHLT designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 4.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

Scientific Program – Morning Course

8:00 AM – 8:10 AM  WELCOME AND OVERVIEW  
Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA  
Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

8:10 AM – 10:15 AM SMALL GROUP INTERACTIVE DISCUSSION A: IABP, ECMO AND BEYOND - SHORT TERM MCS FOR PROFOUND CARDIOGENIC SHOCK / INTERMACS 0-1 PROFILES  
Moderator: Jens Garbade, MD, PhD, MHBA

CASE SCENARIO A1: Short-Term MCS for Cardiogenic Shock: Timing and Device Selection  
Jens Garbade, MD, PhD, MHBA, University of Leipzig, Leipzig, Germany

CASE SCENARIO A2: MCS Weaning and Transition to Permanent MCS  
P. Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany

SMALL GROUP INTERACTIVE DISCUSSION B: TO PULSE OR NOT TO PULSE: IMPLICATIONS ON COAGULATION AND PHYSIOLOGY  
Moderator: Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

CASE SCENARIO B1: Bleeding and Clotting and Both, Oh My!
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

CASE SCENARIO B2: Systemic Infection, Stroke and Secondary Bleeding – The Unhappy Triad of VAD Therapy
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

10:15 AM – 10:45 AM COFFEE BREAK

10:45 AM – 12:50 PM SMALL GROUP INTERACTIVE DISCUSSION C: PATIENT SELECTION AND PRE-OPTERATIVE OPTIMIZATION
Moderator: Melana Yuzefpolskaya, MD

CASE SCENARIO C1: The RV Looks “Bad” - Strategies for Management
Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

CASE SCENARIO C2: The Patient Looks Frail- Should We Move Forward?
Kelsey Flint, MD, University of Colorado, Aurora, CO, USA

SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM MANAGEMENT OF THE LVAD RECIPIENT
Moderator: Finn Gustafsson, MD, PhD

CASE SCENARIO D1: What to Do with ICD: Pacing Strategies and Minimizing Shocks
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

CASE SCENARIO D2: Low Flow Alarms and Blood Pressure Management: Nuances Among Different Devices
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

12:50 PM – 1:00 PM CLOSING REMARKS/EVALUATION
Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA
Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

1:00 PM ADJOURN

Scientific Program – Afternoon Course

2:00 PM – 2:10 PM WELCOME AND OVERVIEW
Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA
Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

2:10 PM – 4:15 PM SMALL GROUP INTERACTIVE DISCUSSION A: IABP, ECMO AND BEYOND - SHORT TERM MCS FOR PROFOUND CARDIOGENIC SHOCK / INTERMACS 0-1 PROFILES
Moderator: Jens Garbade, MD, PhD, MHBA

CASE SCENARIO A1: Short-Term MCS for Cardiogenic Shock: Timing and Device Selection
Jens Garbade, MD, PhD, MHBA, University of Leipzig, Leipzig, Germany

CASE SCENARIO A2: MCS Weaning and Transition to Permanent MCS
P. Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany

SMALL GROUP INTERACTIVE DISCUSSION B: TO PULSE OR NOT TO PULSE: IMPLICATIONS ON COAGULATION AND PHYSIOLOGY
Moderator: Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

CASE SCENARIO B1: Bleeding and Clotting and Both, Oh My!
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

CASE SCENARIO B2: Systemic Infection, Stroke and Secondary Bleeding – The Unhappy Triad of
VAD Therapy
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

4:15 PM – 4:45 PM  COFFEE BREAK

4:45 AM – 6:50 PM  SMALL GROUP INTERACTIVE DISCUSSION C: PATIENT SELECTION AND PRE-OPERATIVE OPTIMIZATION
Moderator: Melana Yuzefpolskaya, MD

CASE SCENARIO C1: The RV Looks “Bad” - Strategies for Management
Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA

CASE SCENARIO C2: The Patient Looks Frail—Should We Move Forward?
Kelsey Flint, MD, University of Colorado, Aurora, CO, USA

SMALL GROUP INTERACTIVE DISCUSSION D: LONG TERM MANAGEMENT OF THE LVAD RECIPIENT
Moderator: Finn Gustafsson, MD, PhD

CASE SCENARIO D1: What to Do with ICD: Pacing Strategies and Minimizing Shocks
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

CASE SCENARIO D2: Low Flow Alarms and Blood Pressure Management: Nuances Among Different Devices
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

6:50 PM – 7:00 PM  CLOSING REMARKS/EVALUATION
Susan Joseph, MD, Baylor University and Vascular Hospital, Dallas, TX, USA
Daniel Zimpfer, MD, MBA, Medical University of Vienna, Vienna, Austria

7:00 PM  ADJOURN
ISHLT AFFILIATE EVENTS
(as of March 20, 2019)

Tuesday, April 2, 2019

12:00 PM – 6:00 PM
Toronto Annual Lung Transplant Biospecimen Workshop
(Hard Rock Café)

2:00 PM - 6:00 PM
Infectious Diseases/HCV Consensus Document
Consensus Statement on the Use of Hepatitis C Virus-Infected Organ Donors for Cardiothoracic Transplantation
(Grand Caribbean 8-10)

6:00 PM - 9:00 PM
Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Learning Network Meeting
(Oceana 3)

Wednesday, April 3, 2019

7:00 AM – 7:45 AM
SUSTAIN-IT Trial Investigator Meeting
(St. Croix 1)

12:15 PM – 1:45 PM
Cystic Fibrosis Foundation Lung Transplant Initiative Surgeon Lunch
(Caicos 5)

12:15 PM – 1:30 PM
PEDS Council Pediatric Lung Failure Workforce Meeting
(St. Croix 1)

12:30 PM – 1:30 PM
Donor Heart Selection Consensus Paper Meeting
(Grand Caribbean 10)

12:30 PM – 2:00 PM
MCS Guidelines Update Task Force Meeting
(Turks 1)

12:45 PM - 1:45 PM
Pediatrics Council – Donor Consensus Document Meeting
(Caicos 3)

6:00 PM – 8:00 PM
UPMC Cocktail Reception
(Grand Caribbean 12)

6:15 PM - 10:00 PM
ICCAC Annual Meeting
(Oceana 3-5)

Thursday, April 4, 2019

7:00 AM – 8:00 AM
ISHLT Consensus Statement on Lung Transplantation in Patients with Connective Tissue Disease (CTD): Epidemiology, Risk Factors, Candidate Selection Criteria, Surgical and ICU management and Post-transplant care” SSc Subgroup Meeting
(Admiralty Boardroom)

9:45 AM – 10:15 AM
BAL Standardization Workforce Meet and Greet
12:00 PM – 12:45 PM
ID Council Symposia Submission Working Group Meeting
(Oceana 1)

12:00 PM - 1:30 PM
Junior Faculty and Trainee Council Planning Session for ISHLT2020 Symposium Development
(St. Croix 1)

12:00 PM - 1:45 PM
Pulmonary Transplant Council Quality of Life Workforce Meeting
(Admiralty Boardroom)

12:00 PM – 1:45 PM
NIH-Funded DTRT Investigators Meeting
(Barbados Boardroom)

12:10 PM – 1:10 PM
ISHLT Consensus Statement on Lung Transplantation in Patients with Connective Tissue Disease (CTD): Epidemiology, Risk Factors, Candidate Selection Criteria, Surgical and ICU management and Post-transplant care” Chairs and Co-Chairs Meeting
(Grand Caribbean 12)

12:30 PM – 1:30 PM
STS INTERMACS Taskforce Committee Meeting
(St. Croix 2)

12:45 PM – 1:30 PM
ID Council Workforce: Optimizing Outcomes in Older Thoracic Transplant and MCSD Recipients Group Meeting
(Oceana 1)

3:30 PM – 4:00 PM
Education Workforce Leaders Group Meeting
(Barbados Boardroom)

7:15 - 8:15 pm
International Engagement Committee Latin America Regional Meeting
(Oceana 3-5)

**Friday, April 5**

7:00 AM-8:00 AM
EUROMACS Committee Meeting
(Barbados Boardroom)

7:30 AM – 8:00 AM
Peri-operative PH Consensus Workgroup Meeting
(Admiralty Boardroom)

12:30 PM – 2:00 PM
SimVAD Study Investigators Meeting
(Grand Caribbean 10)

7:15 - 8:15 pm
International Engagement Committee Asia Pacific Regional Meeting
(Oceana 3-5)
ISHLT CORPORATE EVENTS and INDUSTRY THEATERS
(as of March 19, 2019)

Wednesday, April 3, 2019

12:30 PM – 1:30 PM
TAI Diagnostics Lunch Symposium
Cell-free DNA Done Right! An Overview of the myTAIHEART™ Test and Examples of its Clinical Application in Monitoring of Heart Transplant Rejection.
(Private event, pre-registration required)
(Oceana 3-5)

12:15 PM – 2:00 PM
SynCardia Symposium
Patient Selection for MCS – The Right Patient, The Right Time and The Right Device
(Grand Caribbean 11)

12:30 PM – 1:30 PM
Medtronic Lunch Symposium
Don’t Be Misled…A Scientific Analysis of VAD Data
(Oceana 1)

12:30 PM – 1:30 PM
Bayer Industry Theater
Evolutions in CTEPH: Then & Now
(Oceana 2)

8:00 PM – 10:00 PM
CareDX, Inc. Reception
(Cayman Court)

Thursday, April 4, 2019

7:00 AM – 8:00 AM
NuPulse iVas Study Meeting
(Barbados Boardroom)

9:45 AM – 10:15 AM
TandemLife | LivaNova Industry Theater
(Oceana 2)

12:00 PM – 1:00 PM
One Lambda, Inc., A Thermo Fisher Scientific Brand Industry Theater
The Journey from DSA to Molecular Microscope® in Heart & Lung Transplant Recipients
(Oceana 2)

12:00 PM – 1:45 PM
TransMedics Organ Care System (OCST™)
State-of-the-Art Thoracic Organ Perfusion Symposium – Redefining What’s Possible in Heart and Lung Transplantation
(Oceana 3-5)

12:00 PM – 1:45 PM
CareDX, Inc. Lunch Symposium
HeartCare: Comprehensive Surveillance for Personalized Transplant Care
(Pacifica 10-12)

12:00 PM – 2:00 PM
Paragonix SherpaPak™
CTS 2019 International Heart Summit
(Grand Caribbean 10)
12:15 PM – 1:15 PM
Medtronic Athena Physician Update Meeting
(Grand Caribbean 11)

6:00 PM – 7:00 PM
SynCardia Symposium
Red Flags, Inflow, Outflow, and Obstructions with the Artificial Heart Patient
(Gardenia 1)

6:00 PM – 9:30 PM
Bayer CTEPH Mini-Advisory Board Dinner
(Hard Rock Café)

6:30 PM – 8:30 PM
United Therapeutics Jenesis Innovative Research Awards Dinner
(Grand Caribbean 12)

6:30 PM – 8:30 PM
Medtronic Dinner
The Power of Strategic Outreach: Successful VAD Programs in Today’s Changing Landscape
(South China Sea)

**Friday, April 5**

6:30 AM – 8:00 AM
Medtronic O.H. Frazier Fellowship Recipient Breakfast
(Grand Caribbean 10)

12:15 PM – 1:15 PM
XVIVO Perfusion AB Industry Theater
Ex-Vivo Lung Perfusion – Current Practices and Future Opportunities
(Oceana 2)

**Saturday, April 6**

2:00 PM – 4:00 PM
Biotest AG Corporate Event
The Role of IgM and DSA Development in Transplantation
(South China Sea)
# 2019 Exhibitors and Booth Numbers by Exhibitor Name

<table>
<thead>
<tr>
<th>Booth #</th>
<th>Exhibitor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>211</td>
<td>Abbott Laboratories</td>
</tr>
<tr>
<td>323</td>
<td>Abiomed</td>
</tr>
<tr>
<td>105</td>
<td>Acelis Connected Health</td>
</tr>
<tr>
<td>107</td>
<td>Actelion Pharmaceuticals US Inc</td>
</tr>
<tr>
<td>434</td>
<td>ActiCare Health</td>
</tr>
<tr>
<td>429</td>
<td>AdventHealth Transplant Institute</td>
</tr>
<tr>
<td>329</td>
<td>Atara Biotherapeutics</td>
</tr>
<tr>
<td>127</td>
<td>Bayer</td>
</tr>
<tr>
<td>307</td>
<td>Berlin Heart</td>
</tr>
<tr>
<td>113</td>
<td>CareDx, Inc.</td>
</tr>
<tr>
<td>204</td>
<td>CARMAT</td>
</tr>
<tr>
<td>428</td>
<td>CD Leycom</td>
</tr>
<tr>
<td>408</td>
<td>CHF Solutions</td>
</tr>
<tr>
<td>335</td>
<td>Elsevier</td>
</tr>
<tr>
<td>410</td>
<td>Essential Pharmaceuticals</td>
</tr>
<tr>
<td>404</td>
<td>Evaheart</td>
</tr>
<tr>
<td>232</td>
<td>Getinge</td>
</tr>
<tr>
<td>206</td>
<td>Hibernicor LLC</td>
</tr>
<tr>
<td>305</td>
<td>Hugo Sachs, Harvard Apparatus</td>
</tr>
<tr>
<td>407</td>
<td>ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)</td>
</tr>
<tr>
<td>134</td>
<td>International Institute for the Advancement of Medicine – IIAM</td>
</tr>
<tr>
<td>423</td>
<td>ISHLT Registries</td>
</tr>
<tr>
<td>425</td>
<td>Jackson Health System</td>
</tr>
<tr>
<td>208</td>
<td>Jarvik Heart, Inc.</td>
</tr>
<tr>
<td>433</td>
<td>Kroger Specialty Pharmacy</td>
</tr>
<tr>
<td>427</td>
<td>Leviticus Cardio</td>
</tr>
<tr>
<td>413</td>
<td>Mallinckrodt Pharmaceuticals</td>
</tr>
<tr>
<td>119</td>
<td>Medtronic</td>
</tr>
<tr>
<td>417</td>
<td>Memorial Healthcare System</td>
</tr>
<tr>
<td>419</td>
<td>Miller Pharmacal Group, Inc.</td>
</tr>
<tr>
<td>106</td>
<td>Nebraska Medicine/UNMC</td>
</tr>
<tr>
<td>108</td>
<td>One Lambda, Inc.</td>
</tr>
<tr>
<td>409</td>
<td>Paragonix Technologies, Inc.</td>
</tr>
<tr>
<td>405</td>
<td>Pediatric Heart Transplant Society (PHTS)</td>
</tr>
<tr>
<td>132</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>235</td>
<td>SynCardia Systems, LLC</td>
</tr>
<tr>
<td>133</td>
<td>TAI Diagnostics</td>
</tr>
<tr>
<td>415</td>
<td>TandemLife</td>
</tr>
<tr>
<td>334</td>
<td>Texas Children’s Hospital</td>
</tr>
<tr>
<td>315</td>
<td>TransMedics, Inc.</td>
</tr>
<tr>
<td>431</td>
<td>UF Health Transplant Center</td>
</tr>
<tr>
<td>205</td>
<td>United Therapeutics</td>
</tr>
<tr>
<td>430</td>
<td>University of Chicago Medicine</td>
</tr>
<tr>
<td>331</td>
<td>UPMC</td>
</tr>
<tr>
<td>227</td>
<td>XVIVO Perfusion AB</td>
</tr>
</tbody>
</table>
### 2019 EXHIBITORS AND BOOTH NUMBERS
#### BY BOOTH NUMBER

<table>
<thead>
<tr>
<th>BOOTH #</th>
<th>EXHIBITOR NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>105</td>
<td>Acelis Connected Health</td>
</tr>
<tr>
<td>106</td>
<td>Nebraska Medicine/UNMC</td>
</tr>
<tr>
<td>107</td>
<td>Actelion Pharmaceuticals US Inc</td>
</tr>
<tr>
<td>108</td>
<td>One Lambda, Inc. A Thermo Fisher Scientific Brand</td>
</tr>
<tr>
<td>113</td>
<td>CareDx, Inc.</td>
</tr>
<tr>
<td>119</td>
<td>Medtronic</td>
</tr>
<tr>
<td>127</td>
<td>Bayer</td>
</tr>
<tr>
<td>132</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>133</td>
<td>TAI Diagnostics</td>
</tr>
<tr>
<td>134</td>
<td>International Institute for the Advancement of Medicine – IIAM</td>
</tr>
<tr>
<td>204</td>
<td>CARMAT</td>
</tr>
<tr>
<td>205</td>
<td>United Therapeutics</td>
</tr>
<tr>
<td>206</td>
<td>Hibernicor LLC</td>
</tr>
<tr>
<td>208</td>
<td>JarvikHeart, Inc.</td>
</tr>
<tr>
<td>211</td>
<td>Abbott Laboratories</td>
</tr>
<tr>
<td>227</td>
<td>XVIVO Perfusion AB</td>
</tr>
<tr>
<td>232</td>
<td>Getinge</td>
</tr>
<tr>
<td>235</td>
<td>SynCardia Systems, LLC</td>
</tr>
<tr>
<td>305</td>
<td>Hugo Sachs, Harvard Apparatus</td>
</tr>
<tr>
<td>307</td>
<td>Berlin Heart</td>
</tr>
<tr>
<td>315</td>
<td>TransMedics, Inc.</td>
</tr>
<tr>
<td>323</td>
<td>Abiomed</td>
</tr>
<tr>
<td>329</td>
<td>Atara Biotherapeutics</td>
</tr>
<tr>
<td>331</td>
<td>UPMC</td>
</tr>
<tr>
<td>334</td>
<td>Texas Children’s Hospital</td>
</tr>
<tr>
<td>335</td>
<td>Elsevier</td>
</tr>
<tr>
<td>404</td>
<td>Evaheart</td>
</tr>
<tr>
<td>405</td>
<td>Pediatric Heart Transplant Society (PHTS)</td>
</tr>
<tr>
<td>407</td>
<td>ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)</td>
</tr>
<tr>
<td>408</td>
<td>CHF Solutions</td>
</tr>
<tr>
<td>409</td>
<td>Paragonix Technologies, Inc.</td>
</tr>
<tr>
<td>410</td>
<td>Essential Pharmaceuticals</td>
</tr>
<tr>
<td>413</td>
<td>Mallinckrodt Pharmaceuticals</td>
</tr>
<tr>
<td>415</td>
<td>TandemLife</td>
</tr>
<tr>
<td>417</td>
<td>Memorial Healthcare System</td>
</tr>
<tr>
<td>419</td>
<td>MillerPharmaceuticals Group, Inc.</td>
</tr>
<tr>
<td>423</td>
<td>ISHLT Registries</td>
</tr>
<tr>
<td>425</td>
<td>Jackson Health System</td>
</tr>
<tr>
<td>427</td>
<td>LeviticusCardio</td>
</tr>
<tr>
<td>428</td>
<td>CD Leycom</td>
</tr>
<tr>
<td>429</td>
<td>AdventHealth Transplant Institute</td>
</tr>
<tr>
<td>430</td>
<td>University of Chicago Medicine</td>
</tr>
<tr>
<td>431</td>
<td>UF Health Transplant Center</td>
</tr>
<tr>
<td>433</td>
<td>Kroger Specialty Pharmacy</td>
</tr>
<tr>
<td>434</td>
<td>ActiCare Health</td>
</tr>
</tbody>
</table>
2019 EXHIBITORS PRODUCT DESCRIPTIONS

Abbott Laboratories BOOTH No. 211
100 Abbott Park Road
Abbott Park, Illinois 60064-3500 USA
https://www.abbott.com/

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world — in nutrition, diagnostics, medical devices and branded generic pharmaceuticals — that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

Abiomed BOOTH No. 323
22 Cherry Hill Drive
Danvers, MA 01923 USA
http://www.abiomed.com/

Abiomed is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, Chairman, and President Michael R. Minogue has focused the company’s efforts on developing ground-breaking technologies designed to improve the patient outcomes focused on native heart recovery. Founded in 1981 for the purpose of developing the world’s first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

Acelis Connected Health BOOTH No. 105
6465 National Drive
Livermore, CA 94550 USA
http://www.acelis.com

At Acelis Connected Health we help individuals manage their health. Our ecosystem of products and services supports the management of people’s health away from hospitals and labs with remote monitoring and connected data solutions. With a focus on engaging the individual in their own care, our services center around real-time biometric data management, certified training, and clinical support — creating a comprehensive and effortless digital health experience focused on the individual. Currently, our offerings enable individuals to monitor their warfarin therapy or ventricular assist device implant from their home or wherever they want to be.

Actelion Pharmaceuticals US Inc BOOTH No. 107
5000 Shoreline Court
South Francisco, CA 94080 USA
http://www.actelionus.com

"In June 2017, Actelion Ltd. became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs."

ActiCare Health BOOTH No. 434
6111 Southfront Road, Suite M
Livermore, CA 94551 USA
www.acticarehealth.com

ActiCare Health (Booth #434) offers the first and only VAD, heart transplant and lung transplant tele-health and advanced monitoring platform with 24x7 support, empowering both patients and clinicians to achieve remarkable outcomes with reduced stress. In response to the immense administrative and operational challenges faced by VAD and transplant departments, we’ve designed a program to provide enhanced visibility into patients’ health status, modernize patient safety and communication, optimize discharge plan adherence, and minimize adverse clinical and financial events. Our program is designed to positively affect health outcomes and quality of life, enhance care coordination and staff efficiency, and reduce costs.
AdventHealth Transplant Institute BOOTH No. 429
2415 N. Orange Ave, Suite 700
Orlando, FL 32804 USA
http://www.AdventHealthTransplantInstitute.com

As the only transplant center in the AdventHealth system and ranked as one of the top transplant facilities in the nation, the AdventHealth Transplant Institute is your multi-organ specialists for all your treatment needs. Along with the best in class physicians and facilities, we provide you with your own transplant team so you’re never alone on your journey. Starting back with kidney transplants in 1973, we have created a multi-organ program that is in the top one percent nationally for patient satisfaction, with median transplant wait times and 1-year survival outcomes better than national averages.

Atara Biotherapeutics BOOTH No. 329
611 Gateway Blvd
South San Francisco, California 94080 USA
https://www.atarabio.com/

Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s most advanced T-cell immunotherapy, tab-cel® (tabelecleucel), is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV-associated hematological malignancies and solid tumors, including nasopharyngeal carcinoma. Atara is also developing T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis.

Bayer BOOTH No. 127
100 Bayer Boulevard
Whippany, NJ 07981 USA
http://www.bayer.com

Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women’s health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.

Berlin Heart BOOTH No. 307
200 Valleywood Rd, Ste B100
The Woodlands, TX 77380 USA
http://www.berlinheart.com/

Berlin Heart, the only company worldwide, that develops, manufactures and distributes VADs for patients of every age and body size. EXCOR® Pediatric provides medium to long-term circulatory support specifically for infants and children awaiting heart transplants. EXCOR Pediatric is approved for use in the USA under HDE regulations by FDA.

CareDx, Inc. BOOTH No. 113
3260 Bayshore Blvd
Brisbane, CA 94005 USA
www.CareDx.com

CareDx is a recognized leader in transplant care. We are dedicated to improving the lives of organ transplant patients through innovative and non-invasive diagnostics. HeartCare is a non-invasive blood test for heart transplant patients. HeartCare provides information about transplant recipient immune activity and donor graft injury, including both AlloMap® (gene expression profiling) and AlloSure-Heart® (donor-derived cell-free DNA analysis).
CARMAT BOOTH No. 204
36, avenue de l’Europe - CS 40533
Velizy-Villacoublay, 78140 FRANCE
www.carmatsa.com

CARMAT (contraction of founders’ names Professor Carpentier and Matra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart with its power supply and monitoring systems. Key differentiating features of this device are: use of bovine pericardium for most parts in contact with blood, which potentially reduces thromboembolic risks, and automatically adjustable pulsatile flow in response to patients’ physiological needs thanks to embedded sensors and electronics. CARMAT heart is an investigational device only and is not commercially available. The First-in-Man feasibility study was completed early in 2016. A CE MARK pivotal study is currently ongoing in Europe.

Elsevier BOOTH No. 335
230 Park Avenue, Suite 800
New York, NY 10169 USA
www.elsevier.com

Elsevier is a world-leading provider of information solutions that help you make better decisions, deliver better care, and sometimes make groundbreaking discoveries in science, health, and technology. We provide web-based, digital solutions - among them ScienceDirect, Scopus, Evolve, Knovel, Reaxys, and ClinicalKey - and publish over 2,500 journals and more than 33,000 book titles.

Getinge BOOTH No. 232
45 Barbour Pond Dr
Wayne, NJ 07470 USA
http://www.getinge.com

Getinge is a leading global provider of innovative solutions for operating rooms, intensive-care units, hospital wards, sterilization departments and for life science companies and institutions. From now on, names you already know like Maquet, Lancer, Atrium, Pulsion, Datascope, Steritec, Getinge, Stericool and Trans will be working even closer together under one brand, Getinge. Our job is to simplify your workflow and raise the bar in terms of how efficient, safe and productive you and your colleagues can be. Getinge offers innovative healthcare solutions that improve every-day life for people, today and tomorrow.

Hibernicor LLC BOOTH No. 206
253 Ridge Dr
Jackson, MS 39216 USA
http://www.hibernicor.com

Hibernicor is a innovative technology company developing the Asporto device which addresses a problem that many donated hearts – about 20 percent – are not used because the current ice cooler method only allows 3-4 hours of transport time. The solution to this problem is Asporto; a microcomputer controlled cardioplegic pump and hypothermic carbon-fiber cooler designed to improve the quality of the donor heart; thus allowing a greater transport distance. Asporto is not FDA or CE approved and is available only for laboratory research. For more information: www.hibernicor.com

Hugo Sachs, Harvard Apparatus BOOTH No. 305
84 October Hill Rd
Holliston, MA 01746 USA
http://www.harvardapparatus.com

Hugo Sachs Elektronik provides Advanced Tools for Physiology. It is the industry leader for providing advanced isolated organ and tissue perfusion systems as well as the PLUGSYS modular amplifier system for cardiovascular and respiratory applications. Harvard Apparatus is a major US manufacturer of specialized physiological research laboratory equipment with current headquarters in Holliston, Massachusetts, serving your research needs since 1901. Hugo Sachs and Harvard Apparatus are both part of the Harvard Bioscience family of companies. Harvard Bioscience (Nasdaq: HBIO) is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments.
IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place. The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

International Institute for the Advancement of Medicine - IIAM BOOTH No. 134
125 May Street
Edison, NJ 08837 USA
http://www.iiiam.org

IIAM is a world-leading provider of non-transplantable, healthy and diseased, human organs and tissues for medical research, education and development. These tissues are recovered with minimal ischemia from organ transplant donors who have authorized use of the non-transplantable organs for research. Stored in preservation solution, the organs are shipped directly from the recovery suite and delivered to the researcher’s lab in 12-24 hours. With access to over 15,000 organs for research each year, IIAM enables qualified researchers, healthcare and biotech professionals to study human tissues in order to alleviate human disease and advance medicine. Please visit our website at www.iiam.org.

ISHLT Registries BOOTH No. 423
700 N 4th Street
Richmond, VA 23219 USA
www.ishlt.org

The International Thoracic Organ Transplant (TTX) Registry was created to provide on-going, current data regarding patient, donor, and transplant characteristics as well as post-transplant outcomes. Our Registry is the only one of its kind. All institutions and countries performing heart, heart-lung, and/or lung transplantation are invited to submit data to the TTX Registry.

Jackson Health System | Miami Transplant Institute BOOTH No. 425
1801 N.W. 9th Avenue, Miami, FL 33136
Miami, FL 33136 USA
www.MiamiTransplant.org

The Miami Transplant Institute (MTI), an affiliation between Jackson Health System and UHealth – University of Miami Health System, has been giving a second chance at life to patients on a local, national, and international level for more than 45 years. The MTI transplant team performs more than 650 transplant surgeries annually at Jackson Memorial Hospital, one of the largest public teaching hospitals in the United States, and is one of the largest and most comprehensive programs in the nation. It is also the only center in South Florida that performs all organ transplants for both adult and pediatric patients.
Jarvik Heart, Inc. is a privately held, New York City based company that develops, manufactures and sells unique cardiac assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available* for the long-term treatment of Heart Failure. The New Jarvik 15mm VAD has been designed for pediatric and small patients and will enter clinical trials in the USA and EU in 2019.

*Jarvik 2000 available, in US, only in FDA clinical trial.

Kroger Specialty Pharmacy is a nationwide Clinical Pharmacy dedicated to servicing patients with chronic illnesses requiring complex care. We offer unique programs designed to empower patients, including education and resources, counseling and side effect management, and financial assistance options.

Leviticus Cardio's wireless power transfer technology, Coplanar Energy Transfer (CET), combined with an existing Ventricular Assist system, provides a new, comprehensive hybrid solution for CHF patients. FiVAD is wirelessly charged using an external belt along with an internal battery that lasts 6-8 hours. The system completely removes the risk of infection often caused by the transcutaneous drive line which protrudes from the abdomen in standard Ventricular Assist devices. FiVAD also allows patients to walk without external equipment up to 8 hours a day, thereby significantly improving the patient's quality of life.

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people's lives. Mallinckrodt’s growing portfolio of specialty pharmaceuticals help treat a wide variety of health conditions. We invest in our areas of focus that include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. For more information, please visit our website www.mallinckrodt.com.

Patients are at the center of everything we do — and we believe medical technology can play an even greater role in improving people’s lives. Medtronic Mechanical Circulatory Support is committed to continuous learning and innovation, to further advance the treatment of end-stage heart failure. We strive to improve patient outcomes and the clinical experience of your practice. Stop by the Medtronic booth to learn more and to see the latest HeartWare™ HVAD™ System enhancements. Join us in our commitment to take healthcare Further, Together. Be inspired at medtronic.com.
Memorial Healthcare System BOOTH No. 417
3501 Johnson Street
Hollywood, FL 33021 USA
http://www.memorialphysician.com

Memorial Healthcare System, one of the largest public healthcare systems in the U.S., has several physician career opportunities available for an adult cardiac surgeon, adult HF/HT cardiologist, and pediatric HF/HT cardiologist. The Memorial Cardiac and Vascular Institute’s program has earned and maintained a three-star rating. Joe DiMaggio Children’s Hospital, part of Memorial, has just celebrated their 50th pediatric heart transplant. Memorial Healthcare System is located in South Florida, a region with a high quality of life and no state income tax that attracts new residents from all over the country. Stop by booth #417 to learn more about these opportunities.

Miller Pharmacal Group, Inc. BOOTH No. 419
350 Randy Rd, Ste 2
Carol Stream, IL 60188 USA

Miller Pharmacal's magnesium supplement "MG Plus Protein" is used at many transplant centers for the treatment and prevention of the hypomagnesemia caused by CI's, without the GI disturbances common with magnesium oxide. "MG Plus Protein" is: Well-tolerated, effective, inexpensive and easy for patients to swallow.

Nebraska Medicine/UNMC BOOTH No. 106
S 42nd & Emile St.
Omaha, NE 68198-8132 USA
http://nebraskamed.com

The Heart and Vascular Network at Nebraska Medicine includes physicians who subspecialize in areas such as structural heart disease, diagnostic cardiovascular imaging, congenital heart disease, advanced heart failure, heart transplantation and lung transplantation. Our Heart Failure and Transplant/MCS Program was one of the top 10 enrollment centers in the MOMENTUM 3 clinical trial. In 2018 they performed 41 transplants and implanted 51 VAD's and our skilled team of cardiac surgeons performed 74 ECMO cases. Our Lung Transplant Program accommodates dual listings with a median wait list time of 33 days. In 2018 this multidisciplinary team performed 11 lung transplants.

One Lambda, Inc. A Thermo Fisher Scientific Brand BOOTH No. 108
22801 Roscoe Blvd
Los Angeles, CA 91304 USA

One Lambda, Inc., is a global leader in transplant diagnostics with a commitment to improve the lives of patients worldwide by driving innovation and delivering quality products. Our comprehensive product portfolio includes a broad range of industry-leading antibody detection and monitoring solutions, HLA Typing products, laboratory instrumentation and software, and industry-leading customer support.

Paragonix Technologies, Inc. BOOTH No. 409
639 Granite Street, Suite 408
Braintree, MA 02184, MA 02184 USA
http://www.paragonixtechnologies.com

The Paragonix SherpaPak™ Cardiac Transport System (CTS) safeguards hearts during the journey from donor to patient. Our device incorporates clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide unprecedented physical and thermal protection. Paragonix SherpaPak™ CTS is the only commercially available FDA cleared and CE marked medical device for heart transportation.
The Pediatric Heart Transplant Society is a multidisciplinary, professional organization dedicated to advancing the science and treatment of children during listing and following heart transplantation. The ultimate goal is to improve the lives of pediatric heart transplant recipients. The purposes of the Society are to maintain an international, prospective, event driven, quality improvement registry for pediatric heart transplantation; promote collaboration among professionals in the field of pediatric heart transplantation; encourage and stimulate basic and clinical research; promote new therapeutics; provide educational resources for patients and families and develop best practices and procedures for caring for children after transplant.

The Scanlan Family has been designing and manufacturing the highest quality surgical products since 1921. Quality is important because a surgical instrument is an extension of a surgeon’s hand. When purchasing instruments, consider precision, balance, feel and durability then demand Scanlan. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, Scanlan® SUPER CUT™ and PREMIER Scissors. Full line of VATS/MIS Thoracoscopic instruments including the Chitwood Aortic Clamp, Knot Pusher and SUPER CUT™ Suture Cutter. Also offering custom instrument designs and modifications for your individual needs. See our full-line of instrumentation at our Exhibit #132.

The SynCardia temporary Total Artificial Heart (TAH-t), the world’s most used artificial heart, is now available in two sizes to serve more patients. The 70cc TAH-t is FDA, Health Canada and CE approved as a bridge to transplant for patients with end-stage biventricular failure. The new, smaller 50cc TAH-t, CE approved in Europe and undergoing an Investigational Device Exemption clinical study in the U.S., is designed for patients of smaller stature, including women and adolescents. Stable patients can be discharged to wait for a matching donor heart at home using the Freedom® portable driver. Visit our booth to learn more.

TAI Diagnostics, Inc. is a leading biotechnology company focused on providing accurate, fast, cost-effective, non-invasive diagnostic tests to monitor the health of transplanted organs in patients who have received solid organ transplants. The myTAI-HEART™ test measures the donor fraction of cell-free DNA as a direct measure of selective damage to a recipient’s donated heart. The level of donor fraction is used to stratify the recipient as at low versus increased risk of moderate to severe acute cellular rejection. This ultra-sensitive test also detects other forms of selective donor organ injury, such as acute antibody mediated rejection and graft vasculopathy.

TandemLife is now LivaNova! Emergent cardiac & respiratory rescue for more patients in more places. The TandemLife family of temporary CPB support devices, provides a “Time to Decide™” strategy with rapid device deployment to stabilize and support the patient, giving you time to diagnose and treat the underlying issue. Stop by the LivaNova booth to see how our devices are delivering life support simplified.
Texas Children’s Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children’s hospital in Texas, and among the top in the nation, Texas Children’s has garnered widespread recognition for its expertise and breakthroughs in pediatric and women’s health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Center for pediatric research; Texas Children’s Pavilion for Women, a comprehensive obstetrics/gynecology facility; Texas Children’s Hospital West Campus; and Texas Children’s Hospital The Woodlands.

TransMedics Organ Care System (OCS™) The Organ Care System is a portable organ perfusion, optimization and monitoring system that replicates near-physiologic conditions for donor organs outside of the human body. The OCS technology platform is designed to maintain organs in a living, functioning state. Because the OCS significantly reduces injurious ischemic time on donor organs as compared to cold storage, and enables the optimization and assessment of these organs, it has demonstrated improved clinical outcomes relative to cold storage and offers the potential to significantly improve donor organ utilization.

UF Health Lung Transplant Program is in the top 10 facilities in the United States for volume, performing 70 combined adult and pediatric transplants in 2018. Superior outcomes exceed national averages for patient survival and wait list. ECMO is used before and during surgery along with unique treatments such as XVIVO to help create an expanded pool of donor lungs. The UF Health Congenital Heart Center is the largest, nationally ranked pediatric heart, heart-lung and the only pediatric lung transplant program in Florida, as well as one of the largest in the southeastern United States. UF Health Pediatrics offers a complete range of pediatric cardiac and pulmonary subspecialties and diagnostic procedures.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life threatening conditions.

XVIVO Perfusion develops, manufactures and markets solutions and systems for transplantation; - Perfadex® Plus for hypothermic flushing and preservation of donor lungs during transport - STEEN Solution™ for normothermic ex vivo lung perfusion and evaluation - XPS™ and LST™ platforms for warm perfusion and evaluation of lungs ex vivo  XPS™ is approved in Europe, USA, Canada and Australia and LST™ is approved in Europe, Canada and Australia  XVIVO Perfusion aims to increase the number of organs available for transplantation and to improve success rates through developing new transplantation concepts and techniques. We believe that nobody should die waiting for a new organ.
2020
40th Annual Meeting and Scientific Sessions
Palais de Congrès de Montréal
Montréal, Canada
April 22-25, 2020

2021
41st Annual Meeting and Scientific Sessions
International Convention Center Sydney
Sydney, Australia
April 21-24, 2021

2022
42nd Annual Meeting and Scientific Sessions
John B. Hynes Veterans Memorial Convention Center
Boston, MA, USA
April 27-30, 2022